1	The	_	_	O
2	aim	_	_	O
3	of	_	_	O
4	this	_	_	O
5	study	_	_	O
6	was	_	_	O
7	to	_	_	O
8	compare	_	_	O
9	the	_	_	O
10	efficacy	_	_	O
11	of	_	_	O
12	augmenting	_	_	O
13	trabeculectomy	_	_	O
14	with	_	_	O
15	subconjunctival	_	_	O
16	mitomycin	_	_	O
17	C	_	_	O
18	(	_	_	O
19	TMMC	_	_	O
20	)	_	_	O
21	versus	_	_	O
22	5-fluorouracil	_	_	O
23	(	_	_	O
24	T5-FU	_	_	O
25	)	_	_	O
26	in	_	_	O
27	lowering	_	_	O
28	intraocular	_	_	O
29	pressure	_	_	O
30	(	_	_	O
31	IOP	_	_	O
32	)	_	_	O
33	.	_	_	O

34	Forty	_	_	O
35	eyes	_	_	O
36	from	_	_	O
37	40	_	_	O
38	patients	_	_	O
39	referred	_	_	O
40	to	_	_	O
41	the	_	_	O
42	Nikoukari	_	_	O
43	Ophthalmology	_	_	O
44	University	_	_	O
45	Hospital	_	_	O
46	,	_	_	O
47	Tabriz	_	_	O
48	University	_	_	O
49	of	_	_	O
50	Medical	_	_	O
51	Sciences	_	_	O
52	,	_	_	O
53	Tabriz	_	_	O
54	,	_	_	O
55	Iran	_	_	O
56	,	_	_	O
57	were	_	_	O
58	enrolled	_	_	O
59	in	_	_	O
60	a	_	_	O
61	randomized	_	_	O
62	clinical	_	_	O
63	trial	_	_	O
64	.	_	_	O

65	Patients	_	_	O
66	with	_	_	O
67	high-risk	_	_	O
68	open	_	_	O
69	angle	_	_	O
70	glaucoma	_	_	O
71	were	_	_	O
72	allocated	_	_	O
73	to	_	_	O
74	receive	_	_	O
75	either	_	_	O
76	subconjunctival	_	_	O
77	TMMC	_	_	O
78	or	_	_	O
79	T5-FU	_	_	O
80	.	_	_	O

81	Mean	_	_	O
82	overall	_	_	O
83	preoperative	_	_	O
84	IOP	_	_	O
85	was	_	_	O
86	30.8	_	_	O
87	mmHg	_	_	O
88	.	_	_	O

89	Mean	_	_	B-Premise
90	preoperative	_	_	I-Premise
91	IOPs	_	_	I-Premise
92	in	_	_	I-Premise
93	the	_	_	I-Premise
94	TMMC	_	_	I-Premise
95	and	_	_	I-Premise
96	T5-FU	_	_	I-Premise
97	groups	_	_	I-Premise
98	were	_	_	I-Premise
99	31.2	_	_	I-Premise
100	±	_	_	I-Premise
101	9.8	_	_	I-Premise
102	and	_	_	I-Premise
103	30.6	_	_	I-Premise
104	±	_	_	I-Premise
105	9.9	_	_	I-Premise
106	mmHg	_	_	I-Premise
107	,	_	_	I-Premise
108	respectively	_	_	I-Premise
109	.	_	_	I-Premise

110	Postoperatively	_	_	I-Premise
111	,	_	_	I-Premise
112	mean	_	_	I-Premise
113	IOPs	_	_	I-Premise
114	were	_	_	I-Premise
115	11.4	_	_	I-Premise
116	±	_	_	I-Premise
117	4.9	_	_	I-Premise
118	and	_	_	I-Premise
119	13.6	_	_	I-Premise
120	±	_	_	I-Premise
121	3.9	_	_	I-Premise
122	mmHg	_	_	I-Premise
123	,	_	_	I-Premise
124	respectively	_	_	I-Premise
125	for	_	_	I-Premise
126	TMMC	_	_	I-Premise
127	and	_	_	I-Premise
128	T5-FU	_	_	I-Premise
129	groups	_	_	I-Premise
130	after	_	_	I-Premise
131	6	_	_	I-Premise
132	months	_	_	I-Premise
133	.	_	_	I-Premise

134	In	_	_	O
135	spite	_	_	O
136	of	_	_	O
137	some	_	_	O
138	existing	_	_	O
139	descriptive	_	_	O
140	differences	_	_	O
141	in	_	_	O
142	IOP	_	_	O
143	between	_	_	O
144	the	_	_	O
145	groups	_	_	O
146	,	_	_	O
147	statistical	_	_	B-Premise
148	tests	_	_	I-Premise
149	showed	_	_	I-Premise
150	no	_	_	I-Premise
151	difference	_	_	I-Premise
152	in	_	_	I-Premise
153	mean	_	_	I-Premise
154	and	_	_	I-Premise
155	median	_	_	I-Premise
156	IOP	_	_	I-Premise
157	.	_	_	I-Premise

158	Three	_	_	B-Premise
159	cases	_	_	I-Premise
160	of	_	_	I-Premise
161	hypotonia	_	_	I-Premise
162	(	_	_	I-Premise
163	IOP	_	_	I-Premise
164	<	_	_	I-Premise
165	6	_	_	I-Premise
166	mmHg	_	_	I-Premise
167	)	_	_	I-Premise
168	and	_	_	I-Premise
169	1	_	_	I-Premise
170	case	_	_	I-Premise
171	of	_	_	I-Premise
172	epithelial	_	_	I-Premise
173	keratitis	_	_	I-Premise
174	were	_	_	I-Premise
175	detected	_	_	I-Premise
176	.	_	_	I-Premise

177	TMMC	_	_	B-Claim
178	and	_	_	I-Claim
179	T5-FU	_	_	I-Claim
180	appeared	_	_	I-Claim
181	to	_	_	I-Claim
182	have	_	_	I-Claim
183	similar	_	_	I-Claim
184	efficacy	_	_	I-Claim
185	in	_	_	I-Claim
186	lowering	_	_	I-Claim
187	IOP	_	_	I-Claim
188	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	establish	_	_	O
8	the	_	_	O
9	efficacy	_	_	O
10	and	_	_	O
11	safety	_	_	O
12	of	_	_	O
13	the	_	_	O
14	Ex-PRESS	_	_	O
15	(	_	_	O
16	Optonol	_	_	O
17	Ltd.	_	_	O
18	,	_	_	O
19	Neve	_	_	O
20	Ilan	_	_	O
21	,	_	_	O
22	Israel	_	_	O
23	)	_	_	O
24	mini	_	_	O
25	glaucoma	_	_	O
26	shunt	_	_	O
27	in	_	_	O
28	open-angle	_	_	O
29	glaucoma	_	_	O
30	.	_	_	O

31	This	_	_	O
32	was	_	_	O
33	a	_	_	O
34	prospective	_	_	O
35	,	_	_	O
36	randomized	_	_	O
37	trial	_	_	O
38	.	_	_	O

39	Eyes	_	_	O
40	from	_	_	O
41	enrolled	_	_	O
42	patients	_	_	O
43	were	_	_	O
44	randomly	_	_	O
45	assigned	_	_	O
46	to	_	_	O
47	either	_	_	O
48	Ex-PRESS	_	_	O
49	implantation	_	_	O
50	under	_	_	O
51	a	_	_	O
52	scleral	_	_	O
53	flap	_	_	O
54	,	_	_	O
55	or	_	_	O
56	trabeculectomy	_	_	O
57	.	_	_	O

58	The	_	_	O
59	main	_	_	O
60	outcome	_	_	O
61	measures	_	_	O
62	were	_	_	O
63	:	_	_	O
64	mean	_	_	O
65	intraocular	_	_	O
66	pressure	_	_	O
67	(	_	_	O
68	IOP	_	_	O
69	)	_	_	O
70	,	_	_	O
71	postoperative	_	_	O
72	medication	_	_	O
73	use	_	_	O
74	,	_	_	O
75	visual	_	_	O
76	acuity	_	_	O
77	,	_	_	O
78	and	_	_	O
79	incidence	_	_	O
80	of	_	_	O
81	complications	_	_	O
82	.	_	_	O

83	Complete	_	_	O
84	success	_	_	O
85	was	_	_	O
86	defined	_	_	O
87	as	_	_	O
88	an	_	_	O
89	IOP	_	_	O
90	of	_	_	O
91	>	_	_	O
92	4	_	_	O
93	mmHg	_	_	O
94	and	_	_	O
95	<	_	_	O
96	or=18	_	_	O
97	mmHg	_	_	O
98	without	_	_	O
99	the	_	_	O
100	use	_	_	O
101	of	_	_	O
102	antiglaucoma	_	_	O
103	medications	_	_	O
104	.	_	_	O

105	A	_	_	O
106	more	_	_	O
107	stringent	_	_	O
108	target	_	_	O
109	of	_	_	O
110	IOP	_	_	O
111	>	_	_	O
112	4	_	_	O
113	mmHg	_	_	O
114	and	_	_	O
115	<	_	_	O
116	or=15	_	_	O
117	mmHg	_	_	O
118	was	_	_	O
119	also	_	_	O
120	noted	_	_	O
121	.	_	_	O

122	There	_	_	O
123	were	_	_	O
124	78	_	_	O
125	patients	_	_	O
126	(	_	_	O
127	80	_	_	O
128	eyes	_	_	O
129	)	_	_	O
130	with	_	_	O
131	primary	_	_	O
132	open-angle	_	_	O
133	,	_	_	O
134	pseudoexfoliative	_	_	O
135	,	_	_	O
136	or	_	_	O
137	pigmentary	_	_	O
138	glaucoma	_	_	O
139	enrolled	_	_	O
140	in	_	_	O
141	the	_	_	O
142	study	_	_	O
143	.	_	_	O

144	A	_	_	O
145	total	_	_	O
146	of	_	_	O
147	84.6	_	_	O
148	%	_	_	O
149	of	_	_	O
150	patients	_	_	O
151	receiving	_	_	O
152	Ex-PRESS	_	_	O
153	and	_	_	O
154	60.0	_	_	O
155	%	_	_	O
156	of	_	_	O
157	patients	_	_	O
158	receiving	_	_	O
159	trabeculectomy	_	_	O
160	(	_	_	O
161	P=0.0230	_	_	O
162	)	_	_	O
163	achieved	_	_	O
164	complete	_	_	O
165	success	_	_	O
166	.	_	_	O

167	The	_	_	O
168	respective	_	_	O
169	proportions	_	_	O
170	of	_	_	O
171	patients	_	_	O
172	achieving	_	_	O
173	an	_	_	O
174	IOP	_	_	O
175	>	_	_	O
176	4	_	_	O
177	mmHg	_	_	O
178	and	_	_	O
179	<	_	_	O
180	or=15	_	_	O
181	mmHg	_	_	O
182	were	_	_	O
183	76.9	_	_	O
184	%	_	_	O
185	and	_	_	O
186	50.0	_	_	O
187	%	_	_	O
188	(	_	_	O
189	P=0.0193	_	_	O
190	)	_	_	O
191	.	_	_	O

192	At	_	_	B-Premise
193	1-year	_	_	I-Premise
194	follow-up	_	_	I-Premise
195	,	_	_	I-Premise
196	complete	_	_	I-Premise
197	success	_	_	I-Premise
198	rates	_	_	I-Premise
199	were	_	_	I-Premise
200	81.8	_	_	I-Premise
201	%	_	_	I-Premise
202	for	_	_	I-Premise
203	Ex-PRESS	_	_	I-Premise
204	and	_	_	I-Premise
205	47.5	_	_	I-Premise
206	%	_	_	I-Premise
207	for	_	_	I-Premise
208	trabeculectomy	_	_	I-Premise
209	(	_	_	I-Premise
210	P=0.0020	_	_	I-Premise
211	)	_	_	I-Premise
212	,	_	_	I-Premise
213	and	_	_	I-Premise
214	71.7	_	_	I-Premise
215	%	_	_	I-Premise
216	and	_	_	I-Premise
217	37.5	_	_	I-Premise
218	%	_	_	I-Premise
219	(	_	_	I-Premise
220	P=0.0070	_	_	I-Premise
221	)	_	_	I-Premise
222	,	_	_	I-Premise
223	respectively	_	_	I-Premise
224	,	_	_	I-Premise
225	for	_	_	I-Premise
226	the	_	_	I-Premise
227	more	_	_	I-Premise
228	stringent	_	_	I-Premise
229	target	_	_	I-Premise
230	.	_	_	I-Premise

231	There	_	_	B-Premise
232	was	_	_	I-Premise
233	a	_	_	I-Premise
234	similar	_	_	I-Premise
235	level	_	_	I-Premise
236	of	_	_	I-Premise
237	postoperative	_	_	I-Premise
238	interventions	_	_	I-Premise
239	and	_	_	I-Premise
240	complications	_	_	I-Premise
241	for	_	_	I-Premise
242	each	_	_	I-Premise
243	group	_	_	I-Premise
244	.	_	_	I-Premise

245	In	_	_	B-Claim
246	open-angle	_	_	I-Claim
247	glaucoma	_	_	I-Claim
248	,	_	_	I-Claim
249	the	_	_	I-Claim
250	Ex-PRESS	_	_	I-Claim
251	mini	_	_	I-Claim
252	glaucoma	_	_	I-Claim
253	shunt	_	_	I-Claim
254	implanted	_	_	I-Claim
255	under	_	_	I-Claim
256	a	_	_	I-Claim
257	superficial	_	_	I-Claim
258	scleral	_	_	I-Claim
259	flap	_	_	I-Claim
260	produces	_	_	I-Claim
261	significantly	_	_	I-Claim
262	higher	_	_	I-Claim
263	success	_	_	I-Claim
264	rates	_	_	I-Claim
265	,	_	_	I-Claim
266	and	_	_	I-Claim
267	a	_	_	I-Claim
268	similar	_	_	I-Claim
269	complication	_	_	I-Claim
270	rate	_	_	I-Claim
271	,	_	_	I-Claim
272	compared	_	_	I-Claim
273	with	_	_	I-Claim
274	trabeculectomy	_	_	I-Claim
275	.	_	_	I-Claim

276	The	_	_	B-Claim
277	Ex-PRESS	_	_	I-Claim
278	is	_	_	I-Claim
279	a	_	_	I-Claim
280	safe	_	_	I-Claim
281	and	_	_	I-Claim
282	effective	_	_	I-Claim
283	device	_	_	I-Claim
284	for	_	_	I-Claim
285	treating	_	_	I-Claim
286	open-angle	_	_	I-Claim
287	glaucoma	_	_	I-Claim
288	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effects	_	_	O
4	on	_	_	O
5	intraocular	_	_	O
6	pressure	_	_	O
7	(	_	_	O
8	IOP	_	_	O
9	)	_	_	O
10	and	_	_	O
11	side	_	_	O
12	effects	_	_	O
13	of	_	_	O
14	monotherapy	_	_	O
15	with	_	_	O
16	either	_	_	O
17	latanoprost	_	_	O
18	or	_	_	O
19	dorzolamide	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	glaucoma	_	_	O
24	or	_	_	O
25	ocular	_	_	O
26	hypertension	_	_	O
27	.	_	_	O

28	224	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	open	_	_	O
32	angle	_	_	O
33	glaucoma	_	_	O
34	or	_	_	O
35	ocular	_	_	O
36	hypertension	_	_	O
37	were	_	_	O
38	recruited	_	_	O
39	to	_	_	O
40	a	_	_	O
41	3	_	_	O
42	month	_	_	O
43	open	_	_	O
44	labelled	_	_	O
45	study	_	_	O
46	.	_	_	O

47	Previous	_	_	O
48	glaucoma	_	_	O
49	medications	_	_	O
50	were	_	_	O
51	washed	_	_	O
52	out	_	_	O
53	and	_	_	O
54	the	_	_	O
55	patients	_	_	O
56	were	_	_	O
57	randomised	_	_	O
58	to	_	_	O
59	receive	_	_	O
60	either	_	_	O
61	latanoprost	_	_	O
62	0.005	_	_	O
63	%	_	_	O
64	once	_	_	O
65	daily	_	_	O
66	or	_	_	O
67	dorzolamide	_	_	O
68	2	_	_	O
69	%	_	_	O
70	three	_	_	O
71	times	_	_	O
72	daily	_	_	O
73	.	_	_	O

74	Of	_	_	O
75	224	_	_	O
76	patients	_	_	O
77	213	_	_	O
78	were	_	_	O
79	included	_	_	O
80	in	_	_	O
81	the	_	_	O
82	analysis	_	_	O
83	of	_	_	O
84	efficacy	_	_	O
85	.	_	_	O

86	After	_	_	B-Premise
87	3	_	_	I-Premise
88	months	_	_	I-Premise
89	,	_	_	I-Premise
90	latanoprost	_	_	I-Premise
91	reduced	_	_	I-Premise
92	mean	_	_	I-Premise
93	baseline	_	_	I-Premise
94	diurnal	_	_	I-Premise
95	IOP	_	_	I-Premise
96	from	_	_	I-Premise
97	27.2	_	_	I-Premise
98	(	_	_	I-Premise
99	SD	_	_	I-Premise
100	3.0	_	_	I-Premise
101	)	_	_	I-Premise
102	mm	_	_	I-Premise
103	Hg	_	_	I-Premise
104	by	_	_	I-Premise
105	8.5	_	_	I-Premise
106	(	_	_	I-Premise
107	3.3	_	_	I-Premise
108	)	_	_	I-Premise
109	mm	_	_	I-Premise
110	Hg	_	_	I-Premise
111	.	_	_	I-Premise

112	The	_	_	B-Premise
113	corresponding	_	_	I-Premise
114	figures	_	_	I-Premise
115	for	_	_	I-Premise
116	dorzolamide	_	_	I-Premise
117	were	_	_	I-Premise
118	27.2	_	_	I-Premise
119	(	_	_	I-Premise
120	3.4	_	_	I-Premise
121	)	_	_	I-Premise
122	and	_	_	I-Premise
123	5.6	_	_	I-Premise
124	(	_	_	I-Premise
125	2.6	_	_	I-Premise
126	)	_	_	I-Premise
127	mm	_	_	I-Premise
128	Hg	_	_	I-Premise
129	.	_	_	I-Premise

130	The	_	_	B-Premise
131	difference	_	_	I-Premise
132	of	_	_	I-Premise
133	2.9	_	_	I-Premise
134	mm	_	_	I-Premise
135	Hg	_	_	I-Premise
136	(	_	_	I-Premise
137	95	_	_	I-Premise
138	%	_	_	I-Premise
139	CI	_	_	I-Premise
140	:	_	_	I-Premise
141	2.3-3.6	_	_	I-Premise
142	)	_	_	I-Premise
143	was	_	_	I-Premise
144	highly	_	_	I-Premise
145	significant	_	_	I-Premise
146	(	_	_	I-Premise
147	p	_	_	I-Premise
148	<	_	_	I-Premise
149	0.001	_	_	I-Premise
150	,	_	_	I-Premise
151	ANCOVA	_	_	I-Premise
152	)	_	_	I-Premise
153	.	_	_	I-Premise

154	Latanoprost	_	_	B-Premise
155	reduced	_	_	I-Premise
156	IOP	_	_	I-Premise
157	at	_	_	I-Premise
158	peak	_	_	I-Premise
159	by	_	_	I-Premise
160	8.6	_	_	I-Premise
161	mm	_	_	I-Premise
162	Hg	_	_	I-Premise
163	(	_	_	I-Premise
164	32	_	_	I-Premise
165	%	_	_	I-Premise
166	)	_	_	I-Premise
167	compared	_	_	I-Premise
168	with	_	_	I-Premise
169	6.2	_	_	I-Premise
170	mm	_	_	I-Premise
171	Hg	_	_	I-Premise
172	(	_	_	I-Premise
173	23	_	_	I-Premise
174	%	_	_	I-Premise
175	)	_	_	I-Premise
176	for	_	_	I-Premise
177	dorzolamide	_	_	I-Premise
178	,	_	_	I-Premise
179	and	_	_	I-Premise
180	the	_	_	I-Premise
181	difference	_	_	I-Premise
182	of	_	_	I-Premise
183	2.4	_	_	I-Premise
184	mm	_	_	I-Premise
185	Hg	_	_	I-Premise
186	was	_	_	I-Premise
187	significant	_	_	I-Premise
188	(	_	_	I-Premise
189	p	_	_	I-Premise
190	<	_	_	I-Premise
191	0.001	_	_	I-Premise
192	,	_	_	I-Premise
193	ANCOVA	_	_	I-Premise
194	)	_	_	I-Premise
195	.	_	_	I-Premise

196	The	_	_	B-Premise
197	corresponding	_	_	I-Premise
198	figures	_	_	I-Premise
199	at	_	_	I-Premise
200	trough	_	_	I-Premise
201	were	_	_	I-Premise
202	8.1	_	_	I-Premise
203	mm	_	_	I-Premise
204	Hg	_	_	I-Premise
205	(	_	_	I-Premise
206	31	_	_	I-Premise
207	%	_	_	I-Premise
208	)	_	_	I-Premise
209	for	_	_	I-Premise
210	latanoprost	_	_	I-Premise
211	and	_	_	I-Premise
212	4.7	_	_	I-Premise
213	mm	_	_	I-Premise
214	Hg	_	_	I-Premise
215	(	_	_	I-Premise
216	17	_	_	I-Premise
217	%	_	_	I-Premise
218	)	_	_	I-Premise
219	for	_	_	I-Premise
220	dorzolamide	_	_	I-Premise
221	,	_	_	I-Premise
222	a	_	_	I-Premise
223	significant	_	_	I-Premise
224	difference	_	_	I-Premise
225	of	_	_	I-Premise
226	3.4	_	_	I-Premise
227	mm	_	_	I-Premise
228	Hg	_	_	I-Premise
229	(	_	_	I-Premise
230	p	_	_	I-Premise
231	<	_	_	I-Premise
232	0.001	_	_	I-Premise
233	,	_	_	I-Premise
234	ANCOVA	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	Both	_	_	B-Claim
238	drugs	_	_	I-Claim
239	were	_	_	I-Claim
240	well	_	_	I-Claim
241	tolerated	_	_	I-Claim
242	systemically	_	_	I-Claim
243	and	_	_	I-Claim
244	locally	_	_	I-Claim
245	.	_	_	I-Claim

246	Latanoprost	_	_	B-Claim
247	was	_	_	I-Claim
248	superior	_	_	I-Claim
249	to	_	_	I-Claim
250	dorzolamide	_	_	I-Claim
251	in	_	_	I-Claim
252	reducing	_	_	I-Claim
253	the	_	_	I-Claim
254	IOP	_	_	I-Claim
255	,	_	_	I-Claim
256	judged	_	_	I-Claim
257	both	_	_	I-Claim
258	from	_	_	I-Claim
259	the	_	_	I-Claim
260	effect	_	_	I-Claim
261	on	_	_	I-Claim
262	IOP	_	_	I-Claim
263	at	_	_	I-Claim
264	peak	_	_	I-Claim
265	and	_	_	I-Claim
266	trough	_	_	I-Claim
267	and	_	_	I-Claim
268	by	_	_	I-Claim
269	the	_	_	I-Claim
270	effect	_	_	I-Claim
271	on	_	_	I-Claim
272	diurnal	_	_	I-Claim
273	IOP	_	_	I-Claim
274	.	_	_	I-Claim


0	Approximately	_	_	O
1	40	_	_	O
2	%	_	_	O
3	of	_	_	O
4	patients	_	_	O
5	with	_	_	O
6	glaucoma	_	_	O
7	are	_	_	O
8	concomitantly	_	_	O
9	prescribed	_	_	O
10	>	_	_	O
11	or=2	_	_	O
12	different	_	_	O
13	intraocular	_	_	O
14	pressure	_	_	O
15	(	_	_	O
16	IOP	_	_	O
17	)	_	_	O
18	-lowering	_	_	O
19	medications	_	_	O
20	.	_	_	O

21	An	_	_	O
22	effective	_	_	O
23	and	_	_	O
24	well-tolerated	_	_	O
25	fixed	_	_	O
26	combination	_	_	O
27	of	_	_	O
28	agents	_	_	O
29	requiring	_	_	O
30	once-daily	_	_	O
31	instillation	_	_	O
32	may	_	_	O
33	improve	_	_	O
34	patient	_	_	O
35	compliance	_	_	O
36	.	_	_	O

37	The	_	_	O
38	purpose	_	_	O
39	of	_	_	O
40	this	_	_	O
41	study	_	_	O
42	was	_	_	O
43	to	_	_	O
44	compare	_	_	O
45	the	_	_	O
46	efficacy	_	_	O
47	and	_	_	O
48	safety	_	_	O
49	profile	_	_	O
50	of	_	_	O
51	the	_	_	O
52	fixed	_	_	O
53	combination	_	_	O
54	latanoprost	_	_	O
55	0.005	_	_	O
56	%	_	_	O
57	+	_	_	O
58	timolol	_	_	O
59	maleate	_	_	O
60	0.5	_	_	O
61	%	_	_	O
62	QD	_	_	O
63	with	_	_	O
64	those	_	_	O
65	of	_	_	O
66	latanoprost	_	_	O
67	0.005	_	_	O
68	%	_	_	O
69	monotherapy	_	_	O
70	QD	_	_	O
71	in	_	_	O
72	patients	_	_	O
73	whose	_	_	O
74	elevated	_	_	O
75	IOP	_	_	O
76	(	_	_	O
77	>	_	_	O
78	or=21	_	_	O
79	mm	_	_	O
80	Hg	_	_	O
81	)	_	_	O
82	was	_	_	O
83	inadequately	_	_	O
84	controlled	_	_	O
85	by	_	_	O
86	latanoprost	_	_	O
87	.	_	_	O

88	This	_	_	O
89	21-day	_	_	O
90	,	_	_	O
91	randomized	_	_	O
92	,	_	_	O
93	double-masked	_	_	O
94	,	_	_	O
95	active-control	_	_	O
96	study	_	_	O
97	was	_	_	O
98	conducted	_	_	O
99	at	_	_	O
100	49	_	_	O
101	study	_	_	O
102	sites	_	_	O
103	in	_	_	O
104	Argentina	_	_	O
105	,	_	_	O
106	Brazil	_	_	O
107	,	_	_	O
108	Colombia	_	_	O
109	,	_	_	O
110	Mexico	_	_	O
111	,	_	_	O
112	Peru	_	_	O
113	,	_	_	O
114	the	_	_	O
115	United	_	_	O
116	States	_	_	O
117	,	_	_	O
118	and	_	_	O
119	Venezuela	_	_	O
120	.	_	_	O

121	Adults	_	_	O
122	with	_	_	O
123	glaucoma	_	_	O
124	or	_	_	O
125	ocular	_	_	O
126	hypertension	_	_	O
127	who	_	_	O
128	had	_	_	O
129	failed	_	_	O
130	to	_	_	O
131	reach	_	_	O
132	an	_	_	O
133	IOP	_	_	O
134	of	_	_	O
135	<	_	_	O
136	21	_	_	O
137	mm	_	_	O
138	Hg	_	_	O
139	while	_	_	O
140	receiving	_	_	O
141	latanoprost	_	_	O
142	for	_	_	O
143	at	_	_	O
144	least	_	_	O
145	28	_	_	O
146	days	_	_	O
147	were	_	_	O
148	enrolled	_	_	O
149	.	_	_	O

150	After	_	_	O
151	an	_	_	O
152	additional	_	_	O
153	28	_	_	O
154	days	_	_	O
155	of	_	_	O
156	latanoprost	_	_	O
157	run-in	_	_	O
158	,	_	_	O
159	patients	_	_	O
160	were	_	_	O
161	randomly	_	_	O
162	assigned	_	_	O
163	to	_	_	O
164	continue	_	_	O
165	latanoprost	_	_	O
166	monotherapy	_	_	O
167	or	_	_	O
168	to	_	_	O
169	switch	_	_	O
170	to	_	_	O
171	the	_	_	O
172	fixed	_	_	O
173	combination	_	_	O
174	for	_	_	O
175	21	_	_	O
176	days	_	_	O
177	.	_	_	O

178	The	_	_	O
179	intent-to-treat	_	_	O
180	(	_	_	O
181	ITT	_	_	O
182	)	_	_	O
183	population	_	_	O
184	included	_	_	O
185	all	_	_	O
186	patients	_	_	O
187	who	_	_	O
188	received	_	_	O
189	at	_	_	O
190	least	_	_	O
191	1	_	_	O
192	dose	_	_	O
193	of	_	_	O
194	double-masked	_	_	O
195	study	_	_	O
196	medication	_	_	O
197	;	_	_	O
198	the	_	_	O
199	per-protocol	_	_	O
200	(	_	_	O
201	PP	_	_	O
202	)	_	_	O
203	analysis	_	_	O
204	included	_	_	O
205	patients	_	_	O
206	who	_	_	O
207	completed	_	_	O
208	the	_	_	O
209	study	_	_	O
210	without	_	_	O
211	a	_	_	O
212	major	_	_	O
213	protocol	_	_	O
214	violation	_	_	O
215	and	_	_	O
216	who	_	_	O
217	had	_	_	O
218	IOP	_	_	O
219	measurements	_	_	O
220	both	_	_	O
221	at	_	_	O
222	baseline	_	_	O
223	and	_	_	O
224	at	_	_	O
225	day	_	_	O
226	21	_	_	O
227	.	_	_	O

228	The	_	_	O
229	primary	_	_	O
230	end	_	_	O
231	point	_	_	O
232	was	_	_	O
233	the	_	_	O
234	proportion	_	_	O
235	of	_	_	O
236	patients	_	_	O
237	whose	_	_	O
238	IOP	_	_	O
239	was	_	_	O
240	decreased	_	_	O
241	>	_	_	O
242	or=2	_	_	O
243	mm	_	_	O
244	Hg	_	_	O
245	from	_	_	O
246	the	_	_	O
247	baseline	_	_	O
248	level	_	_	O
249	on	_	_	O
250	day	_	_	O
251	21	_	_	O
252	.	_	_	O

253	Proportions	_	_	O
254	of	_	_	O
255	patients	_	_	O
256	demonstrating	_	_	O
257	IOP	_	_	O
258	decreases	_	_	O
259	>	_	_	O
260	or=3	_	_	O
261	,	_	_	O
262	>	_	_	O
263	or=4	_	_	O
264	,	_	_	O
265	or	_	_	O
266	>	_	_	O
267	or=5	_	_	O
268	mm	_	_	O
269	Hg	_	_	O
270	from	_	_	O
271	the	_	_	O
272	baseline	_	_	O
273	level	_	_	O
274	and	_	_	O
275	of	_	_	O
276	patients	_	_	O
277	reaching	_	_	O
278	an	_	_	O
279	10P	_	_	O
280	<	_	_	O
281	or=18	_	_	O
282	mm	_	_	O
283	Hg	_	_	O
284	were	_	_	O
285	evaluated	_	_	O
286	.	_	_	O

287	Adverse	_	_	O
288	events	_	_	O
289	(	_	_	O
290	AEs	_	_	O
291	)	_	_	O
292	were	_	_	O
293	also	_	_	O
294	assessed	_	_	O
295	.	_	_	O

296	A	_	_	O
297	total	_	_	O
298	of	_	_	O
299	350	_	_	O
300	patients	_	_	O
301	were	_	_	O
302	enrolled	_	_	O
303	.	_	_	O

304	In	_	_	O
305	all	_	_	O
306	,	_	_	O
307	348	_	_	O
308	patients	_	_	O
309	were	_	_	O
310	included	_	_	O
311	in	_	_	O
312	the	_	_	O
313	ITT	_	_	O
314	and	_	_	O
315	tolerability	_	_	O
316	analyses	_	_	O
317	(	_	_	O
318	fixed	_	_	O
319	combination	_	_	O
320	,	_	_	O
321	n	_	_	O
322	=	_	_	O
323	175	_	_	O
324	;	_	_	O
325	latanoprost	_	_	O
326	,	_	_	O
327	n	_	_	O
328	=	_	_	O
329	173	_	_	O
330	;	_	_	O
331	mean	_	_	O
332	[	_	_	O
333	SD	_	_	O
334	]	_	_	O
335	age	_	_	O
336	,	_	_	O
337	64.4	_	_	O
338	[	_	_	O
339	13.2	_	_	O
340	]	_	_	O
341	and	_	_	O
342	63.2	_	_	O
343	[	_	_	O
344	14.0	_	_	O
345	]	_	_	O
346	years	_	_	O
347	,	_	_	O
348	respectively	_	_	O
349	;	_	_	O
350	103	_	_	O
351	women	_	_	O
352	in	_	_	O
353	each	_	_	O
354	group	_	_	O
355	)	_	_	O
356	.	_	_	O

357	Baseline	_	_	O
358	demographic	_	_	O
359	and	_	_	O
360	clinical	_	_	O
361	characteristics	_	_	O
362	were	_	_	O
363	similar	_	_	O
364	between	_	_	O
365	groups	_	_	O
366	.	_	_	O

367	A	_	_	B-Premise
368	higher	_	_	I-Premise
369	percentage	_	_	I-Premise
370	of	_	_	I-Premise
371	patients	_	_	I-Premise
372	receiving	_	_	I-Premise
373	the	_	_	I-Premise
374	fixed	_	_	I-Premise
375	combination	_	_	I-Premise
376	had	_	_	I-Premise
377	IOP	_	_	I-Premise
378	decreases	_	_	I-Premise
379	of	_	_	I-Premise
380	2	_	_	I-Premise
381	mm	_	_	I-Premise
382	Hg	_	_	I-Premise
383	on	_	_	I-Premise
384	day	_	_	I-Premise
385	21	_	_	I-Premise
386	relative	_	_	I-Premise
387	to	_	_	I-Premise
388	baseline	_	_	I-Premise
389	compared	_	_	I-Premise
390	with	_	_	I-Premise
391	latanoprost-treated	_	_	I-Premise
392	patients	_	_	I-Premise
393	(	_	_	I-Premise
394	79.4	_	_	I-Premise
395	%	_	_	I-Premise
396	vs	_	_	I-Premise
397	51.4	_	_	I-Premise
398	%	_	_	I-Premise
399	,	_	_	I-Premise
400	respectively	_	_	I-Premise
401	;	_	_	I-Premise
402	P	_	_	I-Premise
403	<	_	_	I-Premise
404	0.001	_	_	I-Premise
405	)	_	_	I-Premise
406	.	_	_	I-Premise

407	PP	_	_	B-Premise
408	analyses	_	_	I-Premise
409	found	_	_	I-Premise
410	that	_	_	I-Premise
411	more	_	_	I-Premise
412	patients	_	_	I-Premise
413	in	_	_	I-Premise
414	the	_	_	I-Premise
415	fixed-combination	_	_	I-Premise
416	group	_	_	I-Premise
417	had	_	_	I-Premise
418	IOP	_	_	I-Premise
419	decreases	_	_	I-Premise
420	>	_	_	I-Premise
421	or=3	_	_	I-Premise
422	,	_	_	I-Premise
423	>	_	_	I-Premise
424	or=4	_	_	I-Premise
425	,	_	_	I-Premise
426	or	_	_	I-Premise
427	>	_	_	I-Premise
428	or=5	_	_	I-Premise
429	mm	_	_	I-Premise
430	Hg	_	_	I-Premise
431	(	_	_	I-Premise
432	for	_	_	I-Premise
433	each	_	_	I-Premise
434	target	_	_	I-Premise
435	level	_	_	I-Premise
436	,	_	_	I-Premise
437	P	_	_	I-Premise
438	<	_	_	I-Premise
439	0.001	_	_	I-Premise
440	vs	_	_	I-Premise
441	latanoprost	_	_	I-Premise
442	group	_	_	I-Premise
443	)	_	_	I-Premise
444	or	_	_	I-Premise
445	final	_	_	I-Premise
446	IOP	_	_	I-Premise
447	18	_	_	I-Premise
448	mm	_	_	I-Premise
449	Hg	_	_	I-Premise
450	(	_	_	I-Premise
451	fixed	_	_	I-Premise
452	-combination	_	_	I-Premise
453	,	_	_	I-Premise
454	35.1	_	_	I-Premise
455	%	_	_	I-Premise
456	;	_	_	I-Premise
457	latanoprost	_	_	I-Premise
458	,	_	_	I-Premise
459	17.8	_	_	I-Premise
460	%	_	_	I-Premise
461	;	_	_	I-Premise
462	P	_	_	I-Premise
463	<	_	_	I-Premise
464	0.001	_	_	I-Premise
465	)	_	_	I-Premise
466	.	_	_	I-Premise

467	Both	_	_	B-Claim
468	treatments	_	_	I-Claim
469	were	_	_	I-Claim
470	well	_	_	I-Claim
471	tolerated	_	_	I-Claim
472	.	_	_	I-Claim

473	Similar	_	_	B-Premise
474	proportions	_	_	I-Premise
475	of	_	_	I-Premise
476	patients	_	_	I-Premise
477	in	_	_	I-Premise
478	the	_	_	I-Premise
479	fixed-combination	_	_	I-Premise
480	and	_	_	I-Premise
481	latanoprost	_	_	I-Premise
482	groups	_	_	I-Premise
483	reported	_	_	I-Premise
484	at	_	_	I-Premise
485	least	_	_	I-Premise
486	1	_	_	I-Premise
487	treatment-emergent	_	_	I-Premise
488	AE	_	_	I-Premise
489	(	_	_	I-Premise
490	10.9	_	_	I-Premise
491	%	_	_	I-Premise
492	and	_	_	I-Premise
493	12.1	_	_	I-Premise
494	%	_	_	I-Premise
495	,	_	_	I-Premise
496	respectively	_	_	I-Premise
497	)	_	_	I-Premise
498	.	_	_	I-Premise

499	In	_	_	O
500	this	_	_	O
501	selected	_	_	O
502	population	_	_	O
503	of	_	_	O
504	patients	_	_	B-Claim
505	with	_	_	I-Claim
506	an	_	_	I-Claim
507	inadequate	_	_	I-Claim
508	initial	_	_	I-Claim
509	IOP	_	_	I-Claim
510	response	_	_	I-Claim
511	to	_	_	I-Claim
512	latanoprost	_	_	I-Claim
513	,	_	_	I-Claim
514	switching	_	_	I-Claim
515	to	_	_	I-Claim
516	fixed-combination	_	_	I-Claim
517	latanoprosttimolol	_	_	I-Claim
518	resulted	_	_	I-Claim
519	in	_	_	I-Claim
520	a	_	_	I-Claim
521	greater	_	_	I-Claim
522	decrease	_	_	I-Claim
523	in	_	_	I-Claim
524	IOP	_	_	I-Claim
525	and	_	_	I-Claim
526	similar	_	_	I-Claim
527	tolerability	_	_	I-Claim
528	compared	_	_	I-Claim
529	with	_	_	I-Claim
530	continuing	_	_	I-Claim
531	latanoprost	_	_	I-Claim
532	therapy	_	_	I-Claim
533	.	_	_	I-Claim


1	To	_	_	O
2	verify	_	_	O
3	the	_	_	O
4	safety	_	_	O
5	and	_	_	O
6	efficacy	_	_	O
7	of	_	_	O
8	Ologen	_	_	O
9	(	_	_	O
10	OLO	_	_	O
11	)	_	_	O
12	implant	_	_	O
13	as	_	_	O
14	adjuvant	_	_	O
15	compared	_	_	O
16	with	_	_	O
17	low-dosage	_	_	O
18	mitomycin-C	_	_	O
19	(	_	_	O
20	MMC	_	_	O
21	)	_	_	O
22	in	_	_	O
23	trabeculectomy	_	_	O
24	.	_	_	O

25	This	_	_	O
26	was	_	_	O
27	a	_	_	O
28	prospective	_	_	O
29	randomized	_	_	O
30	clinical	_	_	O
31	trial	_	_	O
32	with	_	_	O
33	a	_	_	O
34	24-month	_	_	O
35	follow-up	_	_	O
36	.	_	_	O

37	Forty	_	_	O
38	glaucoma	_	_	O
39	patients	_	_	O
40	(	_	_	O
41	40	_	_	O
42	eyes	_	_	O
43	)	_	_	O
44	were	_	_	O
45	assigned	_	_	O
46	to	_	_	O
47	trabeculectomy	_	_	O
48	with	_	_	O
49	MMC	_	_	O
50	or	_	_	O
51	OLO	_	_	O
52	.	_	_	O

53	Primary	_	_	O
54	outcome	_	_	O
55	includes	_	_	O
56	target	_	_	O
57	IOP	_	_	O
58	at	_	_	O
59	≤21	_	_	O
60	,	_	_	O
61	≤17	_	_	O
62	,	_	_	O
63	and	_	_	O
64	≤15	_	_	O
65	mmHg	_	_	O
66	;	_	_	O
67	complete	_	_	O
68	(	_	_	O
69	target	_	_	O
70	IOP	_	_	O
71	without	_	_	O
72	medications	_	_	O
73	)	_	_	O
74	,	_	_	O
75	and	_	_	O
76	qualified	_	_	O
77	success	_	_	O
78	(	_	_	O
79	target	_	_	O
80	IOP	_	_	O
81	regardless	_	_	O
82	of	_	_	O
83	medications	_	_	O
84	)	_	_	O
85	.	_	_	O

86	Secondary	_	_	O
87	outcomes	_	_	O
88	include	_	_	O
89	bleb	_	_	O
90	evaluation	_	_	O
91	,	_	_	O
92	according	_	_	O
93	to	_	_	O
94	Moorfields	_	_	O
95	Bleb	_	_	O
96	Grading	_	_	O
97	System	_	_	O
98	(	_	_	O
99	MBGS	_	_	O
100	)	_	_	O
101	;	_	_	O
102	spectral	_	_	O
103	domain	_	_	O
104	optical	_	_	O
105	coherence	_	_	O
106	tomography	_	_	O
107	(	_	_	O
108	SD-OCT	_	_	O
109	)	_	_	O
110	examination	_	_	O
111	;	_	_	O
112	number	_	_	O
113	of	_	_	O
114	glaucoma	_	_	O
115	medications	_	_	O
116	;	_	_	O
117	and	_	_	O
118	frequency	_	_	O
119	of	_	_	O
120	postoperative	_	_	O
121	adjunctive	_	_	O
122	procedures	_	_	O
123	and	_	_	O
124	complications	_	_	O
125	.	_	_	O

126	The	_	_	O
127	mean	_	_	O
128	preoperative	_	_	O
129	IOP	_	_	O
130	was	_	_	O
131	26.5	_	_	O
132	(	_	_	O
133	±5.2	_	_	O
134	)	_	_	O
135	in	_	_	O
136	MMC	_	_	O
137	and	_	_	O
138	27.3	_	_	O
139	(	_	_	O
140	±6.0	_	_	O
141	)	_	_	O
142	in	_	_	O
143	OLO	_	_	O
144	eyes	_	_	O
145	,	_	_	O
146	without	_	_	O
147	statistical	_	_	O
148	significance	_	_	O
149	.	_	_	O

150	One-day	_	_	B-Premise
151	postoperatively	_	_	I-Premise
152	,	_	_	I-Premise
153	the	_	_	I-Premise
154	IOP	_	_	I-Premise
155	dropped	_	_	I-Premise
156	to	_	_	I-Premise
157	5.2	_	_	I-Premise
158	(	_	_	I-Premise
159	±3.5	_	_	I-Premise
160	)	_	_	I-Premise
161	and	_	_	I-Premise
162	9.2	_	_	I-Premise
163	(	_	_	I-Premise
164	±5.5	_	_	I-Premise
165	)	_	_	I-Premise
166	mm	_	_	I-Premise
167	Hg	_	_	I-Premise
168	,	_	_	I-Premise
169	respectively	_	_	I-Premise
170	(	_	_	I-Premise
171	P=0.009	_	_	I-Premise
172	)	_	_	I-Premise
173	.	_	_	I-Premise

174	The	_	_	B-Premise
175	IOP	_	_	I-Premise
176	reduction	_	_	I-Premise
177	was	_	_	I-Premise
178	significant	_	_	I-Premise
179	at	_	_	I-Premise
180	end	_	_	I-Premise
181	point	_	_	I-Premise
182	in	_	_	I-Premise
183	all	_	_	I-Premise
184	groups	_	_	I-Premise
185	(	_	_	I-Premise
186	P=0.01	_	_	I-Premise
187	)	_	_	I-Premise
188	,	_	_	I-Premise
189	with	_	_	I-Premise
190	a	_	_	I-Premise
191	mean	_	_	I-Premise
192	IOP	_	_	I-Premise
193	of	_	_	I-Premise
194	16.0	_	_	I-Premise
195	(	_	_	I-Premise
196	±2.9	_	_	I-Premise
197	)	_	_	I-Premise
198	and	_	_	I-Premise
199	16.5	_	_	I-Premise
200	(	_	_	I-Premise
201	±2.1	_	_	I-Premise
202	)	_	_	I-Premise
203	mm	_	_	I-Premise
204	Hg	_	_	I-Premise
205	in	_	_	I-Premise
206	MMC	_	_	I-Premise
207	and	_	_	I-Premise
208	OLO	_	_	I-Premise
209	,	_	_	I-Premise
210	respectively	_	_	I-Premise
211	.	_	_	I-Premise

212	The	_	_	B-Premise
213	rates	_	_	I-Premise
214	and	_	_	I-Premise
215	Kaplan-Meier	_	_	I-Premise
216	curves	_	_	I-Premise
217	did	_	_	I-Premise
218	not	_	_	I-Premise
219	differ	_	_	I-Premise
220	for	_	_	I-Premise
221	both	_	_	I-Premise
222	complete	_	_	I-Premise
223	and	_	_	I-Premise
224	qualified	_	_	I-Premise
225	success	_	_	I-Premise
226	at	_	_	I-Premise
227	any	_	_	I-Premise
228	target	_	_	I-Premise
229	IOP	_	_	I-Premise
230	.	_	_	I-Premise

231	The	_	_	B-Premise
232	bleb	_	_	I-Premise
233	height	_	_	I-Premise
234	in	_	_	I-Premise
235	OLO	_	_	I-Premise
236	group	_	_	I-Premise
237	was	_	_	I-Premise
238	higher	_	_	I-Premise
239	than	_	_	I-Premise
240	MMC	_	_	I-Premise
241	one	_	_	I-Premise
242	(	_	_	I-Premise
243	P	_	_	I-Premise
244	<	_	_	I-Premise
245	0.05	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	SD-OCT	_	_	B-Premise
249	analysis	_	_	I-Premise
250	of	_	_	I-Premise
251	successful/unsuccessful	_	_	I-Premise
252	bleb	_	_	I-Premise
253	in	_	_	I-Premise
254	patients	_	_	I-Premise
255	with	_	_	I-Premise
256	or	_	_	I-Premise
257	without	_	_	I-Premise
258	complete	_	_	I-Premise
259	success	_	_	I-Premise
260	at	_	_	I-Premise
261	IOP	_	_	I-Premise
262	=17	_	_	I-Premise
263	mm	_	_	I-Premise
264	Hg	_	_	I-Premise
265	indicated	_	_	I-Premise
266	a	_	_	I-Premise
267	sensitivity	_	_	I-Premise
268	of	_	_	I-Premise
269	83	_	_	I-Premise
270	%	_	_	I-Premise
271	and	_	_	I-Premise
272	73	_	_	I-Premise
273	%	_	_	I-Premise
274	and	_	_	I-Premise
275	a	_	_	I-Premise
276	specificity	_	_	I-Premise
277	of	_	_	I-Premise
278	75	_	_	I-Premise
279	%	_	_	I-Premise
280	and	_	_	I-Premise
281	67	_	_	I-Premise
282	%	_	_	I-Premise
283	,	_	_	I-Premise
284	respectively	_	_	I-Premise
285	,	_	_	I-Premise
286	for	_	_	I-Premise
287	MMC	_	_	I-Premise
288	and	_	_	I-Premise
289	OLO	_	_	I-Premise
290	groups	_	_	I-Premise
291	.	_	_	I-Premise

292	No	_	_	B-Premise
293	adverse	_	_	I-Premise
294	reaction	_	_	I-Premise
295	to	_	_	I-Premise
296	OLO	_	_	I-Premise
297	was	_	_	I-Premise
298	noted	_	_	I-Premise
299	.	_	_	I-Premise

300	Our	_	_	B-Claim
301	results	_	_	I-Claim
302	suggest	_	_	I-Claim
303	that	_	_	I-Claim
304	OLO	_	_	I-Claim
305	implant	_	_	I-Claim
306	could	_	_	I-Claim
307	be	_	_	I-Claim
308	a	_	_	I-Claim
309	new	_	_	I-Claim
310	,	_	_	I-Claim
311	safe	_	_	I-Claim
312	,	_	_	I-Claim
313	and	_	_	I-Claim
314	effective	_	_	I-Claim
315	alternative	_	_	I-Claim
316	to	_	_	I-Claim
317	MMC	_	_	I-Claim
318	,	_	_	I-Claim
319	with	_	_	I-Claim
320	similar	_	_	I-Claim
321	long-term	_	_	I-Claim
322	success	_	_	I-Claim
323	rate	_	_	I-Claim
324	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure-lowering	_	_	O
5	effect	_	_	O
6	of	_	_	O
7	latanoprost	_	_	O
8	with	_	_	O
9	that	_	_	O
10	of	_	_	O
11	dorzolamide	_	_	O
12	when	_	_	O
13	added	_	_	O
14	to	_	_	O
15	timolol	_	_	O
16	.	_	_	O

17	This	_	_	O
18	randomized	_	_	O
19	,	_	_	O
20	open-label	_	_	O
21	study	_	_	O
22	with	_	_	O
23	two	_	_	O
24	parallel	_	_	O
25	groups	_	_	O
26	was	_	_	O
27	conducted	_	_	O
28	in	_	_	O
29	five	_	_	O
30	centers	_	_	O
31	in	_	_	O
32	Greece	_	_	O
33	.	_	_	O

34	The	_	_	O
35	study	_	_	O
36	enrolled	_	_	O
37	148	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	inadequately	_	_	O
41	controlled	_	_	O
42	open-angle	_	_	O
43	or	_	_	O
44	pseudoexfoliation	_	_	O
45	glaucoma	_	_	O
46	(	_	_	O
47	intraocular	_	_	O
48	pressure	_	_	O
49	of	_	_	O
50	at	_	_	O
51	least	_	_	O
52	22	_	_	O
53	mm	_	_	O
54	Hg	_	_	O
55	)	_	_	O
56	or	_	_	O
57	ocular	_	_	O
58	hypertension	_	_	O
59	(	_	_	O
60	intraocular	_	_	O
61	pressure	_	_	O
62	of	_	_	O
63	at	_	_	O
64	least	_	_	O
65	27	_	_	O
66	mm	_	_	O
67	Hg	_	_	O
68	)	_	_	O
69	who	_	_	O
70	were	_	_	O
71	receiving	_	_	O
72	monotherapy	_	_	O
73	with	_	_	O
74	a	_	_	O
75	beta-blocker	_	_	O
76	or	_	_	O
77	dual	_	_	O
78	therapy	_	_	O
79	in	_	_	O
80	which	_	_	O
81	one	_	_	O
82	of	_	_	O
83	the	_	_	O
84	agents	_	_	O
85	was	_	_	O
86	a	_	_	O
87	beta-blocker	_	_	O
88	.	_	_	O

89	The	_	_	O
90	patients	_	_	O
91	were	_	_	O
92	switched	_	_	O
93	to	_	_	O
94	timolol	_	_	O
95	0.5	_	_	O
96	%	_	_	O
97	twice	_	_	O
98	daily	_	_	O
99	for	_	_	O
100	2	_	_	O
101	to	_	_	O
102	4	_	_	O
103	weeks	_	_	O
104	(	_	_	O
105	run-in	_	_	O
106	period	_	_	O
107	)	_	_	O
108	before	_	_	O
109	the	_	_	O
110	start	_	_	O
111	of	_	_	O
112	the	_	_	O
113	study	_	_	O
114	(	_	_	O
115	baseline	_	_	O
116	)	_	_	O
117	.	_	_	O

118	At	_	_	O
119	baseline	_	_	O
120	,	_	_	O
121	the	_	_	O
122	patients	_	_	O
123	were	_	_	O
124	randomized	_	_	O
125	to	_	_	O
126	receive	_	_	O
127	latanoprost	_	_	O
128	0.005	_	_	O
129	%	_	_	O
130	once	_	_	O
131	daily	_	_	O
132	or	_	_	O
133	dorzolamide	_	_	O
134	2	_	_	O
135	%	_	_	O
136	twice	_	_	O
137	daily	_	_	O
138	as	_	_	O
139	add-on	_	_	O
140	therapy	_	_	O
141	to	_	_	O
142	timolol	_	_	O
143	.	_	_	O

144	The	_	_	O
145	intraocular	_	_	O
146	pressure	_	_	O
147	was	_	_	O
148	recorded	_	_	O
149	at	_	_	O
150	9:30	_	_	O
151	AM	_	_	O
152	,	_	_	O
153	12:30	_	_	O
154	PM	_	_	O
155	,	_	_	O
156	and	_	_	O
157	3:30	_	_	O
158	PM	_	_	O
159	at	_	_	O
160	baseline	_	_	O
161	and	_	_	O
162	at	_	_	O
163	3	_	_	O
164	months	_	_	O
165	.	_	_	O

166	Safety	_	_	O
167	was	_	_	O
168	followed	_	_	O
169	throughout	_	_	O
170	the	_	_	O
171	study	_	_	O
172	.	_	_	O

173	The	_	_	B-Premise
174	diurnal	_	_	I-Premise
175	intraocular	_	_	I-Premise
176	pressure	_	_	I-Premise
177	reduction	_	_	I-Premise
178	was	_	_	I-Premise
179	significant	_	_	I-Premise
180	in	_	_	I-Premise
181	both	_	_	I-Premise
182	groups	_	_	I-Premise
183	(	_	_	I-Premise
184	P	_	_	I-Premise
185	<	_	_	I-Premise
186	0.001	_	_	I-Premise
187	)	_	_	I-Premise
188	.	_	_	I-Premise

189	The	_	_	B-Premise
190	mean	_	_	I-Premise
191	intraocular	_	_	I-Premise
192	pressure	_	_	I-Premise
193	reduction	_	_	I-Premise
194	from	_	_	I-Premise
195	baseline	_	_	I-Premise
196	was	_	_	I-Premise
197	32	_	_	I-Premise
198	%	_	_	I-Premise
199	for	_	_	I-Premise
200	the	_	_	I-Premise
201	latanoprost	_	_	I-Premise
202	plus	_	_	I-Premise
203	timolol	_	_	I-Premise
204	group	_	_	I-Premise
205	and	_	_	I-Premise
206	20	_	_	I-Premise
207	%	_	_	I-Premise
208	for	_	_	I-Premise
209	the	_	_	I-Premise
210	dorzolamide	_	_	I-Premise
211	plus	_	_	I-Premise
212	timolol	_	_	I-Premise
213	group	_	_	I-Premise
214	.	_	_	I-Premise

215	The	_	_	B-Premise
216	least	_	_	I-Premise
217	square	_	_	I-Premise
218	estimate	_	_	I-Premise
219	of	_	_	I-Premise
220	the	_	_	I-Premise
221	mean	_	_	I-Premise
222	diurnal	_	_	I-Premise
223	intraocular	_	_	I-Premise
224	pressure	_	_	I-Premise
225	reduction	_	_	I-Premise
226	after	_	_	I-Premise
227	3	_	_	I-Premise
228	months	_	_	I-Premise
229	was	_	_	I-Premise
230	-7.06	_	_	I-Premise
231	mm	_	_	I-Premise
232	Hg	_	_	I-Premise
233	in	_	_	I-Premise
234	the	_	_	I-Premise
235	latanoprost	_	_	I-Premise
236	plus	_	_	I-Premise
237	timolol	_	_	I-Premise
238	group	_	_	I-Premise
239	and	_	_	I-Premise
240	-4.44	_	_	I-Premise
241	mm	_	_	I-Premise
242	Hg	_	_	I-Premise
243	in	_	_	I-Premise
244	the	_	_	I-Premise
245	dorzolamide	_	_	I-Premise
246	plus	_	_	I-Premise
247	timolol	_	_	I-Premise
248	group	_	_	I-Premise
249	(	_	_	I-Premise
250	P	_	_	I-Premise
251	<	_	_	I-Premise
252	0.001	_	_	I-Premise
253	)	_	_	I-Premise
254	.	_	_	I-Premise

255	Drugs	_	_	B-Claim
256	administered	_	_	I-Claim
257	in	_	_	I-Claim
258	both	_	_	I-Claim
259	treatment	_	_	I-Claim
260	groups	_	_	I-Claim
261	were	_	_	I-Claim
262	well	_	_	I-Claim
263	tolerated	_	_	I-Claim
264	.	_	_	I-Claim

265	This	_	_	B-Claim
266	study	_	_	I-Claim
267	clearly	_	_	I-Claim
268	showed	_	_	I-Claim
269	that	_	_	I-Claim
270	the	_	_	I-Claim
271	additive	_	_	I-Claim
272	diurnal	_	_	I-Claim
273	intraocular	_	_	I-Claim
274	pressure-lowering	_	_	I-Claim
275	effect	_	_	I-Claim
276	of	_	_	I-Claim
277	latanoprost	_	_	I-Claim
278	is	_	_	I-Claim
279	superior	_	_	I-Claim
280	to	_	_	I-Claim
281	that	_	_	I-Claim
282	of	_	_	I-Claim
283	dorzolamide	_	_	I-Claim
284	in	_	_	I-Claim
285	patients	_	_	I-Claim
286	treated	_	_	I-Claim
287	with	_	_	I-Claim
288	timolol	_	_	I-Claim
289	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	latanoprost	_	_	O
8	or	_	_	O
9	brimonidine	_	_	O
10	in	_	_	O
11	patients	_	_	O
12	with	_	_	O
13	elevated	_	_	O
14	intraocular	_	_	O
15	pressure	_	_	O
16	(	_	_	O
17	IOP	_	_	O
18	)	_	_	O
19	.	_	_	O

20	This	_	_	O
21	prospective	_	_	O
22	,	_	_	O
23	randomized	_	_	O
24	,	_	_	O
25	masked-evaluator	_	_	O
26	,	_	_	O
27	parallel-group	_	_	O
28	,	_	_	O
29	multicenter	_	_	O
30	study	_	_	O
31	in	_	_	O
32	the	_	_	O
33	United	_	_	O
34	States	_	_	O
35	included	_	_	O
36	patients	_	_	O
37	with	_	_	O
38	primary	_	_	O
39	open	_	_	O
40	angle	_	_	O
41	glaucoma	_	_	O
42	or	_	_	O
43	ocular	_	_	O
44	hypertension	_	_	O
45	.	_	_	O

46	Patients	_	_	O
47	received	_	_	O
48	latanoprost	_	_	O
49	0.005	_	_	O
50	%	_	_	O
51	once	_	_	O
52	daily	_	_	O
53	(	_	_	O
54	8:00	_	_	O
55	AM	_	_	O
56	;	_	_	O
57	n	_	_	O
58	=	_	_	O
59	152	_	_	O
60	)	_	_	O
61	or	_	_	O
62	brimonidine	_	_	O
63	tartrate	_	_	O
64	0.2	_	_	O
65	%	_	_	O
66	twice	_	_	O
67	daily	_	_	O
68	(	_	_	O
69	8:00	_	_	O
70	AM	_	_	O
71	and	_	_	O
72	8:00	_	_	O
73	PM	_	_	O
74	;	_	_	O
75	n	_	_	O
76	=	_	_	O
77	151	_	_	O
78	)	_	_	O
79	.	_	_	O

80	Patients	_	_	O
81	underwent	_	_	O
82	evaluation	_	_	O
83	at	_	_	O
84	screening	_	_	O
85	,	_	_	O
86	baseline	_	_	O
87	(	_	_	O
88	randomization	_	_	O
89	)	_	_	O
90	,	_	_	O
91	and	_	_	O
92	after	_	_	O
93	0.5	_	_	O
94	,	_	_	O
95	3	_	_	O
96	,	_	_	O
97	and	_	_	O
98	6	_	_	O
99	months	_	_	O
100	of	_	_	O
101	treatment	_	_	O
102	.	_	_	O

103	IOP	_	_	O
104	was	_	_	O
105	measured	_	_	O
106	at	_	_	O
107	8:00	_	_	O
108	AM	_	_	O
109	,	_	_	O
110	10:00	_	_	O
111	AM	_	_	O
112	,	_	_	O
113	noon	_	_	O
114	,	_	_	O
115	and	_	_	O
116	4:00	_	_	O
117	PM	_	_	O
118	at	_	_	O
119	baseline	_	_	O
120	and	_	_	O
121	the	_	_	O
122	months	_	_	O
123	3	_	_	O
124	and	_	_	O
125	6	_	_	O
126	visits	_	_	O
127	,	_	_	O
128	and	_	_	O
129	at	_	_	O
130	8:00	_	_	O
131	AM	_	_	O
132	only	_	_	O
133	at	_	_	O
134	week	_	_	O
135	2	_	_	O
136	.	_	_	O

137	The	_	_	O
138	main	_	_	O
139	outcome	_	_	O
140	measure	_	_	O
141	was	_	_	O
142	the	_	_	O
143	difference	_	_	O
144	in	_	_	O
145	diurnal	_	_	O
146	IOP	_	_	O
147	change	_	_	O
148	from	_	_	O
149	baseline	_	_	O
150	to	_	_	O
151	month	_	_	O
152	6	_	_	O
153	between	_	_	O
154	treatment	_	_	O
155	groups	_	_	O
156	.	_	_	O

157	Adverse	_	_	O
158	events	_	_	O
159	were	_	_	O
160	recorded	_	_	O
161	at	_	_	O
162	each	_	_	O
163	visit	_	_	O
164	.	_	_	O

165	Baseline	_	_	O
166	mean	_	_	O
167	diurnal	_	_	O
168	IOP	_	_	O
169	levels	_	_	O
170	were	_	_	O
171	similar	_	_	O
172	between	_	_	O
173	groups	_	_	O
174	.	_	_	O

175	At	_	_	B-Premise
176	month	_	_	I-Premise
177	6	_	_	I-Premise
178	,	_	_	I-Premise
179	the	_	_	I-Premise
180	adjusted	_	_	I-Premise
181	mean	_	_	I-Premise
182	(	_	_	I-Premise
183	+/-	_	_	I-Premise
184	SEM	_	_	I-Premise
185	)	_	_	I-Premise
186	diurnal	_	_	I-Premise
187	IOP	_	_	I-Premise
188	reduction	_	_	I-Premise
189	was	_	_	I-Premise
190	5.7	_	_	I-Premise
191	+/-	_	_	I-Premise
192	0.3	_	_	I-Premise
193	mm	_	_	I-Premise
194	Hg	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	latanoprost	_	_	I-Premise
198	group	_	_	I-Premise
199	and	_	_	I-Premise
200	3.1	_	_	I-Premise
201	+/-	_	_	I-Premise
202	0.3	_	_	I-Premise
203	mm	_	_	I-Premise
204	Hg	_	_	I-Premise
205	in	_	_	I-Premise
206	patients	_	_	I-Premise
207	receiving	_	_	I-Premise
208	brimonidine	_	_	I-Premise
209	(	_	_	I-Premise
210	P	_	_	I-Premise
211	<	_	_	I-Premise
212	0.001	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	The	_	_	B-Premise
216	mean	_	_	I-Premise
217	difference	_	_	I-Premise
218	in	_	_	I-Premise
219	diurnal	_	_	I-Premise
220	IOP	_	_	I-Premise
221	reduction	_	_	I-Premise
222	was	_	_	I-Premise
223	2.5	_	_	I-Premise
224	+/-	_	_	I-Premise
225	0.3	_	_	I-Premise
226	mm	_	_	I-Premise
227	Hg	_	_	I-Premise
228	(	_	_	I-Premise
229	95	_	_	I-Premise
230	%	_	_	I-Premise
231	CI	_	_	I-Premise
232	:	_	_	I-Premise
233	1.9	_	_	I-Premise
234	,	_	_	I-Premise
235	3.2	_	_	I-Premise
236	;	_	_	I-Premise
237	P	_	_	I-Premise
238	<	_	_	I-Premise
239	0.001	_	_	I-Premise
240	)	_	_	I-Premise
241	.	_	_	I-Premise

242	Five	_	_	B-Premise
243	times	_	_	I-Premise
244	more	_	_	I-Premise
245	patients	_	_	I-Premise
246	receiving	_	_	I-Premise
247	brimonidine	_	_	I-Premise
248	than	_	_	I-Premise
249	latanoprost	_	_	I-Premise
250	were	_	_	I-Premise
251	withdrawn	_	_	I-Premise
252	from	_	_	I-Premise
253	the	_	_	I-Premise
254	study	_	_	I-Premise
255	due	_	_	I-Premise
256	to	_	_	I-Premise
257	adverse	_	_	I-Premise
258	events	_	_	I-Premise
259	.	_	_	I-Premise

260	Latanoprost	_	_	B-Claim
261	instilled	_	_	I-Claim
262	once	_	_	I-Claim
263	daily	_	_	I-Claim
264	is	_	_	I-Claim
265	more	_	_	I-Claim
266	effective	_	_	I-Claim
267	and	_	_	I-Claim
268	better	_	_	I-Claim
269	tolerated	_	_	I-Claim
270	than	_	_	I-Claim
271	brimonidine	_	_	I-Claim
272	administered	_	_	I-Claim
273	twice	_	_	I-Claim
274	daily	_	_	I-Claim
275	for	_	_	I-Claim
276	the	_	_	I-Claim
277	treatment	_	_	I-Claim
278	of	_	_	I-Claim
279	patients	_	_	I-Claim
280	with	_	_	I-Claim
281	glaucoma	_	_	I-Claim
282	or	_	_	I-Claim
283	ocular	_	_	I-Claim
284	hypertension	_	_	I-Claim
285	.	_	_	I-Claim

286	During	_	_	B-Claim
287	therapy	_	_	I-Claim
288	,	_	_	I-Claim
289	the	_	_	I-Claim
290	range	_	_	I-Claim
291	of	_	_	I-Claim
292	daily	_	_	I-Claim
293	fluctuation	_	_	I-Claim
294	of	_	_	I-Claim
295	IOP	_	_	I-Claim
296	is	_	_	I-Claim
297	less	_	_	I-Claim
298	for	_	_	I-Claim
299	latanoprost	_	_	I-Claim
300	compared	_	_	I-Claim
301	with	_	_	I-Claim
302	brimonidine	_	_	I-Claim
303	.	_	_	I-Claim


0	Brimonidin	_	_	O
1	tartrate	_	_	O
2	is	_	_	O
3	a	_	_	O
4	highly	_	_	O
5	selective	_	_	O
6	alpha	_	_	O
7	2-agonist	_	_	O
8	.	_	_	O

9	This	_	_	O
10	study	_	_	O
11	investigates	_	_	O
12	the	_	_	O
13	safety	_	_	O
14	and	_	_	O
15	efficacy	_	_	O
16	of	_	_	O
17	0.2	_	_	O
18	%	_	_	O
19	brimonidine	_	_	O
20	administered	_	_	O
21	twice	_	_	O
22	daily	_	_	O
23	for	_	_	O
24	1	_	_	O
25	year	_	_	O
26	in	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	glaucoma	_	_	O
30	or	_	_	O
31	ocular	_	_	O
32	hypertension	_	_	O
33	.	_	_	O

34	The	_	_	O
35	study	_	_	O
36	design	_	_	O
37	was	_	_	O
38	a	_	_	O
39	multicenter	_	_	O
40	,	_	_	O
41	double-masked	_	_	O
42	,	_	_	O
43	randomized	_	_	O
44	,	_	_	O
45	parallel-group	_	_	O
46	,	_	_	O
47	active-controlled	_	_	O
48	comparison	_	_	O
49	clinical	_	_	O
50	trial	_	_	O
51	.	_	_	O

52	Subjects	_	_	O
53	instilled	_	_	O
54	0.2	_	_	O
55	%	_	_	O
56	brimonidine	_	_	O
57	or	_	_	O
58	0.5	_	_	O
59	%	_	_	O
60	timolol	_	_	O
61	maleate	_	_	O
62	twice	_	_	O
63	daily	_	_	O
64	for	_	_	O
65	12	_	_	O
66	months	_	_	O
67	.	_	_	O

68	Subjects	_	_	O
69	were	_	_	O
70	examined	_	_	O
71	at	_	_	O
72	baseline	_	_	O
73	,	_	_	O
74	week	_	_	O
75	1	_	_	O
76	,	_	_	O
77	and	_	_	O
78	months	_	_	O
79	1	_	_	O
80	,	_	_	O
81	2	_	_	O
82	,	_	_	O
83	3	_	_	O
84	,	_	_	O
85	6	_	_	O
86	,	_	_	O
87	9	_	_	O
88	,	_	_	O
89	and	_	_	O
90	12	_	_	O
91	.	_	_	O

92	A	_	_	O
93	subset	_	_	O
94	of	_	_	O
95	subjects	_	_	O
96	was	_	_	O
97	examined	_	_	O
98	at	_	_	O
99	week	_	_	O
100	2	_	_	O
101	.	_	_	O

102	Of	_	_	O
103	443	_	_	O
104	subjects	_	_	O
105	enrolled	_	_	O
106	in	_	_	O
107	this	_	_	O
108	study	_	_	O
109	,	_	_	O
110	374	_	_	O
111	met	_	_	O
112	the	_	_	O
113	entry	_	_	O
114	criteria	_	_	O
115	;	_	_	O
116	186	_	_	O
117	received	_	_	O
118	brimonidine	_	_	O
119	and	_	_	O
120	188	_	_	O
121	received	_	_	O
122	timolol	_	_	O
123	.	_	_	O

124	Brimonidine-treated	_	_	B-Premise
125	subjects	_	_	I-Premise
126	showed	_	_	I-Premise
127	an	_	_	I-Premise
128	overall	_	_	I-Premise
129	mean	_	_	I-Premise
130	peak	_	_	I-Premise
131	reduction	_	_	I-Premise
132	in	_	_	I-Premise
133	intraocular	_	_	I-Premise
134	pressure	_	_	I-Premise
135	(	_	_	I-Premise
136	IOP	_	_	I-Premise
137	)	_	_	I-Premise
138	of	_	_	I-Premise
139	6.5	_	_	I-Premise
140	mm	_	_	I-Premise
141	Hg	_	_	I-Premise
142	;	_	_	I-Premise
143	timolol-treated	_	_	I-Premise
144	subjects	_	_	I-Premise
145	had	_	_	I-Premise
146	a	_	_	I-Premise
147	mean	_	_	I-Premise
148	peak	_	_	I-Premise
149	reduction	_	_	I-Premise
150	in	_	_	I-Premise
151	IOP	_	_	I-Premise
152	of	_	_	I-Premise
153	6.1	_	_	I-Premise
154	mm	_	_	I-Premise
155	Hg	_	_	I-Premise
156	.	_	_	I-Premise

157	Brimonidine	_	_	B-Premise
158	lowered	_	_	I-Premise
159	mean	_	_	I-Premise
160	peak	_	_	I-Premise
161	IOP	_	_	I-Premise
162	significantly	_	_	I-Premise
163	more	_	_	I-Premise
164	than	_	_	I-Premise
165	timolol	_	_	I-Premise
166	at	_	_	I-Premise
167	week	_	_	I-Premise
168	2	_	_	I-Premise
169	and	_	_	I-Premise
170	month	_	_	I-Premise
171	3	_	_	I-Premise
172	(	_	_	I-Premise
173	P	_	_	I-Premise
174	<	_	_	I-Premise
175	.03	_	_	I-Premise
176	)	_	_	I-Premise
177	;	_	_	O
178	no	_	_	O
179	significant	_	_	O
180	difference	_	_	O
181	was	_	_	O
182	observed	_	_	O
183	between	_	_	O
184	the	_	_	O
185	groups	_	_	O
186	for	_	_	O
187	this	_	_	O
188	variable	_	_	O
189	at	_	_	O
190	other	_	_	O
191	visits	_	_	O
192	throughout	_	_	O
193	the	_	_	O
194	1-year	_	_	O
195	course	_	_	O
196	of	_	_	O
197	the	_	_	O
198	study	_	_	O
199	.	_	_	O

200	No	_	_	B-Premise
201	evidence	_	_	I-Premise
202	of	_	_	I-Premise
203	tachyphylaxis	_	_	I-Premise
204	was	_	_	I-Premise
205	seen	_	_	I-Premise
206	in	_	_	I-Premise
207	either	_	_	I-Premise
208	group	_	_	I-Premise
209	.	_	_	I-Premise

210	Allergy	_	_	B-Premise
211	was	_	_	I-Premise
212	seen	_	_	I-Premise
213	in	_	_	I-Premise
214	9	_	_	I-Premise
215	%	_	_	I-Premise
216	of	_	_	I-Premise
217	subjects	_	_	I-Premise
218	treated	_	_	I-Premise
219	with	_	_	I-Premise
220	brimonidine	_	_	I-Premise
221	.	_	_	I-Premise

222	Dry	_	_	B-Premise
223	mouth	_	_	I-Premise
224	was	_	_	I-Premise
225	more	_	_	I-Premise
226	common	_	_	I-Premise
227	in	_	_	I-Premise
228	the	_	_	I-Premise
229	brimonidine-treated	_	_	I-Premise
230	group	_	_	I-Premise
231	than	_	_	I-Premise
232	in	_	_	I-Premise
233	the	_	_	I-Premise
234	timolol-treated	_	_	I-Premise
235	group	_	_	I-Premise
236	(	_	_	I-Premise
237	33.0	_	_	I-Premise
238	%	_	_	I-Premise
239	vs	_	_	I-Premise
240	19.4	_	_	I-Premise
241	%	_	_	I-Premise
242	)	_	_	I-Premise
243	,	_	_	I-Premise
244	but	_	_	O
245	complaints	_	_	B-Premise
246	of	_	_	I-Premise
247	burning	_	_	I-Premise
248	and	_	_	I-Premise
249	stinging	_	_	I-Premise
250	were	_	_	I-Premise
251	more	_	_	I-Premise
252	common	_	_	I-Premise
253	in	_	_	I-Premise
254	the	_	_	I-Premise
255	timolol-treated	_	_	I-Premise
256	group	_	_	I-Premise
257	(	_	_	I-Premise
258	41.9	_	_	I-Premise
259	%	_	_	I-Premise
260	)	_	_	I-Premise
261	than	_	_	I-Premise
262	in	_	_	I-Premise
263	the	_	_	I-Premise
264	brimonidine-treated	_	_	I-Premise
265	patients	_	_	I-Premise
266	(	_	_	I-Premise
267	28.1	_	_	I-Premise
268	%	_	_	I-Premise
269	)	_	_	I-Premise
270	.	_	_	I-Premise

271	Headache	_	_	B-Premise
272	,	_	_	I-Premise
273	fatigue	_	_	I-Premise
274	,	_	_	I-Premise
275	and	_	_	I-Premise
276	drowsiness	_	_	I-Premise
277	were	_	_	I-Premise
278	similar	_	_	I-Premise
279	in	_	_	I-Premise
280	the	_	_	I-Premise
281	2	_	_	I-Premise
282	groups	_	_	I-Premise
283	.	_	_	I-Premise

284	In	_	_	O
285	general	_	_	O
286	,	_	_	O
287	the	_	_	O
288	tolerance	_	_	O
289	to	_	_	O
290	medication	_	_	O
291	was	_	_	O
292	acceptable	_	_	O
293	.	_	_	O

294	Brimonidine	_	_	B-Claim
295	is	_	_	I-Claim
296	safe	_	_	I-Claim
297	and	_	_	I-Claim
298	effective	_	_	I-Claim
299	in	_	_	I-Claim
300	lowering	_	_	I-Claim
301	IOP	_	_	I-Claim
302	in	_	_	I-Claim
303	glaucomatous	_	_	I-Claim
304	eyes	_	_	I-Claim
305	.	_	_	I-Claim

306	Brimonidine	_	_	B-Claim
307	provides	_	_	I-Claim
308	a	_	_	I-Claim
309	sustained	_	_	I-Claim
310	long-term	_	_	I-Claim
311	ocular	_	_	I-Claim
312	hypotensive	_	_	I-Claim
313	effect	_	_	I-Claim
314	,	_	_	I-Claim
315	is	_	_	I-Claim
316	well	_	_	I-Claim
317	tolerated	_	_	I-Claim
318	,	_	_	I-Claim
319	and	_	_	I-Claim
320	has	_	_	I-Claim
321	a	_	_	I-Claim
322	low	_	_	I-Claim
323	rate	_	_	I-Claim
324	of	_	_	I-Claim
325	allergic	_	_	I-Claim
326	response	_	_	I-Claim
327	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	phacoemulsification	_	_	O
3	versus	_	_	O
4	trabeculectomy	_	_	O
5	with	_	_	O
6	adjunctive	_	_	O
7	mitomycin	_	_	O
8	C	_	_	O
9	in	_	_	O
10	medically	_	_	O
11	uncontrolled	_	_	O
12	chronic	_	_	O
13	angle-closure	_	_	O
14	glaucoma	_	_	O
15	(	_	_	O
16	CACG	_	_	O
17	)	_	_	O
18	without	_	_	O
19	cataract	_	_	O
20	.	_	_	O

21	Prospective	_	_	O
22	,	_	_	O
23	randomized	_	_	O
24	clinical	_	_	O
25	trial	_	_	O
26	.	_	_	O

27	Fifty	_	_	O
28	medically	_	_	O
29	uncontrolled	_	_	O
30	CACG	_	_	O
31	eyes	_	_	O
32	without	_	_	O
33	cataract	_	_	O
34	of	_	_	O
35	50	_	_	O
36	patients	_	_	O
37	.	_	_	O

38	Patients	_	_	O
39	were	_	_	O
40	randomized	_	_	O
41	into	_	_	O
42	undergoing	_	_	O
43	either	_	_	O
44	phacoemulsification	_	_	O
45	or	_	_	O
46	trabeculectomy	_	_	O
47	with	_	_	O
48	adjunctive	_	_	O
49	mitomycin	_	_	O
50	C.	_	_	O
51	After	_	_	O
52	surgery	_	_	O
53	,	_	_	O
54	patients	_	_	O
55	were	_	_	O
56	followed	_	_	O
57	up	_	_	O
58	every	_	_	O
59	3	_	_	O
60	months	_	_	O
61	for	_	_	O
62	2	_	_	O
63	years	_	_	O
64	.	_	_	O

65	Intraocular	_	_	O
66	pressure	_	_	O
67	(	_	_	O
68	IOP	_	_	O
69	)	_	_	O
70	and	_	_	O
71	requirement	_	_	O
72	for	_	_	O
73	glaucoma	_	_	O
74	drugs	_	_	O
75	.	_	_	O

76	Twenty-six	_	_	O
77	CACG	_	_	O
78	eyes	_	_	O
79	were	_	_	O
80	randomized	_	_	O
81	to	_	_	O
82	receive	_	_	O
83	phacoemulsification	_	_	O
84	,	_	_	O
85	and	_	_	O
86	24	_	_	O
87	eyes	_	_	O
88	underwent	_	_	O
89	trabeculectomy	_	_	O
90	with	_	_	O
91	mitomycin	_	_	O
92	C.	_	_	O
93	Phacoemulsification	_	_	B-Premise
94	and	_	_	I-Premise
95	trabeculectomy	_	_	I-Premise
96	resulted	_	_	I-Premise
97	in	_	_	I-Premise
98	significant	_	_	I-Premise
99	and	_	_	I-Premise
100	comparable	_	_	I-Premise
101	IOP	_	_	I-Premise
102	reduction	_	_	I-Premise
103	at	_	_	I-Premise
104	24	_	_	I-Premise
105	months	_	_	I-Premise
106	after	_	_	I-Premise
107	surgery	_	_	I-Premise
108	(	_	_	I-Premise
109	reduction	_	_	I-Premise
110	of	_	_	I-Premise
111	8.4	_	_	I-Premise
112	mmHg	_	_	I-Premise
113	or	_	_	I-Premise
114	34	_	_	I-Premise
115	%	_	_	I-Premise
116	for	_	_	I-Premise
117	phacoemulsification	_	_	I-Premise
118	vs	_	_	I-Premise
119	8.9	_	_	I-Premise
120	mmHg	_	_	I-Premise
121	or	_	_	I-Premise
122	36	_	_	I-Premise
123	%	_	_	I-Premise
124	for	_	_	I-Premise
125	trabeculectomy	_	_	I-Premise
126	;	_	_	I-Premise
127	P=0.76	_	_	I-Premise
128	)	_	_	I-Premise
129	.	_	_	I-Premise

130	Over	_	_	B-Premise
131	first	_	_	I-Premise
132	24	_	_	I-Premise
133	months	_	_	I-Premise
134	,	_	_	I-Premise
135	trabeculectomy-treated	_	_	I-Premise
136	eyes	_	_	I-Premise
137	required	_	_	I-Premise
138	on	_	_	I-Premise
139	average	_	_	I-Premise
140	1.1	_	_	I-Premise
141	fewer	_	_	I-Premise
142	drugs	_	_	I-Premise
143	than	_	_	I-Premise
144	phacoemulsification-treated	_	_	I-Premise
145	eyes	_	_	I-Premise
146	(	_	_	I-Premise
147	P	_	_	I-Premise
148	<	_	_	I-Premise
149	0.001	_	_	I-Premise
150	)	_	_	I-Premise
151	.	_	_	I-Premise

152	However	_	_	O
153	,	_	_	O
154	trabeculectomy	_	_	B-Premise
155	was	_	_	I-Premise
156	associated	_	_	I-Premise
157	with	_	_	I-Premise
158	significantly	_	_	I-Premise
159	more	_	_	I-Premise
160	surgical	_	_	I-Premise
161	complications	_	_	I-Premise
162	than	_	_	I-Premise
163	phacoemulsification	_	_	I-Premise
164	(	_	_	I-Premise
165	46	_	_	I-Premise
166	%	_	_	I-Premise
167	vs	_	_	I-Premise
168	4	_	_	I-Premise
169	%	_	_	I-Premise
170	;	_	_	I-Premise
171	P=0.001	_	_	I-Premise
172	)	_	_	I-Premise
173	.	_	_	I-Premise

174	Eight	_	_	B-Premise
175	(	_	_	I-Premise
176	33	_	_	I-Premise
177	%	_	_	I-Premise
178	)	_	_	I-Premise
179	of	_	_	I-Premise
180	24	_	_	I-Premise
181	trabeculectomy	_	_	I-Premise
182	eyes	_	_	I-Premise
183	demonstrated	_	_	I-Premise
184	cataract	_	_	I-Premise
185	during	_	_	I-Premise
186	follow-up	_	_	I-Premise
187	.	_	_	I-Premise

188	Both	_	_	B-Claim
189	phacoemulsification	_	_	I-Claim
190	and	_	_	I-Claim
191	trabeculectomy	_	_	I-Claim
192	are	_	_	I-Claim
193	effective	_	_	I-Claim
194	in	_	_	I-Claim
195	reducing	_	_	I-Claim
196	IOP	_	_	I-Claim
197	in	_	_	I-Claim
198	medically	_	_	I-Claim
199	uncontrolled	_	_	I-Claim
200	CACG	_	_	I-Claim
201	eyes	_	_	I-Claim
202	without	_	_	I-Claim
203	cataract	_	_	I-Claim
204	.	_	_	I-Claim

205	Trabeculectomy	_	_	B-Claim
206	is	_	_	I-Claim
207	more	_	_	I-Claim
208	effective	_	_	I-Claim
209	than	_	_	I-Claim
210	phacoemulsification	_	_	I-Claim
211	in	_	_	I-Claim
212	reducing	_	_	I-Claim
213	dependence	_	_	I-Claim
214	on	_	_	I-Claim
215	glaucoma	_	_	I-Claim
216	drugs	_	_	I-Claim
217	,	_	_	I-Claim
218	but	_	_	I-Claim
219	is	_	_	I-Claim
220	associated	_	_	I-Claim
221	with	_	_	I-Claim
222	more	_	_	I-Claim
223	complications	_	_	I-Claim
224	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	phacoemulsification	_	_	O
3	alone	_	_	O
4	and	_	_	O
5	phacoemulsification	_	_	O
6	with	_	_	O
7	micro-bypass	_	_	O
8	stent	_	_	O
9	implantation	_	_	O
10	in	_	_	O
11	eyes	_	_	O
12	with	_	_	O
13	primary	_	_	O
14	open-angle	_	_	O
15	glaucoma	_	_	O
16	.	_	_	O

17	Instituto	_	_	O
18	di	_	_	O
19	Fisiopatologia	_	_	O
20	Clinica	_	_	O
21	,	_	_	O
22	Clinica	_	_	O
23	Oculistica	_	_	O
24	,	_	_	O
25	Universita	_	_	O
26	'	_	_	O
27	di	_	_	O
28	Torino	_	_	O
29	,	_	_	O
30	Torino	_	_	O
31	,	_	_	O
32	Italy	_	_	O
33	.	_	_	O

34	In	_	_	O
35	this	_	_	O
36	prospective	_	_	O
37	double-masked	_	_	O
38	randomized	_	_	O
39	clinical	_	_	O
40	trial	_	_	O
41	,	_	_	O
42	patients	_	_	O
43	had	_	_	O
44	phacoemulsification	_	_	O
45	alone	_	_	O
46	(	_	_	O
47	control	_	_	O
48	group	_	_	O
49	)	_	_	O
50	or	_	_	O
51	phacoemulsification	_	_	O
52	with	_	_	O
53	iStent	_	_	O
54	implantation	_	_	O
55	(	_	_	O
56	combined	_	_	O
57	group	_	_	O
58	)	_	_	O
59	.	_	_	O

60	Primary	_	_	O
61	outcomes	_	_	O
62	were	_	_	O
63	intraocular	_	_	O
64	pressure	_	_	O
65	(	_	_	O
66	IOP	_	_	O
67	)	_	_	O
68	and	_	_	O
69	reduction	_	_	O
70	in	_	_	O
71	medication	_	_	O
72	use	_	_	O
73	over	_	_	O
74	15	_	_	O
75	months	_	_	O
76	and	_	_	O
77	IOP	_	_	O
78	after	_	_	O
79	a	_	_	O
80	1-month	_	_	O
81	washout	_	_	O
82	of	_	_	O
83	ocular	_	_	O
84	hypotensive	_	_	O
85	agents	_	_	O
86	(	_	_	O
87	ie	_	_	O
88	,	_	_	O
89	16	_	_	O
90	months	_	_	O
91	postoperatively	_	_	O
92	)	_	_	O
93	.	_	_	O

94	The	_	_	O
95	baseline	_	_	O
96	IOP	_	_	O
97	was	_	_	O
98	similar	_	_	O
99	between	_	_	O
100	groups	_	_	O
101	(	_	_	O
102	combined	_	_	O
103	group	_	_	O
104	:	_	_	O
105	17.9	_	_	O
106	mm	_	_	O
107	Hg	_	_	O
108	+/-	_	_	O
109	2.6	_	_	O
110	[	_	_	O
111	SD	_	_	O
112	]	_	_	O
113	;	_	_	O
114	control	_	_	O
115	group	_	_	O
116	:	_	_	O
117	17.3	_	_	O
118	+/-	_	_	O
119	3.0	_	_	O
120	mm	_	_	O
121	Hg	_	_	O
122	)	_	_	O
123	(	_	_	O
124	P	_	_	O
125	=	_	_	O
126	.512	_	_	O
127	)	_	_	O
128	.	_	_	O

129	Three	_	_	O
130	patients	_	_	O
131	in	_	_	O
132	the	_	_	O
133	control	_	_	O
134	group	_	_	O
135	were	_	_	O
136	lost	_	_	O
137	to	_	_	O
138	follow-up	_	_	O
139	.	_	_	O

140	The	_	_	B-Premise
141	mean	_	_	I-Premise
142	IOP	_	_	I-Premise
143	was	_	_	I-Premise
144	14.8	_	_	I-Premise
145	+/-	_	_	I-Premise
146	1.2	_	_	I-Premise
147	mm	_	_	I-Premise
148	Hg	_	_	I-Premise
149	in	_	_	I-Premise
150	the	_	_	I-Premise
151	combined	_	_	I-Premise
152	group	_	_	I-Premise
153	and	_	_	I-Premise
154	15.7	_	_	I-Premise
155	+/-	_	_	I-Premise
156	1.1	_	_	I-Premise
157	mm	_	_	I-Premise
158	Hg	_	_	I-Premise
159	in	_	_	I-Premise
160	the	_	_	I-Premise
161	control	_	_	I-Premise
162	group	_	_	I-Premise
163	at	_	_	I-Premise
164	15	_	_	I-Premise
165	months	_	_	I-Premise
166	and	_	_	I-Premise
167	16.6	_	_	I-Premise
168	+/-	_	_	I-Premise
169	3.1	_	_	I-Premise
170	mm	_	_	I-Premise
171	Hg	_	_	I-Premise
172	and	_	_	I-Premise
173	19.2	_	_	I-Premise
174	+/-	_	_	I-Premise
175	3.5	_	_	I-Premise
176	mm	_	_	I-Premise
177	Hg	_	_	I-Premise
178	,	_	_	I-Premise
179	respectively	_	_	I-Premise
180	,	_	_	I-Premise
181	after	_	_	I-Premise
182	washout	_	_	I-Premise
183	;	_	_	I-Premise
184	the	_	_	B-Premise
185	IOP	_	_	I-Premise
186	was	_	_	I-Premise
187	statistically	_	_	I-Premise
188	significantly	_	_	I-Premise
189	lower	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	combined	_	_	I-Premise
193	group	_	_	I-Premise
194	than	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	control	_	_	I-Premise
198	group	_	_	I-Premise
199	at	_	_	I-Premise
200	both	_	_	I-Premise
201	time	_	_	I-Premise
202	points	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	.031	_	_	I-Premise
207	and	_	_	I-Premise
208	P	_	_	I-Premise
209	=	_	_	I-Premise
210	.042	_	_	I-Premise
211	,	_	_	I-Premise
212	respectively	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	At	_	_	B-Premise
216	15	_	_	I-Premise
217	months	_	_	I-Premise
218	,	_	_	I-Premise
219	the	_	_	I-Premise
220	mean	_	_	I-Premise
221	number	_	_	I-Premise
222	of	_	_	I-Premise
223	medications	_	_	I-Premise
224	was	_	_	I-Premise
225	lower	_	_	I-Premise
226	in	_	_	I-Premise
227	the	_	_	I-Premise
228	combined	_	_	I-Premise
229	group	_	_	I-Premise
230	than	_	_	I-Premise
231	in	_	_	I-Premise
232	the	_	_	I-Premise
233	control	_	_	I-Premise
234	group	_	_	I-Premise
235	(	_	_	I-Premise
236	0.4	_	_	I-Premise
237	+/-	_	_	I-Premise
238	0.7	_	_	I-Premise
239	and	_	_	I-Premise
240	1.3	_	_	I-Premise
241	+/-	_	_	I-Premise
242	1.0	_	_	I-Premise
243	,	_	_	I-Premise
244	respectively	_	_	I-Premise
245	;	_	_	I-Premise
246	P	_	_	I-Premise
247	=	_	_	I-Premise
248	.007	_	_	I-Premise
249	)	_	_	I-Premise
250	,	_	_	I-Premise
251	as	_	_	I-Premise
252	was	_	_	I-Premise
253	the	_	_	I-Premise
254	proportion	_	_	I-Premise
255	of	_	_	I-Premise
256	patients	_	_	I-Premise
257	on	_	_	I-Premise
258	ocular	_	_	I-Premise
259	hypotensive	_	_	I-Premise
260	medication	_	_	I-Premise
261	(	_	_	I-Premise
262	33	_	_	I-Premise
263	%	_	_	I-Premise
264	and	_	_	I-Premise
265	76	_	_	I-Premise
266	%	_	_	I-Premise
267	,	_	_	I-Premise
268	respectively	_	_	I-Premise
269	)	_	_	I-Premise
270	.	_	_	I-Premise

271	Phacoemulsification	_	_	B-Claim
272	with	_	_	I-Claim
273	stent	_	_	I-Claim
274	implantation	_	_	I-Claim
275	was	_	_	I-Claim
276	more	_	_	I-Claim
277	effective	_	_	I-Claim
278	in	_	_	I-Claim
279	controlling	_	_	I-Claim
280	IOP	_	_	I-Claim
281	than	_	_	I-Claim
282	phacoemulsification	_	_	I-Claim
283	alone	_	_	I-Claim
284	;	_	_	I-Claim
285	the	_	_	O
286	safety	_	_	O
287	profiles	_	_	O
288	were	_	_	O
289	similar	_	_	O
290	.	_	_	O


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	(	_	_	O
6	IOP	_	_	O
7	)	_	_	O
8	lowering	_	_	O
9	efficacy	_	_	O
10	and	_	_	O
11	side	_	_	O
12	effects	_	_	O
13	of	_	_	O
14	latanoprost	_	_	O
15	0.005	_	_	O
16	%	_	_	O
17	and	_	_	O
18	bimatoprost	_	_	O
19	0.03	_	_	O
20	%	_	_	O
21	in	_	_	O
22	subjects	_	_	O
23	with	_	_	O
24	chronic	_	_	O
25	primary	_	_	O
26	angle	_	_	O
27	closure	_	_	O
28	glaucoma	_	_	O
29	(	_	_	O
30	PACG	_	_	O
31	)	_	_	O
32	.	_	_	O

33	This	_	_	O
34	was	_	_	O
35	an	_	_	O
36	observer-masked	_	_	O
37	randomised	_	_	O
38	crossover	_	_	O
39	study	_	_	O
40	of	_	_	O
41	60	_	_	O
42	PACG	_	_	O
43	subjects	_	_	O
44	who	_	_	O
45	received	_	_	O
46	either	_	_	O
47	latanoprost	_	_	O
48	or	_	_	O
49	bimatoprost	_	_	O
50	for	_	_	O
51	6	_	_	O
52	weeks	_	_	O
53	,	_	_	O
54	after	_	_	O
55	which	_	_	O
56	they	_	_	O
57	were	_	_	O
58	crossed	_	_	O
59	over	_	_	O
60	to	_	_	O
61	the	_	_	O
62	other	_	_	O
63	medication	_	_	O
64	for	_	_	O
65	another	_	_	O
66	6	_	_	O
67	weeks	_	_	O
68	.	_	_	O

69	The	_	_	O
70	IOP-reducing	_	_	O
71	effect	_	_	O
72	of	_	_	O
73	the	_	_	O
74	medications	_	_	O
75	was	_	_	O
76	assessed	_	_	O
77	by	_	_	O
78	the	_	_	O
79	reduction	_	_	O
80	in	_	_	O
81	IOP	_	_	O
82	after	_	_	O
83	6	_	_	O
84	weeks	_	_	O
85	of	_	_	O
86	treatment	_	_	O
87	compared	_	_	O
88	with	_	_	O
89	baseline	_	_	O
90	.	_	_	O

91	Fifty-four	_	_	O
92	subjects	_	_	O
93	(	_	_	O
94	80	_	_	O
95	eyes	_	_	O
96	)	_	_	O
97	completed	_	_	O
98	the	_	_	O
99	study	_	_	O
100	.	_	_	O

101	Latanoprost	_	_	B-Premise
102	reduced	_	_	I-Premise
103	IOP	_	_	I-Premise
104	(	_	_	I-Premise
105	mean	_	_	I-Premise
106	(	_	_	I-Premise
107	SD	_	_	I-Premise
108	)	_	_	I-Premise
109	)	_	_	I-Premise
110	by	_	_	I-Premise
111	8.4	_	_	I-Premise
112	(	_	_	I-Premise
113	3.8	_	_	I-Premise
114	)	_	_	I-Premise
115	mm	_	_	I-Premise
116	Hg	_	_	I-Premise
117	and	_	_	I-Premise
118	bimatoprost	_	_	I-Premise
119	by	_	_	I-Premise
120	8.9	_	_	I-Premise
121	(	_	_	I-Premise
122	3.9	_	_	I-Premise
123	)	_	_	I-Premise
124	mm	_	_	I-Premise
125	Hg	_	_	I-Premise
126	from	_	_	I-Premise
127	a	_	_	I-Premise
128	baseline	_	_	I-Premise
129	of	_	_	I-Premise
130	25.2	_	_	I-Premise
131	(	_	_	I-Premise
132	3.6	_	_	I-Premise
133	)	_	_	I-Premise
134	mm	_	_	I-Premise
135	Hg	_	_	I-Premise
136	and	_	_	I-Premise
137	25.2	_	_	I-Premise
138	(	_	_	I-Premise
139	3.6	_	_	I-Premise
140	)	_	_	I-Premise
141	mm	_	_	I-Premise
142	Hg	_	_	I-Premise
143	respectively	_	_	I-Premise
144	(	_	_	I-Premise
145	p	_	_	I-Premise
146	=	_	_	I-Premise
147	0.23	_	_	I-Premise
148	)	_	_	I-Premise
149	.	_	_	I-Premise

150	Adverse	_	_	B-Premise
151	events	_	_	I-Premise
152	were	_	_	I-Premise
153	mild	_	_	I-Premise
154	in	_	_	I-Premise
155	both	_	_	I-Premise
156	groups	_	_	I-Premise
157	;	_	_	I-Premise
158	however	_	_	B-Premise
159	there	_	_	I-Premise
160	were	_	_	I-Premise
161	twice	_	_	I-Premise
162	as	_	_	I-Premise
163	many	_	_	I-Premise
164	reports	_	_	I-Premise
165	of	_	_	I-Premise
166	an	_	_	I-Premise
167	adverse	_	_	I-Premise
168	event	_	_	I-Premise
169	in	_	_	I-Premise
170	the	_	_	I-Premise
171	bimatoprost	_	_	I-Premise
172	group	_	_	I-Premise
173	(	_	_	I-Premise
174	81	_	_	I-Premise
175	%	_	_	I-Premise
176	)	_	_	I-Premise
177	compared	_	_	I-Premise
178	with	_	_	I-Premise
179	the	_	_	I-Premise
180	latanoprost	_	_	I-Premise
181	group	_	_	I-Premise
182	(	_	_	I-Premise
183	40	_	_	I-Premise
184	%	_	_	I-Premise
185	,	_	_	I-Premise
186	p	_	_	I-Premise
187	<	_	_	I-Premise
188	0.01	_	_	I-Premise
189	)	_	_	I-Premise
190	.	_	_	I-Premise

191	Ocular	_	_	O
192	irritation	_	_	O
193	was	_	_	O
194	the	_	_	O
195	most	_	_	O
196	frequently	_	_	O
197	reported	_	_	O
198	adverse	_	_	O
199	event	_	_	O
200	in	_	_	O
201	both	_	_	O
202	groups	_	_	O
203	;	_	_	O
204	22	_	_	B-Premise
205	subjects	_	_	I-Premise
206	(	_	_	I-Premise
207	37.9	_	_	I-Premise
208	%	_	_	I-Premise
209	)	_	_	I-Premise
210	treated	_	_	I-Premise
211	with	_	_	I-Premise
212	bimatoprost	_	_	I-Premise
213	experienced	_	_	I-Premise
214	ocular	_	_	I-Premise
215	hyperaemia	_	_	I-Premise
216	as	_	_	I-Premise
217	compared	_	_	I-Premise
218	with	_	_	I-Premise
219	13	_	_	I-Premise
220	subjects	_	_	I-Premise
221	(	_	_	I-Premise
222	22.4	_	_	I-Premise
223	%	_	_	I-Premise
224	)	_	_	I-Premise
225	treated	_	_	I-Premise
226	with	_	_	I-Premise
227	latanoprost	_	_	I-Premise
228	(	_	_	I-Premise
229	p	_	_	I-Premise
230	=	_	_	I-Premise
231	0.11	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	Bimatoprost	_	_	B-Claim
235	once	_	_	I-Claim
236	daily	_	_	I-Claim
237	was	_	_	I-Claim
238	similarly	_	_	I-Claim
239	effective	_	_	I-Claim
240	in	_	_	I-Claim
241	reducing	_	_	I-Claim
242	IOP	_	_	I-Claim
243	compared	_	_	I-Claim
244	with	_	_	I-Claim
245	latanoprost	_	_	I-Claim
246	once	_	_	I-Claim
247	daily	_	_	I-Claim
248	in	_	_	I-Claim
249	subjects	_	_	I-Claim
250	with	_	_	I-Claim
251	chronic	_	_	I-Claim
252	PACG	_	_	I-Claim
253	.	_	_	I-Claim

254	Both	_	_	B-Claim
255	drugs	_	_	I-Claim
256	were	_	_	I-Claim
257	well	_	_	I-Claim
258	tolerated	_	_	I-Claim
259	with	_	_	I-Claim
260	mild	_	_	I-Claim
261	ocular	_	_	I-Claim
262	adverse	_	_	I-Claim
263	events	_	_	I-Claim
264	.	_	_	I-Claim


0	Latanoprost	_	_	O
1	,	_	_	O
2	a	_	_	O
3	new	_	_	O
4	prostaglandin	_	_	O
5	analogue	_	_	O
6	,	_	_	O
7	was	_	_	O
8	compared	_	_	O
9	with	_	_	O
10	timolol	_	_	O
11	for	_	_	O
12	ocular	_	_	O
13	hypotensive	_	_	O
14	efficacy	_	_	O
15	and	_	_	O
16	side	_	_	O
17	effects	_	_	O
18	.	_	_	O

19	In	_	_	O
20	a	_	_	O
21	multicenter	_	_	O
22	,	_	_	O
23	randomized	_	_	O
24	,	_	_	O
25	double-masked	_	_	O
26	,	_	_	O
27	parallel	_	_	O
28	group	_	_	O
29	study	_	_	O
30	,	_	_	O
31	268	_	_	O
32	patients	_	_	O
33	with	_	_	O
34	ocular	_	_	O
35	hypertension	_	_	O
36	or	_	_	O
37	early	_	_	O
38	primary	_	_	O
39	open-angle	_	_	O
40	glaucoma	_	_	O
41	received	_	_	O
42	either	_	_	O
43	0.005	_	_	O
44	%	_	_	O
45	latanoprost	_	_	O
46	once	_	_	O
47	daily	_	_	O
48	or	_	_	O
49	0.5	_	_	O
50	%	_	_	O
51	timolol	_	_	O
52	twice	_	_	O
53	daily	_	_	O
54	for	_	_	O
55	6	_	_	O
56	months	_	_	O
57	.	_	_	O

58	All	_	_	O
59	except	_	_	O
60	ten	_	_	O
61	patients	_	_	O
62	from	_	_	O
63	each	_	_	O
64	group	_	_	O
65	successfully	_	_	O
66	completed	_	_	O
67	the	_	_	O
68	study	_	_	O
69	.	_	_	O

70	Intraocular	_	_	B-Premise
71	pressure	_	_	I-Premise
72	(	_	_	I-Premise
73	IOP	_	_	I-Premise
74	)	_	_	I-Premise
75	was	_	_	I-Premise
76	significantly	_	_	I-Premise
77	(	_	_	I-Premise
78	P	_	_	I-Premise
79	<	_	_	I-Premise
80	0.001	_	_	I-Premise
81	)	_	_	I-Premise
82	reduced	_	_	I-Premise
83	and	_	_	I-Premise
84	maintained	_	_	I-Premise
85	by	_	_	I-Premise
86	both	_	_	I-Premise
87	medications	_	_	I-Premise
88	without	_	_	I-Premise
89	evidence	_	_	I-Premise
90	of	_	_	I-Premise
91	a	_	_	I-Premise
92	long-term	_	_	I-Premise
93	drift	_	_	I-Premise
94	over	_	_	I-Premise
95	6	_	_	I-Premise
96	months	_	_	I-Premise
97	.	_	_	I-Premise

98	Comparing	_	_	B-Premise
99	6-month	_	_	I-Premise
100	with	_	_	I-Premise
101	baseline	_	_	I-Premise
102	diurnal	_	_	I-Premise
103	IOP	_	_	I-Premise
104	values	_	_	I-Premise
105	,	_	_	I-Premise
106	the	_	_	I-Premise
107	IOP	_	_	I-Premise
108	reduction	_	_	I-Premise
109	(	_	_	I-Premise
110	mean	_	_	I-Premise
111	+/-	_	_	I-Premise
112	standard	_	_	I-Premise
113	deviation	_	_	I-Premise
114	)	_	_	I-Premise
115	achieved	_	_	I-Premise
116	with	_	_	I-Premise
117	latanoprost	_	_	I-Premise
118	(	_	_	I-Premise
119	-6.7	_	_	I-Premise
120	+/-	_	_	I-Premise
121	3.4	_	_	I-Premise
122	mmHg	_	_	I-Premise
123	)	_	_	I-Premise
124	was	_	_	I-Premise
125	significantly	_	_	I-Premise
126	(	_	_	I-Premise
127	P	_	_	I-Premise
128	<	_	_	I-Premise
129	0.001	_	_	I-Premise
130	)	_	_	I-Premise
131	greater	_	_	I-Premise
132	than	_	_	I-Premise
133	that	_	_	I-Premise
134	produced	_	_	I-Premise
135	with	_	_	I-Premise
136	timolol	_	_	I-Premise
137	(	_	_	I-Premise
138	4.9	_	_	I-Premise
139	+/-	_	_	I-Premise
140	2.9	_	_	I-Premise
141	mmHg	_	_	I-Premise
142	)	_	_	I-Premise
143	.	_	_	I-Premise

144	Four	_	_	O
145	patients	_	_	O
146	treated	_	_	O
147	with	_	_	O
148	timolol	_	_	O
149	and	_	_	O
150	none	_	_	O
151	treated	_	_	O
152	with	_	_	O
153	latanoprost	_	_	O
154	were	_	_	O
155	withdrawn	_	_	O
156	from	_	_	O
157	the	_	_	O
158	study	_	_	O
159	because	_	_	O
160	of	_	_	O
161	inadequate	_	_	O
162	IOP	_	_	O
163	control	_	_	O
164	.	_	_	O

165	Pulse	_	_	B-Premise
166	rate	_	_	I-Premise
167	was	_	_	I-Premise
168	significantly	_	_	I-Premise
169	reduced	_	_	I-Premise
170	with	_	_	I-Premise
171	timolol	_	_	I-Premise
172	,	_	_	I-Premise
173	but	_	_	I-Premise
174	not	_	_	I-Premise
175	with	_	_	I-Premise
176	latanoprost	_	_	I-Premise
177	.	_	_	I-Premise

178	Slightly	_	_	B-Premise
179	more	_	_	I-Premise
180	conjunctival	_	_	I-Premise
181	hyperemia	_	_	I-Premise
182	appeared	_	_	I-Premise
183	in	_	_	I-Premise
184	latanoprost-treated	_	_	I-Premise
185	compared	_	_	I-Premise
186	with	_	_	I-Premise
187	timolol-treated	_	_	I-Premise
188	eyes	_	_	I-Premise
189	.	_	_	I-Premise

190	Fewer	_	_	B-Claim
191	subjective	_	_	I-Claim
192	side	_	_	I-Claim
193	effects	_	_	I-Claim
194	occurred	_	_	I-Claim
195	in	_	_	I-Claim
196	latanoprost-treated	_	_	I-Claim
197	eyes	_	_	I-Claim
198	.	_	_	I-Claim

199	Both	_	_	B-Premise
200	eyes	_	_	I-Premise
201	of	_	_	I-Premise
202	a	_	_	I-Premise
203	patient	_	_	I-Premise
204	with	_	_	I-Premise
205	a	_	_	I-Premise
206	characteristic	_	_	I-Premise
207	,	_	_	I-Premise
208	concentric	_	_	I-Premise
209	iris	_	_	I-Premise
210	heterochromia	_	_	I-Premise
211	(	_	_	I-Premise
212	darker	_	_	I-Premise
213	centrally	_	_	I-Premise
214	)	_	_	I-Premise
215	at	_	_	I-Premise
216	baseline	_	_	I-Premise
217	showed	_	_	I-Premise
218	a	_	_	I-Premise
219	definite	_	_	I-Premise
220	,	_	_	I-Premise
221	photographically	_	_	I-Premise
222	documented	_	_	I-Premise
223	increase	_	_	I-Premise
224	in	_	_	I-Premise
225	pigmentation	_	_	I-Premise
226	during	_	_	I-Premise
227	latanoprost	_	_	I-Premise
228	treatment	_	_	I-Premise
229	,	_	_	I-Premise
230	making	_	_	I-Premise
231	the	_	_	I-Premise
232	irides	_	_	I-Premise
233	uniformly	_	_	I-Premise
234	darker	_	_	I-Premise
235	.	_	_	I-Premise

236	Three	_	_	O
237	additional	_	_	O
238	patients	_	_	O
239	treated	_	_	O
240	with	_	_	O
241	latanoprost	_	_	O
242	were	_	_	O
243	suspects	_	_	O
244	for	_	_	O
245	this	_	_	O
246	color	_	_	O
247	change	_	_	O
248	.	_	_	O

249	Otherwise	_	_	O
250	,	_	_	O
251	no	_	_	B-Claim
252	significant	_	_	I-Claim
253	difference	_	_	I-Claim
254	between	_	_	I-Claim
255	treatment	_	_	I-Claim
256	groups	_	_	I-Claim
257	occurred	_	_	I-Claim
258	visual	_	_	I-Claim
259	acuity	_	_	I-Claim
260	,	_	_	I-Claim
261	slit-lamp	_	_	I-Claim
262	examination	_	_	I-Claim
263	,	_	_	I-Claim
264	blood	_	_	I-Claim
265	pressure	_	_	I-Claim
266	,	_	_	I-Claim
267	and	_	_	I-Claim
268	laboratory	_	_	I-Claim
269	values	_	_	I-Claim
270	.	_	_	I-Claim

271	Latanoprost	_	_	B-Claim
272	has	_	_	I-Claim
273	the	_	_	I-Claim
274	potential	_	_	I-Claim
275	for	_	_	I-Claim
276	becoming	_	_	I-Claim
277	a	_	_	I-Claim
278	new	_	_	I-Claim
279	first-line	_	_	I-Claim
280	treatment	_	_	I-Claim
281	for	_	_	I-Claim
282	glaucoma	_	_	I-Claim
283	.	_	_	I-Claim


0	Efficacy	_	_	O
1	of	_	_	O
2	the	_	_	O
3	latanoprost	_	_	O
4	versus	_	_	O
5	timolol/dorzolamide	_	_	O
6	combination	_	_	O
7	therapy	_	_	O
8	in	_	_	O
9	patients	_	_	O
10	with	_	_	O
11	primary	_	_	O
12	open	_	_	O
13	angle	_	_	O
14	glaucoma	_	_	O

15	The	_	_	O
16	study	_	_	O
17	was	_	_	O
18	designed	_	_	O
19	as	_	_	O
20	a	_	_	O
21	6	_	_	O
22	months	_	_	O
23	randomized	_	_	O
24	,	_	_	O
25	observer-masked	_	_	O
26	study	_	_	O
27	comprising	_	_	O
28	120	_	_	O
29	patients	_	_	O
30	with	_	_	O
31	primary	_	_	O
32	open-angle	_	_	O
33	glaucoma	_	_	O
34	in	_	_	O
35	Feiz	_	_	O
36	Hospital	_	_	O
37	,	_	_	O
38	Isfahan	_	_	O
39	,	_	_	O
40	Iran	_	_	O
41	,	_	_	O
42	from	_	_	O
43	2006	_	_	O
44	to	_	_	O
45	2007	_	_	O
46	.	_	_	O

47	The	_	_	O
48	patients	_	_	O
49	were	_	_	O
50	randomized	_	_	O
51	(	_	_	O
52	latanoprost	_	_	O
53	,	_	_	O
54	n	_	_	O
55	=	_	_	O
56	60	_	_	O
57	;	_	_	O
58	dorzolamide/timolol	_	_	O
59	,	_	_	O
60	n	_	_	O
61	=	_	_	O
62	60	_	_	O
63	)	_	_	O
64	to	_	_	O
65	treatment	_	_	O
66	with	_	_	O
67	either	_	_	O
68	latanoprost	_	_	O
69	,	_	_	O
70	0.005	_	_	O
71	%	_	_	O
72	once	_	_	O
73	daily	_	_	O
74	,	_	_	O
75	or	_	_	O
76	the	_	_	O
77	combination	_	_	O
78	of	_	_	O
79	timolol	_	_	O
80	0.5	_	_	O
81	%	_	_	O
82	twice	_	_	O
83	daily	_	_	O
84	,	_	_	O
85	and	_	_	O
86	dorzolamide	_	_	O
87	2	_	_	O
88	%	_	_	O
89	3	_	_	O
90	times	_	_	O
91	daily	_	_	O
92	.	_	_	O

93	The	_	_	O
94	mean	_	_	O
95	intraocular	_	_	O
96	pressure	_	_	O
97	(	_	_	O
98	IOP	_	_	O
99	)	_	_	O
100	after	_	_	O
101	one	_	_	O
102	,	_	_	O
103	3	_	_	O
104	,	_	_	O
105	and	_	_	O
106	6	_	_	O
107	months	_	_	O
108	of	_	_	O
109	treatment	_	_	O
110	was	_	_	O
111	compared	_	_	O
112	with	_	_	O
113	baseline	_	_	O
114	in	_	_	O
115	the	_	_	O
116	2	_	_	O
117	groups	_	_	O
118	.	_	_	O

119	A	_	_	O
120	total	_	_	O
121	of	_	_	O
122	120	_	_	O
123	patients	_	_	O
124	were	_	_	O
125	randomized	_	_	O
126	to	_	_	O
127	2	_	_	O
128	equal	_	_	O
129	treatment	_	_	O
130	groups	_	_	O
131	.	_	_	O

132	The	_	_	O
133	mean	_	_	O
134	baseline	_	_	O
135	IOP	_	_	O
136	values	_	_	O
137	were	_	_	O
138	similar	_	_	O
139	between	_	_	O
140	the	_	_	O
141	2	_	_	O
142	groups	_	_	O
143	.	_	_	O

144	The	_	_	B-Premise
145	mean	_	_	I-Premise
146	(	_	_	I-Premise
147	standard	_	_	I-Premise
148	error	_	_	I-Premise
149	of	_	_	I-Premise
150	mean	_	_	I-Premise
151	[	_	_	I-Premise
152	SE	_	_	I-Premise
153	]	_	_	I-Premise
154	)	_	_	I-Premise
155	IOP	_	_	I-Premise
156	reductions	_	_	I-Premise
157	at	_	_	I-Premise
158	months	_	_	I-Premise
159	one	_	_	I-Premise
160	was	_	_	I-Premise
161	7.2	_	_	I-Premise
162	(	_	_	I-Premise
163	0.4	_	_	I-Premise
164	)	_	_	I-Premise
165	,	_	_	I-Premise
166	at	_	_	I-Premise
167	month	_	_	I-Premise
168	3	_	_	I-Premise
169	was	_	_	I-Premise
170	7.3	_	_	I-Premise
171	(	_	_	I-Premise
172	0.4	_	_	I-Premise
173	)	_	_	I-Premise
174	,	_	_	I-Premise
175	and	_	_	I-Premise
176	at	_	_	I-Premise
177	month	_	_	I-Premise
178	6	_	_	I-Premise
179	was	_	_	I-Premise
180	7.1	_	_	I-Premise
181	(	_	_	I-Premise
182	0.3	_	_	I-Premise
183	)	_	_	I-Premise
184	mm	_	_	I-Premise
185	Hg	_	_	I-Premise
186	for	_	_	I-Premise
187	the	_	_	I-Premise
188	latanoprost	_	_	I-Premise
189	group	_	_	I-Premise
190	and	_	_	I-Premise
191	7.5	_	_	I-Premise
192	(	_	_	I-Premise
193	0.3	_	_	I-Premise
194	)	_	_	I-Premise
195	,	_	_	I-Premise
196	7.8	_	_	I-Premise
197	(	_	_	I-Premise
198	0.3	_	_	I-Premise
199	)	_	_	I-Premise
200	,	_	_	I-Premise
201	and	_	_	I-Premise
202	7.4	_	_	I-Premise
203	(	_	_	I-Premise
204	0.3	_	_	I-Premise
205	)	_	_	I-Premise
206	mm	_	_	I-Premise
207	Hg	_	_	I-Premise
208	for	_	_	I-Premise
209	the	_	_	I-Premise
210	dorzolamide/timolol	_	_	I-Premise
211	group	_	_	I-Premise
212	.	_	_	I-Premise

213	The	_	_	B-Claim
214	2	_	_	I-Claim
215	therapies	_	_	I-Claim
216	were	_	_	I-Claim
217	similarly	_	_	I-Claim
218	effective	_	_	I-Claim
219	.	_	_	I-Claim

220	The	_	_	B-Claim
221	latanoprost	_	_	I-Claim
222	and	_	_	I-Claim
223	dorzolamide/timolol	_	_	I-Claim
224	combination	_	_	I-Claim
225	were	_	_	I-Claim
226	equally	_	_	I-Claim
227	effective	_	_	I-Claim
228	at	_	_	I-Claim
229	lowering	_	_	I-Claim
230	IOP	_	_	I-Claim
231	compared	_	_	I-Claim
232	to	_	_	I-Claim
233	untreated	_	_	I-Claim
234	baseline	_	_	I-Claim
235	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effectiveness	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	excimer	_	_	O
8	laser	_	_	O
9	trabeculotomy	_	_	O
10	(	_	_	O
11	ELT	_	_	O
12	)	_	_	O
13	ab	_	_	O
14	interno	_	_	O
15	vs	_	_	O
16	selective	_	_	O
17	laser	_	_	O
18	trabeculoplasty	_	_	O
19	(	_	_	O
20	SLT	_	_	O
21	)	_	_	O
22	over	_	_	O
23	24	_	_	O
24	months	_	_	O
25	of	_	_	O
26	follow-up	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	primary	_	_	O
31	open-angle	_	_	O
32	glaucoma	_	_	O
33	(	_	_	O
34	POAG	_	_	O
35	)	_	_	O
36	refractory	_	_	O
37	to	_	_	O
38	medical	_	_	O
39	therapy	_	_	O
40	.	_	_	O

41	This	_	_	O
42	prospective	_	_	O
43	,	_	_	O
44	randomized	_	_	O
45	study	_	_	O
46	included	_	_	O
47	30	_	_	O
48	consecutive	_	_	O
49	eyes	_	_	O
50	assigned	_	_	O
51	randomly	_	_	O
52	to	_	_	O
53	either	_	_	O
54	ELT	_	_	O
55	or	_	_	O
56	SLT	_	_	O
57	group	_	_	O
58	.	_	_	O

59	ELT	_	_	O
60	was	_	_	O
61	carried	_	_	O
62	out	_	_	O
63	using	_	_	O
64	a	_	_	O
65	XeCl	_	_	O
66	Excimer	_	_	O
67	Laser	_	_	O
68	with	_	_	O
69	an	_	_	O
70	emission	_	_	O
71	wavelength	_	_	O
72	of	_	_	O
73	308	_	_	O
74	nm	_	_	O
75	.	_	_	O

76	Eight	_	_	O
77	spots	_	_	O
78	were	_	_	O
79	equally	_	_	O
80	distributed	_	_	O
81	at	_	_	O
82	a	_	_	O
83	distance	_	_	O
84	of	_	_	O
85	500	_	_	O
86	microm	_	_	O
87	from	_	_	O
88	one	_	_	O
89	another	_	_	O
90	over	_	_	O
91	the	_	_	O
92	anterior	_	_	O
93	trabeculum	_	_	O
94	.	_	_	O

95	The	_	_	O
96	SLT	_	_	O
97	patients	_	_	O
98	were	_	_	O
99	treated	_	_	O
100	with	_	_	O
101	a	_	_	O
102	frequency-doubled	_	_	O
103	q-switched	_	_	O
104	neodymium	_	_	O
105	:	_	_	O
106	yytrium-aluminum-garnet	_	_	O
107	laser	_	_	O
108	(	_	_	O
109	wavelength	_	_	O
110	532	_	_	O
111	nm	_	_	O
112	)	_	_	O
113	.	_	_	O

114	Approximately	_	_	O
115	50	_	_	O
116	adjacent	_	_	O
117	,	_	_	O
118	but	_	_	O
119	not	_	_	O
120	overlapping	_	_	O
121	,	_	_	O
122	laser	_	_	O
123	spots	_	_	O
124	were	_	_	O
125	distributed	_	_	O
126	over	_	_	O
127	180	_	_	O
128	degrees	_	_	O
129	of	_	_	O
130	the	_	_	O
131	trabecular	_	_	O
132	meshwork	_	_	O
133	,	_	_	O
134	using	_	_	O
135	an	_	_	O
136	energy	_	_	O
137	level	_	_	O
138	ranging	_	_	O
139	from	_	_	O
140	0.7	_	_	O
141	to	_	_	O
142	1.0	_	_	O
143	mJ	_	_	O
144	per	_	_	O
145	pulse	_	_	O
146	.	_	_	O

147	The	_	_	O
148	main	_	_	O
149	outcome	_	_	O
150	measure	_	_	O
151	was	_	_	O
152	intraocular	_	_	O
153	pressure	_	_	O
154	(	_	_	O
155	IOP	_	_	O
156	)	_	_	O
157	lowering	_	_	O
158	after	_	_	O
159	ELT	_	_	O
160	and	_	_	O
161	SLT	_	_	O
162	.	_	_	O

163	Success	_	_	O
164	was	_	_	O
165	defined	_	_	O
166	as	_	_	O
167	>	_	_	O
168	or=20	_	_	O
169	%	_	_	O
170	reduction	_	_	O
171	in	_	_	O
172	IOP	_	_	O
173	without	_	_	O
174	further	_	_	O
175	glaucoma	_	_	O
176	intervention	_	_	O
177	.	_	_	O

178	At	_	_	B-Premise
179	24	_	_	I-Premise
180	months	_	_	I-Premise
181	,	_	_	I-Premise
182	complete	_	_	I-Premise
183	success	_	_	I-Premise
184	rates	_	_	I-Premise
185	were	_	_	I-Premise
186	53.3	_	_	I-Premise
187	%	_	_	I-Premise
188	for	_	_	I-Premise
189	the	_	_	I-Premise
190	ELT	_	_	I-Premise
191	group	_	_	I-Premise
192	and	_	_	I-Premise
193	40	_	_	I-Premise
194	%	_	_	I-Premise
195	for	_	_	I-Premise
196	the	_	_	I-Premise
197	SLT	_	_	I-Premise
198	group	_	_	I-Premise
199	(	_	_	I-Premise
200	P=0.35	_	_	I-Premise
201	,	_	_	I-Premise
202	Fisher	_	_	I-Premise
203	's	_	_	I-Premise
204	exact	_	_	I-Premise
205	test	_	_	I-Premise
206	)	_	_	I-Premise
207	;	_	_	I-Premise
208	qualified	_	_	B-Premise
209	success	_	_	I-Premise
210	rates	_	_	I-Premise
211	were	_	_	I-Premise
212	33.3	_	_	I-Premise
213	%	_	_	I-Premise
214	for	_	_	I-Premise
215	the	_	_	I-Premise
216	ELT	_	_	I-Premise
217	and	_	_	I-Premise
218	26.6	_	_	I-Premise
219	%	_	_	I-Premise
220	for	_	_	I-Premise
221	the	_	_	I-Premise
222	SLT	_	_	I-Premise
223	group	_	_	I-Premise
224	(	_	_	I-Premise
225	P=0.5	_	_	I-Premise
226	,	_	_	I-Premise
227	Fisher	_	_	I-Premise
228	's	_	_	I-Premise
229	exact	_	_	I-Premise
230	test	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	Mean	_	_	B-Premise
234	IOP	_	_	I-Premise
235	decreased	_	_	I-Premise
236	from	_	_	I-Premise
237	25.0+/-1.9	_	_	I-Premise
238	to	_	_	I-Premise
239	17.6+/-2.2	_	_	I-Premise
240	mmHg	_	_	I-Premise
241	(	_	_	I-Premise
242	-29.6	_	_	I-Premise
243	%	_	_	I-Premise
244	;	_	_	I-Premise
245	P	_	_	I-Premise
246	<	_	_	I-Premise
247	0.0001	_	_	I-Premise
248	)	_	_	I-Premise
249	in	_	_	I-Premise
250	the	_	_	I-Premise
251	ELT	_	_	I-Premise
252	group	_	_	I-Premise
253	and	_	_	I-Premise
254	from	_	_	I-Premise
255	23.9+/-0.9	_	_	I-Premise
256	to	_	_	I-Premise
257	19.1+/-1.8	_	_	I-Premise
258	mmHg	_	_	I-Premise
259	(	_	_	I-Premise
260	-21	_	_	I-Premise
261	%	_	_	I-Premise
262	;	_	_	I-Premise
263	P	_	_	I-Premise
264	<	_	_	I-Premise
265	0.0001	_	_	I-Premise
266	)	_	_	I-Premise
267	in	_	_	I-Premise
268	the	_	_	I-Premise
269	SLT	_	_	I-Premise
270	group	_	_	I-Premise
271	.	_	_	I-Premise

272	Both	_	_	B-Claim
273	ELT	_	_	I-Claim
274	and	_	_	I-Claim
275	SLT	_	_	I-Claim
276	proved	_	_	I-Claim
277	to	_	_	I-Claim
278	be	_	_	I-Claim
279	effective	_	_	I-Claim
280	techniques	_	_	I-Claim
281	in	_	_	I-Claim
282	the	_	_	I-Claim
283	treatment	_	_	I-Claim
284	of	_	_	I-Claim
285	POAG	_	_	I-Claim
286	refractory	_	_	I-Claim
287	to	_	_	I-Claim
288	medical	_	_	I-Claim
289	therapy	_	_	I-Claim
290	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	ocular	_	_	O
4	hypotensive	_	_	O
5	activity	_	_	O
6	and	_	_	O
7	safety	_	_	O
8	profile	_	_	O
9	of	_	_	O
10	long-acting	_	_	O
11	1	_	_	O
12	%	_	_	O
13	carteolol	_	_	O
14	hydrochloride	_	_	O
15	eye	_	_	O
16	drops	_	_	O
17	(	_	_	O
18	long-acting	_	_	O
19	formulation	_	_	O
20	)	_	_	O
21	to	_	_	O
22	those	_	_	O
23	of	_	_	O
24	1	_	_	O
25	%	_	_	O
26	carteolol	_	_	O
27	hydrochloride	_	_	O
28	eye	_	_	O
29	drops	_	_	O
30	(	_	_	O
31	currently	_	_	O
32	prescribed	_	_	O
33	drug	_	_	O
34	)	_	_	O
35	for	_	_	O
36	reduction	_	_	O
37	of	_	_	O
38	intraocular	_	_	O
39	pressure	_	_	O
40	.	_	_	O

41	Patients	_	_	O
42	with	_	_	O
43	primary	_	_	O
44	open-angle	_	_	O
45	glaucoma	_	_	O
46	or	_	_	O
47	ocular	_	_	O
48	hypertension	_	_	O
49	(	_	_	O
50	146	_	_	O
51	cases	_	_	O
52	)	_	_	O
53	were	_	_	O
54	assigned	_	_	O
55	randomly	_	_	O
56	to	_	_	O
57	the	_	_	O
58	long-acting	_	_	O
59	drug	_	_	O
60	group	_	_	O
61	(	_	_	O
62	74	_	_	O
63	cases	_	_	O
64	)	_	_	O
65	and	_	_	O
66	the	_	_	O
67	currently-prescribed	_	_	O
68	drug	_	_	O
69	group	_	_	O
70	(	_	_	O
71	72	_	_	O
72	cases	_	_	O
73	)	_	_	O
74	.	_	_	O

75	Long-acting	_	_	O
76	eye	_	_	O
77	drops	_	_	O
78	were	_	_	O
79	instilled	_	_	O
80	once	_	_	O
81	a	_	_	O
82	day	_	_	O
83	in	_	_	O
84	the	_	_	O
85	morning	_	_	O
86	(	_	_	O
87	along	_	_	O
88	with	_	_	O
89	one	_	_	O
90	drop	_	_	O
91	of	_	_	O
92	placebo	_	_	O
93	at	_	_	O
94	night	_	_	O
95	)	_	_	O
96	,	_	_	O
97	and	_	_	O
98	currently-prescribed	_	_	O
99	eye	_	_	O
100	drops	_	_	O
101	were	_	_	O
102	instilled	_	_	O
103	twice	_	_	O
104	a	_	_	O
105	day	_	_	O
106	in	_	_	O
107	the	_	_	O
108	morning	_	_	O
109	and	_	_	O
110	at	_	_	O
111	night	_	_	O
112	.	_	_	O

113	Eye	_	_	O
114	drops	_	_	O
115	were	_	_	O
116	administered	_	_	O
117	for	_	_	O
118	8	_	_	O
119	weeks	_	_	O
120	.	_	_	O

121	Intraocular	_	_	O
122	pressure	_	_	O
123	was	_	_	O
124	monitored	_	_	O
125	at	_	_	O
126	2	_	_	O
127	,	_	_	O
128	4	_	_	O
129	,	_	_	O
130	and	_	_	O
131	8	_	_	O
132	weeks	_	_	O
133	after	_	_	O
134	the	_	_	O
135	initiation	_	_	O
136	of	_	_	O
137	drug	_	_	O
138	instillation	_	_	O
139	for	_	_	O
140	evaluation	_	_	O
141	of	_	_	O
142	equivalence	_	_	O
143	.	_	_	O

144	Intraocular	_	_	B-Premise
145	pressure	_	_	I-Premise
146	was	_	_	I-Premise
147	significantly	_	_	I-Premise
148	reduced	_	_	I-Premise
149	during	_	_	I-Premise
150	the	_	_	I-Premise
151	entire	_	_	I-Premise
152	follow-up	_	_	I-Premise
153	period	_	_	I-Premise
154	in	_	_	I-Premise
155	both	_	_	I-Premise
156	groups	_	_	I-Premise
157	.	_	_	I-Premise

158	In	_	_	B-Premise
159	the	_	_	I-Premise
160	long-acting	_	_	I-Premise
161	drug	_	_	I-Premise
162	group	_	_	I-Premise
163	,	_	_	I-Premise
164	the	_	_	I-Premise
165	reduction	_	_	I-Premise
166	of	_	_	I-Premise
167	intraocular	_	_	I-Premise
168	pressure	_	_	I-Premise
169	was	_	_	I-Premise
170	-3.5	_	_	I-Premise
171	+/-	_	_	I-Premise
172	0.2	_	_	I-Premise
173	,	_	_	I-Premise
174	-4.3	_	_	I-Premise
175	+/-	_	_	I-Premise
176	0.2	_	_	I-Premise
177	and	_	_	I-Premise
178	-4.6	_	_	I-Premise
179	+/-	_	_	I-Premise
180	0.3	_	_	I-Premise
181	mmHg	_	_	I-Premise
182	at	_	_	I-Premise
183	2	_	_	I-Premise
184	,	_	_	I-Premise
185	4	_	_	I-Premise
186	,	_	_	I-Premise
187	and	_	_	I-Premise
188	8	_	_	I-Premise
189	weeks	_	_	I-Premise
190	,	_	_	I-Premise
191	respectively	_	_	I-Premise
192	(	_	_	I-Premise
193	paired	_	_	I-Premise
194	t	_	_	I-Premise
195	test	_	_	I-Premise
196	)	_	_	I-Premise
197	.	_	_	I-Premise

198	In	_	_	B-Premise
199	the	_	_	I-Premise
200	currently-prescribed	_	_	I-Premise
201	drug	_	_	I-Premise
202	group	_	_	I-Premise
203	,	_	_	I-Premise
204	the	_	_	I-Premise
205	reduction	_	_	I-Premise
206	of	_	_	I-Premise
207	intraocular	_	_	I-Premise
208	pressure	_	_	I-Premise
209	was	_	_	I-Premise
210	-4.1	_	_	I-Premise
211	+/-	_	_	I-Premise
212	0.2	_	_	I-Premise
213	,	_	_	I-Premise
214	-4.4	_	_	I-Premise
215	+/-	_	_	I-Premise
216	0.3	_	_	I-Premise
217	and	_	_	I-Premise
218	--	_	_	I-Premise
219	4.6	_	_	I-Premise
220	+/-	_	_	I-Premise
221	0.2	_	_	I-Premise
222	mmHg	_	_	I-Premise
223	at	_	_	I-Premise
224	2	_	_	I-Premise
225	,	_	_	I-Premise
226	4	_	_	I-Premise
227	,	_	_	I-Premise
228	and	_	_	I-Premise
229	8	_	_	I-Premise
230	weeks	_	_	I-Premise
231	(	_	_	I-Premise
232	paired	_	_	I-Premise
233	t	_	_	I-Premise
234	test	_	_	I-Premise
235	)	_	_	I-Premise
236	.	_	_	I-Premise

237	The	_	_	B-Claim
238	safety	_	_	I-Claim
239	profile	_	_	I-Claim
240	was	_	_	I-Claim
241	similar	_	_	I-Claim
242	in	_	_	I-Claim
243	both	_	_	I-Claim
244	groups	_	_	I-Claim
245	,	_	_	I-Claim
246	and	_	_	I-Claim
247	the	_	_	I-Claim
248	tolerance	_	_	I-Claim
249	for	_	_	I-Claim
250	the	_	_	I-Claim
251	long-acting	_	_	I-Claim
252	eye	_	_	I-Claim
253	drops	_	_	I-Claim
254	was	_	_	I-Claim
255	as	_	_	I-Claim
256	good	_	_	I-Claim
257	as	_	_	I-Claim
258	for	_	_	I-Claim
259	the	_	_	I-Claim
260	currently-prescribed	_	_	I-Claim
261	eye	_	_	I-Claim
262	drops	_	_	I-Claim
263	.	_	_	I-Claim

264	Because	_	_	B-Claim
265	the	_	_	I-Claim
266	efficacy	_	_	I-Claim
267	of	_	_	I-Claim
268	both	_	_	I-Claim
269	drugs	_	_	I-Claim
270	was	_	_	I-Claim
271	equivalent	_	_	I-Claim
272	,	_	_	I-Claim
273	with	_	_	I-Claim
274	an	_	_	I-Claim
275	identical	_	_	I-Claim
276	safety	_	_	I-Claim
277	profile	_	_	I-Claim
278	,	_	_	I-Claim
279	the	_	_	B-Claim
280	long-acting	_	_	I-Claim
281	eye	_	_	I-Claim
282	drops	_	_	I-Claim
283	seem	_	_	I-Claim
284	to	_	_	I-Claim
285	be	_	_	I-Claim
286	an	_	_	I-Claim
287	efficacious	_	_	I-Claim
288	formulation	_	_	I-Claim
289	for	_	_	I-Claim
290	clinical	_	_	I-Claim
291	use	_	_	I-Claim
292	in	_	_	I-Claim
293	Japanese	_	_	I-Claim
294	glaucoma	_	_	I-Claim
295	patients	_	_	I-Claim
296	.	_	_	I-Claim


0	The	_	_	O
1	newer	_	_	O
2	ocular	_	_	O
3	hypotensive	_	_	O
4	agents	_	_	O
5	available	_	_	O
6	to	_	_	O
7	treat	_	_	O
8	glaucoma	_	_	O
9	and	_	_	O
10	ocular	_	_	O
11	hypertension	_	_	O
12	(	_	_	O
13	OHT	_	_	O
14	)	_	_	O
15	include	_	_	O
16	latanoprost	_	_	O
17	,	_	_	O
18	a	_	_	O
19	prostaglandin	_	_	O
20	F	_	_	O
21	(	_	_	O
22	2alpha	_	_	O
23	)	_	_	O
24	analogue	_	_	O
25	,	_	_	O
26	and	_	_	O
27	the	_	_	O
28	fixed	_	_	O
29	combination	_	_	O
30	of	_	_	O
31	dorzolamide	_	_	O
32	hydrochloride	_	_	O
33	,	_	_	O
34	a	_	_	O
35	carbonic	_	_	O
36	anhydrase	_	_	O
37	inhibitor	_	_	O
38	,	_	_	O
39	and	_	_	O
40	timolol	_	_	O
41	maleate	_	_	O
42	,	_	_	O
43	a	_	_	O
44	beta-blocker	_	_	O
45	.	_	_	O

46	The	_	_	O
47	aim	_	_	O
48	of	_	_	O
49	this	_	_	O
50	study	_	_	O
51	was	_	_	O
52	to	_	_	O
53	compare	_	_	O
54	the	_	_	O
55	efficacy	_	_	O
56	and	_	_	O
57	tolerability	_	_	O
58	of	_	_	O
59	latanoprost	_	_	O
60	with	_	_	O
61	that	_	_	O
62	of	_	_	O
63	the	_	_	O
64	fixed	_	_	O
65	combination	_	_	O
66	of	_	_	O
67	dorzolamide	_	_	O
68	and	_	_	O
69	timolol	_	_	O
70	over	_	_	O
71	8	_	_	O
72	weeks	_	_	O
73	.	_	_	O

74	This	_	_	O
75	interventional	_	_	O
76	,	_	_	O
77	8-week	_	_	O
78	,	_	_	O
79	randomized	_	_	O
80	,	_	_	O
81	open-label	_	_	O
82	,	_	_	O
83	parallel-group	_	_	O
84	study	_	_	O
85	was	_	_	O
86	conducted	_	_	O
87	at	_	_	O
88	18	_	_	O
89	centers	_	_	O
90	in	_	_	O
91	6	_	_	O
92	Latin	_	_	O
93	American	_	_	O
94	countries	_	_	O
95	.	_	_	O

96	Patients	_	_	O
97	with	_	_	O
98	unilateral	_	_	O
99	or	_	_	O
100	bilateral	_	_	O
101	primary	_	_	O
102	open-angle	_	_	O
103	,	_	_	O
104	pigmentary	_	_	O
105	,	_	_	O
106	or	_	_	O
107	exfoliative	_	_	O
108	glaucoma	_	_	O
109	or	_	_	O
110	OHT	_	_	O
111	were	_	_	O
112	randomized	_	_	O
113	to	_	_	O
114	receive	_	_	O
115	latanoprost	_	_	O
116	,	_	_	O
117	1	_	_	O
118	drop	_	_	O
119	in	_	_	O
120	the	_	_	O
121	affected	_	_	O
122	eye	_	_	O
123	QD	_	_	O
124	(	_	_	O
125	evening	_	_	O
126	)	_	_	O
127	,	_	_	O
128	or	_	_	O
129	fixed	_	_	O
130	combination	_	_	O
131	dorzolamide/timolol	_	_	O
132	,	_	_	O
133	1	_	_	O
134	drop	_	_	O
135	in	_	_	O
136	the	_	_	O
137	affected	_	_	O
138	eye	_	_	O
139	BID	_	_	O
140	(	_	_	O
141	morning	_	_	O
142	and	_	_	O
143	evening	_	_	O
144	)	_	_	O
145	.	_	_	O

146	Medications	_	_	O
147	were	_	_	O
148	self-administered	_	_	O
149	,	_	_	O
150	1	_	_	O
151	drop	_	_	O
152	per	_	_	O
153	affected	_	_	O
154	eye	_	_	O
155	.	_	_	O

156	At	_	_	O
157	baseline	_	_	O
158	and	_	_	O
159	week	_	_	O
160	8	_	_	O
161	,	_	_	O
162	intraocular	_	_	O
163	pressure	_	_	O
164	(	_	_	O
165	IOP	_	_	O
166	)	_	_	O
167	was	_	_	O
168	measured	_	_	O
169	3	_	_	O
170	times	_	_	O
171	each	_	_	O
172	at	_	_	O
173	8:30	_	_	O
174	am	_	_	O
175	,	_	_	O
176	10:00	_	_	O
177	am	_	_	O
178	,	_	_	O
179	2:00	_	_	O
180	pm	_	_	O
181	,	_	_	O
182	and	_	_	O
183	5:00	_	_	O
184	pm	_	_	O
185	and	_	_	O
186	after	_	_	O
187	the	_	_	O
188	water-drinking	_	_	O
189	test	_	_	O
190	,	_	_	O
191	which	_	_	O
192	estimates	_	_	O
193	the	_	_	O
194	IOP	_	_	O
195	peak	_	_	O
196	of	_	_	O
197	diurnal	_	_	O
198	tension	_	_	O
199	curve	_	_	O
200	,	_	_	O
201	performed	_	_	O
202	following	_	_	O
203	the	_	_	O
204	5:00	_	_	O
205	pm	_	_	O
206	IOP	_	_	O
207	assessment	_	_	O
208	.	_	_	O

209	The	_	_	O
210	primary	_	_	O
211	efficacy	_	_	O
212	outcome	_	_	O
213	was	_	_	O
214	change	_	_	O
215	in	_	_	O
216	diurnal	_	_	O
217	IOP	_	_	O
218	(	_	_	O
219	the	_	_	O
220	mean	_	_	O
221	of	_	_	O
222	IOP	_	_	O
223	measurements	_	_	O
224	)	_	_	O
225	from	_	_	O
226	baseline	_	_	O
227	to	_	_	O
228	week	_	_	O
229	8	_	_	O
230	.	_	_	O

231	Adverse	_	_	O
232	effect	_	_	O
233	(	_	_	O
234	AE	_	_	O
235	)	_	_	O
236	data	_	_	O
237	were	_	_	O
238	recorded	_	_	O
239	at	_	_	O
240	each	_	_	O
241	visit	_	_	O
242	.	_	_	O

243	A	_	_	O
244	total	_	_	O
245	of	_	_	O
246	229	_	_	O
247	patients	_	_	O
248	were	_	_	O
249	randomized	_	_	O
250	(	_	_	O
251	latanoprost	_	_	O
252	,	_	_	O
253	n	_	_	O
254	=	_	_	O
255	112	_	_	O
256	;	_	_	O
257	dorzolamide/timolol	_	_	O
258	,	_	_	O
259	n	_	_	O
260	=	_	_	O
261	117	_	_	O
262	)	_	_	O
263	.	_	_	O

264	Mean	_	_	B-Premise
265	baseline	_	_	I-Premise
266	diurnal	_	_	I-Premise
267	IOP	_	_	I-Premise
268	values	_	_	I-Premise
269	were	_	_	I-Premise
270	similar	_	_	I-Premise
271	between	_	_	I-Premise
272	the	_	_	I-Premise
273	2	_	_	I-Premise
274	groups	_	_	I-Premise
275	.	_	_	I-Premise

276	Mean	_	_	B-Premise
277	(	_	_	I-Premise
278	SD	_	_	I-Premise
279	)	_	_	I-Premise
280	diurnal	_	_	I-Premise
281	IOP	_	_	I-Premise
282	reductions	_	_	I-Premise
283	at	_	_	I-Premise
284	week	_	_	I-Premise
285	8	_	_	I-Premise
286	before	_	_	I-Premise
287	the	_	_	I-Premise
288	water-drinking	_	_	I-Premise
289	test	_	_	I-Premise
290	were	_	_	I-Premise
291	6.9	_	_	I-Premise
292	(	_	_	I-Premise
293	3.0	_	_	I-Premise
294	)	_	_	I-Premise
295	mm	_	_	I-Premise
296	Hg	_	_	I-Premise
297	for	_	_	I-Premise
298	the	_	_	I-Premise
299	latanoprost	_	_	I-Premise
300	group	_	_	I-Premise
301	and	_	_	I-Premise
302	6.4	_	_	I-Premise
303	(	_	_	I-Premise
304	3.2	_	_	I-Premise
305	)	_	_	I-Premise
306	mm	_	_	I-Premise
307	Hg	_	_	I-Premise
308	for	_	_	I-Premise
309	the	_	_	I-Premise
310	dorzolamide/timolol	_	_	I-Premise
311	group	_	_	I-Premise
312	.	_	_	I-Premise

313	Mean	_	_	B-Premise
314	IOP	_	_	I-Premise
315	values	_	_	I-Premise
316	were	_	_	I-Premise
317	similar	_	_	I-Premise
318	at	_	_	I-Premise
319	all	_	_	I-Premise
320	time	_	_	I-Premise
321	points	_	_	I-Premise
322	except	_	_	I-Premise
323	at	_	_	I-Premise
324	5:00	_	_	I-Premise
325	pm	_	_	I-Premise
326	,	_	_	I-Premise
327	when	_	_	I-Premise
328	levels	_	_	I-Premise
329	were	_	_	I-Premise
330	significantly	_	_	I-Premise
331	lower	_	_	I-Premise
332	in	_	_	I-Premise
333	latanoprost-treated	_	_	I-Premise
334	patients	_	_	I-Premise
335	(	_	_	I-Premise
336	P	_	_	I-Premise
337	=	_	_	I-Premise
338	0.025	_	_	I-Premise
339	)	_	_	I-Premise
340	.	_	_	I-Premise

341	After	_	_	B-Premise
342	the	_	_	I-Premise
343	water-drinking	_	_	I-Premise
344	test	_	_	I-Premise
345	,	_	_	I-Premise
346	the	_	_	I-Premise
347	increase	_	_	I-Premise
348	in	_	_	I-Premise
349	IOP	_	_	I-Premise
350	values	_	_	I-Premise
351	was	_	_	I-Premise
352	similar	_	_	I-Premise
353	between	_	_	I-Premise
354	groups	_	_	I-Premise
355	at	_	_	I-Premise
356	baseline	_	_	I-Premise
357	but	_	_	I-Premise
358	lower	_	_	I-Premise
359	in	_	_	I-Premise
360	latanoprost-treated	_	_	I-Premise
361	patients	_	_	I-Premise
362	at	_	_	I-Premise
363	week	_	_	I-Premise
364	8	_	_	I-Premise
365	(	_	_	I-Premise
366	adjusted	_	_	I-Premise
367	difference	_	_	I-Premise
368	,	_	_	I-Premise
369	1.08	_	_	I-Premise
370	mm	_	_	I-Premise
371	Hg	_	_	I-Premise
372	;	_	_	I-Premise
373	P	_	_	I-Premise
374	=	_	_	I-Premise
375	0.012	_	_	I-Premise
376	)	_	_	I-Premise
377	.	_	_	I-Premise

378	Fewer	_	_	B-Premise
379	patients	_	_	I-Premise
380	treated	_	_	I-Premise
381	with	_	_	I-Premise
382	latanoprost	_	_	I-Premise
383	reported	_	_	I-Premise
384	ocular	_	_	I-Premise
385	or	_	_	I-Premise
386	systemic	_	_	I-Premise
387	AEs	_	_	I-Premise
388	(	_	_	I-Premise
389	P	_	_	I-Premise
390	=	_	_	I-Premise
391	0.025	_	_	I-Premise
392	and	_	_	I-Premise
393	P	_	_	I-Premise
394	<	_	_	I-Premise
395	0.001	_	_	I-Premise
396	,	_	_	I-Premise
397	respectively	_	_	I-Premise
398	)	_	_	I-Premise
399	.	_	_	I-Premise

400	In	_	_	B-Claim
401	this	_	_	I-Claim
402	study	_	_	I-Claim
403	of	_	_	I-Claim
404	patients	_	_	I-Claim
405	with	_	_	I-Claim
406	unilateral	_	_	I-Claim
407	or	_	_	I-Claim
408	bilateral	_	_	I-Claim
409	primary	_	_	I-Claim
410	open-angle	_	_	I-Claim
411	,	_	_	I-Claim
412	pigmentary	_	_	I-Claim
413	,	_	_	I-Claim
414	or	_	_	I-Claim
415	exfoliative	_	_	I-Claim
416	glaucoma	_	_	I-Claim
417	or	_	_	I-Claim
418	OHT	_	_	I-Claim
419	IOP	_	_	I-Claim
420	reductions	_	_	I-Claim
421	generally	_	_	I-Claim
422	were	_	_	I-Claim
423	similar	_	_	I-Claim
424	between	_	_	I-Claim
425	treatment	_	_	I-Claim
426	groups	_	_	I-Claim
427	,	_	_	I-Claim
428	except	_	_	B-Claim
429	at	_	_	I-Claim
430	5:00	_	_	I-Claim
431	pm	_	_	I-Claim
432	,	_	_	I-Claim
433	when	_	_	I-Claim
434	the	_	_	I-Claim
435	mean	_	_	I-Claim
436	IOP	_	_	I-Claim
437	level	_	_	I-Claim
438	was	_	_	I-Claim
439	significantly	_	_	I-Claim
440	lower	_	_	I-Claim
441	in	_	_	I-Claim
442	latanoprost-treated	_	_	I-Claim
443	patients	_	_	I-Claim
444	.	_	_	I-Claim

445	Latanoprost	_	_	B-Claim
446	was	_	_	I-Claim
447	better	_	_	I-Claim
448	tolerated	_	_	I-Claim
449	than	_	_	I-Claim
450	fixed-combination	_	_	I-Claim
451	dorzolamide	_	_	I-Claim
452	and	_	_	I-Claim
453	timolol	_	_	I-Claim
454	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	clinical	_	_	O
4	success	_	_	O
5	rates	_	_	O
6	and	_	_	O
7	quality	_	_	O
8	of	_	_	O
9	life	_	_	O
10	impact	_	_	O
11	of	_	_	O
12	brimonidine	_	_	O
13	0.2	_	_	O
14	%	_	_	O
15	with	_	_	O
16	timolol	_	_	O
17	0.5	_	_	O
18	%	_	_	O
19	in	_	_	O
20	newly	_	_	O
21	diagnosed	_	_	O
22	patients	_	_	O
23	naive	_	_	O
24	to	_	_	O
25	glaucoma	_	_	O
26	therapy	_	_	O
27	.	_	_	O

28	A	_	_	O
29	prospective	_	_	O
30	,	_	_	O
31	multicenter	_	_	O
32	,	_	_	O
33	randomized	_	_	O
34	,	_	_	O
35	double-masked	_	_	O
36	,	_	_	O
37	clinical	_	_	O
38	effectiveness	_	_	O
39	trial	_	_	O
40	in	_	_	O
41	which	_	_	O
42	the	_	_	O
43	clinical	_	_	O
44	outcomes	_	_	O
45	of	_	_	O
46	twice	_	_	O
47	daily	_	_	O
48	brimonidine	_	_	O
49	tartrate	_	_	O
50	0.2	_	_	O
51	%	_	_	O
52	were	_	_	O
53	compared	_	_	O
54	with	_	_	O
55	those	_	_	O
56	of	_	_	O
57	timolol	_	_	O
58	maleate	_	_	O
59	0.5	_	_	O
60	%	_	_	O
61	in	_	_	O
62	patients	_	_	O
63	with	_	_	O
64	glaucoma	_	_	O
65	and	_	_	O
66	ocular	_	_	O
67	hypertension	_	_	O
68	was	_	_	O
69	conducted	_	_	O
70	.	_	_	O

71	Two	_	_	O
72	hundred	_	_	O
73	nineteen	_	_	O
74	patients	_	_	O
75	were	_	_	O
76	enrolled	_	_	O
77	--	_	_	O
78	111	_	_	O
79	in	_	_	O
80	the	_	_	O
81	brimonidine	_	_	O
82	group	_	_	O
83	and	_	_	O
84	108	_	_	O
85	in	_	_	O
86	the	_	_	O
87	timolol	_	_	O
88	group	_	_	O
89	.	_	_	O

90	Patients	_	_	O
91	instilled	_	_	O
92	their	_	_	O
93	study	_	_	O
94	medications	_	_	O
95	twice	_	_	O
96	daily	_	_	O
97	for	_	_	O
98	4	_	_	O
99	months	_	_	O
100	.	_	_	O

101	Factors	_	_	O
102	for	_	_	O
103	determining	_	_	O
104	clinical	_	_	O
105	success	_	_	O
106	were	_	_	O
107	reduction	_	_	O
108	of	_	_	O
109	intraocular	_	_	O
110	pressure	_	_	O
111	(	_	_	O
112	IOP	_	_	O
113	)	_	_	O
114	,	_	_	O
115	safety	_	_	O
116	,	_	_	O
117	and	_	_	O
118	adverse	_	_	O
119	events	_	_	O
120	.	_	_	O

121	Quality	_	_	O
122	of	_	_	O
123	life	_	_	O
124	effects	_	_	O
125	were	_	_	O
126	assessed	_	_	O
127	with	_	_	O
128	the	_	_	O
129	SF-36	_	_	O
130	Health	_	_	O
131	Survey	_	_	O
132	and	_	_	O
133	Glaucoma	_	_	O
134	Disability	_	_	O
135	Index	_	_	O
136	questionnaires	_	_	O
137	.	_	_	O

138	Clinical	_	_	B-Premise
139	success	_	_	I-Premise
140	was	_	_	I-Premise
141	71	_	_	I-Premise
142	%	_	_	I-Premise
143	(	_	_	I-Premise
144	75/106	_	_	I-Premise
145	)	_	_	I-Premise
146	with	_	_	I-Premise
147	brimonidine	_	_	I-Premise
148	and	_	_	I-Premise
149	70	_	_	I-Premise
150	%	_	_	I-Premise
151	(	_	_	I-Premise
152	73/105	_	_	I-Premise
153	)	_	_	I-Premise
154	with	_	_	I-Premise
155	timolol	_	_	I-Premise
156	as	_	_	I-Premise
157	initial	_	_	I-Premise
158	treatment	_	_	I-Premise
159	.	_	_	I-Premise

160	The	_	_	B-Premise
161	overall	_	_	I-Premise
162	mean	_	_	I-Premise
163	decrease	_	_	I-Premise
164	in	_	_	I-Premise
165	IOP	_	_	I-Premise
166	was	_	_	I-Premise
167	6.5	_	_	I-Premise
168	mm	_	_	I-Premise
169	Hg	_	_	I-Premise
170	with	_	_	I-Premise
171	brimonidine	_	_	I-Premise
172	and	_	_	I-Premise
173	6.2	_	_	I-Premise
174	mm	_	_	I-Premise
175	Hg	_	_	I-Premise
176	with	_	_	I-Premise
177	timolol	_	_	I-Premise
178	.	_	_	I-Premise

179	Few	_	_	B-Premise
180	patients	_	_	I-Premise
181	reported	_	_	I-Premise
182	a	_	_	I-Premise
183	specific	_	_	I-Premise
184	adverse	_	_	I-Premise
185	event	_	_	I-Premise
186	and	_	_	O
187	,	_	_	O
188	with	_	_	B-Premise
189	the	_	_	I-Premise
190	exception	_	_	I-Premise
191	of	_	_	I-Premise
192	a	_	_	I-Premise
193	slightly	_	_	I-Premise
194	higher	_	_	I-Premise
195	rate	_	_	I-Premise
196	of	_	_	I-Premise
197	ocular	_	_	I-Premise
198	burning	_	_	I-Premise
199	and	_	_	I-Premise
200	stinging	_	_	I-Premise
201	in	_	_	I-Premise
202	the	_	_	I-Premise
203	brimonidine	_	_	I-Premise
204	group	_	_	I-Premise
205	,	_	_	I-Premise
206	there	_	_	I-Premise
207	were	_	_	I-Premise
208	no	_	_	I-Premise
209	significant	_	_	I-Premise
210	between-group	_	_	I-Premise
211	differences	_	_	I-Premise
212	.	_	_	I-Premise

213	No	_	_	B-Premise
214	significant	_	_	I-Premise
215	chronotropic	_	_	I-Premise
216	effects	_	_	I-Premise
217	on	_	_	I-Premise
218	the	_	_	I-Premise
219	heart	_	_	I-Premise
220	were	_	_	I-Premise
221	seen	_	_	I-Premise
222	with	_	_	I-Premise
223	brimonidine	_	_	I-Premise
224	,	_	_	O
225	while	_	_	O
226	small	_	_	B-Premise
227	but	_	_	I-Premise
228	significant	_	_	I-Premise
229	mean	_	_	I-Premise
230	decreases	_	_	I-Premise
231	in	_	_	I-Premise
232	heart	_	_	I-Premise
233	rate	_	_	I-Premise
234	were	_	_	I-Premise
235	seen	_	_	I-Premise
236	at	_	_	I-Premise
237	months	_	_	I-Premise
238	1	_	_	I-Premise
239	and	_	_	I-Premise
240	4	_	_	I-Premise
241	with	_	_	I-Premise
242	timolol	_	_	I-Premise
243	.	_	_	I-Premise

244	Mean	_	_	B-Premise
245	systolic	_	_	I-Premise
246	and	_	_	I-Premise
247	diastolic	_	_	I-Premise
248	blood	_	_	I-Premise
249	pressure	_	_	I-Premise
250	remained	_	_	I-Premise
251	relatively	_	_	I-Premise
252	stable	_	_	I-Premise
253	in	_	_	I-Premise
254	both	_	_	I-Premise
255	groups	_	_	I-Premise
256	.	_	_	I-Premise

257	Quality	_	_	B-Premise
258	of	_	_	I-Premise
259	life	_	_	I-Premise
260	remained	_	_	I-Premise
261	stable	_	_	I-Premise
262	,	_	_	I-Premise
263	with	_	_	I-Premise
264	no	_	_	I-Premise
265	significant	_	_	I-Premise
266	between-group	_	_	I-Premise
267	differences	_	_	I-Premise
268	.	_	_	I-Premise

269	As	_	_	B-Claim
270	a	_	_	I-Claim
271	first-line	_	_	I-Claim
272	agent	_	_	I-Claim
273	for	_	_	I-Claim
274	the	_	_	I-Claim
275	treatment	_	_	I-Claim
276	of	_	_	I-Claim
277	glaucoma	_	_	I-Claim
278	and	_	_	I-Claim
279	ocular	_	_	I-Claim
280	hypertension	_	_	I-Claim
281	,	_	_	I-Claim
282	brimonidine	_	_	I-Claim
283	has	_	_	I-Claim
284	clinical	_	_	I-Claim
285	effectiveness	_	_	I-Claim
286	equivalent	_	_	I-Claim
287	to	_	_	I-Claim
288	timolol	_	_	I-Claim
289	,	_	_	I-Claim
290	but	_	_	I-Claim
291	with	_	_	I-Claim
292	less	_	_	I-Claim
293	chronotropic	_	_	I-Claim
294	effect	_	_	I-Claim
295	on	_	_	I-Claim
296	the	_	_	I-Claim
297	heart	_	_	I-Claim
298	.	_	_	I-Claim

299	Brimonidine	_	_	B-Claim
300	is	_	_	I-Claim
301	a	_	_	I-Claim
302	viable	_	_	I-Claim
303	alternative	_	_	I-Claim
304	to	_	_	I-Claim
305	timolol	_	_	I-Claim
306	for	_	_	I-Claim
307	first-line	_	_	I-Claim
308	therapy	_	_	I-Claim
309	in	_	_	I-Claim
310	glaucoma	_	_	I-Claim
311	and	_	_	I-Claim
312	ocular	_	_	I-Claim
313	hypertension	_	_	I-Claim
314	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	alpha2-adrenergic	_	_	O
4	agonist	_	_	O
5	brimonidine	_	_	O
6	tartrate	_	_	O
7	0.2	_	_	O
8	%	_	_	O
9	to	_	_	O
10	the	_	_	O
11	beta-adrenergic	_	_	O
12	antagonist	_	_	O
13	timolol	_	_	O
14	maleate	_	_	O
15	0.5	_	_	O
16	%	_	_	O
17	in	_	_	O
18	preserving	_	_	O
19	visual	_	_	O
20	function	_	_	O
21	in	_	_	O
22	low-pressure	_	_	O
23	glaucoma	_	_	O
24	.	_	_	O

25	Randomized	_	_	O
26	,	_	_	O
27	double-masked	_	_	O
28	,	_	_	O
29	multicenter	_	_	O
30	clinical	_	_	O
31	trial	_	_	O
32	.	_	_	O

33	Exclusion	_	_	O
34	criteria	_	_	O
35	included	_	_	O
36	untreated	_	_	O
37	intraocular	_	_	O
38	pressure	_	_	O
39	(	_	_	O
40	IOP	_	_	O
41	)	_	_	O
42	>	_	_	O
43	21	_	_	O
44	mm	_	_	O
45	Hg	_	_	O
46	,	_	_	O
47	visual	_	_	O
48	field	_	_	O
49	mean	_	_	O
50	deviation	_	_	O
51	worse	_	_	O
52	than	_	_	O
53	-16	_	_	O
54	decibels	_	_	O
55	,	_	_	O
56	or	_	_	O
57	contraindications	_	_	O
58	to	_	_	O
59	study	_	_	O
60	medications	_	_	O
61	.	_	_	O

62	Both	_	_	O
63	eyes	_	_	O
64	received	_	_	O
65	twice-daily	_	_	O
66	monotherapy	_	_	O
67	randomized	_	_	O
68	in	_	_	O
69	blocks	_	_	O
70	of	_	_	O
71	7	_	_	O
72	(	_	_	O
73	4	_	_	O
74	brimonidine	_	_	O
75	to	_	_	O
76	3	_	_	O
77	timolol	_	_	O
78	)	_	_	O
79	.	_	_	O

80	Standard	_	_	O
81	automated	_	_	O
82	perimetry	_	_	O
83	and	_	_	O
84	tonometry	_	_	O
85	were	_	_	O
86	performed	_	_	O
87	at	_	_	O
88	4-month	_	_	O
89	intervals	_	_	O
90	.	_	_	O

91	Main	_	_	O
92	outcome	_	_	O
93	measure	_	_	O
94	was	_	_	O
95	field	_	_	O
96	progression	_	_	O
97	in	_	_	O
98	either	_	_	O
99	eye	_	_	O
100	,	_	_	O
101	defined	_	_	O
102	as	_	_	O
103	the	_	_	O
104	same	_	_	O
105	3	_	_	O
106	or	_	_	O
107	more	_	_	O
108	points	_	_	O
109	with	_	_	O
110	a	_	_	O
111	negative	_	_	O
112	slope	_	_	O
113	-1	_	_	O
114	dB/year	_	_	O
115	at	_	_	O
116	P	_	_	O
117	<	_	_	O
118	5	_	_	O
119	%	_	_	O
120	,	_	_	O
121	on	_	_	O
122	3	_	_	O
123	consecutive	_	_	O
124	tests	_	_	O
125	,	_	_	O
126	assessed	_	_	O
127	by	_	_	O
128	pointwise	_	_	O
129	linear	_	_	O
130	regression	_	_	O
131	.	_	_	O

132	Secondary	_	_	O
133	outcome	_	_	O
134	measures	_	_	O
135	were	_	_	O
136	progression	_	_	O
137	based	_	_	O
138	on	_	_	O
139	glaucoma	_	_	O
140	change	_	_	O
141	probability	_	_	O
142	maps	_	_	O
143	(	_	_	O
144	GCPM	_	_	O
145	)	_	_	O
146	of	_	_	O
147	pattern	_	_	O
148	deviation	_	_	O
149	and	_	_	O
150	the	_	_	O
151	3-omitting	_	_	O
152	method	_	_	O
153	for	_	_	O
154	pointwise	_	_	O
155	linear	_	_	O
156	regression	_	_	O
157	.	_	_	O

158	Ninety-nine	_	_	O
159	patients	_	_	O
160	were	_	_	O
161	randomized	_	_	O
162	to	_	_	O
163	brimonidine	_	_	O
164	and	_	_	O
165	79	_	_	O
166	to	_	_	O
167	timolol	_	_	O
168	.	_	_	O

169	Mean	_	_	O
170	(	_	_	O
171	+/-	_	_	O
172	SE	_	_	O
173	)	_	_	O
174	months	_	_	O
175	of	_	_	O
176	follow-up	_	_	O
177	for	_	_	O
178	all	_	_	O
179	patients	_	_	O
180	was	_	_	O
181	30.0	_	_	O
182	+/-	_	_	O
183	2	_	_	O
184	.	_	_	O

185	Statistically	_	_	B-Premise
186	fewer	_	_	I-Premise
187	brimonidine-treated	_	_	I-Premise
188	patients	_	_	I-Premise
189	(	_	_	I-Premise
190	9	_	_	I-Premise
191	,	_	_	I-Premise
192	9.1	_	_	I-Premise
193	%	_	_	I-Premise
194	)	_	_	I-Premise
195	had	_	_	I-Premise
196	visual	_	_	I-Premise
197	field	_	_	I-Premise
198	progression	_	_	I-Premise
199	by	_	_	I-Premise
200	pointwise	_	_	I-Premise
201	linear	_	_	I-Premise
202	regression	_	_	I-Premise
203	than	_	_	I-Premise
204	timolol-treated	_	_	I-Premise
205	patients	_	_	I-Premise
206	(	_	_	I-Premise
207	31	_	_	I-Premise
208	,	_	_	I-Premise
209	39.2	_	_	I-Premise
210	%	_	_	I-Premise
211	,	_	_	I-Premise
212	log-rank	_	_	I-Premise
213	12.4	_	_	I-Premise
214	,	_	_	I-Premise
215	P=.001	_	_	I-Premise
216	)	_	_	I-Premise
217	.	_	_	I-Premise

218	Mean	_	_	B-Premise
219	treated	_	_	I-Premise
220	IOP	_	_	I-Premise
221	was	_	_	I-Premise
222	similar	_	_	I-Premise
223	for	_	_	I-Premise
224	brimonidine-	_	_	I-Premise
225	and	_	_	I-Premise
226	timolol-treated	_	_	I-Premise
227	patients	_	_	I-Premise
228	at	_	_	I-Premise
229	all	_	_	I-Premise
230	time	_	_	I-Premise
231	points	_	_	I-Premise
232	.	_	_	I-Premise

233	More	_	_	B-Premise
234	brimonidine-treated	_	_	I-Premise
235	(	_	_	I-Premise
236	28	_	_	I-Premise
237	,	_	_	I-Premise
238	28.3	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	than	_	_	I-Premise
242	timolol-treated	_	_	I-Premise
243	(	_	_	I-Premise
244	9	_	_	I-Premise
245	,	_	_	I-Premise
246	11.4	_	_	I-Premise
247	%	_	_	I-Premise
248	)	_	_	I-Premise
249	patients	_	_	I-Premise
250	discontinued	_	_	I-Premise
251	study	_	_	I-Premise
252	participation	_	_	I-Premise
253	because	_	_	I-Premise
254	of	_	_	I-Premise
255	drug-related	_	_	I-Premise
256	adverse	_	_	I-Premise
257	events	_	_	I-Premise
258	(	_	_	I-Premise
259	P=.008	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	Similar	_	_	B-Claim
263	differences	_	_	I-Claim
264	in	_	_	I-Claim
265	progression	_	_	I-Claim
266	were	_	_	I-Claim
267	observed	_	_	I-Claim
268	when	_	_	I-Claim
269	analyzed	_	_	I-Claim
270	by	_	_	I-Claim
271	GCPM	_	_	I-Claim
272	and	_	_	I-Claim
273	the	_	_	I-Claim
274	3-omitting	_	_	I-Claim
275	method	_	_	I-Claim
276	.	_	_	I-Claim

277	Low-pressure	_	_	B-Claim
278	glaucoma	_	_	I-Claim
279	patients	_	_	I-Claim
280	treated	_	_	I-Claim
281	with	_	_	I-Claim
282	brimonidine	_	_	I-Claim
283	0.2	_	_	I-Claim
284	%	_	_	I-Claim
285	who	_	_	I-Claim
286	do	_	_	I-Claim
287	not	_	_	I-Claim
288	develop	_	_	I-Claim
289	ocular	_	_	I-Claim
290	allergy	_	_	I-Claim
291	are	_	_	I-Claim
292	less	_	_	I-Claim
293	likely	_	_	I-Claim
294	to	_	_	I-Claim
295	have	_	_	I-Claim
296	field	_	_	I-Claim
297	progression	_	_	I-Claim
298	than	_	_	I-Claim
299	patients	_	_	I-Claim
300	treated	_	_	I-Claim
301	with	_	_	I-Claim
302	timolol	_	_	I-Claim
303	0.5	_	_	I-Claim
304	%	_	_	I-Claim
305	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	two	_	_	O
3	intraocular	_	_	O
4	irrigating	_	_	O
5	solutions	_	_	O
6	,	_	_	O
7	Balanced	_	_	O
8	Salt	_	_	O
9	Solution	_	_	O
10	Plus	_	_	O
11	(	_	_	O
12	BSS	_	_	O
13	Plus	_	_	O
14	)	_	_	O
15	versus	_	_	O
16	Lactated	_	_	O
17	Ringer	_	_	O
18	's	_	_	O
19	(	_	_	O
20	Ringer	_	_	O
21	)	_	_	O
22	,	_	_	O
23	for	_	_	O
24	the	_	_	O
25	preservation	_	_	O
26	of	_	_	O
27	corneal	_	_	O
28	integrity	_	_	O
29	after	_	_	O
30	phacoemulsification	_	_	O
31	.	_	_	O

32	110	_	_	O
33	patients	_	_	O
34	undergoing	_	_	O
35	phacoemulsification	_	_	O
36	were	_	_	O
37	randomised	_	_	O
38	to	_	_	O
39	either	_	_	O
40	BSS	_	_	O
41	Plus	_	_	O
42	(	_	_	O
43	n=55	_	_	O
44	)	_	_	O
45	or	_	_	O
46	Ringer	_	_	O
47	(	_	_	O
48	n=55	_	_	O
49	)	_	_	O
50	as	_	_	O
51	the	_	_	O
52	irrigating	_	_	O
53	solution	_	_	O
54	.	_	_	O

55	Patients	_	_	O
56	were	_	_	O
57	examined	_	_	O
58	at	_	_	O
59	baseline	_	_	O
60	and	_	_	O
61	at	_	_	O
62	1	_	_	O
63	,	_	_	O
64	8	_	_	O
65	,	_	_	O
66	15	_	_	O
67	,	_	_	O
68	30	_	_	O
69	and	_	_	O
70	60	_	_	O
71	days	_	_	O
72	postoperatively	_	_	O
73	.	_	_	O

74	Evaluations	_	_	O
75	included	_	_	O
76	specular	_	_	O
77	microscopy	_	_	O
78	to	_	_	O
79	evaluate	_	_	O
80	endothelial	_	_	O
81	cell	_	_	O
82	density	_	_	O
83	(	_	_	O
84	ECD	_	_	O
85	)	_	_	O
86	and	_	_	O
87	endothelial	_	_	O
88	cell	_	_	O
89	size	_	_	O
90	variability	_	_	O
91	(	_	_	O
92	CV	_	_	O
93	)	_	_	O
94	,	_	_	O
95	and	_	_	O
96	corneal	_	_	O
97	pachymetry	_	_	O
98	for	_	_	O
99	central	_	_	O
100	corneal	_	_	O
101	thickness	_	_	O
102	(	_	_	O
103	CCT	_	_	O
104	)	_	_	O
105	measurement	_	_	O
106	.	_	_	O

107	Groups	_	_	O
108	were	_	_	O
109	well	_	_	O
110	balanced	_	_	O
111	regarding	_	_	O
112	baseline	_	_	O
113	ECD	_	_	O
114	,	_	_	O
115	CV	_	_	O
116	and	_	_	O
117	CCT	_	_	O
118	(	_	_	O
119	p	_	_	O
120	>	_	_	O
121	0.05	_	_	O
122	)	_	_	O
123	.	_	_	O

124	There	_	_	B-Premise
125	was	_	_	I-Premise
126	no	_	_	I-Premise
127	statistically	_	_	I-Premise
128	significant	_	_	I-Premise
129	difference	_	_	I-Premise
130	between	_	_	I-Premise
131	ECD	_	_	I-Premise
132	reduction	_	_	I-Premise
133	in	_	_	I-Premise
134	group	_	_	I-Premise
135	BSS	_	_	I-Premise
136	Plus	_	_	I-Premise
137	13.1	_	_	I-Premise
138	±	_	_	I-Premise
139	2.0	_	_	I-Premise
140	%	_	_	I-Premise
141	and	_	_	I-Premise
142	Ringer	_	_	I-Premise
143	9.2	_	_	I-Premise
144	±	_	_	I-Premise
145	1.9	_	_	I-Premise
146	%	_	_	I-Premise
147	(	_	_	I-Premise
148	p	_	_	I-Premise
149	<	_	_	I-Premise
150	0.05	_	_	I-Premise
151	)	_	_	I-Premise
152	at	_	_	I-Premise
153	day	_	_	I-Premise
154	60	_	_	I-Premise
155	or	_	_	I-Premise
156	in	_	_	I-Premise
157	any	_	_	I-Premise
158	study	_	_	I-Premise
159	visit	_	_	I-Premise
160	.	_	_	I-Premise

161	There	_	_	B-Premise
162	was	_	_	I-Premise
163	no	_	_	I-Premise
164	statistically	_	_	I-Premise
165	significant	_	_	I-Premise
166	difference	_	_	I-Premise
167	between	_	_	I-Premise
168	CV	_	_	I-Premise
169	increase	_	_	I-Premise
170	in	_	_	I-Premise
171	group	_	_	I-Premise
172	BSS	_	_	I-Premise
173	Plus	_	_	I-Premise
174	23.0	_	_	I-Premise
175	±	_	_	I-Premise
176	3.0	_	_	I-Premise
177	%	_	_	I-Premise
178	and	_	_	I-Premise
179	Ringer	_	_	I-Premise
180	20.2	_	_	I-Premise
181	±	_	_	I-Premise
182	4.0	_	_	I-Premise
183	%	_	_	I-Premise
184	(	_	_	I-Premise
185	p	_	_	I-Premise
186	<	_	_	I-Premise
187	0.05	_	_	I-Premise
188	)	_	_	I-Premise
189	at	_	_	I-Premise
190	day	_	_	I-Premise
191	60	_	_	I-Premise
192	or	_	_	I-Premise
193	in	_	_	I-Premise
194	any	_	_	I-Premise
195	study	_	_	I-Premise
196	visit	_	_	I-Premise
197	.	_	_	I-Premise

198	CCT	_	_	B-Premise
199	was	_	_	I-Premise
200	significantly	_	_	I-Premise
201	increased	_	_	I-Premise
202	(	_	_	I-Premise
203	p	_	_	I-Premise
204	<	_	_	I-Premise
205	0.05	_	_	I-Premise
206	)	_	_	I-Premise
207	at	_	_	I-Premise
208	1	_	_	I-Premise
209	,	_	_	I-Premise
210	8	_	_	I-Premise
211	,	_	_	I-Premise
212	15	_	_	I-Premise
213	and	_	_	I-Premise
214	30	_	_	I-Premise
215	days	_	_	I-Premise
216	postoperatively	_	_	I-Premise
217	,	_	_	I-Premise
218	returning	_	_	I-Premise
219	to	_	_	I-Premise
220	baseline	_	_	I-Premise
221	at	_	_	I-Premise
222	60	_	_	I-Premise
223	days	_	_	I-Premise
224	in	_	_	I-Premise
225	both	_	_	I-Premise
226	groups	_	_	I-Premise
227	.	_	_	I-Premise

228	There	_	_	B-Premise
229	was	_	_	I-Premise
230	no	_	_	I-Premise
231	significant	_	_	I-Premise
232	difference	_	_	I-Premise
233	in	_	_	I-Premise
234	CCT	_	_	I-Premise
235	increase	_	_	I-Premise
236	in	_	_	I-Premise
237	both	_	_	I-Premise
238	groups	_	_	I-Premise
239	at	_	_	I-Premise
240	any	_	_	I-Premise
241	visit	_	_	I-Premise
242	.	_	_	I-Premise

243	Interestingly	_	_	O
244	,	_	_	O
245	there	_	_	B-Premise
246	were	_	_	I-Premise
247	statistically	_	_	I-Premise
248	significant	_	_	I-Premise
249	correlations	_	_	I-Premise
250	between	_	_	I-Premise
251	ECD	_	_	I-Premise
252	loss	_	_	I-Premise
253	and	_	_	I-Premise
254	phacoemulsification	_	_	I-Premise
255	time	_	_	I-Premise
256	(	_	_	I-Premise
257	p	_	_	I-Premise
258	<	_	_	I-Premise
259	0.0001	_	_	I-Premise
260	)	_	_	I-Premise
261	and	_	_	I-Premise
262	ECD	_	_	I-Premise
263	loss	_	_	I-Premise
264	and	_	_	I-Premise
265	irrigation	_	_	I-Premise
266	solution	_	_	I-Premise
267	volume	_	_	I-Premise
268	(	_	_	I-Premise
269	p	_	_	I-Premise
270	<	_	_	I-Premise
271	0.0001	_	_	I-Premise
272	)	_	_	I-Premise
273	in	_	_	I-Premise
274	the	_	_	I-Premise
275	Ringer	_	_	I-Premise
276	group	_	_	I-Premise
277	,	_	_	I-Premise
278	but	_	_	I-Premise
279	not	_	_	I-Premise
280	in	_	_	I-Premise
281	the	_	_	I-Premise
282	BSS	_	_	I-Premise
283	Plus	_	_	I-Premise
284	group	_	_	I-Premise
285	.	_	_	I-Premise

286	Ringers	_	_	B-Claim
287	solution	_	_	I-Claim
288	was	_	_	I-Claim
289	similar	_	_	I-Claim
290	to	_	_	I-Claim
291	BSS	_	_	I-Claim
292	Plus	_	_	I-Claim
293	for	_	_	I-Claim
294	corneal	_	_	I-Claim
295	preservation	_	_	I-Claim
296	in	_	_	I-Claim
297	atraumatic	_	_	I-Claim
298	cataract	_	_	I-Claim
299	surgery	_	_	I-Claim
300	.	_	_	I-Claim

301	However	_	_	B-Claim
302	,	_	_	I-Claim
303	our	_	_	I-Claim
304	study	_	_	I-Claim
305	demonstrates	_	_	I-Claim
306	that	_	_	I-Claim
307	there	_	_	I-Claim
308	is	_	_	I-Claim
309	a	_	_	I-Claim
310	trend	_	_	I-Claim
311	towards	_	_	I-Claim
312	lower	_	_	I-Claim
313	postoperative	_	_	I-Claim
314	endothelial	_	_	I-Claim
315	cell	_	_	I-Claim
316	density	_	_	I-Claim
317	for	_	_	I-Claim
318	surgeries	_	_	I-Claim
319	with	_	_	I-Claim
320	longer	_	_	I-Claim
321	phacoemulsification	_	_	I-Claim
322	time	_	_	I-Claim
323	and	_	_	I-Claim
324	higher	_	_	I-Claim
325	irrigation	_	_	I-Claim
326	volumes	_	_	I-Claim
327	if	_	_	I-Claim
328	Ringer	_	_	I-Claim
329	is	_	_	I-Claim
330	used	_	_	I-Claim
331	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	the	_	_	O
8	fixed	_	_	O
9	combination	_	_	O
10	of	_	_	O
11	timolol	_	_	O
12	maleate	_	_	O
13	0.5	_	_	O
14	%	_	_	O
15	/brimonidine	_	_	O
16	tartrate	_	_	O
17	0.2	_	_	O
18	%	_	_	O
19	versus	_	_	O
20	fixed	_	_	O
21	combination	_	_	O
22	of	_	_	O
23	timolol	_	_	O
24	maleate	_	_	O
25	0.5	_	_	O
26	%	_	_	O
27	/dorzolamide	_	_	O
28	2	_	_	O
29	%	_	_	O
30	in	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	elevated	_	_	O
34	intraocular	_	_	O
35	pressure	_	_	O
36	(	_	_	O
37	IOP	_	_	O
38	)	_	_	O
39	over	_	_	O
40	8	_	_	O
41	weeks	_	_	O
42	.	_	_	O

43	This	_	_	O
44	8-week	_	_	O
45	,	_	_	O
46	multicentric	_	_	O
47	,	_	_	O
48	interventional	_	_	O
49	,	_	_	O
50	randomized	_	_	O
51	,	_	_	O
52	open-label	_	_	O
53	,	_	_	O
54	parallel	_	_	O
55	group	_	_	O
56	study	_	_	O
57	was	_	_	O
58	conducted	_	_	O
59	at	_	_	O
60	4	_	_	O
61	centers	_	_	O
62	in	_	_	O
63	Brazil	_	_	O
64	and	_	_	O
65	1	_	_	O
66	center	_	_	O
67	in	_	_	O
68	Argentina	_	_	O
69	.	_	_	O

70	Patients	_	_	O
71	with	_	_	O
72	open-angle	_	_	O
73	glaucoma	_	_	O
74	or	_	_	O
75	ocular	_	_	O
76	hypertension	_	_	O
77	were	_	_	O
78	randomized	_	_	O
79	to	_	_	O
80	receive	_	_	O
81	bilaterally	_	_	O
82	fixed	_	_	O
83	combination	_	_	O
84	of	_	_	O
85	brimonidine/timolol	_	_	O
86	maleate	_	_	O
87	0.5	_	_	O
88	%	_	_	O
89	or	_	_	O
90	fixed	_	_	O
91	combination	_	_	O
92	of	_	_	O
93	dorzolamide	_	_	O
94	2	_	_	O
95	%	_	_	O
96	/timolol	_	_	O
97	0.5	_	_	O
98	%	_	_	O
99	twice	_	_	O
100	daily	_	_	O
101	at	_	_	O
102	8:00	_	_	O
103	AM	_	_	O
104	and	_	_	O
105	8:00	_	_	O
106	PM	_	_	O
107	.	_	_	O

108	A	_	_	O
109	modified	_	_	O
110	diurnal	_	_	O
111	tension	_	_	O
112	curve	_	_	O
113	(	_	_	O
114	8:00	_	_	O
115	AM	_	_	O
116	,	_	_	O
117	10:30	_	_	O
118	AM	_	_	O
119	,	_	_	O
120	02:00	_	_	O
121	PM	_	_	O
122	,	_	_	O
123	and	_	_	O
124	4:00	_	_	O
125	PM	_	_	O
126	)	_	_	O
127	followed	_	_	O
128	by	_	_	O
129	the	_	_	O
130	water	_	_	O
131	drinking	_	_	O
132	test	_	_	O
133	(	_	_	O
134	WDT	_	_	O
135	)	_	_	O
136	,	_	_	O
137	which	_	_	O
138	estimates	_	_	O
139	IOP	_	_	O
140	peak	_	_	O
141	of	_	_	O
142	diurnal	_	_	O
143	tension	_	_	O
144	curve	_	_	O
145	,	_	_	O
146	were	_	_	O
147	performed	_	_	O
148	in	_	_	O
149	the	_	_	O
150	baseline	_	_	O
151	and	_	_	O
152	week-8	_	_	O
153	visits	_	_	O
154	.	_	_	O

155	Adverse	_	_	O
156	events	_	_	O
157	data	_	_	O
158	were	_	_	O
159	recorded	_	_	O
160	at	_	_	O
161	each	_	_	O
162	visit	_	_	O
163	.	_	_	O

164	A	_	_	O
165	total	_	_	O
166	of	_	_	O
167	210	_	_	O
168	patients	_	_	O
169	were	_	_	O
170	randomized	_	_	O
171	(	_	_	O
172	brimonidine/timolol	_	_	O
173	,	_	_	O
174	n=111	_	_	O
175	;	_	_	O
176	dorzolamide/timolol	_	_	O
177	,	_	_	O
178	n=99	_	_	O
179	)	_	_	O
180	.	_	_	O

181	Mean	_	_	O
182	baseline	_	_	O
183	IOP	_	_	O
184	was	_	_	O
185	23.43+/-3.22	_	_	O
186	mm	_	_	O
187	Hg	_	_	O
188	and	_	_	O
189	23.43+/-4.06	_	_	O
190	mm	_	_	O
191	Hg	_	_	O
192	in	_	_	O
193	the	_	_	O
194	patients	_	_	O
195	treated	_	_	O
196	with	_	_	O
197	brimonidine/timolol	_	_	O
198	and	_	_	O
199	dorzolamide/timolol	_	_	O
200	,	_	_	O
201	respectively	_	_	O
202	(	_	_	O
203	P=0.993	_	_	O
204	)	_	_	O
205	.	_	_	O

206	Mean	_	_	B-Premise
207	diurnal	_	_	I-Premise
208	IOP	_	_	I-Premise
209	reduction	_	_	I-Premise
210	after	_	_	I-Premise
211	8	_	_	I-Premise
212	weeks	_	_	I-Premise
213	were	_	_	I-Premise
214	7.02+/-3.06	_	_	I-Premise
215	mm	_	_	I-Premise
216	Hg	_	_	I-Premise
217	and	_	_	I-Premise
218	6.91+/-3.67	_	_	I-Premise
219	mm	_	_	I-Premise
220	Hg	_	_	I-Premise
221	,	_	_	I-Premise
222	respectively	_	_	I-Premise
223	(	_	_	I-Premise
224	P=0.811	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	The	_	_	B-Premise
228	adjusted	_	_	I-Premise
229	difference	_	_	I-Premise
230	between	_	_	I-Premise
231	groups	_	_	I-Premise
232	(	_	_	I-Premise
233	analysis	_	_	I-Premise
234	of	_	_	I-Premise
235	covariance	_	_	I-Premise
236	)	_	_	I-Premise
237	at	_	_	I-Premise
238	week	_	_	I-Premise
239	8	_	_	I-Premise
240	was	_	_	I-Premise
241	not	_	_	I-Premise
242	statistically	_	_	I-Premise
243	significant	_	_	I-Premise
244	(	_	_	I-Premise
245	P=0.847	_	_	I-Premise
246	)	_	_	I-Premise
247	.	_	_	I-Premise

248	Mean	_	_	B-Premise
249	baseline	_	_	I-Premise
250	WDT	_	_	I-Premise
251	peak	_	_	I-Premise
252	was	_	_	I-Premise
253	27.79+/-4.29	_	_	I-Premise
254	mm	_	_	I-Premise
255	Hg	_	_	I-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	brimonidine/timolol	_	_	I-Premise
259	group	_	_	I-Premise
260	and	_	_	I-Premise
261	27.68+/-5.46	_	_	I-Premise
262	mm	_	_	I-Premise
263	Hg	_	_	I-Premise
264	in	_	_	I-Premise
265	the	_	_	I-Premise
266	dorzolamide/timolol	_	_	I-Premise
267	group	_	_	I-Premise
268	.	_	_	I-Premise

269	After	_	_	B-Premise
270	8	_	_	I-Premise
271	weeks	_	_	I-Premise
272	of	_	_	I-Premise
273	treatment	_	_	I-Premise
274	,	_	_	I-Premise
275	mean	_	_	I-Premise
276	WDT	_	_	I-Premise
277	peaks	_	_	I-Premise
278	were	_	_	I-Premise
279	20.94+/-3.76	_	_	I-Premise
280	mm	_	_	I-Premise
281	Hg	_	_	I-Premise
282	(	_	_	I-Premise
283	P	_	_	I-Premise
284	<	_	_	I-Premise
285	0.001	_	_	I-Premise
286	)	_	_	I-Premise
287	and	_	_	I-Premise
288	20.98+/-4.19	_	_	I-Premise
289	(	_	_	I-Premise
290	P	_	_	I-Premise
291	<	_	_	I-Premise
292	0.001	_	_	I-Premise
293	)	_	_	I-Premise
294	,	_	_	I-Premise
295	respectively	_	_	I-Premise
296	.	_	_	I-Premise

297	The	_	_	O
298	adjusted	_	_	O
299	difference	_	_	O
300	between	_	_	O
301	groups	_	_	O
302	(	_	_	O
303	analysis	_	_	O
304	of	_	_	O
305	covariance	_	_	O
306	)	_	_	O
307	was	_	_	O
308	not	_	_	O
309	statistically	_	_	O
310	significant	_	_	O
311	(	_	_	O
312	P=0.469	_	_	O
313	)	_	_	O
314	.	_	_	O

315	No	_	_	B-Premise
316	statistical	_	_	I-Premise
317	difference	_	_	I-Premise
318	in	_	_	I-Premise
319	terms	_	_	I-Premise
320	of	_	_	I-Premise
321	adverse	_	_	I-Premise
322	events	_	_	I-Premise
323	was	_	_	I-Premise
324	found	_	_	I-Premise
325	between	_	_	I-Premise
326	groups	_	_	I-Premise
327	.	_	_	I-Premise

328	Both	_	_	B-Claim
329	fixed	_	_	I-Claim
330	combinations	_	_	I-Claim
331	were	_	_	I-Claim
332	capable	_	_	I-Claim
333	of	_	_	I-Claim
334	significantly	_	_	I-Claim
335	reducing	_	_	I-Claim
336	the	_	_	I-Claim
337	mean	_	_	I-Claim
338	diurnal	_	_	I-Claim
339	IOP	_	_	I-Claim
340	,	_	_	I-Claim
341	mean	_	_	I-Claim
342	diurnal	_	_	I-Claim
343	peak	_	_	I-Claim
344	,	_	_	I-Claim
345	and	_	_	I-Claim
346	mean	_	_	I-Claim
347	WDT	_	_	I-Claim
348	peak	_	_	I-Claim
349	after	_	_	I-Claim
350	8	_	_	I-Claim
351	weeks	_	_	I-Claim
352	of	_	_	I-Claim
353	treatment	_	_	I-Claim
354	.	_	_	I-Claim

355	Also	_	_	O
356	,	_	_	O
357	both	_	_	B-Claim
358	fixed	_	_	I-Claim
359	combinations	_	_	I-Claim
360	are	_	_	I-Claim
361	well	_	_	I-Claim
362	tolerated	_	_	I-Claim
363	with	_	_	I-Claim
364	few	_	_	I-Claim
365	side	_	_	I-Claim
366	effects	_	_	I-Claim
367	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	)	_	_	O
6	-lowering	_	_	O
7	effect	_	_	O
8	and	_	_	O
9	side	_	_	O
10	effects	_	_	O
11	of	_	_	O
12	latanoprost	_	_	O
13	0.005	_	_	O
14	%	_	_	O
15	once	_	_	O
16	daily	_	_	O
17	with	_	_	O
18	unoprostone	_	_	O
19	0.12	_	_	O
20	%	_	_	O
21	twice	_	_	O
22	daily	_	_	O
23	.	_	_	O

24	Sixty	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	primary	_	_	O
28	open-angle	_	_	O
29	glaucoma	_	_	O
30	or	_	_	O
31	ocular	_	_	O
32	hypertension	_	_	O
33	were	_	_	O
34	randomized	_	_	O
35	to	_	_	O
36	receive	_	_	O
37	either	_	_	O
38	latanoprost	_	_	O
39	once	_	_	O
40	daily	_	_	O
41	in	_	_	O
42	the	_	_	O
43	evening	_	_	O
44	and	_	_	O
45	placebo	_	_	O
46	once	_	_	O
47	daily	_	_	O
48	in	_	_	O
49	the	_	_	O
50	morning	_	_	O
51	,	_	_	O
52	or	_	_	O
53	unoprostone	_	_	O
54	twice	_	_	O
55	daily	_	_	O
56	in	_	_	O
57	the	_	_	O
58	morning	_	_	O
59	and	_	_	O
60	evening	_	_	O
61	.	_	_	O

62	The	_	_	O
63	study	_	_	O
64	was	_	_	O
65	double	_	_	O
66	masked	_	_	O
67	and	_	_	O
68	followed	_	_	O
69	a	_	_	O
70	crossover	_	_	O
71	design	_	_	O
72	with	_	_	O
73	two	_	_	O
74	treatment	_	_	O
75	periods	_	_	O
76	of	_	_	O
77	1	_	_	O
78	month	_	_	O
79	separated	_	_	O
80	by	_	_	O
81	a	_	_	O
82	3-week	_	_	O
83	washout	_	_	O
84	period	_	_	O
85	.	_	_	O

86	The	_	_	O
87	intraocular	_	_	O
88	pressure	_	_	O
89	was	_	_	O
90	measured	_	_	O
91	at	_	_	O
92	9	_	_	O
93	AM	_	_	O
94	and	_	_	O
95	5	_	_	O
96	PM	_	_	O
97	on	_	_	O
98	the	_	_	O
99	baseline	_	_	O
100	and	_	_	O
101	day	_	_	O
102	28	_	_	O
103	visits	_	_	O
104	,	_	_	O
105	and	_	_	O
106	at	_	_	O
107	9	_	_	O
108	AM	_	_	O
109	on	_	_	O
110	day	_	_	O
111	2	_	_	O
112	and	_	_	O
113	day	_	_	O
114	14	_	_	O
115	visits	_	_	O
116	of	_	_	O
117	each	_	_	O
118	treatment	_	_	O
119	period	_	_	O
120	.	_	_	O

121	The	_	_	O
122	9	_	_	O
123	AM	_	_	O
124	measurement	_	_	O
125	was	_	_	O
126	taken	_	_	O
127	2	_	_	O
128	hours	_	_	O
129	and	_	_	O
130	13	_	_	O
131	hours	_	_	O
132	after	_	_	O
133	the	_	_	O
134	last	_	_	O
135	drop	_	_	O
136	of	_	_	O
137	unoprostone	_	_	O
138	and	_	_	O
139	latanoprost	_	_	O
140	,	_	_	O
141	and	_	_	O
142	the	_	_	O
143	5	_	_	O
144	PM	_	_	O
145	measurement	_	_	O
146	was	_	_	O
147	at	_	_	O
148	10	_	_	O
149	and	_	_	O
150	21	_	_	O
151	hours	_	_	O
152	,	_	_	O
153	respectively	_	_	O
154	.	_	_	O

155	The	_	_	O
156	mean	_	_	O
157	of	_	_	O
158	the	_	_	O
159	measurements	_	_	O
160	was	_	_	O
161	calculated	_	_	O
162	.	_	_	O

163	Safety	_	_	O
164	parameters	_	_	O
165	were	_	_	O
166	also	_	_	O
167	recorded	_	_	O
168	.	_	_	O

169	Fifty-six	_	_	O
170	patients	_	_	O
171	completed	_	_	O
172	both	_	_	O
173	treatment	_	_	O
174	periods	_	_	O
175	and	_	_	O
176	had	_	_	O
177	intraocular	_	_	O
178	pressure	_	_	O
179	data	_	_	O
180	available	_	_	O
181	for	_	_	O
182	evaluation	_	_	O
183	.	_	_	O

184	After	_	_	B-Premise
185	1	_	_	I-Premise
186	month	_	_	I-Premise
187	of	_	_	I-Premise
188	treatment	_	_	I-Premise
189	,	_	_	I-Premise
190	latanoprost	_	_	I-Premise
191	significantly	_	_	I-Premise
192	reduced	_	_	I-Premise
193	intraocular	_	_	I-Premise
194	pressure	_	_	I-Premise
195	(	_	_	I-Premise
196	mean	_	_	I-Premise
197	+/-	_	_	I-Premise
198	SEM	_	_	I-Premise
199	)	_	_	I-Premise
200	by	_	_	I-Premise
201	6.1	_	_	I-Premise
202	+/-	_	_	I-Premise
203	0.5	_	_	I-Premise
204	mm	_	_	I-Premise
205	Hg	_	_	I-Premise
206	(	_	_	I-Premise
207	P	_	_	I-Premise
208	<	_	_	I-Premise
209	.001	_	_	I-Premise
210	)	_	_	I-Premise
211	and	_	_	I-Premise
212	unoprostone	_	_	I-Premise
213	by	_	_	I-Premise
214	4.2	_	_	I-Premise
215	+/-	_	_	I-Premise
216	0.4	_	_	I-Premise
217	mm	_	_	I-Premise
218	Hg	_	_	I-Premise
219	(	_	_	I-Premise
220	P	_	_	I-Premise
221	<	_	_	I-Premise
222	.001	_	_	I-Premise
223	)	_	_	I-Premise
224	adjusted	_	_	I-Premise
225	from	_	_	I-Premise
226	an	_	_	I-Premise
227	overall	_	_	I-Premise
228	baseline	_	_	I-Premise
229	of	_	_	I-Premise
230	22.3	_	_	I-Premise
231	+/-	_	_	I-Premise
232	0.5	_	_	I-Premise
233	mm	_	_	I-Premise
234	Hg	_	_	I-Premise
235	and	_	_	I-Premise
236	23.2	_	_	I-Premise
237	+/-	_	_	I-Premise
238	0.4	_	_	I-Premise
239	mm	_	_	I-Premise
240	Hg	_	_	I-Premise
241	,	_	_	I-Premise
242	respectively	_	_	I-Premise
243	.	_	_	I-Premise

244	The	_	_	B-Premise
245	difference	_	_	I-Premise
246	of	_	_	I-Premise
247	1.9	_	_	I-Premise
248	mm	_	_	I-Premise
249	Hg	_	_	I-Premise
250	between	_	_	I-Premise
251	treatments	_	_	I-Premise
252	was	_	_	I-Premise
253	statistically	_	_	I-Premise
254	significant	_	_	I-Premise
255	in	_	_	I-Premise
256	favor	_	_	I-Premise
257	of	_	_	I-Premise
258	latanoprost	_	_	I-Premise
259	[	_	_	I-Premise
260	P	_	_	I-Premise
261	=.003	_	_	I-Premise
262	,	_	_	I-Premise
263	analysis	_	_	I-Premise
264	of	_	_	I-Premise
265	covariance	_	_	I-Premise
266	(	_	_	I-Premise
267	ANCOVA	_	_	I-Premise
268	)	_	_	I-Premise
269	]	_	_	I-Premise
270	.	_	_	I-Premise

271	Unadjusted	_	_	B-Premise
272	analysis	_	_	I-Premise
273	of	_	_	I-Premise
274	responders	_	_	I-Premise
275	using	_	_	I-Premise
276	the	_	_	I-Premise
277	percentage	_	_	I-Premise
278	decrease	_	_	I-Premise
279	in	_	_	I-Premise
280	intraocular	_	_	I-Premise
281	pressure	_	_	I-Premise
282	showed	_	_	I-Premise
283	that	_	_	I-Premise
284	the	_	_	I-Premise
285	proportion	_	_	I-Premise
286	of	_	_	I-Premise
287	responders	_	_	I-Premise
288	in	_	_	I-Premise
289	the	_	_	I-Premise
290	latanoprost-treated	_	_	I-Premise
291	group	_	_	I-Premise
292	was	_	_	I-Premise
293	greater	_	_	I-Premise
294	than	_	_	I-Premise
295	in	_	_	I-Premise
296	the	_	_	I-Premise
297	unoprostone-treated	_	_	I-Premise
298	group	_	_	I-Premise
299	.	_	_	I-Premise

300	Adverse	_	_	B-Premise
301	ocular	_	_	I-Premise
302	symptoms	_	_	I-Premise
303	and	_	_	I-Premise
304	findings	_	_	I-Premise
305	were	_	_	I-Premise
306	mild	_	_	I-Premise
307	in	_	_	I-Premise
308	both	_	_	I-Premise
309	treatment	_	_	I-Premise
310	groups	_	_	I-Premise
311	.	_	_	I-Premise

312	Eye	_	_	B-Premise
313	redness	_	_	I-Premise
314	and	_	_	I-Premise
315	ocular	_	_	I-Premise
316	irritation	_	_	I-Premise
317	were	_	_	I-Premise
318	the	_	_	I-Premise
319	most	_	_	I-Premise
320	frequently	_	_	I-Premise
321	reported	_	_	I-Premise
322	events	_	_	I-Premise
323	.	_	_	I-Premise

324	Latanoprost	_	_	B-Claim
325	once	_	_	I-Claim
326	daily	_	_	I-Claim
327	was	_	_	I-Claim
328	significantly	_	_	I-Claim
329	more	_	_	I-Claim
330	effective	_	_	I-Claim
331	in	_	_	I-Claim
332	reducing	_	_	I-Claim
333	intraocular	_	_	I-Claim
334	pressure	_	_	I-Claim
335	compared	_	_	I-Claim
336	with	_	_	I-Claim
337	unoprostone	_	_	I-Claim
338	twice	_	_	I-Claim
339	daily	_	_	I-Claim
340	after	_	_	I-Claim
341	1	_	_	I-Claim
342	month	_	_	I-Claim
343	of	_	_	I-Claim
344	treatment	_	_	I-Claim
345	in	_	_	I-Claim
346	patients	_	_	I-Claim
347	with	_	_	I-Claim
348	primary	_	_	I-Claim
349	open-angle	_	_	I-Claim
350	glaucoma	_	_	I-Claim
351	and	_	_	I-Claim
352	ocular	_	_	I-Claim
353	hypertension	_	_	I-Claim
354	.	_	_	I-Claim

355	Both	_	_	B-Claim
356	drugs	_	_	I-Claim
357	were	_	_	I-Claim
358	well	_	_	I-Claim
359	tolerated	_	_	I-Claim
360	with	_	_	I-Claim
361	few	_	_	I-Claim
362	ocular	_	_	I-Claim
363	adverse	_	_	I-Claim
364	events	_	_	I-Claim
365	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	latanoprost	_	_	O
3	and	_	_	O
4	timolol	_	_	O
5	with	_	_	O
6	regard	_	_	O
7	to	_	_	O
8	changes	_	_	O
9	in	_	_	O
10	the	_	_	O
11	intervisit	_	_	O
12	intraocular	_	_	O
13	pressure	_	_	O
14	(	_	_	O
15	IOP	_	_	O
16	)	_	_	O
17	range	_	_	O
18	,	_	_	O
19	a	_	_	O
20	measure	_	_	O
21	of	_	_	O
22	long-term	_	_	O
23	IOP	_	_	O
24	fluctuation	_	_	O
25	.	_	_	O

26	Post	_	_	O
27	hoc	_	_	O
28	analysis	_	_	O
29	of	_	_	O
30	three	_	_	O
31	6-month	_	_	O
32	,	_	_	O
33	multicenter	_	_	O
34	,	_	_	O
35	randomized	_	_	O
36	(	_	_	O
37	1:1	_	_	O
38	)	_	_	O
39	,	_	_	O
40	double-masked	_	_	O
41	registration	_	_	O
42	trials	_	_	O
43	of	_	_	O
44	latanoprost	_	_	O
45	(	_	_	O
46	n	_	_	O
47	=	_	_	O
48	313	_	_	O
49	)	_	_	O
50	vs	_	_	O
51	timolol	_	_	O
52	(	_	_	O
53	n	_	_	O
54	=	_	_	O
55	318	_	_	O
56	)	_	_	O
57	.	_	_	O

58	Analyses	_	_	O
59	included	_	_	O
60	patients	_	_	O
61	with	_	_	O
62	glaucoma	_	_	O
63	or	_	_	O
64	ocular	_	_	O
65	hypertension	_	_	O
66	who	_	_	O
67	instilled	_	_	O
68	latanoprost	_	_	O
69	once	_	_	O
70	daily	_	_	O
71	in	_	_	O
72	the	_	_	O
73	evening	_	_	O
74	and	_	_	O
75	vehicle	_	_	O
76	in	_	_	O
77	the	_	_	O
78	morning	_	_	O
79	and	_	_	O
80	those	_	_	O
81	instilling	_	_	O
82	timolol	_	_	O
83	twice	_	_	O
84	daily	_	_	O
85	.	_	_	O

86	Pretreatment	_	_	O
87	intervisit	_	_	O
88	IOP	_	_	O
89	range	_	_	O
90	:	_	_	O
91	highest	_	_	O
92	IOP	_	_	O
93	minus	_	_	O
94	lowest	_	_	O
95	IOP	_	_	O
96	of	_	_	O
97	4	_	_	O
98	measurements	_	_	O
99	obtained	_	_	O
100	at	_	_	O
101	screening	_	_	O
102	and	_	_	O
103	baseline	_	_	O
104	.	_	_	O

105	Posttreatment	_	_	O
106	intervisit	_	_	O
107	IOP	_	_	O
108	range	_	_	O
109	:	_	_	O
110	highest	_	_	O
111	IOP	_	_	O
112	minus	_	_	O
113	lowest	_	_	O
114	IOP	_	_	O
115	of	_	_	O
116	4	_	_	O
117	measurements	_	_	O
118	obtained	_	_	O
119	at	_	_	O
120	weeks	_	_	O
121	18	_	_	O
122	and	_	_	O
123	26	_	_	O
124	.	_	_	O

125	Ranges	_	_	O
126	were	_	_	O
127	dichotomized	_	_	O
128	to	_	_	O
129	high	_	_	O
130	(	_	_	O
131	>	_	_	O
132	6	_	_	O
133	mm	_	_	O
134	Hg	_	_	O
135	)	_	_	O
136	and	_	_	O
137	low	_	_	O
138	(	_	_	O
139	<	_	_	O
140	or	_	_	O
141	=	_	_	O
142	6	_	_	O
143	mm	_	_	O
144	Hg	_	_	O
145	)	_	_	O
146	.	_	_	O

147	Both	_	_	B-Claim
148	treatments	_	_	I-Claim
149	resulted	_	_	I-Claim
150	in	_	_	I-Claim
151	significant	_	_	I-Claim
152	reductions	_	_	I-Claim
153	in	_	_	I-Claim
154	mean	_	_	I-Claim
155	intervisit	_	_	I-Claim
156	IOP	_	_	I-Claim
157	range	_	_	I-Claim
158	during	_	_	I-Claim
159	26	_	_	I-Claim
160	weeks	_	_	I-Claim
161	.	_	_	I-Claim

162	Pretreatment	_	_	O
163	,	_	_	O
164	comparable	_	_	O
165	proportions	_	_	O
166	of	_	_	O
167	patients	_	_	O
168	treated	_	_	O
169	with	_	_	O
170	latanoprost	_	_	O
171	and	_	_	O
172	timolol	_	_	O
173	had	_	_	O
174	high	_	_	O
175	intervisit	_	_	O
176	IOP	_	_	O
177	ranges	_	_	O
178	(	_	_	O
179	22	_	_	O
180	%	_	_	O
181	[	_	_	O
182	70/313	_	_	O
183	]	_	_	O
184	and	_	_	O
185	23	_	_	O
186	%	_	_	O
187	[	_	_	O
188	72/318	_	_	O
189	]	_	_	O
190	,	_	_	O
191	respectively	_	_	O
192	;	_	_	O
193	P	_	_	O
194	=	_	_	O
195	.934	_	_	O
196	)	_	_	O
197	.	_	_	O

198	After	_	_	B-Premise
199	treatment	_	_	I-Premise
200	,	_	_	I-Premise
201	6	_	_	I-Premise
202	%	_	_	I-Premise
203	(	_	_	I-Premise
204	19/313	_	_	I-Premise
205	)	_	_	I-Premise
206	and	_	_	I-Premise
207	11	_	_	I-Premise
208	%	_	_	I-Premise
209	(	_	_	I-Premise
210	35/318	_	_	I-Premise
211	)	_	_	I-Premise
212	of	_	_	I-Premise
213	patients	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	latanoprost	_	_	I-Premise
217	and	_	_	I-Premise
218	timolol	_	_	I-Premise
219	groups	_	_	I-Premise
220	,	_	_	I-Premise
221	respectively	_	_	I-Premise
222	,	_	_	I-Premise
223	had	_	_	I-Premise
224	high	_	_	I-Premise
225	intervisit	_	_	I-Premise
226	IOP	_	_	I-Premise
227	ranges	_	_	I-Premise
228	(	_	_	I-Premise
229	P	_	_	I-Premise
230	=	_	_	I-Premise
231	.026	_	_	I-Premise
232	)	_	_	I-Premise
233	.	_	_	I-Premise

234	Significant	_	_	B-Premise
235	risk	_	_	I-Premise
236	factors	_	_	I-Premise
237	for	_	_	I-Premise
238	high	_	_	I-Premise
239	posttreatment	_	_	I-Premise
240	intervisit	_	_	I-Premise
241	range	_	_	I-Premise
242	(	_	_	I-Premise
243	multivariate	_	_	I-Premise
244	logistic	_	_	I-Premise
245	regression	_	_	I-Premise
246	)	_	_	I-Premise
247	were	_	_	I-Premise
248	high	_	_	I-Premise
249	pretreatment	_	_	I-Premise
250	intervisit	_	_	I-Premise
251	IOP	_	_	I-Premise
252	range	_	_	I-Premise
253	,	_	_	I-Premise
254	treatment	_	_	I-Premise
255	with	_	_	I-Premise
256	timolol	_	_	I-Premise
257	,	_	_	I-Premise
258	Black	_	_	I-Premise
259	race	_	_	I-Premise
260	,	_	_	I-Premise
261	longer	_	_	I-Premise
262	time	_	_	I-Premise
263	since	_	_	I-Premise
264	diagnosis	_	_	I-Premise
265	,	_	_	I-Premise
266	and	_	_	I-Premise
267	higher	_	_	I-Premise
268	mean	_	_	I-Premise
269	pretreatment	_	_	I-Premise
270	IOP	_	_	I-Premise
271	.	_	_	I-Premise

272	Compared	_	_	B-Claim
273	with	_	_	I-Claim
274	timolol	_	_	I-Claim
275	,	_	_	I-Claim
276	treatment	_	_	I-Claim
277	with	_	_	I-Claim
278	latanoprost	_	_	I-Claim
279	results	_	_	I-Claim
280	in	_	_	I-Claim
281	significantly	_	_	I-Claim
282	fewer	_	_	I-Claim
283	patients	_	_	I-Claim
284	with	_	_	I-Claim
285	a	_	_	I-Claim
286	high	_	_	I-Claim
287	IOP	_	_	I-Claim
288	fluctuation	_	_	I-Claim
289	.	_	_	I-Claim

290	The	_	_	O
291	impact	_	_	O
292	of	_	_	O
293	reducing	_	_	O
294	high	_	_	O
295	IOP	_	_	O
296	fluctuation	_	_	O
297	on	_	_	O
298	progressive	_	_	O
299	glaucomatous	_	_	O
300	damage	_	_	O
301	deserves	_	_	O
302	further	_	_	O
303	investigation	_	_	O
304	in	_	_	O
305	prospective	_	_	O
306	studies	_	_	O
307	.	_	_	O


0	To	_	_	O
1	report	_	_	O
2	a	_	_	O
3	randomized	_	_	O
4	clinical	_	_	O
5	trial	_	_	O
6	of	_	_	O
7	postoperative	_	_	O
8	subconjunctival	_	_	O
9	injections	_	_	O
10	of	_	_	O
11	low-dose	_	_	O
12	5-fluorouracil	_	_	O
13	in	_	_	O
14	patients	_	_	O
15	undergoing	_	_	O
16	primary	_	_	O
17	trabeculectomy	_	_	O
18	.	_	_	O

19	In	_	_	O
20	a	_	_	O
21	prospective	_	_	O
22	,	_	_	O
23	randomized	_	_	O
24	clinical	_	_	O
25	trial	_	_	O
26	,	_	_	O
27	40	_	_	O
28	eyes	_	_	O
29	of	_	_	O
30	40	_	_	O
31	patients	_	_	O
32	were	_	_	O
33	randomized	_	_	O
34	to	_	_	O
35	the	_	_	O
36	low-dose	_	_	O
37	5-fluorouracil	_	_	O
38	group	_	_	O
39	and	_	_	O
40	received	_	_	O
41	three	_	_	O
42	subconjunctival	_	_	O
43	injections	_	_	O
44	of	_	_	O
45	5	_	_	O
46	mg	_	_	O
47	each	_	_	O
48	over	_	_	O
49	11	_	_	O
50	postoperative	_	_	O
51	days	_	_	O
52	,	_	_	O
53	and	_	_	O
54	40	_	_	O
55	eyes	_	_	O
56	of	_	_	O
57	40	_	_	O
58	patients	_	_	O
59	were	_	_	O
60	randomized	_	_	O
61	to	_	_	O
62	trabeculectomy	_	_	O
63	without	_	_	O
64	5-fluorouracil	_	_	O
65	.	_	_	O

66	Mean	_	_	B-Premise
67	(	_	_	I-Premise
68	+/-SD	_	_	I-Premise
69	)	_	_	I-Premise
70	preoperative	_	_	I-Premise
71	and	_	_	I-Premise
72	1-year	_	_	I-Premise
73	postoperative	_	_	I-Premise
74	intraocular	_	_	I-Premise
75	pressures	_	_	I-Premise
76	in	_	_	I-Premise
77	the	_	_	I-Premise
78	5-fluorouracil	_	_	I-Premise
79	group	_	_	I-Premise
80	were	_	_	I-Premise
81	26.9	_	_	I-Premise
82	(	_	_	I-Premise
83	+/-9.5	_	_	I-Premise
84	)	_	_	I-Premise
85	and	_	_	I-Premise
86	15.3	_	_	I-Premise
87	(	_	_	I-Premise
88	+/-5.8	_	_	I-Premise
89	)	_	_	I-Premise
90	mm	_	_	I-Premise
91	Hg	_	_	I-Premise
92	,	_	_	I-Premise
93	respectively	_	_	I-Premise
94	.	_	_	I-Premise

95	In	_	_	B-Premise
96	the	_	_	I-Premise
97	control	_	_	I-Premise
98	group	_	_	I-Premise
99	these	_	_	I-Premise
100	were	_	_	I-Premise
101	25.9	_	_	I-Premise
102	(	_	_	I-Premise
103	+/-8.1	_	_	I-Premise
104	)	_	_	I-Premise
105	mm	_	_	I-Premise
106	Hg	_	_	I-Premise
107	,	_	_	I-Premise
108	and	_	_	I-Premise
109	15.8	_	_	I-Premise
110	(	_	_	I-Premise
111	+/-5.1	_	_	I-Premise
112	)	_	_	I-Premise
113	mm	_	_	I-Premise
114	Hg	_	_	I-Premise
115	,	_	_	I-Premise
116	respectively	_	_	I-Premise
117	.	_	_	I-Premise

118	The	_	_	B-Premise
119	patients	_	_	I-Premise
120	who	_	_	I-Premise
121	received	_	_	I-Premise
122	5-fluorouracil	_	_	I-Premise
123	had	_	_	I-Premise
124	a	_	_	I-Premise
125	mean	_	_	I-Premise
126	reduction	_	_	I-Premise
127	in	_	_	I-Premise
128	intraocular	_	_	I-Premise
129	pressure	_	_	I-Premise
130	of	_	_	I-Premise
131	11.5	_	_	I-Premise
132	(	_	_	I-Premise
133	+/-9.1	_	_	I-Premise
134	)	_	_	I-Premise
135	mm	_	_	I-Premise
136	Hg	_	_	I-Premise
137	at	_	_	I-Premise
138	a	_	_	I-Premise
139	median	_	_	I-Premise
140	follow-up	_	_	I-Premise
141	of	_	_	I-Premise
142	52.3	_	_	I-Premise
143	weeks	_	_	I-Premise
144	.	_	_	I-Premise

145	The	_	_	B-Premise
146	control	_	_	I-Premise
147	group	_	_	I-Premise
148	had	_	_	I-Premise
149	a	_	_	I-Premise
150	mean	_	_	I-Premise
151	reduction	_	_	I-Premise
152	in	_	_	I-Premise
153	intraocular	_	_	I-Premise
154	pressure	_	_	I-Premise
155	of	_	_	I-Premise
156	10.2	_	_	I-Premise
157	(	_	_	I-Premise
158	+/-8.7	_	_	I-Premise
159	)	_	_	I-Premise
160	mm	_	_	I-Premise
161	Hg	_	_	I-Premise
162	at	_	_	I-Premise
163	a	_	_	I-Premise
164	median	_	_	I-Premise
165	follow-up	_	_	I-Premise
166	of	_	_	I-Premise
167	52.6	_	_	I-Premise
168	weeks	_	_	I-Premise
169	.	_	_	I-Premise

170	These	_	_	B-Premise
171	differences	_	_	I-Premise
172	were	_	_	I-Premise
173	not	_	_	I-Premise
174	statistically	_	_	I-Premise
175	significant	_	_	I-Premise
176	.	_	_	I-Premise

177	Three	_	_	B-Premise
178	postoperative	_	_	I-Premise
179	subconjunctival	_	_	I-Premise
180	5-fluorouracil	_	_	I-Premise
181	injections	_	_	I-Premise
182	of	_	_	I-Premise
183	5	_	_	I-Premise
184	mg	_	_	I-Premise
185	each	_	_	I-Premise
186	after	_	_	I-Premise
187	trabeculectomy	_	_	I-Premise
188	in	_	_	I-Premise
189	eyes	_	_	I-Premise
190	at	_	_	I-Premise
191	low	_	_	I-Premise
192	risk	_	_	I-Premise
193	for	_	_	I-Premise
194	failure	_	_	I-Premise
195	had	_	_	I-Premise
196	no	_	_	I-Premise
197	statistically	_	_	I-Premise
198	or	_	_	I-Premise
199	clinically	_	_	I-Premise
200	significant	_	_	I-Premise
201	effect	_	_	I-Premise
202	on	_	_	I-Premise
203	reduction	_	_	I-Premise
204	of	_	_	I-Premise
205	intraocular	_	_	I-Premise
206	pressure	_	_	I-Premise
207	with	_	_	I-Premise
208	1-year	_	_	I-Premise
209	follow-up	_	_	I-Premise
210	.	_	_	I-Premise

211	Enhancement	_	_	B-Claim
212	of	_	_	I-Claim
213	success	_	_	I-Claim
214	in	_	_	I-Claim
215	this	_	_	I-Claim
216	group	_	_	I-Claim
217	of	_	_	I-Claim
218	patients	_	_	I-Claim
219	may	_	_	I-Claim
220	require	_	_	I-Claim
221	a	_	_	I-Claim
222	larger	_	_	I-Claim
223	total	_	_	I-Claim
224	dose	_	_	I-Claim
225	of	_	_	I-Claim
226	5-fluorouracil	_	_	I-Claim
227	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	longitudinal	_	_	O
4	effects	_	_	O
5	of	_	_	O
6	treatment	_	_	O
7	on	_	_	O
8	intraocular	_	_	O
9	pressure	_	_	O
10	(	_	_	O
11	IOP	_	_	O
12	)	_	_	O
13	and	_	_	O
14	visual	_	_	O
15	field	_	_	O
16	performance	_	_	O
17	in	_	_	O
18	Japanese	_	_	O
19	normal-tension	_	_	O
20	glaucoma	_	_	O
21	(	_	_	O
22	NTG	_	_	O
23	)	_	_	O
24	between	_	_	O
25	latanoprost	_	_	O
26	and	_	_	O
27	timolol	_	_	O
28	.	_	_	O

29	This	_	_	O
30	is	_	_	O
31	an	_	_	O
32	open-label	_	_	O
33	,	_	_	O
34	randomized	_	_	O
35	,	_	_	O
36	study	_	_	O
37	.	_	_	O

38	A	_	_	O
39	total	_	_	O
40	of	_	_	O
41	62	_	_	O
42	NTG	_	_	O
43	patients	_	_	O
44	were	_	_	O
45	prospectively	_	_	O
46	,	_	_	O
47	consecutively	_	_	O
48	enrolled	_	_	O
49	.	_	_	O

50	All	_	_	O
51	study	_	_	O
52	subjects	_	_	O
53	were	_	_	O
54	randomly	_	_	O
55	assigned	_	_	O
56	to	_	_	O
57	0.005	_	_	O
58	%	_	_	O
59	latanoprost	_	_	O
60	instillation	_	_	O
61	once	_	_	O
62	daily	_	_	O
63	in	_	_	O
64	the	_	_	O
65	morning	_	_	O
66	or	_	_	O
67	0.5	_	_	O
68	%	_	_	O
69	timolol	_	_	O
70	instillation	_	_	O
71	twice	_	_	O
72	daily	_	_	O
73	for	_	_	O
74	a	_	_	O
75	prospective	_	_	O
76	3-year	_	_	O
77	follow-up	_	_	O
78	,	_	_	O
79	and	_	_	O
80	underwent	_	_	O
81	a	_	_	O
82	routine	_	_	O
83	ocular	_	_	O
84	examination	_	_	O
85	every	_	_	O
86	month	_	_	O
87	.	_	_	O

88	Automated	_	_	O
89	perimetry	_	_	O
90	was	_	_	O
91	performed	_	_	O
92	every	_	_	O
93	6	_	_	O
94	months	_	_	O
95	using	_	_	O
96	Humphrey	_	_	O
97	field	_	_	O
98	analysers	_	_	O
99	.	_	_	O

100	Stereophotographs	_	_	O
101	of	_	_	O
102	optic	_	_	O
103	discs	_	_	O
104	were	_	_	O
105	also	_	_	O
106	obtained	_	_	O
107	every	_	_	O
108	6	_	_	O
109	months	_	_	O
110	.	_	_	O

111	Percentage	_	_	B-Premise
112	of	_	_	I-Premise
113	IOP	_	_	I-Premise
114	reduction	_	_	I-Premise
115	or	_	_	I-Premise
116	the	_	_	I-Premise
117	magnitude	_	_	I-Premise
118	of	_	_	I-Premise
119	IOP	_	_	I-Premise
120	reduction	_	_	I-Premise
121	showed	_	_	I-Premise
122	no	_	_	I-Premise
123	intergroup	_	_	I-Premise
124	differences	_	_	I-Premise
125	either	_	_	I-Premise
126	at	_	_	I-Premise
127	any	_	_	I-Premise
128	time	_	_	I-Premise
129	point	_	_	I-Premise
130	(	_	_	I-Premise
131	13-15	_	_	I-Premise
132	%	_	_	I-Premise
133	)	_	_	I-Premise
134	.	_	_	I-Premise

135	In	_	_	B-Premise
136	the	_	_	I-Premise
137	visual	_	_	I-Premise
138	field	_	_	I-Premise
139	,	_	_	I-Premise
140	the	_	_	I-Premise
141	estimated	_	_	I-Premise
142	rate	_	_	I-Premise
143	of	_	_	I-Premise
144	change	_	_	I-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	MD	_	_	I-Premise
148	value	_	_	I-Premise
149	(	_	_	I-Premise
150	dB/year	_	_	I-Premise
151	)	_	_	I-Premise
152	was	_	_	I-Premise
153	-0.34+/-0.17	_	_	I-Premise
154	(	_	_	I-Premise
155	SE	_	_	I-Premise
156	)	_	_	I-Premise
157	for	_	_	I-Premise
158	the	_	_	I-Premise
159	latanoprost	_	_	I-Premise
160	group	_	_	I-Premise
161	,	_	_	I-Premise
162	and	_	_	I-Premise
163	-0.10+/-0.18	_	_	I-Premise
164	(	_	_	I-Premise
165	SE	_	_	I-Premise
166	)	_	_	I-Premise
167	for	_	_	I-Premise
168	the	_	_	I-Premise
169	timolol	_	_	I-Premise
170	group	_	_	I-Premise
171	.	_	_	I-Premise

172	The	_	_	B-Premise
173	estimated	_	_	I-Premise
174	rate	_	_	I-Premise
175	of	_	_	I-Premise
176	change	_	_	I-Premise
177	in	_	_	I-Premise
178	MD	_	_	I-Premise
179	showed	_	_	I-Premise
180	no	_	_	I-Premise
181	significant	_	_	I-Premise
182	difference	_	_	I-Premise
183	from	_	_	I-Premise
184	zero	_	_	I-Premise
185	in	_	_	I-Premise
186	both	_	_	I-Premise
187	groups	_	_	I-Premise
188	,	_	_	I-Premise
189	and	_	_	I-Premise
190	there	_	_	I-Premise
191	were	_	_	I-Premise
192	no	_	_	I-Premise
193	statistical	_	_	I-Premise
194	intergroup	_	_	I-Premise
195	differences	_	_	I-Premise
196	.	_	_	I-Premise

197	No	_	_	B-Premise
198	changes	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	optic	_	_	I-Premise
202	nerve	_	_	I-Premise
203	head	_	_	I-Premise
204	topography	_	_	I-Premise
205	in	_	_	I-Premise
206	the	_	_	I-Premise
207	vertical	_	_	I-Premise
208	cup-to-disc	_	_	I-Premise
209	ratio	_	_	I-Premise
210	and	_	_	I-Premise
211	rim	_	_	I-Premise
212	area	_	_	I-Premise
213	measured	_	_	I-Premise
214	by	_	_	I-Premise
215	image-analysis	_	_	I-Premise
216	techniques	_	_	I-Premise
217	were	_	_	I-Premise
218	observed	_	_	I-Premise
219	in	_	_	I-Premise
220	either	_	_	I-Premise
221	group	_	_	I-Premise
222	.	_	_	I-Premise

223	There	_	_	B-Premise
224	were	_	_	I-Premise
225	no	_	_	I-Premise
226	patients	_	_	I-Premise
227	who	_	_	I-Premise
228	dropped	_	_	I-Premise
229	out	_	_	I-Premise
230	due	_	_	I-Premise
231	to	_	_	I-Premise
232	the	_	_	I-Premise
233	side	_	_	I-Premise
234	effects	_	_	I-Premise
235	of	_	_	I-Premise
236	treatment	_	_	I-Premise
237	regimens	_	_	I-Premise
238	.	_	_	I-Premise

239	Both	_	_	B-Claim
240	latanoprost	_	_	I-Claim
241	and	_	_	I-Claim
242	timolol	_	_	I-Claim
243	single	_	_	I-Claim
244	treatments	_	_	I-Claim
245	reduced	_	_	I-Claim
246	IOP	_	_	I-Claim
247	by	_	_	I-Claim
248	13-15	_	_	I-Claim
249	%	_	_	I-Claim
250	at	_	_	I-Claim
251	their	_	_	I-Claim
252	trough	_	_	I-Claim
253	effects	_	_	I-Claim
254	for	_	_	I-Claim
255	3	_	_	I-Claim
256	years	_	_	I-Claim
257	in	_	_	I-Claim
258	Japanese	_	_	I-Claim
259	NTG	_	_	I-Claim
260	patients	_	_	I-Claim
261	;	_	_	O
262	both	_	_	B-Claim
263	showed	_	_	I-Claim
264	similar	_	_	I-Claim
265	effects	_	_	I-Claim
266	on	_	_	I-Claim
267	visual	_	_	I-Claim
268	field	_	_	I-Claim
269	performance	_	_	I-Claim
270	.	_	_	I-Claim


0	Latanoprost	_	_	O
1	is	_	_	O
2	a	_	_	O
3	PGF2	_	_	O
4	alpha	_	_	O
5	analogue	_	_	O
6	which	_	_	O
7	reduces	_	_	O
8	the	_	_	O
9	intraocular	_	_	O
10	pressure	_	_	O
11	(	_	_	O
12	IOP	_	_	O
13	)	_	_	O
14	by	_	_	O
15	increasing	_	_	O
16	the	_	_	O
17	uveoscleral	_	_	O
18	outflow	_	_	O
19	.	_	_	O

20	The	_	_	O
21	objective	_	_	O
22	of	_	_	O
23	this	_	_	O
24	study	_	_	O
25	was	_	_	O
26	to	_	_	O
27	investigate	_	_	O
28	the	_	_	O
29	effect	_	_	O
30	of	_	_	O
31	two	_	_	O
32	different	_	_	O
33	regimens	_	_	O
34	of	_	_	O
35	latanoprost	_	_	O
36	on	_	_	O
37	the	_	_	O
38	diurnal	_	_	O
39	IOP	_	_	O
40	and	_	_	O
41	also	_	_	O
42	the	_	_	O
43	effect	_	_	O
44	of	_	_	O
45	latanoprost	_	_	O
46	on	_	_	O
47	the	_	_	O
48	blood-aqueous	_	_	O
49	barrier	_	_	O
50	measured	_	_	O
51	with	_	_	O
52	a	_	_	O
53	laser	_	_	O
54	flare	_	_	O
55	cell	_	_	O
56	meter	_	_	O
57	(	_	_	O
58	Kowa	_	_	O
59	FM-500	_	_	O
60	)	_	_	O
61	.	_	_	O

62	Moreover	_	_	O
63	,	_	_	O
64	the	_	_	O
65	safety	_	_	O
66	aspects	_	_	O
67	of	_	_	O
68	the	_	_	O
69	two	_	_	O
70	regimens	_	_	O
71	regarding	_	_	O
72	hyperemia	_	_	O
73	were	_	_	O
74	studied	_	_	O
75	.	_	_	O

76	A	_	_	O
77	double-masked	_	_	O
78	,	_	_	O
79	randomized	_	_	O
80	study	_	_	O
81	was	_	_	O
82	performed	_	_	O
83	in	_	_	O
84	30	_	_	O
85	patients	_	_	O
86	(	_	_	O
87	9	_	_	O
88	males	_	_	O
89	,	_	_	O
90	21	_	_	O
91	females	_	_	O
92	;	_	_	O
93	mean	_	_	O
94	age	_	_	O
95	61.9	_	_	O
96	years	_	_	O
97	)	_	_	O
98	with	_	_	O
99	primary	_	_	O
100	open-angle	_	_	O
101	glaucoma	_	_	O
102	or	_	_	O
103	pseudoexfoliation	_	_	O
104	glaucoma	_	_	O
105	.	_	_	O

106	Twenty	_	_	O
107	patients	_	_	O
108	were	_	_	O
109	treated	_	_	O
110	with	_	_	O
111	latanoprost	_	_	O
112	0.0015	_	_	O
113	%	_	_	O
114	twice	_	_	O
115	daily	_	_	O
116	or	_	_	O
117	0.005	_	_	O
118	%	_	_	O
119	once	_	_	O
120	daily	_	_	O
121	for	_	_	O
122	3	_	_	O
123	weeks	_	_	O
124	in	_	_	O
125	a	_	_	O
126	cross-over	_	_	O
127	design	_	_	O
128	.	_	_	O

129	Ten	_	_	O
130	patients	_	_	O
131	received	_	_	O
132	timolol	_	_	O
133	0.5	_	_	O
134	%	_	_	O
135	twice	_	_	O
136	daily	_	_	O
137	as	_	_	O
138	control	_	_	O
139	.	_	_	O

140	Latanoprost	_	_	B-Premise
141	0.005	_	_	I-Premise
142	%	_	_	I-Premise
143	once	_	_	I-Premise
144	daily	_	_	I-Premise
145	reduced	_	_	I-Premise
146	IOP	_	_	I-Premise
147	(	_	_	I-Premise
148	+/-	_	_	I-Premise
149	SEM	_	_	I-Premise
150	)	_	_	I-Premise
151	more	_	_	I-Premise
152	effectively	_	_	I-Premise
153	than	_	_	I-Premise
154	latanoprost	_	_	I-Premise
155	0.0015	_	_	I-Premise
156	%	_	_	I-Premise
157	twice	_	_	I-Premise
158	daily	_	_	I-Premise
159	(	_	_	I-Premise
160	9.8	_	_	I-Premise
161	+/-	_	_	I-Premise
162	0.9	_	_	I-Premise
163	mm	_	_	I-Premise
164	Hg	_	_	I-Premise
165	and	_	_	I-Premise
166	6.7	_	_	I-Premise
167	+/-	_	_	I-Premise
168	0.9	_	_	I-Premise
169	mm	_	_	I-Premise
170	Hg	_	_	I-Premise
171	,	_	_	I-Premise
172	respectively	_	_	I-Premise
173	)	_	_	I-Premise
174	.	_	_	I-Premise

175	There	_	_	B-Premise
176	was	_	_	I-Premise
177	a	_	_	I-Premise
178	statistically	_	_	I-Premise
179	significant	_	_	I-Premise
180	increase	_	_	I-Premise
181	in	_	_	I-Premise
182	the	_	_	I-Premise
183	aqueous	_	_	I-Premise
184	humour	_	_	I-Premise
185	protein	_	_	I-Premise
186	concentration	_	_	I-Premise
187	within	_	_	I-Premise
188	the	_	_	I-Premise
189	timolol	_	_	I-Premise
190	group	_	_	I-Premise
191	(	_	_	I-Premise
192	P	_	_	I-Premise
193	=	_	_	I-Premise
194	0.004	_	_	I-Premise
195	)	_	_	I-Premise
196	,	_	_	I-Premise
197	but	_	_	I-Premise
198	not	_	_	I-Premise
199	within	_	_	I-Premise
200	the	_	_	I-Premise
201	latanoprost	_	_	I-Premise
202	group	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	0.97	_	_	I-Premise
207	)	_	_	I-Premise
208	.	_	_	I-Premise

209	There	_	_	B-Premise
210	was	_	_	I-Premise
211	no	_	_	I-Premise
212	statistically	_	_	I-Premise
213	significant	_	_	I-Premise
214	difference	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	change	_	_	I-Premise
218	in	_	_	I-Premise
219	aqueous	_	_	I-Premise
220	humour	_	_	I-Premise
221	protein	_	_	I-Premise
222	concentration	_	_	I-Premise
223	from	_	_	I-Premise
224	baseline	_	_	I-Premise
225	between	_	_	I-Premise
226	latanoprost	_	_	I-Premise
227	and	_	_	I-Premise
228	timolol	_	_	I-Premise
229	groups	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	=	_	_	I-Premise
233	0.08	_	_	I-Premise
234	)	_	_	I-Premise
235	.	_	_	I-Premise

236	No	_	_	B-Premise
237	statistically	_	_	I-Premise
238	significant	_	_	I-Premise
239	difference	_	_	I-Premise
240	in	_	_	I-Premise
241	conjunctival	_	_	I-Premise
242	hyperemia	_	_	I-Premise
243	between	_	_	I-Premise
244	the	_	_	I-Premise
245	two	_	_	I-Premise
246	latanoprost	_	_	I-Premise
247	regimens	_	_	I-Premise
248	was	_	_	I-Premise
249	found	_	_	I-Premise
250	(	_	_	I-Premise
251	P	_	_	I-Premise
252	=	_	_	I-Premise
253	0.37	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	Latanoprost	_	_	B-Premise
257	0.005	_	_	I-Premise
258	%	_	_	I-Premise
259	once	_	_	I-Premise
260	daily	_	_	I-Premise
261	reduced	_	_	I-Premise
262	IOP	_	_	I-Premise
263	more	_	_	I-Premise
264	effectively	_	_	I-Premise
265	than	_	_	I-Premise
266	latanoprost	_	_	I-Premise
267	0.0015	_	_	I-Premise
268	%	_	_	I-Premise
269	twice	_	_	I-Premise
270	daily	_	_	I-Premise
271	(	_	_	I-Premise
272	P	_	_	I-Premise
273	<	_	_	I-Premise
274	0.001	_	_	I-Premise
275	)	_	_	I-Premise
276	.	_	_	I-Premise

277	Latanoprost	_	_	B-Claim
278	had	_	_	I-Claim
279	no	_	_	I-Claim
280	statistically	_	_	I-Claim
281	or	_	_	I-Claim
282	clinically	_	_	I-Claim
283	significant	_	_	I-Claim
284	effect	_	_	I-Claim
285	on	_	_	I-Claim
286	the	_	_	I-Claim
287	blood-aqueous	_	_	I-Claim
288	barrier	_	_	I-Claim
289	.	_	_	I-Claim

290	There	_	_	B-Claim
291	was	_	_	I-Claim
292	no	_	_	I-Claim
293	difference	_	_	I-Claim
294	in	_	_	I-Claim
295	hyperemia	_	_	I-Claim
296	between	_	_	I-Claim
297	the	_	_	I-Claim
298	two	_	_	I-Claim
299	regimens	_	_	I-Claim
300	.	_	_	I-Claim

301	Both	_	_	B-Claim
302	concentrations	_	_	I-Claim
303	of	_	_	I-Claim
304	latanoprost	_	_	I-Claim
305	reduced	_	_	I-Claim
306	IOP	_	_	I-Claim
307	at	_	_	I-Claim
308	least	_	_	I-Claim
309	as	_	_	I-Claim
310	well	_	_	I-Claim
311	as	_	_	I-Claim
312	timolol	_	_	I-Claim
313	0.5	_	_	I-Claim
314	%	_	_	I-Claim
315	eye	_	_	I-Claim
316	drops	_	_	I-Claim
317	.	_	_	I-Claim


0	We	_	_	O
1	conducted	_	_	O
2	a	_	_	O
3	prospective	_	_	O
4	,	_	_	O
5	randomized	_	_	O
6	study	_	_	O
7	to	_	_	O
8	compare	_	_	O
9	mitomycin	_	_	O
10	with	_	_	O
11	fluorouracil	_	_	O
12	for	_	_	O
13	efficacy	_	_	O
14	and	_	_	O
15	safety	_	_	O
16	as	_	_	O
17	an	_	_	O
18	adjunct	_	_	O
19	to	_	_	O
20	trabeculectomy	_	_	O
21	in	_	_	O
22	eyes	_	_	O
23	with	_	_	O
24	glaucoma	_	_	O
25	with	_	_	O
26	poor	_	_	O
27	surgical	_	_	O
28	prognosis	_	_	O
29	.	_	_	O

30	Thirty-two	_	_	O
31	eyes	_	_	O
32	of	_	_	O
33	32	_	_	O
34	patients	_	_	O
35	were	_	_	O
36	randomly	_	_	O
37	allocated	_	_	O
38	to	_	_	O
39	either	_	_	O
40	mitomycin	_	_	O
41	(	_	_	O
42	17	_	_	O
43	eyes	_	_	O
44	)	_	_	O
45	or	_	_	O
46	fluorouracil	_	_	O
47	therapy	_	_	O
48	(	_	_	O
49	15	_	_	O
50	eyes	_	_	O
51	)	_	_	O
52	.	_	_	O

53	Mitomycin	_	_	O
54	(	_	_	O
55	0.2	_	_	O
56	mg	_	_	O
57	)	_	_	O
58	was	_	_	O
59	applied	_	_	O
60	only	_	_	O
61	once	_	_	O
62	during	_	_	O
63	trabeculectomy	_	_	O
64	,	_	_	O
65	and	_	_	O
66	fluorouracil	_	_	O
67	(	_	_	O
68	5	_	_	O
69	mg	_	_	O
70	)	_	_	O
71	was	_	_	O
72	subconjunctivally	_	_	O
73	injected	_	_	O
74	10	_	_	O
75	times	_	_	O
76	in	_	_	O
77	the	_	_	O
78	2	_	_	O
79	weeks	_	_	O
80	after	_	_	O
81	surgery	_	_	O
82	.	_	_	O

83	Fifteen	_	_	B-Premise
84	eyes	_	_	I-Premise
85	(	_	_	I-Premise
86	88	_	_	I-Premise
87	%	_	_	I-Premise
88	)	_	_	I-Premise
89	in	_	_	I-Premise
90	the	_	_	I-Premise
91	mitomycin	_	_	I-Premise
92	group	_	_	I-Premise
93	and	_	_	I-Premise
94	seven	_	_	I-Premise
95	(	_	_	I-Premise
96	47	_	_	I-Premise
97	%	_	_	I-Premise
98	)	_	_	I-Premise
99	in	_	_	I-Premise
100	the	_	_	I-Premise
101	fluorouracil	_	_	I-Premise
102	group	_	_	I-Premise
103	achieved	_	_	I-Premise
104	an	_	_	I-Premise
105	intraocular	_	_	I-Premise
106	pressure	_	_	I-Premise
107	of	_	_	I-Premise
108	less	_	_	I-Premise
109	than	_	_	I-Premise
110	or	_	_	I-Premise
111	equal	_	_	I-Premise
112	to	_	_	I-Premise
113	20	_	_	I-Premise
114	mm	_	_	I-Premise
115	Hg	_	_	I-Premise
116	without	_	_	I-Premise
117	antiglaucoma	_	_	I-Premise
118	medication	_	_	I-Premise
119	.	_	_	I-Premise

120	The	_	_	O
121	follow-up	_	_	O
122	period	_	_	O
123	was	_	_	O
124	7	_	_	O
125	to	_	_	O
126	12	_	_	O
127	months	_	_	O
128	.	_	_	O

129	Corneal	_	_	B-Premise
130	complications	_	_	I-Premise
131	were	_	_	I-Premise
132	less	_	_	I-Premise
133	common	_	_	I-Premise
134	in	_	_	I-Premise
135	the	_	_	I-Premise
136	group	_	_	I-Premise
137	given	_	_	I-Premise
138	mitomycin	_	_	I-Premise
139	than	_	_	I-Premise
140	in	_	_	I-Premise
141	that	_	_	I-Premise
142	given	_	_	I-Premise
143	fluorouracil	_	_	I-Premise
144	(	_	_	I-Premise
145	12	_	_	I-Premise
146	%	_	_	I-Premise
147	vs	_	_	I-Premise
148	53	_	_	I-Premise
149	%	_	_	I-Premise
150	)	_	_	I-Premise
151	.	_	_	I-Premise

152	The	_	_	B-Claim
153	incidence	_	_	I-Claim
154	of	_	_	I-Claim
155	other	_	_	I-Claim
156	complications	_	_	I-Claim
157	was	_	_	I-Claim
158	similar	_	_	I-Claim
159	between	_	_	I-Claim
160	the	_	_	I-Claim
161	two	_	_	I-Claim
162	groups	_	_	I-Claim
163	.	_	_	I-Claim


0	trabeculectomy	_	_	O
1	is	_	_	O
2	the	_	_	O
3	standard	_	_	O
4	surgical	_	_	O
5	procedure	_	_	O
6	for	_	_	O
7	management	_	_	O
8	of	_	_	O
9	glaucoma	_	_	O
10	.	_	_	O

11	to	_	_	O
12	compare	_	_	O
13	the	_	_	O
14	outcome	_	_	O
15	of	_	_	O
16	triangular	_	_	O
17	and	_	_	O
18	rectangular	_	_	O
19	scleral	_	_	O
20	flaps	_	_	O
21	in	_	_	O
22	trabeculectomy	_	_	O
23	.	_	_	O

24	this	_	_	O
25	study	_	_	O
26	was	_	_	O
27	carried	_	_	O
28	out	_	_	O
29	in	_	_	O
30	the	_	_	O
31	Department	_	_	O
32	ofOphthalmology	_	_	O
33	,	_	_	O
34	BPKIHS	_	_	O
35	,	_	_	O
36	Dharan	_	_	O
37	,	_	_	O
38	over	_	_	O
39	a	_	_	O
40	period	_	_	O
41	of	_	_	O
42	one	_	_	O
43	year	_	_	O
44	.	_	_	O

45	A	_	_	O
46	total	_	_	O
47	of	_	_	O
48	22	_	_	O
49	patients	_	_	O
50	undergoing	_	_	O
51	trabeculectomy	_	_	O
52	were	_	_	O
53	randomized	_	_	O
54	to	_	_	O
55	undergo	_	_	O
56	either	_	_	O
57	trabeculectomy	_	_	O
58	with	_	_	O
59	triangular	_	_	O
60	scleral	_	_	O
61	flap	_	_	O
62	(	_	_	O
63	Group	_	_	O
64	A=	_	_	O
65	11	_	_	O
66	eyes	_	_	O
67	)	_	_	O
68	or	_	_	O
69	trabeculectomy	_	_	O
70	with	_	_	O
71	rectangular	_	_	O
72	flap	_	_	O
73	(	_	_	O
74	Group	_	_	O
75	B	_	_	O
76	=	_	_	O
77	11	_	_	O
78	eyes	_	_	O
79	)	_	_	O
80	.	_	_	O

81	the	_	_	O
82	parameters	_	_	O
83	studied	_	_	O
84	were	_	_	O
85	intraocular	_	_	O
86	pressure	_	_	O
87	(	_	_	O
88	IOP	_	_	O
89	)	_	_	O
90	,	_	_	O
91	anterior	_	_	O
92	chamber	_	_	O
93	depth	_	_	O
94	(	_	_	O
95	ACD	_	_	O
96	)	_	_	O
97	,	_	_	O
98	bleb	_	_	O
99	characteristics	_	_	O
100	and	_	_	O
101	surgical	_	_	O
102	complications	_	_	O
103	.	_	_	O

104	P	_	_	O
105	value	_	_	O
106	of	_	_	O
107	<	_	_	O
108	0.05	_	_	O
109	was	_	_	O
110	considered	_	_	O
111	significant	_	_	O
112	.	_	_	O

113	All	_	_	O
114	calculations	_	_	O
115	were	_	_	O
116	executed	_	_	O
117	using	_	_	O
118	SPSS	_	_	O
119	11.0	_	_	O
120	software	_	_	O
121	program	_	_	O
122	.	_	_	O

123	the	_	_	O
124	age	_	_	O
125	ranged	_	_	O
126	between	_	_	O
127	40	_	_	O
128	to	_	_	O
129	76	_	_	O
130	years	_	_	O
131	with	_	_	O
132	the	_	_	O
133	mean	_	_	O
134	of	_	_	O
135	56.5	_	_	O
136	+/-	_	_	O
137	9.25	_	_	O
138	years	_	_	O
139	.	_	_	O

140	The	_	_	O
141	most	_	_	O
142	common	_	_	O
143	preoperative	_	_	O
144	diagnosis	_	_	O
145	was	_	_	O
146	angle	_	_	O
147	closure	_	_	O
148	glaucoma	_	_	O
149	.	_	_	O

150	The	_	_	B-Premise
151	postoperative	_	_	I-Premise
152	percentage	_	_	I-Premise
153	of	_	_	I-Premise
154	IOP	_	_	I-Premise
155	reduction	_	_	I-Premise
156	(	_	_	I-Premise
157	Group	_	_	I-Premise
158	A	_	_	I-Premise
159	68.9	_	_	I-Premise
160	%	_	_	I-Premise
161	;	_	_	I-Premise
162	Group	_	_	I-Premise
163	B	_	_	I-Premise
164	66.51	_	_	I-Premise
165	%	_	_	I-Premise
166	)	_	_	I-Premise
167	was	_	_	I-Premise
168	statically	_	_	I-Premise
169	significant	_	_	I-Premise
170	in	_	_	I-Premise
171	both	_	_	I-Premise
172	the	_	_	I-Premise
173	groups	_	_	I-Premise
174	(	_	_	I-Premise
175	p=0.001	_	_	I-Premise
176	)	_	_	I-Premise
177	.	_	_	I-Premise

178	Trabeculectomy	_	_	B-Premise
179	was	_	_	I-Premise
180	almost	_	_	I-Premise
181	equally	_	_	I-Premise
182	effective	_	_	I-Premise
183	with	_	_	I-Premise
184	complete	_	_	I-Premise
185	surgical	_	_	I-Premise
186	success	_	_	I-Premise
187	of	_	_	I-Premise
188	91	_	_	I-Premise
189	%	_	_	I-Premise
190	in	_	_	I-Premise
191	group	_	_	I-Premise
192	A	_	_	I-Premise
193	,	_	_	I-Premise
194	and	_	_	I-Premise
195	82	_	_	I-Premise
196	%	_	_	I-Premise
197	in	_	_	I-Premise
198	group	_	_	I-Premise
199	B	_	_	I-Premise
200	(	_	_	I-Premise
201	p=0.534	_	_	I-Premise
202	)	_	_	I-Premise
203	.	_	_	I-Premise

204	Final	_	_	B-Premise
205	bleb	_	_	I-Premise
206	scores	_	_	I-Premise
207	were	_	_	I-Premise
208	almost	_	_	I-Premise
209	similar	_	_	I-Premise
210	in	_	_	I-Premise
211	both	_	_	I-Premise
212	the	_	_	I-Premise
213	groups	_	_	I-Premise
214	with	_	_	I-Premise
215	3.27	_	_	I-Premise
216	+/-	_	_	I-Premise
217	1.5	_	_	I-Premise
218	in	_	_	I-Premise
219	group	_	_	I-Premise
220	A	_	_	I-Premise
221	and	_	_	I-Premise
222	3.36	_	_	I-Premise
223	+/-	_	_	I-Premise
224	1.21	_	_	I-Premise
225	in	_	_	I-Premise
226	group	_	_	I-Premise
227	B	_	_	I-Premise
228	(	_	_	I-Premise
229	p=0.877	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	Hypotony	_	_	B-Premise
233	with	_	_	I-Premise
234	the	_	_	I-Premise
235	IOP	_	_	I-Premise
236	less	_	_	I-Premise
237	than	_	_	I-Premise
238	6	_	_	I-Premise
239	mmHg	_	_	I-Premise
240	was	_	_	I-Premise
241	found	_	_	I-Premise
242	in	_	_	I-Premise
243	the	_	_	I-Premise
244	first	_	_	I-Premise
245	post-operative	_	_	I-Premise
246	day	_	_	I-Premise
247	in	_	_	I-Premise
248	2	_	_	I-Premise
249	patients	_	_	I-Premise
250	in	_	_	I-Premise
251	Group	_	_	I-Premise
252	A	_	_	I-Premise
253	and	_	_	I-Premise
254	in	_	_	I-Premise
255	1	_	_	I-Premise
256	in	_	_	I-Premise
257	Group	_	_	I-Premise
258	B	_	_	I-Premise
259	.	_	_	I-Premise

260	All	_	_	O
261	of	_	_	O
262	them	_	_	O
263	improved	_	_	O
264	spontaneously	_	_	O
265	within	_	_	O
266	a	_	_	O
267	week	_	_	O
268	.	_	_	O

269	both	_	_	B-Claim
270	triangular	_	_	I-Claim
271	and	_	_	I-Claim
272	rectangular	_	_	I-Claim
273	scleral	_	_	I-Claim
274	flaps	_	_	I-Claim
275	in	_	_	I-Claim
276	trabeculectomy	_	_	I-Claim
277	are	_	_	I-Claim
278	equally	_	_	I-Claim
279	effective	_	_	I-Claim
280	in	_	_	I-Claim
281	terms	_	_	I-Claim
282	of	_	_	I-Claim
283	post	_	_	I-Claim
284	surgical	_	_	I-Claim
285	IOP	_	_	I-Claim
286	control	_	_	I-Claim
287	,	_	_	I-Claim
288	bleb	_	_	I-Claim
289	characteristics	_	_	I-Claim
290	and	_	_	I-Claim
291	complications	_	_	I-Claim
292	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	topical	_	_	O
8	bimatoprost	_	_	O
9	(	_	_	O
10	LUMIGAN	_	_	O
11	;	_	_	O
12	Allergan	_	_	O
13	,	_	_	O
14	Inc.	_	_	O
15	,	_	_	O
16	Irvine	_	_	O
17	,	_	_	O
18	CA	_	_	O
19	)	_	_	O
20	once	_	_	O
21	daily	_	_	O
22	with	_	_	O
23	that	_	_	O
24	of	_	_	O
25	topical	_	_	O
26	combined	_	_	O
27	timolol	_	_	O
28	and	_	_	O
29	dorzolamide	_	_	O
30	(	_	_	O
31	Cosopt	_	_	O
32	;	_	_	O
33	Merck	_	_	O
34	and	_	_	O
35	Co	_	_	O
36	,	_	_	O
37	Inc.	_	_	O
38	,	_	_	O
39	Whitehouse	_	_	O
40	Station	_	_	O
41	,	_	_	O
42	NJ	_	_	O
43	)	_	_	O
44	twice	_	_	O
45	daily	_	_	O
46	.	_	_	O

47	Prospective	_	_	O
48	,	_	_	O
49	randomized	_	_	O
50	,	_	_	O
51	double-masked	_	_	O
52	,	_	_	O
53	multicenter	_	_	O
54	clinical	_	_	O
55	trial	_	_	O
56	.	_	_	O

57	One	_	_	O
58	hundred	_	_	O
59	seventy-seven	_	_	O
60	patients	_	_	O
61	with	_	_	O
62	a	_	_	O
63	diagnosis	_	_	O
64	of	_	_	O
65	glaucoma	_	_	O
66	or	_	_	O
67	ocular	_	_	O
68	hypertension	_	_	O
69	and	_	_	O
70	inadequate	_	_	O
71	control	_	_	O
72	of	_	_	O
73	intraocular	_	_	O
74	pressure	_	_	O
75	(	_	_	O
76	IOP	_	_	O
77	)	_	_	O
78	after	_	_	O
79	at	_	_	O
80	least	_	_	O
81	2	_	_	O
82	weeks	_	_	O
83	of	_	_	O
84	topical	_	_	O
85	timolol	_	_	O
86	maleate	_	_	O
87	0.5	_	_	O
88	%	_	_	O
89	monotherapy	_	_	O
90	.	_	_	O

91	Patients	_	_	O
92	were	_	_	O
93	randomized	_	_	O
94	to	_	_	O
95	receive	_	_	O
96	bimatoprost	_	_	O
97	0.03	_	_	O
98	%	_	_	O
99	once	_	_	O
100	daily	_	_	O
101	(	_	_	O
102	n	_	_	O
103	=	_	_	O
104	90	_	_	O
105	)	_	_	O
106	or	_	_	O
107	combined	_	_	O
108	timolol	_	_	O
109	0.5	_	_	O
110	%	_	_	O
111	and	_	_	O
112	dorzolamide	_	_	O
113	2	_	_	O
114	%	_	_	O
115	twice	_	_	O
116	daily	_	_	O
117	(	_	_	O
118	n	_	_	O
119	=	_	_	O
120	87	_	_	O
121	)	_	_	O
122	over	_	_	O
123	a	_	_	O
124	3-month	_	_	O
125	period	_	_	O
126	.	_	_	O

127	Intraocular	_	_	O
128	pressure	_	_	O
129	,	_	_	O
130	the	_	_	O
131	primary	_	_	O
132	end	_	_	O
133	point	_	_	O
134	,	_	_	O
135	was	_	_	O
136	measured	_	_	O
137	at	_	_	O
138	8	_	_	O
139	AM	_	_	O
140	and	_	_	O
141	10	_	_	O
142	AM	_	_	O
143	at	_	_	O
144	baseline	_	_	O
145	,	_	_	O
146	week	_	_	O
147	1	_	_	O
148	,	_	_	O
149	and	_	_	O
150	months	_	_	O
151	1	_	_	O
152	,	_	_	O
153	2	_	_	O
154	,	_	_	O
155	and	_	_	O
156	3	_	_	O
157	,	_	_	O
158	and	_	_	O
159	also	_	_	O
160	at	_	_	O
161	4	_	_	O
162	PM	_	_	O
163	and	_	_	O
164	8	_	_	O
165	PM	_	_	O
166	at	_	_	O
167	baseline	_	_	O
168	and	_	_	O
169	month	_	_	O
170	3	_	_	O
171	.	_	_	O

172	Bimatoprost	_	_	B-Premise
173	provided	_	_	I-Premise
174	significantly	_	_	I-Premise
175	greater	_	_	I-Premise
176	IOP	_	_	I-Premise
177	lowering	_	_	I-Premise
178	compared	_	_	I-Premise
179	with	_	_	I-Premise
180	combined	_	_	I-Premise
181	timolol	_	_	I-Premise
182	and	_	_	I-Premise
183	dorzolamide	_	_	I-Premise
184	.	_	_	I-Premise

185	At	_	_	B-Premise
186	the	_	_	I-Premise
187	8	_	_	I-Premise
188	AM	_	_	I-Premise
189	measurements	_	_	I-Premise
190	,	_	_	I-Premise
191	bimatoprost	_	_	I-Premise
192	lowered	_	_	I-Premise
193	mean	_	_	I-Premise
194	IOP	_	_	I-Premise
195	6.8	_	_	I-Premise
196	mmHg	_	_	I-Premise
197	to	_	_	I-Premise
198	7.6	_	_	I-Premise
199	mmHg	_	_	I-Premise
200	from	_	_	I-Premise
201	baseline	_	_	I-Premise
202	,	_	_	I-Premise
203	whereas	_	_	I-Premise
204	combined	_	_	I-Premise
205	timolol	_	_	I-Premise
206	and	_	_	I-Premise
207	dorzolamide	_	_	I-Premise
208	lowered	_	_	I-Premise
209	mean	_	_	I-Premise
210	IOP	_	_	I-Premise
211	4.4	_	_	I-Premise
212	to	_	_	I-Premise
213	5.0	_	_	I-Premise
214	mmHg	_	_	I-Premise
215	from	_	_	I-Premise
216	baseline	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	<	_	_	I-Premise
220	0.001	_	_	I-Premise
221	)	_	_	I-Premise
222	.	_	_	I-Premise

223	At	_	_	B-Premise
224	the	_	_	I-Premise
225	last	_	_	I-Premise
226	follow-up	_	_	I-Premise
227	,	_	_	I-Premise
228	patients	_	_	I-Premise
229	had	_	_	I-Premise
230	better	_	_	I-Premise
231	diurnal	_	_	I-Premise
232	IOP	_	_	I-Premise
233	control	_	_	I-Premise
234	with	_	_	I-Premise
235	bimatoprost	_	_	I-Premise
236	than	_	_	I-Premise
237	combined	_	_	I-Premise
238	timolol	_	_	I-Premise
239	and	_	_	I-Premise
240	dorzolamide	_	_	I-Premise
241	.	_	_	I-Premise

242	At	_	_	B-Premise
243	8	_	_	I-Premise
244	AM	_	_	I-Premise
245	at	_	_	I-Premise
246	the	_	_	I-Premise
247	3-month	_	_	I-Premise
248	visit	_	_	I-Premise
249	,	_	_	I-Premise
250	the	_	_	I-Premise
251	percentages	_	_	I-Premise
252	of	_	_	I-Premise
253	patients	_	_	I-Premise
254	achieving	_	_	I-Premise
255	IOPs	_	_	I-Premise
256	of	_	_	I-Premise
257	<	_	_	I-Premise
258	or	_	_	I-Premise
259	=13	_	_	I-Premise
260	mmHg	_	_	I-Premise
261	,	_	_	I-Premise
262	<	_	_	I-Premise
263	or	_	_	I-Premise
264	=14	_	_	I-Premise
265	mmHg	_	_	I-Premise
266	,	_	_	I-Premise
267	<	_	_	I-Premise
268	or	_	_	I-Premise
269	=15	_	_	I-Premise
270	mmHg	_	_	I-Premise
271	,	_	_	I-Premise
272	or	_	_	I-Premise
273	<	_	_	I-Premise
274	or	_	_	I-Premise
275	=16	_	_	I-Premise
276	mmHg	_	_	I-Premise
277	were	_	_	I-Premise
278	more	_	_	I-Premise
279	than	_	_	I-Premise
280	twice	_	_	I-Premise
281	as	_	_	I-Premise
282	high	_	_	I-Premise
283	for	_	_	I-Premise
284	bimatoprost	_	_	I-Premise
285	than	_	_	I-Premise
286	for	_	_	I-Premise
287	combined	_	_	I-Premise
288	timolol	_	_	I-Premise
289	and	_	_	I-Premise
290	dorzolamide	_	_	I-Premise
291	(	_	_	I-Premise
292	all	_	_	I-Premise
293	P	_	_	I-Premise
294	<	_	_	I-Premise
295	or	_	_	I-Premise
296	=0.008	_	_	I-Premise
297	)	_	_	I-Premise
298	.	_	_	I-Premise

299	Taste	_	_	B-Premise
300	perversion	_	_	I-Premise
301	,	_	_	I-Premise
302	ocular	_	_	I-Premise
303	burning	_	_	I-Premise
304	,	_	_	I-Premise
305	and	_	_	I-Premise
306	stinging	_	_	I-Premise
307	with	_	_	I-Premise
308	instillation	_	_	I-Premise
309	were	_	_	I-Premise
310	more	_	_	I-Premise
311	common	_	_	I-Premise
312	with	_	_	I-Premise
313	combined	_	_	I-Premise
314	timolol	_	_	I-Premise
315	and	_	_	I-Premise
316	dorzolamide	_	_	I-Premise
317	,	_	_	I-Premise
318	whereas	_	_	I-Premise
319	conjunctival	_	_	I-Premise
320	hyperemia	_	_	I-Premise
321	was	_	_	I-Premise
322	more	_	_	I-Premise
323	common	_	_	I-Premise
324	with	_	_	I-Premise
325	bimatoprost	_	_	I-Premise
326	.	_	_	I-Premise

327	In	_	_	B-Claim
328	individuals	_	_	I-Claim
329	with	_	_	I-Claim
330	glaucoma	_	_	I-Claim
331	or	_	_	I-Claim
332	ocular	_	_	I-Claim
333	hypertension	_	_	I-Claim
334	,	_	_	I-Claim
335	uncontrolled	_	_	I-Claim
336	on	_	_	I-Claim
337	a	_	_	I-Claim
338	topical	_	_	I-Claim
339	beta-blocker	_	_	I-Claim
340	alone	_	_	I-Claim
341	,	_	_	I-Claim
342	bimatoprost	_	_	I-Claim
343	lowered	_	_	I-Claim
344	IOP	_	_	I-Claim
345	more	_	_	I-Claim
346	consistently	_	_	I-Claim
347	than	_	_	I-Claim
348	did	_	_	I-Claim
349	combined	_	_	I-Claim
350	timolol	_	_	I-Claim
351	and	_	_	I-Claim
352	dorzolamide	_	_	I-Claim
353	.	_	_	I-Claim


0	In	_	_	O
1	a	_	_	O
2	randomized	_	_	O
3	clinical	_	_	O
4	trial	_	_	O
5	,	_	_	O
6	the	_	_	O
7	authors	_	_	O
8	compared	_	_	O
9	the	_	_	O
10	use	_	_	O
11	of	_	_	O
12	postoperative	_	_	O
13	subconjunctival	_	_	O
14	injections	_	_	O
15	of	_	_	O
16	5-fluorouracil	_	_	O
17	(	_	_	O
18	5-FU	_	_	O
19	)	_	_	O
20	in	_	_	O
21	19	_	_	O
22	eyes	_	_	O
23	with	_	_	O
24	a	_	_	O
25	single	_	_	O
26	intraoperative	_	_	O
27	application	_	_	O
28	of	_	_	O
29	subconjunctival	_	_	O
30	mitomycin	_	_	O
31	(	_	_	O
32	MMC	_	_	O
33	)	_	_	O
34	at	_	_	O
35	the	_	_	O
36	filtering	_	_	O
37	site	_	_	O
38	in	_	_	O
39	20	_	_	O
40	eyes	_	_	O
41	at	_	_	O
42	high	_	_	O
43	risk	_	_	O
44	for	_	_	O
45	failure	_	_	O
46	of	_	_	O
47	glaucoma	_	_	O
48	filtering	_	_	O
49	surgery	_	_	O
50	.	_	_	O

51	Six	_	_	B-Premise
52	months	_	_	I-Premise
53	after	_	_	I-Premise
54	surgery	_	_	I-Premise
55	,	_	_	I-Premise
56	intraocular	_	_	I-Premise
57	pressures	_	_	I-Premise
58	averaged	_	_	I-Premise
59	10.9	_	_	I-Premise
60	+/-	_	_	I-Premise
61	5.3	_	_	I-Premise
62	mmHg	_	_	I-Premise
63	(	_	_	I-Premise
64	mean	_	_	I-Premise
65	+/-	_	_	I-Premise
66	standard	_	_	I-Premise
67	deviation	_	_	I-Premise
68	)	_	_	I-Premise
69	in	_	_	I-Premise
70	the	_	_	I-Premise
71	MMC-treated	_	_	I-Premise
72	eyes	_	_	I-Premise
73	versus	_	_	I-Premise
74	14.2	_	_	I-Premise
75	+/-	_	_	I-Premise
76	5.5	_	_	I-Premise
77	mmHg	_	_	I-Premise
78	in	_	_	I-Premise
79	the	_	_	I-Premise
80	5-FU-treated	_	_	I-Premise
81	eyes	_	_	I-Premise
82	(	_	_	I-Premise
83	P	_	_	I-Premise
84	=	_	_	I-Premise
85	0.08	_	_	I-Premise
86	)	_	_	I-Premise
87	and	_	_	I-Premise
88	were	_	_	I-Premise
89	less	_	_	I-Premise
90	than	_	_	I-Premise
91	or	_	_	I-Premise
92	equal	_	_	I-Premise
93	to	_	_	I-Premise
94	12	_	_	I-Premise
95	mmHg	_	_	I-Premise
96	in	_	_	I-Premise
97	60.0	_	_	I-Premise
98	%	_	_	I-Premise
99	of	_	_	I-Premise
100	MMC-treated	_	_	I-Premise
101	eyes	_	_	I-Premise
102	and	_	_	I-Premise
103	21.1	_	_	I-Premise
104	%	_	_	I-Premise
105	of	_	_	I-Premise
106	5-FU-treated	_	_	I-Premise
107	eyes	_	_	I-Premise
108	(	_	_	I-Premise
109	P	_	_	I-Premise
110	=	_	_	I-Premise
111	0.03	_	_	I-Premise
112	)	_	_	I-Premise
113	.	_	_	I-Premise

114	Mitomycin-treated	_	_	O
115	eyes	_	_	O
116	were	_	_	O
117	receiving	_	_	O
118	an	_	_	O
119	average	_	_	O
120	of	_	_	O
121	0.3	_	_	O
122	+/-	_	_	O
123	0.5	_	_	O
124	medications	_	_	O
125	for	_	_	O
126	intraocular	_	_	O
127	pressure	_	_	O
128	control	_	_	O
129	,	_	_	O
130	and	_	_	O
131	5-FU-treated	_	_	O
132	eyes	_	_	O
133	were	_	_	O
134	receiving	_	_	O
135	an	_	_	O
136	average	_	_	O
137	of	_	_	O
138	1.1	_	_	O
139	+/-	_	_	O
140	1.1	_	_	O
141	medications	_	_	O
142	(	_	_	O
143	P	_	_	O
144	=	_	_	O
145	0.01	_	_	O
146	)	_	_	O
147	.	_	_	O

148	Drug-induced	_	_	B-Premise
149	corneal	_	_	I-Premise
150	epithelial	_	_	I-Premise
151	defects	_	_	I-Premise
152	were	_	_	I-Premise
153	seen	_	_	I-Premise
154	in	_	_	I-Premise
155	nine	_	_	I-Premise
156	5-FU-treated	_	_	I-Premise
157	eyes	_	_	I-Premise
158	and	_	_	I-Premise
159	in	_	_	I-Premise
160	no	_	_	I-Premise
161	MMC-treated	_	_	I-Premise
162	eyes	_	_	I-Premise
163	(	_	_	I-Premise
164	P	_	_	I-Premise
165	=	_	_	I-Premise
166	0.0004	_	_	I-Premise
167	)	_	_	I-Premise
168	.	_	_	I-Premise

169	These	_	_	B-Claim
170	results	_	_	I-Claim
171	suggest	_	_	I-Claim
172	that	_	_	I-Claim
173	intraoperative	_	_	I-Claim
174	MMC	_	_	I-Claim
175	may	_	_	I-Claim
176	be	_	_	I-Claim
177	a	_	_	I-Claim
178	viable	_	_	I-Claim
179	alternative	_	_	I-Claim
180	to	_	_	I-Claim
181	postoperative	_	_	I-Claim
182	5-FU	_	_	I-Claim
183	,	_	_	I-Claim
184	with	_	_	I-Claim
185	lower	_	_	I-Claim
186	overall	_	_	I-Claim
187	intraocular	_	_	I-Claim
188	pressures	_	_	I-Claim
189	,	_	_	I-Claim
190	decreased	_	_	I-Claim
191	dependence	_	_	I-Claim
192	on	_	_	I-Claim
193	postoperative	_	_	I-Claim
194	ocular	_	_	I-Claim
195	antihypertensive	_	_	I-Claim
196	medications	_	_	I-Claim
197	,	_	_	I-Claim
198	and	_	_	I-Claim
199	decreased	_	_	I-Claim
200	corneal	_	_	I-Claim
201	toxicity	_	_	I-Claim
202	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	(	_	_	O
6	IOP	_	_	O
7	)	_	_	O
8	-reducing	_	_	O
9	effect	_	_	O
10	and	_	_	O
11	side	_	_	O
12	effects	_	_	O
13	of	_	_	O
14	0.005	_	_	O
15	%	_	_	O
16	latanoprost	_	_	O
17	administered	_	_	O
18	once	_	_	O
19	daily	_	_	O
20	with	_	_	O
21	0.5	_	_	O
22	%	_	_	O
23	timolol	_	_	O
24	administered	_	_	O
25	twice	_	_	O
26	daily	_	_	O
27	in	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	open-angle	_	_	O
31	glaucoma	_	_	O
32	or	_	_	O
33	ocular	_	_	O
34	hypertension	_	_	O
35	.	_	_	O

36	This	_	_	O
37	was	_	_	O
38	a	_	_	O
39	randomized	_	_	O
40	,	_	_	O
41	double-masked	_	_	O
42	study	_	_	O
43	with	_	_	O
44	two	_	_	O
45	parallel	_	_	O
46	groups	_	_	O
47	and	_	_	O
48	a	_	_	O
49	treatment	_	_	O
50	period	_	_	O
51	of	_	_	O
52	6	_	_	O
53	months	_	_	O
54	.	_	_	O

55	The	_	_	O
56	primary	_	_	O
57	objective	_	_	O
58	of	_	_	O
59	the	_	_	O
60	study	_	_	O
61	is	_	_	O
62	to	_	_	O
63	compare	_	_	O
64	the	_	_	O
65	IOP-reducing	_	_	O
66	effect	_	_	O
67	of	_	_	O
68	latanoprost	_	_	O
69	with	_	_	O
70	that	_	_	O
71	of	_	_	O
72	timolol	_	_	O
73	at	_	_	O
74	the	_	_	O
75	end	_	_	O
76	of	_	_	O
77	the	_	_	O
78	6-month	_	_	O
79	treatment	_	_	O
80	period	_	_	O
81	.	_	_	O

82	A	_	_	O
83	total	_	_	O
84	of	_	_	O
85	294	_	_	O
86	patients	_	_	O
87	were	_	_	O
88	included	_	_	O
89	:	_	_	O
90	149	_	_	O
91	were	_	_	O
92	in	_	_	O
93	the	_	_	O
94	latanoprost	_	_	O
95	group	_	_	O
96	and	_	_	O
97	145	_	_	O
98	were	_	_	O
99	in	_	_	O
100	timolol	_	_	O
101	group	_	_	O
102	.	_	_	O

103	Latanoprost	_	_	O
104	was	_	_	O
105	administered	_	_	O
106	in	_	_	O
107	the	_	_	O
108	evening	_	_	O
109	.	_	_	O

110	Diurnal	_	_	B-Premise
111	IOP	_	_	I-Premise
112	(	_	_	I-Premise
113	9:00	_	_	I-Premise
114	am	_	_	I-Premise
115	,	_	_	I-Premise
116	1:00	_	_	I-Premise
117	pm	_	_	I-Premise
118	,	_	_	I-Premise
119	5:00	_	_	I-Premise
120	pm	_	_	I-Premise
121	)	_	_	I-Premise
122	was	_	_	I-Premise
123	reduced	_	_	I-Premise
124	from	_	_	I-Premise
125	25.2	_	_	I-Premise
126	to	_	_	I-Premise
127	16.7	_	_	I-Premise
128	mmHg	_	_	I-Premise
129	(	_	_	I-Premise
130	33.7	_	_	I-Premise
131	%	_	_	I-Premise
132	)	_	_	I-Premise
133	with	_	_	I-Premise
134	lantanoprost	_	_	I-Premise
135	and	_	_	I-Premise
136	from	_	_	I-Premise
137	25.4	_	_	I-Premise
138	to	_	_	I-Premise
139	17.1	_	_	I-Premise
140	mmHg	_	_	I-Premise
141	(	_	_	I-Premise
142	32.7	_	_	I-Premise
143	%	_	_	I-Premise
144	)	_	_	I-Premise
145	with	_	_	I-Premise
146	timolol	_	_	I-Premise
147	as	_	_	I-Premise
148	determined	_	_	I-Premise
149	at	_	_	I-Premise
150	the	_	_	I-Premise
151	end	_	_	I-Premise
152	of	_	_	I-Premise
153	the	_	_	I-Premise
154	6-month	_	_	I-Premise
155	treatment	_	_	I-Premise
156	period	_	_	I-Premise
157	.	_	_	I-Premise

158	No	_	_	O
159	upward	_	_	O
160	drift	_	_	O
161	in	_	_	O
162	IOP	_	_	O
163	occurred	_	_	O
164	with	_	_	O
165	either	_	_	O
166	drug	_	_	O
167	during	_	_	O
168	the	_	_	O
169	treatment	_	_	O
170	period	_	_	O
171	.	_	_	O

172	Latanoprost	_	_	B-Premise
173	caused	_	_	I-Premise
174	a	_	_	I-Premise
175	somewhat	_	_	I-Premise
176	more	_	_	I-Premise
177	conjunctival	_	_	I-Premise
178	hyperemia	_	_	I-Premise
179	than	_	_	I-Premise
180	timolol	_	_	I-Premise
181	and	_	_	I-Premise
182	more	_	_	I-Premise
183	corneal	_	_	I-Premise
184	punctuate	_	_	I-Premise
185	epithelial	_	_	I-Premise
186	erosions	_	_	I-Premise
187	.	_	_	I-Premise

188	However	_	_	O
189	,	_	_	O
190	both	_	_	B-Premise
191	drugs	_	_	I-Premise
192	were	_	_	I-Premise
193	generally	_	_	I-Premise
194	well	_	_	I-Premise
195	tolerated	_	_	I-Premise
196	.	_	_	I-Premise

197	The	_	_	B-Premise
198	most	_	_	I-Premise
199	significant	_	_	I-Premise
200	side	_	_	I-Premise
201	effect	_	_	I-Premise
202	of	_	_	I-Premise
203	latanoprost	_	_	I-Premise
204	was	_	_	I-Premise
205	increased	_	_	I-Premise
206	pigmentation	_	_	I-Premise
207	of	_	_	I-Premise
208	the	_	_	I-Premise
209	iris	_	_	I-Premise
210	which	_	_	I-Premise
211	was	_	_	I-Premise
212	observed	_	_	I-Premise
213	in	_	_	I-Premise
214	15	_	_	I-Premise
215	patients	_	_	I-Premise
216	(	_	_	I-Premise
217	10.1	_	_	I-Premise
218	%	_	_	I-Premise
219	)	_	_	I-Premise
220	.	_	_	I-Premise

221	Timolol	_	_	B-Claim
222	caused	_	_	I-Claim
223	more	_	_	I-Claim
224	systemic	_	_	I-Claim
225	side	_	_	I-Claim
226	effects	_	_	I-Claim
227	than	_	_	I-Claim
228	latanoprost	_	_	I-Claim
229	.	_	_	I-Claim

230	Latanoprost	_	_	B-Claim
231	0.005	_	_	I-Claim
232	%	_	_	I-Claim
233	administered	_	_	I-Claim
234	once	_	_	I-Claim
235	daily	_	_	I-Claim
236	in	_	_	I-Claim
237	the	_	_	I-Claim
238	evening	_	_	I-Claim
239	reduced	_	_	I-Claim
240	IOP	_	_	I-Claim
241	at	_	_	I-Claim
242	least	_	_	I-Claim
243	as	_	_	I-Claim
244	well	_	_	I-Claim
245	as	_	_	I-Claim
246	timolol	_	_	I-Claim
247	0.5	_	_	I-Claim
248	%	_	_	I-Claim
249	administered	_	_	I-Claim
250	twice	_	_	I-Claim
251	daily	_	_	I-Claim
252	.	_	_	I-Claim

253	Latanoprost	_	_	B-Claim
254	was	_	_	I-Claim
255	generally	_	_	I-Claim
256	well	_	_	I-Claim
257	tolerated	_	_	I-Claim
258	systemically	_	_	I-Claim
259	and	_	_	I-Claim
260	in	_	_	I-Claim
261	the	_	_	I-Claim
262	eye	_	_	I-Claim
263	.	_	_	I-Claim

264	However	_	_	O
265	,	_	_	O
266	the	_	_	O
267	drug	_	_	O
268	has	_	_	O
269	an	_	_	O
270	unusual	_	_	O
271	side	_	_	O
272	effect	_	_	O
273	of	_	_	O
274	increasing	_	_	O
275	the	_	_	O
276	pigmentation	_	_	O
277	of	_	_	O
278	the	_	_	O
279	iris	_	_	O
280	,	_	_	O
281	particularly	_	_	O
282	in	_	_	O
283	individuals	_	_	O
284	with	_	_	O
285	green-brown	_	_	O
286	or	_	_	O
287	blue-brown	_	_	O
288	eyes	_	_	O
289	.	_	_	O


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	long-term	_	_	O
4	intraocular	_	_	O
5	pressure	_	_	O
6	(	_	_	O
7	IOP	_	_	O
8	)	_	_	O
9	control	_	_	O
10	of	_	_	O
11	trabeculectomy	_	_	O
12	and	_	_	O
13	triple	_	_	O
14	procedure	_	_	O
15	(	_	_	O
16	cataract	_	_	O
17	extraction	_	_	O
18	by	_	_	O
19	phacoemulsification	_	_	O
20	,	_	_	O
21	intraocular	_	_	O
22	lens	_	_	O
23	implantation	_	_	O
24	and	_	_	O
25	trabeculectomy	_	_	O
26	)	_	_	O
27	,	_	_	O
28	1,542	_	_	O
29	eyes	_	_	O
30	of	_	_	O
31	900	_	_	O
32	patients	_	_	O
33	with	_	_	O
34	primary	_	_	O
35	open	_	_	O
36	angle	_	_	O
37	glaucoma	_	_	O
38	(	_	_	O
39	POAG	_	_	O
40	)	_	_	O
41	or	_	_	O
42	chronic	_	_	O
43	primary	_	_	O
44	angle	_	_	O
45	closure	_	_	O
46	glaucoma	_	_	O
47	(	_	_	O
48	CPACG	_	_	O
49	)	_	_	O
50	were	_	_	O
51	included	_	_	O
52	.	_	_	O

53	When	_	_	O
54	success	_	_	O
55	was	_	_	O
56	defined	_	_	O
57	as	_	_	O
58	an	_	_	O
59	IOP	_	_	O
60	reduction	_	_	O
61	of	_	_	O
62	at	_	_	O
63	least	_	_	O
64	30	_	_	O
65	%	_	_	O
66	from	_	_	O
67	baseline	_	_	O
68	,	_	_	O
69	with	_	_	O
70	or	_	_	O
71	without	_	_	O
72	antiglaucoma	_	_	O
73	medications	_	_	O
74	,	_	_	O
75	the	_	_	B-Premise
76	overall	_	_	I-Premise
77	probability	_	_	I-Premise
78	of	_	_	I-Premise
79	success	_	_	I-Premise
80	of	_	_	I-Premise
81	trabeculectomy	_	_	I-Premise
82	and	_	_	I-Premise
83	triple	_	_	I-Premise
84	procedure	_	_	I-Premise
85	was	_	_	I-Premise
86	0.613	_	_	I-Premise
87	and	_	_	I-Premise
88	0.733	_	_	I-Premise
89	at	_	_	I-Premise
90	15	_	_	I-Premise
91	years	_	_	I-Premise
92	,	_	_	I-Premise
93	respectively	_	_	I-Premise
94	.	_	_	I-Premise

95	The	_	_	B-Premise
96	success	_	_	I-Premise
97	probability	_	_	I-Premise
98	of	_	_	I-Premise
99	trabeculectomy	_	_	I-Premise
100	and	_	_	I-Premise
101	triple	_	_	I-Premise
102	procedure	_	_	I-Premise
103	in	_	_	I-Premise
104	reducing	_	_	I-Premise
105	IOP	_	_	I-Premise
106	below	_	_	I-Premise
107	18	_	_	I-Premise
108	mm	_	_	I-Premise
109	Hg	_	_	I-Premise
110	was	_	_	I-Premise
111	0.748	_	_	I-Premise
112	and	_	_	I-Premise
113	0.825	_	_	I-Premise
114	at	_	_	I-Premise
115	15	_	_	I-Premise
116	years	_	_	I-Premise
117	,	_	_	I-Premise
118	respectively	_	_	I-Premise
119	.	_	_	I-Premise

120	In	_	_	B-Claim
121	POAG	_	_	I-Claim
122	and	_	_	I-Claim
123	CPACG	_	_	I-Claim
124	patients	_	_	I-Claim
125	,	_	_	I-Claim
126	trabeculectomy	_	_	I-Claim
127	and	_	_	I-Claim
128	triple	_	_	I-Claim
129	procedure	_	_	I-Claim
130	were	_	_	I-Claim
131	effective	_	_	I-Claim
132	in	_	_	I-Claim
133	reducing	_	_	I-Claim
134	IOP	_	_	I-Claim
135	for	_	_	I-Claim
136	up	_	_	I-Claim
137	to	_	_	I-Claim
138	15	_	_	I-Claim
139	years	_	_	I-Claim
140	after	_	_	I-Claim
141	surgery	_	_	I-Claim
142	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	oral	_	_	O
8	clonidine	_	_	O
9	in	_	_	O
10	decreasing	_	_	O
11	the	_	_	O
12	prevalence	_	_	O
13	and	_	_	O
14	intensity	_	_	O
15	of	_	_	O
16	postoperative	_	_	O
17	intraocular	_	_	O
18	pressure	_	_	O
19	(	_	_	O
20	IOP	_	_	O
21	)	_	_	O
22	rise	_	_	O
23	in	_	_	O
24	those	_	_	O
25	undergoing	_	_	O
26	phacoemulsification	_	_	O
27	.	_	_	O

28	This	_	_	O
29	was	_	_	O
30	a	_	_	O
31	prospective	_	_	O
32	randomized	_	_	O
33	,	_	_	O
34	double-blind	_	_	O
35	,	_	_	O
36	placebo-controlled	_	_	O
37	,	_	_	O
38	clinical	_	_	O
39	trial	_	_	O
40	including	_	_	O
41	62	_	_	O
42	patients	_	_	O
43	(	_	_	O
44	each	_	_	O
45	with	_	_	O
46	1	_	_	O
47	affected	_	_	O
48	aye	_	_	O
49	)	_	_	O
50	with	_	_	O
51	senile	_	_	O
52	cataract	_	_	O
53	scheduled	_	_	O
54	for	_	_	O
55	phacoemulsification	_	_	O
56	who	_	_	O
57	were	_	_	O
58	randomly	_	_	O
59	assigned	_	_	O
60	to	_	_	O
61	receive	_	_	O
62	preoperative	_	_	O
63	oral	_	_	O
64	clonidine	_	_	O
65	(	_	_	O
66	5g/kg	_	_	O
67	,	_	_	O
68	31	_	_	O
69	patients	_	_	O
70	)	_	_	O
71	or	_	_	O
72	placebo	_	_	O
73	(	_	_	O
74	1	_	_	O
75	tablet	_	_	O
76	,	_	_	O
77	31	_	_	O
78	patients	_	_	O
79	)	_	_	O
80	.	_	_	O

81	The	_	_	O
82	IOP	_	_	O
83	was	_	_	O
84	measured	_	_	O
85	preoperatively	_	_	O
86	and	_	_	O
87	at	_	_	O
88	6	_	_	O
89	,	_	_	O
90	12	_	_	O
91	,	_	_	O
92	and	_	_	O
93	24h	_	_	O
94	postoperatively	_	_	O
95	.	_	_	O

96	The	_	_	O
97	prevalence	_	_	O
98	and	_	_	O
99	intensity	_	_	O
100	of	_	_	O
101	the	_	_	O
102	acute	_	_	O
103	postoperative	_	_	O
104	IOP	_	_	O
105	rise	_	_	O
106	was	_	_	O
107	compared	_	_	O
108	between	_	_	O
109	and	_	_	O
110	within	_	_	O
111	the	_	_	O
112	groups	_	_	O
113	.	_	_	O

114	There	_	_	B-Premise
115	was	_	_	I-Premise
116	no	_	_	I-Premise
117	significant	_	_	I-Premise
118	difference	_	_	I-Premise
119	between	_	_	I-Premise
120	the	_	_	I-Premise
121	2	_	_	I-Premise
122	study	_	_	I-Premise
123	groups	_	_	I-Premise
124	regarding	_	_	I-Premise
125	the	_	_	I-Premise
126	baseline	_	_	I-Premise
127	characteristics	_	_	I-Premise
128	and	_	_	I-Premise
129	the	_	_	I-Premise
130	baseline	_	_	I-Premise
131	IOP	_	_	I-Premise
132	(	_	_	I-Premise
133	P=0.628	_	_	I-Premise
134	)	_	_	I-Premise
135	.	_	_	I-Premise

136	Patients	_	_	B-Premise
137	who	_	_	I-Premise
138	received	_	_	I-Premise
139	placebo	_	_	I-Premise
140	as	_	_	I-Premise
141	premedication	_	_	I-Premise
142	had	_	_	I-Premise
143	significantly	_	_	I-Premise
144	higher	_	_	I-Premise
145	IOP	_	_	I-Premise
146	at	_	_	I-Premise
147	6	_	_	I-Premise
148	(	_	_	I-Premise
149	17.96±5.49	_	_	I-Premise
150	vs	_	_	I-Premise
151	13.61±4.09	_	_	I-Premise
152	;	_	_	I-Premise
153	P	_	_	I-Premise
154	<	_	_	I-Premise
155	0.001	_	_	I-Premise
156	)	_	_	I-Premise
157	and	_	_	I-Premise
158	12	_	_	I-Premise
159	(	_	_	I-Premise
160	16.90±4.11	_	_	I-Premise
161	vs	_	_	I-Premise
162	13.96±3.25	_	_	I-Premise
163	;	_	_	I-Premise
164	P=0.003	_	_	I-Premise
165	)	_	_	I-Premise
166	h	_	_	I-Premise
167	postoperatively	_	_	I-Premise
168	compared	_	_	I-Premise
169	with	_	_	I-Premise
170	those	_	_	I-Premise
171	who	_	_	I-Premise
172	received	_	_	I-Premise
173	oral	_	_	I-Premise
174	clonidine	_	_	I-Premise
175	.	_	_	I-Premise

176	However	_	_	O
177	,	_	_	O
178	there	_	_	B-Premise
179	was	_	_	I-Premise
180	no	_	_	I-Premise
181	significant	_	_	I-Premise
182	difference	_	_	I-Premise
183	between	_	_	I-Premise
184	the	_	_	I-Premise
185	2	_	_	I-Premise
186	groups	_	_	I-Premise
187	regarding	_	_	I-Premise
188	the	_	_	I-Premise
189	IOP	_	_	I-Premise
190	at	_	_	I-Premise
191	24h	_	_	I-Premise
192	after	_	_	I-Premise
193	operation	_	_	I-Premise
194	(	_	_	I-Premise
195	15.41±3.96	_	_	I-Premise
196	vs	_	_	I-Premise
197	16.01±3.41	_	_	I-Premise
198	;	_	_	I-Premise
199	P=0.0539	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	The	_	_	B-Premise
203	prevalence	_	_	I-Premise
204	of	_	_	I-Premise
205	acute	_	_	I-Premise
206	IOP	_	_	I-Premise
207	rise	_	_	I-Premise
208	(	_	_	I-Premise
209	>	_	_	I-Premise
210	21	_	_	I-Premise
211	mmHg	_	_	I-Premise
212	)	_	_	I-Premise
213	was	_	_	I-Premise
214	significantly	_	_	I-Premise
215	higher	_	_	I-Premise
216	in	_	_	I-Premise
217	placebo	_	_	I-Premise
218	group	_	_	I-Premise
219	compared	_	_	I-Premise
220	with	_	_	I-Premise
221	clonidine	_	_	I-Premise
222	group	_	_	I-Premise
223	(	_	_	I-Premise
224	25.8	_	_	I-Premise
225	%	_	_	I-Premise
226	vs	_	_	I-Premise
227	9.6	_	_	I-Premise
228	%	_	_	I-Premise
229	;	_	_	I-Premise
230	P=0.091	_	_	I-Premise
231	)	_	_	I-Premise
232	.	_	_	I-Premise

233	Administering	_	_	B-Claim
234	preoperative	_	_	I-Claim
235	oral	_	_	I-Claim
236	clonidine	_	_	I-Claim
237	in	_	_	I-Claim
238	a	_	_	I-Claim
239	dosage	_	_	I-Claim
240	of	_	_	I-Claim
241	5g/kg	_	_	I-Claim
242	,	_	_	I-Claim
243	2h	_	_	I-Claim
244	before	_	_	I-Claim
245	phacoemulsification	_	_	I-Claim
246	,	_	_	I-Claim
247	significantly	_	_	I-Claim
248	decreases	_	_	I-Claim
249	the	_	_	I-Claim
250	prevalence	_	_	I-Claim
251	and	_	_	I-Claim
252	intensity	_	_	I-Claim
253	of	_	_	I-Claim
254	acute	_	_	I-Claim
255	postoperative	_	_	I-Claim
256	IOP	_	_	I-Claim
257	rise	_	_	I-Claim
258	in	_	_	I-Claim
259	those	_	_	I-Claim
260	undergoing	_	_	I-Claim
261	general	_	_	I-Claim
262	anesthesia	_	_	I-Claim
263	.	_	_	I-Claim

264	Oral	_	_	B-Claim
265	clonidine	_	_	I-Claim
266	is	_	_	I-Claim
267	safe	_	_	I-Claim
268	,	_	_	I-Claim
269	cheap	_	_	I-Claim
270	,	_	_	I-Claim
271	and	_	_	I-Claim
272	easily	_	_	I-Claim
273	accessible	_	_	I-Claim
274	and	_	_	I-Claim
275	,	_	_	I-Claim
276	thus	_	_	I-Claim
277	,	_	_	I-Claim
278	it	_	_	I-Claim
279	is	_	_	I-Claim
280	recommended	_	_	I-Claim
281	for	_	_	I-Claim
282	controlling	_	_	I-Claim
283	the	_	_	I-Claim
284	IOP	_	_	I-Claim
285	after	_	_	I-Claim
286	phacoemulsification	_	_	I-Claim
287	,	_	_	I-Claim
288	especially	_	_	I-Claim
289	in	_	_	I-Claim
290	high-risk	_	_	I-Claim
291	patients	_	_	I-Claim
292	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	long-term	_	_	O
4	efficacy	_	_	O
5	and	_	_	O
6	safety	_	_	O
7	of	_	_	O
8	combined	_	_	O
9	trabeculectomy	_	_	O
10	and	_	_	O
11	cataract	_	_	O
12	extraction	_	_	O
13	versus	_	_	O
14	trabeculectomy	_	_	O
15	alone	_	_	O
16	in	_	_	O
17	primary	_	_	O
18	angle-closure	_	_	O
19	glaucoma	_	_	O
20	(	_	_	O
21	PACG	_	_	O
22	)	_	_	O
23	.	_	_	O

24	Hospital	_	_	O
25	files	_	_	O
26	were	_	_	O
27	retrospectively	_	_	O
28	examined	_	_	O
29	for	_	_	O
30	99	_	_	O
31	Chinese	_	_	O
32	PACG	_	_	O
33	patients	_	_	O
34	;	_	_	O
35	75	_	_	O
36	patients	_	_	O
37	underwent	_	_	O
38	combined	_	_	O
39	surgery	_	_	O
40	and	_	_	O
41	24	_	_	O
42	underwent	_	_	O
43	trabeculectomy	_	_	O
44	alone	_	_	O
45	.	_	_	O

46	Success	_	_	O
47	rates	_	_	O
48	were	_	_	O
49	assessed	_	_	O
50	with	_	_	O
51	the	_	_	O
52	Kaplan-Meier	_	_	O
53	survival	_	_	O
54	analysis	_	_	O
55	.	_	_	O

56	The	_	_	O
57	main	_	_	O
58	outcome	_	_	O
59	was	_	_	O
60	the	_	_	O
61	complete	_	_	O
62	success	_	_	O
63	rate	_	_	O
64	defined	_	_	O
65	as	_	_	O
66	either	_	_	O
67	a	_	_	O
68	>	_	_	O
69	20	_	_	O
70	%	_	_	O
71	reduction	_	_	O
72	in	_	_	O
73	intraocular	_	_	O
74	pressure	_	_	O
75	(	_	_	O
76	IOP	_	_	O
77	)	_	_	O
78	or	_	_	O
79	an	_	_	O
80	IOP	_	_	O
81	that	_	_	O
82	remained	_	_	O
83	below	_	_	O
84	15	_	_	O
85	mm	_	_	O
86	Hg	_	_	O
87	,	_	_	O
88	with	_	_	O
89	no	_	_	O
90	medications	_	_	O
91	required	_	_	O
92	.	_	_	O

93	Patients	_	_	O
94	in	_	_	O
95	the	_	_	O
96	combined	_	_	O
97	group	_	_	O
98	and	_	_	O
99	trabeculectomy	_	_	O
100	group	_	_	O
101	had	_	_	O
102	a	_	_	O
103	mean	_	_	O
104	follow-up	_	_	O
105	period	_	_	O
106	of	_	_	O
107	25.8	_	_	O
108	(	_	_	O
109	SD	_	_	O
110	10.8	_	_	O
111	)	_	_	O
112	months	_	_	O
113	and	_	_	O
114	31.4	_	_	O
115	(	_	_	O
116	8.9	_	_	O
117	)	_	_	O
118	months	_	_	O
119	,	_	_	O
120	respectively	_	_	O
121	.	_	_	O

122	Survival	_	_	O
123	analysis	_	_	O
124	showed	_	_	O
125	that	_	_	O
126	the	_	_	O
127	complete	_	_	O
128	success	_	_	O
129	rate	_	_	O
130	at	_	_	O
131	3	_	_	O
132	years	_	_	O
133	was	_	_	O
134	56	_	_	O
135	%	_	_	O
136	in	_	_	O
137	the	_	_	O
138	combined	_	_	O
139	group	_	_	O
140	and	_	_	O
141	54	_	_	O
142	%	_	_	O
143	in	_	_	O
144	the	_	_	O
145	trabeculectomy	_	_	O
146	group	_	_	O
147	(	_	_	O
148	p	_	_	O
149	=	_	_	O
150	0.903	_	_	O
151	)	_	_	O
152	.	_	_	O

153	There	_	_	O
154	were	_	_	O
155	no	_	_	O
156	significant	_	_	O
157	differences	_	_	O
158	between	_	_	O
159	groups	_	_	O
160	in	_	_	O
161	either	_	_	O
162	IOP	_	_	O
163	or	_	_	O
164	the	_	_	O
165	number	_	_	O
166	of	_	_	O
167	glaucoma	_	_	O
168	medications	_	_	O
169	throughout	_	_	O
170	the	_	_	O
171	3-year	_	_	O
172	follow-up	_	_	O
173	.	_	_	O

174	The	_	_	B-Premise
175	incidences	_	_	I-Premise
176	of	_	_	I-Premise
177	postoperative	_	_	I-Premise
178	complications	_	_	I-Premise
179	were	_	_	I-Premise
180	similar	_	_	I-Premise
181	between	_	_	I-Premise
182	groups	_	_	I-Premise
183	(	_	_	I-Premise
184	p	_	_	I-Premise
185	=	_	_	I-Premise
186	0.232	_	_	I-Premise
187	)	_	_	I-Premise
188	.	_	_	I-Premise

189	No	_	_	B-Premise
190	additional	_	_	I-Premise
191	IOP-lowering	_	_	I-Premise
192	surgical	_	_	I-Premise
193	procedures	_	_	I-Premise
194	were	_	_	I-Premise
195	required	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	combined	_	_	I-Premise
199	group	_	_	I-Premise
200	,	_	_	I-Premise
201	while	_	_	I-Premise
202	13	_	_	I-Premise
203	(	_	_	I-Premise
204	54	_	_	I-Premise
205	%	_	_	I-Premise
206	)	_	_	I-Premise
207	eyes	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	trabeculectomy	_	_	I-Premise
211	group	_	_	I-Premise
212	required	_	_	I-Premise
213	either	_	_	I-Premise
214	cataract	_	_	I-Premise
215	extraction	_	_	I-Premise
216	or	_	_	I-Premise
217	further	_	_	I-Premise
218	IOP-lowering	_	_	I-Premise
219	surgical	_	_	I-Premise
220	procedures	_	_	I-Premise
221	(	_	_	I-Premise
222	p	_	_	I-Premise
223	<	_	_	I-Premise
224	0.001	_	_	I-Premise
225	)	_	_	I-Premise
226	.	_	_	I-Premise

227	In	_	_	B-Claim
228	patients	_	_	I-Claim
229	with	_	_	I-Claim
230	PACG	_	_	I-Claim
231	,	_	_	I-Claim
232	the	_	_	I-Claim
233	long-term	_	_	I-Claim
234	IOP-lowering	_	_	I-Claim
235	effect	_	_	I-Claim
236	and	_	_	I-Claim
237	surgical	_	_	I-Claim
238	complications	_	_	I-Claim
239	of	_	_	I-Claim
240	combined	_	_	I-Claim
241	trabeculectomy	_	_	I-Claim
242	and	_	_	I-Claim
243	cataract	_	_	I-Claim
244	extraction	_	_	I-Claim
245	are	_	_	I-Claim
246	comparable	_	_	I-Claim
247	with	_	_	I-Claim
248	those	_	_	I-Claim
249	of	_	_	I-Claim
250	trabeculectomy	_	_	I-Claim
251	alone	_	_	I-Claim
252	.	_	_	I-Claim

253	However	_	_	B-Claim
254	,	_	_	I-Claim
255	the	_	_	I-Claim
256	combined	_	_	I-Claim
257	surgery	_	_	I-Claim
258	incurred	_	_	I-Claim
259	fewer	_	_	I-Claim
260	subsequent	_	_	I-Claim
261	surgical	_	_	I-Claim
262	interventions	_	_	I-Claim
263	.	_	_	I-Claim


0	Carteolol	_	_	O
1	is	_	_	O
2	a	_	_	O
3	beta-adrenoceptor	_	_	O
4	antagonist	_	_	O
5	with	_	_	O
6	intrinsic	_	_	O
7	sympathomimetic	_	_	O
8	activity	_	_	O
9	.	_	_	O

10	Used	_	_	O
11	topically	_	_	O
12	to	_	_	O
13	reduce	_	_	O
14	intraocular	_	_	O
15	pressure	_	_	O
16	,	_	_	O
17	it	_	_	O
18	is	_	_	O
19	typically	_	_	O
20	applied	_	_	O
21	twice	_	_	O
22	daily	_	_	O
23	.	_	_	O

24	In	_	_	O
25	an	_	_	O
26	effort	_	_	O
27	to	_	_	O
28	provide	_	_	O
29	a	_	_	O
30	once-daily	_	_	O
31	dosing	_	_	O
32	regimen	_	_	O
33	,	_	_	O
34	carteolol	_	_	O
35	was	_	_	O
36	formulated	_	_	O
37	with	_	_	O
38	1	_	_	O
39	%	_	_	O
40	alginic	_	_	O
41	acid	_	_	O
42	.	_	_	O

43	Sodium	_	_	O
44	alginate	_	_	O
45	is	_	_	O
46	a	_	_	O
47	natural	_	_	O
48	polymer	_	_	O
49	product	_	_	O
50	with	_	_	O
51	bioadhesive	_	_	O
52	properties	_	_	O
53	providing	_	_	O
54	increased	_	_	O
55	corneal	_	_	O
56	contact	_	_	O
57	time	_	_	O
58	and	_	_	O
59	a	_	_	O
60	better	_	_	O
61	carteolol	_	_	O
62	penetration	_	_	O
63	through	_	_	O
64	the	_	_	O
65	cornea	_	_	O
66	.	_	_	O

67	The	_	_	O
68	objective	_	_	O
69	of	_	_	O
70	this	_	_	O
71	study	_	_	O
72	was	_	_	O
73	to	_	_	O
74	evaluate	_	_	O
75	the	_	_	O
76	efficacy	_	_	O
77	and	_	_	O
78	safety	_	_	O
79	of	_	_	O
80	long-acting	_	_	O
81	1	_	_	O
82	%	_	_	O
83	carteolol	_	_	O
84	alginate	_	_	O
85	solution	_	_	O
86	compared	_	_	O
87	to	_	_	O
88	standard	_	_	O
89	1	_	_	O
90	%	_	_	O
91	carteolol	_	_	O
92	solution	_	_	O
93	.	_	_	O

94	This	_	_	O
95	was	_	_	O
96	a	_	_	O
97	double-masked	_	_	O
98	,	_	_	O
99	parallel	_	_	O
100	group	_	_	O
101	,	_	_	O
102	multicentre	_	_	O
103	study	_	_	O
104	.	_	_	O

105	Patients	_	_	O
106	with	_	_	O
107	ocular	_	_	O
108	hypertension	_	_	O
109	or	_	_	O
110	open	_	_	O
111	angle	_	_	O
112	glaucoma	_	_	O
113	(	_	_	O
114	n=151	_	_	O
115	)	_	_	O
116	were	_	_	O
117	randomly	_	_	O
118	assigned	_	_	O
119	to	_	_	O
120	receive	_	_	O
121	either	_	_	O
122	1	_	_	O
123	%	_	_	O
124	carteolol	_	_	O
125	alginate	_	_	O
126	once	_	_	O
127	daily	_	_	O
128	(	_	_	O
129	AM	_	_	O
130	)	_	_	O
131	or	_	_	O
132	standard	_	_	O
133	1	_	_	O
134	%	_	_	O
135	carteolol	_	_	O
136	solution	_	_	O
137	twice	_	_	O
138	daily	_	_	O
139	for	_	_	O
140	2	_	_	O
141	months	_	_	O
142	.	_	_	O

143	The	_	_	O
144	masking	_	_	O
145	was	_	_	O
146	maintained	_	_	O
147	through	_	_	O
148	the	_	_	O
149	use	_	_	O
150	of	_	_	O
151	a	_	_	O
152	placebo	_	_	O
153	in	_	_	O
154	the	_	_	O
155	evening	_	_	O
156	for	_	_	O
157	the	_	_	O
158	alginate	_	_	O
159	group	_	_	O
160	.	_	_	O

161	Entry	_	_	O
162	into	_	_	O
163	the	_	_	O
164	study	_	_	O
165	required	_	_	O
166	unmedicated	_	_	O
167	intraocular	_	_	O
168	pressure	_	_	O
169	(	_	_	O
170	IOP	_	_	O
171	)	_	_	O
172	between	_	_	O
173	23	_	_	O
174	mmHg	_	_	O
175	and	_	_	O
176	32	_	_	O
177	mmHg	_	_	O
178	at	_	_	O
179	9	_	_	O
180	AM	_	_	O
181	and	_	_	O
182	11	_	_	O
183	AM	_	_	O
184	.	_	_	O

185	Patients	_	_	O
186	using	_	_	O
187	ocular	_	_	O
188	hypotensive	_	_	O
189	medication	_	_	O
190	were	_	_	O
191	required	_	_	O
192	to	_	_	O
193	undergo	_	_	O
194	a	_	_	O
195	washout	_	_	O
196	.	_	_	O

197	All	_	_	O
198	patients	_	_	O
199	provided	_	_	O
200	written	_	_	O
201	informed	_	_	O
202	consent	_	_	O
203	.	_	_	O

204	Excluded	_	_	O
205	from	_	_	O
206	the	_	_	O
207	study	_	_	O
208	were	_	_	O
209	patients	_	_	O
210	with	_	_	O
211	angle	_	_	O
212	closure	_	_	O
213	,	_	_	O
214	congenital	_	_	O
215	,	_	_	O
216	secondary	_	_	O
217	glaucoma	_	_	O
218	or	_	_	O
219	advanced	_	_	O
220	glaucoma	_	_	O
221	;	_	_	O
222	any	_	_	O
223	intraocular	_	_	O
224	infection	_	_	O
225	or	_	_	O
226	inflammation	_	_	O
227	,	_	_	O
228	ocular	_	_	O
229	trauma	_	_	O
230	,	_	_	O
231	ocular	_	_	O
232	surgery	_	_	O
233	or	_	_	O
234	laser	_	_	O
235	trabeculoplasty	_	_	O
236	within	_	_	O
237	the	_	_	O
238	previous	_	_	O
239	3	_	_	O
240	months	_	_	O
241	;	_	_	O
242	contraindications	_	_	O
243	to	_	_	O
244	the	_	_	O
245	use	_	_	O
246	of	_	_	O
247	beta	_	_	O
248	adrenoceptor	_	_	O
249	antagonists	_	_	O
250	;	_	_	O
251	systemic	_	_	O
252	medications	_	_	O
253	likely	_	_	O
254	to	_	_	O
255	modify	_	_	O
256	IOP	_	_	O
257	prescribed	_	_	O
258	or	_	_	O
259	modified	_	_	O
260	during	_	_	O
261	the	_	_	O
262	previous	_	_	O
263	3	_	_	O
264	months	_	_	O
265	;	_	_	O
266	ocular	_	_	O
267	steroid	_	_	O
268	use	_	_	O
269	;	_	_	O
270	contact	_	_	O
271	lens	_	_	O
272	wear	_	_	O
273	;	_	_	O
274	and	_	_	O
275	pregnant	_	_	O
276	and	_	_	O
277	lactating	_	_	O
278	women	_	_	O
279	.	_	_	O

280	Patients	_	_	O
281	were	_	_	O
282	evaluated	_	_	O
283	at	_	_	O
284	baseline	_	_	O
285	,	_	_	O
286	15	_	_	O
287	and	_	_	O
288	60	_	_	O
289	days	_	_	O
290	,	_	_	O
291	with	_	_	O
292	IOP	_	_	O
293	measurements	_	_	O
294	at	_	_	O
295	9	_	_	O
296	AM	_	_	O
297	and	_	_	O
298	11	_	_	O
299	AM	_	_	O
300	.	_	_	O

301	At	_	_	O
302	day	_	_	O
303	15	_	_	O
304	and	_	_	O
305	day	_	_	O
306	60	_	_	O
307	,	_	_	O
308	IOP	_	_	O
309	was	_	_	O
310	measured	_	_	O
311	just	_	_	O
312	before	_	_	O
313	instillation	_	_	O
314	of	_	_	O
315	medication	_	_	O
316	(	_	_	O
317	9	_	_	O
318	AM	_	_	O
319	)	_	_	O
320	and	_	_	O
321	2	_	_	O
322	hours	_	_	O
323	after	_	_	O
324	(	_	_	O
325	11	_	_	O
326	AM	_	_	O
327	)	_	_	O
328	.	_	_	O

329	Slit	_	_	O
330	lamp	_	_	O
331	examinations	_	_	O
332	were	_	_	O
333	performed	_	_	O
334	at	_	_	O
335	each	_	_	O
336	follow-up	_	_	O
337	examination	_	_	O
338	,	_	_	O
339	together	_	_	O
340	with	_	_	O
341	measurement	_	_	O
342	of	_	_	O
343	heart	_	_	O
344	rate	_	_	O
345	and	_	_	O
346	blood	_	_	O
347	pressure	_	_	O
348	(	_	_	O
349	10	_	_	O
350	AM	_	_	O
351	)	_	_	O
352	and	_	_	O
353	ocular	_	_	O
354	tolerance	_	_	O
355	after	_	_	O
356	medication	_	_	O
357	(	_	_	O
358	11	_	_	O
359	AM	_	_	O
360	)	_	_	O
361	.	_	_	O

362	The	_	_	O
363	primary	_	_	O
364	efficacy	_	_	O
365	criterion	_	_	O
366	was	_	_	O
367	the	_	_	O
368	decrease	_	_	O
369	in	_	_	O
370	IOP	_	_	O
371	from	_	_	O
372	baseline	_	_	O
373	at	_	_	O
374	day	_	_	O
375	60	_	_	O
376	for	_	_	O
377	each	_	_	O
378	measurement	_	_	O
379	at	_	_	O
380	9	_	_	O
381	AM	_	_	O
382	and	_	_	O
383	11	_	_	O
384	AM	_	_	O
385	.	_	_	O

386	The	_	_	O
387	study	_	_	O
388	eye	_	_	O
389	was	_	_	O
390	the	_	_	O
391	eye	_	_	O
392	with	_	_	O
393	the	_	_	O
394	higher	_	_	O
395	IOP	_	_	O
396	at	_	_	O
397	day	_	_	O
398	0	_	_	O
399	or	_	_	O
400	,	_	_	O
401	if	_	_	O
402	equal	_	_	O
403	,	_	_	O
404	the	_	_	O
405	right	_	_	O
406	eye	_	_	O
407	.	_	_	O

408	Efficacy-of	_	_	O
409	the	_	_	O
410	151	_	_	O
411	patients	_	_	O
412	included	_	_	O
413	in	_	_	O
414	the	_	_	O
415	study	_	_	O
416	,	_	_	O
417	149	_	_	O
418	were	_	_	O
419	evaluated	_	_	O
420	(	_	_	O
421	two	_	_	O
422	patients	_	_	O
423	were	_	_	O
424	lost	_	_	O
425	to	_	_	O
426	follow-up	_	_	O
427	after	_	_	O
428	day	_	_	O
429	0	_	_	O
430	)	_	_	O
431	:	_	_	O
432	74	_	_	O
433	in	_	_	O
434	the	_	_	O
435	alginate	_	_	O
436	group	_	_	O
437	and	_	_	O
438	75	_	_	O
439	in	_	_	O
440	the	_	_	O
441	standard	_	_	O
442	group	_	_	O
443	.	_	_	O

444	Both	_	_	O
445	treatment	_	_	O
446	groups	_	_	O
447	were	_	_	O
448	comparable	_	_	O
449	at	_	_	O
450	day	_	_	O
451	0	_	_	O
452	except	_	_	O
453	for	_	_	O
454	sex	_	_	O
455	,	_	_	O
456	diastolic	_	_	O
457	blood	_	_	O
458	pressure	_	_	O
459	,	_	_	O
460	and	_	_	O
461	IOP	_	_	O
462	in	_	_	O
463	the	_	_	O
464	fellow	_	_	O
465	eye	_	_	O
466	.	_	_	O

467	At	_	_	B-Premise
468	09.00	_	_	I-Premise
469	hours	_	_	I-Premise
470	(	_	_	I-Premise
471	presumed	_	_	I-Premise
472	trough	_	_	I-Premise
473	)	_	_	I-Premise
474	on	_	_	I-Premise
475	day	_	_	I-Premise
476	60	_	_	I-Premise
477	,	_	_	I-Premise
478	mean	_	_	I-Premise
479	reductions	_	_	I-Premise
480	from	_	_	I-Premise
481	baseline	_	_	I-Premise
482	in	_	_	I-Premise
483	intraocular	_	_	I-Premise
484	pressure	_	_	I-Premise
485	were	_	_	I-Premise
486	6.32+/-2.87	_	_	I-Premise
487	and	_	_	I-Premise
488	5.67+/-3.30	_	_	I-Premise
489	mmHg	_	_	I-Premise
490	for	_	_	I-Premise
491	the	_	_	I-Premise
492	alginate	_	_	I-Premise
493	carteolol	_	_	I-Premise
494	and	_	_	I-Premise
495	standard	_	_	I-Premise
496	groups	_	_	I-Premise
497	,	_	_	I-Premise
498	respectively	_	_	I-Premise
499	.	_	_	I-Premise

500	At	_	_	B-Premise
501	11.00	_	_	I-Premise
502	hours	_	_	I-Premise
503	(	_	_	I-Premise
504	presumed	_	_	I-Premise
505	peak	_	_	I-Premise
506	)	_	_	I-Premise
507	,	_	_	I-Premise
508	mean	_	_	I-Premise
509	reductions	_	_	I-Premise
510	were	_	_	I-Premise
511	6.70+/-2.81	_	_	I-Premise
512	and	_	_	I-Premise
513	6.55+/-3.35	_	_	I-Premise
514	mmHg	_	_	I-Premise
515	,	_	_	I-Premise
516	respectively	_	_	I-Premise
517	.	_	_	I-Premise

518	At	_	_	B-Premise
519	each	_	_	I-Premise
520	evaluation	_	_	I-Premise
521	time	_	_	I-Premise
522	,	_	_	I-Premise
523	the	_	_	I-Premise
524	two	_	_	I-Premise
525	unilateral	_	_	I-Premise
526	t	_	_	I-Premise
527	tests	_	_	I-Premise
528	were	_	_	I-Premise
529	highly	_	_	I-Premise
530	significant	_	_	I-Premise
531	(	_	_	I-Premise
532	p	_	_	I-Premise
533	<	_	_	I-Premise
534	0.005	_	_	I-Premise
535	)	_	_	I-Premise
536	,	_	_	I-Premise
537	confirming	_	_	O
538	the	_	_	O
539	equivalence	_	_	O
540	of	_	_	O
541	both	_	_	O
542	treatments	_	_	O
543	.	_	_	O

544	Conclusions	_	_	O
545	were	_	_	O
546	not	_	_	O
547	modified	_	_	O
548	taking	_	_	O
549	into	_	_	O
550	account	_	_	O
551	sex	_	_	O
552	and	_	_	O
553	diastolic	_	_	O
554	blood	_	_	O
555	pressure	_	_	O
556	.	_	_	O

557	Safety-	_	_	B-Premise
558	Slight	_	_	I-Premise
559	decreases	_	_	I-Premise
560	in	_	_	I-Premise
561	heart	_	_	I-Premise
562	rate	_	_	I-Premise
563	and	_	_	I-Premise
564	blood	_	_	I-Premise
565	pressure	_	_	I-Premise
566	means	_	_	I-Premise
567	were	_	_	I-Premise
568	observed	_	_	I-Premise
569	in	_	_	I-Premise
570	both	_	_	I-Premise
571	groups	_	_	I-Premise
572	at	_	_	I-Premise
573	follow-up	_	_	I-Premise
574	visits	_	_	I-Premise
575	with	_	_	I-Premise
576	no	_	_	I-Premise
577	significant	_	_	I-Premise
578	difference	_	_	I-Premise
579	between	_	_	I-Premise
580	groups	_	_	I-Premise
581	.	_	_	I-Premise

582	Subjective	_	_	B-Premise
583	tolerance	_	_	I-Premise
584	upon	_	_	I-Premise
585	instillation	_	_	I-Premise
586	was	_	_	I-Premise
587	judged	_	_	I-Premise
588	good	_	_	I-Premise
589	or	_	_	I-Premise
590	very	_	_	I-Premise
591	good	_	_	I-Premise
592	at	_	_	I-Premise
593	day	_	_	I-Premise
594	60	_	_	I-Premise
595	by	_	_	I-Premise
596	100	_	_	I-Premise
597	%	_	_	I-Premise
598	of	_	_	I-Premise
599	alginate	_	_	I-Premise
600	patients	_	_	I-Premise
601	and	_	_	I-Premise
602	by	_	_	I-Premise
603	98.7	_	_	I-Premise
604	%	_	_	I-Premise
605	of	_	_	I-Premise
606	standard	_	_	I-Premise
607	patients	_	_	I-Premise
608	.	_	_	I-Premise

609	Transient	_	_	B-Premise
610	discomfort	_	_	I-Premise
611	(	_	_	I-Premise
612	mainly	_	_	I-Premise
613	stinging	_	_	I-Premise
614	or	_	_	I-Premise
615	burning	_	_	I-Premise
616	sensation	_	_	I-Premise
617	)	_	_	I-Premise
618	was	_	_	I-Premise
619	reported	_	_	I-Premise
620	by	_	_	I-Premise
621	approximately	_	_	I-Premise
622	4	_	_	I-Premise
623	%	_	_	I-Premise
624	-	_	_	I-Premise
625	6	_	_	I-Premise
626	%	_	_	I-Premise
627	of	_	_	I-Premise
628	patients	_	_	I-Premise
629	in	_	_	I-Premise
630	each	_	_	I-Premise
631	treatment	_	_	I-Premise
632	group	_	_	I-Premise
633	at	_	_	I-Premise
634	each	_	_	I-Premise
635	visit	_	_	I-Premise
636	.	_	_	I-Premise

637	A	_	_	B-Premise
638	blurred	_	_	I-Premise
639	vision	_	_	I-Premise
640	sensation	_	_	I-Premise
641	was	_	_	I-Premise
642	reported	_	_	I-Premise
643	by	_	_	I-Premise
644	2	_	_	I-Premise
645	out	_	_	I-Premise
646	of	_	_	I-Premise
647	74	_	_	I-Premise
648	patients	_	_	I-Premise
649	of	_	_	I-Premise
650	the	_	_	I-Premise
651	alginate	_	_	I-Premise
652	group	_	_	I-Premise
653	.	_	_	I-Premise

654	Among	_	_	B-Premise
655	the	_	_	I-Premise
656	17	_	_	I-Premise
657	reported	_	_	I-Premise
658	adverse	_	_	I-Premise
659	events	_	_	I-Premise
660	,	_	_	I-Premise
661	three	_	_	I-Premise
662	were	_	_	I-Premise
663	assessed	_	_	I-Premise
664	as	_	_	I-Premise
665	drug-related	_	_	I-Premise
666	:	_	_	I-Premise
667	one	_	_	I-Premise
668	vertigo	_	_	I-Premise
669	,	_	_	I-Premise
670	one	_	_	I-Premise
671	superficial	_	_	I-Premise
672	punctate	_	_	I-Premise
673	keratitis	_	_	I-Premise
674	in	_	_	I-Premise
675	the	_	_	I-Premise
676	alginate	_	_	I-Premise
677	group	_	_	I-Premise
678	and	_	_	I-Premise
679	one	_	_	I-Premise
680	decrease	_	_	I-Premise
681	in	_	_	I-Premise
682	blood	_	_	I-Premise
683	pressure	_	_	I-Premise
684	in	_	_	I-Premise
685	the	_	_	I-Premise
686	standard	_	_	I-Premise
687	group	_	_	I-Premise
688	.	_	_	I-Premise

689	No	_	_	B-Premise
690	serious	_	_	I-Premise
691	adverse	_	_	I-Premise
692	events	_	_	I-Premise
693	were	_	_	I-Premise
694	reported	_	_	I-Premise
695	.	_	_	I-Premise

696	The	_	_	B-Claim
697	new	_	_	I-Claim
698	alginate	_	_	I-Claim
699	formulation	_	_	I-Claim
700	of	_	_	I-Claim
701	long-acting	_	_	I-Claim
702	carteolol	_	_	I-Claim
703	1	_	_	I-Claim
704	%	_	_	I-Claim
705	given	_	_	I-Claim
706	once	_	_	I-Claim
707	daily	_	_	I-Claim
708	is	_	_	I-Claim
709	as	_	_	I-Claim
710	effective	_	_	I-Claim
711	as	_	_	I-Claim
712	standard	_	_	I-Claim
713	1	_	_	I-Claim
714	%	_	_	I-Claim
715	carteolol	_	_	I-Claim
716	given	_	_	I-Claim
717	twice	_	_	I-Claim
718	daily	_	_	I-Claim
719	,	_	_	I-Claim
720	with	_	_	I-Claim
721	no	_	_	I-Claim
722	meaningful	_	_	I-Claim
723	differences	_	_	I-Claim
724	regarding	_	_	I-Claim
725	safety	_	_	I-Claim
726	.	_	_	I-Claim

727	This	_	_	O
728	efficacy	_	_	O
729	wasy	_	_	O
730	was	_	_	O
731	verified	_	_	O
732	at	_	_	O
733	9	_	_	O
734	AM	_	_	O
735	(	_	_	O
736	24	_	_	O
737	hours	_	_	O
738	after	_	_	O
739	the	_	_	O
740	last	_	_	O
741	drop	_	_	O
742	of	_	_	O
743	long-acting	_	_	O
744	carteolol	_	_	O
745	or	_	_	O
746	12	_	_	O
747	hours	_	_	O
748	after	_	_	O
749	that	_	_	O
750	of	_	_	O
751	standard	_	_	O
752	carteolol	_	_	O
753	)	_	_	O
754	and	_	_	O
755	at	_	_	O
756	11	_	_	O
757	AM	_	_	O
758	(	_	_	O
759	2	_	_	O
760	hours	_	_	O
761	after	_	_	O
762	the	_	_	O
763	morning	_	_	O
764	drop	_	_	O
765	)	_	_	O
766	.	_	_	O

767	The	_	_	B-Claim
768	new	_	_	I-Claim
769	alginate	_	_	I-Claim
770	formulation	_	_	I-Claim
771	of	_	_	I-Claim
772	long-acting	_	_	I-Claim
773	carteolol	_	_	I-Claim
774	1	_	_	I-Claim
775	%	_	_	I-Claim
776	given	_	_	I-Claim
777	once	_	_	I-Claim
778	a	_	_	I-Claim
779	day	_	_	I-Claim
780	is	_	_	I-Claim
781	effective	_	_	I-Claim
782	and	_	_	I-Claim
783	well	_	_	I-Claim
784	tolerated	_	_	I-Claim
785	by	_	_	I-Claim
786	glaucoma	_	_	I-Claim
787	patients	_	_	I-Claim
788	who	_	_	I-Claim
789	require	_	_	I-Claim
790	chronic	_	_	I-Claim
791	treatment	_	_	I-Claim
792	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	postoperative	_	_	O
4	intraocular	_	_	O
5	pressure	_	_	O
6	(	_	_	O
7	IOP	_	_	O
8	)	_	_	O
9	and	_	_	O
10	incidence	_	_	O
11	of	_	_	O
12	early	_	_	O
13	complications	_	_	O
14	after	_	_	O
15	trabeculectomy	_	_	O
16	with	_	_	O
17	releasable	_	_	O
18	suture	_	_	O
19	to	_	_	O
20	standard	_	_	O
21	trabeculectomy	_	_	O
22	in	_	_	O
23	Chinese	_	_	O
24	patients	_	_	O
25	with	_	_	O
26	primary	_	_	O
27	angle-closure	_	_	O
28	glaucoma	_	_	O
29	.	_	_	O

30	One	_	_	O
31	hundred	_	_	O
32	seventy-five	_	_	O
33	patients	_	_	O
34	diagnosed	_	_	O
35	as	_	_	O
36	primary	_	_	O
37	angle-closure	_	_	O
38	glaucoma	_	_	O
39	with	_	_	O
40	6	_	_	O
41	clock-hours	_	_	O
42	or	_	_	O
43	more	_	_	O
44	of	_	_	O
45	peripheral	_	_	O
46	anterior	_	_	O
47	synechia	_	_	O
48	were	_	_	O
49	randomly	_	_	O
50	allocated	_	_	O
51	to	_	_	O
52	2	_	_	O
53	treatment	_	_	O
54	groups	_	_	O
55	:	_	_	O
56	87	_	_	O
57	underwent	_	_	O
58	standard	_	_	O
59	trabeculectomy	_	_	O
60	(	_	_	O
61	S	_	_	O
62	group	_	_	O
63	:	_	_	O
64	2	_	_	O
65	interrupted	_	_	O
66	permanent	_	_	O
67	sutures	_	_	O
68	to	_	_	O
69	the	_	_	O
70	scleral	_	_	O
71	flap	_	_	O
72	)	_	_	O
73	and	_	_	O
74	88	_	_	O
75	received	_	_	O
76	trabeculectomy	_	_	O
77	with	_	_	O
78	2	_	_	O
79	permanent	_	_	O
80	and	_	_	O
81	2	_	_	O
82	releasable	_	_	O
83	sutures	_	_	O
84	(	_	_	O
85	R	_	_	O
86	group	_	_	O
87	)	_	_	O
88	.	_	_	O

89	The	_	_	O
90	postoperative	_	_	O
91	IOP	_	_	O
92	and	_	_	O
93	complications	_	_	O
94	during	_	_	O
95	the	_	_	O
96	first	_	_	O
97	3	_	_	O
98	months	_	_	O
99	after	_	_	O
100	surgery	_	_	O
101	were	_	_	O
102	compared	_	_	O
103	.	_	_	O

104	One	_	_	O
105	hundred	_	_	O
106	seventy-one	_	_	O
107	patients	_	_	O
108	(	_	_	O
109	97.7	_	_	O
110	%	_	_	O
111	)	_	_	O
112	attended	_	_	O
113	the	_	_	O
114	3-month	_	_	O
115	visit	_	_	O
116	.	_	_	O

117	The	_	_	B-Premise
118	IOP	_	_	I-Premise
119	in	_	_	I-Premise
120	the	_	_	I-Premise
121	first	_	_	I-Premise
122	week	_	_	I-Premise
123	after	_	_	I-Premise
124	trabeculectomy	_	_	I-Premise
125	was	_	_	I-Premise
126	significantly	_	_	I-Premise
127	higher	_	_	I-Premise
128	in	_	_	I-Premise
129	the	_	_	I-Premise
130	R	_	_	I-Premise
131	group	_	_	I-Premise
132	:	_	_	I-Premise
133	day	_	_	I-Premise
134	1	_	_	I-Premise
135	,	_	_	I-Premise
136	17.3	_	_	I-Premise
137	±	_	_	I-Premise
138	8.6	_	_	I-Premise
139	versus	_	_	I-Premise
140	12.7	_	_	I-Premise
141	±	_	_	I-Premise
142	6.0	_	_	I-Premise
143	mm	_	_	I-Premise
144	Hg	_	_	I-Premise
145	(	_	_	I-Premise
146	P	_	_	I-Premise
147	<	_	_	I-Premise
148	0.001	_	_	I-Premise
149	)	_	_	I-Premise
150	;	_	_	I-Premise
151	day	_	_	I-Premise
152	3	_	_	I-Premise
153	,	_	_	I-Premise
154	18.0	_	_	I-Premise
155	±	_	_	I-Premise
156	7.3	_	_	I-Premise
157	versus	_	_	I-Premise
158	12.9	_	_	I-Premise
159	±	_	_	I-Premise
160	6.3	_	_	I-Premise
161	mm	_	_	I-Premise
162	Hg	_	_	I-Premise
163	(	_	_	I-Premise
164	P	_	_	I-Premise
165	<	_	_	I-Premise
166	0.001	_	_	I-Premise
167	)	_	_	I-Premise
168	;	_	_	I-Premise
169	day	_	_	I-Premise
170	7	_	_	I-Premise
171	,	_	_	I-Premise
172	14.8	_	_	I-Premise
173	±	_	_	I-Premise
174	6.3	_	_	I-Premise
175	versus	_	_	I-Premise
176	12.0	_	_	I-Premise
177	±	_	_	I-Premise
178	4.9	_	_	I-Premise
179	mm	_	_	I-Premise
180	Hg	_	_	I-Premise
181	(	_	_	I-Premise
182	P=0.001	_	_	I-Premise
183	)	_	_	I-Premise
184	,	_	_	I-Premise
185	but	_	_	O
186	no	_	_	B-Premise
187	difference	_	_	I-Premise
188	was	_	_	I-Premise
189	observed	_	_	I-Premise
190	after	_	_	I-Premise
191	the	_	_	I-Premise
192	second	_	_	I-Premise
193	week	_	_	I-Premise
194	(	_	_	I-Premise
195	P=0.659	_	_	I-Premise
196	to	_	_	I-Premise
197	0.753	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	The	_	_	B-Premise
201	incidence	_	_	I-Premise
202	of	_	_	I-Premise
203	transient	_	_	I-Premise
204	hypotony	_	_	I-Premise
205	was	_	_	I-Premise
206	higher	_	_	I-Premise
207	in	_	_	I-Premise
208	S	_	_	I-Premise
209	group	_	_	I-Premise
210	(	_	_	I-Premise
211	20.4	_	_	I-Premise
212	%	_	_	I-Premise
213	)	_	_	I-Premise
214	than	_	_	I-Premise
215	the	_	_	I-Premise
216	R	_	_	I-Premise
217	group	_	_	I-Premise
218	(	_	_	I-Premise
219	9.1	_	_	I-Premise
220	%	_	_	I-Premise
221	)	_	_	I-Premise
222	(	_	_	I-Premise
223	P=0.046	_	_	I-Premise
224	)	_	_	I-Premise
225	;	_	_	I-Premise
226	hypotony	_	_	B-Premise
227	recovered	_	_	I-Premise
228	in	_	_	I-Premise
229	80.8	_	_	I-Premise
230	%	_	_	I-Premise
231	(	_	_	I-Premise
232	21/26	_	_	I-Premise
233	)	_	_	I-Premise
234	within	_	_	I-Premise
235	1	_	_	I-Premise
236	week	_	_	I-Premise
237	.	_	_	I-Premise

238	There	_	_	B-Premise
239	was	_	_	I-Premise
240	no	_	_	I-Premise
241	difference	_	_	I-Premise
242	in	_	_	I-Premise
243	the	_	_	I-Premise
244	occurrence	_	_	I-Premise
245	of	_	_	I-Premise
246	shallow	_	_	I-Premise
247	chamber	_	_	I-Premise
248	,	_	_	I-Premise
249	choroidal	_	_	I-Premise
250	detachment	_	_	I-Premise
251	,	_	_	I-Premise
252	macular	_	_	I-Premise
253	edema	_	_	I-Premise
254	,	_	_	I-Premise
255	additional	_	_	I-Premise
256	surgery	_	_	I-Premise
257	,	_	_	I-Premise
258	or	_	_	I-Premise
259	hyphema	_	_	I-Premise
260	(	_	_	I-Premise
261	P=0.56	_	_	I-Premise
262	to	_	_	I-Premise
263	1.0	_	_	I-Premise
264	)	_	_	I-Premise
265	.	_	_	I-Premise

266	The	_	_	B-Claim
267	technique	_	_	I-Claim
268	of	_	_	I-Claim
269	releasable	_	_	I-Claim
270	sutures	_	_	I-Claim
271	for	_	_	I-Claim
272	trabeculectomy	_	_	I-Claim
273	used	_	_	I-Claim
274	in	_	_	I-Claim
275	this	_	_	I-Claim
276	study	_	_	I-Claim
277	did	_	_	I-Claim
278	not	_	_	I-Claim
279	demonstrate	_	_	I-Claim
280	significant	_	_	I-Claim
281	advantages	_	_	I-Claim
282	over	_	_	I-Claim
283	standard	_	_	I-Claim
284	trabeculectomy	_	_	I-Claim
285	.	_	_	I-Claim

286	Releasable	_	_	B-Claim
287	sutures	_	_	I-Claim
288	were	_	_	I-Claim
289	associated	_	_	I-Claim
290	with	_	_	I-Claim
291	some	_	_	I-Claim
292	decrease	_	_	I-Claim
293	in	_	_	I-Claim
294	visual	_	_	I-Claim
295	acuity	_	_	I-Claim
296	and	_	_	I-Claim
297	increase	_	_	I-Claim
298	in	_	_	I-Claim
299	postoperative	_	_	I-Claim
300	complaints	_	_	I-Claim
301	.	_	_	I-Claim


0	The	_	_	O
1	objective	_	_	O
2	of	_	_	O
3	the	_	_	O
4	study	_	_	O
5	was	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	long-term	_	_	O
10	efficacy	_	_	O
11	and	_	_	O
12	safety	_	_	O
13	of	_	_	O
14	tafluprost	_	_	O
15	0.0015	_	_	O
16	%	_	_	O
17	with	_	_	O
18	latanoprost	_	_	O
19	0.005	_	_	O
20	%	_	_	O
21	eye	_	_	O
22	drops	_	_	O
23	in	_	_	O
24	patients	_	_	O
25	with	_	_	O
26	open-angle	_	_	O
27	glaucoma	_	_	O
28	or	_	_	O
29	ocular	_	_	O
30	hypertension	_	_	O
31	.	_	_	O

32	This	_	_	O
33	double-masked	_	_	O
34	,	_	_	O
35	active-controlled	_	_	O
36	,	_	_	O
37	parallel-group	_	_	O
38	,	_	_	O
39	multinational	_	_	O
40	,	_	_	O
41	multicentre	_	_	O
42	,	_	_	O
43	phase	_	_	O
44	III	_	_	O
45	study	_	_	O
46	was	_	_	O
47	conducted	_	_	O
48	at	_	_	O
49	49	_	_	O
50	centres	_	_	O
51	in	_	_	O
52	8	_	_	O
53	countries	_	_	O
54	.	_	_	O

55	Eligible	_	_	O
56	patients	_	_	O
57	were	_	_	O
58	assigned	_	_	O
59	to	_	_	O
60	treatment	_	_	O
61	administered	_	_	O
62	once	_	_	O
63	daily	_	_	O
64	at	_	_	O
65	20:00	_	_	O
66	hrs	_	_	O
67	for	_	_	O
68	up	_	_	O
69	to	_	_	O
70	24	_	_	O
71	months	_	_	O
72	.	_	_	O

73	Change	_	_	O
74	from	_	_	O
75	baseline	_	_	O
76	intraocular	_	_	O
77	pressure	_	_	O
78	(	_	_	O
79	IOP	_	_	O
80	)	_	_	O
81	was	_	_	O
82	the	_	_	O
83	primary	_	_	O
84	efficacy	_	_	O
85	variable	_	_	O
86	.	_	_	O

87	Adverse	_	_	O
88	events	_	_	O
89	were	_	_	O
90	recorded	_	_	O
91	and	_	_	O
92	ocular	_	_	O
93	safety	_	_	O
94	was	_	_	O
95	evaluated	_	_	O
96	.	_	_	O

97	Both	_	_	O
98	tafluprost	_	_	O
99	and	_	_	O
100	latanoprost	_	_	O
101	were	_	_	O
102	preserved	_	_	O
103	with	_	_	O
104	benzalkonium	_	_	O
105	chloride	_	_	O
106	.	_	_	O

107	From	_	_	O
108	533	_	_	O
109	patients	_	_	O
110	randomized	_	_	O
111	,	_	_	O
112	402	_	_	O
113	patients	_	_	O
114	completed	_	_	O
115	24	_	_	O
116	months	_	_	O
117	of	_	_	O
118	therapy	_	_	O
119	.	_	_	O

120	Both	_	_	B-Premise
121	treatments	_	_	I-Premise
122	had	_	_	I-Premise
123	a	_	_	I-Premise
124	substantial	_	_	I-Premise
125	IOP-lowering	_	_	I-Premise
126	effect	_	_	I-Premise
127	which	_	_	I-Premise
128	persisted	_	_	I-Premise
129	throughout	_	_	I-Premise
130	the	_	_	I-Premise
131	study	_	_	I-Premise
132	(	_	_	I-Premise
133	-7.1	_	_	I-Premise
134	mmHg	_	_	I-Premise
135	for	_	_	I-Premise
136	tafluprost	_	_	I-Premise
137	and	_	_	I-Premise
138	-7.7	_	_	I-Premise
139	mmHg	_	_	I-Premise
140	for	_	_	I-Premise
141	latanoprost	_	_	I-Premise
142	at	_	_	I-Premise
143	24	_	_	I-Premise
144	months	_	_	I-Premise
145	)	_	_	I-Premise
146	.	_	_	I-Premise

147	Although	_	_	O
148	the	_	_	B-Claim
149	IOP-lowering	_	_	I-Claim
150	effect	_	_	I-Claim
151	during	_	_	I-Claim
152	the	_	_	I-Claim
153	study	_	_	I-Claim
154	was	_	_	I-Claim
155	slightly	_	_	I-Claim
156	larger	_	_	I-Claim
157	with	_	_	I-Claim
158	latanoprost	_	_	I-Claim
159	,	_	_	I-Claim
160	this	_	_	B-Premise
161	difference	_	_	I-Premise
162	was	_	_	I-Premise
163	clinically	_	_	I-Premise
164	small	_	_	I-Premise
165	and	_	_	I-Premise
166	the	_	_	I-Premise
167	noninferiority	_	_	I-Premise
168	of	_	_	I-Premise
169	tafluprost	_	_	I-Premise
170	to	_	_	I-Premise
171	latanoprost	_	_	I-Premise
172	over	_	_	I-Premise
173	all	_	_	I-Premise
174	diurnal	_	_	I-Premise
175	IOP	_	_	I-Premise
176	measurements	_	_	I-Premise
177	was	_	_	I-Premise
178	shown	_	_	I-Premise
179	with	_	_	I-Premise
180	anova	_	_	I-Premise
181	and	_	_	I-Premise
182	almost	_	_	I-Premise
183	reached	_	_	I-Premise
184	with	_	_	I-Premise
185	ancova	_	_	I-Premise
186	(	_	_	I-Premise
187	upper	_	_	I-Premise
188	limits	_	_	I-Premise
189	of	_	_	I-Premise
190	the	_	_	I-Premise
191	95	_	_	I-Premise
192	%	_	_	I-Premise
193	confidence	_	_	I-Premise
194	intervals	_	_	I-Premise
195	1.38	_	_	I-Premise
196	and	_	_	I-Premise
197	1.52	_	_	I-Premise
198	for	_	_	I-Premise
199	the	_	_	I-Premise
200	overall	_	_	I-Premise
201	period	_	_	I-Premise
202	,	_	_	I-Premise
203	respectively	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	The	_	_	O
207	noninferiority	_	_	O
208	limit	_	_	O
209	was	_	_	O
210	1.5	_	_	O
211	mmHg	_	_	O
212	.	_	_	O

213	Tafluprost	_	_	B-Claim
214	is	_	_	I-Claim
215	a	_	_	I-Claim
216	new	_	_	I-Claim
217	effective	_	_	I-Claim
218	and	_	_	I-Claim
219	well-tolerated	_	_	I-Claim
220	treatment	_	_	I-Claim
221	for	_	_	I-Claim
222	glaucoma	_	_	I-Claim
223	and	_	_	I-Claim
224	ocular	_	_	I-Claim
225	hypertension	_	_	I-Claim
226	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	bimatoprost	_	_	O
6	and	_	_	O
7	travoprost	_	_	O
8	on	_	_	O
9	intraocular	_	_	O
10	pressure	_	_	O
11	(	_	_	O
12	IOP	_	_	O
13	)	_	_	O
14	reduction	_	_	O
15	in	_	_	O
16	an	_	_	O
17	Egyptian	_	_	O
18	population	_	_	O
19	.	_	_	O

20	Patients	_	_	O
21	with	_	_	O
22	primary	_	_	O
23	open-angle	_	_	O
24	glaucoma	_	_	O
25	or	_	_	O
26	ocular	_	_	O
27	hypertension	_	_	O
28	were	_	_	O
29	randomized	_	_	O
30	to	_	_	O
31	receive	_	_	O
32	either	_	_	O
33	bimatoprost	_	_	O
34	0.03	_	_	O
35	%	_	_	O
36	or	_	_	O
37	travoprost	_	_	O
38	0.004	_	_	O
39	%	_	_	O
40	once	_	_	O
41	daily	_	_	O
42	.	_	_	O

43	IOPs	_	_	O
44	were	_	_	O
45	measured	_	_	O
46	at	_	_	O
47	baseline	_	_	O
48	;	_	_	O
49	2	_	_	O
50	weeks	_	_	O
51	;	_	_	O
52	and	_	_	O
53	1	_	_	O
54	,	_	_	O
55	2	_	_	O
56	,	_	_	O
57	4	_	_	O
58	,	_	_	O
59	and	_	_	O
60	6	_	_	O
61	months	_	_	O
62	using	_	_	O
63	Goldman	_	_	O
64	applanation	_	_	O
65	tonometery	_	_	O
66	.	_	_	O

67	Seventy-two	_	_	O
68	patients	_	_	O
69	were	_	_	O
70	included	_	_	O
71	:	_	_	O
72	34	_	_	O
73	and	_	_	O
74	38	_	_	O
75	(	_	_	O
76	P=0.142	_	_	O
77	)	_	_	O
78	with	_	_	O
79	a	_	_	O
80	baseline	_	_	O
81	mean	_	_	O
82	IOP	_	_	O
83	26.52	_	_	O
84	±	_	_	O
85	5.185	_	_	O
86	and	_	_	O
87	26.36	_	_	O
88	±	_	_	O
89	1.605	_	_	O
90	mm	_	_	O
91	Hg	_	_	O
92	(	_	_	O
93	P=0.629	_	_	O
94	)	_	_	O
95	for	_	_	O
96	bimatoprost	_	_	O
97	and	_	_	O
98	travoprost	_	_	O
99	,	_	_	O
100	respectively	_	_	O
101	.	_	_	O

102	Both	_	_	B-Premise
103	drops	_	_	I-Premise
104	provided	_	_	I-Premise
105	statistically	_	_	I-Premise
106	significant	_	_	I-Premise
107	IOP	_	_	I-Premise
108	reductions	_	_	I-Premise
109	from	_	_	I-Premise
110	baseline	_	_	I-Premise
111	at	_	_	I-Premise
112	all	_	_	I-Premise
113	visits	_	_	I-Premise
114	(	_	_	I-Premise
115	P	_	_	I-Premise
116	<	_	_	I-Premise
117	0.001	_	_	I-Premise
118	)	_	_	I-Premise
119	.	_	_	I-Premise

120	Bimatoprost	_	_	B-Claim
121	provided	_	_	I-Claim
122	greater	_	_	I-Claim
123	(	_	_	I-Claim
124	nonsignificant	_	_	I-Claim
125	)	_	_	I-Claim
126	mean	_	_	I-Claim
127	IOP	_	_	I-Claim
128	reductions	_	_	I-Claim
129	from	_	_	I-Claim
130	baseline	_	_	I-Claim
131	than	_	_	I-Claim
132	travoprost	_	_	I-Claim
133	at	_	_	I-Claim
134	each	_	_	I-Claim
135	visit	_	_	I-Claim
136	.	_	_	I-Claim

137	Mean	_	_	B-Premise
138	IOP	_	_	I-Premise
139	reduction	_	_	I-Premise
140	was	_	_	I-Premise
141	8.77	_	_	I-Premise
142	mm	_	_	I-Premise
143	Hg	_	_	I-Premise
144	(	_	_	I-Premise
145	33.39	_	_	I-Premise
146	%	_	_	I-Premise
147	)	_	_	I-Premise
148	and	_	_	I-Premise
149	8.42	_	_	I-Premise
150	mm	_	_	I-Premise
151	Hg	_	_	I-Premise
152	(	_	_	I-Premise
153	31.54	_	_	I-Premise
154	%	_	_	I-Premise
155	)	_	_	I-Premise
156	at	_	_	I-Premise
157	2	_	_	I-Premise
158	weeks	_	_	I-Premise
159	(	_	_	I-Premise
160	P	_	_	I-Premise
161	=	_	_	I-Premise
162	0.703	_	_	I-Premise
163	)	_	_	I-Premise
164	,	_	_	I-Premise
165	and	_	_	I-Premise
166	8.47	_	_	I-Premise
167	mm	_	_	I-Premise
168	Hg	_	_	I-Premise
169	(	_	_	I-Premise
170	31.61	_	_	I-Premise
171	%	_	_	I-Premise
172	)	_	_	I-Premise
173	and	_	_	I-Premise
174	7.84	_	_	I-Premise
175	mm	_	_	I-Premise
176	Hg	_	_	I-Premise
177	(	_	_	I-Premise
178	29.50	_	_	I-Premise
179	%	_	_	I-Premise
180	)	_	_	I-Premise
181	at	_	_	I-Premise
182	6	_	_	I-Premise
183	months	_	_	I-Premise
184	(	_	_	I-Premise
185	P	_	_	I-Premise
186	=	_	_	I-Premise
187	0.536	_	_	I-Premise
188	)	_	_	I-Premise
189	for	_	_	I-Premise
190	bimatoprost	_	_	I-Premise
191	and	_	_	I-Premise
192	travoprost	_	_	I-Premise
193	,	_	_	I-Premise
194	respectively	_	_	I-Premise
195	.	_	_	I-Premise

196	IOPs	_	_	B-Premise
197	at	_	_	I-Premise
198	2	_	_	I-Premise
199	weeks	_	_	I-Premise
200	were	_	_	I-Premise
201	18	_	_	I-Premise
202	mm	_	_	I-Premise
203	Hg	_	_	I-Premise
204	in	_	_	I-Premise
205	20	_	_	I-Premise
206	(	_	_	I-Premise
207	58.8	_	_	I-Premise
208	%	_	_	I-Premise
209	)	_	_	I-Premise
210	versus	_	_	I-Premise
211	19	_	_	I-Premise
212	(	_	_	I-Premise
213	50	_	_	I-Premise
214	%	_	_	I-Premise
215	)	_	_	I-Premise
216	eyes	_	_	I-Premise
217	(	_	_	I-Premise
218	P	_	_	I-Premise
219	=	_	_	I-Premise
220	0.603	_	_	I-Premise
221	)	_	_	I-Premise
222	,	_	_	I-Premise
223	and	_	_	I-Premise
224	16	_	_	I-Premise
225	mm	_	_	I-Premise
226	Hg	_	_	I-Premise
227	in	_	_	I-Premise
228	12	_	_	I-Premise
229	(	_	_	I-Premise
230	35	_	_	I-Premise
231	%	_	_	I-Premise
232	)	_	_	I-Premise
233	versus	_	_	I-Premise
234	12	_	_	I-Premise
235	(	_	_	I-Premise
236	32	_	_	I-Premise
237	%	_	_	I-Premise
238	)	_	_	I-Premise
239	eyes	_	_	I-Premise
240	(	_	_	I-Premise
241	P	_	_	I-Premise
242	=	_	_	I-Premise
243	0.456	_	_	I-Premise
244	)	_	_	I-Premise
245	;	_	_	I-Premise
246	and	_	_	I-Premise
247	at	_	_	I-Premise
248	6	_	_	I-Premise
249	months	_	_	I-Premise
250	18	_	_	I-Premise
251	mm	_	_	I-Premise
252	Hg	_	_	I-Premise
253	in	_	_	I-Premise
254	22	_	_	I-Premise
255	(	_	_	I-Premise
256	65	_	_	I-Premise
257	%	_	_	I-Premise
258	)	_	_	I-Premise
259	versus	_	_	I-Premise
260	14	_	_	I-Premise
261	(	_	_	I-Premise
262	37	_	_	I-Premise
263	%	_	_	I-Premise
264	)	_	_	I-Premise
265	eyes	_	_	I-Premise
266	(	_	_	I-Premise
267	P	_	_	I-Premise
268	=	_	_	I-Premise
269	0.045	_	_	I-Premise
270	)	_	_	I-Premise
271	,	_	_	I-Premise
272	and	_	_	I-Premise
273	16	_	_	I-Premise
274	mm	_	_	I-Premise
275	Hg	_	_	I-Premise
276	in	_	_	I-Premise
277	12	_	_	I-Premise
278	(	_	_	I-Premise
279	35	_	_	I-Premise
280	%	_	_	I-Premise
281	)	_	_	I-Premise
282	versus	_	_	I-Premise
283	7	_	_	I-Premise
284	(	_	_	I-Premise
285	18	_	_	I-Premise
286	%	_	_	I-Premise
287	)	_	_	I-Premise
288	eyes	_	_	I-Premise
289	(	_	_	I-Premise
290	P	_	_	I-Premise
291	=	_	_	I-Premise
292	0.037	_	_	I-Premise
293	)	_	_	I-Premise
294	for	_	_	I-Premise
295	bimatoprost	_	_	I-Premise
296	and	_	_	I-Premise
297	travoprost	_	_	I-Premise
298	,	_	_	I-Premise
299	respectively	_	_	I-Premise
300	.	_	_	I-Premise

301	Ocular	_	_	B-Claim
302	adverse	_	_	I-Claim
303	and	_	_	I-Claim
304	clinical	_	_	I-Claim
305	success	_	_	I-Claim
306	occurred	_	_	I-Claim
307	equally	_	_	I-Claim
308	with	_	_	I-Claim
309	both	_	_	I-Claim
310	drops	_	_	I-Claim
311	.	_	_	I-Claim

312	Both	_	_	B-Claim
313	drops	_	_	I-Claim
314	lowered	_	_	I-Claim
315	IOP	_	_	I-Claim
316	effectively	_	_	I-Claim
317	but	_	_	B-Claim
318	bimatoprost	_	_	I-Claim
319	showed	_	_	I-Claim
320	a	_	_	I-Claim
321	greater	_	_	I-Claim
322	non-significant	_	_	I-Claim
323	reductions	_	_	I-Claim
324	in	_	_	I-Claim
325	mean	_	_	I-Claim
326	IOP	_	_	I-Claim
327	from	_	_	I-Claim
328	baseline	_	_	I-Claim
329	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	bimatoprost/timolol	_	_	O
6	(	_	_	O
7	BTFC	_	_	O
8	)	_	_	O
9	or	_	_	O
10	travoprost/timolol	_	_	O
11	(	_	_	O
12	TTFC	_	_	O
13	)	_	_	O
14	fixed	_	_	O
15	combinations	_	_	O
16	on	_	_	O
17	intraocular	_	_	O
18	pressure	_	_	O
19	(	_	_	O
20	IOP	_	_	O
21	)	_	_	O
22	reduction	_	_	O
23	in	_	_	O
24	an	_	_	O
25	Egyptian	_	_	O
26	population	_	_	O
27	.	_	_	O

28	Patients	_	_	O
29	with	_	_	O
30	primary	_	_	O
31	open	_	_	O
32	angle	_	_	O
33	glaucoma	_	_	O
34	were	_	_	O
35	randomized	_	_	O
36	to	_	_	O
37	receive	_	_	O
38	either	_	_	O
39	BTFC	_	_	O
40	or	_	_	O
41	TTFC	_	_	O
42	.	_	_	O

43	IOPs	_	_	O
44	were	_	_	O
45	measured	_	_	O
46	at	_	_	O
47	baseline	_	_	O
48	,	_	_	O
49	2	_	_	O
50	weeks	_	_	O
51	,	_	_	O
52	and	_	_	O
53	1	_	_	O
54	,	_	_	O
55	2	_	_	O
56	,	_	_	O
57	4	_	_	O
58	,	_	_	O
59	and	_	_	O
60	6	_	_	O
61	months	_	_	O
62	.	_	_	O

63	The	_	_	O
64	primary	_	_	O
65	outcome	_	_	O
66	measure	_	_	O
67	was	_	_	O
68	the	_	_	O
69	mean	_	_	O
70	change	_	_	O
71	in	_	_	O
72	IOP	_	_	O
73	from	_	_	O
74	baseline	_	_	O
75	at	_	_	O
76	each	_	_	O
77	visit	_	_	O
78	.	_	_	O

79	Secondary	_	_	O
80	outcome	_	_	O
81	measures	_	_	O
82	included	_	_	O
83	the	_	_	O
84	incidence	_	_	O
85	of	_	_	O
86	adverse	_	_	O
87	events	_	_	O
88	.	_	_	O

89	Eighty	_	_	O
90	patients	_	_	O
91	(	_	_	O
92	80	_	_	O
93	eyes	_	_	O
94	)	_	_	O
95	were	_	_	O
96	included	_	_	O
97	finally	_	_	O
98	:	_	_	O
99	40	_	_	O
100	eyes	_	_	O
101	in	_	_	O
102	each	_	_	O
103	group	_	_	O
104	.	_	_	O

105	Baseline	_	_	O
106	mean	_	_	O
107	IOPs	_	_	O
108	were	_	_	O
109	24.78±3.53	_	_	O
110	and	_	_	O
111	25.26±3.51	_	_	O
112	mm	_	_	O
113	Hg	_	_	O
114	for	_	_	O
115	BTFC	_	_	O
116	and	_	_	O
117	TTFC	_	_	O
118	,	_	_	O
119	respectively	_	_	O
120	(	_	_	O
121	P=0.344	_	_	O
122	)	_	_	O
123	.	_	_	O

124	Both	_	_	B-Premise
125	drops	_	_	I-Premise
126	provided	_	_	I-Premise
127	statistically	_	_	I-Premise
128	significant	_	_	I-Premise
129	IOP	_	_	I-Premise
130	reductions	_	_	I-Premise
131	from	_	_	I-Premise
132	baseline	_	_	I-Premise
133	at	_	_	I-Premise
134	all	_	_	I-Premise
135	visits	_	_	I-Premise
136	(	_	_	I-Premise
137	P	_	_	I-Premise
138	<	_	_	I-Premise
139	0.001	_	_	I-Premise
140	)	_	_	I-Premise
141	.	_	_	I-Premise

142	BTFC	_	_	B-Premise
143	provided	_	_	I-Premise
144	greater	_	_	I-Premise
145	significant	_	_	I-Premise
146	mean	_	_	I-Premise
147	IOP	_	_	I-Premise
148	reductions	_	_	I-Premise
149	from	_	_	I-Premise
150	baseline	_	_	I-Premise
151	than	_	_	I-Premise
152	TTFC	_	_	I-Premise
153	at	_	_	I-Premise
154	each	_	_	I-Premise
155	visit	_	_	I-Premise
156	(	_	_	I-Premise
157	P	_	_	I-Premise
158	<	_	_	I-Premise
159	0.001	_	_	I-Premise
160	)	_	_	I-Premise
161	.	_	_	I-Premise

162	Mean	_	_	B-Premise
163	IOP	_	_	I-Premise
164	reductions	_	_	I-Premise
165	were	_	_	I-Premise
166	11.34	_	_	I-Premise
167	and	_	_	I-Premise
168	6.42	_	_	I-Premise
169	mm	_	_	I-Premise
170	Hg	_	_	I-Premise
171	at	_	_	I-Premise
172	2	_	_	I-Premise
173	weeks	_	_	I-Premise
174	(	_	_	I-Premise
175	P=0.000	_	_	I-Premise
176	)	_	_	I-Premise
177	,	_	_	I-Premise
178	and	_	_	I-Premise
179	11.17	_	_	I-Premise
180	and	_	_	I-Premise
181	7.89	_	_	I-Premise
182	mmHg	_	_	I-Premise
183	at	_	_	I-Premise
184	6	_	_	I-Premise
185	months	_	_	I-Premise
186	(	_	_	I-Premise
187	P=0.001	_	_	I-Premise
188	)	_	_	I-Premise
189	for	_	_	I-Premise
190	BTFC	_	_	I-Premise
191	and	_	_	I-Premise
192	TTFC	_	_	I-Premise
193	,	_	_	I-Premise
194	respectively	_	_	I-Premise
195	.	_	_	I-Premise

196	IOPs	_	_	B-Premise
197	at	_	_	I-Premise
198	2	_	_	I-Premise
199	weeks	_	_	I-Premise
200	were	_	_	I-Premise
201	18	_	_	I-Premise
202	mm	_	_	I-Premise
203	Hg	_	_	I-Premise
204	in	_	_	I-Premise
205	36	_	_	I-Premise
206	(	_	_	I-Premise
207	90.8	_	_	I-Premise
208	%	_	_	I-Premise
209	)	_	_	I-Premise
210	versus	_	_	I-Premise
211	22	_	_	I-Premise
212	(	_	_	I-Premise
213	55	_	_	I-Premise
214	%	_	_	I-Premise
215	)	_	_	I-Premise
216	eyes	_	_	I-Premise
217	and	_	_	I-Premise
218	16	_	_	I-Premise
219	mm	_	_	I-Premise
220	Hg	_	_	I-Premise
221	in	_	_	I-Premise
222	28	_	_	I-Premise
223	(	_	_	I-Premise
224	70	_	_	I-Premise
225	%	_	_	I-Premise
226	)	_	_	I-Premise
227	versus	_	_	I-Premise
228	16	_	_	I-Premise
229	(	_	_	I-Premise
230	40	_	_	I-Premise
231	%	_	_	I-Premise
232	)	_	_	I-Premise
233	eyes	_	_	I-Premise
234	(	_	_	I-Premise
235	P	_	_	I-Premise
236	<	_	_	I-Premise
237	0.001	_	_	I-Premise
238	)	_	_	I-Premise
239	,	_	_	I-Premise
240	and	_	_	I-Premise
241	at	_	_	I-Premise
242	6	_	_	I-Premise
243	months	_	_	I-Premise
244	,	_	_	I-Premise
245	18	_	_	I-Premise
246	mm	_	_	I-Premise
247	Hg	_	_	I-Premise
248	in	_	_	I-Premise
249	38	_	_	I-Premise
250	(	_	_	I-Premise
251	95	_	_	I-Premise
252	%	_	_	I-Premise
253	)	_	_	I-Premise
254	versus	_	_	I-Premise
255	28	_	_	I-Premise
256	(	_	_	I-Premise
257	70	_	_	I-Premise
258	%	_	_	I-Premise
259	)	_	_	I-Premise
260	eyes	_	_	I-Premise
261	and	_	_	I-Premise
262	16	_	_	I-Premise
263	mm	_	_	I-Premise
264	Hg	_	_	I-Premise
265	in	_	_	I-Premise
266	30	_	_	I-Premise
267	(	_	_	I-Premise
268	75	_	_	I-Premise
269	%	_	_	I-Premise
270	)	_	_	I-Premise
271	versus	_	_	I-Premise
272	18	_	_	I-Premise
273	(	_	_	I-Premise
274	45	_	_	I-Premise
275	%	_	_	I-Premise
276	)	_	_	I-Premise
277	eyes	_	_	I-Premise
278	for	_	_	I-Premise
279	BTFC	_	_	I-Premise
280	and	_	_	I-Premise
281	TTFC	_	_	I-Premise
282	,	_	_	I-Premise
283	respectively	_	_	I-Premise
284	(	_	_	I-Premise
285	P	_	_	I-Premise
286	<	_	_	I-Premise
287	0.001	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	Both	_	_	B-Claim
291	drops	_	_	I-Claim
292	provided	_	_	I-Claim
293	effective	_	_	I-Claim
294	IOP	_	_	I-Claim
295	reduction	_	_	I-Claim
296	that	_	_	I-Claim
297	was	_	_	I-Claim
298	greater	_	_	I-Claim
299	and	_	_	O
300	patients	_	_	B-Claim
301	were	_	_	I-Claim
302	more	_	_	I-Claim
303	likely	_	_	I-Claim
304	to	_	_	I-Claim
305	achieve	_	_	I-Claim
306	lower	_	_	I-Claim
307	target	_	_	I-Claim
308	pressures	_	_	I-Claim
309	with	_	_	I-Claim
310	BTFC	_	_	I-Claim
311	than	_	_	I-Claim
312	with	_	_	I-Claim
313	TTFC	_	_	I-Claim
314	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	a	_	_	O
8	once-daily	_	_	O
9	evening	_	_	O
10	dose	_	_	O
11	of	_	_	O
12	bimatoprost/timolol	_	_	O
13	fixed	_	_	O
14	combination	_	_	O
15	(	_	_	O
16	BTFC	_	_	O
17	)	_	_	O
18	with	_	_	O
19	that	_	_	O
20	of	_	_	O
21	a	_	_	O
22	once-daily	_	_	O
23	evening	_	_	O
24	dose	_	_	O
25	of	_	_	O
26	latanoprost/timolol	_	_	O
27	fixed	_	_	O
28	combination	_	_	O
29	(	_	_	O
30	LTFC	_	_	O
31	)	_	_	O
32	in	_	_	O
33	patients	_	_	O
34	not	_	_	O
35	controlled	_	_	O
36	with	_	_	O
37	prostaglandins	_	_	O
38	analogues	_	_	O
39	monotherapy	_	_	O
40	.	_	_	O

41	A	_	_	O
42	total	_	_	O
43	of	_	_	O
44	82	_	_	O
45	patients	_	_	O
46	on	_	_	O
47	prostaglandin	_	_	O
48	analogues	_	_	O
49	monotherapy	_	_	O
50	were	_	_	O
51	enrolled	_	_	O
52	in	_	_	O
53	this	_	_	O
54	prospective	_	_	O
55	,	_	_	O
56	multicenter	_	_	O
57	,	_	_	O
58	investigator	_	_	O
59	masked	_	_	O
60	,	_	_	O
61	clinical	_	_	O
62	study	_	_	O
63	and	_	_	O
64	were	_	_	O
65	randomized	_	_	O
66	to	_	_	O
67	either	_	_	O
68	BTFC	_	_	O
69	(	_	_	O
70	n=47	_	_	O
71	)	_	_	O
72	or	_	_	O
73	LTFC	_	_	O
74	(	_	_	O
75	n=35	_	_	O
76	)	_	_	O
77	topical	_	_	O
78	therapy	_	_	O
79	once	_	_	O
80	at	_	_	O
81	night	_	_	O
82	for	_	_	O
83	12	_	_	O
84	weeks	_	_	O
85	.	_	_	O

86	The	_	_	O
87	primary	_	_	O
88	endpoint	_	_	O
89	of	_	_	O
90	the	_	_	O
91	study	_	_	O
92	was	_	_	O
93	to	_	_	O
94	compare	_	_	O
95	the	_	_	O
96	mean	_	_	O
97	daily	_	_	O
98	intraocular	_	_	O
99	pressure	_	_	O
100	(	_	_	O
101	IOP	_	_	O
102	)	_	_	O
103	reduction	_	_	O
104	from	_	_	O
105	baseline	_	_	O
106	between	_	_	O
107	the	_	_	O
108	two	_	_	O
109	treatment	_	_	O
110	arms	_	_	O
111	.	_	_	O

112	Secondary	_	_	O
113	endpoints	_	_	O
114	included	_	_	O
115	the	_	_	O
116	mean	_	_	O
117	daily	_	_	O
118	IOP	_	_	O
119	at	_	_	O
120	1	_	_	O
121	and	_	_	O
122	3	_	_	O
123	months	_	_	O
124	compared	_	_	O
125	to	_	_	O
126	baseline	_	_	O
127	and	_	_	O
128	the	_	_	O
129	percentage	_	_	O
130	of	_	_	O
131	patients	_	_	O
132	showing	_	_	O
133	a	_	_	O
134	mean	_	_	O
135	IOP	_	_	O
136	reduction	_	_	O
137	from	_	_	O
138	baseline	_	_	O
139	greater	_	_	O
140	than	_	_	O
141	or	_	_	O
142	equal	_	_	O
143	to	_	_	O
144	15	_	_	O
145	%	_	_	O
146	or	_	_	O
147	20	_	_	O
148	%	_	_	O
149	.	_	_	O

150	Mean	_	_	O
151	IOP	_	_	O
152	at	_	_	O
153	baseline	_	_	O
154	was	_	_	O
155	22.7+/-2.0	_	_	O
156	and	_	_	O
157	22.1+/-2.6	_	_	O
158	mmHg	_	_	O
159	in	_	_	O
160	the	_	_	O
161	BTFC	_	_	O
162	and	_	_	O
163	LTFC	_	_	O
164	groups	_	_	O
165	,	_	_	O
166	respectively	_	_	O
167	(	_	_	O
168	p=0.23	_	_	O
169	)	_	_	O
170	.	_	_	O

171	Both	_	_	O
172	treatments	_	_	O
173	were	_	_	O
174	effective	_	_	O
175	in	_	_	O
176	reducing	_	_	O
177	the	_	_	O
178	IOP	_	_	O
179	from	_	_	O
180	baseline	_	_	O
181	.	_	_	O

182	The	_	_	B-Premise
183	mean	_	_	I-Premise
184	IOP	_	_	I-Premise
185	reduction	_	_	I-Premise
186	was	_	_	I-Premise
187	significantly	_	_	I-Premise
188	greater	_	_	I-Premise
189	in	_	_	I-Premise
190	the	_	_	I-Premise
191	BTFC	_	_	I-Premise
192	group	_	_	I-Premise
193	than	_	_	I-Premise
194	in	_	_	I-Premise
195	the	_	_	I-Premise
196	LTFC	_	_	I-Premise
197	group	_	_	I-Premise
198	(	_	_	I-Premise
199	-21.4	_	_	I-Premise
200	%	_	_	I-Premise
201	vs	_	_	I-Premise
202	-13.7	_	_	I-Premise
203	%	_	_	I-Premise
204	,	_	_	I-Premise
205	p	_	_	I-Premise
206	<	_	_	I-Premise
207	0.001	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	A	_	_	B-Premise
211	higher	_	_	I-Premise
212	percentage	_	_	I-Premise
213	of	_	_	I-Premise
214	patients	_	_	I-Premise
215	in	_	_	I-Premise
216	the	_	_	I-Premise
217	BTFC	_	_	I-Premise
218	group	_	_	I-Premise
219	showed	_	_	I-Premise
220	a	_	_	I-Premise
221	mean	_	_	I-Premise
222	IOP	_	_	I-Premise
223	reduction	_	_	I-Premise
224	from	_	_	I-Premise
225	baseline	_	_	I-Premise
226	>	_	_	I-Premise
227	or=15	_	_	I-Premise
228	%	_	_	I-Premise
229	(	_	_	I-Premise
230	72.3	_	_	I-Premise
231	%	_	_	I-Premise
232	vs	_	_	I-Premise
233	40.0	_	_	I-Premise
234	%	_	_	I-Premise
235	)	_	_	I-Premise
236	and	_	_	I-Premise
237	>	_	_	I-Premise
238	or=20	_	_	I-Premise
239	%	_	_	I-Premise
240	(	_	_	I-Premise
241	61.7	_	_	I-Premise
242	%	_	_	I-Premise
243	vs	_	_	I-Premise
244	17.1	_	_	I-Premise
245	%	_	_	I-Premise
246	)	_	_	I-Premise
247	compared	_	_	I-Premise
248	to	_	_	I-Premise
249	patients	_	_	I-Premise
250	in	_	_	I-Premise
251	the	_	_	I-Premise
252	LTFC	_	_	I-Premise
253	group	_	_	I-Premise
254	.	_	_	I-Premise

255	Both	_	_	B-Claim
256	BTFC	_	_	I-Claim
257	and	_	_	I-Claim
258	LTFC	_	_	I-Claim
259	were	_	_	I-Claim
260	more	_	_	I-Claim
261	effective	_	_	I-Claim
262	versus	_	_	I-Claim
263	the	_	_	I-Claim
264	monotherapy	_	_	I-Claim
265	with	_	_	I-Claim
266	prostaglandin	_	_	I-Claim
267	analogues	_	_	I-Claim
268	.	_	_	I-Claim

269	BTFC	_	_	B-Claim
270	demonstrated	_	_	I-Claim
271	higher	_	_	I-Claim
272	performance	_	_	I-Claim
273	than	_	_	I-Claim
274	LTFC	_	_	I-Claim
275	in	_	_	I-Claim
276	terms	_	_	I-Claim
277	of	_	_	I-Claim
278	relative	_	_	I-Claim
279	IOP	_	_	I-Claim
280	reduction	_	_	I-Claim
281	.	_	_	I-Claim


0	Oral	_	_	B-Claim
1	carbonic	_	_	I-Claim
2	anhydrase	_	_	I-Claim
3	inhibitors	_	_	I-Claim
4	used	_	_	I-Claim
5	to	_	_	I-Claim
6	treat	_	_	I-Claim
7	glaucoma	_	_	I-Claim
8	have	_	_	I-Claim
9	significant	_	_	I-Claim
10	systemic	_	_	I-Claim
11	side	_	_	I-Claim
12	effects	_	_	I-Claim
13	.	_	_	I-Claim

14	Brinzolamide	_	_	O
15	1.0	_	_	O
16	%	_	_	O
17	,	_	_	O
18	a	_	_	O
19	new	_	_	O
20	topical	_	_	O
21	ocular	_	_	O
22	carbonic	_	_	O
23	anhydrase	_	_	O
24	inhibitor	_	_	O
25	,	_	_	O
26	is	_	_	O
27	effective	_	_	O
28	apparently	_	_	O
29	without	_	_	O
30	significant	_	_	O
31	systemic	_	_	O
32	side	_	_	O
33	effects	_	_	O
34	.	_	_	O

35	This	_	_	O
36	study	_	_	O
37	was	_	_	O
38	performed	_	_	O
39	to	_	_	O
40	establish	_	_	O
41	the	_	_	O
42	long-term	_	_	O
43	safety	_	_	O
44	and	_	_	O
45	efficacy	_	_	O
46	of	_	_	O
47	brinzolamide	_	_	O
48	1.0	_	_	O
49	%	_	_	O
50	two	_	_	O
51	and	_	_	O
52	three	_	_	O
53	times	_	_	O
54	daily	_	_	O
55	for	_	_	O
56	primary	_	_	O
57	open-angle	_	_	O
58	glaucoma	_	_	O
59	and	_	_	O
60	ocular	_	_	O
61	hypertension	_	_	O
62	.	_	_	O

63	An	_	_	O
64	18-month	_	_	O
65	,	_	_	O
66	multicenter	_	_	O
67	,	_	_	O
68	double-masked	_	_	O
69	,	_	_	O
70	parallel	_	_	O
71	,	_	_	O
72	controlled	_	_	O
73	study	_	_	O
74	was	_	_	O
75	conducted	_	_	O
76	.	_	_	O

77	Patients	_	_	O
78	were	_	_	O
79	randomized	_	_	O
80	to	_	_	O
81	brinzolamide	_	_	O
82	two	_	_	O
83	or	_	_	O
84	three	_	_	O
85	times	_	_	O
86	daily	_	_	O
87	or	_	_	O
88	timolol	_	_	O
89	0.5	_	_	O
90	%	_	_	O
91	twice	_	_	O
92	daily	_	_	O
93	in	_	_	O
94	a	_	_	O
95	2:2:1	_	_	O
96	ratio	_	_	O
97	(	_	_	O
98	n	_	_	O
99	=	_	_	O
100	150	_	_	O
101	,	_	_	O
102	153	_	_	O
103	,	_	_	O
104	and	_	_	O
105	75	_	_	O
106	,	_	_	O
107	respectively	_	_	O
108	)	_	_	O
109	.	_	_	O

110	Intraocular	_	_	O
111	pressure	_	_	O
112	was	_	_	O
113	measured	_	_	O
114	at	_	_	O
115	8:00	_	_	O
116	AM	_	_	O
117	at	_	_	O
118	eligibility	_	_	O
119	and	_	_	O
120	months	_	_	O
121	1	_	_	O
122	,	_	_	O
123	3	_	_	O
124	,	_	_	O
125	6	_	_	O
126	,	_	_	O
127	9	_	_	O
128	,	_	_	O
129	12	_	_	O
130	,	_	_	O
131	15	_	_	O
132	,	_	_	O
133	and	_	_	O
134	18	_	_	O
135	.	_	_	O

136	Efficacy	_	_	O
137	was	_	_	O
138	based	_	_	O
139	on	_	_	O
140	intraocular	_	_	O
141	pressure	_	_	O
142	reduction	_	_	O
143	from	_	_	O
144	baseline	_	_	O
145	.	_	_	O

146	Safety	_	_	O
147	was	_	_	O
148	also	_	_	O
149	evaluated	_	_	O
150	.	_	_	O

151	All	_	_	B-Premise
152	regimens	_	_	I-Premise
153	produced	_	_	I-Premise
154	clinically	_	_	I-Premise
155	relevant	_	_	I-Premise
156	and	_	_	I-Premise
157	statistically	_	_	I-Premise
158	significant	_	_	I-Premise
159	(	_	_	I-Premise
160	P	_	_	I-Premise
161	<	_	_	I-Premise
162	.05	_	_	I-Premise
163	)	_	_	I-Premise
164	intraocular	_	_	I-Premise
165	pressure	_	_	I-Premise
166	reductions	_	_	I-Premise
167	from	_	_	I-Premise
168	baseline	_	_	I-Premise
169	.	_	_	I-Premise

170	Mean	_	_	B-Premise
171	changes	_	_	I-Premise
172	in	_	_	I-Premise
173	intraocular	_	_	I-Premise
174	pressure	_	_	I-Premise
175	trough	_	_	I-Premise
176	measurements	_	_	I-Premise
177	ranged	_	_	I-Premise
178	from	_	_	I-Premise
179	-2.7	_	_	I-Premise
180	to	_	_	I-Premise
181	-3.9	_	_	I-Premise
182	mm	_	_	I-Premise
183	Hg	_	_	I-Premise
184	with	_	_	I-Premise
185	brinzolamide	_	_	I-Premise
186	twice-daily	_	_	I-Premise
187	dosing	_	_	I-Premise
188	and	_	_	I-Premise
189	-2.8	_	_	I-Premise
190	to	_	_	I-Premise
191	-3.8	_	_	I-Premise
192	mm	_	_	I-Premise
193	Hg	_	_	I-Premise
194	three	_	_	I-Premise
195	times	_	_	I-Premise
196	daily	_	_	I-Premise
197	dosing	_	_	I-Premise
198	compared	_	_	I-Premise
199	with	_	_	I-Premise
200	-4.7	_	_	I-Premise
201	to	_	_	I-Premise
202	-5.6	_	_	I-Premise
203	mm	_	_	I-Premise
204	Hg	_	_	I-Premise
205	with	_	_	I-Premise
206	timolol	_	_	I-Premise
207	.	_	_	I-Premise

208	The	_	_	O
209	intraocular	_	_	O
210	pressure	_	_	O
211	reductions	_	_	O
212	with	_	_	O
213	brinzolamide	_	_	O
214	two	_	_	O
215	and	_	_	O
216	three	_	_	O
217	times	_	_	O
218	daily	_	_	O
219	were	_	_	O
220	clinically	_	_	O
221	and	_	_	O
222	statistically	_	_	O
223	equivalent	_	_	O
224	.	_	_	O

225	One	_	_	O
226	hundred	_	_	O
227	forty-four	_	_	O
228	patients	_	_	O
229	were	_	_	O
230	discontinued	_	_	O
231	from	_	_	O
232	the	_	_	O
233	study	_	_	O
234	after	_	_	O
235	randomization	_	_	O
236	with	_	_	O
237	the	_	_	O
238	most	_	_	O
239	common	_	_	O
240	reasons	_	_	O
241	being	_	_	O
242	the	_	_	O
243	occurrence	_	_	O
244	of	_	_	O
245	an	_	_	O
246	adverse	_	_	O
247	event	_	_	O
248	(	_	_	O
249	46	_	_	O
250	)	_	_	O
251	,	_	_	O
252	inadequate	_	_	O
253	intraocular	_	_	O
254	pressure	_	_	O
255	control	_	_	O
256	(	_	_	O
257	23	_	_	O
258	)	_	_	O
259	,	_	_	O
260	patient	_	_	O
261	decision	_	_	O
262	unrelated	_	_	O
263	to	_	_	O
264	study	_	_	O
265	medication	_	_	O
266	(	_	_	O
267	11	_	_	O
268	)	_	_	O
269	,	_	_	O
270	lost	_	_	O
271	to	_	_	O
272	follow-up	_	_	O
273	(	_	_	O
274	16	_	_	O
275	)	_	_	O
276	,	_	_	O
277	and	_	_	O
278	noncompliance	_	_	O
279	(	_	_	O
280	9	_	_	O
281	)	_	_	O
282	.	_	_	O

283	Adverse	_	_	B-Premise
284	events	_	_	I-Premise
285	were	_	_	I-Premise
286	nonserious	_	_	I-Premise
287	and	_	_	I-Premise
288	resolved	_	_	I-Premise
289	without	_	_	I-Premise
290	sequelae	_	_	I-Premise
291	.	_	_	I-Premise

292	There	_	_	O
293	were	_	_	O
294	no	_	_	O
295	clinically	_	_	O
296	relevant	_	_	O
297	changes	_	_	O
298	in	_	_	O
299	safety	_	_	O
300	parameters	_	_	O
301	.	_	_	O

302	Brinzolamide	_	_	B-Claim
303	produced	_	_	I-Claim
304	less	_	_	I-Claim
305	ocular	_	_	I-Claim
306	discomfort	_	_	I-Claim
307	(	_	_	I-Claim
308	burning/stinging	_	_	I-Claim
309	)	_	_	I-Claim
310	than	_	_	I-Claim
311	timolol	_	_	I-Claim
312	,	_	_	I-Claim
313	and	_	_	I-Claim
314	total	_	_	I-Claim
315	carbonic	_	_	I-Claim
316	anhydrase	_	_	I-Claim
317	inhibition	_	_	I-Claim
318	levels	_	_	I-Claim
319	remained	_	_	I-Claim
320	below	_	_	I-Claim
321	that	_	_	I-Claim
322	known	_	_	I-Claim
323	to	_	_	I-Claim
324	cause	_	_	I-Claim
325	systemic	_	_	I-Claim
326	side	_	_	I-Claim
327	effects	_	_	I-Claim
328	.	_	_	I-Claim

329	Brinzolamide	_	_	B-Claim
330	produced	_	_	I-Claim
331	significant	_	_	I-Claim
332	and	_	_	I-Claim
333	equivalent	_	_	I-Claim
334	reductions	_	_	I-Claim
335	in	_	_	I-Claim
336	intraocular	_	_	I-Claim
337	pressure	_	_	I-Claim
338	when	_	_	I-Claim
339	dosed	_	_	I-Claim
340	two	_	_	I-Claim
341	and	_	_	I-Claim
342	three	_	_	I-Claim
343	times	_	_	I-Claim
344	daily	_	_	I-Claim
345	for	_	_	I-Claim
346	18	_	_	I-Claim
347	months	_	_	I-Claim
348	.	_	_	I-Claim

349	Brinzolamide	_	_	B-Claim
350	was	_	_	I-Claim
351	safe	_	_	I-Claim
352	and	_	_	I-Claim
353	well	_	_	I-Claim
354	tolerated	_	_	I-Claim
355	by	_	_	I-Claim
356	patients	_	_	I-Claim
357	,	_	_	I-Claim
358	with	_	_	I-Claim
359	minimal	_	_	I-Claim
360	ocular	_	_	I-Claim
361	discomfort	_	_	I-Claim
362	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	and	_	_	O
5	efficacy	_	_	O
6	of	_	_	O
7	the	_	_	O
8	iStent	_	_	O
9	trabecular	_	_	O
10	micro-bypass	_	_	O
11	stent	_	_	O
12	(	_	_	O
13	Glaukos	_	_	O
14	Corporation	_	_	O
15	,	_	_	O
16	Laguna	_	_	O
17	Hills	_	_	O
18	,	_	_	O
19	CA	_	_	O
20	)	_	_	O
21	in	_	_	O
22	combination	_	_	O
23	with	_	_	O
24	cataract	_	_	O
25	surgery	_	_	O
26	in	_	_	O
27	subjects	_	_	O
28	with	_	_	O
29	mild	_	_	O
30	to	_	_	O
31	moderate	_	_	O
32	open-angle	_	_	O
33	glaucoma	_	_	O
34	.	_	_	O

35	Prospective	_	_	O
36	,	_	_	O
37	randomized	_	_	O
38	,	_	_	O
39	open-label	_	_	O
40	,	_	_	O
41	controlled	_	_	O
42	,	_	_	O
43	multicenter	_	_	O
44	clinical	_	_	O
45	trial	_	_	O
46	.	_	_	O

47	A	_	_	O
48	total	_	_	O
49	of	_	_	O
50	240	_	_	O
51	eyes	_	_	O
52	with	_	_	O
53	mild	_	_	O
54	to	_	_	O
55	moderate	_	_	O
56	open-angle	_	_	O
57	glaucoma	_	_	O
58	with	_	_	O
59	intraocular	_	_	O
60	pressure	_	_	O
61	(	_	_	O
62	IOP	_	_	O
63	)	_	_	O
64	=24	_	_	O
65	mmHg	_	_	O
66	controlled	_	_	O
67	on	_	_	O
68	1	_	_	O
69	to	_	_	O
70	3	_	_	O
71	medications	_	_	O
72	were	_	_	O
73	randomized	_	_	O
74	to	_	_	O
75	undergo	_	_	O
76	cataract	_	_	O
77	surgery	_	_	O
78	with	_	_	O
79	iStent	_	_	O
80	implantation	_	_	O
81	(	_	_	O
82	treatment	_	_	O
83	group	_	_	O
84	)	_	_	O
85	or	_	_	O
86	cataract	_	_	O
87	surgery	_	_	O
88	only	_	_	O
89	(	_	_	O
90	control	_	_	O
91	)	_	_	O
92	.	_	_	O

93	Fifty	_	_	O
94	additional	_	_	O
95	subjects	_	_	O
96	were	_	_	O
97	enrolled	_	_	O
98	to	_	_	O
99	undergo	_	_	O
100	cataract	_	_	O
101	surgery	_	_	O
102	with	_	_	O
103	iStent	_	_	O
104	implantation	_	_	O
105	under	_	_	O
106	protocol	_	_	O
107	expansion	_	_	O
108	.	_	_	O

109	Data	_	_	O
110	in	_	_	O
111	this	_	_	O
112	report	_	_	O
113	are	_	_	O
114	based	_	_	O
115	on	_	_	O
116	the	_	_	O
117	first	_	_	O
118	240	_	_	O
119	eyes	_	_	O
120	enrolled	_	_	O
121	.	_	_	O

122	Implantation	_	_	O
123	of	_	_	O
124	the	_	_	O
125	iStent	_	_	O
126	trabecular	_	_	O
127	micro-bypass	_	_	O
128	stent	_	_	O
129	in	_	_	O
130	conjunction	_	_	O
131	with	_	_	O
132	cataract	_	_	O
133	surgery	_	_	O
134	or	_	_	O
135	cataract	_	_	O
136	surgery	_	_	O
137	only	_	_	O
138	.	_	_	O

139	The	_	_	O
140	primary	_	_	O
141	efficacy	_	_	O
142	measure	_	_	O
143	was	_	_	O
144	unmedicated	_	_	O
145	IOP	_	_	O
146	≤21	_	_	O
147	mmHg	_	_	O
148	at	_	_	O
149	1	_	_	O
150	year	_	_	O
151	.	_	_	O

152	A	_	_	O
153	secondary	_	_	O
154	measure	_	_	O
155	was	_	_	O
156	unmedicated	_	_	O
157	IOP	_	_	O
158	reduction	_	_	O
159	≥20	_	_	O
160	%	_	_	O
161	at	_	_	O
162	1	_	_	O
163	year	_	_	O
164	.	_	_	O

165	Safety	_	_	O
166	measures	_	_	O
167	included	_	_	O
168	best-corrected	_	_	O
169	visual	_	_	O
170	acuity	_	_	O
171	(	_	_	O
172	BCVA	_	_	O
173	)	_	_	O
174	,	_	_	O
175	slit-lamp	_	_	O
176	observations	_	_	O
177	,	_	_	O
178	complications	_	_	O
179	,	_	_	O
180	and	_	_	O
181	adverse	_	_	O
182	events	_	_	O
183	.	_	_	O

184	The	_	_	O
185	study	_	_	O
186	met	_	_	O
187	the	_	_	O
188	primary	_	_	O
189	outcome	_	_	O
190	,	_	_	O
191	with	_	_	O
192	72	_	_	O
193	%	_	_	O
194	of	_	_	O
195	treatment	_	_	O
196	eyes	_	_	O
197	versus	_	_	O
198	50	_	_	O
199	%	_	_	O
200	of	_	_	O
201	control	_	_	O
202	eyes	_	_	O
203	achieving	_	_	O
204	the	_	_	O
205	criterion	_	_	O
206	(	_	_	O
207	P	_	_	O
208	<	_	_	O
209	0.001	_	_	O
210	)	_	_	O
211	.	_	_	O

212	At	_	_	B-Premise
213	1	_	_	I-Premise
214	year	_	_	I-Premise
215	,	_	_	I-Premise
216	IOP	_	_	I-Premise
217	in	_	_	I-Premise
218	both	_	_	I-Premise
219	treatment	_	_	I-Premise
220	groups	_	_	I-Premise
221	was	_	_	I-Premise
222	statistically	_	_	I-Premise
223	significantly	_	_	I-Premise
224	lower	_	_	I-Premise
225	from	_	_	I-Premise
226	baseline	_	_	I-Premise
227	values	_	_	I-Premise
228	.	_	_	I-Premise

229	Sixty-six	_	_	B-Premise
230	percent	_	_	I-Premise
231	of	_	_	I-Premise
232	treatment	_	_	I-Premise
233	eyes	_	_	I-Premise
234	versus	_	_	I-Premise
235	48	_	_	I-Premise
236	%	_	_	I-Premise
237	of	_	_	I-Premise
238	control	_	_	I-Premise
239	eyes	_	_	I-Premise
240	achieved	_	_	I-Premise
241	=20	_	_	I-Premise
242	%	_	_	I-Premise
243	IOP	_	_	I-Premise
244	reduction	_	_	I-Premise
245	without	_	_	I-Premise
246	medication	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	=	_	_	I-Premise
250	0.003	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	The	_	_	B-Premise
254	overall	_	_	I-Premise
255	incidence	_	_	I-Premise
256	of	_	_	I-Premise
257	adverse	_	_	I-Premise
258	events	_	_	I-Premise
259	was	_	_	I-Premise
260	similar	_	_	I-Premise
261	between	_	_	I-Premise
262	groups	_	_	I-Premise
263	with	_	_	I-Premise
264	no	_	_	I-Premise
265	unanticipated	_	_	I-Premise
266	adverse	_	_	I-Premise
267	device	_	_	I-Premise
268	effects	_	_	I-Premise
269	.	_	_	I-Premise

270	Pressure	_	_	B-Claim
271	reduction	_	_	I-Claim
272	on	_	_	I-Claim
273	fewer	_	_	I-Claim
274	medications	_	_	I-Claim
275	was	_	_	I-Claim
276	clinically	_	_	I-Claim
277	and	_	_	I-Claim
278	statistically	_	_	I-Claim
279	significantly	_	_	I-Claim
280	better	_	_	I-Claim
281	1	_	_	I-Claim
282	year	_	_	I-Claim
283	after	_	_	I-Claim
284	stent	_	_	I-Claim
285	plus	_	_	I-Claim
286	cataract	_	_	I-Claim
287	surgery	_	_	I-Claim
288	versus	_	_	I-Claim
289	cataract	_	_	I-Claim
290	surgery	_	_	I-Claim
291	alone	_	_	I-Claim
292	,	_	_	I-Claim
293	with	_	_	I-Claim
294	an	_	_	I-Claim
295	overall	_	_	I-Claim
296	safety	_	_	I-Claim
297	profile	_	_	I-Claim
298	similar	_	_	I-Claim
299	to	_	_	I-Claim
300	that	_	_	I-Claim
301	of	_	_	I-Claim
302	cataract	_	_	I-Claim
303	surgery	_	_	I-Claim
304	alone	_	_	I-Claim
305	.	_	_	I-Claim


0	Fixed	_	_	B-Claim
1	combinations	_	_	I-Claim
2	of	_	_	I-Claim
3	0.2	_	_	I-Claim
4	%	_	_	I-Claim
5	brimonidine-0.5	_	_	I-Claim
6	%	_	_	I-Claim
7	timolol	_	_	I-Claim
8	and	_	_	I-Claim
9	2	_	_	I-Claim
10	%	_	_	I-Claim
11	dorzolamide-0.5	_	_	I-Claim
12	%	_	_	I-Claim
13	timolol	_	_	I-Claim
14	are	_	_	I-Claim
15	used	_	_	I-Claim
16	to	_	_	I-Claim
17	lower	_	_	I-Claim
18	intraocular	_	_	I-Claim
19	pressure	_	_	I-Claim
20	(	_	_	I-Claim
21	IOP	_	_	I-Claim
22	)	_	_	I-Claim
23	.	_	_	I-Claim

24	The	_	_	O
25	objective	_	_	O
26	of	_	_	O
27	this	_	_	O
28	study	_	_	O
29	was	_	_	O
30	to	_	_	O
31	evaluate	_	_	O
32	the	_	_	O
33	IOP-lowering	_	_	O
34	efficacy	_	_	O
35	and	_	_	O
36	ocular	_	_	O
37	tolerability	_	_	O
38	of	_	_	O
39	brimonidine-timolol	_	_	O
40	compared	_	_	O
41	with	_	_	O
42	dorzolamide-timolol	_	_	O
43	when	_	_	O
44	used	_	_	O
45	as	_	_	O
46	monotherapy	_	_	O
47	or	_	_	O
48	as	_	_	O
49	adjunctive	_	_	O
50	therapy	_	_	O
51	to	_	_	O
52	a	_	_	O
53	prostaglandin	_	_	O
54	analog	_	_	O
55	(	_	_	O
56	PGA	_	_	O
57	)	_	_	O
58	in	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	glaucoma	_	_	O
62	or	_	_	O
63	ocular	_	_	O
64	hypertension	_	_	O
65	.	_	_	O

66	Pooled	_	_	O
67	data	_	_	O
68	analysis	_	_	O
69	of	_	_	O
70	two	_	_	O
71	randomized	_	_	O
72	,	_	_	O
73	investigator-masked	_	_	O
74	,	_	_	O
75	3-month	_	_	O
76	,	_	_	O
77	parallel-group	_	_	O
78	studies	_	_	O
79	with	_	_	O
80	identical	_	_	O
81	protocols	_	_	O
82	(	_	_	O
83	ten	_	_	O
84	sites	_	_	O
85	)	_	_	O
86	.	_	_	O

87	In	_	_	O
88	all	_	_	O
89	,	_	_	O
90	180	_	_	O
91	patients	_	_	O
92	with	_	_	O
93	open-angle	_	_	O
94	glaucoma	_	_	O
95	or	_	_	O
96	ocular	_	_	O
97	hypertension	_	_	O
98	who	_	_	O
99	were	_	_	O
100	in	_	_	O
101	need	_	_	O
102	of	_	_	O
103	lower	_	_	O
104	IOP	_	_	O
105	received	_	_	O
106	topical	_	_	O
107	brimonidine-timolol	_	_	O
108	BID	_	_	O
109	or	_	_	O
110	dorzolamide-timolol	_	_	O
111	BID	_	_	O
112	as	_	_	O
113	monotherapy	_	_	O
114	(	_	_	O
115	n	_	_	O
116	=	_	_	O
117	101	_	_	O
118	)	_	_	O
119	or	_	_	O
120	as	_	_	O
121	adjunctive	_	_	O
122	therapy	_	_	O
123	to	_	_	O
124	a	_	_	O
125	PGA	_	_	O
126	(	_	_	O
127	latanoprost	_	_	O
128	,	_	_	O
129	bimatoprost	_	_	O
130	,	_	_	O
131	or	_	_	O
132	travoprost	_	_	O
133	)	_	_	O
134	(	_	_	O
135	n	_	_	O
136	=	_	_	O
137	79	_	_	O
138	)	_	_	O
139	.	_	_	O

140	IOP	_	_	O
141	was	_	_	O
142	measured	_	_	O
143	at	_	_	O
144	10	_	_	O
145	a.m.	_	_	O
146	(	_	_	O
147	peak	_	_	O
148	effect	_	_	O
149	)	_	_	O
150	at	_	_	O
151	baseline	_	_	O
152	and	_	_	O
153	at	_	_	O
154	months	_	_	O
155	1	_	_	O
156	and	_	_	O
157	3	_	_	O
158	.	_	_	O

159	Tolerability/comfort	_	_	O
160	was	_	_	O
161	evaluated	_	_	O
162	using	_	_	O
163	a	_	_	O
164	patient	_	_	O
165	questionnaire	_	_	O
166	.	_	_	O

167	There	_	_	O
168	were	_	_	O
169	no	_	_	O
170	statistically	_	_	O
171	significant	_	_	O
172	between-group	_	_	O
173	differences	_	_	O
174	in	_	_	O
175	patient	_	_	O
176	demographics	_	_	O
177	.	_	_	O

178	Most	_	_	O
179	patients	_	_	O
180	were	_	_	O
181	Caucasian	_	_	O
182	,	_	_	O
183	and	_	_	O
184	the	_	_	O
185	mean	_	_	O
186	age	_	_	O
187	was	_	_	O
188	68	_	_	O
189	years	_	_	O
190	.	_	_	O

191	There	_	_	O
192	were	_	_	O
193	also	_	_	O
194	no	_	_	O
195	statistically	_	_	O
196	significant	_	_	O
197	differences	_	_	O
198	between	_	_	O
199	treatment	_	_	O
200	groups	_	_	O
201	in	_	_	O
202	baseline	_	_	O
203	IOP	_	_	O
204	.	_	_	O

205	At	_	_	B-Premise
206	month	_	_	I-Premise
207	3	_	_	I-Premise
208	,	_	_	I-Premise
209	the	_	_	I-Premise
210	mean	_	_	I-Premise
211	(	_	_	I-Premise
212	SD	_	_	I-Premise
213	)	_	_	I-Premise
214	reduction	_	_	I-Premise
215	from	_	_	I-Premise
216	baseline	_	_	I-Premise
217	IOP	_	_	I-Premise
218	for	_	_	I-Premise
219	patients	_	_	I-Premise
220	on	_	_	I-Premise
221	fixed-combination	_	_	I-Premise
222	monotherapy	_	_	I-Premise
223	was	_	_	I-Premise
224	7.7	_	_	I-Premise
225	(	_	_	I-Premise
226	4.2	_	_	I-Premise
227	)	_	_	I-Premise
228	mmHg	_	_	I-Premise
229	(	_	_	I-Premise
230	32.3	_	_	I-Premise
231	%	_	_	I-Premise
232	)	_	_	I-Premise
233	with	_	_	I-Premise
234	brimonidine-timolol	_	_	I-Premise
235	versus	_	_	I-Premise
236	6.7	_	_	I-Premise
237	(	_	_	I-Premise
238	5.0	_	_	I-Premise
239	)	_	_	I-Premise
240	mmHg	_	_	I-Premise
241	(	_	_	I-Premise
242	26.1	_	_	I-Premise
243	%	_	_	I-Premise
244	)	_	_	I-Premise
245	with	_	_	I-Premise
246	dorzolamide-timolol	_	_	I-Premise
247	(	_	_	I-Premise
248	p	_	_	I-Premise
249	=	_	_	I-Premise
250	0.040	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	The	_	_	B-Premise
254	mean	_	_	I-Premise
255	reduction	_	_	I-Premise
256	from	_	_	I-Premise
257	PGA-treated	_	_	I-Premise
258	baseline	_	_	I-Premise
259	IOP	_	_	I-Premise
260	for	_	_	I-Premise
261	patients	_	_	I-Premise
262	on	_	_	I-Premise
263	fixed-combination	_	_	I-Premise
264	adjunctive	_	_	I-Premise
265	therapy	_	_	I-Premise
266	was	_	_	I-Premise
267	6.9	_	_	I-Premise
268	(	_	_	I-Premise
269	4.8	_	_	I-Premise
270	)	_	_	I-Premise
271	mmHg	_	_	I-Premise
272	(	_	_	I-Premise
273	29.3	_	_	I-Premise
274	%	_	_	I-Premise
275	)	_	_	I-Premise
276	with	_	_	I-Premise
277	brimonidine-timolol	_	_	I-Premise
278	versus	_	_	I-Premise
279	5.2	_	_	I-Premise
280	(	_	_	I-Premise
281	3.7	_	_	I-Premise
282	)	_	_	I-Premise
283	mmHg	_	_	I-Premise
284	(	_	_	I-Premise
285	23.5	_	_	I-Premise
286	%	_	_	I-Premise
287	)	_	_	I-Premise
288	with	_	_	I-Premise
289	dorzolamide-timolol	_	_	I-Premise
290	(	_	_	I-Premise
291	p	_	_	I-Premise
292	=	_	_	I-Premise
293	0.213	_	_	I-Premise
294	)	_	_	I-Premise
295	.	_	_	I-Premise

296	Patients	_	_	B-Premise
297	on	_	_	I-Premise
298	brimonidine-timolol	_	_	I-Premise
299	reported	_	_	I-Premise
300	less	_	_	I-Premise
301	burning	_	_	I-Premise
302	(	_	_	I-Premise
303	p	_	_	I-Premise
304	<	_	_	I-Premise
305	0.001	_	_	I-Premise
306	)	_	_	I-Premise
307	,	_	_	I-Premise
308	stinging	_	_	I-Premise
309	(	_	_	I-Premise
310	p	_	_	I-Premise
311	<	_	_	I-Premise
312	0.001	_	_	I-Premise
313	)	_	_	I-Premise
314	,	_	_	I-Premise
315	and	_	_	I-Premise
316	unusual	_	_	I-Premise
317	taste	_	_	I-Premise
318	(	_	_	I-Premise
319	p	_	_	I-Premise
320	<	_	_	I-Premise
321	0.001	_	_	I-Premise
322	)	_	_	I-Premise
323	than	_	_	I-Premise
324	patients	_	_	I-Premise
325	on	_	_	I-Premise
326	dorzolamide-timolol	_	_	I-Premise
327	.	_	_	I-Premise

328	Fixed-combination	_	_	B-Claim
329	brimonidine-timolol	_	_	I-Claim
330	provided	_	_	I-Claim
331	the	_	_	I-Claim
332	same	_	_	I-Claim
333	or	_	_	I-Claim
334	greater	_	_	I-Claim
335	IOP	_	_	I-Claim
336	lowering	_	_	I-Claim
337	compared	_	_	I-Claim
338	with	_	_	I-Claim
339	fixed-combination	_	_	I-Claim
340	dorzolamide-timolol	_	_	I-Claim
341	.	_	_	I-Claim

342	Both	_	_	B-Claim
343	fixed-combination	_	_	I-Claim
344	medications	_	_	I-Claim
345	were	_	_	I-Claim
346	safe	_	_	I-Claim
347	and	_	_	I-Claim
348	well-tolerated	_	_	I-Claim
349	.	_	_	I-Claim

350	Brimonidine-timolol	_	_	O
351	received	_	_	O
352	higher	_	_	O
353	ratings	_	_	O
354	of	_	_	O
355	ocular	_	_	O
356	comfort	_	_	O
357	than	_	_	O
358	dorzolamide-timolol	_	_	O
359	.	_	_	O

360	The	_	_	O
361	duration	_	_	O
362	of	_	_	O
363	the	_	_	O
364	studies	_	_	O
365	was	_	_	O
366	3	_	_	O
367	months	_	_	O
368	,	_	_	O
369	and	_	_	O
370	additional	_	_	O
371	studies	_	_	O
372	will	_	_	O
373	be	_	_	O
374	needed	_	_	O
375	to	_	_	O
376	compare	_	_	O
377	the	_	_	O
378	efficacy	_	_	O
379	and	_	_	O
380	tolerability	_	_	O
381	of	_	_	O
382	brimonidine-timolol	_	_	O
383	and	_	_	O
384	dorzolamide-timolol	_	_	O
385	during	_	_	O
386	long-term	_	_	O
387	treatment	_	_	O
388	.	_	_	O


0	To	_	_	O
1	test	_	_	O
2	the	_	_	O
3	hypothesis	_	_	O
4	that	_	_	O
5	neodymium	_	_	B-Claim
6	:	_	_	I-Claim
7	yttrium-aluminum-garnet	_	_	I-Claim
8	(	_	_	I-Claim
9	Nd	_	_	I-Claim
10	:	_	_	I-Claim
11	YAG	_	_	I-Claim
12	)	_	_	I-Claim
13	laser	_	_	I-Claim
14	peripheral	_	_	I-Claim
15	iridotomy	_	_	I-Claim
16	(	_	_	I-Claim
17	LPI	_	_	I-Claim
18	)	_	_	I-Claim
19	significantly	_	_	I-Claim
20	reduces	_	_	I-Claim
21	the	_	_	I-Claim
22	incidence	_	_	I-Claim
23	of	_	_	I-Claim
24	conversion	_	_	I-Claim
25	from	_	_	I-Claim
26	pigment	_	_	I-Claim
27	dispersion	_	_	I-Claim
28	syndrome	_	_	I-Claim
29	(	_	_	I-Claim
30	PDS	_	_	I-Claim
31	)	_	_	I-Claim
32	with	_	_	I-Claim
33	ocular	_	_	I-Claim
34	hypertension	_	_	I-Claim
35	(	_	_	I-Claim
36	OHT	_	_	I-Claim
37	)	_	_	I-Claim
38	to	_	_	I-Claim
39	pigmentary	_	_	I-Claim
40	glaucoma	_	_	I-Claim
41	(	_	_	I-Claim
42	PG	_	_	I-Claim
43	)	_	_	I-Claim
44	.	_	_	I-Claim

45	Prospective	_	_	O
46	,	_	_	O
47	randomized	_	_	O
48	,	_	_	O
49	controlled	_	_	O
50	3-year	_	_	O
51	trial	_	_	O
52	.	_	_	O

53	One	_	_	O
54	hundred	_	_	O
55	sixteen	_	_	O
56	eyes	_	_	O
57	of	_	_	O
58	116	_	_	O
59	patients	_	_	O
60	with	_	_	O
61	PDS	_	_	O
62	and	_	_	O
63	OHT	_	_	O
64	.	_	_	O

65	Patients	_	_	O
66	were	_	_	O
67	assigned	_	_	O
68	randomly	_	_	O
69	either	_	_	O
70	to	_	_	O
71	Nd	_	_	O
72	:	_	_	O
73	YAG	_	_	O
74	LPI	_	_	O
75	or	_	_	O
76	to	_	_	O
77	a	_	_	O
78	control	_	_	O
79	group	_	_	O
80	(	_	_	O
81	no	_	_	O
82	laser	_	_	O
83	)	_	_	O
84	.	_	_	O

85	The	_	_	O
86	primary	_	_	O
87	outcome	_	_	O
88	measure	_	_	O
89	was	_	_	O
90	conversion	_	_	O
91	to	_	_	O
92	PG	_	_	O
93	within	_	_	O
94	3	_	_	O
95	years	_	_	O
96	,	_	_	O
97	based	_	_	O
98	on	_	_	O
99	full-threshold	_	_	O
100	visual	_	_	O
101	field	_	_	O
102	(	_	_	O
103	VF	_	_	O
104	)	_	_	O
105	analysis	_	_	O
106	using	_	_	O
107	the	_	_	O
108	Ocular	_	_	O
109	Hypertension	_	_	O
110	Treatment	_	_	O
111	Study	_	_	O
112	criteria	_	_	O
113	.	_	_	O

114	Secondary	_	_	O
115	outcome	_	_	O
116	measures	_	_	O
117	were	_	_	O
118	whether	_	_	O
119	eyes	_	_	O
120	required	_	_	O
121	topical	_	_	O
122	antiglaucoma	_	_	O
123	medications	_	_	O
124	during	_	_	O
125	the	_	_	O
126	study	_	_	O
127	period	_	_	O
128	and	_	_	O
129	the	_	_	O
130	time	_	_	O
131	to	_	_	O
132	conversion	_	_	O
133	or	_	_	O
134	medication	_	_	O
135	.	_	_	O

136	Fifty-seven	_	_	O
137	patients	_	_	O
138	were	_	_	O
139	randomized	_	_	O
140	to	_	_	O
141	undergo	_	_	O
142	laser	_	_	O
143	treatment	_	_	O
144	and	_	_	O
145	59	_	_	O
146	were	_	_	O
147	randomized	_	_	O
148	to	_	_	O
149	no	_	_	O
150	laser	_	_	O
151	(	_	_	O
152	controls	_	_	O
153	)	_	_	O
154	.	_	_	O

155	Age	_	_	O
156	,	_	_	O
157	gender	_	_	O
158	,	_	_	O
159	spherical	_	_	O
160	equivalent	_	_	O
161	refraction	_	_	O
162	,	_	_	O
163	and	_	_	O
164	intraocular	_	_	O
165	pressure	_	_	O
166	at	_	_	O
167	baseline	_	_	O
168	were	_	_	O
169	similar	_	_	O
170	between	_	_	O
171	groups	_	_	O
172	.	_	_	O

173	Outcome	_	_	O
174	data	_	_	O
175	were	_	_	O
176	available	_	_	O
177	for	_	_	O
178	105	_	_	O
179	(	_	_	O
180	90	_	_	O
181	%	_	_	O
182	)	_	_	O
183	of	_	_	O
184	recruited	_	_	O
185	subjects	_	_	O
186	,	_	_	O
187	52	_	_	O
188	in	_	_	O
189	the	_	_	O
190	laser	_	_	O
191	treatment	_	_	O
192	group	_	_	O
193	and	_	_	O
194	53	_	_	O
195	in	_	_	O
196	the	_	_	O
197	no	_	_	O
198	laser	_	_	O
199	treatment	_	_	O
200	group	_	_	O
201	.	_	_	O

202	Patients	_	_	O
203	were	_	_	O
204	followed	_	_	O
205	up	_	_	O
206	for	_	_	O
207	a	_	_	O
208	median	_	_	O
209	of	_	_	O
210	35.9	_	_	O
211	months	_	_	O
212	(	_	_	O
213	range	_	_	O
214	,	_	_	O
215	10-36	_	_	O
216	months	_	_	O
217	)	_	_	O
218	in	_	_	O
219	the	_	_	O
220	laser	_	_	O
221	arm	_	_	O
222	and	_	_	O
223	35.9	_	_	O
224	months	_	_	O
225	(	_	_	O
226	range	_	_	O
227	,	_	_	O
228	1-36	_	_	O
229	months	_	_	O
230	)	_	_	O
231	in	_	_	O
232	the	_	_	O
233	control	_	_	O
234	arm	_	_	O
235	.	_	_	O

236	Eight	_	_	B-Premise
237	eyes	_	_	I-Premise
238	(	_	_	I-Premise
239	15	_	_	I-Premise
240	%	_	_	I-Premise
241	)	_	_	I-Premise
242	in	_	_	I-Premise
243	the	_	_	I-Premise
244	laser	_	_	I-Premise
245	group	_	_	I-Premise
246	and	_	_	I-Premise
247	3	_	_	I-Premise
248	eyes	_	_	I-Premise
249	(	_	_	I-Premise
250	6	_	_	I-Premise
251	%	_	_	I-Premise
252	)	_	_	I-Premise
253	in	_	_	I-Premise
254	the	_	_	I-Premise
255	control	_	_	I-Premise
256	group	_	_	I-Premise
257	converted	_	_	I-Premise
258	to	_	_	I-Premise
259	glaucoma	_	_	I-Premise
260	in	_	_	I-Premise
261	the	_	_	I-Premise
262	study	_	_	I-Premise
263	period	_	_	I-Premise
264	.	_	_	I-Premise

265	The	_	_	B-Premise
266	proportion	_	_	I-Premise
267	of	_	_	I-Premise
268	eyes	_	_	I-Premise
269	started	_	_	I-Premise
270	on	_	_	I-Premise
271	medical	_	_	I-Premise
272	treatment	_	_	I-Premise
273	was	_	_	I-Premise
274	similar	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	2	_	_	I-Premise
278	groups	_	_	I-Premise
279	:	_	_	I-Premise
280	8	_	_	I-Premise
281	eyes	_	_	I-Premise
282	(	_	_	I-Premise
283	15	_	_	I-Premise
284	%	_	_	I-Premise
285	)	_	_	I-Premise
286	in	_	_	I-Premise
287	the	_	_	I-Premise
288	laser	_	_	I-Premise
289	group	_	_	I-Premise
290	and	_	_	I-Premise
291	9	_	_	I-Premise
292	eyes	_	_	I-Premise
293	(	_	_	I-Premise
294	17	_	_	I-Premise
295	%	_	_	I-Premise
296	)	_	_	I-Premise
297	in	_	_	I-Premise
298	the	_	_	I-Premise
299	control	_	_	I-Premise
300	group	_	_	I-Premise
301	.	_	_	I-Premise

302	Survival	_	_	B-Claim
303	analyses	_	_	I-Claim
304	showed	_	_	I-Claim
305	no	_	_	I-Claim
306	evidence	_	_	I-Claim
307	of	_	_	I-Claim
308	any	_	_	I-Claim
309	difference	_	_	I-Claim
310	in	_	_	I-Claim
311	time	_	_	I-Claim
312	to	_	_	I-Claim
313	VF	_	_	I-Claim
314	progression	_	_	I-Claim
315	or	_	_	I-Claim
316	commencement	_	_	I-Claim
317	of	_	_	I-Claim
318	topical	_	_	I-Claim
319	therapy	_	_	I-Claim
320	between	_	_	I-Claim
321	the	_	_	I-Claim
322	2	_	_	I-Claim
323	groups	_	_	I-Claim
324	.	_	_	I-Claim

325	Cataract	_	_	B-Premise
326	extraction	_	_	I-Premise
327	was	_	_	I-Premise
328	performed	_	_	I-Premise
329	on	_	_	I-Premise
330	1	_	_	I-Premise
331	patient	_	_	I-Premise
332	in	_	_	I-Premise
333	the	_	_	I-Premise
334	laser	_	_	I-Premise
335	group	_	_	I-Premise
336	and	_	_	I-Premise
337	in	_	_	I-Premise
338	1	_	_	I-Premise
339	patient	_	_	I-Premise
340	in	_	_	I-Premise
341	the	_	_	I-Premise
342	control	_	_	I-Premise
343	group	_	_	I-Premise
344	during	_	_	I-Premise
345	the	_	_	I-Premise
346	study	_	_	I-Premise
347	period	_	_	I-Premise
348	(	_	_	I-Premise
349	laser	_	_	I-Premise
350	eye	_	_	I-Premise
351	at	_	_	I-Premise
352	18	_	_	I-Premise
353	months	_	_	I-Premise
354	;	_	_	I-Premise
355	control	_	_	I-Premise
356	eye	_	_	I-Premise
357	at	_	_	I-Premise
358	34	_	_	I-Premise
359	months	_	_	I-Premise
360	)	_	_	I-Premise
361	.	_	_	I-Premise

362	This	_	_	B-Claim
363	study	_	_	I-Claim
364	suggests	_	_	I-Claim
365	that	_	_	I-Claim
366	there	_	_	I-Claim
367	was	_	_	I-Claim
368	no	_	_	I-Claim
369	benefit	_	_	I-Claim
370	of	_	_	I-Claim
371	Nd	_	_	I-Claim
372	:	_	_	I-Claim
373	YAG	_	_	I-Claim
374	LPI	_	_	I-Claim
375	in	_	_	I-Claim
376	preventing	_	_	I-Claim
377	progression	_	_	I-Claim
378	from	_	_	I-Claim
379	PDS	_	_	I-Claim
380	with	_	_	I-Claim
381	OHT	_	_	I-Claim
382	to	_	_	I-Claim
383	PG	_	_	I-Claim
384	within	_	_	I-Claim
385	3	_	_	I-Claim
386	years	_	_	I-Claim
387	of	_	_	I-Claim
388	follow-up	_	_	I-Claim
389	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	analgesic	_	_	O
4	effect	_	_	O
5	of	_	_	O
6	supplemental	_	_	O
7	intracameral	_	_	O
8	lidocaine	_	_	O
9	1	_	_	O
10	%	_	_	O
11	during	_	_	O
12	phacoemulsification	_	_	O
13	under	_	_	O
14	topical	_	_	O
15	anaesthesia	_	_	O
16	,	_	_	O
17	and	_	_	O
18	to	_	_	O
19	assess	_	_	O
20	the	_	_	O
21	risk	_	_	O
22	factors	_	_	O
23	associated	_	_	O
24	with	_	_	O
25	pain	_	_	O
26	.	_	_	O

27	In	_	_	O
28	a	_	_	O
29	double-masked	_	_	O
30	,	_	_	O
31	randomised	_	_	O
32	,	_	_	O
33	clinical	_	_	O
34	trial	_	_	O
35	,	_	_	O
36	506	_	_	O
37	patients	_	_	O
38	undergoing	_	_	O
39	phacoemulsification	_	_	O
40	under	_	_	O
41	topical	_	_	O
42	anaesthesia	_	_	O
43	were	_	_	O
44	randomised	_	_	O
45	to	_	_	O
46	receive	_	_	O
47	a	_	_	O
48	supplemental	_	_	O
49	intracameral	_	_	O
50	injection	_	_	O
51	of	_	_	O
52	either	_	_	O
53	0.5	_	_	O
54	cc	_	_	O
55	of	_	_	O
56	1	_	_	O
57	%	_	_	O
58	lidocaine	_	_	O
59	(	_	_	O
60	277	_	_	O
61	patients	_	_	O
62	,	_	_	O
63	54.7	_	_	O
64	%	_	_	O
65	)	_	_	O
66	or	_	_	O
67	balanced	_	_	O
68	salt	_	_	O
69	solution	_	_	O
70	(	_	_	O
71	BSS	_	_	O
72	)	_	_	O
73	(	_	_	O
74	229	_	_	O
75	patients	_	_	O
76	,	_	_	O
77	45.3	_	_	O
78	%	_	_	O
79	)	_	_	O
80	.	_	_	O

81	Patients	_	_	O
82	were	_	_	O
83	interviewed	_	_	O
84	by	_	_	O
85	a	_	_	O
86	trained	_	_	O
87	interviewer	_	_	O
88	using	_	_	O
89	a	_	_	O
90	standardised	_	_	O
91	questionnaire	_	_	O
92	.	_	_	O

93	The	_	_	O
94	main	_	_	O
95	outcome	_	_	O
96	measure	_	_	O
97	was	_	_	O
98	intraoperative	_	_	O
99	pain	_	_	O
100	,	_	_	O
101	scored	_	_	O
102	on	_	_	O
103	a	_	_	O
104	visual	_	_	O
105	analogue	_	_	O
106	scale	_	_	O
107	of	_	_	O
108	0-10	_	_	O
109	.	_	_	O

110	Logistic	_	_	O
111	regression	_	_	O
112	was	_	_	O
113	performed	_	_	O
114	to	_	_	O
115	assess	_	_	O
116	ORs	_	_	O
117	.	_	_	O

118	125	_	_	B-Premise
119	of	_	_	I-Premise
120	277	_	_	I-Premise
121	patients	_	_	I-Premise
122	(	_	_	I-Premise
123	45.1	_	_	I-Premise
124	%	_	_	I-Premise
125	)	_	_	I-Premise
126	experienced	_	_	I-Premise
127	pain	_	_	I-Premise
128	in	_	_	I-Premise
129	the	_	_	I-Premise
130	lidocaine	_	_	I-Premise
131	group	_	_	I-Premise
132	,	_	_	I-Premise
133	compared	_	_	I-Premise
134	with	_	_	I-Premise
135	123	_	_	I-Premise
136	of	_	_	I-Premise
137	229	_	_	I-Premise
138	patients	_	_	I-Premise
139	(	_	_	I-Premise
140	53.7	_	_	I-Premise
141	%	_	_	I-Premise
142	)	_	_	I-Premise
143	in	_	_	I-Premise
144	the	_	_	I-Premise
145	BSS	_	_	I-Premise
146	group	_	_	I-Premise
147	.	_	_	I-Premise

148	The	_	_	B-Claim
149	proportion	_	_	I-Claim
150	of	_	_	I-Claim
151	patients	_	_	I-Claim
152	who	_	_	I-Claim
153	experienced	_	_	I-Claim
154	pain	_	_	I-Claim
155	was	_	_	I-Claim
156	significantly	_	_	I-Claim
157	lower	_	_	I-Claim
158	in	_	_	I-Claim
159	the	_	_	I-Claim
160	intracameral	_	_	I-Claim
161	lidocaine	_	_	I-Claim
162	group	_	_	I-Claim
163	compared	_	_	I-Claim
164	with	_	_	I-Claim
165	the	_	_	I-Claim
166	BSS	_	_	I-Claim
167	group	_	_	I-Claim
168	(	_	_	I-Claim
169	multivariate	_	_	I-Claim
170	OR	_	_	I-Claim
171	0.68	_	_	I-Claim
172	,	_	_	I-Claim
173	95	_	_	I-Claim
174	%	_	_	I-Claim
175	CI	_	_	I-Claim
176	0.47	_	_	I-Claim
177	to	_	_	I-Claim
178	0.97	_	_	I-Claim
179	;	_	_	I-Claim
180	p=0.034	_	_	I-Claim
181	)	_	_	I-Claim
182	.	_	_	I-Claim

183	The	_	_	B-Premise
184	median	_	_	I-Premise
185	pain	_	_	I-Premise
186	score	_	_	I-Premise
187	(	_	_	I-Premise
188	range	_	_	I-Premise
189	)	_	_	I-Premise
190	was	_	_	I-Premise
191	0.0	_	_	I-Premise
192	for	_	_	I-Premise
193	intracameral	_	_	I-Premise
194	lidocaine	_	_	I-Premise
195	group	_	_	I-Premise
196	compared	_	_	I-Premise
197	with	_	_	I-Premise
198	1.0	_	_	I-Premise
199	for	_	_	I-Premise
200	BSS	_	_	I-Premise
201	group	_	_	I-Premise
202	(	_	_	I-Premise
203	p=0.039	_	_	I-Premise
204	)	_	_	I-Premise
205	.	_	_	I-Premise

206	Pain	_	_	B-Premise
207	was	_	_	I-Premise
208	more	_	_	I-Premise
209	common	_	_	I-Premise
210	in	_	_	I-Premise
211	females	_	_	I-Premise
212	(	_	_	I-Premise
213	54.3	_	_	I-Premise
214	%	_	_	I-Premise
215	vs	_	_	I-Premise
216	43.6	_	_	I-Premise
217	%	_	_	I-Premise
218	;	_	_	I-Premise
219	OR	_	_	I-Premise
220	1.56	_	_	I-Premise
221	)	_	_	I-Premise
222	,	_	_	I-Premise
223	non-Chinese	_	_	I-Premise
224	(	_	_	I-Premise
225	62.3	_	_	I-Premise
226	%	_	_	I-Premise
227	vs	_	_	I-Premise
228	46.9	_	_	I-Premise
229	%	_	_	I-Premise
230	;	_	_	I-Premise
231	OR	_	_	I-Premise
232	2.13	_	_	I-Premise
233	)	_	_	I-Premise
234	and	_	_	I-Premise
235	those	_	_	I-Premise
236	who	_	_	I-Premise
237	had	_	_	I-Premise
238	previous	_	_	I-Premise
239	cataract	_	_	I-Premise
240	surgery	_	_	I-Premise
241	to	_	_	I-Premise
242	the	_	_	I-Premise
243	fellow	_	_	I-Premise
244	eye	_	_	I-Premise
245	(	_	_	I-Premise
246	55.3	_	_	I-Premise
247	%	_	_	I-Premise
248	vs	_	_	I-Premise
249	44.7	_	_	I-Premise
250	%	_	_	I-Premise
251	;	_	_	I-Premise
252	OR	_	_	I-Premise
253	1.61	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	The	_	_	B-Claim
257	use	_	_	I-Claim
258	of	_	_	I-Claim
259	0.5	_	_	I-Claim
260	cc	_	_	I-Claim
261	of	_	_	I-Claim
262	1	_	_	I-Claim
263	%	_	_	I-Claim
264	intracameral	_	_	I-Claim
265	lidocaine	_	_	I-Claim
266	during	_	_	I-Claim
267	phacoemulsification	_	_	I-Claim
268	under	_	_	I-Claim
269	topical	_	_	I-Claim
270	anaesthesia	_	_	I-Claim
271	significantly	_	_	I-Claim
272	reduces	_	_	I-Claim
273	pain	_	_	I-Claim
274	experienced	_	_	I-Claim
275	by	_	_	I-Claim
276	patients	_	_	I-Claim
277	.	_	_	I-Claim

278	Risk	_	_	B-Claim
279	factors	_	_	I-Claim
280	for	_	_	I-Claim
281	pain	_	_	I-Claim
282	include	_	_	I-Claim
283	females	_	_	I-Claim
284	,	_	_	I-Claim
285	non-Chinese	_	_	I-Claim
286	and	_	_	I-Claim
287	previous	_	_	I-Claim
288	cataract	_	_	I-Claim
289	surgery	_	_	I-Claim
290	.	_	_	I-Claim


0	Brimonidine	_	_	O
1	is	_	_	O
2	a	_	_	O
3	highly	_	_	O
4	selective	_	_	O
5	alpha-2	_	_	O
6	adrenergic	_	_	O
7	receptor	_	_	O
8	agonist	_	_	O
9	with	_	_	O
10	intraocular	_	_	O
11	pressure	_	_	O
12	(	_	_	O
13	IOP	_	_	O
14	)	_	_	O
15	reducing	_	_	O
16	effect	_	_	O
17	.	_	_	O

18	We	_	_	O
19	conducted	_	_	O
20	this	_	_	O
21	study	_	_	O
22	in	_	_	O
23	Taiwan	_	_	O
24	to	_	_	O
25	compare	_	_	O
26	the	_	_	O
27	safety	_	_	O
28	and	_	_	O
29	efficacy	_	_	O
30	of	_	_	O
31	brimonidine	_	_	O
32	0.2	_	_	O
33	%	_	_	O
34	with	_	_	O
35	timolol	_	_	O
36	0.5	_	_	O
37	%	_	_	O
38	for	_	_	O
39	the	_	_	O
40	treatment	_	_	O
41	of	_	_	O
42	glaucoma	_	_	O
43	.	_	_	O

44	A	_	_	O
45	prospective	_	_	O
46	,	_	_	O
47	randomized	_	_	O
48	,	_	_	O
49	single-masked	_	_	O
50	,	_	_	O
51	1-month	_	_	O
52	clinical	_	_	O
53	efficacy	_	_	O
54	and	_	_	O
55	safety	_	_	O
56	trial	_	_	O
57	was	_	_	O
58	conducted	_	_	O
59	from	_	_	O
60	March	_	_	O
61	to	_	_	O
62	September	_	_	O
63	2000	_	_	O
64	.	_	_	O

65	Forty	_	_	O
66	glaucoma	_	_	O
67	patients	_	_	O
68	were	_	_	O
69	enrolled	_	_	O
70	--	_	_	O
71	29	_	_	O
72	in	_	_	O
73	the	_	_	O
74	brimonidine	_	_	O
75	group	_	_	O
76	and	_	_	O
77	11	_	_	O
78	in	_	_	O
79	the	_	_	O
80	timolol	_	_	O
81	group	_	_	O
82	.	_	_	O

83	Patients	_	_	O
84	instilled	_	_	O
85	their	_	_	O
86	study	_	_	O
87	medications	_	_	O
88	twice	_	_	O
89	daily	_	_	O
90	for	_	_	O
91	4	_	_	O
92	weeks	_	_	O
93	,	_	_	O
94	and	_	_	O
95	were	_	_	O
96	followed	_	_	O
97	at	_	_	O
98	baseline	_	_	O
99	visit	_	_	O
100	,	_	_	O
101	weeks	_	_	O
102	2	_	_	O
103	and	_	_	O
104	4	_	_	O
105	.	_	_	O

106	Demographic	_	_	O
107	data	_	_	O
108	,	_	_	O
109	reduction	_	_	O
110	of	_	_	O
111	IOP	_	_	O
112	,	_	_	O
113	safety	_	_	O
114	and	_	_	O
115	adverse	_	_	O
116	events	_	_	O
117	were	_	_	O
118	obtained	_	_	O
119	and	_	_	O
120	analyzed	_	_	O
121	.	_	_	O

122	Both	_	_	O
123	drugs	_	_	O
124	showed	_	_	O
125	sustained	_	_	O
126	ocular	_	_	O
127	hypotensive	_	_	O
128	efficacy	_	_	O
129	in	_	_	O
130	the	_	_	O
131	study	_	_	O
132	period	_	_	O
133	.	_	_	O

134	At	_	_	B-Premise
135	baseline	_	_	I-Premise
136	,	_	_	I-Premise
137	the	_	_	I-Premise
138	mean	_	_	I-Premise
139	IOP	_	_	I-Premise
140	was	_	_	I-Premise
141	24.48	_	_	I-Premise
142	+/-	_	_	I-Premise
143	2.29	_	_	I-Premise
144	mmHg	_	_	I-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	brimonidine	_	_	I-Premise
148	group	_	_	I-Premise
149	and	_	_	I-Premise
150	23.32	_	_	I-Premise
151	+/-	_	_	I-Premise
152	0.82	_	_	I-Premise
153	mmHg	_	_	I-Premise
154	in	_	_	I-Premise
155	the	_	_	I-Premise
156	timolol	_	_	I-Premise
157	group	_	_	I-Premise
158	.	_	_	I-Premise

159	The	_	_	B-Premise
160	IOP	_	_	I-Premise
161	readings	_	_	I-Premise
162	after	_	_	I-Premise
163	treatment	_	_	I-Premise
164	were	_	_	I-Premise
165	significantly	_	_	I-Premise
166	lower	_	_	I-Premise
167	than	_	_	I-Premise
168	their	_	_	I-Premise
169	baseline	_	_	I-Premise
170	levels	_	_	I-Premise
171	in	_	_	I-Premise
172	both	_	_	I-Premise
173	groups	_	_	I-Premise
174	at	_	_	I-Premise
175	all	_	_	I-Premise
176	visits	_	_	I-Premise
177	(	_	_	I-Premise
178	p	_	_	I-Premise
179	<	_	_	I-Premise
180	0.001	_	_	I-Premise
181	)	_	_	I-Premise
182	.	_	_	I-Premise

183	At	_	_	B-Premise
184	peak	_	_	I-Premise
185	,	_	_	I-Premise
186	the	_	_	I-Premise
187	mean	_	_	I-Premise
188	decreases	_	_	I-Premise
189	from	_	_	I-Premise
190	the	_	_	I-Premise
191	baseline	_	_	I-Premise
192	IOP	_	_	I-Premise
193	ranged	_	_	I-Premise
194	from	_	_	I-Premise
195	5.22	_	_	I-Premise
196	+/-	_	_	I-Premise
197	0.30	_	_	I-Premise
198	mmHg	_	_	I-Premise
199	to	_	_	I-Premise
200	6.96	_	_	I-Premise
201	+/-	_	_	I-Premise
202	0.33	_	_	I-Premise
203	mmHg	_	_	I-Premise
204	for	_	_	I-Premise
205	brimonidine	_	_	I-Premise
206	and	_	_	I-Premise
207	from	_	_	I-Premise
208	4.55	_	_	I-Premise
209	+/-	_	_	I-Premise
210	0.49	_	_	I-Premise
211	mmHg	_	_	I-Premise
212	to	_	_	I-Premise
213	6.64	_	_	I-Premise
214	+/-	_	_	I-Premise
215	0.53	_	_	I-Premise
216	mmHg	_	_	I-Premise
217	for	_	_	I-Premise
218	timolol	_	_	I-Premise
219	.	_	_	I-Premise

220	At	_	_	B-Premise
221	trough	_	_	I-Premise
222	,	_	_	I-Premise
223	the	_	_	I-Premise
224	mean	_	_	I-Premise
225	decreases	_	_	I-Premise
226	from	_	_	I-Premise
227	baseline	_	_	I-Premise
228	ranged	_	_	I-Premise
229	from	_	_	I-Premise
230	3.72	_	_	I-Premise
231	+/-	_	_	I-Premise
232	0.32	_	_	I-Premise
233	mmHg	_	_	I-Premise
234	to	_	_	I-Premise
235	4.55	_	_	I-Premise
236	+/-	_	_	I-Premise
237	0.32	_	_	I-Premise
238	mmHg	_	_	I-Premise
239	for	_	_	I-Premise
240	brimonidine	_	_	I-Premise
241	and	_	_	I-Premise
242	3.82	_	_	I-Premise
243	+/-	_	_	I-Premise
244	0.52	_	_	I-Premise
245	mmHg	_	_	I-Premise
246	to	_	_	I-Premise
247	4.27	_	_	I-Premise
248	+/-	_	_	I-Premise
249	0.51	_	_	I-Premise
250	mmHg	_	_	I-Premise
251	for	_	_	I-Premise
252	timolol	_	_	I-Premise
253	.	_	_	I-Premise

254	No	_	_	O
255	significant	_	_	O
256	between-group	_	_	O
257	differences	_	_	O
258	were	_	_	O
259	seen	_	_	O
260	at	_	_	O
261	peak	_	_	O
262	or	_	_	O
263	trough	_	_	O
264	at	_	_	O
265	all	_	_	O
266	visits	_	_	O
267	.	_	_	O

268	The	_	_	B-Premise
269	clinical	_	_	I-Premise
270	success	_	_	I-Premise
271	rate	_	_	I-Premise
272	was	_	_	I-Premise
273	86.2	_	_	I-Premise
274	%	_	_	I-Premise
275	in	_	_	I-Premise
276	the	_	_	I-Premise
277	brimonidine	_	_	I-Premise
278	group	_	_	I-Premise
279	and	_	_	I-Premise
280	81.8	_	_	I-Premise
281	%	_	_	I-Premise
282	in	_	_	I-Premise
283	the	_	_	I-Premise
284	timolol	_	_	I-Premise
285	group	_	_	I-Premise
286	,	_	_	I-Premise
287	making	_	_	I-Premise
288	no	_	_	I-Premise
289	statistically	_	_	I-Premise
290	significant	_	_	I-Premise
291	difference	_	_	I-Premise
292	between	_	_	I-Premise
293	them	_	_	I-Premise
294	(	_	_	I-Premise
295	p	_	_	I-Premise
296	=	_	_	I-Premise
297	0.817	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	17.2	_	_	B-Premise
301	%	_	_	I-Premise
302	of	_	_	I-Premise
303	patients	_	_	I-Premise
304	in	_	_	I-Premise
305	brimonidine	_	_	I-Premise
306	group	_	_	I-Premise
307	and	_	_	I-Premise
308	9.0	_	_	I-Premise
309	%	_	_	I-Premise
310	patients	_	_	I-Premise
311	in	_	_	I-Premise
312	timolol	_	_	I-Premise
313	group	_	_	I-Premise
314	reported	_	_	I-Premise
315	mild	_	_	I-Premise
316	adverse	_	_	I-Premise
317	events	_	_	I-Premise
318	.	_	_	I-Premise

319	Ocular	_	_	B-Premise
320	allergy	_	_	I-Premise
321	occurred	_	_	I-Premise
322	in	_	_	I-Premise
323	10.3	_	_	I-Premise
324	%	_	_	I-Premise
325	of	_	_	I-Premise
326	patients	_	_	I-Premise
327	in	_	_	I-Premise
328	brimonidine	_	_	I-Premise
329	group	_	_	I-Premise
330	.	_	_	I-Premise

331	No	_	_	B-Premise
332	significant	_	_	I-Premise
333	changes	_	_	I-Premise
334	in	_	_	I-Premise
335	visual	_	_	I-Premise
336	acuity	_	_	I-Premise
337	,	_	_	I-Premise
338	biomicroscopy	_	_	I-Premise
339	or	_	_	I-Premise
340	ophthalmoscopy	_	_	I-Premise
341	were	_	_	I-Premise
342	observed	_	_	I-Premise
343	in	_	_	I-Premise
344	both	_	_	I-Premise
345	groups	_	_	I-Premise
346	.	_	_	I-Premise

347	Mean	_	_	B-Premise
348	systolic	_	_	I-Premise
349	and	_	_	I-Premise
350	diastolic	_	_	I-Premise
351	blood	_	_	I-Premise
352	pressure	_	_	I-Premise
353	remained	_	_	I-Premise
354	relatively	_	_	I-Premise
355	stable	_	_	I-Premise
356	in	_	_	I-Premise
357	both	_	_	I-Premise
358	groups	_	_	I-Premise
359	except	_	_	B-Premise
360	in	_	_	I-Premise
361	week	_	_	I-Premise
362	2	_	_	I-Premise
363	(	_	_	I-Premise
364	p	_	_	I-Premise
365	=	_	_	I-Premise
366	0.016	_	_	I-Premise
367	)	_	_	I-Premise
368	when	_	_	I-Premise
369	brimonidine	_	_	I-Premise
370	had	_	_	I-Premise
371	lower	_	_	I-Premise
372	systolic	_	_	I-Premise
373	blood	_	_	I-Premise
374	pressure	_	_	I-Premise
375	.	_	_	I-Premise

376	However	_	_	O
377	,	_	_	O
378	brimonidine	_	_	O
379	showed	_	_	O
380	no	_	_	O
381	significant	_	_	O
382	difference	_	_	O
383	in	_	_	O
384	week	_	_	O
385	4	_	_	O
386	from	_	_	O
387	baseline	_	_	O
388	.	_	_	O

389	The	_	_	B-Premise
390	mean	_	_	I-Premise
391	heart	_	_	I-Premise
392	rate	_	_	I-Premise
393	in	_	_	I-Premise
394	the	_	_	I-Premise
395	brimonidine	_	_	I-Premise
396	group	_	_	I-Premise
397	was	_	_	I-Premise
398	relatively	_	_	I-Premise
399	unchanged	_	_	I-Premise
400	over	_	_	I-Premise
401	the	_	_	I-Premise
402	study	_	_	I-Premise
403	period	_	_	I-Premise
404	.	_	_	I-Premise

405	Patients	_	_	B-Premise
406	receiving	_	_	I-Premise
407	timolol	_	_	I-Premise
408	experienced	_	_	I-Premise
409	statistically	_	_	I-Premise
410	significant	_	_	I-Premise
411	mean	_	_	I-Premise
412	heart	_	_	I-Premise
413	rate	_	_	I-Premise
414	decreases	_	_	I-Premise
415	from	_	_	I-Premise
416	baseline	_	_	I-Premise
417	(	_	_	I-Premise
418	p	_	_	I-Premise
419	=	_	_	I-Premise
420	0.020	_	_	I-Premise
421	)	_	_	I-Premise
422	in	_	_	I-Premise
423	week	_	_	I-Premise
424	4	_	_	I-Premise
425	.	_	_	I-Premise

426	Topically	_	_	B-Claim
427	applied	_	_	I-Claim
428	twice	_	_	I-Claim
429	daily	_	_	I-Claim
430	for	_	_	I-Claim
431	one	_	_	I-Claim
432	month	_	_	I-Claim
433	,	_	_	I-Claim
434	brimonidine	_	_	I-Claim
435	tartrate	_	_	I-Claim
436	0.2	_	_	I-Claim
437	%	_	_	I-Claim
438	has	_	_	I-Claim
439	clinical	_	_	I-Claim
440	effectiveness	_	_	I-Claim
441	equivalent	_	_	I-Claim
442	to	_	_	I-Claim
443	timolol	_	_	I-Claim
444	0.5	_	_	I-Claim
445	%	_	_	I-Claim
446	in	_	_	I-Claim
447	Taiwanese	_	_	I-Claim
448	patients	_	_	I-Claim
449	with	_	_	I-Claim
450	glaucoma	_	_	I-Claim
451	.	_	_	I-Claim

452	It	_	_	B-Claim
453	has	_	_	I-Claim
454	a	_	_	I-Claim
455	safe	_	_	I-Claim
456	systemic	_	_	I-Claim
457	profile	_	_	I-Claim
458	with	_	_	I-Claim
459	minimum	_	_	I-Claim
460	effect	_	_	I-Claim
461	on	_	_	I-Claim
462	the	_	_	I-Claim
463	heart	_	_	I-Claim
464	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	intraoperative	_	_	O
8	mitomycin	_	_	O
9	C	_	_	O
10	(	_	_	O
11	MMC	_	_	O
12	)	_	_	O
13	in	_	_	O
14	eyes	_	_	O
15	undergoing	_	_	O
16	Ahmed	_	_	O
17	Glaucoma	_	_	O
18	Valve	_	_	O
19	implantation	_	_	O
20	.	_	_	O

21	Randomized	_	_	O
22	controlled	_	_	O
23	clinical	_	_	O
24	trial	_	_	O
25	.	_	_	O

26	Sixty	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	refractory	_	_	O
30	glaucoma	_	_	O
31	.	_	_	O

32	Sixty	_	_	O
33	eyes	_	_	O
34	of	_	_	O
35	60	_	_	O
36	patients	_	_	O
37	with	_	_	O
38	refractory	_	_	O
39	glaucoma	_	_	O
40	were	_	_	O
41	randomized	_	_	O
42	to	_	_	O
43	receive	_	_	O
44	intraoperative	_	_	O
45	MMC	_	_	O
46	(	_	_	O
47	0.5	_	_	O
48	mg/ml	_	_	O
49	for	_	_	O
50	5	_	_	O
51	minutes	_	_	O
52	)	_	_	O
53	(	_	_	O
54	n	_	_	O
55	=	_	_	O
56	34	_	_	O
57	)	_	_	O
58	or	_	_	O
59	balanced	_	_	O
60	salt	_	_	O
61	solution	_	_	O
62	(	_	_	O
63	n	_	_	O
64	=	_	_	O
65	26	_	_	O
66	)	_	_	O
67	during	_	_	O
68	Ahmed	_	_	O
69	Glaucoma	_	_	O
70	Valve	_	_	O
71	implantation	_	_	O
72	.	_	_	O

73	Surgical	_	_	O
74	success	_	_	O
75	was	_	_	O
76	defined	_	_	O
77	according	_	_	O
78	to	_	_	O
79	2	_	_	O
80	different	_	_	O
81	criteria	_	_	O
82	:	_	_	O
83	(	_	_	O
84	1	_	_	O
85	)	_	_	O
86	postoperative	_	_	O
87	intraocular	_	_	O
88	pressure	_	_	O
89	(	_	_	O
90	IOP	_	_	O
91	)	_	_	O
92	between	_	_	O
93	6	_	_	O
94	and	_	_	O
95	21	_	_	O
96	mmHg	_	_	O
97	,	_	_	O
98	with	_	_	O
99	or	_	_	O
100	without	_	_	O
101	antiglaucoma	_	_	O
102	medications	_	_	O
103	,	_	_	O
104	and	_	_	O
105	(	_	_	O
106	2	_	_	O
107	)	_	_	O
108	IOP	_	_	O
109	reduction	_	_	O
110	of	_	_	O
111	at	_	_	O
112	least	_	_	O
113	30	_	_	O
114	%	_	_	O
115	relative	_	_	O
116	to	_	_	O
117	preoperative	_	_	O
118	values	_	_	O
119	.	_	_	O

120	Eyes	_	_	O
121	requiring	_	_	O
122	additional	_	_	O
123	glaucoma	_	_	O
124	surgery	_	_	O
125	,	_	_	O
126	developing	_	_	O
127	phthisis	_	_	O
128	,	_	_	O
129	or	_	_	O
130	showing	_	_	O
131	loss	_	_	O
132	of	_	_	O
133	light	_	_	O
134	perception	_	_	O
135	were	_	_	O
136	classified	_	_	O
137	as	_	_	O
138	failures	_	_	O
139	.	_	_	O

140	Success	_	_	O
141	rates	_	_	O
142	in	_	_	O
143	both	_	_	O
144	groups	_	_	O
145	were	_	_	O
146	compared	_	_	O
147	using	_	_	O
148	Kaplan-Meier	_	_	O
149	survival	_	_	O
150	curves	_	_	O
151	and	_	_	O
152	the	_	_	O
153	log	_	_	O
154	rank	_	_	O
155	test	_	_	O
156	.	_	_	O

157	Other	_	_	O
158	outcome	_	_	O
159	measures	_	_	O
160	were	_	_	O
161	mean	_	_	O
162	IOP	_	_	O
163	,	_	_	O
164	number	_	_	O
165	of	_	_	O
166	glaucoma	_	_	O
167	medications	_	_	O
168	,	_	_	O
169	and	_	_	O
170	complications	_	_	O
171	.	_	_	O

172	After	_	_	B-Premise
173	a	_	_	I-Premise
174	mean	_	_	I-Premise
175	follow-up	_	_	I-Premise
176	of	_	_	I-Premise
177	12.3	_	_	I-Premise
178	months	_	_	I-Premise
179	,	_	_	I-Premise
180	Kaplan-Meier	_	_	I-Premise
181	survival	_	_	I-Premise
182	analysis	_	_	I-Premise
183	showed	_	_	I-Premise
184	a	_	_	I-Premise
185	probability	_	_	I-Premise
186	of	_	_	I-Premise
187	success	_	_	I-Premise
188	of	_	_	I-Premise
189	59	_	_	I-Premise
190	%	_	_	I-Premise
191	at	_	_	I-Premise
192	18	_	_	I-Premise
193	months	_	_	I-Premise
194	for	_	_	I-Premise
195	the	_	_	I-Premise
196	MMC	_	_	I-Premise
197	group	_	_	I-Premise
198	and	_	_	I-Premise
199	61	_	_	I-Premise
200	%	_	_	I-Premise
201	for	_	_	I-Premise
202	the	_	_	I-Premise
203	control	_	_	I-Premise
204	group	_	_	I-Premise
205	when	_	_	I-Premise
206	the	_	_	I-Premise
207	first	_	_	I-Premise
208	criterion	_	_	I-Premise
209	for	_	_	I-Premise
210	success	_	_	I-Premise
211	was	_	_	I-Premise
212	used	_	_	I-Premise
213	(	_	_	I-Premise
214	IOP	_	_	I-Premise
215	between	_	_	I-Premise
216	6	_	_	I-Premise
217	and	_	_	I-Premise
218	21	_	_	I-Premise
219	mmHg	_	_	I-Premise
220	)	_	_	I-Premise
221	.	_	_	I-Premise

222	When	_	_	B-Premise
223	an	_	_	I-Premise
224	IOP	_	_	I-Premise
225	reduction	_	_	I-Premise
226	of	_	_	I-Premise
227	at	_	_	I-Premise
228	least	_	_	I-Premise
229	30	_	_	I-Premise
230	%	_	_	I-Premise
231	was	_	_	I-Premise
232	used	_	_	I-Premise
233	as	_	_	I-Premise
234	the	_	_	I-Premise
235	criterion	_	_	I-Premise
236	to	_	_	I-Premise
237	define	_	_	I-Premise
238	success	_	_	I-Premise
239	,	_	_	I-Premise
240	the	_	_	I-Premise
241	Kaplan-Meier	_	_	I-Premise
242	survival	_	_	I-Premise
243	analysis	_	_	I-Premise
244	demonstrated	_	_	I-Premise
245	a	_	_	I-Premise
246	probability	_	_	I-Premise
247	of	_	_	I-Premise
248	success	_	_	I-Premise
249	at	_	_	I-Premise
250	18	_	_	I-Premise
251	months	_	_	I-Premise
252	of	_	_	I-Premise
253	62	_	_	I-Premise
254	%	_	_	I-Premise
255	for	_	_	I-Premise
256	the	_	_	I-Premise
257	MMC	_	_	I-Premise
258	group	_	_	I-Premise
259	and	_	_	I-Premise
260	67	_	_	I-Premise
261	%	_	_	I-Premise
262	for	_	_	I-Premise
263	the	_	_	I-Premise
264	control	_	_	I-Premise
265	group	_	_	I-Premise
266	.	_	_	I-Premise

267	There	_	_	B-Premise
268	were	_	_	I-Premise
269	no	_	_	I-Premise
270	significant	_	_	I-Premise
271	differences	_	_	I-Premise
272	in	_	_	I-Premise
273	survival	_	_	I-Premise
274	rates	_	_	I-Premise
275	between	_	_	I-Premise
276	the	_	_	I-Premise
277	2	_	_	I-Premise
278	groups	_	_	I-Premise
279	with	_	_	I-Premise
280	either	_	_	I-Premise
281	criterion	_	_	I-Premise
282	(	_	_	I-Premise
283	P	_	_	I-Premise
284	=	_	_	I-Premise
285	0.75	_	_	I-Premise
286	and	_	_	I-Premise
287	P	_	_	I-Premise
288	=	_	_	I-Premise
289	0.37	_	_	I-Premise
290	,	_	_	I-Premise
291	respectively	_	_	I-Premise
292	)	_	_	I-Premise
293	.	_	_	I-Premise

294	After	_	_	B-Premise
295	15	_	_	I-Premise
296	days	_	_	I-Premise
297	postoperatively	_	_	I-Premise
298	,	_	_	I-Premise
299	the	_	_	I-Premise
300	mean	_	_	I-Premise
301	IOP	_	_	I-Premise
302	did	_	_	I-Premise
303	not	_	_	I-Premise
304	significantly	_	_	I-Premise
305	differ	_	_	I-Premise
306	for	_	_	I-Premise
307	both	_	_	I-Premise
308	MMC	_	_	I-Premise
309	and	_	_	I-Premise
310	control	_	_	I-Premise
311	eyes	_	_	I-Premise
312	.	_	_	I-Premise

313	Mean	_	_	B-Premise
314	numbers	_	_	I-Premise
315	of	_	_	I-Premise
316	postoperative	_	_	I-Premise
317	antiglaucoma	_	_	I-Premise
318	medications	_	_	I-Premise
319	were	_	_	I-Premise
320	similar	_	_	I-Premise
321	in	_	_	I-Premise
322	MMC-treated	_	_	I-Premise
323	eyes	_	_	I-Premise
324	and	_	_	I-Premise
325	controls	_	_	I-Premise
326	.	_	_	I-Premise

327	There	_	_	B-Premise
328	was	_	_	I-Premise
329	no	_	_	I-Premise
330	significant	_	_	I-Premise
331	difference	_	_	I-Premise
332	between	_	_	I-Premise
333	the	_	_	I-Premise
334	incidences	_	_	I-Premise
335	of	_	_	I-Premise
336	postoperative	_	_	I-Premise
337	complications	_	_	I-Premise
338	in	_	_	I-Premise
339	both	_	_	I-Premise
340	groups	_	_	I-Premise
341	.	_	_	I-Premise

342	Mitomycin	_	_	B-Claim
343	C	_	_	I-Claim
344	did	_	_	I-Claim
345	not	_	_	I-Claim
346	increase	_	_	I-Claim
347	the	_	_	I-Claim
348	short-	_	_	I-Claim
349	or	_	_	I-Claim
350	intermediate-term	_	_	I-Claim
351	success	_	_	I-Claim
352	rates	_	_	I-Claim
353	of	_	_	I-Claim
354	Ahmed	_	_	I-Claim
355	Glaucoma	_	_	I-Claim
356	Valve	_	_	I-Claim
357	implantation	_	_	I-Claim
358	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	the	_	_	O
6	fixed	_	_	O
7	dorzolamide	_	_	O
8	2	_	_	O
9	%	_	_	O
10	/timolol	_	_	O
11	0.5	_	_	O
12	%	_	_	O
13	combination	_	_	O
14	(	_	_	O
15	COSOPT	_	_	O
16	)	_	_	O
17	versus	_	_	O
18	latanoprost	_	_	O
19	0.005	_	_	O
20	%	_	_	O
21	(	_	_	O
22	XALATAN	_	_	O
23	)	_	_	O
24	.	_	_	O

25	Two	_	_	O
26	3-month	_	_	O
27	,	_	_	O
28	parallel	_	_	O
29	group	_	_	O
30	,	_	_	O
31	randomized	_	_	O
32	,	_	_	O
33	observer-masked	_	_	O
34	and	_	_	O
35	patient-masked	_	_	O
36	,	_	_	O
37	multicentre	_	_	O
38	,	_	_	O
39	clinical	_	_	O
40	trials	_	_	O
41	were	_	_	O
42	performed	_	_	O
43	in	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	ocular	_	_	O
47	hypertension	_	_	O
48	or	_	_	O
49	open-angle	_	_	O
50	glaucoma	_	_	O
51	.	_	_	O

52	Study	_	_	O
53	1	_	_	O
54	(	_	_	O
55	n=256	_	_	O
56	)	_	_	O
57	was	_	_	O
58	conducted	_	_	O
59	in	_	_	O
60	the	_	_	O
61	United	_	_	O
62	States	_	_	O
63	and	_	_	O
64	Study	_	_	O
65	2	_	_	O
66	(	_	_	O
67	n=288	_	_	O
68	)	_	_	O
69	was	_	_	O
70	conducted	_	_	O
71	in	_	_	O
72	Europe/Israel	_	_	O
73	.	_	_	O

74	Patients	_	_	O
75	could	_	_	O
76	be	_	_	O
77	included	_	_	O
78	whether	_	_	O
79	or	_	_	O
80	not	_	_	O
81	they	_	_	O
82	were	_	_	O
83	currently	_	_	O
84	taking	_	_	O
85	ocular	_	_	O
86	hypotensive	_	_	O
87	therapy	_	_	O
88	,	_	_	O
89	and	_	_	O
90	regardless	_	_	O
91	of	_	_	O
92	the	_	_	O
93	effectiveness	_	_	O
94	of	_	_	O
95	any	_	_	O
96	previous	_	_	O
97	therapy	_	_	O
98	.	_	_	O

99	Patients	_	_	O
100	were	_	_	O
101	washed	_	_	O
102	out	_	_	O
103	from	_	_	O
104	their	_	_	O
105	usual	_	_	O
106	ocular	_	_	O
107	hypotensive	_	_	O
108	medications	_	_	O
109	and	_	_	O
110	then	_	_	O
111	those	_	_	O
112	with	_	_	O
113	a	_	_	O
114	baseline	_	_	O
115	intraocular	_	_	O
116	pressure	_	_	O
117	(	_	_	O
118	IOP	_	_	O
119	)	_	_	O
120	>	_	_	O
121	/=	_	_	O
122	24	_	_	O
123	mmHg	_	_	O
124	were	_	_	O
125	randomized	_	_	O
126	to	_	_	O
127	either	_	_	O
128	the	_	_	O
129	dorzolamide/timolol	_	_	O
130	combination	_	_	O
131	eye	_	_	O
132	drops	_	_	O
133	twice	_	_	O
134	daily	_	_	O
135	or	_	_	O
136	latanoprost	_	_	O
137	eye	_	_	O
138	drops	_	_	O
139	once	_	_	O
140	daily	_	_	O
141	in	_	_	O
142	both	_	_	O
143	eyes	_	_	O
144	.	_	_	O

145	Efficacy	_	_	O
146	was	_	_	O
147	assessed	_	_	O
148	by	_	_	O
149	daytime	_	_	O
150	diurnal	_	_	O
151	IOP	_	_	O
152	(	_	_	O
153	the	_	_	O
154	mean	_	_	O
155	of	_	_	O
156	measurements	_	_	O
157	made	_	_	O
158	at	_	_	O
159	0800	_	_	O
160	,	_	_	O
161	1000	_	_	O
162	,	_	_	O
163	1400	_	_	O
164	and	_	_	O
165	1600	_	_	O
166	h	_	_	O
167	)	_	_	O
168	.	_	_	O

169	At	_	_	B-Premise
170	baseline	_	_	I-Premise
171	,	_	_	I-Premise
172	the	_	_	I-Premise
173	mean	_	_	I-Premise
174	daytime	_	_	I-Premise
175	diurnal	_	_	I-Premise
176	IOP	_	_	I-Premise
177	was	_	_	I-Premise
178	26.1	_	_	I-Premise
179	mmHg	_	_	I-Premise
180	in	_	_	I-Premise
181	the	_	_	I-Premise
182	dorzolamide/timolol	_	_	I-Premise
183	combination	_	_	I-Premise
184	group	_	_	I-Premise
185	versus	_	_	I-Premise
186	25.6	_	_	I-Premise
187	mmHg	_	_	I-Premise
188	in	_	_	I-Premise
189	the	_	_	I-Premise
190	latanoprost	_	_	I-Premise
191	group	_	_	I-Premise
192	in	_	_	I-Premise
193	Study	_	_	I-Premise
194	1	_	_	I-Premise
195	,	_	_	I-Premise
196	and	_	_	I-Premise
197	25.3	_	_	I-Premise
198	mmHg	_	_	I-Premise
199	in	_	_	I-Premise
200	the	_	_	I-Premise
201	dorzolamide/timolol	_	_	I-Premise
202	combination	_	_	I-Premise
203	group	_	_	I-Premise
204	versus	_	_	I-Premise
205	24.7	_	_	I-Premise
206	mmHg	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	latanoprost	_	_	I-Premise
210	group	_	_	I-Premise
211	in	_	_	I-Premise
212	Study	_	_	I-Premise
213	2	_	_	I-Premise
214	.	_	_	I-Premise

215	After	_	_	B-Premise
216	3	_	_	I-Premise
217	months	_	_	I-Premise
218	,	_	_	I-Premise
219	the	_	_	I-Premise
220	mean	_	_	I-Premise
221	daytime	_	_	I-Premise
222	diurnal	_	_	I-Premise
223	IOP	_	_	I-Premise
224	was	_	_	I-Premise
225	18.9	_	_	I-Premise
226	mmHg	_	_	I-Premise
227	for	_	_	I-Premise
228	the	_	_	I-Premise
229	dorzolamide/timolol	_	_	I-Premise
230	combination	_	_	I-Premise
231	versus	_	_	I-Premise
232	18.4	_	_	I-Premise
233	mmHg	_	_	I-Premise
234	for	_	_	I-Premise
235	latanoprost	_	_	I-Premise
236	in	_	_	I-Premise
237	Study	_	_	I-Premise
238	1	_	_	I-Premise
239	,	_	_	I-Premise
240	and	_	_	I-Premise
241	17.4	_	_	I-Premise
242	mmHg	_	_	I-Premise
243	for	_	_	I-Premise
244	the	_	_	I-Premise
245	dorzolamide/timolol	_	_	I-Premise
246	combination	_	_	I-Premise
247	versus	_	_	I-Premise
248	17.5	_	_	I-Premise
249	for	_	_	I-Premise
250	latanoprost	_	_	I-Premise
251	in	_	_	I-Premise
252	Study	_	_	I-Premise
253	2	_	_	I-Premise
254	.	_	_	I-Premise

255	The	_	_	B-Premise
256	difference	_	_	I-Premise
257	between	_	_	I-Premise
258	treatments	_	_	I-Premise
259	in	_	_	I-Premise
260	mean	_	_	I-Premise
261	IOP	_	_	I-Premise
262	change	_	_	I-Premise
263	at	_	_	I-Premise
264	3	_	_	I-Premise
265	months	_	_	I-Premise
266	was	_	_	I-Premise
267	-0.04	_	_	I-Premise
268	mmHg	_	_	I-Premise
269	[	_	_	I-Premise
270	95	_	_	I-Premise
271	%	_	_	I-Premise
272	confidence	_	_	I-Premise
273	interval	_	_	I-Premise
274	(	_	_	I-Premise
275	CI	_	_	I-Premise
276	)	_	_	I-Premise
277	-0.85	_	_	I-Premise
278	,	_	_	I-Premise
279	0.77	_	_	I-Premise
280	]	_	_	I-Premise
281	in	_	_	I-Premise
282	Study	_	_	I-Premise
283	1	_	_	I-Premise
284	,	_	_	I-Premise
285	and	_	_	I-Premise
286	-0.57	_	_	I-Premise
287	mmHg	_	_	I-Premise
288	(	_	_	I-Premise
289	95	_	_	I-Premise
290	%	_	_	I-Premise
291	CI	_	_	I-Premise
292	-1.31	_	_	I-Premise
293	,	_	_	I-Premise
294	0.16	_	_	I-Premise
295	)	_	_	I-Premise
296	in	_	_	I-Premise
297	Study	_	_	I-Premise
298	2	_	_	I-Premise
299	.	_	_	I-Premise

300	The	_	_	B-Premise
301	probability	_	_	I-Premise
302	that	_	_	I-Premise
303	the	_	_	I-Premise
304	true	_	_	I-Premise
305	difference	_	_	I-Premise
306	lay	_	_	I-Premise
307	between	_	_	I-Premise
308	-1.5	_	_	I-Premise
309	and	_	_	I-Premise
310	1.5	_	_	I-Premise
311	mmHg	_	_	I-Premise
312	,	_	_	I-Premise
313	the	_	_	I-Premise
314	predefined	_	_	I-Premise
315	bounds	_	_	I-Premise
316	for	_	_	I-Premise
317	equivalence	_	_	I-Premise
318	,	_	_	I-Premise
319	was	_	_	I-Premise
320	>	_	_	I-Premise
321	0.950	_	_	I-Premise
322	in	_	_	I-Premise
323	both	_	_	I-Premise
324	studies	_	_	I-Premise
325	.	_	_	I-Premise

326	Both	_	_	B-Claim
327	treatments	_	_	I-Claim
328	were	_	_	I-Claim
329	well	_	_	I-Claim
330	tolerated	_	_	I-Claim
331	over	_	_	I-Claim
332	3	_	_	I-Claim
333	months	_	_	I-Claim
334	,	_	_	I-Claim
335	although	_	_	B-Premise
336	ocular	_	_	I-Premise
337	stinging	_	_	I-Premise
338	occurred	_	_	I-Premise
339	more	_	_	I-Premise
340	frequently	_	_	I-Premise
341	with	_	_	I-Premise
342	the	_	_	I-Premise
343	dorzolamide/timolol	_	_	I-Premise
344	combination	_	_	I-Premise
345	.	_	_	I-Premise

346	The	_	_	B-Claim
347	dorzolamide/timolol	_	_	I-Claim
348	combination	_	_	I-Claim
349	and	_	_	I-Claim
350	latanoprost	_	_	I-Claim
351	were	_	_	I-Claim
352	equally	_	_	I-Claim
353	effective	_	_	I-Claim
354	at	_	_	I-Claim
355	lowering	_	_	I-Claim
356	IOP	_	_	I-Claim
357	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	safety	_	_	O
4	and	_	_	O
5	efficacy	_	_	O
6	of	_	_	O
7	intraoperative	_	_	O
8	5-fluorouracil	_	_	O
9	(	_	_	O
10	5-FU	_	_	O
11	)	_	_	O
12	or	_	_	O
13	Intraoperative	_	_	O
14	mitomycin	_	_	O
15	C	_	_	O
16	(	_	_	O
17	MMC	_	_	O
18	)	_	_	O
19	in	_	_	O
20	eyes	_	_	O
21	undergoing	_	_	O
22	primary	_	_	O
23	trabeculectomy	_	_	O
24	.	_	_	O

25	Prospective	_	_	O
26	double-masked	_	_	O
27	randomized	_	_	O
28	clinical	_	_	O
29	trial	_	_	O
30	.	_	_	O

31	One	_	_	O
32	hundred	_	_	O
33	fifteen	_	_	O
34	eyes	_	_	O
35	of	_	_	O
36	103	_	_	O
37	patients	_	_	O
38	with	_	_	O
39	uncontrolled	_	_	O
40	intraocular	_	_	O
41	pressure	_	_	O
42	(	_	_	O
43	IOP	_	_	O
44	)	_	_	O
45	despite	_	_	O
46	maximally	_	_	O
47	tolerated	_	_	O
48	medical	_	_	O
49	therapy	_	_	O
50	or	_	_	O
51	laser	_	_	O
52	were	_	_	O
53	prospectively	_	_	O
54	randomized	_	_	O
55	in	_	_	O
56	a	_	_	O
57	double-masked	_	_	O
58	fashion	_	_	O
59	to	_	_	O
60	one	_	_	O
61	of	_	_	O
62	two	_	_	O
63	treatment	_	_	O
64	groups	_	_	O
65	in	_	_	O
66	a	_	_	O
67	single	_	_	O
68	institution	_	_	O
69	setting	_	_	O
70	.	_	_	O

71	Subject	_	_	O
72	's	_	_	O
73	eyes	_	_	O
74	underwent	_	_	O
75	primary	_	_	O
76	trabeculectomy	_	_	O
77	with	_	_	O
78	either	_	_	O
79	topical	_	_	O
80	5-FU	_	_	O
81	(	_	_	O
82	50	_	_	O
83	mg/ml	_	_	O
84	for	_	_	O
85	5	_	_	O
86	minutes	_	_	O
87	)	_	_	O
88	or	_	_	O
89	topical	_	_	O
90	MMC	_	_	O
91	(	_	_	O
92	0.2	_	_	O
93	mg/ml	_	_	O
94	for	_	_	O
95	2	_	_	O
96	minutes	_	_	O
97	)	_	_	O
98	.	_	_	O

99	Primary	_	_	O
100	outcome	_	_	O
101	measures	_	_	O
102	included	_	_	O
103	the	_	_	O
104	number	_	_	O
105	of	_	_	O
106	eyes	_	_	O
107	achieving	_	_	O
108	target	_	_	O
109	pressures	_	_	O
110	of	_	_	O
111	21	_	_	O
112	,	_	_	O
113	18	_	_	O
114	,	_	_	O
115	15	_	_	O
116	,	_	_	O
117	and	_	_	O
118	12	_	_	O
119	mm	_	_	O
120	Hg	_	_	O
121	at	_	_	O
122	6	_	_	O
123	and	_	_	O
124	12	_	_	O
125	months	_	_	O
126	postoperatively	_	_	O
127	.	_	_	O

128	Secondary	_	_	O
129	outcome	_	_	O
130	measures	_	_	O
131	included	_	_	O
132	IOP	_	_	O
133	,	_	_	O
134	best-corrected	_	_	O
135	visual	_	_	O
136	acuity	_	_	O
137	,	_	_	O
138	complications	_	_	O
139	,	_	_	O
140	and	_	_	O
141	interventions	_	_	O
142	.	_	_	O

143	Of	_	_	O
144	the	_	_	O
145	115	_	_	O
146	eyes	_	_	O
147	,	_	_	O
148	57	_	_	O
149	received	_	_	O
150	5-FU	_	_	O
151	while	_	_	O
152	58	_	_	O
153	received	_	_	O
154	MMC	_	_	O
155	.	_	_	O

156	A	_	_	B-Premise
157	target	_	_	I-Premise
158	IOP	_	_	I-Premise
159	of	_	_	I-Premise
160	21	_	_	I-Premise
161	mm	_	_	I-Premise
162	Hg	_	_	I-Premise
163	at	_	_	I-Premise
164	6	_	_	I-Premise
165	months	_	_	I-Premise
166	was	_	_	I-Premise
167	achieved	_	_	I-Premise
168	in	_	_	I-Premise
169	53	_	_	I-Premise
170	of	_	_	I-Premise
171	56	_	_	I-Premise
172	(	_	_	I-Premise
173	95	_	_	I-Premise
174	%	_	_	I-Premise
175	)	_	_	I-Premise
176	eyes	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	5-FU	_	_	I-Premise
180	group	_	_	I-Premise
181	and	_	_	I-Premise
182	54	_	_	I-Premise
183	of	_	_	I-Premise
184	57	_	_	I-Premise
185	(	_	_	I-Premise
186	95	_	_	I-Premise
187	%	_	_	I-Premise
188	)	_	_	I-Premise
189	eyes	_	_	I-Premise
190	in	_	_	I-Premise
191	the	_	_	I-Premise
192	MMC	_	_	I-Premise
193	group	_	_	I-Premise
194	(	_	_	I-Premise
195	P	_	_	I-Premise
196	=	_	_	I-Premise
197	1.00	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	At	_	_	B-Premise
201	12	_	_	I-Premise
202	months	_	_	I-Premise
203	,	_	_	I-Premise
204	45	_	_	I-Premise
205	of	_	_	I-Premise
206	48	_	_	I-Premise
207	(	_	_	I-Premise
208	94	_	_	I-Premise
209	%	_	_	I-Premise
210	)	_	_	I-Premise
211	eyes	_	_	I-Premise
212	in	_	_	I-Premise
213	the	_	_	I-Premise
214	5-FU	_	_	I-Premise
215	group	_	_	I-Premise
216	met	_	_	I-Premise
217	a	_	_	I-Premise
218	target	_	_	I-Premise
219	IOP	_	_	I-Premise
220	of	_	_	I-Premise
221	21	_	_	I-Premise
222	mm	_	_	I-Premise
223	Hg	_	_	I-Premise
224	while	_	_	I-Premise
225	48	_	_	I-Premise
226	of	_	_	I-Premise
227	54	_	_	I-Premise
228	(	_	_	I-Premise
229	89	_	_	I-Premise
230	%	_	_	I-Premise
231	)	_	_	I-Premise
232	eyes	_	_	I-Premise
233	in	_	_	I-Premise
234	the	_	_	I-Premise
235	MMC	_	_	I-Premise
236	group	_	_	I-Premise
237	did	_	_	I-Premise
238	(	_	_	I-Premise
239	P	_	_	I-Premise
240	=.49	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	The	_	_	B-Premise
244	most	_	_	I-Premise
245	common	_	_	I-Premise
246	complications	_	_	I-Premise
247	in	_	_	I-Premise
248	each	_	_	I-Premise
249	group	_	_	I-Premise
250	were	_	_	I-Premise
251	persistent	_	_	I-Premise
252	choroidal	_	_	I-Premise
253	effusions	_	_	I-Premise
254	and	_	_	I-Premise
255	bleb	_	_	I-Premise
256	leak	_	_	I-Premise
257	.	_	_	I-Premise

258	Our	_	_	B-Claim
259	study	_	_	I-Claim
260	suggests	_	_	I-Claim
261	that	_	_	I-Claim
262	intraoperative	_	_	I-Claim
263	topical	_	_	I-Claim
264	5-FU	_	_	I-Claim
265	is	_	_	I-Claim
266	at	_	_	I-Claim
267	least	_	_	I-Claim
268	as	_	_	I-Claim
269	effective	_	_	I-Claim
270	as	_	_	I-Claim
271	intraoperative	_	_	I-Claim
272	topical	_	_	I-Claim
273	MMC	_	_	I-Claim
274	in	_	_	I-Claim
275	reducing	_	_	I-Claim
276	IOP	_	_	I-Claim
277	of	_	_	I-Claim
278	eyes	_	_	I-Claim
279	undergoing	_	_	I-Claim
280	primary	_	_	I-Claim
281	trabeculectomy	_	_	I-Claim
282	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	randomized	_	_	O
5	clinical	_	_	O
6	trial	_	_	O
7	was	_	_	O
8	to	_	_	O
9	compare	_	_	O
10	the	_	_	O
11	effectiveness	_	_	O
12	and	_	_	O
13	safety	_	_	O
14	of	_	_	O
15	viscocanalostomy	_	_	O
16	(	_	_	O
17	visco	_	_	O
18	)	_	_	O
19	with	_	_	O
20	trabeculectomy	_	_	O
21	(	_	_	O
22	trab	_	_	O
23	)	_	_	O
24	in	_	_	O
25	the	_	_	O
26	management	_	_	O
27	of	_	_	O
28	primary	_	_	O
29	open	_	_	O
30	angle	_	_	O
31	glaucoma	_	_	O
32	(	_	_	O
33	POAG	_	_	O
34	)	_	_	O
35	.	_	_	O

36	Patients	_	_	O
37	were	_	_	O
38	randomized	_	_	O
39	to	_	_	O
40	have	_	_	O
41	a	_	_	O
42	viscocanalostomy	_	_	O
43	(	_	_	O
44	25	_	_	O
45	eyes	_	_	O
46	)	_	_	O
47	or	_	_	O
48	a	_	_	O
49	trabeculectomy	_	_	O
50	(	_	_	O
51	25	_	_	O
52	eyes	_	_	O
53	)	_	_	O
54	performed	_	_	O
55	by	_	_	O
56	one	_	_	O
57	surgeon	_	_	O
58	(	_	_	O
59	TDM	_	_	O
60	)	_	_	O
61	and	_	_	O
62	followed	_	_	O
63	up	_	_	O
64	prospectively	_	_	O
65	.	_	_	O

66	Patients	_	_	O
67	were	_	_	O
68	examined	_	_	O
69	preoperatively	_	_	O
70	,	_	_	O
71	at	_	_	O
72	day	_	_	O
73	1	_	_	O
74	,	_	_	O
75	day	_	_	O
76	3	_	_	O
77	if	_	_	O
78	required	_	_	O
79	,	_	_	O
80	day	_	_	O
81	6	_	_	O
82	,	_	_	O
83	week	_	_	O
84	2	_	_	O
85	and	_	_	O
86	thereafter	_	_	O
87	as	_	_	O
88	near	_	_	O
89	as	_	_	O
90	possible	_	_	O
91	to	_	_	O
92	1	_	_	O
93	,	_	_	O
94	3	_	_	O
95	,	_	_	O
96	6	_	_	O
97	,	_	_	O
98	12	_	_	O
99	,	_	_	O
100	18	_	_	O
101	,	_	_	O
102	24	_	_	O
103	,	_	_	O
104	30	_	_	O
105	,	_	_	O
106	36	_	_	O
107	,	_	_	O
108	48	_	_	O
109	,	_	_	O
110	54	_	_	O
111	,	_	_	O
112	and	_	_	O
113	60	_	_	O
114	months	_	_	O
115	.	_	_	O

116	We	_	_	O
117	recorded	_	_	O
118	intraocular	_	_	O
119	pressure	_	_	O
120	(	_	_	O
121	IOP	_	_	O
122	)	_	_	O
123	,	_	_	O
124	presence	_	_	O
125	or	_	_	O
126	absence	_	_	O
127	of	_	_	O
128	any	_	_	O
129	complications	_	_	O
130	,	_	_	O
131	presence	_	_	O
132	and	_	_	O
133	description	_	_	O
134	of	_	_	O
135	any	_	_	O
136	bleb	_	_	O
137	,	_	_	O
138	visual	_	_	O
139	acuity	_	_	O
140	with	_	_	O
141	glasses	_	_	O
142	,	_	_	O
143	and	_	_	O
144	full	_	_	O
145	examinations	_	_	O
146	as	_	_	O
147	routine	_	_	O
148	to	_	_	O
149	monitor	_	_	O
150	any	_	_	O
151	progression	_	_	O
152	of	_	_	O
153	the	_	_	O
154	glaucoma	_	_	O
155	.	_	_	O

156	Bleb	_	_	O
157	interventions	_	_	O
158	including	_	_	O
159	needling	_	_	O
160	and	_	_	O
161	antimetabolites	_	_	O
162	were	_	_	O
163	allowed	_	_	O
164	and	_	_	O
165	recorded	_	_	O
166	in	_	_	O
167	both	_	_	O
168	groups	_	_	O
169	.	_	_	O

170	YAG	_	_	O
171	laser	_	_	O
172	goniopuncture	_	_	O
173	was	_	_	O
174	allowed	_	_	O
175	in	_	_	O
176	the	_	_	O
177	viscocanalostomy	_	_	O
178	group	_	_	O
179	.	_	_	O

180	Mean	_	_	O
181	follow-up	_	_	O
182	was	_	_	O
183	40	_	_	O
184	months	_	_	O
185	(	_	_	O
186	SD	_	_	O
187	15	_	_	O
188	)	_	_	O
189	,	_	_	O
190	with	_	_	O
191	a	_	_	O
192	range	_	_	O
193	from	_	_	O
194	6	_	_	O
195	to	_	_	O
196	60	_	_	O
197	months	_	_	O
198	.	_	_	O

199	Forty-two	_	_	B-Premise
200	percent	_	_	I-Premise
201	(	_	_	I-Premise
202	n=10	_	_	I-Premise
203	)	_	_	I-Premise
204	of	_	_	I-Premise
205	the	_	_	I-Premise
206	patients	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	trabeculectomy	_	_	I-Premise
210	group	_	_	I-Premise
211	had	_	_	I-Premise
212	a	_	_	I-Premise
213	successful	_	_	I-Premise
214	outcome	_	_	I-Premise
215	(	_	_	I-Premise
216	IOP	_	_	I-Premise
217	<	_	_	I-Premise
218	18	_	_	I-Premise
219	mm	_	_	I-Premise
220	Hg	_	_	I-Premise
221	with	_	_	I-Premise
222	no	_	_	I-Premise
223	treatment	_	_	I-Premise
224	)	_	_	I-Premise
225	at	_	_	I-Premise
226	last	_	_	I-Premise
227	follow-up	_	_	I-Premise
228	visit	_	_	I-Premise
229	,	_	_	I-Premise
230	compared	_	_	I-Premise
231	to	_	_	I-Premise
232	21	_	_	I-Premise
233	%	_	_	I-Premise
234	(	_	_	I-Premise
235	n=5	_	_	I-Premise
236	)	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	viscocanalostomy	_	_	I-Premise
240	group	_	_	I-Premise
241	.	_	_	I-Premise

242	IOP	_	_	B-Premise
243	was	_	_	I-Premise
244	lower	_	_	I-Premise
245	in	_	_	I-Premise
246	the	_	_	I-Premise
247	trab	_	_	I-Premise
248	group	_	_	I-Premise
249	with	_	_	I-Premise
250	differences	_	_	I-Premise
251	in	_	_	I-Premise
252	IOP	_	_	I-Premise
253	being	_	_	I-Premise
254	statistically	_	_	I-Premise
255	significant	_	_	I-Premise
256	at	_	_	I-Premise
257	month	_	_	I-Premise
258	12	_	_	I-Premise
259	(	_	_	I-Premise
260	P=	_	_	I-Premise
261	<	_	_	I-Premise
262	0.001	_	_	I-Premise
263	)	_	_	I-Premise
264	,	_	_	I-Premise
265	24	_	_	I-Premise
266	(	_	_	I-Premise
267	P=	_	_	I-Premise
268	<	_	_	I-Premise
269	0.001	_	_	I-Premise
270	)	_	_	I-Premise
271	,	_	_	I-Premise
272	30	_	_	I-Premise
273	(	_	_	I-Premise
274	P=0.030	_	_	I-Premise
275	)	_	_	I-Premise
276	,	_	_	I-Premise
277	36	_	_	I-Premise
278	(	_	_	I-Premise
279	P=	_	_	I-Premise
280	<	_	_	I-Premise
281	0.001	_	_	I-Premise
282	)	_	_	I-Premise
283	,	_	_	I-Premise
284	and	_	_	I-Premise
285	48	_	_	I-Premise
286	(	_	_	I-Premise
287	P=0.018	_	_	I-Premise
288	)	_	_	I-Premise
289	.	_	_	I-Premise

290	The	_	_	B-Premise
291	trabeculectomy	_	_	I-Premise
292	group	_	_	I-Premise
293	required	_	_	I-Premise
294	less	_	_	I-Premise
295	postoperative	_	_	I-Premise
296	topical	_	_	I-Premise
297	IOP-lowering	_	_	I-Premise
298	medication	_	_	I-Premise
299	(	_	_	I-Premise
300	P=0.011	_	_	I-Premise
301	)	_	_	I-Premise
302	.	_	_	I-Premise

303	In	_	_	O
304	this	_	_	O
305	study	_	_	O
306	,	_	_	O
307	we	_	_	B-Claim
308	found	_	_	I-Claim
309	trabeculectomy	_	_	I-Claim
310	to	_	_	I-Claim
311	be	_	_	I-Claim
312	more	_	_	I-Claim
313	effective	_	_	I-Claim
314	at	_	_	I-Claim
315	lowering	_	_	I-Claim
316	IOP	_	_	I-Claim
317	than	_	_	I-Claim
318	viscocanalostomy	_	_	I-Claim
319	in	_	_	I-Claim
320	POAG	_	_	I-Claim
321	patients	_	_	I-Claim
322	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effectiveness	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	viscocanalostomy	_	_	O
8	and	_	_	O
9	trabeculectomy	_	_	O
10	in	_	_	O
11	adults	_	_	O
12	with	_	_	O
13	uncontrolled	_	_	O
14	open-angle	_	_	O
15	glaucoma	_	_	O
16	.	_	_	O

17	Single-masked	_	_	O
18	,	_	_	O
19	parallel-group	_	_	O
20	,	_	_	O
21	prospective	_	_	O
22	,	_	_	O
23	randomized	_	_	O
24	24-month	_	_	O
25	trial	_	_	O
26	,	_	_	O
27	with	_	_	O
28	90	_	_	O
29	%	_	_	O
30	power	_	_	O
31	to	_	_	O
32	detect	_	_	O
33	a	_	_	O
34	clinically	_	_	O
35	important	_	_	O
36	difference	_	_	O
37	between	_	_	O
38	groups	_	_	O
39	.	_	_	O

40	Fifty	_	_	O
41	consecutive	_	_	O
42	patients	_	_	O
43	(	_	_	O
44	50	_	_	O
45	eyes	_	_	O
46	)	_	_	O
47	with	_	_	O
48	primary	_	_	O
49	open-angle	_	_	O
50	or	_	_	O
51	pseudoexfoliative	_	_	O
52	glaucoma	_	_	O
53	.	_	_	O

54	Eyes	_	_	O
55	were	_	_	O
56	assigned	_	_	O
57	randomly	_	_	O
58	to	_	_	O
59	either	_	_	O
60	viscocanalostomy	_	_	O
61	(	_	_	O
62	group	_	_	O
63	1	_	_	O
64	)	_	_	O
65	or	_	_	O
66	trabeculectomy	_	_	O
67	(	_	_	O
68	group	_	_	O
69	2	_	_	O
70	)	_	_	O
71	with	_	_	O
72	no	_	_	O
73	intraoperative	_	_	O
74	antifibrotics	_	_	O
75	in	_	_	O
76	the	_	_	O
77	study	_	_	O
78	eye	_	_	O
79	.	_	_	O

80	In	_	_	O
81	group	_	_	O
82	1	_	_	O
83	,	_	_	O
84	no	_	_	O
85	further	_	_	O
86	intervention	_	_	O
87	was	_	_	O
88	allowed	_	_	O
89	,	_	_	O
90	whereas	_	_	O
91	trabeculectomy	_	_	O
92	eyes	_	_	O
93	could	_	_	O
94	receive	_	_	O
95	subconjunctival	_	_	O
96	5-fluorouracil	_	_	O
97	(	_	_	O
98	5-FU	_	_	O
99	)	_	_	O
100	injections	_	_	O
101	or	_	_	O
102	laser	_	_	O
103	suture	_	_	O
104	lysis	_	_	O
105	after	_	_	O
106	surgery	_	_	O
107	.	_	_	O

108	Success	_	_	O
109	rate	_	_	O
110	based	_	_	O
111	on	_	_	O
112	intraocular	_	_	O
113	pressure	_	_	O
114	(	_	_	O
115	IOP	_	_	O
116	)	_	_	O
117	,	_	_	O
118	visual	_	_	O
119	acuity	_	_	O
120	,	_	_	O
121	discomfort	_	_	O
122	,	_	_	O
123	and	_	_	O
124	other	_	_	O
125	complications	_	_	O
126	.	_	_	O

127	At	_	_	B-Premise
128	the	_	_	I-Premise
129	end	_	_	I-Premise
130	of	_	_	I-Premise
131	the	_	_	I-Premise
132	24-month	_	_	I-Premise
133	follow-up	_	_	I-Premise
134	,	_	_	I-Premise
135	IOP	_	_	I-Premise
136	of	_	_	I-Premise
137	21	_	_	I-Premise
138	mmHg	_	_	I-Premise
139	or	_	_	I-Premise
140	less	_	_	I-Premise
141	and	_	_	I-Premise
142	more	_	_	I-Premise
143	than	_	_	I-Premise
144	6	_	_	I-Premise
145	mmHg	_	_	I-Premise
146	was	_	_	I-Premise
147	achieved	_	_	I-Premise
148	in	_	_	I-Premise
149	76	_	_	I-Premise
150	%	_	_	I-Premise
151	in	_	_	I-Premise
152	group	_	_	I-Premise
153	1	_	_	I-Premise
154	(	_	_	I-Premise
155	n	_	_	I-Premise
156	=	_	_	I-Premise
157	19	_	_	I-Premise
158	)	_	_	I-Premise
159	and	_	_	I-Premise
160	in	_	_	I-Premise
161	80	_	_	I-Premise
162	%	_	_	I-Premise
163	in	_	_	I-Premise
164	group	_	_	I-Premise
165	2	_	_	I-Premise
166	(	_	_	I-Premise
167	n	_	_	I-Premise
168	=	_	_	I-Premise
169	20	_	_	I-Premise
170	;	_	_	I-Premise
171	log-rank	_	_	I-Premise
172	P	_	_	I-Premise
173	=	_	_	I-Premise
174	0.60	_	_	I-Premise
175	)	_	_	I-Premise
176	;	_	_	I-Premise
177	an	_	_	B-Premise
178	IOP	_	_	I-Premise
179	between	_	_	I-Premise
180	6	_	_	I-Premise
181	and	_	_	I-Premise
182	16	_	_	I-Premise
183	mmHg	_	_	I-Premise
184	was	_	_	I-Premise
185	obtained	_	_	I-Premise
186	in	_	_	I-Premise
187	56	_	_	I-Premise
188	%	_	_	I-Premise
189	in	_	_	I-Premise
190	group	_	_	I-Premise
191	1	_	_	I-Premise
192	(	_	_	I-Premise
193	n	_	_	I-Premise
194	=	_	_	I-Premise
195	14	_	_	I-Premise
196	)	_	_	I-Premise
197	and	_	_	I-Premise
198	in	_	_	I-Premise
199	72	_	_	I-Premise
200	%	_	_	I-Premise
201	in	_	_	I-Premise
202	group	_	_	I-Premise
203	2	_	_	I-Premise
204	(	_	_	I-Premise
205	n	_	_	I-Premise
206	=	_	_	I-Premise
207	18	_	_	I-Premise
208	;	_	_	I-Premise
209	log-rank	_	_	I-Premise
210	P	_	_	I-Premise
211	=	_	_	I-Premise
212	0.17	_	_	I-Premise
213	;	_	_	I-Premise
214	Kaplan-Meier	_	_	I-Premise
215	cumulative	_	_	I-Premise
216	probability	_	_	I-Premise
217	of	_	_	I-Premise
218	success	_	_	I-Premise
219	)	_	_	I-Premise
220	.	_	_	I-Premise

221	Complications	_	_	B-Premise
222	of	_	_	I-Premise
223	viscocanalostomy	_	_	I-Premise
224	included	_	_	I-Premise
225	one	_	_	I-Premise
226	intraoperative	_	_	I-Premise
227	conversion	_	_	I-Premise
228	into	_	_	I-Premise
229	trabeculectomy	_	_	I-Premise
230	;	_	_	I-Premise
231	microruptures	_	_	I-Premise
232	in	_	_	I-Premise
233	Descemet	_	_	I-Premise
234	's	_	_	I-Premise
235	membrane	_	_	I-Premise
236	in	_	_	I-Premise
237	five	_	_	I-Premise
238	eyes	_	_	I-Premise
239	;	_	_	I-Premise
240	three	_	_	I-Premise
241	cases	_	_	I-Premise
242	of	_	_	I-Premise
243	iris	_	_	I-Premise
244	incarceration	_	_	I-Premise
245	in	_	_	I-Premise
246	the	_	_	I-Premise
247	Decemet	_	_	I-Premise
248	's	_	_	I-Premise
249	window	_	_	I-Premise
250	,	_	_	I-Premise
251	two	_	_	I-Premise
252	of	_	_	I-Premise
253	which	_	_	I-Premise
254	caused	_	_	I-Premise
255	early	_	_	I-Premise
256	failure	_	_	I-Premise
257	of	_	_	I-Premise
258	the	_	_	I-Premise
259	procedure	_	_	I-Premise
260	requiring	_	_	I-Premise
261	reoperation	_	_	I-Premise
262	;	_	_	I-Premise
263	and	_	_	I-Premise
264	a	_	_	I-Premise
265	1-mm	_	_	I-Premise
266	to	_	_	I-Premise
267	2-mm	_	_	I-Premise
268	transient	_	_	I-Premise
269	self-resolving	_	_	I-Premise
270	hyphema	_	_	I-Premise
271	in	_	_	I-Premise
272	three	_	_	I-Premise
273	cases	_	_	I-Premise
274	.	_	_	O

275	Complications	_	_	B-Premise
276	of	_	_	I-Premise
277	trabeculectomy	_	_	I-Premise
278	included	_	_	I-Premise
279	one	_	_	I-Premise
280	case	_	_	I-Premise
281	of	_	_	I-Premise
282	postoperative	_	_	I-Premise
283	bleb	_	_	I-Premise
284	bleeding	_	_	I-Premise
285	with	_	_	I-Premise
286	early	_	_	I-Premise
287	transient	_	_	I-Premise
288	IOP	_	_	I-Premise
289	spike	_	_	I-Premise
290	;	_	_	I-Premise
291	one	_	_	I-Premise
292	early	_	_	I-Premise
293	hyphema	_	_	I-Premise
294	;	_	_	I-Premise
295	five	_	_	I-Premise
296	cases	_	_	I-Premise
297	of	_	_	I-Premise
298	postoperative	_	_	I-Premise
299	hypotony	_	_	I-Premise
300	,	_	_	I-Premise
301	two	_	_	I-Premise
302	of	_	_	I-Premise
303	which	_	_	I-Premise
304	had	_	_	I-Premise
305	a	_	_	I-Premise
306	positive	_	_	I-Premise
307	Seidel	_	_	I-Premise
308	test	_	_	I-Premise
309	from	_	_	I-Premise
310	the	_	_	I-Premise
311	conjunctival	_	_	I-Premise
312	suture	_	_	I-Premise
313	;	_	_	I-Premise
314	three	_	_	I-Premise
315	cases	_	_	I-Premise
316	of	_	_	I-Premise
317	transient	_	_	I-Premise
318	choroidal	_	_	I-Premise
319	detachment	_	_	I-Premise
320	,	_	_	I-Premise
321	two	_	_	I-Premise
322	of	_	_	I-Premise
323	which	_	_	I-Premise
324	had	_	_	I-Premise
325	shallow	_	_	I-Premise
326	anterior	_	_	I-Premise
327	chamber	_	_	I-Premise
328	.	_	_	I-Premise

329	No	_	_	B-Premise
330	patient	_	_	I-Premise
331	required	_	_	I-Premise
332	reoperation	_	_	I-Premise
333	.	_	_	I-Premise

334	Two	_	_	B-Premise
335	eyes	_	_	I-Premise
336	required	_	_	I-Premise
337	argon	_	_	I-Premise
338	laser	_	_	I-Premise
339	suture	_	_	I-Premise
340	lysis	_	_	I-Premise
341	,	_	_	I-Premise
342	and	_	_	I-Premise
343	nine	_	_	I-Premise
344	underwent	_	_	I-Premise
345	one	_	_	I-Premise
346	or	_	_	I-Premise
347	more	_	_	I-Premise
348	5-FU	_	_	I-Premise
349	injections	_	_	I-Premise
350	,	_	_	I-Premise
351	which	_	_	I-Premise
352	caused	_	_	I-Premise
353	punctate	_	_	I-Premise
354	keratopathy	_	_	I-Premise
355	in	_	_	I-Premise
356	three	_	_	I-Premise
357	eyes	_	_	I-Premise
358	.	_	_	I-Premise

359	Viscocanalostomy	_	_	B-Claim
360	is	_	_	I-Claim
361	an	_	_	I-Claim
362	effective	_	_	I-Claim
363	IOP-lowering	_	_	I-Claim
364	procedure	_	_	I-Claim
365	in	_	_	I-Claim
366	white	_	_	I-Claim
367	adults	_	_	I-Claim
368	affected	_	_	I-Claim
369	by	_	_	I-Claim
370	open-angle	_	_	I-Claim
371	glaucoma	_	_	I-Claim
372	.	_	_	I-Claim

373	Trabeculectomy	_	_	B-Claim
374	with	_	_	I-Claim
375	postoperative	_	_	I-Claim
376	5-FU	_	_	I-Claim
377	can	_	_	I-Claim
378	probably	_	_	I-Claim
379	provides	_	_	I-Claim
380	lower	_	_	I-Claim
381	IOPs	_	_	I-Claim
382	but	_	_	I-Claim
383	,	_	_	I-Claim
384	with	_	_	I-Claim
385	more	_	_	I-Claim
386	numerous	_	_	I-Claim
387	complications	_	_	I-Claim
388	,	_	_	I-Claim
389	greater	_	_	I-Claim
390	discomfort	_	_	I-Claim
391	,	_	_	I-Claim
392	and	_	_	I-Claim
393	more	_	_	I-Claim
394	intensive	_	_	I-Claim
395	postoperative	_	_	I-Claim
396	management	_	_	I-Claim
397	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	the	_	_	O
6	Ahmed	_	_	O
7	S2	_	_	O
8	Glaucoma	_	_	O
9	Valve	_	_	O
10	with	_	_	O
11	the	_	_	O
12	Baerveldt	_	_	O
13	250-mm	_	_	O
14	(	_	_	O
15	2	_	_	O
16	)	_	_	O
17	Glaucoma	_	_	O
18	Implant	_	_	O
19	in	_	_	O
20	the	_	_	O
21	treatment	_	_	O
22	of	_	_	O
23	adult	_	_	O
24	glaucoma	_	_	O
25	.	_	_	O

26	Comparative	_	_	O
27	case	_	_	O
28	series	_	_	O
29	.	_	_	O

30	Fifty-nine	_	_	O
31	eyes	_	_	O
32	of	_	_	O
33	59	_	_	O
34	patients	_	_	O
35	who	_	_	O
36	received	_	_	O
37	the	_	_	O
38	Ahmed	_	_	O
39	S2	_	_	O
40	Glaucoma	_	_	O
41	Valve	_	_	O
42	and	_	_	O
43	133	_	_	O
44	eyes	_	_	O
45	of	_	_	O
46	133	_	_	O
47	patients	_	_	O
48	who	_	_	O
49	received	_	_	O
50	the	_	_	O
51	Baerveldt	_	_	O
52	250-mm	_	_	O
53	(	_	_	O
54	2	_	_	O
55	)	_	_	O
56	Glaucoma	_	_	O
57	Implant	_	_	O
58	by	_	_	O
59	the	_	_	O
60	Indiana	_	_	O
61	University	_	_	O
62	Glaucoma	_	_	O
63	Service	_	_	O
64	from	_	_	O
65	1996	_	_	O
66	to	_	_	O
67	2003	_	_	O
68	.	_	_	O

69	Eyes	_	_	O
70	that	_	_	O
71	had	_	_	O
72	previous	_	_	O
73	drainage	_	_	O
74	implant	_	_	O
75	procedures	_	_	O
76	were	_	_	O
77	excluded	_	_	O
78	from	_	_	O
79	both	_	_	O
80	groups	_	_	O
81	.	_	_	O

82	If	_	_	O
83	both	_	_	O
84	eyes	_	_	O
85	of	_	_	O
86	a	_	_	O
87	single	_	_	O
88	patient	_	_	O
89	received	_	_	O
90	an	_	_	O
91	implant	_	_	O
92	,	_	_	O
93	the	_	_	O
94	second	_	_	O
95	eye	_	_	O
96	to	_	_	O
97	undergo	_	_	O
98	implantation	_	_	O
99	was	_	_	O
100	excluded	_	_	O
101	from	_	_	O
102	the	_	_	O
103	study	_	_	O
104	.	_	_	O

105	Kaplan-Meier	_	_	O
106	survival	_	_	O
107	with	_	_	O
108	success	_	_	O
109	defined	_	_	O
110	as	_	_	O
111	intraocular	_	_	O
112	pressure	_	_	O
113	(	_	_	O
114	IOP	_	_	O
115	)	_	_	O
116	>	_	_	O
117	5	_	_	O
118	mmHg	_	_	O
119	and	_	_	O
120	<	_	_	O
121	22	_	_	O
122	mmHg	_	_	O
123	and	_	_	O
124	at	_	_	O
125	least	_	_	O
126	20	_	_	O
127	%	_	_	O
128	reduction	_	_	O
129	from	_	_	O
130	preoperative	_	_	O
131	IOP	_	_	O
132	(	_	_	O
133	with	_	_	O
134	or	_	_	O
135	without	_	_	O
136	antiglaucoma	_	_	O
137	medications	_	_	O
138	)	_	_	O
139	and	_	_	O
140	without	_	_	O
141	loss	_	_	O
142	of	_	_	O
143	light	_	_	O
144	perception	_	_	O
145	.	_	_	O

146	Secondary	_	_	O
147	outcome	_	_	O
148	measures	_	_	O
149	included	_	_	O
150	intraocular	_	_	O
151	pressure	_	_	O
152	,	_	_	O
153	visual	_	_	O
154	acuity	_	_	O
155	,	_	_	O
156	number	_	_	O
157	of	_	_	O
158	glaucoma	_	_	O
159	medications	_	_	O
160	,	_	_	O
161	and	_	_	O
162	surgical	_	_	O
163	complications	_	_	O
164	.	_	_	O

165	The	_	_	O
166	2	_	_	O
167	groups	_	_	O
168	were	_	_	O
169	similar	_	_	O
170	with	_	_	O
171	regards	_	_	O
172	to	_	_	O
173	age	_	_	O
174	,	_	_	O
175	gender	_	_	O
176	,	_	_	O
177	race	_	_	O
178	,	_	_	O
179	neovascular	_	_	O
180	glaucoma	_	_	O
181	diagnosis	_	_	O
182	,	_	_	O
183	number	_	_	O
184	of	_	_	O
185	prior	_	_	O
186	ocular	_	_	O
187	surgeries	_	_	O
188	,	_	_	O
189	preoperative	_	_	O
190	IOP	_	_	O
191	,	_	_	O
192	and	_	_	O
193	number	_	_	O
194	of	_	_	O
195	preoperative	_	_	O
196	glaucoma	_	_	O
197	medications	_	_	O
198	.	_	_	O

199	Mean	_	_	O
200	durations	_	_	O
201	of	_	_	O
202	follow-up	_	_	O
203	were	_	_	O
204	20.0	_	_	O
205	months	_	_	O
206	for	_	_	O
207	Ahmed	_	_	O
208	eyes	_	_	O
209	and	_	_	O
210	22.9	_	_	O
211	months	_	_	O
212	for	_	_	O
213	Baerveldt	_	_	O
214	eyes	_	_	O
215	.	_	_	O

216	Cumulative	_	_	B-Premise
217	successes	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	Ahmed	_	_	I-Premise
221	group	_	_	I-Premise
222	were	_	_	I-Premise
223	0.73	_	_	I-Premise
224	at	_	_	I-Premise
225	1	_	_	I-Premise
226	year	_	_	I-Premise
227	and	_	_	I-Premise
228	0.62	_	_	I-Premise
229	at	_	_	I-Premise
230	2	_	_	I-Premise
231	years	_	_	I-Premise
232	,	_	_	I-Premise
233	whereas	_	_	I-Premise
234	cumulative	_	_	I-Premise
235	successes	_	_	I-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	Baerveldt	_	_	I-Premise
239	group	_	_	I-Premise
240	were	_	_	I-Premise
241	0.92	_	_	I-Premise
242	at	_	_	I-Premise
243	1	_	_	I-Premise
244	year	_	_	I-Premise
245	and	_	_	I-Premise
246	0.85	_	_	I-Premise
247	at	_	_	I-Premise
248	2	_	_	I-Premise
249	years	_	_	I-Premise
250	(	_	_	I-Premise
251	Kaplan-Meier	_	_	I-Premise
252	survival	_	_	I-Premise
253	functions	_	_	I-Premise
254	:	_	_	I-Premise
255	P	_	_	I-Premise
256	=	_	_	I-Premise
257	0.03	_	_	I-Premise
258	,	_	_	I-Premise
259	log	_	_	I-Premise
260	rank	_	_	I-Premise
261	test	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	Male	_	_	B-Claim
265	gender	_	_	I-Claim
266	,	_	_	I-Claim
267	African	_	_	I-Claim
268	descent	_	_	I-Claim
269	,	_	_	I-Claim
270	neovascular	_	_	I-Claim
271	glaucoma	_	_	I-Claim
272	,	_	_	I-Claim
273	and	_	_	I-Claim
274	Ahmed	_	_	I-Claim
275	implantation	_	_	I-Claim
276	were	_	_	I-Claim
277	found	_	_	I-Claim
278	to	_	_	I-Claim
279	be	_	_	I-Claim
280	significant	_	_	I-Claim
281	predictors	_	_	I-Claim
282	of	_	_	I-Claim
283	failure	_	_	I-Claim
284	.	_	_	I-Claim

285	At	_	_	B-Premise
286	last	_	_	I-Premise
287	follow-up	_	_	I-Premise
288	visit	_	_	I-Premise
289	,	_	_	I-Premise
290	eyes	_	_	I-Premise
291	in	_	_	I-Premise
292	the	_	_	I-Premise
293	Ahmed	_	_	I-Premise
294	group	_	_	I-Premise
295	had	_	_	I-Premise
296	a	_	_	I-Premise
297	significantly	_	_	I-Premise
298	higher	_	_	I-Premise
299	mean	_	_	I-Premise
300	IOP	_	_	I-Premise
301	(	_	_	I-Premise
302	19.8+/-9.5	_	_	I-Premise
303	vs.	_	_	I-Premise
304	15.8+/-7.9	_	_	I-Premise
305	mmHg	_	_	I-Premise
306	,	_	_	I-Premise
307	P	_	_	I-Premise
308	=	_	_	I-Premise
309	0.003	_	_	I-Premise
310	,	_	_	I-Premise
311	t	_	_	I-Premise
312	test	_	_	I-Premise
313	)	_	_	I-Premise
314	and	_	_	I-Premise
315	more	_	_	I-Premise
316	antiglaucoma	_	_	I-Premise
317	medications	_	_	I-Premise
318	(	_	_	I-Premise
319	1.4+/-1.2	_	_	I-Premise
320	vs.	_	_	I-Premise
321	0.9+/-1.1	_	_	I-Premise
322	medications	_	_	I-Premise
323	,	_	_	I-Premise
324	P	_	_	I-Premise
325	=	_	_	I-Premise
326	0.008	_	_	I-Premise
327	,	_	_	I-Premise
328	Mann-Whitney	_	_	I-Premise
329	test	_	_	I-Premise
330	)	_	_	I-Premise
331	than	_	_	I-Premise
332	eyes	_	_	I-Premise
333	in	_	_	I-Premise
334	the	_	_	I-Premise
335	Baerveldt	_	_	I-Premise
336	group	_	_	I-Premise
337	.	_	_	I-Premise

338	Two	_	_	O
339	methods	_	_	O
340	for	_	_	O
341	avoiding	_	_	O
342	hypotony	_	_	O
343	after	_	_	O
344	Baerveldt	_	_	O
345	250-mm	_	_	O
346	(	_	_	O
347	2	_	_	O
348	)	_	_	O
349	implantation	_	_	O
350	had	_	_	O
351	similar	_	_	O
352	outcomes	_	_	O
353	.	_	_	O

354	Our	_	_	B-Claim
355	study	_	_	I-Claim
356	suggests	_	_	I-Claim
357	that	_	_	I-Claim
358	the	_	_	I-Claim
359	Ahmed	_	_	I-Claim
360	S2	_	_	I-Claim
361	Glaucoma	_	_	I-Claim
362	Valve	_	_	I-Claim
363	may	_	_	I-Claim
364	be	_	_	I-Claim
365	less	_	_	I-Claim
366	effective	_	_	I-Claim
367	at	_	_	I-Claim
368	lowering	_	_	I-Claim
369	IOP	_	_	I-Claim
370	than	_	_	I-Claim
371	the	_	_	I-Claim
372	Baerveldt	_	_	I-Claim
373	250-mm	_	_	I-Claim
374	(	_	_	I-Claim
375	2	_	_	I-Claim
376	)	_	_	I-Claim
377	Glaucoma	_	_	I-Claim
378	Implant	_	_	I-Claim
379	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	Baerveldt	_	_	O
8	and	_	_	O
9	Ahmed	_	_	O
10	glaucoma	_	_	O
11	drainage	_	_	O
12	implants	_	_	O
13	in	_	_	O
14	Asian	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	refractory	_	_	O
18	glaucoma	_	_	O
19	.	_	_	O

20	Retrospective	_	_	O
21	nonrandomized	_	_	O
22	study	_	_	O
23	.	_	_	O

24	Forty-one	_	_	O
25	patients	_	_	O
26	.	_	_	O

27	The	_	_	O
28	authors	_	_	O
29	reviewed	_	_	O
30	the	_	_	O
31	insertion	_	_	O
32	of	_	_	O
33	18	_	_	O
34	Ahmed	_	_	O
35	glaucoma	_	_	O
36	valved	_	_	O
37	(	_	_	O
38	AGV-S2	_	_	O
39	)	_	_	O
40	implants	_	_	O
41	and	_	_	O
42	24	_	_	O
43	350	_	_	O
44	mm	_	_	O
45	(	_	_	O
46	2	_	_	O
47	)	_	_	O
48	Baerveldt	_	_	O
49	glaucoma	_	_	O
50	implants	_	_	O
51	performed	_	_	O
52	by	_	_	O
53	a	_	_	O
54	single	_	_	O
55	surgeon	_	_	O
56	at	_	_	O
57	the	_	_	O
58	Department	_	_	O
59	of	_	_	O
60	Ophthalmology	_	_	O
61	,	_	_	O
62	National	_	_	O
63	University	_	_	O
64	Hospital	_	_	O
65	,	_	_	O
66	Singapore	_	_	O
67	,	_	_	O
68	from	_	_	O
69	January	_	_	O
70	1	_	_	O
71	,	_	_	O
72	2000	_	_	O
73	,	_	_	O
74	to	_	_	O
75	December	_	_	O
76	31	_	_	O
77	,	_	_	O
78	2000	_	_	O
79	.	_	_	O

80	A	_	_	O
81	total	_	_	O
82	of	_	_	O
83	42	_	_	O
84	glaucoma	_	_	O
85	drainage	_	_	O
86	implants	_	_	O
87	was	_	_	O
88	inserted	_	_	O
89	into	_	_	O
90	the	_	_	O
91	eyes	_	_	O
92	of	_	_	O
93	41	_	_	O
94	patients	_	_	O
95	.	_	_	O

96	All	_	_	O
97	patients	_	_	O
98	had	_	_	O
99	at	_	_	O
100	least	_	_	O
101	6	_	_	O
102	months	_	_	O
103	of	_	_	O
104	follow-up	_	_	O
105	.	_	_	O

106	Intraocular	_	_	O
107	pressure	_	_	O
108	(	_	_	O
109	IOP	_	_	O
110	)	_	_	O
111	,	_	_	O
112	visual	_	_	O
113	acuity	_	_	O
114	,	_	_	O
115	and	_	_	O
116	complications	_	_	O
117	.	_	_	O

118	Both	_	_	B-Premise
119	drainage	_	_	I-Premise
120	implants	_	_	I-Premise
121	achieved	_	_	I-Premise
122	remarkable	_	_	I-Premise
123	reductions	_	_	I-Premise
124	in	_	_	I-Premise
125	IOP	_	_	I-Premise
126	;	_	_	I-Premise
127	from	_	_	I-Premise
128	pretreatment	_	_	I-Premise
129	IOP	_	_	I-Premise
130	of	_	_	I-Premise
131	40.1+/-13.8	_	_	I-Premise
132	mmHg	_	_	I-Premise
133	and	_	_	I-Premise
134	43.7+/-9.3	_	_	I-Premise
135	mmHg	_	_	I-Premise
136	to	_	_	I-Premise
137	postoperative	_	_	I-Premise
138	IOP	_	_	I-Premise
139	of	_	_	I-Premise
140	17.4+/-6.2	_	_	I-Premise
141	and	_	_	I-Premise
142	14.9+/-5.5	_	_	I-Premise
143	mmHg	_	_	I-Premise
144	in	_	_	I-Premise
145	the	_	_	I-Premise
146	Baerveldt	_	_	I-Premise
147	and	_	_	I-Premise
148	Ahmed	_	_	I-Premise
149	groups	_	_	I-Premise
150	,	_	_	I-Premise
151	respectively	_	_	I-Premise
152	.	_	_	I-Premise

153	A	_	_	B-Premise
154	decrease	_	_	I-Premise
155	in	_	_	I-Premise
156	IOP	_	_	I-Premise
157	of	_	_	I-Premise
158	56.6	_	_	I-Premise
159	%	_	_	I-Premise
160	and	_	_	I-Premise
161	65.9	_	_	I-Premise
162	%	_	_	I-Premise
163	had	_	_	I-Premise
164	been	_	_	I-Premise
165	achieved	_	_	I-Premise
166	.	_	_	I-Premise

167	Success	_	_	B-Premise
168	rates	_	_	I-Premise
169	were	_	_	I-Premise
170	20	_	_	I-Premise
171	(	_	_	I-Premise
172	83.3	_	_	I-Premise
173	%	_	_	I-Premise
174	)	_	_	I-Premise
175	for	_	_	I-Premise
176	Baerveldt	_	_	I-Premise
177	and	_	_	I-Premise
178	12	_	_	I-Premise
179	(	_	_	I-Premise
180	66.7	_	_	I-Premise
181	%	_	_	I-Premise
182	)	_	_	I-Premise
183	for	_	_	I-Premise
184	Ahmed	_	_	I-Premise
185	implants	_	_	I-Premise
186	,	_	_	I-Premise
187	whereas	_	_	I-Premise
188	qualified	_	_	I-Premise
189	success	_	_	I-Premise
190	occurred	_	_	I-Premise
191	in	_	_	I-Premise
192	1	_	_	I-Premise
193	(	_	_	I-Premise
194	4.2	_	_	I-Premise
195	%	_	_	I-Premise
196	)	_	_	I-Premise
197	Baerveldt	_	_	I-Premise
198	and	_	_	I-Premise
199	3	_	_	I-Premise
200	(	_	_	I-Premise
201	16.7	_	_	I-Premise
202	%	_	_	I-Premise
203	)	_	_	I-Premise
204	Ahmed	_	_	I-Premise
205	implants	_	_	I-Premise
206	.	_	_	I-Premise

207	Conversely	_	_	B-Premise
208	,	_	_	I-Premise
209	failure	_	_	I-Premise
210	to	_	_	I-Premise
211	control	_	_	I-Premise
212	IOP	_	_	I-Premise
213	occurred	_	_	I-Premise
214	in	_	_	I-Premise
215	3	_	_	I-Premise
216	(	_	_	I-Premise
217	12.5	_	_	I-Premise
218	%	_	_	I-Premise
219	)	_	_	I-Premise
220	Baerveldt	_	_	I-Premise
221	implants	_	_	I-Premise
222	and	_	_	I-Premise
223	3	_	_	I-Premise
224	(	_	_	I-Premise
225	16.7	_	_	I-Premise
226	%	_	_	I-Premise
227	)	_	_	I-Premise
228	Ahmed	_	_	I-Premise
229	implants	_	_	I-Premise
230	.	_	_	I-Premise

231	More	_	_	B-Premise
232	than	_	_	I-Premise
233	80	_	_	I-Premise
234	%	_	_	I-Premise
235	of	_	_	I-Premise
236	the	_	_	I-Premise
237	patients	_	_	I-Premise
238	had	_	_	I-Premise
239	maintained	_	_	I-Premise
240	or	_	_	I-Premise
241	improved	_	_	I-Premise
242	visual	_	_	I-Premise
243	function	_	_	I-Premise
244	,	_	_	I-Premise
245	whereas	_	_	I-Premise
246	only	_	_	I-Premise
247	4	_	_	I-Premise
248	(	_	_	I-Premise
249	16.0	_	_	I-Premise
250	%	_	_	I-Premise
251	)	_	_	I-Premise
252	of	_	_	I-Premise
253	the	_	_	I-Premise
254	patients	_	_	I-Premise
255	with	_	_	I-Premise
256	Baerveldt	_	_	I-Premise
257	implants	_	_	I-Premise
258	and	_	_	I-Premise
259	2	_	_	I-Premise
260	(	_	_	I-Premise
261	16.7	_	_	I-Premise
262	%	_	_	I-Premise
263	)	_	_	I-Premise
264	patients	_	_	I-Premise
265	with	_	_	I-Premise
266	Ahmed	_	_	I-Premise
267	implants	_	_	I-Premise
268	had	_	_	I-Premise
269	loss	_	_	I-Premise
270	of	_	_	I-Premise
271	more	_	_	I-Premise
272	than	_	_	I-Premise
273	1	_	_	I-Premise
274	Snellen	_	_	I-Premise
275	line	_	_	I-Premise
276	.	_	_	I-Premise

277	Both	_	_	B-Claim
278	Baerveldt	_	_	I-Claim
279	and	_	_	I-Claim
280	Ahmed	_	_	I-Claim
281	glaucoma	_	_	I-Claim
282	drainage	_	_	I-Claim
283	implants	_	_	I-Claim
284	performed	_	_	I-Claim
285	well	_	_	I-Claim
286	in	_	_	I-Claim
287	terms	_	_	I-Claim
288	of	_	_	I-Claim
289	IOP	_	_	I-Claim
290	control	_	_	I-Claim
291	,	_	_	I-Claim
292	preservation	_	_	I-Claim
293	of	_	_	I-Claim
294	visual	_	_	I-Claim
295	function	_	_	I-Claim
296	,	_	_	I-Claim
297	and	_	_	I-Claim
298	having	_	_	I-Claim
299	low	_	_	I-Claim
300	complication	_	_	I-Claim
301	rates	_	_	I-Claim
302	.	_	_	I-Claim


0	To	_	_	O
1	report	_	_	O
2	the	_	_	O
3	longer	_	_	O
4	term	_	_	O
5	results	_	_	O
6	of	_	_	O
7	a	_	_	O
8	randomized	_	_	O
9	,	_	_	O
10	clinical	_	_	O
11	trial	_	_	O
12	comparing	_	_	O
13	the	_	_	O
14	350-mm2	_	_	O
15	and	_	_	O
16	the	_	_	O
17	500-mm2	_	_	O
18	Baerveldt	_	_	O
19	glaucoma	_	_	O
20	implants	_	_	O
21	.	_	_	O

22	Extended	_	_	O
23	follow-up	_	_	O
24	on	_	_	O
25	a	_	_	O
26	randomized	_	_	O
27	,	_	_	O
28	controlled	_	_	O
29	trial	_	_	O
30	.	_	_	O

31	Between	_	_	O
32	March	_	_	O
33	1991	_	_	O
34	and	_	_	O
35	April	_	_	O
36	1993	_	_	O
37	,	_	_	O
38	107	_	_	O
39	patients	_	_	O
40	with	_	_	O
41	uncontrolled	_	_	O
42	intraocular	_	_	O
43	pressure	_	_	O
44	(	_	_	O
45	IOP	_	_	O
46	)	_	_	O
47	due	_	_	O
48	to	_	_	O
49	non-neovascular	_	_	O
50	glaucoma	_	_	O
51	associated	_	_	O
52	with	_	_	O
53	aphakia	_	_	O
54	,	_	_	O
55	pseudophakia	_	_	O
56	,	_	_	O
57	or	_	_	O
58	failed	_	_	O
59	filters	_	_	O
60	were	_	_	O
61	randomly	_	_	O
62	assigned	_	_	O
63	for	_	_	O
64	surgical	_	_	O
65	placement	_	_	O
66	of	_	_	O
67	either	_	_	O
68	the	_	_	O
69	350-mm2	_	_	O
70	or	_	_	O
71	the	_	_	O
72	500-mm2	_	_	O
73	Baerveldt	_	_	O
74	implant	_	_	O
75	at	_	_	O
76	the	_	_	O
77	Doheny	_	_	O
78	Eye	_	_	O
79	Institute	_	_	O
80	.	_	_	O

81	A	_	_	O
82	random-numbers	_	_	O
83	table	_	_	O
84	was	_	_	O
85	used	_	_	O
86	to	_	_	O
87	assign	_	_	O
88	each	_	_	O
89	patient	_	_	O
90	to	_	_	O
91	one	_	_	O
92	of	_	_	O
93	the	_	_	O
94	two	_	_	O
95	groups	_	_	O
96	.	_	_	O

97	Preoperative	_	_	O
98	IOPs	_	_	O
99	and	_	_	O
100	visual	_	_	O
101	acuities	_	_	O
102	were	_	_	O
103	recorded	_	_	O
104	.	_	_	O

105	Clinical	_	_	O
106	records	_	_	O
107	were	_	_	O
108	reviewed	_	_	O
109	to	_	_	O
110	ascertain	_	_	O
111	postoperative	_	_	O
112	IOPs	_	_	O
113	,	_	_	O
114	visual	_	_	O
115	acuities	_	_	O
116	,	_	_	O
117	number	_	_	O
118	of	_	_	O
119	medications	_	_	O
120	used	_	_	O
121	,	_	_	O
122	and	_	_	O
123	implant-related	_	_	O
124	complications	_	_	O
125	that	_	_	O
126	occurred	_	_	O
127	throughout	_	_	O
128	the	_	_	O
129	follow-up	_	_	O
130	period	_	_	O
131	.	_	_	O

132	Success	_	_	O
133	was	_	_	O
134	defined	_	_	O
135	as	_	_	O
136	IOP	_	_	O
137	of	_	_	O
138	6	_	_	O
139	mmHg	_	_	O
140	or	_	_	O
141	greater	_	_	O
142	and	_	_	O
143	of	_	_	O
144	21	_	_	O
145	mmHg	_	_	O
146	or	_	_	O
147	less	_	_	O
148	in	_	_	O
149	two	_	_	O
150	or	_	_	O
151	more	_	_	O
152	consecutive	_	_	O
153	follow-up	_	_	O
154	visits	_	_	O
155	without	_	_	O
156	further	_	_	O
157	glaucoma	_	_	O
158	surgery	_	_	O
159	or	_	_	O
160	loss	_	_	O
161	of	_	_	O
162	light	_	_	O
163	perception	_	_	O
164	attributable	_	_	O
165	to	_	_	O
166	glaucoma	_	_	O
167	.	_	_	O

168	The	_	_	B-Premise
169	overall	_	_	I-Premise
170	success	_	_	I-Premise
171	rates	_	_	I-Premise
172	were	_	_	I-Premise
173	87	_	_	I-Premise
174	%	_	_	I-Premise
175	for	_	_	I-Premise
176	the	_	_	I-Premise
177	350-mm2	_	_	I-Premise
178	group	_	_	I-Premise
179	and	_	_	I-Premise
180	70	_	_	I-Premise
181	%	_	_	I-Premise
182	for	_	_	I-Premise
183	the	_	_	I-Premise
184	500-mm2	_	_	I-Premise
185	group	_	_	I-Premise
186	(	_	_	I-Premise
187	P	_	_	I-Premise
188	=	_	_	I-Premise
189	0.05	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	Average	_	_	O
193	follow-up	_	_	O
194	was	_	_	O
195	37	_	_	O
196	months	_	_	O
197	(	_	_	O
198	range	_	_	O
199	,	_	_	O
200	1-76	_	_	O
201	months	_	_	O
202	)	_	_	O
203	for	_	_	O
204	the	_	_	O
205	350-mm2	_	_	O
206	group	_	_	O
207	and	_	_	O
208	34	_	_	O
209	months	_	_	O
210	(	_	_	O
211	range	_	_	O
212	,	_	_	O
213	5-77	_	_	O
214	months	_	_	O
215	)	_	_	O
216	for	_	_	O
217	the	_	_	O
218	500-mm2	_	_	O
219	group	_	_	O
220	.	_	_	O

221	The	_	_	B-Premise
222	life-table	_	_	I-Premise
223	success	_	_	I-Premise
224	rates	_	_	I-Premise
225	declined	_	_	I-Premise
226	over	_	_	I-Premise
227	time	_	_	I-Premise
228	for	_	_	I-Premise
229	both	_	_	I-Premise
230	implant	_	_	I-Premise
231	groups	_	_	I-Premise
232	,	_	_	I-Premise
233	from	_	_	I-Premise
234	a	_	_	I-Premise
235	high	_	_	I-Premise
236	of	_	_	I-Premise
237	98	_	_	I-Premise
238	%	_	_	I-Premise
239	for	_	_	I-Premise
240	the	_	_	I-Premise
241	350-mm2	_	_	I-Premise
242	group	_	_	I-Premise
243	and	_	_	I-Premise
244	92	_	_	I-Premise
245	%	_	_	I-Premise
246	for	_	_	I-Premise
247	the	_	_	I-Premise
248	500-mm2	_	_	I-Premise
249	group	_	_	I-Premise
250	at	_	_	I-Premise
251	1	_	_	I-Premise
252	year	_	_	I-Premise
253	to	_	_	I-Premise
254	a	_	_	I-Premise
255	cumulative	_	_	I-Premise
256	success	_	_	I-Premise
257	rate	_	_	I-Premise
258	of	_	_	I-Premise
259	79	_	_	I-Premise
260	%	_	_	I-Premise
261	for	_	_	I-Premise
262	the	_	_	I-Premise
263	350-mm2	_	_	I-Premise
264	group	_	_	I-Premise
265	and	_	_	I-Premise
266	66	_	_	I-Premise
267	%	_	_	I-Premise
268	for	_	_	I-Premise
269	the	_	_	I-Premise
270	500-mm2	_	_	I-Premise
271	group	_	_	I-Premise
272	at	_	_	I-Premise
273	5	_	_	I-Premise
274	years	_	_	I-Premise
275	.	_	_	I-Premise

276	Visual	_	_	B-Premise
277	acuities	_	_	I-Premise
278	were	_	_	I-Premise
279	better	_	_	I-Premise
280	or	_	_	I-Premise
281	remained	_	_	I-Premise
282	the	_	_	I-Premise
283	same	_	_	I-Premise
284	in	_	_	I-Premise
285	50	_	_	I-Premise
286	%	_	_	I-Premise
287	of	_	_	I-Premise
288	the	_	_	I-Premise
289	patients	_	_	I-Premise
290	in	_	_	I-Premise
291	the	_	_	I-Premise
292	350-mm2	_	_	I-Premise
293	group	_	_	I-Premise
294	and	_	_	I-Premise
295	46	_	_	I-Premise
296	%	_	_	I-Premise
297	of	_	_	I-Premise
298	those	_	_	I-Premise
299	in	_	_	I-Premise
300	the	_	_	I-Premise
301	500-mm2	_	_	I-Premise
302	group	_	_	I-Premise
303	.	_	_	I-Premise

304	Complications	_	_	O
305	during	_	_	O
306	the	_	_	O
307	5-year	_	_	O
308	follow-up	_	_	O
309	were	_	_	O
310	also	_	_	O
311	statistically	_	_	O
312	similar	_	_	O
313	.	_	_	O

314	The	_	_	B-Claim
315	longer	_	_	I-Claim
316	term	_	_	I-Claim
317	results	_	_	I-Claim
318	show	_	_	I-Claim
319	that	_	_	I-Claim
320	the	_	_	I-Claim
321	350-mm2	_	_	I-Claim
322	Baerveldt	_	_	I-Claim
323	implant	_	_	I-Claim
324	is	_	_	I-Claim
325	more	_	_	I-Claim
326	successful	_	_	I-Claim
327	than	_	_	I-Claim
328	the	_	_	I-Claim
329	500-mm2	_	_	I-Claim
330	implant	_	_	I-Claim
331	for	_	_	I-Claim
332	overall	_	_	I-Claim
333	IOP	_	_	I-Claim
334	control	_	_	I-Claim
335	.	_	_	I-Claim

336	Interval	_	_	B-Claim
337	comparisons	_	_	I-Claim
338	indicate	_	_	I-Claim
339	a	_	_	I-Claim
340	higher	_	_	I-Claim
341	rate	_	_	I-Claim
342	of	_	_	I-Claim
343	success	_	_	I-Claim
344	for	_	_	I-Claim
345	the	_	_	I-Claim
346	350-mm2	_	_	I-Claim
347	implant	_	_	I-Claim
348	in	_	_	I-Claim
349	the	_	_	I-Claim
350	first	_	_	I-Claim
351	,	_	_	I-Claim
352	second	_	_	I-Claim
353	,	_	_	I-Claim
354	third	_	_	I-Claim
355	,	_	_	I-Claim
356	fourth	_	_	I-Claim
357	,	_	_	I-Claim
358	and	_	_	I-Claim
359	fifth	_	_	I-Claim
360	years	_	_	I-Claim
361	of	_	_	I-Claim
362	implantation	_	_	I-Claim
363	.	_	_	I-Claim

364	Visual	_	_	O
365	acuities	_	_	O
366	,	_	_	O
367	implant-related	_	_	O
368	complications	_	_	O
369	,	_	_	O
370	and	_	_	O
371	average	_	_	O
372	IOPs	_	_	O
373	were	_	_	O
374	statistically	_	_	O
375	indistinguishable	_	_	O
376	between	_	_	O
377	the	_	_	O
378	two	_	_	O
379	groups	_	_	O
380	.	_	_	O


0	To	_	_	O
1	determine	_	_	O
2	whether	_	_	O
3	treatment	_	_	O
4	with	_	_	O
5	betaxolol	_	_	O
6	can	_	_	O
7	delay	_	_	O
8	or	_	_	O
9	prevent	_	_	O
10	the	_	_	O
11	conversion	_	_	O
12	from	_	_	O
13	ocular	_	_	O
14	hypertension	_	_	O
15	to	_	_	O
16	early	_	_	O
17	glaucoma	_	_	O
18	on	_	_	O
19	the	_	_	O
20	basis	_	_	O
21	of	_	_	O
22	visual	_	_	O
23	field	_	_	O
24	criteria	_	_	O
25	,	_	_	O
26	by	_	_	O
27	means	_	_	O
28	of	_	_	O
29	a	_	_	O
30	prospective	_	_	O
31	,	_	_	O
32	randomised	_	_	O
33	,	_	_	O
34	placebo-controlled	_	_	O
35	trial	_	_	O
36	.	_	_	O

37	Three	_	_	O
38	hundred	_	_	O
39	and	_	_	O
40	fifty-six	_	_	O
41	ocular	_	_	O
42	hypertensives	_	_	O
43	were	_	_	O
44	randomized	_	_	O
45	to	_	_	O
46	treatment	_	_	O
47	with	_	_	O
48	either	_	_	O
49	betaxolol	_	_	O
50	drops	_	_	O
51	or	_	_	O
52	placebo	_	_	O
53	drops	_	_	O
54	during	_	_	O
55	the	_	_	O
56	period	_	_	O
57	1992-1996	_	_	O
58	.	_	_	O

59	Each	_	_	O
60	patient	_	_	O
61	was	_	_	O
62	followed	_	_	O
63	prospectively	_	_	O
64	with	_	_	O
65	4-monthly	_	_	O
66	visits	_	_	O
67	.	_	_	O

68	Examination	_	_	O
69	at	_	_	O
70	each	_	_	O
71	visit	_	_	O
72	included	_	_	O
73	visual	_	_	O
74	field	_	_	O
75	testing	_	_	O
76	,	_	_	O
77	intra-ocular	_	_	O
78	pressure	_	_	O
79	(	_	_	O
80	IOP	_	_	O
81	)	_	_	O
82	measurement	_	_	O
83	and	_	_	O
84	optic	_	_	O
85	disc	_	_	O
86	imaging	_	_	O
87	.	_	_	O

88	Conversion	_	_	O
89	to	_	_	O
90	early	_	_	O
91	glaucoma	_	_	O
92	was	_	_	O
93	defined	_	_	O
94	on	_	_	O
95	the	_	_	O
96	basis	_	_	O
97	of	_	_	O
98	visual	_	_	O
99	field	_	_	O
100	change	_	_	O
101	by	_	_	O
102	AGIS	_	_	O
103	criteria	_	_	O
104	.	_	_	O

105	An	_	_	O
106	intent-to-treat	_	_	O
107	analysis	_	_	O
108	compared	_	_	O
109	visual	_	_	O
110	field	_	_	O
111	conversion	_	_	O
112	after	_	_	O
113	3	_	_	O
114	years	_	_	O
115	in	_	_	O
116	the	_	_	O
117	treatment	_	_	O
118	and	_	_	O
119	placebo	_	_	O
120	arms	_	_	O
121	.	_	_	O

122	Normal	_	_	O
123	visual	_	_	O
124	field	_	_	O
125	survival	_	_	O
126	analysis	_	_	O
127	was	_	_	O
128	also	_	_	O
129	performed	_	_	O
130	.	_	_	O

131	The	_	_	O
132	IOP	_	_	O
133	characteristics	_	_	O
134	of	_	_	O
135	the	_	_	O
136	two	_	_	O
137	treatment	_	_	O
138	groups	_	_	O
139	were	_	_	O
140	compared	_	_	O
141	.	_	_	O

142	Two	_	_	O
143	hundred	_	_	O
144	and	_	_	O
145	fifty-five	_	_	O
146	patients	_	_	O
147	completed	_	_	O
148	the	_	_	O
149	study	_	_	O
150	,	_	_	O
151	which	_	_	O
152	ended	_	_	O
153	in	_	_	O
154	1998	_	_	O
155	,	_	_	O
156	with	_	_	O
157	a	_	_	O
158	range	_	_	O
159	of	_	_	O
160	follow-up	_	_	O
161	of	_	_	O
162	2-6	_	_	O
163	years	_	_	O
164	.	_	_	O

165	Sixteen	_	_	B-Premise
166	(	_	_	I-Premise
167	13.2	_	_	I-Premise
168	%	_	_	I-Premise
169	)	_	_	I-Premise
170	of	_	_	I-Premise
171	121	_	_	I-Premise
172	patients	_	_	I-Premise
173	in	_	_	I-Premise
174	the	_	_	I-Premise
175	placebo	_	_	I-Premise
176	group	_	_	I-Premise
177	converted	_	_	I-Premise
178	to	_	_	I-Premise
179	glaucoma	_	_	I-Premise
180	,	_	_	I-Premise
181	compared	_	_	I-Premise
182	with	_	_	I-Premise
183	12	_	_	I-Premise
184	(	_	_	I-Premise
185	9.0	_	_	I-Premise
186	%	_	_	I-Premise
187	)	_	_	I-Premise
188	of	_	_	I-Premise
189	134	_	_	I-Premise
190	patients	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	betaxolol	_	_	I-Premise
194	group	_	_	I-Premise
195	.	_	_	I-Premise

196	The	_	_	B-Premise
197	intent-to-treat	_	_	I-Premise
198	analysis	_	_	I-Premise
199	demonstrated	_	_	I-Premise
200	no	_	_	I-Premise
201	evidence	_	_	I-Premise
202	of	_	_	I-Premise
203	any	_	_	I-Premise
204	difference	_	_	I-Premise
205	in	_	_	I-Premise
206	conversion	_	_	I-Premise
207	rates	_	_	I-Premise
208	between	_	_	I-Premise
209	the	_	_	I-Premise
210	betaxolol	_	_	I-Premise
211	and	_	_	I-Premise
212	placebo	_	_	I-Premise
213	groups	_	_	I-Premise
214	after	_	_	I-Premise
215	3	_	_	I-Premise
216	years	_	_	I-Premise
217	.	_	_	I-Premise

218	Visual	_	_	B-Premise
219	field	_	_	I-Premise
220	survival	_	_	I-Premise
221	analysis	_	_	I-Premise
222	demonstrated	_	_	I-Premise
223	no	_	_	I-Premise
224	significant	_	_	I-Premise
225	difference	_	_	I-Premise
226	between	_	_	I-Premise
227	the	_	_	I-Premise
228	betaxolol	_	_	I-Premise
229	and	_	_	I-Premise
230	placebo	_	_	I-Premise
231	groups	_	_	I-Premise
232	.	_	_	I-Premise

233	The	_	_	B-Premise
234	betaxolol-treated	_	_	I-Premise
235	group	_	_	I-Premise
236	had	_	_	I-Premise
237	significantly	_	_	I-Premise
238	lower	_	_	I-Premise
239	post-treatment	_	_	I-Premise
240	IOP	_	_	I-Premise
241	values	_	_	I-Premise
242	.	_	_	I-Premise

243	Converters	_	_	B-Premise
244	had	_	_	I-Premise
245	significantly	_	_	I-Premise
246	higher	_	_	I-Premise
247	pre-	_	_	I-Premise
248	and	_	_	I-Premise
249	post-treatment	_	_	I-Premise
250	IOP	_	_	I-Premise
251	values	_	_	I-Premise
252	than	_	_	I-Premise
253	non-converters	_	_	I-Premise
254	.	_	_	I-Premise

255	Betaxolol	_	_	B-Premise
256	significantly	_	_	I-Premise
257	lowered	_	_	I-Premise
258	the	_	_	I-Premise
259	IOP	_	_	I-Premise
260	level	_	_	I-Premise
261	compared	_	_	I-Premise
262	with	_	_	I-Premise
263	placebo	_	_	I-Premise
264	.	_	_	I-Premise

265	Conversion	_	_	B-Premise
266	to	_	_	I-Premise
267	glaucoma	_	_	I-Premise
268	was	_	_	I-Premise
269	found	_	_	I-Premise
270	to	_	_	I-Premise
271	be	_	_	I-Premise
272	related	_	_	I-Premise
273	to	_	_	I-Premise
274	both	_	_	I-Premise
275	the	_	_	I-Premise
276	baseline	_	_	I-Premise
277	and	_	_	I-Premise
278	post-treatment	_	_	I-Premise
279	IOP	_	_	I-Premise
280	levels	_	_	I-Premise
281	.	_	_	I-Premise

282	However	_	_	O
283	the	_	_	B-Claim
284	intent-to-treat	_	_	I-Claim
285	analysis	_	_	I-Claim
286	did	_	_	I-Claim
287	not	_	_	I-Claim
288	demonstrate	_	_	I-Claim
289	a	_	_	I-Claim
290	statistically	_	_	I-Claim
291	significant	_	_	I-Claim
292	reduction	_	_	I-Claim
293	in	_	_	I-Claim
294	the	_	_	I-Claim
295	conversion	_	_	I-Claim
296	rate	_	_	I-Claim
297	in	_	_	I-Claim
298	the	_	_	I-Claim
299	betaxolol-treated	_	_	I-Claim
300	group	_	_	I-Claim
301	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	phacoemulsification	_	_	O
3	alone	_	_	O
4	versus	_	_	O
5	combined	_	_	O
6	phacotrabeculectomy	_	_	O
7	in	_	_	O
8	medically	_	_	O
9	uncontrolled	_	_	O
10	chronic	_	_	O
11	angle	_	_	O
12	closure	_	_	O
13	glaucoma	_	_	O
14	(	_	_	O
15	CACG	_	_	O
16	)	_	_	O
17	with	_	_	O
18	coexisting	_	_	O
19	cataract	_	_	O
20	.	_	_	O

21	Prospective	_	_	O
22	randomized	_	_	O
23	clinical	_	_	O
24	trial	_	_	O
25	.	_	_	O

26	Fifty-one	_	_	O
27	medically	_	_	O
28	uncontrolled	_	_	O
29	CACG	_	_	O
30	eyes	_	_	O
31	with	_	_	O
32	coexisting	_	_	O
33	cataract	_	_	O
34	of	_	_	O
35	51	_	_	O
36	patients	_	_	O
37	.	_	_	O

38	Recruited	_	_	O
39	patients	_	_	O
40	were	_	_	O
41	randomized	_	_	O
42	into	_	_	O
43	group	_	_	O
44	1	_	_	O
45	(	_	_	O
46	phacoemulsification	_	_	O
47	alone	_	_	O
48	)	_	_	O
49	or	_	_	O
50	group	_	_	O
51	2	_	_	O
52	(	_	_	O
53	combined	_	_	O
54	phacotrabeculectomy	_	_	O
55	with	_	_	O
56	adjunctive	_	_	O
57	mitomycin	_	_	O
58	C	_	_	O
59	)	_	_	O
60	.	_	_	O

61	Postoperatively	_	_	O
62	,	_	_	O
63	patients	_	_	O
64	were	_	_	O
65	reviewed	_	_	O
66	every	_	_	O
67	3	_	_	O
68	months	_	_	O
69	for	_	_	O
70	2	_	_	O
71	years	_	_	O
72	.	_	_	O

73	Intraocular	_	_	O
74	pressure	_	_	O
75	(	_	_	O
76	IOP	_	_	O
77	)	_	_	O
78	and	_	_	O
79	requirement	_	_	O
80	for	_	_	O
81	topical	_	_	O
82	glaucoma	_	_	O
83	drugs	_	_	O
84	.	_	_	O

85	Twenty-seven	_	_	O
86	CACG	_	_	O
87	eyes	_	_	O
88	were	_	_	O
89	randomized	_	_	O
90	into	_	_	O
91	group	_	_	O
92	1	_	_	O
93	,	_	_	O
94	and	_	_	O
95	24	_	_	O
96	CACG	_	_	O
97	eyes	_	_	O
98	were	_	_	O
99	randomized	_	_	O
100	into	_	_	O
101	group	_	_	O
102	2	_	_	O
103	.	_	_	O

104	Combined	_	_	B-Premise
105	phacotrabeculectomy	_	_	I-Premise
106	resulted	_	_	I-Premise
107	in	_	_	I-Premise
108	lower	_	_	I-Premise
109	mean	_	_	I-Premise
110	postoperative	_	_	I-Premise
111	IOP	_	_	I-Premise
112	than	_	_	I-Premise
113	phacoemulsification	_	_	I-Premise
114	alone	_	_	I-Premise
115	at	_	_	I-Premise
116	3	_	_	I-Premise
117	months	_	_	I-Premise
118	(	_	_	I-Premise
119	14.0	_	_	I-Premise
120	vs	_	_	I-Premise
121	17.0	_	_	I-Premise
122	mmHg	_	_	I-Premise
123	,	_	_	I-Premise
124	P	_	_	I-Premise
125	=	_	_	I-Premise
126	0.01	_	_	I-Premise
127	)	_	_	I-Premise
128	,	_	_	I-Premise
129	15	_	_	I-Premise
130	months	_	_	I-Premise
131	(	_	_	I-Premise
132	13.2	_	_	I-Premise
133	vs	_	_	I-Premise
134	15.4	_	_	I-Premise
135	mmHg	_	_	I-Premise
136	,	_	_	I-Premise
137	P	_	_	I-Premise
138	=	_	_	I-Premise
139	0.02	_	_	I-Premise
140	)	_	_	I-Premise
141	,	_	_	I-Premise
142	and	_	_	I-Premise
143	18	_	_	I-Premise
144	months	_	_	I-Premise
145	(	_	_	I-Premise
146	13.6	_	_	I-Premise
147	vs	_	_	I-Premise
148	15.9	_	_	I-Premise
149	mmHg	_	_	I-Premise
150	,	_	_	I-Premise
151	P	_	_	I-Premise
152	=	_	_	I-Premise
153	0.01	_	_	I-Premise
154	)	_	_	I-Premise
155	.	_	_	I-Premise

156	Combined	_	_	B-Premise
157	phacotrabeculectomy	_	_	I-Premise
158	resulted	_	_	I-Premise
159	in	_	_	I-Premise
160	1.25	_	_	I-Premise
161	fewer	_	_	I-Premise
162	topical	_	_	I-Premise
163	glaucoma	_	_	I-Premise
164	drugs	_	_	I-Premise
165	(	_	_	I-Premise
166	P	_	_	I-Premise
167	<	_	_	I-Premise
168	0.001	_	_	I-Premise
169	)	_	_	I-Premise
170	in	_	_	I-Premise
171	the	_	_	I-Premise
172	24-month	_	_	I-Premise
173	postoperative	_	_	I-Premise
174	period	_	_	I-Premise
175	,	_	_	I-Premise
176	compared	_	_	I-Premise
177	with	_	_	I-Premise
178	phacoemulsification	_	_	I-Premise
179	alone	_	_	I-Premise
180	.	_	_	I-Premise

181	Combined	_	_	B-Premise
182	surgery	_	_	I-Premise
183	was	_	_	I-Premise
184	associated	_	_	I-Premise
185	with	_	_	I-Premise
186	more	_	_	I-Premise
187	postoperative	_	_	I-Premise
188	complications	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	<	_	_	I-Premise
192	0.001	_	_	I-Premise
193	)	_	_	I-Premise
194	and	_	_	I-Premise
195	more	_	_	I-Premise
196	progression	_	_	I-Premise
197	of	_	_	I-Premise
198	optic	_	_	I-Premise
199	neuropathy	_	_	I-Premise
200	(	_	_	I-Premise
201	P	_	_	I-Premise
202	=	_	_	I-Premise
203	0.03	_	_	I-Premise
204	)	_	_	I-Premise
205	,	_	_	I-Premise
206	compared	_	_	I-Premise
207	with	_	_	I-Premise
208	phacoemulsification	_	_	I-Premise
209	alone	_	_	I-Premise
210	.	_	_	I-Premise

211	Combined	_	_	B-Claim
212	phacotrabeculectomy	_	_	I-Claim
213	with	_	_	I-Claim
214	adjunctive	_	_	I-Claim
215	mitomycin	_	_	I-Claim
216	C	_	_	I-Claim
217	is	_	_	I-Claim
218	more	_	_	I-Claim
219	effective	_	_	I-Claim
220	than	_	_	I-Claim
221	phacoemulsification	_	_	I-Claim
222	alone	_	_	I-Claim
223	in	_	_	I-Claim
224	controlling	_	_	I-Claim
225	IOP	_	_	I-Claim
226	in	_	_	I-Claim
227	medically	_	_	I-Claim
228	uncontrolled	_	_	I-Claim
229	CACG	_	_	I-Claim
230	eyes	_	_	I-Claim
231	with	_	_	I-Claim
232	coexisting	_	_	I-Claim
233	cataract	_	_	I-Claim
234	.	_	_	I-Claim

235	Combined	_	_	B-Claim
236	phacotrabeculectomy	_	_	I-Claim
237	is	_	_	I-Claim
238	associated	_	_	I-Claim
239	with	_	_	I-Claim
240	more	_	_	I-Claim
241	postoperative	_	_	I-Claim
242	complications	_	_	I-Claim
243	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	additional	_	_	O
4	intraocular	_	_	O
5	pressure-lowering	_	_	O
6	effect	_	_	O
7	of	_	_	O
8	latanoprost	_	_	O
9	0.005	_	_	O
10	%	_	_	O
11	administered	_	_	O
12	once	_	_	O
13	daily	_	_	O
14	with	_	_	O
15	that	_	_	O
16	of	_	_	O
17	pilocarpine	_	_	O
18	2	_	_	O
19	%	_	_	O
20	administered	_	_	O
21	three	_	_	O
22	times	_	_	O
23	daily	_	_	O
24	in	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	primary	_	_	O
28	open-angle	_	_	O
29	glaucoma	_	_	O
30	or	_	_	O
31	ocular	_	_	O
32	hypertension	_	_	O
33	currently	_	_	O
34	on	_	_	O
35	monotherapy	_	_	O
36	with	_	_	O
37	timolol	_	_	O
38	0.5	_	_	O
39	%	_	_	O
40	twice	_	_	O
41	daily	_	_	O
42	.	_	_	O

43	In	_	_	O
44	a	_	_	O
45	6-month	_	_	O
46	,	_	_	O
47	multicenter	_	_	O
48	,	_	_	O
49	randomized	_	_	O
50	,	_	_	O
51	open-label	_	_	O
52	study	_	_	O
53	242	_	_	O
54	patients	_	_	O
55	with	_	_	O
56	POAG	_	_	O
57	or	_	_	O
58	OH	_	_	O
59	whose	_	_	O
60	IOP	_	_	O
61	was	_	_	O
62	not	_	_	O
63	controlled	_	_	O
64	with	_	_	O
65	timolol	_	_	O
66	0.5	_	_	O
67	%	_	_	O
68	b.i.d	_	_	O
69	.	_	_	O

70	were	_	_	O
71	enrolled	_	_	O
72	.	_	_	O

73	Eyes	_	_	O
74	had	_	_	O
75	not	_	_	O
76	been	_	_	O
77	treated	_	_	O
78	with	_	_	O
79	pilocarpine	_	_	O
80	and	_	_	O
81	latanoprost	_	_	O
82	for	_	_	O
83	at	_	_	O
84	least	_	_	O
85	2	_	_	O
86	years	_	_	O
87	.	_	_	O

88	An	_	_	O
89	analysis	_	_	O
90	of	_	_	O
91	covariance	_	_	O
92	with	_	_	O
93	diurnal	_	_	O
94	IOP	_	_	O
95	change	_	_	O
96	from	_	_	O
97	baseline	_	_	O
98	to	_	_	O
99	month	_	_	O
100	6	_	_	O
101	for	_	_	O
102	study	_	_	O
103	eyes	_	_	O
104	was	_	_	O
105	performed	_	_	O
106	.	_	_	O

107	Four	_	_	O
108	patients	_	_	O
109	on	_	_	O
110	latanoprost	_	_	O
111	0.005	_	_	O
112	%	_	_	O
113	and	_	_	O
114	35	_	_	O
115	on	_	_	O
116	pilocarpine	_	_	O
117	2	_	_	O
118	%	_	_	O
119	did	_	_	O
120	not	_	_	O
121	complete	_	_	O
122	the	_	_	O
123	study	_	_	O
124	(	_	_	O
125	P	_	_	O
126	<	_	_	O
127	0.001	_	_	O
128	)	_	_	O
129	.	_	_	O

130	Two	_	_	O
131	hundred	_	_	O
132	and	_	_	O
133	forty	_	_	O
134	patients	_	_	O
135	were	_	_	O
136	included	_	_	O
137	in	_	_	O
138	the	_	_	O
139	intent-to-treat	_	_	O
140	analysis	_	_	O
141	.	_	_	O

142	For	_	_	B-Premise
143	both	_	_	I-Premise
144	treatments	_	_	I-Premise
145	the	_	_	I-Premise
146	diurnal	_	_	I-Premise
147	IOP	_	_	I-Premise
148	reduction	_	_	I-Premise
149	after	_	_	I-Premise
150	6	_	_	I-Premise
151	months	_	_	I-Premise
152	was	_	_	I-Premise
153	statistically	_	_	I-Premise
154	significant	_	_	I-Premise
155	(	_	_	I-Premise
156	P	_	_	I-Premise
157	<	_	_	I-Premise
158	0.001	_	_	I-Premise
159	)	_	_	I-Premise
160	.	_	_	I-Premise

161	IOP	_	_	B-Premise
162	(	_	_	I-Premise
163	mean+/-SD	_	_	I-Premise
164	)	_	_	I-Premise
165	was	_	_	I-Premise
166	reduced	_	_	I-Premise
167	from	_	_	I-Premise
168	23.3+/-2.8	_	_	I-Premise
169	to	_	_	I-Premise
170	17.8+/-2.8	_	_	I-Premise
171	(	_	_	I-Premise
172	-5.6	_	_	I-Premise
173	)	_	_	I-Premise
174	mmHg	_	_	I-Premise
175	in	_	_	I-Premise
176	the	_	_	I-Premise
177	latanoprost	_	_	I-Premise
178	0.005	_	_	I-Premise
179	%	_	_	I-Premise
180	group	_	_	I-Premise
181	and	_	_	I-Premise
182	from	_	_	I-Premise
183	23.0+/-3.2	_	_	I-Premise
184	to	_	_	I-Premise
185	18.5+/-2.4	_	_	I-Premise
186	(	_	_	I-Premise
187	-4.8	_	_	I-Premise
188	)	_	_	I-Premise
189	mmHg	_	_	I-Premise
190	in	_	_	I-Premise
191	pilocarpine	_	_	I-Premise
192	2	_	_	I-Premise
193	%	_	_	I-Premise
194	t.i.d.-treated	_	_	I-Premise
195	eyes	_	_	I-Premise
196	.	_	_	I-Premise

197	The	_	_	B-Premise
198	mean	_	_	I-Premise
199	difference	_	_	I-Premise
200	of	_	_	I-Premise
201	-0.8	_	_	I-Premise
202	mmHg	_	_	I-Premise
203	(	_	_	I-Premise
204	per	_	_	I-Premise
205	protocol	_	_	I-Premise
206	,	_	_	I-Premise
207	PP	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	-1.6	_	_	I-Premise
211	mmHg	_	_	I-Premise
212	(	_	_	I-Premise
213	intend-to-treat	_	_	I-Premise
214	,	_	_	I-Premise
215	ITT	_	_	I-Premise
216	)	_	_	I-Premise
217	was	_	_	I-Premise
218	statistically	_	_	I-Premise
219	significant	_	_	I-Premise
220	(	_	_	I-Premise
221	P	_	_	I-Premise
222	<	_	_	I-Premise
223	0.04	_	_	I-Premise
224	,	_	_	I-Premise
225	PP	_	_	I-Premise
226	;	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	0.001	_	_	I-Premise
230	,	_	_	I-Premise
231	ITT	_	_	I-Premise
232	)	_	_	I-Premise
233	in	_	_	I-Premise
234	favor	_	_	I-Premise
235	of	_	_	I-Premise
236	latanoprost	_	_	I-Premise
237	0.005	_	_	I-Premise
238	%	_	_	I-Premise
239	.	_	_	I-Premise

240	Two	_	_	B-Premise
241	eyes	_	_	I-Premise
242	treated	_	_	I-Premise
243	with	_	_	I-Premise
244	latanoprost	_	_	I-Premise
245	showed	_	_	I-Premise
246	an	_	_	I-Premise
247	iris	_	_	I-Premise
248	color	_	_	I-Premise
249	change	_	_	I-Premise
250	.	_	_	I-Premise

251	Thirty-six	_	_	B-Premise
252	patients	_	_	I-Premise
253	in	_	_	I-Premise
254	the	_	_	I-Premise
255	latanoprost	_	_	I-Premise
256	group	_	_	I-Premise
257	and	_	_	I-Premise
258	106	_	_	I-Premise
259	in	_	_	I-Premise
260	the	_	_	I-Premise
261	pilocarpine	_	_	I-Premise
262	2	_	_	I-Premise
263	%	_	_	I-Premise
264	group	_	_	I-Premise
265	reported	_	_	I-Premise
266	ocular	_	_	I-Premise
267	adverse	_	_	I-Premise
268	events	_	_	I-Premise
269	(	_	_	I-Premise
270	P	_	_	I-Premise
271	<	_	_	I-Premise
272	0.001	_	_	I-Premise
273	)	_	_	I-Premise
274	.	_	_	I-Premise

275	From	_	_	B-Claim
276	the	_	_	I-Claim
277	data	_	_	I-Claim
278	we	_	_	I-Claim
279	conclude	_	_	I-Claim
280	that	_	_	I-Claim
281	the	_	_	I-Claim
282	additivity	_	_	I-Claim
283	of	_	_	I-Claim
284	latanoprost	_	_	I-Claim
285	0.005	_	_	I-Claim
286	%	_	_	I-Claim
287	is	_	_	I-Claim
288	at	_	_	I-Claim
289	least	_	_	I-Claim
290	as	_	_	I-Claim
291	effective	_	_	I-Claim
292	as	_	_	I-Claim
293	pilocarpine	_	_	I-Claim
294	2	_	_	I-Claim
295	%	_	_	I-Claim
296	t.i.d	_	_	I-Claim
297	.	_	_	I-Claim

298	in	_	_	I-Claim
299	reducing	_	_	I-Claim
300	IOP	_	_	I-Claim
301	when	_	_	I-Claim
302	added	_	_	I-Claim
303	to	_	_	I-Claim
304	eyes	_	_	I-Claim
305	currently	_	_	I-Claim
306	on	_	_	I-Claim
307	monotherapy	_	_	I-Claim
308	with	_	_	I-Claim
309	timolol	_	_	I-Claim
310	0.5	_	_	I-Claim
311	%	_	_	I-Claim
312	b.i.d	_	_	I-Claim
313	.	_	_	I-Claim

314	Latanoprost	_	_	B-Claim
315	was	_	_	I-Claim
316	better	_	_	I-Claim
317	tolerated	_	_	I-Claim
318	than	_	_	I-Claim
319	pilocarpine	_	_	I-Claim
320	2	_	_	I-Claim
321	%	_	_	I-Claim
322	eye	_	_	I-Claim
323	drops	_	_	I-Claim
324	in	_	_	I-Claim
325	this	_	_	I-Claim
326	study	_	_	I-Claim
327	.	_	_	I-Claim

328	The	_	_	B-Claim
329	increase	_	_	I-Claim
330	in	_	_	I-Claim
331	iris	_	_	I-Claim
332	pigmentation	_	_	I-Claim
333	requires	_	_	I-Claim
334	further	_	_	I-Claim
335	investigation	_	_	I-Claim
336	.	_	_	I-Claim


0	The	_	_	O
1	Baerveldt	_	_	O
2	glaucoma	_	_	O
3	implant	_	_	O
4	is	_	_	O
5	a	_	_	O
6	large	_	_	O
7	equatorial	_	_	O
8	aqueous	_	_	O
9	shunting	_	_	O
10	device	_	_	O
11	that	_	_	O
12	is	_	_	O
13	installed	_	_	O
14	through	_	_	O
15	a	_	_	O
16	single-quadrant	_	_	O
17	conjunctival	_	_	O
18	incision	_	_	O
19	.	_	_	O

20	The	_	_	O
21	intermediate-term	_	_	O
22	results	_	_	O
23	of	_	_	O
24	a	_	_	O
25	randomized	_	_	O
26	study	_	_	O
27	comparing	_	_	O
28	the	_	_	O
29	350-	_	_	O
30	and	_	_	O
31	500-mm2	_	_	O
32	Baerveldt	_	_	O
33	implants	_	_	O
34	are	_	_	O
35	reported	_	_	O
36	.	_	_	O

37	Seventy-three	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	medically	_	_	O
41	uncontrollable	_	_	O
42	,	_	_	O
43	nonneovascular	_	_	O
44	glaucomas	_	_	O
45	associated	_	_	O
46	with	_	_	O
47	aphakia	_	_	O
48	,	_	_	O
49	pseudophakia	_	_	O
50	,	_	_	O
51	or	_	_	O
52	failed	_	_	O
53	filters	_	_	O
54	were	_	_	O
55	enrolled	_	_	O
56	in	_	_	O
57	a	_	_	O
58	randomized	_	_	O
59	,	_	_	O
60	prospective	_	_	O
61	study	_	_	O
62	comparing	_	_	O
63	350-	_	_	O
64	and	_	_	O
65	500-mm2	_	_	O
66	Baerveldt	_	_	O
67	implants	_	_	O
68	.	_	_	O

69	Surgical	_	_	O
70	success	_	_	O
71	was	_	_	O
72	defined	_	_	O
73	as	_	_	O
74	6	_	_	O
75	mmHg	_	_	O
76	<	_	_	O
77	or	_	_	O
78	=	_	_	O
79	final	_	_	O
80	intraocular	_	_	O
81	pressure	_	_	O
82	<	_	_	O
83	or	_	_	O
84	=	_	_	O
85	21	_	_	O
86	mmHg	_	_	O
87	without	_	_	O
88	glaucoma	_	_	O
89	reoperation	_	_	O
90	or	_	_	O
91	devastating	_	_	O
92	complication	_	_	O
93	.	_	_	O

94	Of	_	_	B-Premise
95	patients	_	_	I-Premise
96	with	_	_	I-Premise
97	350-	_	_	I-Premise
98	and	_	_	I-Premise
99	500-mm2	_	_	I-Premise
100	implants	_	_	I-Premise
101	,	_	_	I-Premise
102	93	_	_	I-Premise
103	%	_	_	I-Premise
104	and	_	_	I-Premise
105	88	_	_	I-Premise
106	%	_	_	I-Premise
107	,	_	_	I-Premise
108	respectively	_	_	I-Premise
109	,	_	_	I-Premise
110	achieved	_	_	I-Premise
111	surgical	_	_	I-Premise
112	success	_	_	I-Premise
113	(	_	_	I-Premise
114	18-month	_	_	I-Premise
115	life-table	_	_	I-Premise
116	analysis	_	_	I-Premise
117	,	_	_	I-Premise
118	P	_	_	I-Premise
119	=	_	_	I-Premise
120	0.93	_	_	I-Premise
121	)	_	_	I-Premise
122	.	_	_	I-Premise

123	The	_	_	B-Premise
124	500-mm2	_	_	I-Premise
125	implants	_	_	I-Premise
126	afforded	_	_	I-Premise
127	intraocular	_	_	I-Premise
128	pressure	_	_	I-Premise
129	control	_	_	I-Premise
130	with	_	_	I-Premise
131	significantly	_	_	I-Premise
132	fewer	_	_	I-Premise
133	medications	_	_	I-Premise
134	(	_	_	I-Premise
135	0.7	_	_	I-Premise
136	versus	_	_	I-Premise
137	1.3	_	_	I-Premise
138	;	_	_	I-Premise
139	P	_	_	I-Premise
140	=	_	_	I-Premise
141	0.006	_	_	I-Premise
142	)	_	_	I-Premise
143	.	_	_	I-Premise

144	The	_	_	B-Premise
145	postoperative	_	_	I-Premise
146	visual	_	_	I-Premise
147	acuities	_	_	I-Premise
148	remained	_	_	I-Premise
149	within	_	_	I-Premise
150	one	_	_	I-Premise
151	line	_	_	I-Premise
152	of	_	_	I-Premise
153	the	_	_	I-Premise
154	preoperative	_	_	I-Premise
155	visual	_	_	I-Premise
156	acuities	_	_	I-Premise
157	or	_	_	I-Premise
158	improved	_	_	I-Premise
159	in	_	_	I-Premise
160	62	_	_	I-Premise
161	%	_	_	I-Premise
162	and	_	_	I-Premise
163	66	_	_	I-Premise
164	%	_	_	I-Premise
165	of	_	_	I-Premise
166	patients	_	_	I-Premise
167	in	_	_	I-Premise
168	the	_	_	I-Premise
169	350-	_	_	I-Premise
170	and	_	_	I-Premise
171	500-mm2	_	_	I-Premise
172	groups	_	_	I-Premise
173	,	_	_	I-Premise
174	respectively	_	_	I-Premise
175	(	_	_	I-Premise
176	P	_	_	I-Premise
177	=	_	_	I-Premise
178	0.93	_	_	I-Premise
179	)	_	_	I-Premise
180	.	_	_	I-Premise

181	Complication	_	_	B-Claim
182	rates	_	_	I-Claim
183	were	_	_	I-Claim
184	statistically	_	_	I-Claim
185	similar	_	_	I-Claim
186	.	_	_	I-Claim

187	The	_	_	B-Premise
188	most	_	_	I-Premise
189	frequent	_	_	I-Premise
190	ones	_	_	I-Premise
191	in	_	_	I-Premise
192	the	_	_	I-Premise
193	350-	_	_	I-Premise
194	and	_	_	I-Premise
195	500-mm2	_	_	I-Premise
196	groups	_	_	I-Premise
197	,	_	_	I-Premise
198	respectively	_	_	I-Premise
199	,	_	_	I-Premise
200	were	_	_	I-Premise
201	serous	_	_	I-Premise
202	choroidal	_	_	I-Premise
203	effusion	_	_	I-Premise
204	(	_	_	I-Premise
205	16	_	_	I-Premise
206	%	_	_	I-Premise
207	and	_	_	I-Premise
208	32	_	_	I-Premise
209	%	_	_	I-Premise
210	)	_	_	I-Premise
211	,	_	_	I-Premise
212	strabismus	_	_	I-Premise
213	(	_	_	I-Premise
214	16	_	_	I-Premise
215	%	_	_	I-Premise
216	and	_	_	I-Premise
217	19	_	_	I-Premise
218	%	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	anterior	_	_	I-Premise
222	uveitis	_	_	I-Premise
223	(	_	_	I-Premise
224	14	_	_	I-Premise
225	%	_	_	I-Premise
226	and	_	_	I-Premise
227	11	_	_	I-Premise
228	%	_	_	I-Premise
229	)	_	_	I-Premise
230	,	_	_	I-Premise
231	and	_	_	I-Premise
232	corneal	_	_	I-Premise
233	or	_	_	I-Premise
234	corneal	_	_	I-Premise
235	graft	_	_	I-Premise
236	edema	_	_	I-Premise
237	(	_	_	I-Premise
238	11	_	_	I-Premise
239	%	_	_	I-Premise
240	each	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	The	_	_	B-Claim
244	intermediate-term	_	_	I-Claim
245	results	_	_	I-Claim
246	of	_	_	I-Claim
247	the	_	_	I-Claim
248	350-	_	_	I-Claim
249	and	_	_	I-Claim
250	500-mm2	_	_	I-Claim
251	Baerveldt	_	_	I-Claim
252	implants	_	_	I-Claim
253	were	_	_	I-Claim
254	statistically	_	_	I-Claim
255	comparable	_	_	I-Claim
256	with	_	_	I-Claim
257	respect	_	_	I-Claim
258	to	_	_	I-Claim
259	surgical	_	_	I-Claim
260	and	_	_	I-Claim
261	visual	_	_	I-Claim
262	outcomes	_	_	I-Claim
263	,	_	_	I-Claim
264	as	_	_	I-Claim
265	well	_	_	I-Claim
266	as	_	_	I-Claim
267	complications	_	_	I-Claim
268	,	_	_	O
269	although	_	_	B-Claim
270	the	_	_	I-Claim
271	larger	_	_	I-Claim
272	implant	_	_	I-Claim
273	was	_	_	I-Claim
274	associated	_	_	I-Claim
275	with	_	_	I-Claim
276	a	_	_	I-Claim
277	higher	_	_	I-Claim
278	rate	_	_	I-Claim
279	of	_	_	I-Claim
280	some	_	_	I-Claim
281	complications	_	_	I-Claim
282	.	_	_	I-Claim

283	However	_	_	O
284	,	_	_	O
285	the	_	_	B-Claim
286	500-mm2	_	_	I-Claim
287	Baerveldt	_	_	I-Claim
288	implant	_	_	I-Claim
289	afforded	_	_	I-Claim
290	intraocular	_	_	I-Claim
291	pressure	_	_	I-Claim
292	control	_	_	I-Claim
293	with	_	_	I-Claim
294	fewer	_	_	I-Claim
295	medications	_	_	I-Claim
296	than	_	_	I-Claim
297	the	_	_	I-Claim
298	350-mm2	_	_	I-Claim
299	implant	_	_	I-Claim
300	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	additive	_	_	O
4	intraocular	_	_	O
5	pressure	_	_	O
6	(	_	_	O
7	IOP	_	_	O
8	)	_	_	O
9	-lowering	_	_	O
10	efficacy	_	_	O
11	and	_	_	O
12	safety	_	_	O
13	of	_	_	O
14	fixed	_	_	O
15	combination	_	_	O
16	brimonidine	_	_	O
17	0.2	_	_	O
18	%	_	_	O
19	/timolol	_	_	O
20	0.5	_	_	O
21	%	_	_	O
22	compared	_	_	O
23	with	_	_	O
24	timolol	_	_	O
25	0.5	_	_	O
26	%	_	_	O
27	at	_	_	O
28	peak	_	_	O
29	and	_	_	O
30	trough	_	_	O
31	effect	_	_	O
32	when	_	_	O
33	used	_	_	O
34	as	_	_	O
35	therapy	_	_	O
36	adjunctive	_	_	O
37	to	_	_	O
38	latanoprost	_	_	O
39	0.005	_	_	O
40	%	_	_	O
41	in	_	_	O
42	patients	_	_	O
43	with	_	_	O
44	glaucoma	_	_	O
45	or	_	_	O
46	ocular	_	_	O
47	hypertension	_	_	O
48	who	_	_	O
49	require	_	_	O
50	additional	_	_	O
51	IOP	_	_	O
52	lowering	_	_	O
53	.	_	_	O

54	In	_	_	O
55	this	_	_	O
56	prospective	_	_	O
57	,	_	_	O
58	randomized	_	_	O
59	,	_	_	O
60	multicenter	_	_	O
61	,	_	_	O
62	investigator-masked	_	_	O
63	,	_	_	O
64	parallel-group	_	_	O
65	study	_	_	O
66	,	_	_	O
67	patients	_	_	O
68	were	_	_	O
69	treated	_	_	O
70	with	_	_	O
71	latanoprost	_	_	O
72	monotherapy	_	_	O
73	for	_	_	O
74	at	_	_	O
75	least	_	_	O
76	four	_	_	O
77	weeks	_	_	O
78	prior	_	_	O
79	to	_	_	O
80	baseline	_	_	O
81	.	_	_	O

82	At	_	_	O
83	baseline	_	_	O
84	on	_	_	O
85	latanoprost	_	_	O
86	,	_	_	O
87	patients	_	_	O
88	with	_	_	O
89	IOP	_	_	O
90	21	_	_	O
91	mmHg	_	_	O
92	in	_	_	O
93	at	_	_	O
94	least	_	_	O
95	one	_	_	O
96	eye	_	_	O
97	were	_	_	O
98	randomized	_	_	O
99	to	_	_	O
100	twice-daily	_	_	O
101	fixed	_	_	O
102	brimonidine-timolol	_	_	O
103	(	_	_	O
104	n	_	_	O
105	=	_	_	O
106	102	_	_	O
107	)	_	_	O
108	or	_	_	O
109	timolol	_	_	O
110	(	_	_	O
111	n	_	_	O
112	=	_	_	O
113	102	_	_	O
114	)	_	_	O
115	,	_	_	O
116	each	_	_	O
117	adjunctive	_	_	O
118	to	_	_	O
119	latanoprost	_	_	O
120	for	_	_	O
121	12	_	_	O
122	weeks	_	_	O
123	.	_	_	O

124	IOP	_	_	O
125	was	_	_	O
126	measured	_	_	O
127	at	_	_	O
128	8	_	_	O
129	am	_	_	O
130	and	_	_	O
131	10	_	_	O
132	am	_	_	O
133	at	_	_	O
134	baseline	_	_	O
135	,	_	_	O
136	week	_	_	O
137	6	_	_	O
138	,	_	_	O
139	and	_	_	O
140	week	_	_	O
141	12	_	_	O
142	and	_	_	O
143	evaluated	_	_	O
144	in	_	_	O
145	the	_	_	O
146	per	_	_	O
147	protocol	_	_	O
148	population	_	_	O
149	.	_	_	O

150	The	_	_	O
151	primary	_	_	O
152	efficacy	_	_	O
153	endpoint	_	_	O
154	was	_	_	O
155	peak	_	_	O
156	IOP	_	_	O
157	lowering	_	_	O
158	at	_	_	O
159	10	_	_	O
160	am	_	_	O
161	,	_	_	O
162	week	_	_	O
163	12	_	_	O
164	.	_	_	O

165	Safety	_	_	O
166	measures	_	_	O
167	included	_	_	O
168	adverse	_	_	O
169	events	_	_	O
170	.	_	_	O

171	Baseline	_	_	O
172	mean	_	_	O
173	IOP	_	_	O
174	was	_	_	O
175	similar	_	_	O
176	at	_	_	O
177	10	_	_	O
178	am	_	_	O
179	in	_	_	O
180	the	_	_	O
181	treatment	_	_	O
182	groups	_	_	O
183	(	_	_	O
184	brimonidine-timolol	_	_	O
185	23.4	_	_	O
186	mmHg	_	_	O
187	;	_	_	O
188	timolol	_	_	O
189	23.0	_	_	O
190	mmHg	_	_	O
191	)	_	_	O
192	.	_	_	O

193	The	_	_	B-Premise
194	mean	_	_	I-Premise
195	additional	_	_	I-Premise
196	reduction	_	_	I-Premise
197	from	_	_	I-Premise
198	latanoprost-treated	_	_	I-Premise
199	baseline	_	_	I-Premise
200	IOP	_	_	I-Premise
201	was	_	_	I-Premise
202	8.3	_	_	I-Premise
203	mmHg	_	_	I-Premise
204	(	_	_	I-Premise
205	35.5	_	_	I-Premise
206	%	_	_	I-Premise
207	)	_	_	I-Premise
208	with	_	_	I-Premise
209	fixed	_	_	I-Premise
210	brimonidine-timolol	_	_	I-Premise
211	and	_	_	I-Premise
212	6.2	_	_	I-Premise
213	mmHg	_	_	I-Premise
214	(	_	_	I-Premise
215	27.0	_	_	I-Premise
216	%	_	_	I-Premise
217	)	_	_	I-Premise
218	with	_	_	I-Premise
219	timolol	_	_	I-Premise
220	at	_	_	I-Premise
221	10	_	_	I-Premise
222	am	_	_	I-Premise
223	,	_	_	I-Premise
224	week	_	_	I-Premise
225	12	_	_	I-Premise
226	(	_	_	I-Premise
227	P	_	_	I-Premise
228	<	_	_	I-Premise
229	0.001	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	Patients	_	_	B-Premise
233	treated	_	_	I-Premise
234	with	_	_	I-Premise
235	fixed	_	_	I-Premise
236	brimonidine-timolol	_	_	I-Premise
237	adjunctive	_	_	I-Premise
238	to	_	_	I-Premise
239	latanoprost	_	_	I-Premise
240	were	_	_	I-Premise
241	significantly	_	_	I-Premise
242	more	_	_	I-Premise
243	likely	_	_	I-Premise
244	than	_	_	I-Premise
245	patients	_	_	I-Premise
246	treated	_	_	I-Premise
247	with	_	_	I-Premise
248	adjunctive	_	_	I-Premise
249	timolol	_	_	I-Premise
250	to	_	_	I-Premise
251	achieve	_	_	I-Premise
252	an	_	_	I-Premise
253	IOP	_	_	I-Premise
254	<	_	_	I-Premise
255	18	_	_	I-Premise
256	mmHg	_	_	I-Premise
257	(	_	_	I-Premise
258	P	_	_	I-Premise
259	=	_	_	I-Premise
260	0.028	_	_	I-Premise
261	)	_	_	I-Premise
262	and	_	_	I-Premise
263	a	_	_	I-Premise
264	20	_	_	I-Premise
265	%	_	_	I-Premise
266	reduction	_	_	I-Premise
267	in	_	_	I-Premise
268	IOP	_	_	I-Premise
269	from	_	_	I-Premise
270	baseline	_	_	I-Premise
271	(	_	_	I-Premise
272	P	_	_	I-Premise
273	=	_	_	I-Premise
274	0.047	_	_	I-Premise
275	)	_	_	I-Premise
276	at	_	_	I-Premise
277	both	_	_	I-Premise
278	8	_	_	I-Premise
279	am	_	_	I-Premise
280	and	_	_	I-Premise
281	10	_	_	I-Premise
282	am	_	_	I-Premise
283	in	_	_	I-Premise
284	week	_	_	I-Premise
285	12	_	_	I-Premise
286	.	_	_	I-Premise

287	Adverse	_	_	B-Premise
288	events	_	_	I-Premise
289	occurred	_	_	I-Premise
290	in	_	_	I-Premise
291	14.7	_	_	I-Premise
292	%	_	_	I-Premise
293	of	_	_	I-Premise
294	fixed	_	_	I-Premise
295	brimonidine-timolol	_	_	I-Premise
296	patients	_	_	I-Premise
297	and	_	_	I-Premise
298	12.7	_	_	I-Premise
299	%	_	_	I-Premise
300	of	_	_	I-Premise
301	timolol	_	_	I-Premise
302	patients	_	_	I-Premise
303	.	_	_	I-Premise

304	Biomicroscopy	_	_	B-Premise
305	findings	_	_	I-Premise
306	were	_	_	I-Premise
307	similar	_	_	I-Premise
308	between	_	_	I-Premise
309	the	_	_	I-Premise
310	treatment	_	_	I-Premise
311	groups	_	_	I-Premise
312	after	_	_	I-Premise
313	12	_	_	I-Premise
314	weeks	_	_	I-Premise
315	of	_	_	I-Premise
316	treatment	_	_	I-Premise
317	.	_	_	I-Premise

318	Fixed-combination	_	_	B-Claim
319	brimonidine-timolol	_	_	I-Claim
320	reduced	_	_	I-Claim
321	IOP	_	_	I-Claim
322	significantly	_	_	I-Claim
323	more	_	_	I-Claim
324	effectively	_	_	I-Claim
325	than	_	_	I-Claim
326	timolol	_	_	I-Claim
327	when	_	_	I-Claim
328	used	_	_	I-Claim
329	as	_	_	I-Claim
330	adjunctive	_	_	I-Claim
331	therapy	_	_	I-Claim
332	to	_	_	I-Claim
333	latanoprost	_	_	I-Claim
334	in	_	_	I-Claim
335	patients	_	_	I-Claim
336	with	_	_	I-Claim
337	glaucoma	_	_	I-Claim
338	and	_	_	I-Claim
339	ocular	_	_	I-Claim
340	hypertension	_	_	I-Claim
341	.	_	_	I-Claim

342	Both	_	_	B-Claim
343	fixed	_	_	I-Claim
344	brimonidine-timolol	_	_	I-Claim
345	and	_	_	I-Claim
346	timolol	_	_	I-Claim
347	were	_	_	I-Claim
348	well	_	_	I-Claim
349	tolerated	_	_	I-Claim
350	as	_	_	I-Claim
351	agents	_	_	I-Claim
352	adjunctive	_	_	I-Claim
353	to	_	_	I-Claim
354	latanoprost	_	_	I-Claim
355	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	(	_	_	O
6	IOP	_	_	O
7	)	_	_	O
8	-lowering	_	_	O
9	efficacy	_	_	O
10	and	_	_	O
11	safety	_	_	O
12	of	_	_	O
13	fixed-combination	_	_	O
14	brimonidine	_	_	O
15	0.2	_	_	O
16	%	_	_	O
17	-timolol	_	_	O
18	0.5	_	_	O
19	%	_	_	O
20	compared	_	_	O
21	with	_	_	O
22	latanoprost	_	_	O
23	0.005	_	_	O
24	%	_	_	O
25	in	_	_	O
26	patients	_	_	O
27	with	_	_	O
28	glaucoma	_	_	O
29	or	_	_	O
30	ocular	_	_	O
31	hypertension	_	_	O
32	.	_	_	O

33	This	_	_	O
34	was	_	_	O
35	a	_	_	O
36	prospective	_	_	O
37	,	_	_	O
38	randomized	_	_	O
39	,	_	_	O
40	multicenter	_	_	O
41	,	_	_	O
42	investigator-masked	_	_	O
43	clinical	_	_	O
44	trial	_	_	O
45	.	_	_	O

46	After	_	_	O
47	washout	_	_	O
48	of	_	_	O
49	any	_	_	O
50	previous	_	_	O
51	IOP-lowering	_	_	O
52	medications	_	_	O
53	,	_	_	O
54	patients	_	_	O
55	with	_	_	O
56	IOP	_	_	O
57	of	_	_	O
58	24	_	_	O
59	mmHg	_	_	O
60	or	_	_	O
61	higher	_	_	O
62	were	_	_	O
63	randomized	_	_	O
64	to	_	_	O
65	twice-daily	_	_	O
66	fixed-combination	_	_	O
67	brimonidine	_	_	O
68	0.2	_	_	O
69	%	_	_	O
70	-timolol	_	_	O
71	0.5	_	_	O
72	%	_	_	O
73	(	_	_	O
74	n	_	_	O
75	=	_	_	O
76	73	_	_	O
77	)	_	_	O
78	or	_	_	O
79	once-daily	_	_	O
80	latanoprost	_	_	O
81	0.005	_	_	O
82	%	_	_	O
83	(	_	_	O
84	n	_	_	O
85	=	_	_	O
86	75	_	_	O
87	,	_	_	O
88	dosed	_	_	O
89	in	_	_	O
90	the	_	_	O
91	evening	_	_	O
92	,	_	_	O
93	with	_	_	O
94	vehicle	_	_	O
95	control	_	_	O
96	in	_	_	O
97	the	_	_	O
98	morning	_	_	O
99	to	_	_	O
100	maintain	_	_	O
101	masking	_	_	O
102	)	_	_	O
103	for	_	_	O
104	12	_	_	O
105	weeks	_	_	O
106	.	_	_	O

107	IOP	_	_	O
108	was	_	_	O
109	measured	_	_	O
110	at	_	_	O
111	8	_	_	O
112	a.m.	_	_	O
113	(	_	_	O
114	before	_	_	O
115	dosing	_	_	O
116	)	_	_	O
117	,	_	_	O
118	10	_	_	O
119	a.m.	_	_	O
120	,	_	_	O
121	and	_	_	O
122	3	_	_	O
123	p.m.	_	_	O
124	at	_	_	O
125	baseline	_	_	O
126	,	_	_	O
127	week	_	_	O
128	6	_	_	O
129	,	_	_	O
130	and	_	_	O
131	week	_	_	O
132	12	_	_	O
133	.	_	_	O

134	The	_	_	O
135	primary	_	_	O
136	efficacy	_	_	O
137	endpoint	_	_	O
138	was	_	_	O
139	diurnal	_	_	O
140	IOP	_	_	O
141	(	_	_	O
142	averaged	_	_	O
143	over	_	_	O
144	8	_	_	O
145	a.m.	_	_	O
146	,	_	_	O
147	10	_	_	O
148	a.m.	_	_	O
149	,	_	_	O
150	and	_	_	O
151	3	_	_	O
152	p.m.	_	_	O
153	)	_	_	O
154	at	_	_	O
155	week	_	_	O
156	12	_	_	O
157	.	_	_	O

158	Safety	_	_	O
159	measures	_	_	O
160	included	_	_	O
161	biomicroscopy	_	_	O
162	.	_	_	O

163	There	_	_	O
164	was	_	_	O
165	no	_	_	O
166	statistically	_	_	O
167	significant	_	_	O
168	difference	_	_	O
169	between	_	_	O
170	the	_	_	O
171	treatment	_	_	O
172	groups	_	_	O
173	in	_	_	O
174	mean	_	_	O
175	diurnal	_	_	O
176	IOP	_	_	O
177	at	_	_	O
178	baseline	_	_	O
179	(	_	_	O
180	p	_	_	O
181	=	_	_	O
182	0.118	_	_	O
183	)	_	_	O
184	.	_	_	O

185	At	_	_	B-Premise
186	week	_	_	I-Premise
187	12	_	_	I-Premise
188	,	_	_	I-Premise
189	the	_	_	I-Premise
190	mean	_	_	I-Premise
191	(	_	_	I-Premise
192	SD	_	_	I-Premise
193	)	_	_	I-Premise
194	diurnal	_	_	I-Premise
195	IOP	_	_	I-Premise
196	was	_	_	I-Premise
197	17.8	_	_	I-Premise
198	(	_	_	I-Premise
199	2.9	_	_	I-Premise
200	)	_	_	I-Premise
201	mmHg	_	_	I-Premise
202	with	_	_	I-Premise
203	brimonidine-timolol	_	_	I-Premise
204	and	_	_	I-Premise
205	17.9	_	_	I-Premise
206	(	_	_	I-Premise
207	3.9	_	_	I-Premise
208	)	_	_	I-Premise
209	mmHg	_	_	I-Premise
210	with	_	_	I-Premise
211	latanoprost	_	_	I-Premise
212	(	_	_	I-Premise
213	p	_	_	I-Premise
214	=	_	_	I-Premise
215	0.794	_	_	I-Premise
216	)	_	_	I-Premise
217	.	_	_	I-Premise

218	The	_	_	B-Premise
219	percentage	_	_	I-Premise
220	of	_	_	I-Premise
221	patients	_	_	I-Premise
222	achieving	_	_	I-Premise
223	at	_	_	I-Premise
224	least	_	_	I-Premise
225	a	_	_	I-Premise
226	20	_	_	I-Premise
227	%	_	_	I-Premise
228	decrease	_	_	I-Premise
229	from	_	_	I-Premise
230	baseline	_	_	I-Premise
231	diurnal	_	_	I-Premise
232	IOP	_	_	I-Premise
233	at	_	_	I-Premise
234	week	_	_	I-Premise
235	12	_	_	I-Premise
236	was	_	_	I-Premise
237	87.7	_	_	I-Premise
238	%	_	_	I-Premise
239	in	_	_	I-Premise
240	the	_	_	I-Premise
241	brimonidine-timolol	_	_	I-Premise
242	group	_	_	I-Premise
243	and	_	_	I-Premise
244	77.3	_	_	I-Premise
245	%	_	_	I-Premise
246	in	_	_	I-Premise
247	the	_	_	I-Premise
248	latanoprost	_	_	I-Premise
249	group	_	_	I-Premise
250	(	_	_	I-Premise
251	p	_	_	I-Premise
252	=	_	_	I-Premise
253	0.131	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	Measured	_	_	B-Premise
257	biomicroscopic	_	_	I-Premise
258	changes	_	_	I-Premise
259	from	_	_	I-Premise
260	baseline	_	_	I-Premise
261	to	_	_	I-Premise
262	week	_	_	I-Premise
263	12	_	_	I-Premise
264	were	_	_	I-Premise
265	infrequent	_	_	I-Premise
266	in	_	_	I-Premise
267	both	_	_	I-Premise
268	groups	_	_	I-Premise
269	.	_	_	I-Premise

270	Fixed-combination	_	_	B-Claim
271	brimonidine-timolol	_	_	I-Claim
272	was	_	_	I-Claim
273	as	_	_	I-Claim
274	effective	_	_	I-Claim
275	as	_	_	I-Claim
276	latanoprost	_	_	I-Claim
277	in	_	_	I-Claim
278	reducing	_	_	I-Claim
279	IOP	_	_	I-Claim
280	in	_	_	I-Claim
281	patients	_	_	I-Claim
282	with	_	_	I-Claim
283	glaucoma	_	_	I-Claim
284	or	_	_	I-Claim
285	ocular	_	_	I-Claim
286	hypertension	_	_	I-Claim
287	.	_	_	I-Claim

288	Both	_	_	B-Claim
289	treatments	_	_	I-Claim
290	demonstrated	_	_	I-Claim
291	favorable	_	_	I-Claim
292	ocular	_	_	I-Claim
293	tolerability	_	_	I-Claim
294	.	_	_	I-Claim

295	The	_	_	O
296	duration	_	_	O
297	of	_	_	O
298	the	_	_	O
299	study	_	_	O
300	was	_	_	O
301	12	_	_	O
302	weeks	_	_	O
303	,	_	_	O
304	and	_	_	O
305	additional	_	_	O
306	studies	_	_	O
307	will	_	_	O
308	be	_	_	O
309	needed	_	_	O
310	to	_	_	O
311	compare	_	_	O
312	the	_	_	O
313	efficacy	_	_	O
314	and	_	_	O
315	safety	_	_	O
316	of	_	_	O
317	fixed-combination	_	_	O
318	brimonidine-timolol	_	_	O
319	and	_	_	O
320	latanoprost	_	_	O
321	during	_	_	O
322	long-term	_	_	O
323	treatment	_	_	O
324	.	_	_	O


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	of	_	_	O
5	intraocular	_	_	O
6	pressure	_	_	O
7	(	_	_	O
8	IOP	_	_	O
9	)	_	_	O
10	control	_	_	O
11	of	_	_	O
12	the	_	_	O
13	Baerveldt-350	_	_	O
14	implant	_	_	O
15	with	_	_	O
16	tube	_	_	O
17	ligature	_	_	O
18	and	_	_	O
19	the	_	_	O
20	Ahmed	_	_	O
21	valve	_	_	O
22	in	_	_	O
23	patients	_	_	O
24	with	_	_	O
25	refractory	_	_	O
26	glaucoma	_	_	O
27	.	_	_	O

28	Four	_	_	O
29	hundred	_	_	O
30	seventy	_	_	O
31	glaucoma	_	_	O
32	drainage	_	_	O
33	device	_	_	O
34	procedures	_	_	O
35	from	_	_	O
36	July	_	_	O
37	1995	_	_	O
38	to	_	_	O
39	July	_	_	O
40	2001	_	_	O
41	(	_	_	O
42	6	_	_	O
43	years	_	_	O
44	)	_	_	O
45	were	_	_	O
46	reviewed	_	_	O
47	retrospectively	_	_	O
48	.	_	_	O

49	Thirty-two	_	_	O
50	cases	_	_	O
51	of	_	_	O
52	Baerveldt-350	_	_	O
53	implantation	_	_	O
54	performed	_	_	O
55	in	_	_	O
56	patients	_	_	O
57	with	_	_	O
58	glaucoma	_	_	O
59	refractory	_	_	O
60	to	_	_	O
61	medical	_	_	O
62	treatment	_	_	O
63	and	_	_	O
64	filtering	_	_	O
65	procedures	_	_	O
66	,	_	_	O
67	without	_	_	O
68	previous	_	_	O
69	drainage	_	_	O
70	device	_	_	O
71	or	_	_	O
72	cyclodestructive	_	_	O
73	procedures	_	_	O
74	,	_	_	O
75	and	_	_	O
76	with	_	_	O
77	a	_	_	O
78	minimum	_	_	O
79	of	_	_	O
80	1-year	_	_	O
81	follow-up	_	_	O
82	were	_	_	O
83	identified	_	_	O
84	.	_	_	O

85	Thirty-two	_	_	O
86	cases	_	_	O
87	of	_	_	O
88	Ahmed	_	_	O
89	valve	_	_	O
90	implantation	_	_	O
91	were	_	_	O
92	matched	_	_	O
93	case	_	_	O
94	by	_	_	O
95	case	_	_	O
96	with	_	_	O
97	32	_	_	O
98	Baerveldt-350	_	_	O
99	cases	_	_	O
100	for	_	_	O
101	age	_	_	O
102	,	_	_	O
103	race	_	_	O
104	,	_	_	O
105	gender	_	_	O
106	,	_	_	O
107	glaucoma	_	_	O
108	subtype	_	_	O
109	,	_	_	O
110	previous	_	_	O
111	ocular	_	_	O
112	history	_	_	O
113	,	_	_	O
114	preoperative	_	_	O
115	IOP	_	_	O
116	,	_	_	O
117	and	_	_	O
118	surgeon	_	_	O
119	who	_	_	O
120	performed	_	_	O
121	the	_	_	O
122	implantation	_	_	O
123	.	_	_	O

124	The	_	_	O
125	two	_	_	O
126	groups	_	_	O
127	were	_	_	O
128	compared	_	_	O
129	for	_	_	O
130	IOP	_	_	O
131	control	_	_	O
132	,	_	_	O
133	visual	_	_	O
134	outcome	_	_	O
135	,	_	_	O
136	complication	_	_	O
137	rate	_	_	O
138	,	_	_	O
139	and	_	_	O
140	surgical	_	_	O
141	success	_	_	O
142	rate	_	_	O
143	.	_	_	O

144	Surgical	_	_	B-Premise
145	success	_	_	I-Premise
146	rate	_	_	I-Premise
147	was	_	_	I-Premise
148	defined	_	_	I-Premise
149	as	_	_	I-Premise
150	an	_	_	I-Premise
151	IOP	_	_	I-Premise
152	reduction	_	_	I-Premise
153	greater	_	_	I-Premise
154	than	_	_	I-Premise
155	or	_	_	I-Premise
156	equal	_	_	I-Premise
157	to	_	_	I-Premise
158	30	_	_	I-Premise
159	%	_	_	I-Premise
160	and	_	_	I-Premise
161	final	_	_	I-Premise
162	IOP	_	_	I-Premise
163	more	_	_	I-Premise
164	than	_	_	I-Premise
165	5	_	_	I-Premise
166	mm	_	_	I-Premise
167	Hg	_	_	I-Premise
168	and	_	_	I-Premise
169	less	_	_	I-Premise
170	than	_	_	I-Premise
171	22	_	_	I-Premise
172	mm	_	_	I-Premise
173	Hg	_	_	I-Premise
174	,	_	_	I-Premise
175	without	_	_	I-Premise
176	devastating	_	_	I-Premise
177	complications	_	_	I-Premise
178	.	_	_	I-Premise

179	Over	_	_	B-Premise
180	a	_	_	I-Premise
181	follow-up	_	_	I-Premise
182	period	_	_	I-Premise
183	of	_	_	I-Premise
184	1	_	_	I-Premise
185	year	_	_	I-Premise
186	,	_	_	I-Premise
187	no	_	_	I-Premise
188	statistically	_	_	I-Premise
189	significant	_	_	I-Premise
190	differences	_	_	I-Premise
191	were	_	_	I-Premise
192	detected	_	_	I-Premise
193	between	_	_	I-Premise
194	the	_	_	I-Premise
195	Baerveldt-350	_	_	I-Premise
196	implant	_	_	I-Premise
197	versus	_	_	I-Premise
198	Ahmed	_	_	I-Premise
199	valve	_	_	I-Premise
200	for	_	_	I-Premise
201	IOP	_	_	I-Premise
202	control	_	_	I-Premise
203	(	_	_	I-Premise
204	12.1	_	_	I-Premise
205	+/-	_	_	I-Premise
206	5.3	_	_	I-Premise
207	mm	_	_	I-Premise
208	Hg	_	_	I-Premise
209	vs	_	_	I-Premise
210	13.6	_	_	I-Premise
211	+/-	_	_	I-Premise
212	5.6	_	_	I-Premise
213	mm	_	_	I-Premise
214	Hg	_	_	I-Premise
215	respectively	_	_	I-Premise
216	,	_	_	I-Premise
217	at	_	_	I-Premise
218	a	_	_	I-Premise
219	power	_	_	I-Premise
220	of	_	_	I-Premise
221	90	_	_	I-Premise
222	%	_	_	I-Premise
223	to	_	_	I-Premise
224	detect	_	_	I-Premise
225	a	_	_	I-Premise
226	difference	_	_	I-Premise
227	of	_	_	I-Premise
228	3.2	_	_	I-Premise
229	mm	_	_	I-Premise
230	Hg	_	_	I-Premise
231	between	_	_	I-Premise
232	the	_	_	I-Premise
233	two	_	_	I-Premise
234	groups	_	_	I-Premise
235	and	_	_	I-Premise
236	P	_	_	I-Premise
237	=	_	_	I-Premise
238	0.05	_	_	I-Premise
239	)	_	_	I-Premise
240	,	_	_	I-Premise
241	surgical	_	_	I-Premise
242	success	_	_	I-Premise
243	rate	_	_	I-Premise
244	(	_	_	I-Premise
245	65.6	_	_	I-Premise
246	%	_	_	I-Premise
247	vs.	_	_	I-Premise
248	65.6	_	_	I-Premise
249	%	_	_	I-Premise
250	respectively	_	_	I-Premise
251	,	_	_	I-Premise
252	complete	_	_	I-Premise
253	and	_	_	I-Premise
254	qualified	_	_	I-Premise
255	combined	_	_	I-Premise
256	)	_	_	I-Premise
257	,	_	_	I-Premise
258	postoperative	_	_	I-Premise
259	hypotony	_	_	I-Premise
260	rate	_	_	I-Premise
261	(	_	_	I-Premise
262	37.5	_	_	I-Premise
263	%	_	_	I-Premise
264	vs.	_	_	I-Premise
265	34.4	_	_	I-Premise
266	%	_	_	I-Premise
267	respectively	_	_	I-Premise
268	)	_	_	I-Premise
269	,	_	_	I-Premise
270	and	_	_	I-Premise
271	visual	_	_	I-Premise
272	acuity	_	_	I-Premise
273	changes	_	_	I-Premise
274	of	_	_	I-Premise
275	more	_	_	I-Premise
276	than	_	_	I-Premise
277	1	_	_	I-Premise
278	line	_	_	I-Premise
279	in	_	_	I-Premise
280	Snellen	_	_	I-Premise
281	visual	_	_	I-Premise
282	acuity	_	_	I-Premise
283	(	_	_	I-Premise
284	43.3	_	_	I-Premise
285	%	_	_	I-Premise
286	vs.	_	_	I-Premise
287	29.0	_	_	I-Premise
288	%	_	_	I-Premise
289	respectively	_	_	I-Premise
290	)	_	_	I-Premise
291	.	_	_	I-Premise

292	In	_	_	B-Claim
293	a	_	_	I-Claim
294	case-controlled	_	_	I-Claim
295	comparison	_	_	I-Claim
296	,	_	_	I-Claim
297	the	_	_	I-Claim
298	Baerveldt-350	_	_	I-Claim
299	implant	_	_	I-Claim
300	and	_	_	I-Claim
301	the	_	_	I-Claim
302	Ahmed	_	_	I-Claim
303	valve	_	_	I-Claim
304	had	_	_	I-Claim
305	similar	_	_	I-Claim
306	IOP	_	_	I-Claim
307	control	_	_	I-Claim
308	and	_	_	I-Claim
309	surgical	_	_	I-Claim
310	outcomes	_	_	I-Claim
311	in	_	_	I-Claim
312	patients	_	_	I-Claim
313	with	_	_	I-Claim
314	refractory	_	_	I-Claim
315	glaucoma	_	_	I-Claim
316	at	_	_	I-Claim
317	1-year	_	_	I-Claim
318	follow-up	_	_	I-Claim
319	.	_	_	I-Claim


1	To	_	_	O
2	compare	_	_	O
3	the	_	_	O
4	IOP-lowering	_	_	O
5	efficacy	_	_	O
6	of	_	_	O
7	a.m.-dosed	_	_	O
8	travoprost	_	_	O
9	and	_	_	O
10	latanoprost	_	_	O
11	at	_	_	O
12	24-h	_	_	O
13	post-dose	_	_	O
14	.	_	_	O

15	Open-angle	_	_	O
16	glaucoma	_	_	O
17	patients	_	_	O
18	not	_	_	O
19	naïve	_	_	O
20	to	_	_	O
21	prostaglandin	_	_	O
22	therapy	_	_	O
23	and	_	_	O
24	currently	_	_	O
25	controlled	_	_	O
26	on	_	_	O
27	p.m.-dosed	_	_	O
28	(	_	_	O
29	2100	_	_	O
30	)	_	_	O
31	latanoprost	_	_	O
32	(	_	_	O
33	n	_	_	O
34	=	_	_	O
35	21	_	_	O
36	)	_	_	O
37	or	_	_	O
38	travoprost	_	_	O
39	(	_	_	O
40	n	_	_	O
41	=	_	_	O
42	30	_	_	O
43	)	_	_	O
44	had	_	_	O
45	baseline	_	_	O
46	IOPs	_	_	O
47	measured	_	_	O
48	at	_	_	O
49	0900	_	_	O
50	.	_	_	O

51	In	_	_	O
52	a	_	_	O
53	randomized	_	_	O
54	,	_	_	O
55	single-masked	_	_	O
56	,	_	_	O
57	crossover	_	_	O
58	design	_	_	O
59	,	_	_	O
60	patients	_	_	O
61	received	_	_	O
62	travoprost	_	_	O
63	(	_	_	O
64	Travatan	_	_	O
65	†	_	_	O
66	)	_	_	O
67	or	_	_	O
68	latanoprost	_	_	O
69	(	_	_	O
70	Xalatan	_	_	O
71	‡	_	_	O
72	)	_	_	O
73	at	_	_	O
74	0900	_	_	O
75	for	_	_	O
76	4	_	_	O
77	weeks	_	_	O
78	,	_	_	O
79	then	_	_	O
80	were	_	_	O
81	crossed	_	_	O
82	over	_	_	O
83	to	_	_	O
84	receive	_	_	O
85	the	_	_	O
86	second	_	_	O
87	prostaglandin	_	_	O
88	for	_	_	O
89	another	_	_	O
90	4	_	_	O
91	weeks	_	_	O
92	.	_	_	O

93	Treatment	_	_	O
94	IOP	_	_	O
95	was	_	_	O
96	measured	_	_	O
97	at	_	_	O
98	0900	_	_	O
99	prior	_	_	O
100	to	_	_	O
101	morning	_	_	O
102	dose	_	_	O
103	at	_	_	O
104	both	_	_	O
105	4	_	_	O
106	and	_	_	O
107	8	_	_	O
108	week	_	_	O
109	visits	_	_	O
110	.	_	_	O

111	Patient	_	_	O
112	dosing	_	_	O
113	preference	_	_	O
114	(	_	_	O
115	a.m./p.m	_	_	O
116	.	_	_	O
117	)	_	_	O

118	was	_	_	O
119	surveyed	_	_	O
120	on	_	_	O
121	exit	_	_	O
122	.	_	_	O

123	Main	_	_	O
124	outcome	_	_	O
125	measure	_	_	O
126	:	_	_	O
127	Intraocular	_	_	O
128	pressure	_	_	O
129	(	_	_	O
130	IOP	_	_	O
131	)	_	_	O
132	.	_	_	O

133	†	_	_	O
134	Travatan	_	_	O
135	is	_	_	O
136	a	_	_	O
137	registered	_	_	O
138	trade	_	_	O
139	name	_	_	O
140	of	_	_	O
141	Alcon	_	_	O
142	Laboratories	_	_	O
143	,	_	_	O
144	Inc.	_	_	O
145	,	_	_	O
146	Fort	_	_	O
147	Worth	_	_	O
148	,	_	_	O
149	TX	_	_	O
150	,	_	_	O
151	USA	_	_	O
152	‡	_	_	O
153	Xalatan	_	_	O
154	is	_	_	O
155	a	_	_	O
156	registered	_	_	O
157	trade	_	_	O
158	name	_	_	O
159	of	_	_	O
160	Pfizer	_	_	O
161	,	_	_	O
162	New	_	_	O
163	York	_	_	O
164	,	_	_	O
165	NY	_	_	O
166	,	_	_	O
167	USA	_	_	O
168	.	_	_	O

169	The	_	_	B-Premise
170	mean	_	_	I-Premise
171	IOP	_	_	I-Premise
172	in	_	_	I-Premise
173	the	_	_	I-Premise
174	first	_	_	I-Premise
175	period	_	_	I-Premise
176	when	_	_	I-Premise
177	all	_	_	I-Premise
178	patients	_	_	I-Premise
179	were	_	_	I-Premise
180	dosed	_	_	I-Premise
181	in	_	_	I-Premise
182	the	_	_	I-Premise
183	evening	_	_	I-Premise
184	was	_	_	I-Premise
185	assessed	_	_	I-Premise
186	12	_	_	I-Premise
187	h	_	_	I-Premise
188	after	_	_	I-Premise
189	dosing	_	_	I-Premise
190	at	_	_	I-Premise
191	09:00	_	_	I-Premise
192	and	_	_	I-Premise
193	it	_	_	I-Premise
194	was	_	_	I-Premise
195	similar	_	_	I-Premise
196	in	_	_	I-Premise
197	the	_	_	I-Premise
198	two	_	_	I-Premise
199	treatment	_	_	I-Premise
200	groups	_	_	I-Premise
201	(	_	_	I-Premise
202	mean	_	_	I-Premise
203	+/-	_	_	I-Premise
204	standard	_	_	I-Premise
205	deviation	_	_	I-Premise
206	:	_	_	I-Premise
207	17.9	_	_	I-Premise
208	+/-	_	_	I-Premise
209	2.7	_	_	I-Premise
210	mmHg	_	_	I-Premise
211	for	_	_	I-Premise
212	travoprost	_	_	I-Premise
213	versus	_	_	I-Premise
214	17.7	_	_	I-Premise
215	+/-	_	_	I-Premise
216	2.5	_	_	I-Premise
217	mmHg	_	_	I-Premise
218	for	_	_	I-Premise
219	latanoprost	_	_	I-Premise
220	,	_	_	I-Premise
221	p	_	_	I-Premise
222	=	_	_	I-Premise
223	0.812	_	_	I-Premise
224	)	_	_	I-Premise
225	.	_	_	I-Premise

226	In	_	_	B-Premise
227	the	_	_	I-Premise
228	a.m.-dosing	_	_	I-Premise
229	crossover	_	_	I-Premise
230	comparison	_	_	I-Premise
231	,	_	_	I-Premise
232	the	_	_	I-Premise
233	24-h	_	_	I-Premise
234	post-dose	_	_	I-Premise
235	IOP	_	_	I-Premise
236	was	_	_	I-Premise
237	significantly	_	_	I-Premise
238	lower	_	_	I-Premise
239	(	_	_	I-Premise
240	p	_	_	I-Premise
241	<	_	_	I-Premise
242	0.001	_	_	I-Premise
243	)	_	_	I-Premise
244	on	_	_	I-Premise
245	travoprost	_	_	I-Premise
246	(	_	_	I-Premise
247	16.9	_	_	I-Premise
248	+/-	_	_	I-Premise
249	3.1	_	_	I-Premise
250	mmHg	_	_	I-Premise
251	)	_	_	I-Premise
252	compared	_	_	I-Premise
253	to	_	_	I-Premise
254	latanoprost	_	_	I-Premise
255	(	_	_	I-Premise
256	18.6	_	_	I-Premise
257	+/-	_	_	I-Premise
258	3.3	_	_	I-Premise
259	mmHg	_	_	I-Premise
260	)	_	_	I-Premise
261	.	_	_	I-Premise

262	In	_	_	O
263	the	_	_	O
264	exit	_	_	O
265	survey	_	_	O
266	,	_	_	O
267	51	_	_	O
268	%	_	_	O
269	of	_	_	O
270	patients	_	_	O
271	preferred	_	_	O
272	a.m.-dosing	_	_	O
273	.	_	_	O

274	a.m.-dosed	_	_	B-Claim
275	travoprost	_	_	I-Claim
276	is	_	_	I-Claim
277	superior	_	_	I-Claim
278	to	_	_	I-Claim
279	a.m.-dosed	_	_	I-Claim
280	latanoprost	_	_	I-Claim
281	by	_	_	I-Claim
282	1.7	_	_	I-Claim
283	mmHg	_	_	I-Claim
284	at	_	_	I-Claim
285	24-h	_	_	I-Claim
286	post-dose	_	_	I-Claim
287	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	fixed-combination	_	_	O
8	latanoprost-timolol	_	_	O
9	(	_	_	O
10	FCLT	_	_	O
11	)	_	_	O
12	vs	_	_	O
13	latanoprost	_	_	O
14	or	_	_	O
15	timolol	_	_	O
16	monotherapy	_	_	O
17	.	_	_	O

18	This	_	_	O
19	12-week	_	_	O
20	,	_	_	O
21	randomized	_	_	O
22	,	_	_	O
23	double-masked	_	_	O
24	,	_	_	O
25	parallel-group	_	_	O
26	study	_	_	O
27	included	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	open-angle	_	_	O
31	glaucoma	_	_	O
32	or	_	_	O
33	ocular	_	_	O
34	hypertension	_	_	O
35	treated	_	_	O
36	with	_	_	O
37	a	_	_	O
38	beta-blocker	_	_	O
39	and	_	_	O
40	with	_	_	O
41	baseline	_	_	O
42	intraocular	_	_	O
43	pressure	_	_	O
44	(	_	_	O
45	IOP	_	_	O
46	)	_	_	O
47	of	_	_	O
48	26	_	_	O
49	through	_	_	O
50	36	_	_	O
51	mm	_	_	O
52	Hg	_	_	O
53	.	_	_	O

54	Following	_	_	O
55	washout	_	_	O
56	,	_	_	O
57	eligible	_	_	O
58	patients	_	_	O
59	were	_	_	O
60	randomized	_	_	O
61	to	_	_	O
62	once-daily	_	_	O
63	FCLT	_	_	O
64	in	_	_	O
65	the	_	_	O
66	evening	_	_	O
67	,	_	_	O
68	latanoprost	_	_	O
69	in	_	_	O
70	the	_	_	O
71	evening	_	_	O
72	,	_	_	O
73	or	_	_	O
74	timolol	_	_	O
75	in	_	_	O
76	the	_	_	O
77	morning	_	_	O
78	.	_	_	O

79	Postbaseline	_	_	O
80	IOP	_	_	O
81	assessments	_	_	O
82	at	_	_	O
83	8	_	_	O
84	am	_	_	O
85	,	_	_	O
86	10	_	_	O
87	am	_	_	O
88	,	_	_	O
89	and	_	_	O
90	4	_	_	O
91	pm	_	_	O
92	at	_	_	O
93	weeks	_	_	O
94	2	_	_	O
95	,	_	_	O
96	6	_	_	O
97	,	_	_	O
98	and	_	_	O
99	12	_	_	O
100	;	_	_	O
101	statistical	_	_	O
102	superiority	_	_	O
103	of	_	_	O
104	FCLT	_	_	O
105	for	_	_	O
106	the	_	_	O
107	18	_	_	O
108	pairwise	_	_	O
109	comparisons	_	_	O
110	between	_	_	O
111	FCLT	_	_	O
112	and	_	_	O
113	the	_	_	O
114	2	_	_	O
115	monotherapies	_	_	O
116	,	_	_	O
117	using	_	_	O
118	analysis	_	_	O
119	of	_	_	O
120	variance	_	_	O
121	.	_	_	O

122	All	_	_	O
123	therapies	_	_	O
124	resulted	_	_	O
125	in	_	_	O
126	significant	_	_	O
127	IOP	_	_	O
128	reductions	_	_	O
129	from	_	_	O
130	baseline	_	_	O
131	.	_	_	O

132	Pairwise	_	_	O
133	comparisons	_	_	O
134	favored	_	_	O
135	FCLT	_	_	O
136	at	_	_	O
137	all	_	_	O
138	time	_	_	O
139	points	_	_	O
140	.	_	_	O

141	When	_	_	O
142	the	_	_	O
143	18	_	_	O
144	comparisons	_	_	O
145	were	_	_	O
146	tested	_	_	O
147	simultaneously	_	_	O
148	,	_	_	O
149	FCLT	_	_	B-Premise
150	was	_	_	I-Premise
151	statistically	_	_	I-Premise
152	superior	_	_	I-Premise
153	to	_	_	I-Premise
154	latanoprost	_	_	I-Premise
155	at	_	_	I-Premise
156	7	_	_	I-Premise
157	of	_	_	I-Premise
158	9	_	_	I-Premise
159	time	_	_	I-Premise
160	points	_	_	I-Premise
161	and	_	_	I-Premise
162	at	_	_	I-Premise
163	all	_	_	I-Premise
164	9	_	_	I-Premise
165	time	_	_	I-Premise
166	points	_	_	I-Premise
167	when	_	_	I-Premise
168	compared	_	_	I-Premise
169	with	_	_	I-Premise
170	timolol	_	_	I-Premise
171	.	_	_	I-Premise

172	In	_	_	O
173	addition	_	_	O
174	,	_	_	O
175	FCLT	_	_	B-Premise
176	was	_	_	I-Premise
177	associated	_	_	I-Premise
178	with	_	_	I-Premise
179	greater	_	_	I-Premise
180	percentage	_	_	I-Premise
181	reductions	_	_	I-Premise
182	in	_	_	I-Premise
183	diurnal	_	_	I-Premise
184	IOP	_	_	I-Premise
185	levels	_	_	I-Premise
186	and	_	_	I-Premise
187	a	_	_	I-Premise
188	greater	_	_	I-Premise
189	likelihood	_	_	I-Premise
190	of	_	_	I-Premise
191	achieving	_	_	I-Premise
192	lower	_	_	I-Premise
193	mean	_	_	I-Premise
194	diurnal	_	_	I-Premise
195	IOP	_	_	I-Premise
196	levels	_	_	I-Premise
197	.	_	_	I-Premise

198	Diurnal	_	_	B-Premise
199	IOP	_	_	I-Premise
200	reductions	_	_	I-Premise
201	of	_	_	I-Premise
202	30	_	_	I-Premise
203	%	_	_	I-Premise
204	or	_	_	I-Premise
205	more	_	_	I-Premise
206	from	_	_	I-Premise
207	baseline	_	_	I-Premise
208	to	_	_	I-Premise
209	week	_	_	I-Premise
210	12	_	_	I-Premise
211	were	_	_	I-Premise
212	achieved	_	_	I-Premise
213	by	_	_	I-Premise
214	73.5	_	_	I-Premise
215	%	_	_	I-Premise
216	,	_	_	I-Premise
217	57.5	_	_	I-Premise
218	%	_	_	I-Premise
219	,	_	_	I-Premise
220	and	_	_	I-Premise
221	32.8	_	_	I-Premise
222	%	_	_	I-Premise
223	of	_	_	I-Premise
224	those	_	_	I-Premise
225	treated	_	_	I-Premise
226	with	_	_	I-Premise
227	FCLT	_	_	I-Premise
228	,	_	_	I-Premise
229	latanoprost	_	_	I-Premise
230	,	_	_	I-Premise
231	and	_	_	I-Premise
232	timolol	_	_	I-Premise
233	,	_	_	I-Premise
234	respectively	_	_	I-Premise
235	(	_	_	I-Premise
236	P	_	_	I-Premise
237	=	_	_	I-Premise
238	.007	_	_	I-Premise
239	for	_	_	I-Premise
240	FCLT	_	_	I-Premise
241	vs	_	_	I-Premise
242	timolol	_	_	I-Premise
243	;	_	_	I-Premise
244	P	_	_	I-Premise
245	<	_	_	I-Premise
246	.001	_	_	I-Premise
247	for	_	_	I-Premise
248	FCLT	_	_	I-Premise
249	vs	_	_	I-Premise
250	latanoprost	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	All	_	_	B-Claim
254	therapies	_	_	I-Claim
255	were	_	_	I-Claim
256	well	_	_	I-Claim
257	tolerated	_	_	I-Claim
258	.	_	_	I-Claim

259	Fixed-combination	_	_	B-Claim
260	latanoprost-timolol	_	_	I-Claim
261	therapy	_	_	I-Claim
262	is	_	_	I-Claim
263	as	_	_	I-Claim
264	safe	_	_	I-Claim
265	and	_	_	I-Claim
266	effective	_	_	I-Claim
267	in	_	_	I-Claim
268	lowering	_	_	I-Claim
269	IOP	_	_	I-Claim
270	in	_	_	I-Claim
271	patients	_	_	I-Claim
272	with	_	_	I-Claim
273	either	_	_	I-Claim
274	ocular	_	_	I-Claim
275	hypertension	_	_	I-Claim
276	or	_	_	I-Claim
277	glaucoma	_	_	I-Claim
278	as	_	_	I-Claim
279	monotherapy	_	_	I-Claim
280	with	_	_	I-Claim
281	latanoprost	_	_	I-Claim
282	or	_	_	I-Claim
283	timolol	_	_	I-Claim
284	.	_	_	I-Claim

285	Combination	_	_	B-Claim
286	therapy	_	_	I-Claim
287	can	_	_	I-Claim
288	be	_	_	I-Claim
289	used	_	_	I-Claim
290	to	_	_	I-Claim
291	treat	_	_	I-Claim
292	patients	_	_	I-Claim
293	for	_	_	I-Claim
294	whom	_	_	I-Claim
295	monotherapy	_	_	I-Claim
296	does	_	_	I-Claim
297	not	_	_	I-Claim
298	provide	_	_	I-Claim
299	sufficient	_	_	I-Claim
300	IOP	_	_	I-Claim
301	reduction	_	_	I-Claim
302	.	_	_	I-Claim

303	The	_	_	B-Claim
304	simplicity	_	_	I-Claim
305	,	_	_	I-Claim
306	efficacy	_	_	I-Claim
307	,	_	_	I-Claim
308	and	_	_	I-Claim
309	tolerability	_	_	I-Claim
310	of	_	_	I-Claim
311	FCLT	_	_	I-Claim
312	contribute	_	_	I-Claim
313	to	_	_	I-Claim
314	its	_	_	I-Claim
315	utility	_	_	I-Claim
316	in	_	_	I-Claim
317	clinical	_	_	I-Claim
318	practice	_	_	I-Claim
319	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	scleral	_	_	O
6	flap	_	_	O
7	size	_	_	O
8	on	_	_	O
9	the	_	_	O
10	medium-term	_	_	O
11	intraocular	_	_	O
12	pressure	_	_	O
13	control	_	_	O
14	and	_	_	O
15	complication	_	_	O
16	rates	_	_	O
17	after	_	_	O
18	augmented	_	_	O
19	trabeculectomy	_	_	O
20	.	_	_	O

21	Prospective	_	_	O
22	randomized	_	_	O
23	clinical	_	_	O
24	trial	_	_	O
25	.	_	_	O

26	Glaucoma	_	_	O
27	patients	_	_	O
28	undergoing	_	_	O
29	primary	_	_	O
30	trabeculectomy	_	_	O
31	.	_	_	O

32	Exclusion	_	_	O
33	criteria	_	_	O
34	included	_	_	O
35	previous	_	_	O
36	ocular	_	_	O
37	surgery	_	_	O
38	apart	_	_	O
39	from	_	_	O
40	cataract	_	_	O
41	surgery	_	_	O
42	,	_	_	O
43	secondary	_	_	O
44	glaucoma	_	_	O
45	and	_	_	O
46	age	_	_	O
47	under	_	_	O
48	18	_	_	O
49	.	_	_	O

50	Patients	_	_	O
51	were	_	_	O
52	randomized	_	_	O
53	to	_	_	O
54	either	_	_	O
55	standard	_	_	O
56	trabeculectomy	_	_	O
57	(	_	_	O
58	4	_	_	O
59	×	_	_	O
60	4	_	_	O
61	mm	_	_	O
62	scleral	_	_	O
63	flap	_	_	O
64	)	_	_	O
65	or	_	_	O
66	microtrabeculectomy	_	_	O
67	(	_	_	O
68	2	_	_	O
69	×	_	_	O
70	2	_	_	O
71	mm	_	_	O
72	scleral	_	_	O
73	flap	_	_	O
74	)	_	_	O
75	,	_	_	O
76	both	_	_	O
77	with	_	_	O
78	adjustable	_	_	O
79	sutures	_	_	O
80	and	_	_	O
81	antimetabolites	_	_	O
82	.	_	_	O

83	Bleb	_	_	O
84	needling	_	_	O
85	was	_	_	O
86	performed	_	_	O
87	as	_	_	O
88	required	_	_	O
89	.	_	_	O

90	Patients	_	_	O
91	were	_	_	O
92	evaluated	_	_	O
93	at	_	_	O
94	day	_	_	O
95	1	_	_	O
96	,	_	_	O
97	weeks	_	_	O
98	1	_	_	O
99	,	_	_	O
100	3	_	_	O
101	,	_	_	O
102	6	_	_	O
103	and	_	_	O
104	months	_	_	O
105	3	_	_	O
106	,	_	_	O
107	6	_	_	O
108	,	_	_	O
109	12	_	_	O
110	,	_	_	O
111	18	_	_	O
112	and	_	_	O
113	24	_	_	O
114	postoperatively	_	_	O
115	.	_	_	O

116	Vision	_	_	O
117	,	_	_	O
118	intraocular	_	_	O
119	pressure	_	_	O
120	,	_	_	O
121	complications	_	_	O
122	and	_	_	O
123	failure	_	_	O
124	(	_	_	O
125	intraocular	_	_	O
126	pressure	_	_	O
127	≥	_	_	O
128	21	_	_	O
129	mmHg	_	_	O
130	or	_	_	O
131	not	_	_	O
132	reduced	_	_	O
133	by	_	_	O
134	≥20	_	_	O
135	%	_	_	O
136	from	_	_	O
137	baseline	_	_	O
138	,	_	_	O
139	intraocular	_	_	O
140	pressure	_	_	O
141	≤	_	_	O
142	5	_	_	O
143	mmHg	_	_	O
144	,	_	_	O
145	repeat	_	_	O
146	glaucoma	_	_	O
147	surgery	_	_	O
148	and	_	_	O
149	no	_	_	O
150	light	_	_	O
151	perception	_	_	O
152	vision	_	_	O
153	)	_	_	O
154	.	_	_	O

155	Forty-one	_	_	O
156	patients	_	_	O
157	were	_	_	O
158	recruited	_	_	O
159	;	_	_	O
160	20	_	_	O
161	had	_	_	O
162	standard	_	_	O
163	trabeculectomy	_	_	O
164	,	_	_	O
165	and	_	_	O
166	21	_	_	O
167	had	_	_	O
168	microtrabeculectomy	_	_	O
169	.	_	_	O

170	At	_	_	B-Premise
171	2	_	_	I-Premise
172	years	_	_	I-Premise
173	,	_	_	I-Premise
174	the	_	_	I-Premise
175	mean	_	_	I-Premise
176	intraocular	_	_	I-Premise
177	pressure	_	_	I-Premise
178	and	_	_	I-Premise
179	cumulative	_	_	I-Premise
180	probability	_	_	I-Premise
181	of	_	_	I-Premise
182	failure	_	_	I-Premise
183	was	_	_	I-Premise
184	12.4	_	_	I-Premise
185	±	_	_	I-Premise
186	4.6	_	_	I-Premise
187	mmHg	_	_	I-Premise
188	and	_	_	I-Premise
189	0.28	_	_	I-Premise
190	for	_	_	I-Premise
191	standard	_	_	I-Premise
192	trabeculectomy	_	_	I-Premise
193	,	_	_	I-Premise
194	and	_	_	I-Premise
195	11.5	_	_	I-Premise
196	±	_	_	I-Premise
197	3.6	_	_	I-Premise
198	mmHg	_	_	I-Premise
199	and	_	_	I-Premise
200	0.27	_	_	I-Premise
201	for	_	_	I-Premise
202	microtrabeculectomy	_	_	I-Premise
203	(	_	_	I-Premise
204	P	_	_	I-Premise
205	=	_	_	I-Premise
206	0.50	_	_	I-Premise
207	and	_	_	I-Premise
208	0.89	_	_	I-Premise
209	,	_	_	I-Premise
210	respectively	_	_	I-Premise
211	)	_	_	I-Premise
212	.	_	_	I-Premise

213	One	_	_	B-Premise
214	patient	_	_	I-Premise
215	in	_	_	I-Premise
216	each	_	_	I-Premise
217	group	_	_	I-Premise
218	required	_	_	I-Premise
219	Baerveldt	_	_	I-Premise
220	device	_	_	I-Premise
221	implantation	_	_	I-Premise
222	.	_	_	I-Premise

223	Vision	_	_	B-Premise
224	reduced	_	_	I-Premise
225	≥2	_	_	I-Premise
226	Snellen	_	_	I-Premise
227	lines	_	_	I-Premise
228	in	_	_	I-Premise
229	15	_	_	I-Premise
230	%	_	_	I-Premise
231	in	_	_	I-Premise
232	the	_	_	I-Premise
233	standard	_	_	I-Premise
234	trabeculectomy	_	_	I-Premise
235	group	_	_	I-Premise
236	and	_	_	I-Premise
237	25	_	_	I-Premise
238	%	_	_	I-Premise
239	in	_	_	I-Premise
240	the	_	_	I-Premise
241	microtrabeculectomy	_	_	I-Premise
242	group	_	_	I-Premise
243	,	_	_	I-Premise
244	mainly	_	_	I-Premise
245	from	_	_	I-Premise
246	cataract	_	_	I-Premise
247	(	_	_	I-Premise
248	P	_	_	I-Premise
249	=	_	_	I-Premise
250	0.48	_	_	I-Premise
251	)	_	_	I-Premise
252	.	_	_	I-Premise

253	Both	_	_	B-Claim
254	trabeculectomy	_	_	I-Claim
255	techniques	_	_	I-Claim
256	achieved	_	_	I-Claim
257	good	_	_	I-Claim
258	intraocular	_	_	I-Claim
259	pressure	_	_	I-Claim
260	reduction	_	_	I-Claim
261	and	_	_	I-Claim
262	had	_	_	I-Claim
263	similar	_	_	I-Claim
264	complication	_	_	I-Claim
265	rates	_	_	I-Claim
266	.	_	_	I-Claim

267	Scleral	_	_	B-Claim
268	flap	_	_	I-Claim
269	size	_	_	I-Claim
270	had	_	_	I-Claim
271	no	_	_	I-Claim
272	significant	_	_	I-Claim
273	effect	_	_	I-Claim
274	on	_	_	I-Claim
275	medium-term	_	_	I-Claim
276	intraocular	_	_	I-Claim
277	pressure	_	_	I-Claim
278	control	_	_	I-Claim
279	and	_	_	I-Claim
280	complication	_	_	I-Claim
281	profile	_	_	I-Claim
282	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	tafluprost	_	_	O
8	,	_	_	O
9	a	_	_	O
10	preservative-free	_	_	O
11	(	_	_	O
12	PF	_	_	O
13	)	_	_	O
14	prostaglandin	_	_	O
15	analogue	_	_	O
16	,	_	_	O
17	with	_	_	O
18	PF	_	_	O
19	timolol	_	_	O
20	in	_	_	O
21	patients	_	_	O
22	with	_	_	O
23	open-angle	_	_	O
24	glaucoma	_	_	O
25	or	_	_	O
26	ocular	_	_	O
27	hypertension	_	_	O
28	.	_	_	O

29	Randomized	_	_	O
30	,	_	_	O
31	double-masked	_	_	O
32	,	_	_	O
33	multicenter	_	_	O
34	clinical	_	_	O
35	trial	_	_	O
36	.	_	_	O

37	After	_	_	O
38	discontinuation	_	_	O
39	and	_	_	O
40	washout	_	_	O
41	of	_	_	O
42	existing	_	_	O
43	ocular	_	_	O
44	hypotensive	_	_	O
45	treatment	_	_	O
46	,	_	_	O
47	patients	_	_	O
48	who	_	_	O
49	had	_	_	O
50	intraocular	_	_	O
51	pressure	_	_	O
52	(	_	_	O
53	IOP	_	_	O
54	)	_	_	O
55	=23	_	_	O
56	and	_	_	O
57	=36	_	_	O
58	mm	_	_	O
59	Hg	_	_	O
60	in	_	_	O
61	at	_	_	O
62	least	_	_	O
63	1	_	_	O
64	eye	_	_	O
65	at	_	_	O
66	the	_	_	O
67	08:00	_	_	O
68	hour	_	_	O
69	time	_	_	O
70	point	_	_	O
71	were	_	_	O
72	randomized	_	_	O
73	1:1	_	_	O
74	to	_	_	O
75	12	_	_	O
76	weeks	_	_	O
77	of	_	_	O
78	treatment	_	_	O
79	with	_	_	O
80	either	_	_	O
81	PF	_	_	O
82	tafluprost	_	_	O
83	0.0015	_	_	O
84	%	_	_	O
85	or	_	_	O
86	PF	_	_	O
87	timolol	_	_	O
88	0.5	_	_	O
89	%	_	_	O
90	.	_	_	O

91	IOP	_	_	O
92	was	_	_	O
93	measured	_	_	O
94	3	_	_	O
95	times	_	_	O
96	during	_	_	O
97	the	_	_	O
98	day	_	_	O
99	(	_	_	O
100	08:00	_	_	O
101	,	_	_	O
102	10:00	_	_	O
103	,	_	_	O
104	16:00	_	_	O
105	hours	_	_	O
106	)	_	_	O
107	at	_	_	O
108	baseline	_	_	O
109	and	_	_	O
110	at	_	_	O
111	weeks	_	_	O
112	2	_	_	O
113	,	_	_	O
114	6	_	_	O
115	,	_	_	O
116	and	_	_	O
117	12	_	_	O
118	.	_	_	O

119	It	_	_	O
120	was	_	_	O
121	hypothesized	_	_	O
122	that	_	_	O
123	PF	_	_	O
124	tafluprost	_	_	O
125	would	_	_	O
126	be	_	_	O
127	noninferior	_	_	O
128	to	_	_	O
129	PF	_	_	O
130	timolol	_	_	O
131	over	_	_	O
132	12	_	_	O
133	weeks	_	_	O
134	with	_	_	O
135	regard	_	_	O
136	to	_	_	O
137	change	_	_	O
138	from	_	_	O
139	baseline	_	_	O
140	IOP	_	_	O
141	.	_	_	O

142	The	_	_	O
143	trial	_	_	O
144	was	_	_	O
145	powered	_	_	O
146	for	_	_	O
147	a	_	_	O
148	noninferiority	_	_	O
149	margin	_	_	O
150	of	_	_	O
151	1.5	_	_	O
152	mm	_	_	O
153	Hg	_	_	O
154	at	_	_	O
155	each	_	_	O
156	of	_	_	O
157	the	_	_	O
158	9	_	_	O
159	time	_	_	O
160	points	_	_	O
161	assessed	_	_	O
162	.	_	_	O

163	A	_	_	O
164	total	_	_	O
165	of	_	_	O
166	643	_	_	O
167	patients	_	_	O
168	were	_	_	O
169	randomized	_	_	O
170	and	_	_	O
171	618	_	_	O
172	completed	_	_	O
173	(	_	_	O
174	PF	_	_	O
175	tafluprost	_	_	O
176	=	_	_	O
177	306	_	_	O
178	,	_	_	O
179	PF	_	_	O
180	timolol	_	_	O
181	=	_	_	O
182	312	_	_	O
183	)	_	_	O
184	.	_	_	O

185	IOPs	_	_	B-Premise
186	at	_	_	I-Premise
187	the	_	_	I-Premise
188	3	_	_	I-Premise
189	time	_	_	I-Premise
190	points	_	_	I-Premise
191	assessed	_	_	I-Premise
192	during	_	_	I-Premise
193	the	_	_	I-Premise
194	baseline	_	_	I-Premise
195	visit	_	_	I-Premise
196	ranged	_	_	I-Premise
197	from	_	_	I-Premise
198	23.8	_	_	I-Premise
199	to	_	_	I-Premise
200	26.1	_	_	I-Premise
201	mm	_	_	I-Premise
202	Hg	_	_	I-Premise
203	in	_	_	I-Premise
204	the	_	_	I-Premise
205	PF	_	_	I-Premise
206	tafluprost	_	_	I-Premise
207	group	_	_	I-Premise
208	and	_	_	I-Premise
209	23.5	_	_	I-Premise
210	to	_	_	I-Premise
211	26.0	_	_	I-Premise
212	mm	_	_	I-Premise
213	Hg	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	PF	_	_	I-Premise
217	timolol	_	_	I-Premise
218	group	_	_	I-Premise
219	.	_	_	I-Premise

220	IOPs	_	_	B-Premise
221	at	_	_	I-Premise
222	the	_	_	I-Premise
223	3	_	_	I-Premise
224	time	_	_	I-Premise
225	points	_	_	I-Premise
226	assessed	_	_	I-Premise
227	during	_	_	I-Premise
228	the	_	_	I-Premise
229	12-week	_	_	I-Premise
230	visit	_	_	I-Premise
231	ranged	_	_	I-Premise
232	from	_	_	I-Premise
233	17.4	_	_	I-Premise
234	to	_	_	I-Premise
235	18.6	_	_	I-Premise
236	mm	_	_	I-Premise
237	Hg	_	_	I-Premise
238	for	_	_	I-Premise
239	PF	_	_	I-Premise
240	tafluprost	_	_	I-Premise
241	and	_	_	I-Premise
242	17.9	_	_	I-Premise
243	to	_	_	I-Premise
244	18.5	_	_	I-Premise
245	mm	_	_	I-Premise
246	Hg	_	_	I-Premise
247	for	_	_	I-Premise
248	PF	_	_	I-Premise
249	timolol	_	_	I-Premise
250	.	_	_	I-Premise

251	At	_	_	O
252	all	_	_	O
253	9	_	_	O
254	time	_	_	O
255	points	_	_	O
256	,	_	_	O
257	the	_	_	O
258	upper	_	_	O
259	limits	_	_	O
260	of	_	_	O
261	the	_	_	O
262	2-sided	_	_	O
263	95	_	_	O
264	%	_	_	O
265	confidence	_	_	O
266	intervals	_	_	O
267	for	_	_	O
268	the	_	_	O
269	difference	_	_	O
270	between	_	_	O
271	treatments	_	_	O
272	in	_	_	O
273	IOP	_	_	O
274	lowering	_	_	O
275	were	_	_	O
276	less	_	_	O
277	than	_	_	O
278	the	_	_	O
279	prespecified	_	_	O
280	noninferiority	_	_	O
281	margin	_	_	O
282	.	_	_	O

283	Similar	_	_	B-Premise
284	percentages	_	_	I-Premise
285	of	_	_	I-Premise
286	PF	_	_	I-Premise
287	tafluprost	_	_	I-Premise
288	and	_	_	I-Premise
289	PF	_	_	I-Premise
290	timolol	_	_	I-Premise
291	patients	_	_	I-Premise
292	reported	_	_	I-Premise
293	ocular	_	_	I-Premise
294	pain/stinging/irritation	_	_	I-Premise
295	(	_	_	I-Premise
296	4.4	_	_	I-Premise
297	%	_	_	I-Premise
298	vs	_	_	I-Premise
299	4.6	_	_	I-Premise
300	%	_	_	I-Premise
301	)	_	_	I-Premise
302	and	_	_	I-Premise
303	pruritus	_	_	I-Premise
304	(	_	_	I-Premise
305	2.5	_	_	I-Premise
306	%	_	_	I-Premise
307	vs	_	_	I-Premise
308	1.5	_	_	I-Premise
309	%	_	_	I-Premise
310	)	_	_	I-Premise
311	.	_	_	I-Premise

312	The	_	_	B-Premise
313	percentages	_	_	I-Premise
314	of	_	_	I-Premise
315	PF	_	_	I-Premise
316	tafluprost	_	_	I-Premise
317	and	_	_	I-Premise
318	PF	_	_	I-Premise
319	timolol	_	_	I-Premise
320	patients	_	_	I-Premise
321	reporting	_	_	I-Premise
322	conjunctival	_	_	I-Premise
323	hyperemia	_	_	I-Premise
324	were	_	_	I-Premise
325	4.4	_	_	I-Premise
326	%	_	_	I-Premise
327	vs	_	_	I-Premise
328	1.2	_	_	I-Premise
329	%	_	_	I-Premise
330	(	_	_	I-Premise
331	nominal	_	_	I-Premise
332	P	_	_	I-Premise
333	=	_	_	I-Premise
334	.016	_	_	I-Premise
335	)	_	_	I-Premise
336	.	_	_	I-Premise

337	The	_	_	B-Claim
338	IOP-lowering	_	_	I-Claim
339	effect	_	_	I-Claim
340	of	_	_	I-Claim
341	PF	_	_	I-Claim
342	tafluprost	_	_	I-Claim
343	was	_	_	I-Claim
344	noninferior	_	_	I-Claim
345	to	_	_	I-Claim
346	that	_	_	I-Claim
347	of	_	_	I-Claim
348	PF	_	_	I-Claim
349	timolol	_	_	I-Claim
350	.	_	_	I-Claim

351	PF	_	_	B-Claim
352	tafluprost	_	_	I-Claim
353	is	_	_	I-Claim
354	an	_	_	I-Claim
355	efficacious	_	_	I-Claim
356	and	_	_	I-Claim
357	generally	_	_	I-Claim
358	well-tolerated	_	_	I-Claim
359	ocular	_	_	I-Claim
360	hypotensive	_	_	I-Claim
361	agent	_	_	I-Claim
362	.	_	_	I-Claim


0	To	_	_	O
1	report	_	_	O
2	one-year	_	_	O
3	results	_	_	O
4	of	_	_	O
5	the	_	_	O
6	Tube	_	_	O
7	Versus	_	_	O
8	Trabeculectomy	_	_	O
9	(	_	_	O
10	TVT	_	_	O
11	)	_	_	O
12	Study	_	_	O
13	.	_	_	O

14	Multicenter	_	_	O
15	randomized	_	_	O
16	clinical	_	_	O
17	trial	_	_	O
18	.	_	_	O

19	Setting	_	_	O
20	:	_	_	O
21	17	_	_	O
22	Clinical	_	_	O
23	Centers	_	_	O
24	.	_	_	O

25	Study	_	_	O
26	Population	_	_	O
27	:	_	_	O
28	Patients	_	_	O
29	18	_	_	O
30	to	_	_	O
31	85	_	_	O
32	years	_	_	O
33	of	_	_	O
34	age	_	_	O
35	who	_	_	O
36	had	_	_	O
37	previous	_	_	O
38	trabeculectomy	_	_	O
39	and/or	_	_	O
40	cataract	_	_	O
41	extraction	_	_	O
42	with	_	_	O
43	intraocular	_	_	O
44	lens	_	_	O
45	implantation	_	_	O
46	and	_	_	O
47	uncontrolled	_	_	O
48	glaucoma	_	_	O
49	with	_	_	O
50	intraocular	_	_	O
51	pressure	_	_	O
52	(	_	_	O
53	IOP	_	_	O
54	)	_	_	O
55	>	_	_	O
56	or	_	_	O
57	=18	_	_	O
58	mm	_	_	O
59	Hg	_	_	O
60	and	_	_	O
61	<	_	_	O
62	or	_	_	O
63	=40	_	_	O
64	mm	_	_	O
65	Hg	_	_	O
66	on	_	_	O
67	maximum	_	_	O
68	tolerated	_	_	O
69	medical	_	_	O
70	therapy	_	_	O
71	.	_	_	O

72	Interventions	_	_	O
73	:	_	_	O
74	350	_	_	O
75	mm	_	_	O
76	(	_	_	O
77	2	_	_	O
78	)	_	_	O
79	Baerveldt	_	_	O
80	glaucoma	_	_	O
81	implant	_	_	O
82	or	_	_	O
83	trabeculectomy	_	_	O
84	with	_	_	O
85	mitomycin	_	_	O
86	C	_	_	O
87	(	_	_	O
88	MMC	_	_	O
89	)	_	_	O
90	.	_	_	O

91	Main	_	_	O
92	Outcome	_	_	O
93	Measures	_	_	O
94	:	_	_	O
95	IOP	_	_	O
96	,	_	_	O
97	visual	_	_	O
98	acuity	_	_	O
99	,	_	_	O
100	and	_	_	O
101	reoperation	_	_	O
102	for	_	_	O
103	glaucoma	_	_	O
104	.	_	_	O

105	A	_	_	O
106	total	_	_	O
107	of	_	_	O
108	212	_	_	O
109	eyes	_	_	O
110	of	_	_	O
111	212	_	_	O
112	patients	_	_	O
113	were	_	_	O
114	enrolled	_	_	O
115	,	_	_	O
116	including	_	_	O
117	107	_	_	O
118	in	_	_	O
119	the	_	_	O
120	tube	_	_	O
121	group	_	_	O
122	and	_	_	O
123	105	_	_	O
124	in	_	_	O
125	the	_	_	O
126	trabeculectomy	_	_	O
127	group	_	_	O
128	.	_	_	O

129	At	_	_	O
130	one	_	_	O
131	year	_	_	O
132	,	_	_	O
133	IOP	_	_	O
134	(	_	_	O
135	mean	_	_	O
136	+/-	_	_	O
137	SD	_	_	O
138	)	_	_	O
139	was	_	_	O
140	12.4	_	_	O
141	+/-	_	_	O
142	3.9	_	_	O
143	mm	_	_	O
144	Hg	_	_	O
145	in	_	_	O
146	the	_	_	O
147	tube	_	_	O
148	group	_	_	O
149	and	_	_	O
150	12.7	_	_	O
151	+/-	_	_	O
152	5.8	_	_	O
153	mm	_	_	O
154	Hg	_	_	O
155	in	_	_	O
156	the	_	_	O
157	trabeculectomy	_	_	O
158	group	_	_	O
159	(	_	_	O
160	P	_	_	O
161	=	_	_	O
162	.73	_	_	O
163	)	_	_	O
164	.	_	_	O

165	The	_	_	B-Premise
166	number	_	_	I-Premise
167	of	_	_	I-Premise
168	glaucoma	_	_	I-Premise
169	medications	_	_	I-Premise
170	(	_	_	I-Premise
171	mean	_	_	I-Premise
172	+/-	_	_	I-Premise
173	SD	_	_	I-Premise
174	)	_	_	I-Premise
175	was	_	_	I-Premise
176	1.3	_	_	I-Premise
177	+/-	_	_	I-Premise
178	1.3	_	_	I-Premise
179	in	_	_	I-Premise
180	the	_	_	I-Premise
181	tube	_	_	I-Premise
182	group	_	_	I-Premise
183	and	_	_	I-Premise
184	0.5	_	_	I-Premise
185	+/-	_	_	I-Premise
186	0.9	_	_	I-Premise
187	in	_	_	I-Premise
188	the	_	_	I-Premise
189	trabeculectomy	_	_	I-Premise
190	group	_	_	I-Premise
191	(	_	_	I-Premise
192	P	_	_	I-Premise
193	<	_	_	I-Premise
194	.001	_	_	I-Premise
195	)	_	_	I-Premise
196	.	_	_	I-Premise

197	The	_	_	B-Premise
198	cumulative	_	_	I-Premise
199	probability	_	_	I-Premise
200	of	_	_	I-Premise
201	failure	_	_	I-Premise
202	during	_	_	I-Premise
203	the	_	_	I-Premise
204	first	_	_	I-Premise
205	year	_	_	I-Premise
206	of	_	_	I-Premise
207	follow-up	_	_	I-Premise
208	was	_	_	I-Premise
209	3.9	_	_	I-Premise
210	%	_	_	I-Premise
211	in	_	_	I-Premise
212	the	_	_	I-Premise
213	tube	_	_	I-Premise
214	group	_	_	I-Premise
215	and	_	_	I-Premise
216	13.5	_	_	I-Premise
217	%	_	_	I-Premise
218	in	_	_	I-Premise
219	the	_	_	I-Premise
220	trabeculectomy	_	_	I-Premise
221	group	_	_	I-Premise
222	(	_	_	I-Premise
223	P	_	_	I-Premise
224	=	_	_	I-Premise
225	.017	_	_	I-Premise
226	)	_	_	I-Premise
227	.	_	_	I-Premise

228	Nonvalved	_	_	B-Premise
229	tube	_	_	I-Premise
230	shunt	_	_	I-Premise
231	surgery	_	_	I-Premise
232	was	_	_	I-Premise
233	more	_	_	I-Premise
234	likely	_	_	I-Premise
235	to	_	_	I-Premise
236	maintain	_	_	I-Premise
237	IOP	_	_	I-Premise
238	control	_	_	I-Premise
239	and	_	_	I-Premise
240	avoid	_	_	I-Premise
241	persistent	_	_	I-Premise
242	hypotony	_	_	I-Premise
243	or	_	_	I-Premise
244	reoperation	_	_	I-Premise
245	for	_	_	I-Premise
246	glaucoma	_	_	I-Premise
247	than	_	_	I-Premise
248	trabeculectomy	_	_	I-Premise
249	with	_	_	I-Premise
250	MMC	_	_	I-Premise
251	during	_	_	I-Premise
252	the	_	_	I-Premise
253	first	_	_	I-Premise
254	year	_	_	I-Premise
255	of	_	_	I-Premise
256	follow-up	_	_	I-Premise
257	in	_	_	I-Premise
258	the	_	_	I-Premise
259	TVT	_	_	I-Premise
260	Study	_	_	I-Premise
261	.	_	_	I-Premise

262	Both	_	_	B-Claim
263	surgical	_	_	I-Claim
264	procedures	_	_	I-Claim
265	produced	_	_	I-Claim
266	similar	_	_	I-Claim
267	IOP	_	_	I-Claim
268	reduction	_	_	I-Claim
269	at	_	_	I-Claim
270	one	_	_	I-Claim
271	year	_	_	I-Claim
272	,	_	_	O
273	but	_	_	O
274	there	_	_	B-Claim
275	was	_	_	I-Claim
276	less	_	_	I-Claim
277	need	_	_	I-Claim
278	for	_	_	I-Claim
279	supplemental	_	_	I-Claim
280	medical	_	_	I-Claim
281	therapy	_	_	I-Claim
282	following	_	_	I-Claim
283	trabeculectomy	_	_	I-Claim
284	with	_	_	I-Claim
285	MMC	_	_	I-Claim
286	.	_	_	I-Claim


0	The	_	_	O
1	aim	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	is	_	_	O
6	to	_	_	O
7	assess	_	_	O
8	the	_	_	O
9	efficacy	_	_	O
10	and	_	_	O
11	complications	_	_	O
12	of	_	_	O
13	trabeculectomy	_	_	O
14	with	_	_	O
15	a	_	_	O
16	biodegradable	_	_	O
17	implant	_	_	O
18	(	_	_	O
19	ologen	_	_	O
20	implant	_	_	O
21	)	_	_	O
22	vs	_	_	O
23	trabeculectomy	_	_	O
24	using	_	_	O
25	mitomycin	_	_	O
26	C	_	_	O
27	(	_	_	O
28	MMC	_	_	O
29	)	_	_	O
30	in	_	_	O
31	patients	_	_	O
32	with	_	_	O
33	medically	_	_	O
34	uncontrolled	_	_	O
35	open-angle	_	_	O
36	glaucoma	_	_	O
37	in	_	_	O
38	a	_	_	O
39	prospective	_	_	O
40	randomised	_	_	O
41	clinical	_	_	O
42	trial	_	_	O
43	.	_	_	O

44	In	_	_	O
45	the	_	_	O
46	MMC	_	_	O
47	group	_	_	O
48	(	_	_	O
49	10	_	_	O
50	patients	_	_	O
51	)	_	_	O
52	,	_	_	O
53	trabeculectomy	_	_	O
54	was	_	_	O
55	performed	_	_	O
56	according	_	_	O
57	to	_	_	O
58	standard	_	_	O
59	protocols	_	_	O
60	.	_	_	O

61	In	_	_	O
62	the	_	_	O
63	ologen	_	_	O
64	group	_	_	O
65	(	_	_	O
66	10	_	_	O
67	patients	_	_	O
68	)	_	_	O
69	after	_	_	O
70	standard	_	_	O
71	trabeculectomy	_	_	O
72	the	_	_	O
73	implant	_	_	O
74	was	_	_	O
75	positioned	_	_	O
76	on	_	_	O
77	top	_	_	O
78	of	_	_	O
79	the	_	_	O
80	scleral	_	_	O
81	flap	_	_	O
82	and	_	_	O
83	no	_	_	O
84	MMC	_	_	O
85	was	_	_	O
86	applied	_	_	O
87	.	_	_	O

88	Follow-up	_	_	O
89	was	_	_	O
90	continued	_	_	O
91	for	_	_	O
92	12	_	_	O
93	months	_	_	O
94	after	_	_	O
95	surgery	_	_	O
96	and	_	_	O
97	included	_	_	O
98	testing	_	_	O
99	of	_	_	O
100	intraocular	_	_	O
101	pressure	_	_	O
102	(	_	_	O
103	IOP	_	_	O
104	)	_	_	O
105	,	_	_	O
106	visual	_	_	O
107	acuity	_	_	O
108	,	_	_	O
109	visual	_	_	O
110	field	_	_	O
111	,	_	_	O
112	ultrasound	_	_	O
113	biomicroscopy	_	_	O
114	,	_	_	O
115	and	_	_	O
116	filtering	_	_	O
117	bleb	_	_	O
118	score	_	_	O
119	.	_	_	O

120	The	_	_	O
121	mean	_	_	O
122	preoperative	_	_	O
123	IOP	_	_	O
124	was	_	_	O
125	24.8+/-8.9	_	_	O
126	mm	_	_	O
127	Hg	_	_	O
128	for	_	_	O
129	all	_	_	O
130	patients	_	_	O
131	enrolled	_	_	O
132	.	_	_	O

133	At	_	_	B-Premise
134	1	_	_	I-Premise
135	year	_	_	I-Premise
136	after	_	_	I-Premise
137	surgery	_	_	I-Premise
138	,	_	_	I-Premise
139	the	_	_	I-Premise
140	mean	_	_	I-Premise
141	IOP	_	_	I-Premise
142	was	_	_	I-Premise
143	15.6+/-2.4mm	_	_	I-Premise
144	Hg	_	_	I-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	ologen	_	_	I-Premise
148	group	_	_	I-Premise
149	(	_	_	I-Premise
150	P	_	_	I-Premise
151	<	_	_	I-Premise
152	0.01	_	_	I-Premise
153	,	_	_	I-Premise
154	43	_	_	I-Premise
155	%	_	_	I-Premise
156	reduction	_	_	I-Premise
157	)	_	_	I-Premise
158	and	_	_	I-Premise
159	11.5+/-4.1	_	_	I-Premise
160	mm	_	_	I-Premise
161	Hg	_	_	I-Premise
162	in	_	_	I-Premise
163	the	_	_	I-Premise
164	MMC	_	_	I-Premise
165	group	_	_	I-Premise
166	(	_	_	I-Premise
167	P	_	_	I-Premise
168	<	_	_	I-Premise
169	0.01	_	_	I-Premise
170	,	_	_	I-Premise
171	50	_	_	I-Premise
172	%	_	_	I-Premise
173	reduction	_	_	I-Premise
174	)	_	_	I-Premise
175	.	_	_	I-Premise

176	No	_	_	B-Premise
177	anti-glaucomatous	_	_	I-Premise
178	medication	_	_	I-Premise
179	was	_	_	I-Premise
180	necessary	_	_	I-Premise
181	in	_	_	I-Premise
182	the	_	_	I-Premise
183	MMC	_	_	I-Premise
184	group	_	_	I-Premise
185	in	_	_	I-Premise
186	the	_	_	I-Premise
187	first	_	_	I-Premise
188	year	_	_	I-Premise
189	of	_	_	I-Premise
190	follow-up	_	_	I-Premise
191	,	_	_	I-Premise
192	whereas	_	_	I-Premise
193	five	_	_	I-Premise
194	patients	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	ologen	_	_	I-Premise
198	group	_	_	I-Premise
199	required	_	_	I-Premise
200	topical	_	_	I-Premise
201	treatment	_	_	I-Premise
202	.	_	_	I-Premise

203	The	_	_	B-Premise
204	absolute	_	_	I-Premise
205	success	_	_	I-Premise
206	rate	_	_	I-Premise
207	was	_	_	I-Premise
208	100	_	_	I-Premise
209	%	_	_	I-Premise
210	in	_	_	I-Premise
211	the	_	_	I-Premise
212	MMC	_	_	I-Premise
213	group	_	_	I-Premise
214	and	_	_	I-Premise
215	50	_	_	I-Premise
216	%	_	_	I-Premise
217	in	_	_	I-Premise
218	the	_	_	I-Premise
219	ologen	_	_	I-Premise
220	group	_	_	I-Premise
221	(	_	_	I-Premise
222	P=0.01	_	_	I-Premise
223	)	_	_	I-Premise
224	.	_	_	I-Premise

225	After	_	_	B-Premise
226	1	_	_	I-Premise
227	year	_	_	I-Premise
228	,	_	_	I-Premise
229	filtering	_	_	I-Premise
230	blebs	_	_	I-Premise
231	developed	_	_	I-Premise
232	significantly	_	_	I-Premise
233	more	_	_	I-Premise
234	avascular	_	_	I-Premise
235	areas	_	_	I-Premise
236	in	_	_	I-Premise
237	the	_	_	I-Premise
238	MMC	_	_	I-Premise
239	group	_	_	I-Premise
240	(	_	_	I-Premise
241	score=1.4	_	_	I-Premise
242	)	_	_	I-Premise
243	than	_	_	I-Premise
244	in	_	_	I-Premise
245	the	_	_	I-Premise
246	ologen	_	_	I-Premise
247	group	_	_	I-Premise
248	(	_	_	I-Premise
249	score=2.8	_	_	I-Premise
250	;	_	_	I-Premise
251	P	_	_	I-Premise
252	<	_	_	I-Premise
253	0.01	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	The	_	_	B-Claim
257	complete	_	_	I-Claim
258	success	_	_	I-Claim
259	rate	_	_	I-Claim
260	using	_	_	I-Claim
261	trabeculectomy	_	_	I-Claim
262	with	_	_	I-Claim
263	the	_	_	I-Claim
264	ologen	_	_	I-Claim
265	implant	_	_	I-Claim
266	is	_	_	I-Claim
267	lower	_	_	I-Claim
268	than	_	_	I-Claim
269	that	_	_	I-Claim
270	achieved	_	_	I-Claim
271	by	_	_	I-Claim
272	trabeculectomy	_	_	I-Claim
273	with	_	_	I-Claim
274	MMC	_	_	I-Claim
275	.	_	_	I-Claim

276	However	_	_	B-Claim
277	,	_	_	I-Claim
278	the	_	_	I-Claim
279	bleb	_	_	I-Claim
280	morphology	_	_	I-Claim
281	caused	_	_	I-Claim
282	more	_	_	I-Claim
283	problems	_	_	I-Claim
284	in	_	_	I-Claim
285	the	_	_	I-Claim
286	MMC	_	_	I-Claim
287	group	_	_	I-Claim
288	(	_	_	I-Claim
289	avascularity	_	_	I-Claim
290	score	_	_	I-Claim
291	)	_	_	I-Claim
292	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	on	_	_	O
5	intraocular	_	_	O
6	pressure	_	_	O
7	of	_	_	O
8	latanoprost	_	_	O
9	versus	_	_	O
10	timolol	_	_	O
11	plus	_	_	O
12	dorzolamide	_	_	O
13	in	_	_	O
14	open-angle	_	_	O
15	glaucoma	_	_	O
16	.	_	_	O

17	Thirty-five	_	_	O
18	patients	_	_	O
19	with	_	_	O
20	open-angle	_	_	O
21	glaucoma	_	_	O
22	were	_	_	O
23	randomized	_	_	O
24	,	_	_	O
25	18	_	_	O
26	to	_	_	O
27	latanoprost	_	_	O
28	once	_	_	O
29	daily	_	_	O
30	and	_	_	O
31	17	_	_	O
32	to	_	_	O
33	timolol	_	_	O
34	plus	_	_	O
35	dorzolamide	_	_	O
36	twice	_	_	O
37	daily	_	_	O
38	.	_	_	O

39	Intraocular	_	_	O
40	pressure	_	_	O
41	and	_	_	O
42	ocular	_	_	O
43	side	_	_	O
44	effects	_	_	O
45	were	_	_	O
46	recorded	_	_	O
47	at	_	_	O
48	baseline	_	_	O
49	,	_	_	O
50	and	_	_	O
51	after	_	_	O
52	2	_	_	O
53	weeks	_	_	O
54	and	_	_	O
55	3	_	_	O
56	months	_	_	O
57	of	_	_	O
58	treatment	_	_	O
59	.	_	_	O

60	Latanoprost	_	_	B-Premise
61	reduced	_	_	I-Premise
62	the	_	_	I-Premise
63	intraocular	_	_	I-Premise
64	pressure	_	_	I-Premise
65	1.09	_	_	I-Premise
66	and	_	_	I-Premise
67	1.58	_	_	I-Premise
68	mm	_	_	I-Premise
69	Hg	_	_	I-Premise
70	more	_	_	I-Premise
71	than	_	_	I-Premise
72	timolol	_	_	I-Premise
73	plus	_	_	I-Premise
74	dorzolamide	_	_	I-Premise
75	after	_	_	I-Premise
76	2	_	_	I-Premise
77	weeks	_	_	I-Premise
78	and	_	_	I-Premise
79	3	_	_	I-Premise
80	months	_	_	I-Premise
81	of	_	_	I-Premise
82	treatment	_	_	I-Premise
83	,	_	_	I-Premise
84	respectively	_	_	I-Premise
85	.	_	_	I-Premise

86	These	_	_	B-Premise
87	differences	_	_	I-Premise
88	were	_	_	I-Premise
89	statistically	_	_	I-Premise
90	significant	_	_	I-Premise
91	(	_	_	I-Premise
92	p	_	_	I-Premise
93	<	_	_	I-Premise
94	0.05	_	_	I-Premise
95	)	_	_	I-Premise
96	at	_	_	I-Premise
97	the	_	_	I-Premise
98	end	_	_	I-Premise
99	of	_	_	I-Premise
100	the	_	_	I-Premise
101	study	_	_	I-Premise
102	.	_	_	I-Premise

103	After	_	_	B-Premise
104	3	_	_	I-Premise
105	months	_	_	I-Premise
106	of	_	_	I-Premise
107	treatment	_	_	I-Premise
108	,	_	_	I-Premise
109	32.3	_	_	I-Premise
110	%	_	_	I-Premise
111	of	_	_	I-Premise
112	the	_	_	I-Premise
113	eyes	_	_	I-Premise
114	in	_	_	I-Premise
115	the	_	_	I-Premise
116	latanoprost	_	_	I-Premise
117	group	_	_	I-Premise
118	reduced	_	_	I-Premise
119	the	_	_	I-Premise
120	intraocular	_	_	I-Premise
121	pressure	_	_	I-Premise
122	in	_	_	I-Premise
123	30	_	_	I-Premise
124	%	_	_	I-Premise
125	or	_	_	I-Premise
126	more	_	_	I-Premise
127	with	_	_	I-Premise
128	respect	_	_	I-Premise
129	to	_	_	I-Premise
130	baseline	_	_	I-Premise
131	,	_	_	I-Premise
132	while	_	_	I-Premise
133	15.6	_	_	I-Premise
134	%	_	_	I-Premise
135	of	_	_	I-Premise
136	the	_	_	I-Premise
137	eyes	_	_	I-Premise
138	in	_	_	I-Premise
139	the	_	_	I-Premise
140	timolol	_	_	I-Premise
141	plus	_	_	I-Premise
142	dorzolamide	_	_	I-Premise
143	group	_	_	I-Premise
144	achieved	_	_	I-Premise
145	this	_	_	I-Premise
146	reduction	_	_	I-Premise
147	.	_	_	I-Premise

148	Latanoprost	_	_	B-Claim
149	administered	_	_	I-Claim
150	once	_	_	I-Claim
151	daily	_	_	I-Claim
152	reduced	_	_	I-Claim
153	the	_	_	I-Claim
154	intraocular	_	_	I-Claim
155	pressure	_	_	I-Claim
156	at	_	_	I-Claim
157	least	_	_	I-Claim
158	as	_	_	I-Claim
159	well	_	_	I-Claim
160	as	_	_	I-Claim
161	timolol	_	_	I-Claim
162	plus	_	_	I-Claim
163	dorzolamide	_	_	I-Claim
164	twice	_	_	I-Claim
165	daily	_	_	I-Claim
166	in	_	_	I-Claim
167	patients	_	_	I-Claim
168	with	_	_	I-Claim
169	open-angle	_	_	I-Claim
170	glaucoma	_	_	I-Claim
171	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	intraocular	_	_	O
3	pressure	_	_	O
4	(	_	_	O
5	IOP	_	_	O
6	)	_	_	O
7	control	_	_	O
8	and	_	_	O
9	other	_	_	O
10	clinical	_	_	O
11	outcomes	_	_	O
12	after	_	_	O
13	1-site	_	_	O
14	fornix-based	_	_	O
15	and	_	_	O
16	2-site	_	_	O
17	limbus-based	_	_	O
18	phacotrabeculectomy	_	_	O
19	.	_	_	O

20	Prospective	_	_	O
21	randomized	_	_	O
22	controlled	_	_	O
23	trial	_	_	O
24	.	_	_	O

25	A	_	_	O
26	total	_	_	O
27	of	_	_	O
28	90	_	_	O
29	eyes	_	_	O
30	of	_	_	O
31	76	_	_	O
32	patients	_	_	O
33	with	_	_	O
34	cataract	_	_	O
35	and	_	_	O
36	glaucoma	_	_	O
37	were	_	_	O
38	treated	_	_	O
39	.	_	_	O

40	Forty-four	_	_	O
41	eyes	_	_	O
42	were	_	_	O
43	assigned	_	_	O
44	randomly	_	_	O
45	to	_	_	O
46	receive	_	_	O
47	a	_	_	O
48	1-site	_	_	O
49	phacotrabeculectomy	_	_	O
50	with	_	_	O
51	a	_	_	O
52	fornix-based	_	_	O
53	conjunctival	_	_	O
54	flap	_	_	O
55	,	_	_	O
56	and	_	_	O
57	46	_	_	O
58	eyes	_	_	O
59	were	_	_	O
60	assigned	_	_	O
61	randomly	_	_	O
62	to	_	_	O
63	receive	_	_	O
64	a	_	_	O
65	2-site	_	_	O
66	phacotrabeculectomy	_	_	O
67	with	_	_	O
68	a	_	_	O
69	limbus-based	_	_	O
70	conjunctival	_	_	O
71	flap	_	_	O
72	.	_	_	O

73	All	_	_	O
74	operations	_	_	O
75	were	_	_	O
76	performed	_	_	O
77	with	_	_	O
78	mitomycin	_	_	O
79	C	_	_	O
80	.	_	_	O

81	Intraocular	_	_	O
82	pressure	_	_	O
83	and	_	_	O
84	number	_	_	O
85	of	_	_	O
86	antiglaucoma	_	_	O
87	medications	_	_	O
88	were	_	_	O
89	recorded	_	_	O
90	at	_	_	O
91	baseline	_	_	O
92	and	_	_	O
93	during	_	_	O
94	a	_	_	O
95	3-year	_	_	O
96	follow-up	_	_	O
97	period	_	_	O
98	.	_	_	O

99	Mean	_	_	B-Premise
100	preoperative	_	_	I-Premise
101	IOP	_	_	I-Premise
102	was	_	_	I-Premise
103	20.1+/-3.8	_	_	I-Premise
104	mmHg	_	_	I-Premise
105	in	_	_	I-Premise
106	the	_	_	I-Premise
107	1-site	_	_	I-Premise
108	group	_	_	I-Premise
109	and	_	_	I-Premise
110	19.5+/-5.3	_	_	I-Premise
111	mmHg	_	_	I-Premise
112	in	_	_	I-Premise
113	the	_	_	I-Premise
114	2-site	_	_	I-Premise
115	group	_	_	I-Premise
116	(	_	_	I-Premise
117	P	_	_	I-Premise
118	=	_	_	I-Premise
119	0.56	_	_	I-Premise
120	)	_	_	I-Premise
121	using	_	_	I-Premise
122	a	_	_	I-Premise
123	mean	_	_	I-Premise
124	of	_	_	I-Premise
125	2.3+/-0.9	_	_	I-Premise
126	and	_	_	I-Premise
127	2.5+/-0.9	_	_	I-Premise
128	antiglaucoma	_	_	I-Premise
129	medications	_	_	I-Premise
130	,	_	_	I-Premise
131	respectively	_	_	I-Premise
132	(	_	_	I-Premise
133	P	_	_	I-Premise
134	=	_	_	I-Premise
135	0.27	_	_	I-Premise
136	)	_	_	I-Premise
137	.	_	_	I-Premise

138	After	_	_	B-Premise
139	3	_	_	I-Premise
140	years	_	_	I-Premise
141	of	_	_	I-Premise
142	follow-up	_	_	I-Premise
143	,	_	_	I-Premise
144	the	_	_	I-Premise
145	mean	_	_	I-Premise
146	IOP	_	_	I-Premise
147	was	_	_	I-Premise
148	12.6+/-4.8	_	_	I-Premise
149	mmHg	_	_	I-Premise
150	in	_	_	I-Premise
151	the	_	_	I-Premise
152	1-site	_	_	I-Premise
153	group	_	_	I-Premise
154	and	_	_	I-Premise
155	11.7+/-4.0	_	_	I-Premise
156	mmHg	_	_	I-Premise
157	in	_	_	I-Premise
158	the	_	_	I-Premise
159	2-site	_	_	I-Premise
160	group	_	_	I-Premise
161	(	_	_	I-Premise
162	P	_	_	I-Premise
163	=	_	_	I-Premise
164	0.40	_	_	I-Premise
165	)	_	_	I-Premise
166	,	_	_	I-Premise
167	receiving	_	_	I-Premise
168	a	_	_	I-Premise
169	mean	_	_	I-Premise
170	of	_	_	I-Premise
171	0.3+/-0.7	_	_	I-Premise
172	and	_	_	I-Premise
173	0.4+/-0.9	_	_	I-Premise
174	medications	_	_	I-Premise
175	,	_	_	I-Premise
176	respectively	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	=	_	_	I-Premise
180	0.59	_	_	I-Premise
181	)	_	_	I-Premise
182	.	_	_	I-Premise

183	At	_	_	B-Premise
184	the	_	_	I-Premise
185	end	_	_	I-Premise
186	of	_	_	I-Premise
187	the	_	_	I-Premise
188	study	_	_	I-Premise
189	,	_	_	I-Premise
190	73	_	_	I-Premise
191	%	_	_	I-Premise
192	of	_	_	I-Premise
193	1-site	_	_	I-Premise
194	eyes	_	_	I-Premise
195	and	_	_	I-Premise
196	78.4	_	_	I-Premise
197	%	_	_	I-Premise
198	of	_	_	I-Premise
199	2-site	_	_	I-Premise
200	eyes	_	_	I-Premise
201	had	_	_	I-Premise
202	IOPs	_	_	I-Premise
203	of	_	_	I-Premise
204	less	_	_	I-Premise
205	than	_	_	I-Premise
206	18	_	_	I-Premise
207	mmHg	_	_	I-Premise
208	while	_	_	I-Premise
209	receiving	_	_	I-Premise
210	no	_	_	I-Premise
211	antiglaucoma	_	_	I-Premise
212	medications	_	_	I-Premise
213	(	_	_	I-Premise
214	P	_	_	I-Premise
215	=	_	_	I-Premise
216	0.59	_	_	I-Premise
217	)	_	_	I-Premise
218	.	_	_	I-Premise

219	Visual	_	_	B-Premise
220	acuity	_	_	I-Premise
221	was	_	_	I-Premise
222	similar	_	_	I-Premise
223	for	_	_	I-Premise
224	both	_	_	I-Premise
225	groups	_	_	I-Premise
226	at	_	_	I-Premise
227	3	_	_	I-Premise
228	months	_	_	I-Premise
229	after	_	_	I-Premise
230	surgery	_	_	I-Premise
231	.	_	_	I-Premise

232	There	_	_	B-Premise
233	were	_	_	I-Premise
234	no	_	_	I-Premise
235	significant	_	_	I-Premise
236	differences	_	_	I-Premise
237	in	_	_	I-Premise
238	the	_	_	I-Premise
239	need	_	_	I-Premise
240	for	_	_	I-Premise
241	digital	_	_	I-Premise
242	pressure	_	_	I-Premise
243	,	_	_	I-Premise
244	postoperative	_	_	I-Premise
245	bleb	_	_	I-Premise
246	needling	_	_	I-Premise
247	with	_	_	I-Premise
248	5-fluorouracil	_	_	I-Premise
249	,	_	_	I-Premise
250	or	_	_	I-Premise
251	number	_	_	I-Premise
252	of	_	_	I-Premise
253	postoperative	_	_	I-Premise
254	visits	_	_	I-Premise
255	.	_	_	I-Premise

256	There	_	_	O
257	were	_	_	O
258	2	_	_	O
259	major	_	_	O
260	complications	_	_	O
261	in	_	_	O
262	each	_	_	O
263	group	_	_	O
264	during	_	_	O
265	follow-up	_	_	O
266	.	_	_	O

267	Early	_	_	B-Premise
268	leaks	_	_	I-Premise
269	of	_	_	I-Premise
270	the	_	_	I-Premise
271	conjunctival	_	_	I-Premise
272	wound	_	_	I-Premise
273	closure	_	_	I-Premise
274	occurred	_	_	I-Premise
275	in	_	_	I-Premise
276	6	_	_	I-Premise
277	eyes	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	1-site	_	_	I-Premise
281	group	_	_	I-Premise
282	and	_	_	I-Premise
283	in	_	_	I-Premise
284	0	_	_	I-Premise
285	eyes	_	_	I-Premise
286	in	_	_	I-Premise
287	the	_	_	I-Premise
288	2-site	_	_	I-Premise
289	group	_	_	I-Premise
290	(	_	_	I-Premise
291	P	_	_	I-Premise
292	=	_	_	I-Premise
293	0.03	_	_	I-Premise
294	)	_	_	I-Premise
295	.	_	_	I-Premise

296	Operating	_	_	O
297	time	_	_	O
298	(	_	_	O
299	in	_	_	O
300	minutes	_	_	O
301	)	_	_	O
302	was	_	_	O
303	less	_	_	O
304	in	_	_	O
305	the	_	_	O
306	1-site	_	_	O
307	surgery	_	_	O
308	group	_	_	O
309	(	_	_	O
310	P	_	_	O
311	<	_	_	O
312	0.0001	_	_	O
313	)	_	_	O
314	.	_	_	O

315	Day	_	_	O
316	one	_	_	O
317	postoperative	_	_	O
318	IOP	_	_	O
319	was	_	_	O
320	higher	_	_	O
321	in	_	_	O
322	the	_	_	O
323	2-site	_	_	O
324	group	_	_	O
325	(	_	_	O
326	P	_	_	O
327	=	_	_	O
328	0.0.01	_	_	O
329	)	_	_	O
330	.	_	_	O

331	One-site	_	_	B-Claim
332	fornix-based	_	_	I-Claim
333	and	_	_	I-Claim
334	2-site	_	_	I-Claim
335	limbus-based	_	_	I-Claim
336	phacotrabeculectomy	_	_	I-Claim
337	were	_	_	I-Claim
338	similarly	_	_	I-Claim
339	effective	_	_	I-Claim
340	in	_	_	I-Claim
341	lowering	_	_	I-Claim
342	IOP	_	_	I-Claim
343	and	_	_	I-Claim
344	reducing	_	_	I-Claim
345	the	_	_	I-Claim
346	need	_	_	I-Claim
347	for	_	_	I-Claim
348	antiglaucoma	_	_	I-Claim
349	medications	_	_	I-Claim
350	over	_	_	I-Claim
351	a	_	_	I-Claim
352	3-year	_	_	I-Claim
353	follow-up	_	_	I-Claim
354	period	_	_	I-Claim
355	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	tolerability	_	_	O
6	of	_	_	O
7	brimonidine	_	_	O
8	purite	_	_	O
9	0.1	_	_	O
10	%	_	_	O
11	in	_	_	O
12	comparison	_	_	O
13	to	_	_	O
14	brinzolamide	_	_	O
15	1	_	_	O
16	%	_	_	O
17	when	_	_	O
18	used	_	_	O
19	as	_	_	O
20	adjunctive	_	_	O
21	therapy	_	_	O
22	to	_	_	O
23	latanoprost	_	_	O
24	0.005	_	_	O
25	%	_	_	O
26	in	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	glaucoma	_	_	O
30	or	_	_	O
31	ocular	_	_	O
32	hypertension	_	_	O
33	.	_	_	O

34	Randomized	_	_	O
35	,	_	_	O
36	single-center	_	_	O
37	,	_	_	O
38	investigator-masked	_	_	O
39	,	_	_	O
40	parallel-group	_	_	O
41	clinical	_	_	O
42	study	_	_	O
43	.	_	_	O

44	Patients	_	_	O
45	with	_	_	O
46	IOP	_	_	O
47	>	_	_	O
48	or=	_	_	O
49	18	_	_	O
50	mmHg	_	_	O
51	while	_	_	O
52	on	_	_	O
53	once-daily	_	_	O
54	latanoprost	_	_	O
55	were	_	_	O
56	randomized	_	_	O
57	to	_	_	O
58	adjunctive	_	_	O
59	treatment	_	_	O
60	with	_	_	O
61	brimonidine	_	_	O
62	purite	_	_	O
63	TID	_	_	O
64	(	_	_	O
65	n	_	_	O
66	=	_	_	O
67	20	_	_	O
68	)	_	_	O
69	or	_	_	O
70	brinzolamide	_	_	O
71	TID	_	_	O
72	(	_	_	O
73	n	_	_	O
74	=	_	_	O
75	20	_	_	O
76	)	_	_	O
77	for	_	_	O
78	3	_	_	O
79	months	_	_	O
80	.	_	_	O

81	Intraocular	_	_	O
82	pressure	_	_	O
83	(	_	_	O
84	IOP	_	_	O
85	)	_	_	O
86	was	_	_	O
87	measured	_	_	O
88	at	_	_	O
89	8	_	_	O
90	a.m.	_	_	O
91	,	_	_	O
92	10	_	_	O
93	a.m.	_	_	O
94	,	_	_	O
95	and	_	_	O
96	4	_	_	O
97	p.m.	_	_	O
98	at	_	_	O
99	latanoprost-treated	_	_	O
100	baseline	_	_	O
101	and	_	_	O
102	after	_	_	O
103	1	_	_	O
104	and	_	_	O
105	3	_	_	O
106	months	_	_	O
107	of	_	_	O
108	latanoprost	_	_	O
109	and	_	_	O
110	adjunctive	_	_	O
111	therapy	_	_	O
112	.	_	_	O

113	A	_	_	O
114	patient	_	_	O
115	questionnaire	_	_	O
116	was	_	_	O
117	administered	_	_	O
118	to	_	_	O
119	evaluate	_	_	O
120	the	_	_	O
121	tolerability	_	_	O
122	of	_	_	O
123	eye	_	_	O
124	drop	_	_	O
125	instillation	_	_	O
126	.	_	_	O

127	Baseline	_	_	B-Premise
128	mean	_	_	I-Premise
129	diurnal	_	_	I-Premise
130	IOP	_	_	I-Premise
131	(	_	_	I-Premise
132	+/-	_	_	I-Premise
133	standard	_	_	I-Premise
134	deviation	_	_	I-Premise
135	,	_	_	I-Premise
136	mmHg	_	_	I-Premise
137	)	_	_	I-Premise
138	on	_	_	I-Premise
139	latanoprost	_	_	I-Premise
140	was	_	_	I-Premise
141	comparable	_	_	I-Premise
142	between	_	_	I-Premise
143	groups	_	_	I-Premise
144	(	_	_	I-Premise
145	brimonidine	_	_	I-Premise
146	purite	_	_	I-Premise
147	:	_	_	I-Premise
148	19.6	_	_	I-Premise
149	+/-	_	_	I-Premise
150	2.94	_	_	I-Premise
151	;	_	_	I-Premise
152	brinzolamide	_	_	I-Premise
153	:	_	_	I-Premise
154	19.8	_	_	I-Premise
155	+/-	_	_	I-Premise
156	3.25	_	_	I-Premise
157	;	_	_	I-Premise
158	p	_	_	I-Premise
159	=	_	_	I-Premise
160	0.846	_	_	I-Premise
161	)	_	_	I-Premise
162	.	_	_	I-Premise

163	Mean	_	_	B-Premise
164	diurnal	_	_	I-Premise
165	IOP	_	_	I-Premise
166	at	_	_	I-Premise
167	Month	_	_	I-Premise
168	3	_	_	I-Premise
169	was	_	_	I-Premise
170	16.3	_	_	I-Premise
171	+/-	_	_	I-Premise
172	2.63	_	_	I-Premise
173	mmHg	_	_	I-Premise
174	with	_	_	I-Premise
175	brimonidine	_	_	I-Premise
176	purite	_	_	I-Premise
177	and	_	_	I-Premise
178	17.8	_	_	I-Premise
179	+/-	_	_	I-Premise
180	2.19	_	_	I-Premise
181	mmHg	_	_	I-Premise
182	with	_	_	I-Premise
183	brinzolamide	_	_	I-Premise
184	(	_	_	I-Premise
185	p	_	_	I-Premise
186	=	_	_	I-Premise
187	0.028	_	_	I-Premise
188	)	_	_	I-Premise
189	.	_	_	I-Premise

190	Adjunctive	_	_	B-Premise
191	use	_	_	I-Premise
192	of	_	_	I-Premise
193	brimonidine	_	_	I-Premise
194	purite	_	_	I-Premise
195	provided	_	_	I-Premise
196	greater	_	_	I-Premise
197	IOP	_	_	I-Premise
198	lowering	_	_	I-Premise
199	than	_	_	I-Premise
200	brinzolamide	_	_	I-Premise
201	at	_	_	I-Premise
202	10	_	_	I-Premise
203	a.m.	_	_	I-Premise
204	(	_	_	I-Premise
205	p	_	_	I-Premise
206	<	_	_	I-Premise
207	0.001	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	4	_	_	I-Premise
211	p.m.	_	_	I-Premise
212	(	_	_	I-Premise
213	p	_	_	I-Premise
214	=	_	_	I-Premise
215	0.050	_	_	I-Premise
216	)	_	_	I-Premise
217	and	_	_	I-Premise
218	equivalent	_	_	I-Premise
219	IOP	_	_	I-Premise
220	lowering	_	_	I-Premise
221	to	_	_	I-Premise
222	brinzolamide	_	_	I-Premise
223	at	_	_	I-Premise
224	8	_	_	I-Premise
225	a.m.	_	_	I-Premise
226	(	_	_	I-Premise
227	p	_	_	I-Premise
228	=	_	_	I-Premise
229	0.716	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	Blurred	_	_	B-Premise
233	vision	_	_	I-Premise
234	at	_	_	I-Premise
235	Month	_	_	I-Premise
236	1	_	_	I-Premise
237	and	_	_	I-Premise
238	bitter	_	_	I-Premise
239	taste	_	_	I-Premise
240	at	_	_	I-Premise
241	Months	_	_	I-Premise
242	1	_	_	I-Premise
243	and	_	_	I-Premise
244	3	_	_	I-Premise
245	were	_	_	I-Premise
246	more	_	_	I-Premise
247	common	_	_	I-Premise
248	upon	_	_	I-Premise
249	instillation	_	_	I-Premise
250	of	_	_	I-Premise
251	brinzolamide	_	_	I-Premise
252	eye	_	_	I-Premise
253	drops	_	_	I-Premise
254	.	_	_	I-Premise

255	Brimonidine	_	_	B-Claim
256	purite	_	_	I-Claim
257	0.1	_	_	I-Claim
258	%	_	_	I-Claim
259	provided	_	_	I-Claim
260	significantly	_	_	I-Claim
261	lower	_	_	I-Claim
262	IOP	_	_	I-Claim
263	compared	_	_	I-Claim
264	with	_	_	I-Claim
265	brinzolamide	_	_	I-Claim
266	1	_	_	I-Claim
267	%	_	_	I-Claim
268	when	_	_	I-Claim
269	used	_	_	I-Claim
270	as	_	_	I-Claim
271	adjunctive	_	_	I-Claim
272	therapy	_	_	I-Claim
273	to	_	_	I-Claim
274	latanoprost	_	_	I-Claim
275	.	_	_	I-Claim

276	Both	_	_	B-Claim
277	adjunctive	_	_	I-Claim
278	therapies	_	_	I-Claim
279	were	_	_	I-Claim
280	well	_	_	I-Claim
281	tolerated	_	_	I-Claim
282	.	_	_	I-Claim

283	Limitations	_	_	B-Premise
284	of	_	_	I-Premise
285	this	_	_	I-Premise
286	study	_	_	I-Premise
287	include	_	_	I-Premise
288	the	_	_	I-Premise
289	use	_	_	I-Premise
290	of	_	_	I-Premise
291	a	_	_	I-Premise
292	single	_	_	I-Premise
293	site	_	_	I-Premise
294	and	_	_	I-Premise
295	the	_	_	I-Premise
296	sample	_	_	I-Premise
297	size	_	_	I-Premise
298	.	_	_	I-Premise

299	Additional	_	_	B-Claim
300	studies	_	_	I-Claim
301	are	_	_	I-Claim
302	needed	_	_	I-Claim
303	to	_	_	I-Claim
304	further	_	_	I-Claim
305	evaluate	_	_	I-Claim
306	these	_	_	I-Claim
307	drugs	_	_	I-Claim
308	as	_	_	I-Claim
309	adjunctive	_	_	I-Claim
310	therapy	_	_	I-Claim
311	to	_	_	I-Claim
312	prostaglandin	_	_	I-Claim
313	analogs	_	_	I-Claim
314	.	_	_	I-Claim


1	Ocular	_	_	O
2	blood	_	_	O
3	flow	_	_	O
4	dysregulation	_	_	O
5	has	_	_	O
6	been	_	_	O
7	implicated	_	_	O
8	in	_	_	O
9	the	_	_	O
10	pathogenesis	_	_	O
11	of	_	_	O
12	glaucoma	_	_	O
13	.	_	_	O

14	Whereas	_	_	O
15	the	_	_	O
16	effect	_	_	O
17	of	_	_	O
18	single	_	_	O
19	antiglaucoma	_	_	O
20	substances	_	_	O
21	on	_	_	O
22	ocular	_	_	O
23	blood	_	_	O
24	flow	_	_	O
25	has	_	_	O
26	been	_	_	O
27	addressed	_	_	O
28	in	_	_	O
29	various	_	_	O
30	experiments	_	_	O
31	,	_	_	O
32	evidence	_	_	O
33	for	_	_	O
34	fixed	_	_	O
35	combinations	_	_	O
36	is	_	_	O
37	sparse	_	_	O
38	.	_	_	O

39	In	_	_	O
40	the	_	_	O
41	present	_	_	O
42	study	_	_	O
43	,	_	_	O
44	we	_	_	O
45	set	_	_	O
46	out	_	_	O
47	to	_	_	O
48	compare	_	_	O
49	the	_	_	O
50	effects	_	_	O
51	of	_	_	O
52	latanoprost	_	_	O
53	0.005	_	_	O
54	%	_	_	O
55	/timolol	_	_	O
56	0.5	_	_	O
57	%	_	_	O
58	(	_	_	O
59	LT	_	_	O
60	)	_	_	O
61	fixed	_	_	O
62	combination	_	_	O
63	and	_	_	O
64	brimonidine	_	_	O
65	0.2	_	_	O
66	%	_	_	O
67	/timolol	_	_	O
68	0.5	_	_	O
69	%	_	_	O
70	(	_	_	O
71	BT	_	_	O
72	)	_	_	O
73	fixed	_	_	O
74	combination	_	_	O
75	on	_	_	O
76	intraocular	_	_	O
77	pressure	_	_	O
78	(	_	_	O
79	IOP	_	_	O
80	)	_	_	O
81	and	_	_	O
82	ocular	_	_	O
83	blood	_	_	O
84	flow	_	_	O
85	.	_	_	O

86	In	_	_	O
87	the	_	_	O
88	present	_	_	O
89	study	_	_	O
90	,	_	_	O
91	which	_	_	O
92	followed	_	_	O
93	a	_	_	O
94	randomized	_	_	O
95	,	_	_	O
96	double-masked	_	_	O
97	2-way	_	_	O
98	crossover	_	_	O
99	design	_	_	O
100	,	_	_	O
101	16	_	_	O
102	patients	_	_	O
103	with	_	_	O
104	primary	_	_	O
105	open-angle	_	_	O
106	glaucoma	_	_	O
107	and	_	_	O
108	2	_	_	O
109	patients	_	_	O
110	with	_	_	O
111	ocular	_	_	O
112	hypertension	_	_	O
113	were	_	_	O
114	included	_	_	O
115	.	_	_	O

116	The	_	_	O
117	patients	_	_	O
118	underwent	_	_	O
119	a	_	_	O
120	6-week	_	_	O
121	treatment	_	_	O
122	with	_	_	O
123	LT	_	_	O
124	and	_	_	O
125	a	_	_	O
126	6-week	_	_	O
127	treatment	_	_	O
128	with	_	_	O
129	BT	_	_	O
130	after	_	_	O
131	a	_	_	O
132	washout	_	_	O
133	for	_	_	O
134	previous	_	_	O
135	antiglaucoma	_	_	O
136	medication	_	_	O
137	.	_	_	O

138	Optic	_	_	O
139	nerve	_	_	O
140	head	_	_	O
141	blood	_	_	O
142	flow	_	_	O
143	(	_	_	O
144	ONHBF	_	_	O
145	)	_	_	O
146	was	_	_	O
147	measured	_	_	O
148	using	_	_	O
149	laser	_	_	O
150	Doppler	_	_	O
151	flowmetry	_	_	O
152	;	_	_	O
153	retrobulbar	_	_	O
154	flow	_	_	O
155	velocities	_	_	O
156	were	_	_	O
157	measured	_	_	O
158	using	_	_	O
159	color	_	_	O
160	Doppler	_	_	O
161	imaging	_	_	O
162	in	_	_	O
163	the	_	_	O
164	ophthalmic	_	_	O
165	artery	_	_	O
166	,	_	_	O
167	the	_	_	O
168	central	_	_	O
169	retinal	_	_	O
170	artery	_	_	O
171	,	_	_	O
172	and	_	_	O
173	the	_	_	O
174	posterior	_	_	O
175	ciliary	_	_	O
176	arteries	_	_	O
177	.	_	_	O

178	IOP	_	_	O
179	was	_	_	O
180	measured	_	_	O
181	at	_	_	O
182	8	_	_	O
183	AM	_	_	O
184	,	_	_	O
185	12	_	_	O
186	PM	_	_	O
187	,	_	_	O
188	and	_	_	O
189	4	_	_	O
190	PM	_	_	O
191	.	_	_	O

192	The	_	_	O
193	mean	_	_	O
194	baseline	_	_	O
195	IOP	_	_	O
196	was	_	_	O
197	25.3	_	_	O
198	±2.8	_	_	O
199	mmHg	_	_	O
200	.	_	_	O

201	Both	_	_	B-Premise
202	drugs	_	_	I-Premise
203	were	_	_	I-Premise
204	equally	_	_	I-Premise
205	effective	_	_	I-Premise
206	in	_	_	I-Premise
207	reducing	_	_	I-Premise
208	IOP	_	_	I-Premise
209	(	_	_	I-Premise
210	LT	_	_	I-Premise
211	:	_	_	I-Premise
212	-35.0	_	_	I-Premise
213	%	_	_	I-Premise
214	±10.0	_	_	I-Premise
215	%	_	_	I-Premise
216	;	_	_	I-Premise
217	BT	_	_	I-Premise
218	:	_	_	I-Premise
219	-33.6	_	_	I-Premise
220	%	_	_	I-Premise
221	±8.8	_	_	I-Premise
222	%	_	_	I-Premise
223	,	_	_	I-Premise
224	P=0.463	_	_	I-Premise
225	between	_	_	I-Premise
226	groups	_	_	I-Premise
227	)	_	_	I-Premise
228	.	_	_	I-Premise

229	In	_	_	O
230	addition	_	_	O
231	,	_	_	O
232	no	_	_	B-Premise
233	difference	_	_	I-Premise
234	in	_	_	I-Premise
235	ocular	_	_	I-Premise
236	perfusion	_	_	I-Premise
237	pressure	_	_	I-Premise
238	was	_	_	I-Premise
239	observed	_	_	I-Premise
240	between	_	_	I-Premise
241	the	_	_	I-Premise
242	2	_	_	I-Premise
243	treatment	_	_	I-Premise
244	groups	_	_	I-Premise
245	(	_	_	I-Premise
246	P=0.1	_	_	I-Premise
247	,	_	_	I-Premise
248	between	_	_	I-Premise
249	groups	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	Neither	_	_	B-Premise
253	LT	_	_	I-Premise
254	nor	_	_	I-Premise
255	BT	_	_	I-Premise
256	altered	_	_	I-Premise
257	ONHBF	_	_	I-Premise
258	(	_	_	I-Premise
259	P=0.4	_	_	I-Premise
260	,	_	_	I-Premise
261	baseline	_	_	I-Premise
262	vs.	_	_	I-Premise
263	treatment	_	_	I-Premise
264	)	_	_	I-Premise
265	and	_	_	O
266	no	_	_	B-Premise
267	effect	_	_	I-Premise
268	on	_	_	I-Premise
269	flow	_	_	I-Premise
270	velocities	_	_	I-Premise
271	in	_	_	I-Premise
272	the	_	_	I-Premise
273	retrobulbar	_	_	I-Premise
274	vessels	_	_	I-Premise
275	was	_	_	I-Premise
276	seen	_	_	I-Premise
277	with	_	_	I-Premise
278	either	_	_	I-Premise
279	of	_	_	I-Premise
280	the	_	_	I-Premise
281	2	_	_	I-Premise
282	treatments	_	_	I-Premise
283	.	_	_	I-Premise

284	In	_	_	O
285	the	_	_	O
286	present	_	_	O
287	study	_	_	O
288	,	_	_	O
289	a	_	_	B-Claim
290	6-week	_	_	I-Claim
291	treatment	_	_	I-Claim
292	with	_	_	I-Claim
293	LT	_	_	I-Claim
294	or	_	_	I-Claim
295	BT	_	_	I-Claim
296	was	_	_	I-Claim
297	equally	_	_	I-Claim
298	effective	_	_	I-Claim
299	in	_	_	I-Claim
300	reducing	_	_	I-Claim
301	IOP	_	_	I-Claim
302	.	_	_	I-Claim

303	In	_	_	O
304	addition	_	_	O
305	,	_	_	O
306	none	_	_	B-Claim
307	of	_	_	I-Claim
308	the	_	_	I-Claim
309	administered	_	_	I-Claim
310	drugs	_	_	I-Claim
311	induced	_	_	I-Claim
312	a	_	_	I-Claim
313	significant	_	_	I-Claim
314	effect	_	_	I-Claim
315	on	_	_	I-Claim
316	ocular	_	_	I-Claim
317	blood	_	_	I-Claim
318	flow	_	_	I-Claim
319	parameters	_	_	I-Claim
320	.	_	_	I-Claim


0	Bimatoprost	_	_	O
1	and	_	_	O
2	the	_	_	O
3	fixed	_	_	O
4	combination	_	_	O
5	of	_	_	O
6	latanoprost	_	_	O
7	with	_	_	O
8	timolol	_	_	O
9	maleate	_	_	O
10	are	_	_	O
11	2	_	_	O
12	medications	_	_	O
13	widely	_	_	O
14	used	_	_	O
15	to	_	_	O
16	treat	_	_	O
17	glaucoma	_	_	O
18	and	_	_	O
19	ocular	_	_	O
20	hypertension	_	_	O
21	(	_	_	O
22	OHT	_	_	O
23	)	_	_	O
24	.	_	_	O

25	The	_	_	O
26	aim	_	_	O
27	of	_	_	O
28	the	_	_	O
29	study	_	_	O
30	is	_	_	O
31	to	_	_	O
32	compare	_	_	O
33	the	_	_	O
34	efficacy	_	_	O
35	of	_	_	O
36	these	_	_	O
37	2	_	_	O
38	drugs	_	_	O
39	in	_	_	O
40	reducing	_	_	O
41	intraocular	_	_	O
42	pressure	_	_	O
43	(	_	_	O
44	IOP	_	_	O
45	)	_	_	O
46	after	_	_	O
47	8	_	_	O
48	weeks	_	_	O
49	of	_	_	O
50	treatment	_	_	O
51	in	_	_	O
52	patients	_	_	O
53	with	_	_	O
54	primary	_	_	O
55	open	_	_	O
56	angle	_	_	O
57	glaucoma	_	_	O
58	(	_	_	O
59	POAG	_	_	O
60	)	_	_	O
61	or	_	_	O
62	OHT	_	_	O
63	.	_	_	O

64	In	_	_	O
65	this	_	_	O
66	randomized	_	_	O
67	,	_	_	O
68	open-label	_	_	O
69	trial	_	_	O
70	,	_	_	O
71	44	_	_	O
72	patients	_	_	O
73	with	_	_	O
74	POAG	_	_	O
75	or	_	_	O
76	OHT	_	_	O
77	were	_	_	O
78	allocated	_	_	O
79	to	_	_	O
80	receive	_	_	O
81	either	_	_	O
82	bimatoprost	_	_	O
83	(	_	_	O
84	1	_	_	O
85	drop	_	_	O
86	QD	_	_	O
87	)	_	_	O
88	or	_	_	O
89	latanoprost/timolol	_	_	O
90	(	_	_	O
91	1	_	_	O
92	drop	_	_	O
93	QD	_	_	O
94	)	_	_	O
95	.	_	_	O

96	Primary	_	_	O
97	outcome	_	_	O
98	was	_	_	O
99	the	_	_	O
100	mean	_	_	O
101	diurnal	_	_	O
102	IOP	_	_	O
103	measurement	_	_	O
104	at	_	_	O
105	the	_	_	O
106	8th	_	_	O
107	week	_	_	O
108	,	_	_	O
109	calculated	_	_	O
110	as	_	_	O
111	the	_	_	O
112	mean	_	_	O
113	IOP	_	_	O
114	measurements	_	_	O
115	taken	_	_	O
116	at	_	_	O
117	8:00	_	_	O
118	am	_	_	O
119	,	_	_	O
120	10:00	_	_	O
121	am	_	_	O
122	,	_	_	O
123	and	_	_	O
124	12:00	_	_	O
125	pm	_	_	O
126	Secondary	_	_	O
127	outcomes	_	_	O
128	included	_	_	O
129	the	_	_	O
130	baseline	_	_	O
131	change	_	_	O
132	in	_	_	O
133	IOP	_	_	O
134	measured	_	_	O
135	3	_	_	O
136	times	_	_	O
137	a	_	_	O
138	day	_	_	O
139	,	_	_	O
140	after	_	_	O
141	the	_	_	O
142	water-drinking	_	_	O
143	test	_	_	O
144	(	_	_	O
145	performed	_	_	O
146	after	_	_	O
147	the	_	_	O
148	last	_	_	O
149	IOP	_	_	O
150	measurement	_	_	O
151	)	_	_	O
152	,	_	_	O
153	and	_	_	O
154	the	_	_	O
155	assessment	_	_	O
156	of	_	_	O
157	side	_	_	O
158	effects	_	_	O
159	of	_	_	O
160	each	_	_	O
161	therapy	_	_	O
162	.	_	_	O

163	The	_	_	B-Premise
164	mean	_	_	I-Premise
165	IOP	_	_	I-Premise
166	levels	_	_	I-Premise
167	of	_	_	I-Premise
168	latanoprost/timolol	_	_	I-Premise
169	(	_	_	I-Premise
170	13.83	_	_	I-Premise
171	,	_	_	I-Premise
172	SD	_	_	I-Premise
173	=	_	_	I-Premise
174	2.54	_	_	I-Premise
175	)	_	_	I-Premise
176	was	_	_	I-Premise
177	significantly	_	_	I-Premise
178	lower	_	_	I-Premise
179	than	_	_	I-Premise
180	of	_	_	I-Premise
181	bimatoprost	_	_	I-Premise
182	(	_	_	I-Premise
183	16.16	_	_	I-Premise
184	,	_	_	I-Premise
185	SD	_	_	I-Premise
186	=	_	_	I-Premise
187	3.28	_	_	I-Premise
188	;	_	_	I-Premise
189	P	_	_	I-Premise
190	<	_	_	I-Premise
191	0.0001	_	_	I-Premise
192	)	_	_	I-Premise
193	at	_	_	I-Premise
194	week	_	_	I-Premise
195	8	_	_	I-Premise
196	.	_	_	I-Premise

197	Also	_	_	O
198	,	_	_	O
199	the	_	_	B-Premise
200	change	_	_	I-Premise
201	in	_	_	I-Premise
202	mean	_	_	I-Premise
203	IOP	_	_	I-Premise
204	values	_	_	I-Premise
205	was	_	_	I-Premise
206	significantly	_	_	I-Premise
207	higher	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	latanoprost/timolol	_	_	I-Premise
211	group	_	_	I-Premise
212	at	_	_	I-Premise
213	10:00	_	_	I-Premise
214	am	_	_	I-Premise
215	(	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	0.013	_	_	I-Premise
219	)	_	_	I-Premise
220	and	_	_	I-Premise
221	12:00	_	_	I-Premise
222	pm	_	_	I-Premise
223	(	_	_	I-Premise
224	P	_	_	I-Premise
225	=	_	_	I-Premise
226	0.01	_	_	I-Premise
227	)	_	_	I-Premise
228	,	_	_	I-Premise
229	but	_	_	I-Premise
230	not	_	_	I-Premise
231	at	_	_	I-Premise
232	8:00	_	_	I-Premise
233	am	_	_	I-Premise
234	(	_	_	I-Premise
235	P	_	_	I-Premise
236	=	_	_	I-Premise
237	ns	_	_	I-Premise
238	)	_	_	I-Premise
239	.	_	_	I-Premise

240	During	_	_	O
241	the	_	_	O
242	water-drinking	_	_	O
243	test	_	_	O
244	,	_	_	O
245	there	_	_	O
246	was	_	_	O
247	no	_	_	O
248	significant	_	_	O
249	difference	_	_	O
250	in	_	_	O
251	IOP	_	_	O
252	increase	_	_	O
253	(	_	_	O
254	absolute	_	_	O
255	and	_	_	O
256	percentage	_	_	O
257	)	_	_	O
258	between	_	_	O
259	groups	_	_	O
260	;	_	_	O
261	however	_	_	O
262	,	_	_	O
263	there	_	_	B-Premise
264	was	_	_	I-Premise
265	a	_	_	I-Premise
266	significant	_	_	I-Premise
267	decrease	_	_	I-Premise
268	in	_	_	I-Premise
269	mean	_	_	I-Premise
270	heart	_	_	I-Premise
271	rate	_	_	I-Premise
272	in	_	_	I-Premise
273	the	_	_	I-Premise
274	latanoprost/timolol	_	_	I-Premise
275	group	_	_	I-Premise
276	.	_	_	O

277	Finally	_	_	O
278	,	_	_	O
279	no	_	_	B-Premise
280	significant	_	_	I-Premise
281	changes	_	_	I-Premise
282	in	_	_	I-Premise
283	blood	_	_	I-Premise
284	pressure	_	_	I-Premise
285	and	_	_	I-Premise
286	lung	_	_	I-Premise
287	spirometry	_	_	I-Premise
288	were	_	_	I-Premise
289	observed	_	_	I-Premise
290	in	_	_	I-Premise
291	either	_	_	I-Premise
292	groups	_	_	I-Premise
293	.	_	_	I-Premise

294	The	_	_	B-Claim
295	fixed	_	_	I-Claim
296	combination	_	_	I-Claim
297	of	_	_	I-Claim
298	latanoprost/timolol	_	_	I-Claim
299	was	_	_	I-Claim
300	significantly	_	_	I-Claim
301	superior	_	_	I-Claim
302	to	_	_	I-Claim
303	bimatoprost	_	_	I-Claim
304	alone	_	_	I-Claim
305	in	_	_	I-Claim
306	reducing	_	_	I-Claim
307	IOP	_	_	I-Claim
308	in	_	_	I-Claim
309	patients	_	_	I-Claim
310	with	_	_	I-Claim
311	POAG	_	_	I-Claim
312	or	_	_	I-Claim
313	OHT	_	_	I-Claim
314	.	_	_	I-Claim

315	Further	_	_	B-Claim
316	studies	_	_	I-Claim
317	with	_	_	I-Claim
318	large	_	_	I-Claim
319	sample	_	_	I-Claim
320	sizes	_	_	I-Claim
321	should	_	_	I-Claim
322	be	_	_	I-Claim
323	taken	_	_	I-Claim
324	to	_	_	I-Claim
325	support	_	_	I-Claim
326	the	_	_	I-Claim
327	superior	_	_	I-Claim
328	efficacy	_	_	I-Claim
329	of	_	_	I-Claim
330	latanoprost/timolol	_	_	I-Claim
331	,	_	_	I-Claim
332	as	_	_	I-Claim
333	well	_	_	I-Claim
334	as	_	_	I-Claim
335	to	_	_	I-Claim
336	better	_	_	I-Claim
337	assess	_	_	I-Claim
338	its	_	_	I-Claim
339	profile	_	_	I-Claim
340	of	_	_	I-Claim
341	side	_	_	I-Claim
342	effects	_	_	I-Claim
343	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	laser	_	_	O
8	peripheral	_	_	O
9	iridotomy	_	_	O
10	with	_	_	O
11	or	_	_	O
12	without	_	_	O
13	laser	_	_	O
14	peripheral	_	_	O
15	iridoplasty	_	_	O
16	in	_	_	O
17	the	_	_	O
18	treatment	_	_	O
19	of	_	_	O
20	eyes	_	_	O
21	with	_	_	O
22	synechial	_	_	O
23	primary	_	_	O
24	angle-closure	_	_	O
25	or	_	_	O
26	primary	_	_	O
27	angle-closure	_	_	O
28	glaucoma	_	_	O
29	.	_	_	O

30	Randomized	_	_	O
31	,	_	_	O
32	controlled	_	_	O
33	clinical	_	_	O
34	trial	_	_	O
35	.	_	_	O

36	Consecutive	_	_	O
37	patients	_	_	O
38	older	_	_	O
39	than	_	_	O
40	40	_	_	O
41	years	_	_	O
42	with	_	_	O
43	synechial	_	_	O
44	primary	_	_	O
45	angle-closure	_	_	O
46	or	_	_	O
47	primary	_	_	O
48	angle	_	_	O
49	closure	_	_	O
50	glaucoma	_	_	O
51	were	_	_	O
52	recruited	_	_	O
53	.	_	_	O

54	Eligible	_	_	O
55	patients	_	_	O
56	were	_	_	O
57	randomized	_	_	O
58	to	_	_	O
59	1	_	_	O
60	of	_	_	O
61	2	_	_	O
62	treatment	_	_	O
63	options	_	_	O
64	,	_	_	O
65	iridotomy	_	_	O
66	or	_	_	O
67	iridotomy	_	_	O
68	plus	_	_	O
69	iridoplasty	_	_	O
70	,	_	_	O
71	and	_	_	O
72	were	_	_	O
73	followed	_	_	O
74	up	_	_	O
75	for	_	_	O
76	1	_	_	O
77	year	_	_	O
78	.	_	_	O

79	Main	_	_	O
80	outcome	_	_	O
81	measures	_	_	O
82	were	_	_	O
83	intraocular	_	_	O
84	pressure	_	_	O
85	(	_	_	O
86	IOP	_	_	O
87	)	_	_	O
88	,	_	_	O
89	peripheral	_	_	O
90	anterior	_	_	O
91	synechiae	_	_	O
92	,	_	_	O
93	corneal	_	_	O
94	endothelial	_	_	O
95	cell	_	_	O
96	count	_	_	O
97	,	_	_	O
98	and	_	_	O
99	complications	_	_	O
100	.	_	_	O

101	Seventy-seven	_	_	O
102	eyes	_	_	O
103	(	_	_	O
104	77	_	_	O
105	patients	_	_	O
106	)	_	_	O
107	were	_	_	O
108	randomized	_	_	O
109	to	_	_	O
110	the	_	_	O
111	iridotomy	_	_	O
112	group	_	_	O
113	,	_	_	O
114	and	_	_	O
115	81	_	_	O
116	eyes	_	_	O
117	(	_	_	O
118	81	_	_	O
119	patients	_	_	O
120	)	_	_	O
121	were	_	_	O
122	randomized	_	_	O
123	to	_	_	O
124	the	_	_	O
125	iridotomy	_	_	O
126	plus	_	_	O
127	iridoplasty	_	_	O
128	group	_	_	O
129	.	_	_	O

130	Sixty-one	_	_	O
131	patients	_	_	O
132	(	_	_	O
133	79.2	_	_	O
134	%	_	_	O
135	)	_	_	O
136	in	_	_	O
137	the	_	_	O
138	iridotomy	_	_	O
139	and	_	_	O
140	65	_	_	O
141	patients	_	_	O
142	(	_	_	O
143	80.2	_	_	O
144	%	_	_	O
145	)	_	_	O
146	from	_	_	O
147	the	_	_	O
148	iridotomy	_	_	O
149	plus	_	_	O
150	iridoplasty	_	_	O
151	groups	_	_	O
152	completed	_	_	O
153	1	_	_	O
154	year	_	_	O
155	of	_	_	O
156	follow-up	_	_	O
157	.	_	_	O

158	There	_	_	O
159	were	_	_	O
160	no	_	_	O
161	significant	_	_	O
162	differences	_	_	O
163	between	_	_	O
164	the	_	_	O
165	groups	_	_	O
166	in	_	_	O
167	the	_	_	O
168	baseline	_	_	O
169	data	_	_	O
170	.	_	_	O

171	IOP	_	_	B-Premise
172	was	_	_	I-Premise
173	reduced	_	_	I-Premise
174	from	_	_	I-Premise
175	24.66	_	_	I-Premise
176	+/-	_	_	I-Premise
177	13.76	_	_	I-Premise
178	mm	_	_	I-Premise
179	Hg	_	_	I-Premise
180	to	_	_	I-Premise
181	19.03	_	_	I-Premise
182	+/-	_	_	I-Premise
183	6.21	_	_	I-Premise
184	mm	_	_	I-Premise
185	Hg	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	iridotomy	_	_	I-Premise
189	group	_	_	I-Premise
190	(	_	_	I-Premise
191	P	_	_	I-Premise
192	<	_	_	I-Premise
193	.001	_	_	I-Premise
194	)	_	_	I-Premise
195	and	_	_	I-Premise
196	from	_	_	I-Premise
197	27.96	_	_	I-Premise
198	+/-	_	_	I-Premise
199	13.06	_	_	I-Premise
200	mm	_	_	I-Premise
201	Hg	_	_	I-Premise
202	to	_	_	I-Premise
203	20.45	_	_	I-Premise
204	+/-	_	_	I-Premise
205	7.26	_	_	I-Premise
206	mm	_	_	I-Premise
207	Hg	_	_	I-Premise
208	in	_	_	I-Premise
209	the	_	_	I-Premise
210	iridotomy	_	_	I-Premise
211	plus	_	_	I-Premise
212	iridoplasty	_	_	I-Premise
213	group	_	_	I-Premise
214	(	_	_	I-Premise
215	P	_	_	I-Premise
216	<	_	_	I-Premise
217	.001	_	_	I-Premise
218	)	_	_	I-Premise
219	.	_	_	I-Premise

220	Extent	_	_	B-Premise
221	of	_	_	I-Premise
222	peripheral	_	_	I-Premise
223	anterior	_	_	I-Premise
224	synechiae	_	_	I-Premise
225	was	_	_	I-Premise
226	decreased	_	_	I-Premise
227	by	_	_	I-Premise
228	1	_	_	I-Premise
229	more	_	_	I-Premise
230	clock-hour	_	_	I-Premise
231	after	_	_	I-Premise
232	iridoplasty	_	_	I-Premise
233	compared	_	_	I-Premise
234	with	_	_	I-Premise
235	that	_	_	I-Premise
236	after	_	_	I-Premise
237	iridotomy	_	_	I-Premise
238	in	_	_	I-Premise
239	the	_	_	I-Premise
240	iridotomy	_	_	I-Premise
241	plus	_	_	I-Premise
242	iridoplasty	_	_	I-Premise
243	group	_	_	I-Premise
244	(	_	_	I-Premise
245	P	_	_	I-Premise
246	<	_	_	I-Premise
247	.001	_	_	I-Premise
248	)	_	_	I-Premise
249	.	_	_	I-Premise

250	There	_	_	B-Premise
251	was	_	_	I-Premise
252	no	_	_	I-Premise
253	significant	_	_	I-Premise
254	difference	_	_	I-Premise
255	in	_	_	I-Premise
256	IOP	_	_	I-Premise
257	,	_	_	I-Premise
258	medications	_	_	I-Premise
259	,	_	_	I-Premise
260	need	_	_	I-Premise
261	for	_	_	I-Premise
262	surgery	_	_	I-Premise
263	,	_	_	I-Premise
264	or	_	_	I-Premise
265	visual	_	_	I-Premise
266	function	_	_	I-Premise
267	between	_	_	I-Premise
268	groups	_	_	I-Premise
269	at	_	_	I-Premise
270	the	_	_	I-Premise
271	1-year	_	_	I-Premise
272	visit	_	_	I-Premise
273	.	_	_	I-Premise

274	In	_	_	B-Claim
275	eyes	_	_	I-Claim
276	with	_	_	I-Claim
277	synechial	_	_	I-Claim
278	primary	_	_	I-Claim
279	angle-closure	_	_	I-Claim
280	or	_	_	I-Claim
281	primary	_	_	I-Claim
282	angle-closure	_	_	I-Claim
283	glaucoma	_	_	I-Claim
284	,	_	_	I-Claim
285	both	_	_	I-Claim
286	iridotomy	_	_	I-Claim
287	alone	_	_	I-Claim
288	or	_	_	I-Claim
289	combined	_	_	I-Claim
290	with	_	_	I-Claim
291	iridoplasty	_	_	I-Claim
292	provide	_	_	I-Claim
293	a	_	_	I-Claim
294	significant	_	_	I-Claim
295	and	_	_	I-Claim
296	equivalent	_	_	I-Claim
297	reduction	_	_	I-Claim
298	in	_	_	I-Claim
299	IOP	_	_	I-Claim
300	.	_	_	I-Claim

301	There	_	_	B-Claim
302	is	_	_	I-Claim
303	also	_	_	I-Claim
304	a	_	_	I-Claim
305	possible	_	_	I-Claim
306	reduction	_	_	I-Claim
307	in	_	_	I-Claim
308	peripheral	_	_	I-Claim
309	anterior	_	_	I-Claim
310	synechiae	_	_	I-Claim
311	,	_	_	I-Claim
312	more	_	_	I-Claim
313	so	_	_	I-Claim
314	in	_	_	I-Claim
315	the	_	_	I-Claim
316	iridoplasty	_	_	I-Claim
317	group	_	_	I-Claim
318	.	_	_	I-Claim


1	To	_	_	O
2	compare	_	_	O
3	efficacy	_	_	O
4	(	_	_	O
5	intraocular	_	_	O
6	pressure	_	_	O
7	(	_	_	O
8	IOP	_	_	O
9	)	_	_	O
10	reduction	_	_	O
11	)	_	_	O
12	and	_	_	O
13	safety	_	_	O
14	of	_	_	O
15	preservative-free	_	_	O
16	latanoprost	_	_	O
17	(	_	_	O
18	T2345	_	_	O
19	)	_	_	O
20	to	_	_	O
21	benzalkonium	_	_	O
22	chloride	_	_	O
23	(	_	_	O
24	BAK	_	_	O
25	)	_	_	O
26	-preserved	_	_	O
27	latanoprost	_	_	O
28	(	_	_	O
29	BPL	_	_	O
30	;	_	_	O
31	Xalatan	_	_	O
32	)	_	_	O
33	in	_	_	O
34	ocular	_	_	O
35	hypertension	_	_	O
36	(	_	_	O
37	OHT	_	_	O
38	)	_	_	O
39	or	_	_	O
40	primary	_	_	O
41	open	_	_	O
42	angle	_	_	O
43	glaucoma	_	_	O
44	(	_	_	O
45	POAG	_	_	O
46	)	_	_	O
47	patients	_	_	O
48	.	_	_	O

49	Prospective	_	_	O
50	,	_	_	O
51	international	_	_	O
52	,	_	_	O
53	multicentre	_	_	O
54	,	_	_	O
55	randomised	_	_	O
56	,	_	_	O
57	investigator-masked	_	_	O
58	,	_	_	O
59	parallel-group	_	_	O
60	trial	_	_	O
61	.	_	_	O

62	After	_	_	O
63	a	_	_	O
64	wash-out	_	_	O
65	period	_	_	O
66	,	_	_	O
67	POAG	_	_	O
68	or	_	_	O
69	OHT	_	_	O
70	patients	_	_	O
71	,	_	_	O
72	previously	_	_	O
73	managed	_	_	O
74	by	_	_	O
75	BPL	_	_	O
76	monotherapy	_	_	O
77	,	_	_	O
78	randomly	_	_	O
79	received	_	_	O
80	T2345	_	_	O
81	or	_	_	O
82	BPL	_	_	O
83	(	_	_	O
84	one	_	_	O
85	drop	_	_	O
86	into	_	_	O
87	the	_	_	O
88	affected	_	_	O
89	eye	_	_	O
90	(	_	_	O
91	s	_	_	O
92	)	_	_	O
93	)	_	_	O
94	once	_	_	O
95	daily	_	_	O
96	from	_	_	O
97	D0	_	_	O
98	to	_	_	O
99	D84	_	_	O
100	.	_	_	O

101	Change	_	_	O
102	in	_	_	O
103	IOP	_	_	O
104	was	_	_	O
105	measured	_	_	O
106	at	_	_	O
107	09:00	_	_	O
108	(	_	_	O
109	±1	_	_	O
110	h	_	_	O
111	)	_	_	O
112	from	_	_	O
113	D0	_	_	O
114	to	_	_	O
115	D84	_	_	O
116	in	_	_	O
117	the	_	_	O
118	worse	_	_	O
119	eye	_	_	O
120	.	_	_	O

121	Mean	_	_	B-Premise
122	IOP	_	_	I-Premise
123	reduction	_	_	I-Premise
124	(	_	_	I-Premise
125	D0-D84	_	_	I-Premise
126	)	_	_	I-Premise
127	was	_	_	I-Premise
128	-8.6	_	_	I-Premise
129	±2.6	_	_	I-Premise
130	mm	_	_	I-Premise
131	Hg	_	_	I-Premise
132	(	_	_	I-Premise
133	-36	_	_	I-Premise
134	%	_	_	I-Premise
135	)	_	_	I-Premise
136	on	_	_	I-Premise
137	T2345	_	_	I-Premise
138	and	_	_	I-Premise
139	-9.0	_	_	I-Premise
140	±2.4	_	_	I-Premise
141	mm	_	_	I-Premise
142	Hg	_	_	I-Premise
143	(	_	_	I-Premise
144	-38	_	_	I-Premise
145	%	_	_	I-Premise
146	)	_	_	I-Premise
147	on	_	_	I-Premise
148	BPL	_	_	I-Premise
149	,	_	_	I-Premise
150	confirming	_	_	I-Premise
151	non-inferiority	_	_	I-Premise
152	of	_	_	I-Premise
153	T2345	_	_	I-Premise
154	to	_	_	I-Premise
155	BPL	_	_	I-Premise
156	.	_	_	I-Premise

157	Non-inferiority	_	_	O
158	of	_	_	O
159	T2345	_	_	O
160	was	_	_	O
161	observed	_	_	O
162	from	_	_	O
163	D15	_	_	O
164	.	_	_	O

165	The	_	_	B-Premise
166	most	_	_	I-Premise
167	frequent	_	_	I-Premise
168	ocular	_	_	I-Premise
169	adverse	_	_	I-Premise
170	event	_	_	I-Premise
171	,	_	_	I-Premise
172	drug	_	_	I-Premise
173	intolerance	_	_	I-Premise
174	,	_	_	I-Premise
175	was	_	_	I-Premise
176	reported	_	_	I-Premise
177	in	_	_	I-Premise
178	1	_	_	I-Premise
179	(	_	_	I-Premise
180	0.5	_	_	I-Premise
181	%	_	_	I-Premise
182	)	_	_	I-Premise
183	patient	_	_	I-Premise
184	on	_	_	I-Premise
185	T2345	_	_	I-Premise
186	versus	_	_	I-Premise
187	4	_	_	I-Premise
188	(	_	_	I-Premise
189	2.1	_	_	I-Premise
190	%	_	_	I-Premise
191	)	_	_	I-Premise
192	patients	_	_	I-Premise
193	on	_	_	I-Premise
194	BPL	_	_	I-Premise
195	.	_	_	I-Premise

196	Moderate	_	_	B-Premise
197	to	_	_	I-Premise
198	severe	_	_	I-Premise
199	conjunctival	_	_	I-Premise
200	hyperaemia	_	_	I-Premise
201	was	_	_	I-Premise
202	less	_	_	I-Premise
203	frequent	_	_	I-Premise
204	on	_	_	I-Premise
205	T2345	_	_	I-Premise
206	than	_	_	I-Premise
207	on	_	_	I-Premise
208	BPL	_	_	I-Premise
209	at	_	_	I-Premise
210	D42	_	_	I-Premise
211	(	_	_	I-Premise
212	20.2	_	_	I-Premise
213	%	_	_	I-Premise
214	vs	_	_	I-Premise
215	30.6	_	_	I-Premise
216	%	_	_	I-Premise
217	;	_	_	I-Premise
218	p=0.003	_	_	I-Premise
219	)	_	_	I-Premise
220	and	_	_	I-Premise
221	D84	_	_	I-Premise
222	(	_	_	I-Premise
223	21.4	_	_	I-Premise
224	%	_	_	I-Premise
225	vs	_	_	I-Premise
226	29.1	_	_	I-Premise
227	%	_	_	I-Premise
228	;	_	_	I-Premise
229	p=0.02	_	_	I-Premise
230	)	_	_	I-Premise
231	.	_	_	I-Premise

232	Upon	_	_	B-Premise
233	instillation	_	_	I-Premise
234	,	_	_	I-Premise
235	the	_	_	I-Premise
236	global	_	_	I-Premise
237	subjective	_	_	I-Premise
238	ocular	_	_	I-Premise
239	symptom	_	_	I-Premise
240	score	_	_	I-Premise
241	was	_	_	I-Premise
242	significantly	_	_	I-Premise
243	lower	_	_	I-Premise
244	on	_	_	I-Premise
245	T2345	_	_	I-Premise
246	than	_	_	I-Premise
247	BPL	_	_	I-Premise
248	on	_	_	I-Premise
249	D42	_	_	I-Premise
250	(	_	_	I-Premise
251	0.15	_	_	I-Premise
252	vs	_	_	I-Premise
253	0.41	_	_	I-Premise
254	;	_	_	I-Premise
255	p=0.001	_	_	I-Premise
256	)	_	_	I-Premise
257	and	_	_	I-Premise
258	D84	_	_	I-Premise
259	(	_	_	I-Premise
260	0.18	_	_	I-Premise
261	vs	_	_	I-Premise
262	0.46	_	_	I-Premise
263	;	_	_	I-Premise
264	p=0.001	_	_	I-Premise
265	)	_	_	I-Premise
266	.	_	_	I-Premise

267	Preservative-free	_	_	B-Claim
268	latanoprost	_	_	I-Claim
269	has	_	_	I-Claim
270	the	_	_	I-Claim
271	same	_	_	I-Claim
272	efficacy	_	_	I-Claim
273	as	_	_	I-Claim
274	BPL	_	_	I-Claim
275	,	_	_	I-Claim
276	with	_	_	I-Claim
277	improved	_	_	I-Claim
278	local	_	_	I-Claim
279	tolerance	_	_	I-Claim
280	.	_	_	I-Claim


1	To	_	_	O
2	compare	_	_	O
3	the	_	_	O
4	effect	_	_	O
5	on	_	_	O
6	intraocular	_	_	O
7	pressure	_	_	O
8	(	_	_	O
9	IOP	_	_	O
10	)	_	_	O
11	of	_	_	O
12	the	_	_	O
13	silicone	_	_	O
14	Ahmed	_	_	O
15	glaucoma	_	_	O
16	valve	_	_	O
17	with	_	_	O
18	and	_	_	O
19	without	_	_	O
20	an	_	_	O
21	intravitreal	_	_	O
22	injection	_	_	O
23	of	_	_	O
24	triamcinolone	_	_	O
25	acetonide	_	_	O
26	.	_	_	O

27	Forty-nine	_	_	O
28	patients	_	_	O
29	with	_	_	O
30	clinically	_	_	O
31	uncontrolled	_	_	O
32	neovascular	_	_	O
33	glaucoma	_	_	O
34	were	_	_	O
35	included	_	_	O
36	in	_	_	O
37	the	_	_	O
38	study	_	_	O
39	;	_	_	O
40	22	_	_	O
41	were	_	_	O
42	randomly	_	_	O
43	assigned	_	_	O
44	to	_	_	O
45	the	_	_	O
46	study	_	_	O
47	group	_	_	O
48	(	_	_	O
49	silicone	_	_	O
50	Ahmed	_	_	O
51	glaucoma	_	_	O
52	valve	_	_	O
53	implant	_	_	O
54	with	_	_	O
55	intravitreal	_	_	O
56	triamcinolone	_	_	O
57	acetonide	_	_	O
58	)	_	_	O
59	and	_	_	O
60	27	_	_	O
61	to	_	_	O
62	the	_	_	O
63	control	_	_	O
64	group	_	_	O
65	(	_	_	O
66	silicone	_	_	O
67	Ahmed	_	_	O
68	glaucoma	_	_	O
69	valve	_	_	O
70	)	_	_	O
71	.	_	_	O

72	IOP	_	_	O
73	was	_	_	O
74	the	_	_	O
75	primary	_	_	O
76	outcome	_	_	O
77	measure	_	_	O
78	in	_	_	O
79	this	_	_	O
80	study	_	_	O
81	.	_	_	O

82	The	_	_	O
83	secondary	_	_	O
84	outcome	_	_	O
85	measure	_	_	O
86	was	_	_	O
87	success	_	_	O
88	,	_	_	O
89	defined	_	_	O
90	by	_	_	O
91	IOP	_	_	O
92	lower	_	_	O
93	than	_	_	O
94	22	_	_	O
95	mm	_	_	O
96	Hg	_	_	O
97	and	_	_	O
98	higher	_	_	O
99	than	_	_	O
100	5	_	_	O
101	mm	_	_	O
102	Hg	_	_	O
103	,	_	_	O
104	and	_	_	O
105	no	_	_	O
106	serious	_	_	O
107	complications	_	_	O
108	.	_	_	O

109	Success	_	_	O
110	rates	_	_	O
111	in	_	_	O
112	both	_	_	O
113	the	_	_	O
114	groups	_	_	O
115	were	_	_	O
116	compared	_	_	O
117	using	_	_	O
118	Kaplan-Meier	_	_	O
119	survival	_	_	O
120	curves	_	_	O
121	and	_	_	O
122	the	_	_	O
123	log-rank	_	_	O
124	test	_	_	O
125	.	_	_	O

126	IOP	_	_	O
127	levels	_	_	O
128	were	_	_	O
129	compared	_	_	O
130	using	_	_	O
131	mixed	_	_	O
132	linear	_	_	O
133	model	_	_	O
134	analysis	_	_	O
135	to	_	_	O
136	correct	_	_	O
137	for	_	_	O
138	repeated	_	_	O
139	measures	_	_	O
140	correlation	_	_	O
141	.	_	_	O

142	Forty-three	_	_	O
143	patients	_	_	O
144	,	_	_	O
145	18	_	_	O
146	in	_	_	O
147	the	_	_	O
148	study	_	_	O
149	group	_	_	O
150	and	_	_	O
151	25	_	_	O
152	in	_	_	O
153	the	_	_	O
154	control	_	_	O
155	group	_	_	O
156	,	_	_	O
157	completed	_	_	O
158	the	_	_	O
159	study	_	_	O
160	(	_	_	O
161	follow-up	_	_	O
162	of	_	_	O
163	12	_	_	O
164	mo	_	_	O
165	)	_	_	O
166	.	_	_	O

167	The	_	_	B-Premise
168	mean	_	_	I-Premise
169	IOP	_	_	I-Premise
170	was	_	_	I-Premise
171	significantly	_	_	I-Premise
172	lower	_	_	I-Premise
173	after	_	_	I-Premise
174	1	_	_	I-Premise
175	year	_	_	I-Premise
176	in	_	_	I-Premise
177	both	_	_	I-Premise
178	the	_	_	I-Premise
179	groups	_	_	I-Premise
180	(	_	_	I-Premise
181	P	_	_	I-Premise
182	<	_	_	I-Premise
183	0.001	_	_	I-Premise
184	)	_	_	I-Premise
185	.	_	_	I-Premise

186	The	_	_	B-Premise
187	mean	_	_	I-Premise
188	IOP	_	_	I-Premise
189	in	_	_	I-Premise
190	the	_	_	I-Premise
191	first	_	_	I-Premise
192	month	_	_	I-Premise
193	of	_	_	I-Premise
194	follow-up	_	_	I-Premise
195	was	_	_	I-Premise
196	lower	_	_	I-Premise
197	in	_	_	I-Premise
198	the	_	_	I-Premise
199	study	_	_	I-Premise
200	group	_	_	I-Premise
201	(	_	_	I-Premise
202	control	_	_	I-Premise
203	;	_	_	I-Premise
204	20.4±9.7	_	_	I-Premise
205	,	_	_	I-Premise
206	study	_	_	I-Premise
207	;	_	_	I-Premise
208	13.6±6.5	_	_	I-Premise
209	,	_	_	I-Premise
210	P	_	_	I-Premise
211	<	_	_	I-Premise
212	0.01	_	_	I-Premise
213	)	_	_	I-Premise
214	.	_	_	I-Premise

215	The	_	_	B-Premise
216	success	_	_	I-Premise
217	rate	_	_	I-Premise
218	at	_	_	I-Premise
219	1	_	_	I-Premise
220	year	_	_	I-Premise
221	was	_	_	I-Premise
222	78	_	_	I-Premise
223	%	_	_	I-Premise
224	for	_	_	I-Premise
225	the	_	_	I-Premise
226	study	_	_	I-Premise
227	group	_	_	I-Premise
228	and	_	_	I-Premise
229	76	_	_	I-Premise
230	%	_	_	I-Premise
231	for	_	_	I-Premise
232	the	_	_	I-Premise
233	control	_	_	I-Premise
234	group	_	_	I-Premise
235	(	_	_	I-Premise
236	P=0.82	_	_	I-Premise
237	)	_	_	I-Premise
238	.	_	_	I-Premise

239	Complication	_	_	B-Premise
240	rates	_	_	I-Premise
241	were	_	_	I-Premise
242	not	_	_	I-Premise
243	different	_	_	I-Premise
244	between	_	_	I-Premise
245	the	_	_	I-Premise
246	groups	_	_	I-Premise
247	.	_	_	I-Premise

248	Intravitreal	_	_	B-Claim
249	injection	_	_	I-Claim
250	of	_	_	I-Claim
251	triamcinolone	_	_	I-Claim
252	acetonide	_	_	I-Claim
253	in	_	_	I-Claim
254	neovascular	_	_	I-Claim
255	glaucoma	_	_	I-Claim
256	did	_	_	I-Claim
257	not	_	_	I-Claim
258	affect	_	_	I-Claim
259	the	_	_	I-Claim
260	intermediate-term	_	_	I-Claim
261	success	_	_	I-Claim
262	of	_	_	I-Claim
263	the	_	_	I-Claim
264	silicone	_	_	I-Claim
265	Ahmed	_	_	I-Claim
266	valve	_	_	I-Claim
267	nor	_	_	I-Claim
268	reduce	_	_	I-Claim
269	the	_	_	I-Claim
270	incidence	_	_	I-Claim
271	of	_	_	I-Claim
272	complications	_	_	I-Claim
273	.	_	_	I-Claim

274	The	_	_	B-Premise
275	mean	_	_	I-Premise
276	IOP	_	_	I-Premise
277	spike	_	_	I-Premise
278	in	_	_	I-Premise
279	the	_	_	I-Premise
280	first	_	_	I-Premise
281	month	_	_	I-Premise
282	was	_	_	I-Premise
283	lower	_	_	I-Premise
284	in	_	_	I-Premise
285	the	_	_	I-Premise
286	triamcinolone	_	_	I-Premise
287	group	_	_	I-Premise
288	.	_	_	I-Premise


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	(	_	_	O
6	IOP	_	_	O
7	)	_	_	O
8	-lowering	_	_	O
9	effect	_	_	O
10	of	_	_	O
11	combined	_	_	O
12	viscocanalostomy	_	_	O
13	and	_	_	O
14	phacoemulsification	_	_	O
15	and	_	_	O
16	combined	_	_	O
17	trabeculectomy	_	_	O
18	and	_	_	O
19	phacoemulsification	_	_	O
20	with	_	_	O
21	mitomycin	_	_	O
22	C	_	_	O
23	in	_	_	O
24	eyes	_	_	O
25	with	_	_	O
26	primary	_	_	O
27	open-angle	_	_	O
28	glaucoma	_	_	O
29	.	_	_	O

30	Prospective	_	_	O
31	randomized	_	_	O
32	1-year	_	_	O
33	trial	_	_	O
34	.	_	_	O

35	Forty	_	_	O
36	consecutive	_	_	O
37	patients	_	_	O
38	(	_	_	O
39	40	_	_	O
40	eyes	_	_	O
41	)	_	_	O
42	with	_	_	O
43	primary	_	_	O
44	open-angle	_	_	O
45	glaucoma	_	_	O
46	and	_	_	O
47	cataract	_	_	O
48	.	_	_	O

49	Eyes	_	_	O
50	were	_	_	O
51	assigned	_	_	O
52	randomly	_	_	O
53	either	_	_	O
54	to	_	_	O
55	trabeculectomy	_	_	O
56	with	_	_	O
57	mitomycin	_	_	O
58	C	_	_	O
59	or	_	_	O
60	to	_	_	O
61	viscocanalostomy	_	_	O
62	in	_	_	O
63	combination	_	_	O
64	with	_	_	O
65	phacoemulsification	_	_	O
66	and	_	_	O
67	intraocular	_	_	O
68	lens	_	_	O
69	implantation	_	_	O
70	.	_	_	O

71	Success	_	_	O
72	rate	_	_	O
73	based	_	_	O
74	on	_	_	O
75	IOP	_	_	O
76	.	_	_	O

77	Mean	_	_	B-Premise
78	baseline	_	_	I-Premise
79	IOP	_	_	I-Premise
80	was	_	_	I-Premise
81	24.0+/-2.0	_	_	I-Premise
82	mmHg	_	_	I-Premise
83	in	_	_	I-Premise
84	the	_	_	I-Premise
85	viscocanalostomy	_	_	I-Premise
86	group	_	_	I-Premise
87	and	_	_	I-Premise
88	23.7+/-2.6	_	_	I-Premise
89	mmHg	_	_	I-Premise
90	in	_	_	I-Premise
91	the	_	_	I-Premise
92	trabeculectomy	_	_	I-Premise
93	group	_	_	I-Premise
94	(	_	_	I-Premise
95	P	_	_	I-Premise
96	=	_	_	I-Premise
97	0.7	_	_	I-Premise
98	)	_	_	I-Premise
99	.	_	_	I-Premise

100	Mean	_	_	I-Premise
101	postoperative	_	_	I-Premise
102	IOP	_	_	I-Premise
103	was	_	_	I-Premise
104	13.7+/-2.2	_	_	I-Premise
105	mmHg	_	_	I-Premise
106	at	_	_	I-Premise
107	3	_	_	I-Premise
108	months	_	_	I-Premise
109	,	_	_	I-Premise
110	14.8+/-3.3	_	_	I-Premise
111	mmHg	_	_	I-Premise
112	at	_	_	I-Premise
113	6	_	_	I-Premise
114	months	_	_	I-Premise
115	,	_	_	I-Premise
116	and	_	_	I-Premise
117	14.9+/-3.0	_	_	I-Premise
118	mmHg	_	_	I-Premise
119	at	_	_	I-Premise
120	12	_	_	I-Premise
121	months	_	_	I-Premise
122	in	_	_	I-Premise
123	the	_	_	I-Premise
124	viscocanalostomy	_	_	I-Premise
125	group	_	_	I-Premise
126	and	_	_	I-Premise
127	12.1+/-4.0	_	_	I-Premise
128	mmHg	_	_	I-Premise
129	at	_	_	I-Premise
130	3	_	_	I-Premise
131	months	_	_	I-Premise
132	,	_	_	I-Premise
133	13.8+/-4.7	_	_	I-Premise
134	mmHg	_	_	I-Premise
135	at	_	_	I-Premise
136	6	_	_	I-Premise
137	months	_	_	I-Premise
138	,	_	_	I-Premise
139	and	_	_	I-Premise
140	14.1+/-4.4	_	_	I-Premise
141	mmHg	_	_	I-Premise
142	at	_	_	I-Premise
143	12	_	_	I-Premise
144	months	_	_	I-Premise
145	in	_	_	I-Premise
146	the	_	_	I-Premise
147	trabeculectomy	_	_	I-Premise
148	group	_	_	I-Premise
149	.	_	_	I-Premise

150	There	_	_	O
151	was	_	_	O
152	no	_	_	O
153	significant	_	_	O
154	difference	_	_	O
155	in	_	_	O
156	the	_	_	O
157	mean	_	_	O
158	IOP	_	_	O
159	between	_	_	O
160	the	_	_	O
161	groups	_	_	O
162	at	_	_	O
163	any	_	_	O
164	time	_	_	O
165	.	_	_	O

166	At	_	_	B-Premise
167	12	_	_	I-Premise
168	months	_	_	I-Premise
169	,	_	_	I-Premise
170	17	_	_	I-Premise
171	patients	_	_	I-Premise
172	(	_	_	I-Premise
173	85	_	_	I-Premise
174	%	_	_	I-Premise
175	)	_	_	I-Premise
176	in	_	_	I-Premise
177	the	_	_	I-Premise
178	viscocanalostomy	_	_	I-Premise
179	group	_	_	I-Premise
180	and	_	_	I-Premise
181	16	_	_	I-Premise
182	patients	_	_	I-Premise
183	(	_	_	I-Premise
184	80	_	_	I-Premise
185	%	_	_	I-Premise
186	)	_	_	I-Premise
187	in	_	_	I-Premise
188	the	_	_	I-Premise
189	trabeculectomy	_	_	I-Premise
190	group	_	_	I-Premise
191	achieved	_	_	I-Premise
192	an	_	_	I-Premise
193	IOP	_	_	I-Premise
194	of	_	_	I-Premise
195	20	_	_	I-Premise
196	mmHg	_	_	I-Premise
197	or	_	_	I-Premise
198	less	_	_	I-Premise
199	without	_	_	I-Premise
200	medication	_	_	I-Premise
201	(	_	_	I-Premise
202	P	_	_	I-Premise
203	=	_	_	I-Premise
204	0.7	_	_	I-Premise
205	)	_	_	I-Premise
206	.	_	_	I-Premise

207	Complications	_	_	O
208	included	_	_	O
209	2	_	_	O
210	cases	_	_	O
211	(	_	_	O
212	10	_	_	O
213	%	_	_	O
214	)	_	_	O
215	of	_	_	O
216	flat/shallow	_	_	O
217	anterior	_	_	O
218	chamber	_	_	O
219	and	_	_	O
220	4	_	_	O
221	cases	_	_	O
222	(	_	_	O
223	20	_	_	O
224	%	_	_	O
225	)	_	_	O
226	of	_	_	O
227	hypotony	_	_	O
228	in	_	_	O
229	the	_	_	O
230	trabeculectomy	_	_	O
231	group	_	_	O
232	,	_	_	O
233	whereas	_	_	O
234	intraoperative	_	_	O
235	microperforation	_	_	O
236	of	_	_	O
237	Descemet	_	_	O
238	's	_	_	O
239	membrane	_	_	O
240	occurred	_	_	O
241	in	_	_	O
242	3	_	_	O
243	cases	_	_	O
244	(	_	_	O
245	15	_	_	O
246	%	_	_	O
247	)	_	_	O
248	in	_	_	O
249	the	_	_	O
250	viscocanalostomy	_	_	O
251	group	_	_	O
252	.	_	_	O

253	There	_	_	B-Claim
254	was	_	_	I-Claim
255	no	_	_	I-Claim
256	significant	_	_	I-Claim
257	difference	_	_	I-Claim
258	in	_	_	I-Claim
259	IOP	_	_	I-Claim
260	reduction	_	_	I-Claim
261	between	_	_	I-Claim
262	viscocanalostomy	_	_	I-Claim
263	and	_	_	I-Claim
264	trabeculectomy	_	_	I-Claim
265	with	_	_	I-Claim
266	mitomycin	_	_	I-Claim
267	C	_	_	I-Claim
268	in	_	_	I-Claim
269	combination	_	_	I-Claim
270	with	_	_	I-Claim
271	phacoemulsification	_	_	I-Claim
272	and	_	_	I-Claim
273	intraocular	_	_	I-Claim
274	lens	_	_	I-Claim
275	implantation	_	_	I-Claim
276	in	_	_	I-Claim
277	patients	_	_	I-Claim
278	with	_	_	I-Claim
279	primary	_	_	I-Claim
280	open-angle	_	_	I-Claim
281	glaucoma	_	_	I-Claim
282	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	intraocular	_	_	O
3	pressure	_	_	O
4	(	_	_	O
5	IOP	_	_	O
6	)	_	_	O
7	over	_	_	O
8	time	_	_	O
9	after	_	_	O
10	standard	_	_	O
11	trabeculectomy	_	_	O
12	vs	_	_	O
13	Ex-PRESS	_	_	O
14	implantation	_	_	O
15	in	_	_	O
16	patients	_	_	O
17	with	_	_	O
18	bilateral	_	_	O
19	primary	_	_	O
20	open-angle	_	_	O
21	glaucoma	_	_	O
22	(	_	_	O
23	POAG	_	_	O
24	)	_	_	O
25	.	_	_	O

26	Prospective	_	_	O
27	,	_	_	O
28	randomised	_	_	O
29	study	_	_	O
30	.	_	_	O

31	This	_	_	O
32	study	_	_	O
33	included	_	_	O
34	adult	_	_	O
35	patients	_	_	O
36	with	_	_	O
37	bilateral	_	_	O
38	POAG	_	_	O
39	necessitating	_	_	O
40	surgery	_	_	O
41	.	_	_	O

42	Each	_	_	O
43	patient	_	_	O
44	underwent	_	_	O
45	trabeculectomy	_	_	O
46	in	_	_	O
47	one	_	_	O
48	eye	_	_	O
49	and	_	_	O
50	Ex-PRESS	_	_	O
51	implantation	_	_	O
52	under	_	_	O
53	a	_	_	O
54	scleral	_	_	O
55	flap	_	_	O
56	in	_	_	O
57	the	_	_	O
58	other	_	_	O
59	eye	_	_	O
60	according	_	_	O
61	to	_	_	O
62	randomised	_	_	O
63	contralateral	_	_	O
64	allocations	_	_	O
65	.	_	_	O

66	Efficacy	_	_	O
67	was	_	_	O
68	assessed	_	_	O
69	by	_	_	O
70	IOP	_	_	O
71	values	_	_	O
72	and	_	_	O
73	success	_	_	O
74	rates	_	_	O
75	(	_	_	O
76	IOP	_	_	O
77	threshold	_	_	O
78	and/or	_	_	O
79	need	_	_	O
80	for	_	_	O
81	topical	_	_	O
82	glaucoma	_	_	O
83	medication	_	_	O
84	)	_	_	O
85	during	_	_	O
86	30	_	_	O
87	months	_	_	O
88	.	_	_	O

89	Statistical	_	_	O
90	analysis	_	_	O
91	included	_	_	O
92	Generalised	_	_	O
93	Estimate	_	_	O
94	Equation	_	_	O
95	and	_	_	O
96	Cox	_	_	O
97	Survival	_	_	O
98	models	_	_	O
99	,	_	_	O
100	and	_	_	O
101	paired	_	_	O
102	t-tests	_	_	O
103	.	_	_	O

104	Thirty	_	_	O
105	eyes	_	_	O
106	of	_	_	O
107	15	_	_	O
108	patients	_	_	O
109	were	_	_	O
110	studied	_	_	O
111	for	_	_	O
112	a	_	_	O
113	mean	_	_	O
114	of	_	_	O
115	23.6	_	_	O
116	months	_	_	O
117	(	_	_	O
118	SD	_	_	O
119	,	_	_	O
120	±	_	_	O
121	6.9	_	_	O
122	)	_	_	O
123	.	_	_	O

124	At	_	_	B-Premise
125	the	_	_	I-Premise
126	last	_	_	I-Premise
127	follow-up	_	_	I-Premise
128	visit	_	_	I-Premise
129	,	_	_	I-Premise
130	mean	_	_	I-Premise
131	pre-operative	_	_	I-Premise
132	IOP	_	_	I-Premise
133	decreased	_	_	I-Premise
134	from	_	_	I-Premise
135	31.1	_	_	I-Premise
136	(	_	_	I-Premise
137	±	_	_	I-Premise
138	14.2	_	_	I-Premise
139	)	_	_	I-Premise
140	to	_	_	I-Premise
141	16.2	_	_	I-Premise
142	(	_	_	I-Premise
143	±	_	_	I-Premise
144	1.5	_	_	I-Premise
145	)	_	_	I-Premise
146	mm	_	_	I-Premise
147	Hg	_	_	I-Premise
148	after	_	_	I-Premise
149	trabeculectomy	_	_	I-Premise
150	,	_	_	I-Premise
151	and	_	_	I-Premise
152	from	_	_	I-Premise
153	28.1	_	_	I-Premise
154	(	_	_	I-Premise
155	±	_	_	I-Premise
156	9.0	_	_	I-Premise
157	)	_	_	I-Premise
158	to	_	_	I-Premise
159	15.7	_	_	I-Premise
160	(	_	_	I-Premise
161	±	_	_	I-Premise
162	1.8	_	_	I-Premise
163	)	_	_	I-Premise
164	mm	_	_	I-Premise
165	Hg	_	_	I-Premise
166	after	_	_	I-Premise
167	Ex-PRESS	_	_	I-Premise
168	implantation	_	_	I-Premise
169	(	_	_	I-Premise
170	P=0.001	_	_	I-Premise
171	)	_	_	I-Premise
172	.	_	_	I-Premise

173	The	_	_	B-Premise
174	mean	_	_	I-Premise
175	number	_	_	I-Premise
176	of	_	_	I-Premise
177	anti-glaucoma	_	_	I-Premise
178	medicines	_	_	I-Premise
179	prescribed	_	_	I-Premise
180	at	_	_	I-Premise
181	the	_	_	I-Premise
182	last	_	_	I-Premise
183	follow-up	_	_	I-Premise
184	decreased	_	_	I-Premise
185	from	_	_	I-Premise
186	3.7	_	_	I-Premise
187	pre-operatively	_	_	I-Premise
188	(	_	_	I-Premise
189	both	_	_	I-Premise
190	groups	_	_	I-Premise
191	)	_	_	I-Premise
192	to	_	_	I-Premise
193	0.9	_	_	I-Premise
194	after	_	_	I-Premise
195	trabeculectomy	_	_	I-Premise
196	vs	_	_	I-Premise
197	0.3	_	_	I-Premise
198	after	_	_	I-Premise
199	Ex-PRESS	_	_	I-Premise
200	implantation	_	_	I-Premise
201	(	_	_	I-Premise
202	P=0.001	_	_	I-Premise
203	)	_	_	I-Premise
204	.	_	_	I-Premise

205	Complete	_	_	B-Premise
206	success	_	_	I-Premise
207	rates	_	_	I-Premise
208	(	_	_	I-Premise
209	5	_	_	I-Premise
210	<	_	_	I-Premise
211	IOP	_	_	I-Premise
212	<	_	_	I-Premise
213	18	_	_	I-Premise
214	mm	_	_	I-Premise
215	Hg	_	_	I-Premise
216	without	_	_	I-Premise
217	medications	_	_	I-Premise
218	)	_	_	I-Premise
219	were	_	_	I-Premise
220	higher	_	_	I-Premise
221	with	_	_	I-Premise
222	Ex-PRESS	_	_	I-Premise
223	compared	_	_	I-Premise
224	with	_	_	I-Premise
225	trabeculectomy	_	_	I-Premise
226	(	_	_	I-Premise
227	P=0.0024	_	_	I-Premise
228	)	_	_	I-Premise
229	.	_	_	I-Premise

230	Postoperative	_	_	B-Premise
231	complications	_	_	I-Premise
232	were	_	_	I-Premise
233	more	_	_	I-Premise
234	frequent	_	_	I-Premise
235	after	_	_	I-Premise
236	trabeculectomy	_	_	I-Premise
237	(	_	_	I-Premise
238	33	_	_	I-Premise
239	%	_	_	I-Premise
240	)	_	_	I-Premise
241	compared	_	_	I-Premise
242	with	_	_	I-Premise
243	Ex-PRESS	_	_	I-Premise
244	(	_	_	I-Premise
245	20	_	_	I-Premise
246	%	_	_	I-Premise
247	)	_	_	I-Premise
248	,	_	_	I-Premise
249	with	_	_	I-Premise
250	four	_	_	I-Premise
251	trabeculectomy	_	_	I-Premise
252	eyes	_	_	I-Premise
253	(	_	_	I-Premise
254	27	_	_	I-Premise
255	%	_	_	I-Premise
256	)	_	_	I-Premise
257	needing	_	_	I-Premise
258	postoperative	_	_	I-Premise
259	interventions	_	_	I-Premise
260	,	_	_	I-Premise
261	compared	_	_	I-Premise
262	with	_	_	I-Premise
263	none	_	_	I-Premise
264	with	_	_	I-Premise
265	Ex-PRESS	_	_	I-Premise
266	.	_	_	I-Premise

267	Trabeculectomy	_	_	B-Claim
268	and	_	_	I-Claim
269	Ex-PRESS	_	_	I-Claim
270	implantation	_	_	I-Claim
271	provided	_	_	I-Claim
272	similar	_	_	I-Claim
273	IOP	_	_	I-Claim
274	control	_	_	I-Claim
275	,	_	_	I-Claim
276	but	_	_	O
277	the	_	_	B-Claim
278	Ex-PRESS	_	_	I-Claim
279	group	_	_	I-Claim
280	had	_	_	I-Claim
281	a	_	_	I-Claim
282	lower	_	_	I-Claim
283	rate	_	_	I-Claim
284	of	_	_	I-Claim
285	complications	_	_	I-Claim
286	,	_	_	I-Claim
287	fewer	_	_	I-Claim
288	postoperative	_	_	I-Claim
289	interventions	_	_	I-Claim
290	,	_	_	I-Claim
291	and	_	_	I-Claim
292	needed	_	_	I-Claim
293	less	_	_	I-Claim
294	glaucoma	_	_	I-Claim
295	medications	_	_	I-Claim
296	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	ocular	_	_	O
4	hypotensive	_	_	O
5	efficacy	_	_	O
6	and	_	_	O
7	safety	_	_	O
8	of	_	_	O
9	topical	_	_	O
10	bimatoprost	_	_	O
11	and	_	_	O
12	timolol-dorzolamide	_	_	O
13	combination	_	_	O
14	in	_	_	O
15	patients	_	_	O
16	with	_	_	O
17	primary	_	_	O
18	open-angle	_	_	O
19	glaucoma	_	_	O
20	(	_	_	O
21	POAG	_	_	O
22	)	_	_	O
23	or	_	_	O
24	ocular	_	_	O
25	hypertension	_	_	O
26	during	_	_	O
27	6	_	_	O
28	months	_	_	O
29	of	_	_	O
30	treatment	_	_	O
31	.	_	_	O

32	A	_	_	O
33	sample	_	_	O
34	of	_	_	O
35	65	_	_	O
36	patients	_	_	O
37	with	_	_	O
38	a	_	_	O
39	diagnosis	_	_	O
40	of	_	_	O
41	POAG	_	_	O
42	or	_	_	O
43	ocular	_	_	O
44	hypertension	_	_	O
45	were	_	_	O
46	randomized	_	_	O
47	to	_	_	O
48	receive	_	_	O
49	either	_	_	O
50	bimatoprost	_	_	O
51	0.03	_	_	O
52	%	_	_	O
53	once	_	_	O
54	daily	_	_	O
55	or	_	_	O
56	timolol-dorzolamide	_	_	O
57	combination	_	_	O
58	twice	_	_	O
59	daily	_	_	O
60	.	_	_	O

61	Study	_	_	O
62	visits	_	_	O
63	occurred	_	_	O
64	at	_	_	O
65	baseline	_	_	O
66	and	_	_	O
67	after	_	_	O
68	2	_	_	O
69	weeks	_	_	O
70	and	_	_	O
71	1	_	_	O
72	,	_	_	O
73	3	_	_	O
74	and	_	_	O
75	6	_	_	O
76	months	_	_	O
77	of	_	_	O
78	therapy	_	_	O
79	.	_	_	O

80	Intraocular	_	_	O
81	pressure	_	_	O
82	(	_	_	O
83	IOP	_	_	O
84	)	_	_	O
85	measurements	_	_	O
86	were	_	_	O
87	performed	_	_	O
88	at	_	_	O
89	12.00	_	_	O
90	hours	_	_	O
91	at	_	_	O
92	all	_	_	O
93	study	_	_	O
94	visits	_	_	O
95	and	_	_	O
96	also	_	_	O
97	at	_	_	O
98	08.00	_	_	O
99	hours	_	_	O
100	and	_	_	O
101	16.00	_	_	O
102	hours	_	_	O
103	at	_	_	O
104	baseline	_	_	O
105	and	_	_	O
106	6-month	_	_	O
107	visits	_	_	O
108	.	_	_	O

109	At	_	_	O
110	each	_	_	O
111	visit	_	_	O
112	,	_	_	O
113	local	_	_	O
114	and	_	_	O
115	systemic	_	_	O
116	side-effects	_	_	O
117	that	_	_	O
118	occurred	_	_	O
119	during	_	_	O
120	the	_	_	O
121	treatment	_	_	O
122	period	_	_	O
123	were	_	_	O
124	recorded	_	_	O
125	.	_	_	O

126	Student	_	_	O
127	's	_	_	O
128	t-test	_	_	O
129	was	_	_	O
130	used	_	_	O
131	to	_	_	O
132	compare	_	_	O
133	the	_	_	O
134	differences	_	_	O
135	between	_	_	O
136	IOP	_	_	O
137	values	_	_	O
138	.	_	_	O

139	Differences	_	_	O
140	in	_	_	O
141	IOP	_	_	O
142	between	_	_	O
143	the	_	_	O
144	bimatoprost	_	_	O
145	and	_	_	O
146	timolol-dorzolamide	_	_	O
147	groups	_	_	O
148	were	_	_	O
149	statistically	_	_	O
150	insignificant	_	_	O
151	at	_	_	O
152	all	_	_	O
153	study	_	_	O
154	visits	_	_	O
155	(	_	_	O
156	p	_	_	O
157	>	_	_	O
158	0.05	_	_	O
159	)	_	_	O
160	.	_	_	O

161	In	_	_	B-Premise
162	the	_	_	I-Premise
163	bimatoprost-treated	_	_	I-Premise
164	group	_	_	I-Premise
165	,	_	_	I-Premise
166	the	_	_	I-Premise
167	IOP	_	_	I-Premise
168	reduction	_	_	I-Premise
169	was	_	_	I-Premise
170	6.2	_	_	I-Premise
171	+/-	_	_	I-Premise
172	1.8	_	_	I-Premise
173	mmHg	_	_	I-Premise
174	,	_	_	I-Premise
175	whereas	_	_	I-Premise
176	it	_	_	I-Premise
177	was	_	_	I-Premise
178	6.5	_	_	I-Premise
179	+/-	_	_	I-Premise
180	2.3	_	_	I-Premise
181	mmHg	_	_	I-Premise
182	in	_	_	I-Premise
183	the	_	_	I-Premise
184	timolol-dorzolamide	_	_	I-Premise
185	group	_	_	I-Premise
186	after	_	_	I-Premise
187	6	_	_	I-Premise
188	months	_	_	I-Premise
189	of	_	_	I-Premise
190	treatment	_	_	I-Premise
191	.	_	_	I-Premise

192	The	_	_	B-Premise
193	difference	_	_	I-Premise
194	was	_	_	I-Premise
195	not	_	_	I-Premise
196	statistically	_	_	I-Premise
197	significant	_	_	I-Premise
198	(	_	_	I-Premise
199	p	_	_	I-Premise
200	=	_	_	I-Premise
201	0.48	_	_	I-Premise
202	)	_	_	I-Premise
203	.	_	_	I-Premise

204	The	_	_	B-Premise
205	IOP-lowering	_	_	I-Premise
206	efficacies	_	_	I-Premise
207	of	_	_	I-Premise
208	bimatoprost	_	_	I-Premise
209	and	_	_	I-Premise
210	timolol-dorzolamide	_	_	I-Premise
211	combination	_	_	I-Premise
212	were	_	_	I-Premise
213	similar	_	_	I-Premise
214	over	_	_	I-Premise
215	a	_	_	I-Premise
216	6-month	_	_	I-Premise
217	follow-up	_	_	I-Premise
218	.	_	_	I-Premise

219	Both	_	_	B-Claim
220	bimatoprost	_	_	I-Claim
221	and	_	_	I-Claim
222	the	_	_	I-Claim
223	timolol-dorzolamide	_	_	I-Claim
224	combination	_	_	I-Claim
225	were	_	_	I-Claim
226	well	_	_	I-Claim
227	tolerated	_	_	I-Claim
228	.	_	_	I-Claim

229	Bimatoprost	_	_	B-Claim
230	can	_	_	I-Claim
231	be	_	_	I-Claim
232	used	_	_	I-Claim
233	as	_	_	I-Claim
234	a	_	_	I-Claim
235	longterm	_	_	I-Claim
236	monotherapy	_	_	I-Claim
237	agent	_	_	I-Claim
238	in	_	_	I-Claim
239	the	_	_	I-Claim
240	treatment	_	_	I-Claim
241	of	_	_	I-Claim
242	POAG	_	_	I-Claim
243	and	_	_	I-Claim
244	ocular	_	_	I-Claim
245	hypertension	_	_	I-Claim
246	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	side	_	_	O
6	effects	_	_	O
7	and	_	_	O
8	the	_	_	O
9	effect	_	_	O
10	on	_	_	O
11	aqueous	_	_	O
12	humor	_	_	O
13	dynamics	_	_	O
14	of	_	_	O
15	0.005	_	_	O
16	%	_	_	O
17	latanoprost	_	_	O
18	applied	_	_	O
19	topically	_	_	O
20	once	_	_	O
21	daily	_	_	O
22	with	_	_	O
23	0.5	_	_	O
24	%	_	_	O
25	timolol	_	_	O
26	given	_	_	O
27	twice	_	_	O
28	daily	_	_	O
29	for	_	_	O
30	12	_	_	O
31	months	_	_	O
32	to	_	_	O
33	patients	_	_	O
34	with	_	_	O
35	pigmentary	_	_	O
36	glaucoma	_	_	O
37	.	_	_	O

38	Prospective	_	_	O
39	,	_	_	O
40	randomized	_	_	O
41	,	_	_	O
42	double-masked	_	_	O
43	,	_	_	O
44	clinical	_	_	O
45	study	_	_	O
46	.	_	_	O

47	Thirty-six	_	_	O
48	patients	_	_	O
49	affected	_	_	O
50	with	_	_	O
51	bilateral	_	_	O
52	pigmentary	_	_	O
53	glaucoma	_	_	O
54	controlled	_	_	O
55	with	_	_	O
56	no	_	_	O
57	more	_	_	O
58	than	_	_	O
59	a	_	_	O
60	single	_	_	O
61	hypotensive	_	_	O
62	medication	_	_	O
63	were	_	_	O
64	enrolled	_	_	O
65	in	_	_	O
66	the	_	_	O
67	study	_	_	O
68	.	_	_	O

69	The	_	_	O
70	sample	_	_	O
71	population	_	_	O
72	was	_	_	O
73	randomly	_	_	O
74	divided	_	_	O
75	into	_	_	O
76	2	_	_	O
77	age-	_	_	O
78	and	_	_	O
79	gender-matched	_	_	O
80	groups	_	_	O
81	each	_	_	O
82	of	_	_	O
83	18	_	_	O
84	patients	_	_	O
85	.	_	_	O

86	Group	_	_	O
87	1	_	_	O
88	received	_	_	O
89	0.005	_	_	O
90	%	_	_	O
91	latanoprost	_	_	O
92	eyedrops	_	_	O
93	once	_	_	O
94	daily	_	_	O
95	and	_	_	O
96	the	_	_	O
97	vehicle	_	_	O
98	(	_	_	O
99	placebo	_	_	O
100	)	_	_	O
101	once	_	_	O
102	daily	_	_	O
103	;	_	_	O
104	group	_	_	O
105	2	_	_	O
106	was	_	_	O
107	assigned	_	_	O
108	to	_	_	O
109	timolol	_	_	O
110	0.5	_	_	O
111	%	_	_	O
112	eyedrops	_	_	O
113	twice	_	_	O
114	daily	_	_	O
115	.	_	_	O

116	Diurnal	_	_	O
117	curves	_	_	O
118	of	_	_	O
119	intraocular	_	_	O
120	pressure	_	_	O
121	(	_	_	O
122	IOP	_	_	O
123	)	_	_	O
124	were	_	_	O
125	performed	_	_	O
126	on	_	_	O
127	the	_	_	O
128	baseline	_	_	O
129	day	_	_	O
130	and	_	_	O
131	after	_	_	O
132	0.5	_	_	O
133	,	_	_	O
134	3	_	_	O
135	,	_	_	O
136	6	_	_	O
137	,	_	_	O
138	and	_	_	O
139	12	_	_	O
140	months	_	_	O
141	of	_	_	O
142	treatment	_	_	O
143	.	_	_	O

144	The	_	_	O
145	IOP	_	_	O
146	measurements	_	_	O
147	were	_	_	O
148	performed	_	_	O
149	at	_	_	O
150	8:00	_	_	O
151	AM	_	_	O
152	,	_	_	O
153	12:00	_	_	O
154	noon	_	_	O
155	,	_	_	O
156	4:00	_	_	O
157	PM	_	_	O
158	,	_	_	O
159	and	_	_	O
160	8:00	_	_	O
161	PM	_	_	O
162	.	_	_	O

163	Outflow	_	_	O
164	facility	_	_	O
165	(	_	_	O
166	C	_	_	O
167	)	_	_	O
168	was	_	_	O
169	measured	_	_	O
170	on	_	_	O
171	the	_	_	O
172	baseline	_	_	O
173	day	_	_	O
174	and	_	_	O
175	on	_	_	O
176	the	_	_	O
177	last	_	_	O
178	day	_	_	O
179	of	_	_	O
180	the	_	_	O
181	study	_	_	O
182	with	_	_	O
183	a	_	_	O
184	Schiotz	_	_	O
185	electronic	_	_	O
186	tonometer	_	_	O
187	.	_	_	O

188	A	_	_	O
189	two-tailed	_	_	O
190	Student	_	_	O
191	's	_	_	O
192	t	_	_	O
193	test	_	_	O
194	for	_	_	O
195	paired	_	_	O
196	or	_	_	O
197	unpaired	_	_	O
198	data	_	_	O
199	was	_	_	O
200	used	_	_	O
201	for	_	_	O
202	statistical	_	_	O
203	evaluation	_	_	O
204	of	_	_	O
205	differences	_	_	O
206	between	_	_	O
207	treatment	_	_	O
208	and	_	_	O
209	baseline	_	_	O
210	values	_	_	O
211	or	_	_	O
212	between	_	_	O
213	the	_	_	O
214	latanoprost	_	_	O
215	and	_	_	O
216	timolol	_	_	O
217	group	_	_	O
218	.	_	_	O

219	Diurnal	_	_	O
220	IOP	_	_	O
221	measurements	_	_	O
222	were	_	_	O
223	compared	_	_	O
224	hour	_	_	O
225	by	_	_	O
226	hour	_	_	O
227	.	_	_	O

228	Mean	_	_	O
229	values	_	_	O
230	of	_	_	O
231	the	_	_	O
232	two	_	_	O
233	eyes	_	_	O
234	IOP	_	_	O
235	and	_	_	O
236	C	_	_	O
237	were	_	_	O
238	used	_	_	O
239	for	_	_	O
240	analysis	_	_	O
241	.	_	_	O

242	Compared	_	_	B-Premise
243	with	_	_	I-Premise
244	baseline	_	_	I-Premise
245	measurements	_	_	I-Premise
246	,	_	_	I-Premise
247	both	_	_	I-Premise
248	latanoprost	_	_	I-Premise
249	and	_	_	I-Premise
250	timolol	_	_	I-Premise
251	caused	_	_	I-Premise
252	a	_	_	I-Premise
253	significant	_	_	I-Premise
254	(	_	_	I-Premise
255	P	_	_	I-Premise
256	<	_	_	I-Premise
257	0.001	_	_	I-Premise
258	)	_	_	I-Premise
259	reduction	_	_	I-Premise
260	of	_	_	I-Premise
261	IOP	_	_	I-Premise
262	at	_	_	I-Premise
263	each	_	_	I-Premise
264	hour	_	_	I-Premise
265	of	_	_	I-Premise
266	diurnal	_	_	I-Premise
267	curve	_	_	I-Premise
268	throughout	_	_	I-Premise
269	the	_	_	I-Premise
270	duration	_	_	I-Premise
271	of	_	_	I-Premise
272	therapy	_	_	I-Premise
273	.	_	_	I-Premise

274	Reduction	_	_	B-Premise
275	of	_	_	I-Premise
276	IOP	_	_	I-Premise
277	was	_	_	I-Premise
278	6.0	_	_	I-Premise
279	+/-	_	_	I-Premise
280	4.5	_	_	I-Premise
281	and	_	_	I-Premise
282	5.9	_	_	I-Premise
283	+/-	_	_	I-Premise
284	4.6	_	_	I-Premise
285	with	_	_	I-Premise
286	latanoprost	_	_	I-Premise
287	and	_	_	I-Premise
288	4.8	_	_	I-Premise
289	+/-	_	_	I-Premise
290	3.0	_	_	I-Premise
291	and	_	_	I-Premise
292	4.6	_	_	I-Premise
293	+/-	_	_	I-Premise
294	3.1	_	_	I-Premise
295	with	_	_	I-Premise
296	timolol	_	_	I-Premise
297	after	_	_	I-Premise
298	6	_	_	I-Premise
299	and	_	_	I-Premise
300	12	_	_	I-Premise
301	months	_	_	I-Premise
302	,	_	_	I-Premise
303	respectively	_	_	I-Premise
304	.	_	_	I-Premise

305	Comparison	_	_	B-Premise
306	of	_	_	I-Premise
307	mean	_	_	I-Premise
308	diurnal	_	_	I-Premise
309	measurements	_	_	I-Premise
310	with	_	_	I-Premise
311	latanoprost	_	_	I-Premise
312	and	_	_	I-Premise
313	timolol	_	_	I-Premise
314	showed	_	_	I-Premise
315	a	_	_	I-Premise
316	statistical	_	_	I-Premise
317	significant	_	_	I-Premise
318	(	_	_	I-Premise
319	P	_	_	I-Premise
320	<	_	_	I-Premise
321	0.001	_	_	I-Premise
322	)	_	_	I-Premise
323	difference	_	_	I-Premise
324	at	_	_	I-Premise
325	3	_	_	I-Premise
326	,	_	_	I-Premise
327	6	_	_	I-Premise
328	,	_	_	I-Premise
329	and	_	_	I-Premise
330	12	_	_	I-Premise
331	months	_	_	I-Premise
332	.	_	_	I-Premise

333	Mean	_	_	B-Premise
334	C	_	_	I-Premise
335	was	_	_	I-Premise
336	found	_	_	I-Premise
337	to	_	_	I-Premise
338	be	_	_	I-Premise
339	significantly	_	_	I-Premise
340	enhanced	_	_	I-Premise
341	(	_	_	I-Premise
342	+30	_	_	I-Premise
343	%	_	_	I-Premise
344	)	_	_	I-Premise
345	only	_	_	I-Premise
346	in	_	_	I-Premise
347	the	_	_	I-Premise
348	latanoprost-treated	_	_	I-Premise
349	group	_	_	I-Premise
350	compared	_	_	I-Premise
351	with	_	_	I-Premise
352	the	_	_	I-Premise
353	baseline	_	_	I-Premise
354	(	_	_	I-Premise
355	P	_	_	I-Premise
356	=	_	_	I-Premise
357	0.017	_	_	I-Premise
358	)	_	_	I-Premise
359	.	_	_	I-Premise

360	Mean	_	_	B-Premise
361	conjunctival	_	_	I-Premise
362	hyperemia	_	_	I-Premise
363	was	_	_	I-Premise
364	graded	_	_	I-Premise
365	at	_	_	I-Premise
366	0.3	_	_	I-Premise
367	in	_	_	I-Premise
368	latanoprost-treated	_	_	I-Premise
369	eyes	_	_	I-Premise
370	and	_	_	I-Premise
371	0.2	_	_	I-Premise
372	in	_	_	I-Premise
373	timolol-treated	_	_	I-Premise
374	eyes	_	_	I-Premise
375	.	_	_	I-Premise

376	A	_	_	B-Premise
377	remarkable	_	_	I-Premise
378	change	_	_	I-Premise
379	in	_	_	I-Premise
380	iris	_	_	I-Premise
381	color	_	_	I-Premise
382	was	_	_	I-Premise
383	observed	_	_	I-Premise
384	in	_	_	I-Premise
385	both	_	_	I-Premise
386	eyes	_	_	I-Premise
387	of	_	_	I-Premise
388	1	_	_	I-Premise
389	of	_	_	I-Premise
390	the	_	_	I-Premise
391	18	_	_	I-Premise
392	patients	_	_	I-Premise
393	treated	_	_	I-Premise
394	with	_	_	I-Premise
395	latanoprost	_	_	I-Premise
396	and	_	_	I-Premise
397	none	_	_	I-Premise
398	of	_	_	I-Premise
399	the	_	_	I-Premise
400	18	_	_	I-Premise
401	patients	_	_	I-Premise
402	who	_	_	I-Premise
403	received	_	_	I-Premise
404	timolol	_	_	I-Premise
405	.	_	_	I-Premise

406	Darkening	_	_	O
407	of	_	_	O
408	the	_	_	O
409	peripheral	_	_	O
410	iris	_	_	O
411	stroma	_	_	O
412	was	_	_	O
413	suspected	_	_	O
414	in	_	_	O
415	two	_	_	O
416	patients	_	_	O
417	treated	_	_	O
418	with	_	_	O
419	latanoprost	_	_	O
420	.	_	_	O

421	In	_	_	B-Premise
422	the	_	_	I-Premise
423	timolol	_	_	I-Premise
424	group	_	_	I-Premise
425	,	_	_	I-Premise
426	heart	_	_	I-Premise
427	rate	_	_	I-Premise
428	was	_	_	I-Premise
429	significantly	_	_	I-Premise
430	reduced	_	_	I-Premise
431	from	_	_	I-Premise
432	72	_	_	I-Premise
433	+/-	_	_	I-Premise
434	9	_	_	I-Premise
435	at	_	_	I-Premise
436	baseline	_	_	I-Premise
437	to	_	_	I-Premise
438	67	_	_	I-Premise
439	+/-	_	_	I-Premise
440	10	_	_	I-Premise
441	beats	_	_	I-Premise
442	per	_	_	I-Premise
443	minute	_	_	I-Premise
444	at	_	_	I-Premise
445	12	_	_	I-Premise
446	months	_	_	I-Premise
447	.	_	_	I-Premise

448	Although	_	_	O
449	further	_	_	B-Claim
450	studies	_	_	I-Claim
451	may	_	_	I-Claim
452	need	_	_	I-Claim
453	to	_	_	I-Claim
454	confirm	_	_	I-Claim
455	these	_	_	I-Claim
456	data	_	_	I-Claim
457	on	_	_	I-Claim
458	a	_	_	I-Claim
459	larger	_	_	I-Claim
460	sample	_	_	I-Claim
461	and	_	_	I-Claim
462	to	_	_	I-Claim
463	evaluate	_	_	I-Claim
464	the	_	_	I-Claim
465	side	_	_	I-Claim
466	effect	_	_	I-Claim
467	of	_	_	I-Claim
468	increased	_	_	I-Claim
469	iris	_	_	I-Claim
470	pigmentation	_	_	I-Claim
471	on	_	_	I-Claim
472	long-term	_	_	I-Claim
473	follow-up	_	_	I-Claim
474	,	_	_	I-Claim
475	in	_	_	B-Claim
476	patients	_	_	I-Claim
477	with	_	_	I-Claim
478	pigmentary	_	_	I-Claim
479	glaucoma	_	_	I-Claim
480	,	_	_	I-Claim
481	0.005	_	_	I-Claim
482	%	_	_	I-Claim
483	latanoprost	_	_	I-Claim
484	taken	_	_	I-Claim
485	once	_	_	I-Claim
486	daily	_	_	I-Claim
487	was	_	_	I-Claim
488	well	_	_	I-Claim
489	tolerated	_	_	I-Claim
490	and	_	_	I-Claim
491	more	_	_	I-Claim
492	effective	_	_	I-Claim
493	in	_	_	I-Claim
494	reducing	_	_	I-Claim
495	IOP	_	_	I-Claim
496	than	_	_	I-Claim
497	0.5	_	_	I-Claim
498	%	_	_	I-Claim
499	timolol	_	_	I-Claim
500	taken	_	_	I-Claim
501	twice	_	_	I-Claim
502	daily	_	_	I-Claim
503	.	_	_	I-Claim


0	Increased	_	_	B-Claim
1	intraocular	_	_	I-Claim
2	pressure	_	_	I-Claim
3	(	_	_	I-Claim
4	IOP	_	_	I-Claim
5	)	_	_	I-Claim
6	has	_	_	I-Claim
7	been	_	_	I-Claim
8	shown	_	_	I-Claim
9	to	_	_	I-Claim
10	be	_	_	I-Claim
11	one	_	_	I-Claim
12	of	_	_	I-Claim
13	the	_	_	I-Claim
14	most	_	_	I-Claim
15	important	_	_	I-Claim
16	risk	_	_	I-Claim
17	factors	_	_	I-Claim
18	for	_	_	I-Claim
19	developing	_	_	I-Claim
20	glaucoma	_	_	I-Claim
21	.	_	_	I-Claim

22	Yet	_	_	O
23	it	_	_	O
24	has	_	_	O
25	not	_	_	O
26	been	_	_	O
27	clearly	_	_	O
28	demonstrated	_	_	O
29	that	_	_	O
30	IOP-lowering	_	_	O
31	treatment	_	_	O
32	can	_	_	O
33	reduce	_	_	O
34	the	_	_	O
35	incidence	_	_	O
36	of	_	_	O
37	glaucoma	_	_	O
38	damage	_	_	O
39	in	_	_	O
40	patients	_	_	O
41	with	_	_	O
42	ocular	_	_	O
43	hypertension	_	_	O
44	.	_	_	O

45	The	_	_	O
46	aim	_	_	O
47	of	_	_	O
48	the	_	_	O
49	current	_	_	O
50	paper	_	_	O
51	was	_	_	O
52	to	_	_	O
53	report	_	_	O
54	the	_	_	O
55	results	_	_	O
56	of	_	_	O
57	a	_	_	O
58	long-term	_	_	O
59	study	_	_	O
60	addressing	_	_	O
61	this	_	_	O
62	very	_	_	O
63	problem	_	_	O
64	.	_	_	O

65	We	_	_	O
66	conducted	_	_	O
67	a	_	_	O
68	randomised	_	_	O
69	,	_	_	O
70	double-masked	_	_	O
71	study	_	_	O
72	comparing	_	_	O
73	timolol	_	_	O
74	and	_	_	O
75	placebo	_	_	O
76	treatment	_	_	O
77	in	_	_	O
78	90	_	_	O
79	patients	_	_	O
80	with	_	_	O
81	ocular	_	_	O
82	hypertension	_	_	O
83	plus	_	_	O
84	some	_	_	O
85	additional	_	_	O
86	risk	_	_	O
87	factor	_	_	O
88	.	_	_	O

89	Patients	_	_	O
90	were	_	_	O
91	followed	_	_	O
92	at	_	_	O
93	3-month	_	_	O
94	intervals	_	_	O
95	prospectively	_	_	O
96	for	_	_	O
97	10	_	_	O
98	years	_	_	O
99	or	_	_	O
100	until	_	_	O
101	glaucomatous	_	_	O
102	field	_	_	O
103	loss	_	_	O
104	could	_	_	O
105	be	_	_	O
106	demonstrated	_	_	O
107	with	_	_	O
108	computerised	_	_	O
109	perimetry	_	_	O
110	.	_	_	O

111	A	_	_	O
112	post-study	_	_	O
113	analysis	_	_	O
114	was	_	_	O
115	performed	_	_	O
116	including	_	_	O
117	all	_	_	O
118	available	_	_	O
119	data	_	_	O
120	,	_	_	O
121	thus	_	_	O
122	extending	_	_	O
123	maximum	_	_	O
124	follow-up	_	_	O
125	to	_	_	O
126	17	_	_	O
127	years	_	_	O
128	.	_	_	O

129	After	_	_	B-Premise
130	5	_	_	I-Premise
131	years	_	_	I-Premise
132	of	_	_	I-Premise
133	follow-up	_	_	I-Premise
134	eight	_	_	I-Premise
135	patients	_	_	I-Premise
136	in	_	_	I-Premise
137	the	_	_	I-Premise
138	placebo	_	_	I-Premise
139	group	_	_	I-Premise
140	and	_	_	I-Premise
141	five	_	_	I-Premise
142	patients	_	_	I-Premise
143	in	_	_	I-Premise
144	the	_	_	I-Premise
145	timolol	_	_	I-Premise
146	group	_	_	I-Premise
147	had	_	_	I-Premise
148	developed	_	_	I-Premise
149	glaucomatous	_	_	I-Premise
150	field	_	_	I-Premise
151	loss	_	_	I-Premise
152	(	_	_	I-Premise
153	NS	_	_	I-Premise
154	)	_	_	I-Premise
155	;	_	_	I-Premise
156	the	_	_	B-Premise
157	corresponding	_	_	I-Premise
158	figures	_	_	I-Premise
159	after	_	_	I-Premise
160	10	_	_	I-Premise
161	years	_	_	I-Premise
162	were	_	_	I-Premise
163	15	_	_	I-Premise
164	patients	_	_	I-Premise
165	in	_	_	I-Premise
166	the	_	_	I-Premise
167	placebo	_	_	I-Premise
168	group	_	_	I-Premise
169	and	_	_	I-Premise
170	seven	_	_	I-Premise
171	patients	_	_	I-Premise
172	in	_	_	I-Premise
173	the	_	_	I-Premise
174	timolol	_	_	I-Premise
175	group	_	_	I-Premise
176	.	_	_	I-Premise

177	Survival	_	_	B-Premise
178	analysis	_	_	I-Premise
179	showed	_	_	I-Premise
180	a	_	_	I-Premise
181	tendency	_	_	I-Premise
182	but	_	_	I-Premise
183	no	_	_	I-Premise
184	statistically	_	_	I-Premise
185	significant	_	_	I-Premise
186	difference	_	_	I-Premise
187	between	_	_	I-Premise
188	treatment	_	_	I-Premise
189	groups	_	_	I-Premise
190	(	_	_	I-Premise
191	P	_	_	I-Premise
192	=	_	_	I-Premise
193	0.07	_	_	I-Premise
194	)	_	_	I-Premise
195	.	_	_	I-Premise

196	Study	_	_	B-Premise
197	attrition	_	_	I-Premise
198	was	_	_	I-Premise
199	large	_	_	I-Premise
200	.	_	_	I-Premise

201	Eighteen	_	_	B-Premise
202	patients	_	_	I-Premise
203	in	_	_	I-Premise
204	each	_	_	I-Premise
205	group	_	_	I-Premise
206	had	_	_	I-Premise
207	developed	_	_	I-Premise
208	glaucomatous	_	_	I-Premise
209	field	_	_	I-Premise
210	loss	_	_	I-Premise
211	when	_	_	I-Premise
212	also	_	_	I-Premise
213	post-study	_	_	I-Premise
214	data	_	_	I-Premise
215	were	_	_	I-Premise
216	included	_	_	I-Premise
217	.	_	_	I-Premise

218	IOP	_	_	B-Premise
219	reduction	_	_	I-Premise
220	was	_	_	I-Premise
221	greater	_	_	I-Premise
222	in	_	_	I-Premise
223	eyes	_	_	I-Premise
224	passing	_	_	I-Premise
225	the	_	_	I-Premise
226	10-year	_	_	I-Premise
227	visit	_	_	I-Premise
228	without	_	_	I-Premise
229	field	_	_	I-Premise
230	loss	_	_	I-Premise
231	(	_	_	I-Premise
232	5.7	_	_	I-Premise
233	mmHg	_	_	I-Premise
234	)	_	_	I-Premise
235	,	_	_	I-Premise
236	than	_	_	I-Premise
237	in	_	_	I-Premise
238	those	_	_	I-Premise
239	that	_	_	I-Premise
240	reached	_	_	I-Premise
241	an	_	_	I-Premise
242	end-point	_	_	I-Premise
243	(	_	_	I-Premise
244	2.3	_	_	I-Premise
245	mmHg	_	_	I-Premise
246	;	_	_	I-Premise
247	P	_	_	I-Premise
248	=	_	_	I-Premise
249	0.0002	_	_	I-Premise
250	)	_	_	I-Premise
251	.	_	_	I-Premise

252	In	_	_	B-Claim
253	this	_	_	I-Claim
254	long-term	_	_	I-Claim
255	study	_	_	I-Claim
256	we	_	_	I-Claim
257	found	_	_	I-Claim
258	a	_	_	I-Claim
259	tendency	_	_	I-Claim
260	but	_	_	I-Claim
261	failed	_	_	I-Claim
262	to	_	_	I-Claim
263	prove	_	_	I-Claim
264	a	_	_	I-Claim
265	beneficial	_	_	I-Claim
266	effect	_	_	I-Claim
267	of	_	_	I-Claim
268	topical	_	_	I-Claim
269	timolol	_	_	I-Claim
270	treatment	_	_	I-Claim
271	in	_	_	I-Claim
272	patients	_	_	I-Claim
273	with	_	_	I-Claim
274	elevated	_	_	I-Claim
275	IOP	_	_	I-Claim
276	,	_	_	I-Claim
277	normal	_	_	I-Claim
278	visual	_	_	I-Claim
279	fields	_	_	I-Claim
280	and	_	_	I-Claim
281	some	_	_	I-Claim
282	additional	_	_	I-Claim
283	risk	_	_	I-Claim
284	factor	_	_	I-Claim
285	.	_	_	I-Claim

286	The	_	_	B-Premise
287	intent-to-treat	_	_	I-Premise
288	analysis	_	_	I-Premise
289	showed	_	_	I-Premise
290	no	_	_	I-Premise
291	difference	_	_	I-Premise
292	between	_	_	I-Premise
293	treatment	_	_	I-Premise
294	groups	_	_	I-Premise
295	.	_	_	I-Premise

296	The	_	_	B-Premise
297	high	_	_	I-Premise
298	attrition	_	_	I-Premise
299	shows	_	_	I-Premise
300	the	_	_	I-Premise
301	difficulties	_	_	I-Premise
302	associated	_	_	I-Premise
303	with	_	_	I-Premise
304	very	_	_	I-Premise
305	long	_	_	I-Premise
306	follow-up	_	_	I-Premise
307	.	_	_	I-Premise


0	Trabeculectomy	_	_	O
1	is	_	_	O
2	a	_	_	O
3	commonly	_	_	O
4	used	_	_	O
5	surgical	_	_	O
6	treatment	_	_	O
7	for	_	_	O
8	glaucoma	_	_	O
9	.	_	_	O

10	To	_	_	O
11	evaluate	_	_	O
12	the	_	_	O
13	effectiveness	_	_	O
14	of	_	_	O
15	combination	_	_	O
16	of	_	_	O
17	permanent	_	_	O
18	and	_	_	O
19	releasable	_	_	O
20	scleral	_	_	O
21	flap	_	_	O
22	sutures	_	_	O
23	to	_	_	O
24	minimize	_	_	O
25	the	_	_	O
26	immediate	_	_	O
27	postoperative	_	_	O
28	complications	_	_	O
29	of	_	_	O
30	trabeculectomy	_	_	O
31	.	_	_	O

32	This	_	_	O
33	study	_	_	O
34	was	_	_	O
35	carried	_	_	O
36	out	_	_	O
37	in	_	_	O
38	Department	_	_	O
39	of	_	_	O
40	Ophthalmology	_	_	O
41	,	_	_	O
42	B	_	_	O
43	P	_	_	O
44	Koirala	_	_	O
45	Institute	_	_	O
46	of	_	_	O
47	Health	_	_	O
48	Sciences	_	_	O
49	,	_	_	O
50	Dharan	_	_	O
51	,	_	_	O
52	Nepal	_	_	O
53	.	_	_	O

54	Forty	_	_	O
55	one	_	_	O
56	eyes	_	_	O
57	of	_	_	O
58	34	_	_	O
59	patients	_	_	O
60	undergoing	_	_	O
61	trabeculectomy	_	_	O
62	were	_	_	O
63	randomized	_	_	O
64	to	_	_	O
65	undergo	_	_	O
66	either	_	_	O
67	conventional	_	_	O
68	trabeculectomy	_	_	O
69	(	_	_	O
70	Group	_	_	O
71	A=	_	_	O
72	20	_	_	O
73	eyes	_	_	O
74	)	_	_	O
75	or	_	_	O
76	trabeculectomy	_	_	O
77	with	_	_	O
78	combination	_	_	O
79	of	_	_	O
80	permanent	_	_	O
81	and	_	_	O
82	releasable	_	_	O
83	scleral	_	_	O
84	flap	_	_	O
85	sutures	_	_	O
86	(	_	_	O
87	Group	_	_	O
88	B	_	_	O
89	=21	_	_	O
90	eyes	_	_	O
91	)	_	_	O
92	.	_	_	O

93	The	_	_	O
94	parameters	_	_	O
95	studied	_	_	O
96	were	_	_	O
97	intraocular	_	_	O
98	pressure	_	_	O
99	(	_	_	O
100	IOP	_	_	O
101	)	_	_	O
102	,	_	_	O
103	anterior	_	_	O
104	chamber	_	_	O
105	depth	_	_	O
106	(	_	_	O
107	ACD	_	_	O
108	)	_	_	O
109	and	_	_	O
110	surgical	_	_	O
111	complications	_	_	O
112	over	_	_	O
113	a	_	_	O
114	period	_	_	O
115	of	_	_	O
116	6	_	_	O
117	weeks	_	_	O
118	.	_	_	O

119	Significantly	_	_	B-Premise
120	higher	_	_	I-Premise
121	number	_	_	I-Premise
122	of	_	_	I-Premise
123	eyes	_	_	I-Premise
124	belonging	_	_	I-Premise
125	to	_	_	I-Premise
126	group	_	_	I-Premise
127	A	_	_	I-Premise
128	(	_	_	I-Premise
129	14	_	_	I-Premise
130	eyes	_	_	I-Premise
131	)	_	_	I-Premise
132	had	_	_	I-Premise
133	shallower	_	_	I-Premise
134	anterior	_	_	I-Premise
135	chamber	_	_	I-Premise
136	than	_	_	I-Premise
137	group	_	_	I-Premise
138	B	_	_	I-Premise
139	(	_	_	I-Premise
140	7	_	_	I-Premise
141	eyes	_	_	I-Premise
142	)	_	_	I-Premise
143	on	_	_	I-Premise
144	first	_	_	I-Premise
145	post	_	_	I-Premise
146	operative	_	_	I-Premise
147	day	_	_	I-Premise
148	(	_	_	I-Premise
149	p=0.042	_	_	I-Premise
150	)	_	_	I-Premise
151	.	_	_	I-Premise

152	Six	_	_	B-Premise
153	eyes	_	_	I-Premise
154	(	_	_	I-Premise
155	30	_	_	I-Premise
156	%	_	_	I-Premise
157	)	_	_	I-Premise
158	in	_	_	I-Premise
159	group	_	_	I-Premise
160	A	_	_	I-Premise
161	had	_	_	I-Premise
162	peripheral	_	_	I-Premise
163	or	_	_	I-Premise
164	central	_	_	I-Premise
165	irido-corneal	_	_	I-Premise
166	touch	_	_	I-Premise
167	in	_	_	I-Premise
168	early	_	_	I-Premise
169	postoperative	_	_	I-Premise
170	period	_	_	I-Premise
171	as	_	_	I-Premise
172	compared	_	_	I-Premise
173	to	_	_	I-Premise
174	only	_	_	I-Premise
175	one	_	_	I-Premise
176	in	_	_	I-Premise
177	Group	_	_	I-Premise
178	B.	_	_	I-Premise
179	Hypotony	_	_	B-Premise
180	was	_	_	I-Premise
181	noted	_	_	I-Premise
182	in	_	_	I-Premise
183	3	_	_	I-Premise
184	eyes	_	_	I-Premise
185	in	_	_	I-Premise
186	each	_	_	I-Premise
187	group	_	_	I-Premise
188	.	_	_	I-Premise

189	Two	_	_	O
190	patients	_	_	O
191	in	_	_	O
192	group	_	_	O
193	A	_	_	O
194	required	_	_	O
195	reformation	_	_	O
196	of	_	_	O
197	anterior	_	_	O
198	chamber	_	_	O
199	.	_	_	O

200	Other	_	_	O
201	surgical	_	_	O
202	complications	_	_	O
203	in	_	_	O
204	the	_	_	O
205	two	_	_	O
206	groups	_	_	O
207	were	_	_	O
208	similar	_	_	O
209	.	_	_	O

210	Both	_	_	B-Claim
211	the	_	_	I-Claim
212	groups	_	_	I-Claim
213	had	_	_	I-Claim
214	a	_	_	I-Claim
215	significant	_	_	I-Claim
216	drop	_	_	I-Claim
217	in	_	_	I-Claim
218	IOP	_	_	I-Claim
219	following	_	_	I-Claim
220	surgery	_	_	I-Claim
221	.	_	_	O

222	However	_	_	O
223	,	_	_	O
224	there	_	_	B-Premise
225	was	_	_	I-Premise
226	no	_	_	I-Premise
227	significant	_	_	I-Premise
228	difference	_	_	I-Premise
229	in	_	_	I-Premise
230	the	_	_	I-Premise
231	IOP	_	_	I-Premise
232	between	_	_	I-Premise
233	the	_	_	I-Premise
234	two	_	_	I-Premise
235	groups	_	_	I-Premise
236	after	_	_	I-Premise
237	6	_	_	I-Premise
238	weeks	_	_	I-Premise
239	(	_	_	I-Premise
240	Group	_	_	I-Premise
241	A	_	_	I-Premise
242	:	_	_	I-Premise
243	10.95	_	_	I-Premise
244	+/-	_	_	I-Premise
245	3.03	_	_	I-Premise
246	mmHg	_	_	I-Premise
247	vs.	_	_	I-Premise
248	Group	_	_	I-Premise
249	B	_	_	I-Premise
250	:	_	_	I-Premise
251	12.29	_	_	I-Premise
252	+/-	_	_	I-Premise
253	4.67	_	_	I-Premise
254	mmHg	_	_	I-Premise
255	;	_	_	I-Premise
256	p=0.87	_	_	I-Premise
257	)	_	_	I-Premise
258	.	_	_	I-Premise

259	There	_	_	B-Premise
260	was	_	_	I-Premise
261	a	_	_	I-Premise
262	significant	_	_	I-Premise
263	drop	_	_	I-Premise
264	in	_	_	I-Premise
265	IOP	_	_	I-Premise
266	following	_	_	I-Premise
267	removal	_	_	I-Premise
268	of	_	_	I-Premise
269	sutures	_	_	I-Premise
270	(	_	_	I-Premise
271	15.19	_	_	I-Premise
272	+/-	_	_	I-Premise
273	6.15	_	_	I-Premise
274	mmHg	_	_	I-Premise
275	to	_	_	I-Premise
276	13.19	_	_	I-Premise
277	+/-	_	_	I-Premise
278	6.13	_	_	I-Premise
279	mmHg	_	_	I-Premise
280	;	_	_	I-Premise
281	p=006	_	_	I-Premise
282	)	_	_	I-Premise
283	in	_	_	I-Premise
284	group	_	_	I-Premise
285	B	_	_	I-Premise
286	.	_	_	I-Premise

287	Use	_	_	B-Claim
288	of	_	_	I-Claim
289	combination	_	_	I-Claim
290	of	_	_	I-Claim
291	permanent	_	_	I-Claim
292	and	_	_	I-Claim
293	releasable	_	_	I-Claim
294	scleral	_	_	I-Claim
295	flap	_	_	I-Claim
296	sutures	_	_	I-Claim
297	is	_	_	I-Claim
298	a	_	_	I-Claim
299	safe	_	_	I-Claim
300	technique	_	_	I-Claim
301	that	_	_	I-Claim
302	significantly	_	_	I-Claim
303	reduces	_	_	I-Claim
304	the	_	_	I-Claim
305	incidence	_	_	I-Claim
306	of	_	_	I-Claim
307	immediate	_	_	I-Claim
308	postoperative	_	_	I-Claim
309	shallow	_	_	I-Claim
310	anterior	_	_	I-Claim
311	chamber	_	_	I-Claim
312	after	_	_	I-Claim
313	trabeculectomy	_	_	I-Claim
314	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	selective	_	_	O
6	laser	_	_	O
7	trabeculoplasty	_	_	O
8	(	_	_	O
9	SLT	_	_	O
10	)	_	_	O
11	and	_	_	O
12	travoprost	_	_	O
13	on	_	_	O
14	24-hour	_	_	O
15	IOP	_	_	O
16	fluctuations	_	_	O
17	in	_	_	O
18	primary	_	_	O
19	open-angle	_	_	O
20	glaucoma	_	_	O
21	(	_	_	O
22	POAG	_	_	O
23	)	_	_	O
24	and	_	_	O
25	normal-tension	_	_	O
26	glaucoma	_	_	O
27	(	_	_	O
28	NTG	_	_	O
29	)	_	_	O
30	.	_	_	O

31	Sixty	_	_	O
32	eyes	_	_	O
33	were	_	_	O
34	included	_	_	O
35	.	_	_	O

36	Sixteen	_	_	O
37	and	_	_	O
38	14	_	_	O
39	eyes	_	_	O
40	of	_	_	O
41	POAG	_	_	O
42	patients	_	_	O
43	were	_	_	O
44	randomized	_	_	O
45	to	_	_	O
46	receive	_	_	O
47	360°	_	_	O
48	SLT	_	_	O
49	or	_	_	O
50	0.004	_	_	O
51	%	_	_	O
52	travoprost	_	_	O
53	,	_	_	O
54	respectively	_	_	O
55	.	_	_	O

56	Fourteen	_	_	O
57	and	_	_	O
58	16	_	_	O
59	eyes	_	_	O
60	of	_	_	O
61	NTG	_	_	O
62	patients	_	_	O
63	were	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	receive	_	_	O
67	either	_	_	O
68	SLT	_	_	O
69	or	_	_	O
70	travoprost	_	_	O
71	,	_	_	O
72	respectively	_	_	O
73	.	_	_	O

74	The	_	_	O
75	24-hour	_	_	O
76	IOP	_	_	O
77	data	_	_	O
78	were	_	_	O
79	collected	_	_	O
80	before	_	_	O
81	treatment	_	_	O
82	and	_	_	O
83	6	_	_	O
84	to	_	_	O
85	8	_	_	O
86	weeks	_	_	O
87	after	_	_	O
88	treatment	_	_	O
89	.	_	_	O

90	IOP	_	_	O
91	was	_	_	O
92	measured	_	_	O
93	at	_	_	O
94	2	_	_	O
95	hours	_	_	O
96	intervals	_	_	O
97	in	_	_	O
98	the	_	_	O
99	sitting	_	_	O
100	position	_	_	O
101	during	_	_	O
102	daytime	_	_	O
103	(	_	_	O
104	9	_	_	O
105	AM	_	_	O
106	to	_	_	O
107	7	_	_	O
108	PM	_	_	O
109	)	_	_	O
110	and	_	_	O
111	in	_	_	O
112	the	_	_	O
113	supine	_	_	O
114	position	_	_	O
115	during	_	_	O
116	nighttime	_	_	O
117	(	_	_	O
118	9	_	_	O
119	PM	_	_	O
120	to	_	_	O
121	7	_	_	O
122	AM	_	_	O
123	)	_	_	O
124	.	_	_	O

125	Main	_	_	O
126	outcome	_	_	O
127	measure	_	_	O
128	was	_	_	O
129	the	_	_	O
130	percentage	_	_	O
131	of	_	_	O
132	eyes	_	_	O
133	that	_	_	O
134	achieved	_	_	O
135	posttreatment	_	_	O
136	24-hour	_	_	O
137	IOP	_	_	O
138	fluctuations	_	_	O
139	<	_	_	O
140	3	_	_	O
141	mm	_	_	O
142	Hg	_	_	O
143	.	_	_	O

144	Success	_	_	O
145	in	_	_	O
146	fluctuation	_	_	O
147	reduction	_	_	O
148	was	_	_	O
149	defined	_	_	O
150	as	_	_	O
151	at	_	_	O
152	least	_	_	O
153	a	_	_	O
154	50	_	_	O
155	%	_	_	O
156	reduction	_	_	O
157	in	_	_	O
158	these	_	_	O
159	fluctuations	_	_	O
160	.	_	_	O

161	Fifty-eight	_	_	O
162	eyes	_	_	O
163	were	_	_	O
164	analyzed	_	_	O
165	.	_	_	O

166	Overall	_	_	O
167	,	_	_	O
168	eyes	_	_	B-Premise
169	in	_	_	I-Premise
170	the	_	_	I-Premise
171	SLT	_	_	I-Premise
172	and	_	_	I-Premise
173	the	_	_	I-Premise
174	travoprost	_	_	I-Premise
175	groups	_	_	I-Premise
176	achieved	_	_	I-Premise
177	a	_	_	I-Premise
178	significant	_	_	I-Premise
179	reduction	_	_	I-Premise
180	in	_	_	I-Premise
181	IOP	_	_	I-Premise
182	compared	_	_	I-Premise
183	with	_	_	I-Premise
184	the	_	_	I-Premise
185	baseline	_	_	I-Premise
186	IOP	_	_	I-Premise
187	values	_	_	I-Premise
188	(	_	_	I-Premise
189	-3.7	_	_	I-Premise
190	mm	_	_	I-Premise
191	Hg	_	_	I-Premise
192	[	_	_	I-Premise
193	P	_	_	I-Premise
194	=	_	_	I-Premise
195	0.002	_	_	I-Premise
196	]	_	_	I-Premise
197	vs	_	_	I-Premise
198	-4.1	_	_	I-Premise
199	mm	_	_	I-Premise
200	Hg	_	_	I-Premise
201	[	_	_	I-Premise
202	P	_	_	I-Premise
203	<	_	_	I-Premise
204	0.001	_	_	I-Premise
205	]	_	_	I-Premise
206	,	_	_	I-Premise
207	respectively	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	There	_	_	O
211	was	_	_	O
212	no	_	_	O
213	significant	_	_	O
214	difference	_	_	O
215	in	_	_	O
216	IOP	_	_	O
217	reduction	_	_	O
218	in	_	_	O
219	both	_	_	O
220	groups	_	_	O
221	according	_	_	O
222	to	_	_	O
223	type	_	_	O
224	of	_	_	O
225	glaucoma	_	_	O
226	.	_	_	O

227	During	_	_	O
228	the	_	_	O
229	diurnal	_	_	O
230	period	_	_	O
231	,	_	_	O
232	100	_	_	O
233	%	_	_	O
234	of	_	_	O
235	POAG	_	_	O
236	eyes	_	_	O
237	in	_	_	O
238	the	_	_	O
239	travoprost	_	_	O
240	group	_	_	O
241	achieved	_	_	O
242	posttreatment	_	_	O
243	IOP	_	_	O
244	fluctuations	_	_	O
245	<	_	_	O
246	3	_	_	O
247	mm	_	_	O
248	Hg	_	_	O
249	,	_	_	O
250	and	_	_	O
251	87	_	_	O
252	%	_	_	O
253	of	_	_	O
254	eyes	_	_	O
255	in	_	_	O
256	the	_	_	O
257	SLT	_	_	O
258	group	_	_	O
259	achieved	_	_	O
260	the	_	_	O
261	same	_	_	O
262	level	_	_	O
263	of	_	_	O
264	fluctuations	_	_	O
265	(	_	_	O
266	P	_	_	O
267	<	_	_	O
268	0.001	_	_	O
269	)	_	_	O
270	.	_	_	O

271	Ninety-six	_	_	B-Premise
272	percent	_	_	I-Premise
273	of	_	_	I-Premise
274	NTG	_	_	I-Premise
275	eyes	_	_	I-Premise
276	in	_	_	I-Premise
277	the	_	_	I-Premise
278	travoprost	_	_	I-Premise
279	group	_	_	I-Premise
280	,	_	_	I-Premise
281	and	_	_	I-Premise
282	82	_	_	I-Premise
283	%	_	_	I-Premise
284	of	_	_	I-Premise
285	eyes	_	_	I-Premise
286	in	_	_	I-Premise
287	the	_	_	I-Premise
288	SLT	_	_	I-Premise
289	group	_	_	I-Premise
290	had	_	_	I-Premise
291	IOP	_	_	I-Premise
292	fluctuations	_	_	I-Premise
293	<	_	_	I-Premise
294	3	_	_	I-Premise
295	mm	_	_	I-Premise
296	Hg	_	_	I-Premise
297	(	_	_	I-Premise
298	P	_	_	I-Premise
299	=	_	_	I-Premise
300	0.01	_	_	I-Premise
301	)	_	_	I-Premise
302	.	_	_	I-Premise

303	Success	_	_	B-Premise
304	in	_	_	I-Premise
305	fluctuation	_	_	I-Premise
306	reduction	_	_	I-Premise
307	was	_	_	I-Premise
308	75	_	_	I-Premise
309	%	_	_	I-Premise
310	and	_	_	I-Premise
311	92	_	_	I-Premise
312	%	_	_	I-Premise
313	for	_	_	I-Premise
314	the	_	_	I-Premise
315	SLT	_	_	I-Premise
316	and	_	_	I-Premise
317	travoprost	_	_	I-Premise
318	groups	_	_	I-Premise
319	,	_	_	I-Premise
320	respectively	_	_	I-Premise
321	(	_	_	I-Premise
322	P	_	_	I-Premise
323	=	_	_	I-Premise
324	0.005	_	_	I-Premise
325	)	_	_	I-Premise
326	.	_	_	I-Premise

327	The	_	_	B-Claim
328	effect	_	_	I-Claim
329	of	_	_	I-Claim
330	travoprost	_	_	I-Claim
331	on	_	_	I-Claim
332	IOP	_	_	I-Claim
333	reduction	_	_	I-Claim
334	in	_	_	I-Claim
335	POAG	_	_	I-Claim
336	and	_	_	I-Claim
337	NTG	_	_	I-Claim
338	patients	_	_	I-Claim
339	was	_	_	I-Claim
340	significant	_	_	I-Claim
341	both	_	_	I-Claim
342	during	_	_	I-Claim
343	the	_	_	I-Claim
344	daytime	_	_	I-Claim
345	and	_	_	I-Claim
346	the	_	_	I-Claim
347	nighttime	_	_	I-Claim
348	,	_	_	I-Claim
349	while	_	_	O
350	the	_	_	B-Claim
351	SLT	_	_	I-Claim
352	's	_	_	I-Claim
353	effect	_	_	I-Claim
354	was	_	_	I-Claim
355	significant	_	_	I-Claim
356	only	_	_	I-Claim
357	during	_	_	I-Claim
358	the	_	_	I-Claim
359	nighttime	_	_	I-Claim
360	.	_	_	I-Claim

361	Both	_	_	B-Claim
362	travoprost	_	_	I-Claim
363	and	_	_	I-Claim
364	SLT	_	_	I-Claim
365	can	_	_	I-Claim
366	significantly	_	_	I-Claim
367	reduce	_	_	I-Claim
368	the	_	_	I-Claim
369	IOP	_	_	I-Claim
370	in	_	_	I-Claim
371	patients	_	_	I-Claim
372	with	_	_	I-Claim
373	POAG	_	_	I-Claim
374	and	_	_	I-Claim
375	NTG	_	_	I-Claim
376	.	_	_	I-Claim

377	Based	_	_	O
378	on	_	_	O
379	habitual	_	_	O
380	positions	_	_	O
381	,	_	_	O
382	travoprost	_	_	B-Claim
383	better	_	_	I-Claim
384	controls	_	_	I-Claim
385	IOP	_	_	I-Claim
386	fluctuations	_	_	I-Claim
387	than	_	_	I-Claim
388	SLT	_	_	I-Claim
389	,	_	_	I-Claim
390	especially	_	_	I-Claim
391	during	_	_	I-Claim
392	the	_	_	I-Claim
393	daytime	_	_	I-Claim
394	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	selective	_	_	O
3	laser	_	_	O
4	trabeculoplasty	_	_	O
5	(	_	_	O
6	SLT	_	_	O
7	)	_	_	O
8	and	_	_	O
9	argon	_	_	O
10	laser	_	_	O
11	trabeculoplasty	_	_	O
12	(	_	_	O
13	ALT	_	_	O
14	)	_	_	O
15	,	_	_	O
16	in	_	_	O
17	terms	_	_	O
18	of	_	_	O
19	intraocular	_	_	O
20	pressure	_	_	O
21	(	_	_	O
22	IOP	_	_	O
23	)	_	_	O
24	lowering	_	_	O
25	,	_	_	O
26	in	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	open-angle	_	_	O
30	glaucoma	_	_	O
31	.	_	_	O

32	176	_	_	O
33	eyes	_	_	O
34	of	_	_	O
35	152	_	_	O
36	patients	_	_	O
37	were	_	_	O
38	enrolled	_	_	O
39	in	_	_	O
40	this	_	_	O
41	study	_	_	O
42	,	_	_	O
43	89	_	_	O
44	in	_	_	O
45	the	_	_	O
46	SLT	_	_	O
47	and	_	_	O
48	87	_	_	O
49	in	_	_	O
50	the	_	_	O
51	ALT	_	_	O
52	groups	_	_	O
53	.	_	_	O

54	Patients	_	_	O
55	were	_	_	O
56	randomised	_	_	O
57	to	_	_	O
58	receive	_	_	O
59	either	_	_	O
60	SLT	_	_	O
61	or	_	_	O
62	ALT	_	_	O
63	treatment	_	_	O
64	to	_	_	O
65	180	_	_	O
66	degrees	_	_	O
67	of	_	_	O
68	the	_	_	O
69	trabecular	_	_	O
70	meshwork	_	_	O
71	.	_	_	O

72	Patients	_	_	O
73	were	_	_	O
74	followed	_	_	O
75	up	_	_	O
76	to	_	_	O
77	12	_	_	O
78	months	_	_	O
79	after	_	_	O
80	treatment	_	_	O
81	.	_	_	O

82	The	_	_	O
83	main	_	_	O
84	outcome	_	_	O
85	measured	_	_	O
86	was	_	_	O
87	IOP	_	_	O
88	lowering	_	_	O
89	at	_	_	O
90	12	_	_	O
91	months	_	_	O
92	after	_	_	O
93	treatment	_	_	O
94	,	_	_	O
95	compared	_	_	O
96	between	_	_	O
97	the	_	_	O
98	SLT	_	_	O
99	and	_	_	O
100	ALT	_	_	O
101	groups	_	_	O
102	.	_	_	O

103	No	_	_	B-Premise
104	significant	_	_	I-Premise
105	difference	_	_	I-Premise
106	(	_	_	I-Premise
107	p	_	_	I-Premise
108	=	_	_	I-Premise
109	0.846	_	_	I-Premise
110	)	_	_	I-Premise
111	was	_	_	I-Premise
112	found	_	_	I-Premise
113	in	_	_	I-Premise
114	mean	_	_	I-Premise
115	decrease	_	_	I-Premise
116	in	_	_	I-Premise
117	IOP	_	_	I-Premise
118	between	_	_	I-Premise
119	the	_	_	I-Premise
120	SLT	_	_	I-Premise
121	(	_	_	I-Premise
122	5.86	_	_	I-Premise
123	mm	_	_	I-Premise
124	Hg	_	_	I-Premise
125	)	_	_	I-Premise
126	and	_	_	I-Premise
127	ALT	_	_	I-Premise
128	(	_	_	I-Premise
129	6.04	_	_	I-Premise
130	mm	_	_	I-Premise
131	Hg	_	_	I-Premise
132	)	_	_	I-Premise
133	groups	_	_	I-Premise
134	at	_	_	I-Premise
135	1	_	_	I-Premise
136	year	_	_	I-Premise
137	or	_	_	I-Premise
138	at	_	_	I-Premise
139	any	_	_	I-Premise
140	other	_	_	I-Premise
141	time	_	_	I-Premise
142	points	_	_	I-Premise
143	,	_	_	I-Premise
144	nor	_	_	I-Premise
145	were	_	_	I-Premise
146	there	_	_	I-Premise
147	any	_	_	I-Premise
148	significant	_	_	I-Premise
149	differences	_	_	I-Premise
150	in	_	_	I-Premise
151	the	_	_	I-Premise
152	rate	_	_	I-Premise
153	of	_	_	I-Premise
154	early	_	_	I-Premise
155	or	_	_	I-Premise
156	late	_	_	I-Premise
157	complications	_	_	I-Premise
158	between	_	_	I-Premise
159	the	_	_	I-Premise
160	two	_	_	I-Premise
161	groups	_	_	I-Premise
162	.	_	_	I-Premise

163	SLT	_	_	B-Claim
164	is	_	_	I-Claim
165	equivalent	_	_	I-Claim
166	to	_	_	I-Claim
167	ALT	_	_	I-Claim
168	in	_	_	I-Claim
169	terms	_	_	I-Claim
170	of	_	_	I-Claim
171	IOP	_	_	I-Claim
172	lowering	_	_	I-Claim
173	at	_	_	I-Claim
174	1	_	_	I-Claim
175	year	_	_	I-Claim
176	,	_	_	I-Claim
177	and	_	_	I-Claim
178	is	_	_	I-Claim
179	a	_	_	I-Claim
180	safe	_	_	I-Claim
181	and	_	_	I-Claim
182	effective	_	_	I-Claim
183	procedure	_	_	I-Claim
184	for	_	_	I-Claim
185	patients	_	_	I-Claim
186	with	_	_	I-Claim
187	open-angle	_	_	I-Claim
188	glaucoma	_	_	I-Claim
189	.	_	_	I-Claim


0	Many	_	_	O
1	physicians	_	_	O
2	recommend	_	_	O
3	either	_	_	O
4	brimonidine	_	_	O
5	or	_	_	O
6	latanoprost	_	_	O
7	as	_	_	O
8	firstline	_	_	O
9	therapy	_	_	O
10	for	_	_	O
11	chronic	_	_	O
12	open-angle	_	_	O
13	glaucoma	_	_	O
14	or	_	_	O
15	ocular	_	_	O
16	hypertension	_	_	O
17	.	_	_	O

18	However	_	_	O
19	,	_	_	O
20	a	_	_	O
21	search	_	_	O
22	of	_	_	O
23	MEDLINE	_	_	O
24	indicates	_	_	O
25	that	_	_	O
26	there	_	_	O
27	have	_	_	O
28	been	_	_	O
29	few	_	_	O
30	head-to-head	_	_	O
31	comparisons	_	_	O
32	of	_	_	O
33	the	_	_	O
34	2	_	_	O
35	monotherapies	_	_	O
36	in	_	_	O
37	a	_	_	O
38	clinical	_	_	O
39	setting	_	_	O
40	.	_	_	O

41	This	_	_	O
42	study	_	_	O
43	compared	_	_	O
44	the	_	_	O
45	clinical	_	_	O
46	efficacy	_	_	O
47	and	_	_	O
48	tolerability	_	_	O
49	of	_	_	O
50	brimonidine	_	_	O
51	0.2	_	_	O
52	%	_	_	O
53	twice	_	_	O
54	daily	_	_	O
55	with	_	_	O
56	those	_	_	O
57	of	_	_	O
58	latanoprost	_	_	O
59	0.005	_	_	O
60	%	_	_	O
61	once	_	_	O
62	daily	_	_	O
63	as	_	_	O
64	monotherapy	_	_	O
65	in	_	_	O
66	patients	_	_	O
67	with	_	_	O
68	open-angle	_	_	O
69	glaucoma	_	_	O
70	or	_	_	O
71	ocular	_	_	O
72	hypertension	_	_	O
73	.	_	_	O

74	In	_	_	O
75	this	_	_	O
76	3-month	_	_	O
77	,	_	_	O
78	multicenter	_	_	O
79	,	_	_	O
80	double-masked	_	_	O
81	,	_	_	O
82	parallel-group	_	_	O
83	,	_	_	O
84	4-visit	_	_	O
85	study	_	_	O
86	,	_	_	O
87	treatment-naive	_	_	O
88	and	_	_	O
89	previously	_	_	O
90	treated	_	_	O
91	patients	_	_	O
92	with	_	_	O
93	open-angle	_	_	O
94	glaucoma	_	_	O
95	or	_	_	O
96	ocular	_	_	O
97	hypertension	_	_	O
98	and	_	_	O
99	bilateral	_	_	O
100	intraocular	_	_	O
101	pressure	_	_	O
102	(	_	_	O
103	IOP	_	_	O
104	)	_	_	O
105	after	_	_	O
106	washout	_	_	O
107	of	_	_	O
108	between	_	_	O
109	22	_	_	O
110	and	_	_	O
111	34	_	_	O
112	mm	_	_	O
113	Hg	_	_	O
114	were	_	_	O
115	randomized	_	_	O
116	to	_	_	O
117	receive	_	_	O
118	either	_	_	O
119	brimonidine	_	_	O
120	or	_	_	O
121	latanoprost	_	_	O
122	.	_	_	O

123	Patients	_	_	O
124	who	_	_	O
125	had	_	_	O
126	received	_	_	O
127	previous	_	_	O
128	treatment	_	_	O
129	with	_	_	O
130	either	_	_	O
131	study	_	_	O
132	drug	_	_	O
133	were	_	_	O
134	excluded	_	_	O
135	from	_	_	O
136	the	_	_	O
137	study	_	_	O
138	.	_	_	O

139	The	_	_	O
140	primary	_	_	O
141	outcome	_	_	O
142	measure	_	_	O
143	was	_	_	O
144	response	_	_	O
145	rate	_	_	O
146	,	_	_	O
147	defined	_	_	O
148	as	_	_	O
149	the	_	_	O
150	percentage	_	_	O
151	of	_	_	O
152	patients	_	_	O
153	achieving	_	_	O
154	>	_	_	O
155	or	_	_	O
156	=	_	_	O
157	20	_	_	O
158	%	_	_	O
159	reduction	_	_	O
160	in	_	_	O
161	IOP	_	_	O
162	from	_	_	O
163	baseline	_	_	O
164	to	_	_	O
165	month	_	_	O
166	3	_	_	O
167	.	_	_	O

168	Secondary	_	_	O
169	outcome	_	_	O
170	measures	_	_	O
171	were	_	_	O
172	mean	_	_	O
173	IOP	_	_	O
174	reduction	_	_	O
175	from	_	_	O
176	baseline	_	_	O
177	to	_	_	O
178	month	_	_	O
179	3	_	_	O
180	and	_	_	O
181	clinical	_	_	O
182	success	_	_	O
183	,	_	_	O
184	defined	_	_	O
185	as	_	_	O
186	the	_	_	O
187	investigator	_	_	O
188	's	_	_	O
189	recommendation	_	_	O
190	that	_	_	O
191	the	_	_	O
192	patient	_	_	O
193	continue	_	_	O
194	using	_	_	O
195	the	_	_	O
196	assigned	_	_	O
197	study	_	_	O
198	medication	_	_	O
199	.	_	_	O

200	A	_	_	O
201	total	_	_	O
202	of	_	_	O
203	127	_	_	O
204	patients	_	_	O
205	(	_	_	O
206	55	_	_	O
207	treatment	_	_	O
208	naive	_	_	O
209	)	_	_	O
210	were	_	_	O
211	enrolled	_	_	O
212	,	_	_	O
213	66	_	_	O
214	in	_	_	O
215	the	_	_	O
216	brimonidine	_	_	O
217	group	_	_	O
218	and	_	_	O
219	61	_	_	O
220	in	_	_	O
221	the	_	_	O
222	latanoprost	_	_	O
223	group	_	_	O
224	.	_	_	O

225	After	_	_	B-Premise
226	3	_	_	I-Premise
227	months	_	_	I-Premise
228	of	_	_	I-Premise
229	treatment	_	_	I-Premise
230	,	_	_	I-Premise
231	80	_	_	I-Premise
232	%	_	_	I-Premise
233	of	_	_	I-Premise
234	patients	_	_	I-Premise
235	in	_	_	I-Premise
236	the	_	_	I-Premise
237	brimonidine	_	_	I-Premise
238	group	_	_	I-Premise
239	and	_	_	I-Premise
240	74	_	_	I-Premise
241	%	_	_	I-Premise
242	of	_	_	I-Premise
243	patients	_	_	I-Premise
244	in	_	_	I-Premise
245	the	_	_	I-Premise
246	latanoprost	_	_	I-Premise
247	group	_	_	I-Premise
248	had	_	_	I-Premise
249	achieved	_	_	I-Premise
250	>	_	_	I-Premise
251	or	_	_	I-Premise
252	=	_	_	I-Premise
253	20	_	_	I-Premise
254	%	_	_	I-Premise
255	reduction	_	_	I-Premise
256	in	_	_	I-Premise
257	IOP	_	_	I-Premise
258	from	_	_	I-Premise
259	baseline	_	_	I-Premise
260	.	_	_	I-Premise

261	The	_	_	B-Premise
262	mean	_	_	I-Premise
263	reduction	_	_	I-Premise
264	in	_	_	I-Premise
265	IOP	_	_	I-Premise
266	from	_	_	I-Premise
267	baseline	_	_	I-Premise
268	at	_	_	I-Premise
269	month	_	_	I-Premise
270	3	_	_	I-Premise
271	was	_	_	I-Premise
272	6.8	_	_	I-Premise
273	mm	_	_	I-Premise
274	Hg	_	_	I-Premise
275	with	_	_	I-Premise
276	brimonidine	_	_	I-Premise
277	and	_	_	I-Premise
278	6.5	_	_	I-Premise
279	mm	_	_	I-Premise
280	Hg	_	_	I-Premise
281	with	_	_	I-Premise
282	latanoprost	_	_	I-Premise
283	(	_	_	I-Premise
284	27.8	_	_	I-Premise
285	%	_	_	I-Premise
286	vs	_	_	I-Premise
287	27.0	_	_	I-Premise
288	%	_	_	I-Premise
289	,	_	_	I-Premise
290	respectively	_	_	I-Premise
291	)	_	_	I-Premise
292	.	_	_	I-Premise

293	Among	_	_	B-Premise
294	treatment-naive	_	_	I-Premise
295	patients	_	_	I-Premise
296	,	_	_	I-Premise
297	a	_	_	I-Premise
298	significantly	_	_	I-Premise
299	higher	_	_	I-Premise
300	percentage	_	_	I-Premise
301	of	_	_	I-Premise
302	brimonidine-treated	_	_	I-Premise
303	patients	_	_	I-Premise
304	achieved	_	_	I-Premise
305	>	_	_	I-Premise
306	or	_	_	I-Premise
307	=	_	_	I-Premise
308	20	_	_	I-Premise
309	%	_	_	I-Premise
310	decrease	_	_	I-Premise
311	in	_	_	I-Premise
312	IOP	_	_	I-Premise
313	compared	_	_	I-Premise
314	with	_	_	I-Premise
315	latanoprost-treated	_	_	I-Premise
316	patients	_	_	I-Premise
317	(	_	_	I-Premise
318	88	_	_	I-Premise
319	%	_	_	I-Premise
320	vs	_	_	I-Premise
321	59	_	_	I-Premise
322	%	_	_	I-Premise
323	,	_	_	I-Premise
324	respectively	_	_	I-Premise
325	;	_	_	I-Premise
326	P	_	_	I-Premise
327	=	_	_	I-Premise
328	0.01	_	_	I-Premise
329	)	_	_	I-Premise
330	.	_	_	I-Premise

331	In	_	_	B-Premise
332	previously	_	_	I-Premise
333	treated	_	_	I-Premise
334	patients	_	_	I-Premise
335	,	_	_	I-Premise
336	a	_	_	I-Premise
337	higher	_	_	I-Premise
338	percentage	_	_	I-Premise
339	of	_	_	I-Premise
340	the	_	_	I-Premise
341	latanoprost	_	_	I-Premise
342	group	_	_	I-Premise
343	achieved	_	_	I-Premise
344	>	_	_	I-Premise
345	or	_	_	I-Premise
346	=	_	_	I-Premise
347	20	_	_	I-Premise
348	%	_	_	I-Premise
349	reduction	_	_	I-Premise
350	in	_	_	I-Premise
351	IOP	_	_	I-Premise
352	compared	_	_	I-Premise
353	with	_	_	I-Premise
354	the	_	_	I-Premise
355	brimonidine	_	_	I-Premise
356	group	_	_	I-Premise
357	(	_	_	I-Premise
358	88	_	_	I-Premise
359	%	_	_	I-Premise
360	vs	_	_	I-Premise
361	74	_	_	I-Premise
362	%	_	_	I-Premise
363	,	_	_	I-Premise
364	respectively	_	_	I-Premise
365	)	_	_	I-Premise
366	;	_	_	I-Premise
367	however	_	_	B-Premise
368	,	_	_	I-Premise
369	the	_	_	I-Premise
370	difference	_	_	I-Premise
371	was	_	_	I-Premise
372	not	_	_	I-Premise
373	statistically	_	_	I-Premise
374	significant	_	_	I-Premise
375	.	_	_	I-Premise

376	Significantly	_	_	B-Premise
377	more	_	_	I-Premise
378	patients	_	_	I-Premise
379	in	_	_	I-Premise
380	the	_	_	I-Premise
381	brimonidine	_	_	I-Premise
382	group	_	_	I-Premise
383	achieved	_	_	I-Premise
384	clinical	_	_	I-Premise
385	success	_	_	I-Premise
386	at	_	_	I-Premise
387	month	_	_	I-Premise
388	3	_	_	I-Premise
389	compared	_	_	I-Premise
390	with	_	_	I-Premise
391	patients	_	_	I-Premise
392	in	_	_	I-Premise
393	the	_	_	I-Premise
394	latanoprost	_	_	I-Premise
395	group	_	_	I-Premise
396	(	_	_	I-Premise
397	91	_	_	I-Premise
398	%	_	_	I-Premise
399	vs	_	_	I-Premise
400	74	_	_	I-Premise
401	%	_	_	I-Premise
402	;	_	_	I-Premise
403	P	_	_	I-Premise
404	=	_	_	I-Premise
405	0.01	_	_	I-Premise
406	)	_	_	I-Premise
407	.	_	_	I-Premise

408	At	_	_	B-Premise
409	peak	_	_	I-Premise
410	effect	_	_	I-Premise
411	,	_	_	I-Premise
412	brimonidine	_	_	I-Premise
413	twice	_	_	I-Premise
414	daily	_	_	I-Premise
415	was	_	_	I-Premise
416	as	_	_	I-Premise
417	effective	_	_	I-Premise
418	as	_	_	I-Premise
419	latanoprost	_	_	I-Premise
420	once	_	_	I-Premise
421	daily	_	_	I-Premise
422	in	_	_	I-Premise
423	lowering	_	_	I-Premise
424	IOP	_	_	I-Premise
425	.	_	_	I-Premise

426	In	_	_	B-Premise
427	treatment-naive	_	_	I-Premise
428	patients	_	_	I-Premise
429	,	_	_	I-Premise
430	latanoprost	_	_	I-Premise
431	was	_	_	I-Premise
432	associated	_	_	I-Premise
433	with	_	_	I-Premise
434	a	_	_	I-Premise
435	significantly	_	_	I-Premise
436	higher	_	_	I-Premise
437	rate	_	_	I-Premise
438	of	_	_	I-Premise
439	nonresponse	_	_	I-Premise
440	after	_	_	I-Premise
441	3	_	_	I-Premise
442	months	_	_	I-Premise
443	of	_	_	I-Premise
444	treatment	_	_	I-Premise
445	compared	_	_	I-Premise
446	with	_	_	I-Premise
447	brimonidine	_	_	I-Premise
448	.	_	_	I-Premise

449	This	_	_	B-Claim
450	suggests	_	_	I-Claim
451	that	_	_	I-Claim
452	brimonidine	_	_	I-Claim
453	may	_	_	I-Claim
454	be	_	_	I-Claim
455	the	_	_	I-Claim
456	more	_	_	I-Claim
457	reliable	_	_	I-Claim
458	choice	_	_	I-Claim
459	for	_	_	I-Claim
460	first-line	_	_	I-Claim
461	therapy	_	_	I-Claim
462	of	_	_	I-Claim
463	newly	_	_	I-Claim
464	diagnosed	_	_	I-Claim
465	open-angle	_	_	I-Claim
466	glaucoma	_	_	I-Claim
467	or	_	_	I-Claim
468	ocular	_	_	I-Claim
469	hypertension	_	_	I-Claim
470	.	_	_	I-Claim

471	In	_	_	B-Premise
472	previously	_	_	I-Premise
473	treated	_	_	I-Premise
474	patients	_	_	I-Premise
475	,	_	_	I-Premise
476	however	_	_	I-Premise
477	,	_	_	I-Premise
478	latanoprost	_	_	I-Premise
479	provided	_	_	I-Premise
480	greater	_	_	I-Premise
481	mean	_	_	I-Premise
482	IOP	_	_	I-Premise
483	reduction	_	_	I-Premise
484	than	_	_	I-Premise
485	did	_	_	I-Premise
486	brimonidine	_	_	I-Premise
487	.	_	_	I-Premise

488	Significantly	_	_	B-Claim
489	more	_	_	I-Claim
490	patients	_	_	I-Claim
491	achieved	_	_	I-Claim
492	clinical	_	_	I-Claim
493	success	_	_	I-Claim
494	with	_	_	I-Claim
495	brimonidine	_	_	I-Claim
496	monotherapy	_	_	I-Claim
497	than	_	_	I-Claim
498	with	_	_	I-Claim
499	latanoprost	_	_	I-Claim
500	monotherapy	_	_	I-Claim
501	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	long-term	_	_	O
4	safety	_	_	O
5	and	_	_	O
6	efficacy	_	_	O
7	of	_	_	O
8	a	_	_	O
9	single	_	_	O
10	trabecular	_	_	O
11	micro-bypass	_	_	O
12	stent	_	_	O
13	with	_	_	O
14	concomitant	_	_	O
15	cataract	_	_	O
16	surgery	_	_	O
17	versus	_	_	O
18	cataract	_	_	O
19	surgery	_	_	O
20	alone	_	_	O
21	for	_	_	O
22	mild	_	_	O
23	to	_	_	O
24	moderate	_	_	O
25	open-angle	_	_	O
26	glaucoma	_	_	O
27	.	_	_	O

28	Twenty-nine	_	_	O
29	investigational	_	_	O
30	sites	_	_	O
31	,	_	_	O
32	United	_	_	O
33	States	_	_	O
34	.	_	_	O

35	Prospective	_	_	O
36	randomized	_	_	O
37	controlled	_	_	O
38	multicenter	_	_	O
39	clinical	_	_	O
40	trial	_	_	O
41	.	_	_	O

42	Eyes	_	_	O
43	with	_	_	O
44	mild	_	_	O
45	to	_	_	O
46	moderate	_	_	O
47	glaucoma	_	_	O
48	with	_	_	O
49	an	_	_	O
50	unmedicated	_	_	O
51	intraocular	_	_	O
52	pressure	_	_	O
53	(	_	_	O
54	IOP	_	_	O
55	)	_	_	O
56	of	_	_	O
57	22	_	_	O
58	mm	_	_	O
59	Hg	_	_	O
60	or	_	_	O
61	higher	_	_	O
62	and	_	_	O
63	36	_	_	O
64	mm	_	_	O
65	Hg	_	_	O
66	or	_	_	O
67	lower	_	_	O
68	were	_	_	O
69	randomly	_	_	O
70	assigned	_	_	O
71	to	_	_	O
72	have	_	_	O
73	cataract	_	_	O
74	surgery	_	_	O
75	with	_	_	O
76	iStent	_	_	O
77	trabecular	_	_	O
78	micro-bypass	_	_	O
79	stent	_	_	O
80	implantation	_	_	O
81	(	_	_	O
82	stent	_	_	O
83	group	_	_	O
84	)	_	_	O
85	or	_	_	O
86	cataract	_	_	O
87	surgery	_	_	O
88	alone	_	_	O
89	(	_	_	O
90	control	_	_	O
91	group	_	_	O
92	)	_	_	O
93	.	_	_	O

94	Patients	_	_	O
95	were	_	_	O
96	followed	_	_	O
97	for	_	_	O
98	24	_	_	O
99	months	_	_	O
100	postoperatively	_	_	O
101	.	_	_	O

102	The	_	_	B-Premise
103	incidence	_	_	I-Premise
104	of	_	_	I-Premise
105	adverse	_	_	I-Premise
106	events	_	_	I-Premise
107	was	_	_	I-Premise
108	low	_	_	I-Premise
109	in	_	_	I-Premise
110	both	_	_	I-Premise
111	groups	_	_	I-Premise
112	through	_	_	I-Premise
113	24	_	_	I-Premise
114	months	_	_	I-Premise
115	of	_	_	I-Premise
116	follow-up	_	_	I-Premise
117	.	_	_	I-Premise

118	At	_	_	B-Premise
119	24	_	_	I-Premise
120	months	_	_	I-Premise
121	,	_	_	I-Premise
122	the	_	_	I-Premise
123	proportion	_	_	I-Premise
124	of	_	_	I-Premise
125	patients	_	_	I-Premise
126	with	_	_	I-Premise
127	an	_	_	I-Premise
128	IOP	_	_	I-Premise
129	of	_	_	I-Premise
130	21	_	_	I-Premise
131	mm	_	_	I-Premise
132	Hg	_	_	I-Premise
133	or	_	_	I-Premise
134	lower	_	_	I-Premise
135	without	_	_	I-Premise
136	ocular	_	_	I-Premise
137	hypotensive	_	_	I-Premise
138	medications	_	_	I-Premise
139	was	_	_	I-Premise
140	significantly	_	_	I-Premise
141	higher	_	_	I-Premise
142	in	_	_	I-Premise
143	the	_	_	I-Premise
144	stent	_	_	I-Premise
145	group	_	_	I-Premise
146	than	_	_	I-Premise
147	in	_	_	I-Premise
148	the	_	_	I-Premise
149	control	_	_	I-Premise
150	group	_	_	I-Premise
151	(	_	_	I-Premise
152	P=.036	_	_	I-Premise
153	)	_	_	I-Premise
154	.	_	_	I-Premise

155	Overall	_	_	O
156	,	_	_	O
157	the	_	_	B-Premise
158	mean	_	_	I-Premise
159	IOP	_	_	I-Premise
160	was	_	_	I-Premise
161	stable	_	_	I-Premise
162	between	_	_	I-Premise
163	12	_	_	I-Premise
164	months	_	_	I-Premise
165	and	_	_	I-Premise
166	24	_	_	I-Premise
167	months	_	_	I-Premise
168	(	_	_	I-Premise
169	17.0	_	_	I-Premise
170	mm	_	_	I-Premise
171	Hg	_	_	I-Premise
172	±	_	_	I-Premise
173	2.8	_	_	I-Premise
174	[	_	_	I-Premise
175	SD	_	_	I-Premise
176	]	_	_	I-Premise
177	and	_	_	I-Premise
178	17.1	_	_	I-Premise
179	±	_	_	I-Premise
180	2.9	_	_	I-Premise
181	mm	_	_	I-Premise
182	Hg	_	_	I-Premise
183	,	_	_	I-Premise
184	respectively	_	_	I-Premise
185	)	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	stent	_	_	I-Premise
189	group	_	_	I-Premise
190	but	_	_	I-Premise
191	increased	_	_	I-Premise
192	(	_	_	I-Premise
193	17.0	_	_	I-Premise
194	±	_	_	I-Premise
195	3.1	_	_	I-Premise
196	mm	_	_	I-Premise
197	Hg	_	_	I-Premise
198	to	_	_	I-Premise
199	17.8	_	_	I-Premise
200	±	_	_	I-Premise
201	3.3	_	_	I-Premise
202	mm	_	_	I-Premise
203	Hg	_	_	I-Premise
204	,	_	_	I-Premise
205	respectively	_	_	I-Premise
206	)	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	control	_	_	I-Premise
210	group	_	_	I-Premise
211	.	_	_	I-Premise

212	Ocular	_	_	B-Premise
213	hypotensive	_	_	I-Premise
214	medication	_	_	I-Premise
215	was	_	_	I-Premise
216	statistically	_	_	I-Premise
217	significantly	_	_	I-Premise
218	lower	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	stent	_	_	I-Premise
222	group	_	_	I-Premise
223	at	_	_	I-Premise
224	12	_	_	I-Premise
225	months	_	_	I-Premise
226	;	_	_	I-Premise
227	it	_	_	I-Premise
228	was	_	_	I-Premise
229	also	_	_	I-Premise
230	lower	_	_	I-Premise
231	at	_	_	I-Premise
232	24	_	_	I-Premise
233	months	_	_	I-Premise
234	,	_	_	I-Premise
235	although	_	_	I-Premise
236	the	_	_	I-Premise
237	difference	_	_	I-Premise
238	was	_	_	I-Premise
239	no	_	_	I-Premise
240	longer	_	_	I-Premise
241	statistically	_	_	I-Premise
242	significant	_	_	I-Premise
243	.	_	_	I-Premise

244	Patients	_	_	B-Claim
245	with	_	_	I-Claim
246	combined	_	_	I-Claim
247	single	_	_	I-Claim
248	trabecular	_	_	I-Claim
249	micro-bypass	_	_	I-Claim
250	stent	_	_	I-Claim
251	and	_	_	I-Claim
252	cataract	_	_	I-Claim
253	surgery	_	_	I-Claim
254	had	_	_	I-Claim
255	significantly	_	_	I-Claim
256	better	_	_	I-Claim
257	IOP	_	_	I-Claim
258	control	_	_	I-Claim
259	on	_	_	I-Claim
260	no	_	_	I-Claim
261	medication	_	_	I-Claim
262	through	_	_	I-Claim
263	24	_	_	I-Claim
264	months	_	_	I-Claim
265	than	_	_	I-Claim
266	patients	_	_	I-Claim
267	having	_	_	I-Claim
268	cataract	_	_	I-Claim
269	surgery	_	_	I-Claim
270	alone	_	_	I-Claim
271	.	_	_	I-Claim

272	Both	_	_	B-Claim
273	groups	_	_	I-Claim
274	had	_	_	I-Claim
275	a	_	_	I-Claim
276	similar	_	_	I-Claim
277	favorable	_	_	I-Claim
278	long-term	_	_	I-Claim
279	safety	_	_	I-Claim
280	profile	_	_	I-Claim
281	.	_	_	I-Claim


0	To	_	_	O
1	determine	_	_	O
2	if	_	_	O
3	postoperative	_	_	O
4	topical	_	_	O
5	cyclosporine	_	_	O
6	0.05	_	_	O
7	%	_	_	O
8	has	_	_	O
9	any	_	_	O
10	beneficial	_	_	O
11	effect	_	_	O
12	following	_	_	O
13	trabeculectomy	_	_	O
14	.	_	_	O

15	This	_	_	O
16	was	_	_	O
17	an	_	_	O
18	interventional	_	_	O
19	,	_	_	O
20	randomized	_	_	O
21	,	_	_	O
22	prospective	_	_	O
23	,	_	_	O
24	double-masked	_	_	O
25	clinical	_	_	O
26	trial	_	_	O
27	of	_	_	O
28	44	_	_	O
29	consecutive	_	_	O
30	patients	_	_	O
31	with	_	_	O
32	uncontrolled	_	_	O
33	glaucoma	_	_	O
34	requiring	_	_	O
35	filtration	_	_	O
36	surgery	_	_	O
37	.	_	_	O

38	Ocular	_	_	O
39	surface	_	_	O
40	disease	_	_	O
41	index	_	_	O
42	questionnaire	_	_	O
43	and	_	_	O
44	comprehensive	_	_	O
45	ocular	_	_	O
46	exam	_	_	O
47	,	_	_	O
48	including	_	_	O
49	Schirmer	_	_	O
50	's	_	_	O
51	tear	_	_	O
52	test	_	_	O
53	1	_	_	O
54	,	_	_	O
55	were	_	_	O
56	performed	_	_	O
57	.	_	_	O

58	Patients	_	_	O
59	underwent	_	_	O
60	routine	_	_	O
61	trabeculectomy	_	_	O
62	,	_	_	O
63	with	_	_	O
64	or	_	_	O
65	without	_	_	O
66	phacoemulsification	_	_	O
67	.	_	_	O

68	The	_	_	O
69	study	_	_	O
70	group	_	_	O
71	(	_	_	O
72	n	_	_	O
73	=	_	_	O
74	22	_	_	O
75	)	_	_	O
76	received	_	_	O
77	cyclosporine	_	_	O
78	0.05	_	_	O
79	%	_	_	O
80	,	_	_	O
81	and	_	_	O
82	the	_	_	O
83	control	_	_	O
84	group	_	_	O
85	(	_	_	O
86	n	_	_	O
87	=	_	_	O
88	22	_	_	O
89	)	_	_	O
90	received	_	_	O
91	artificial	_	_	O
92	tears	_	_	O
93	.	_	_	O

94	Patients	_	_	O
95	were	_	_	O
96	evaluated	_	_	O
97	at	_	_	O
98	1	_	_	O
99	and	_	_	O
100	6	_	_	O
101	months	_	_	O
102	post	_	_	O
103	surgery	_	_	O
104	.	_	_	O

105	Outcome	_	_	O
106	measures	_	_	O
107	were	_	_	O
108	intraocular	_	_	O
109	pressure	_	_	O
110	,	_	_	O
111	success	_	_	O
112	rate	_	_	O
113	,	_	_	O
114	bleb	_	_	O
115	appearance	_	_	O
116	,	_	_	O
117	ocular	_	_	O
118	surface	_	_	O
119	disease	_	_	O
120	index	_	_	O
121	,	_	_	O
122	Schirmer	_	_	O
123	's	_	_	O
124	tear	_	_	O
125	test	_	_	O
126	1	_	_	O
127	and	_	_	O
128	conjunctival	_	_	O
129	inflammation	_	_	O
130	.	_	_	O

131	Thirty-nine	_	_	O
132	patients	_	_	O
133	completed	_	_	O
134	the	_	_	O
135	study	_	_	O
136	(	_	_	O
137	19	_	_	O
138	in	_	_	O
139	the	_	_	O
140	study	_	_	O
141	group	_	_	O
142	,	_	_	O
143	20	_	_	O
144	in	_	_	O
145	the	_	_	O
146	control	_	_	O
147	group	_	_	O
148	)	_	_	O
149	.	_	_	O

150	The	_	_	B-Premise
151	mean	_	_	I-Premise
152	baseline	_	_	I-Premise
153	intraocular	_	_	I-Premise
154	pressure	_	_	I-Premise
155	was	_	_	I-Premise
156	23.8	_	_	I-Premise
157	+/-	_	_	I-Premise
158	12.6	_	_	I-Premise
159	mmHg	_	_	I-Premise
160	in	_	_	I-Premise
161	the	_	_	I-Premise
162	study	_	_	I-Premise
163	group	_	_	I-Premise
164	and	_	_	I-Premise
165	25.9	_	_	I-Premise
166	+/-	_	_	I-Premise
167	10.6	_	_	I-Premise
168	mmHg	_	_	I-Premise
169	in	_	_	I-Premise
170	the	_	_	I-Premise
171	control	_	_	I-Premise
172	group	_	_	I-Premise
173	(	_	_	I-Premise
174	P	_	_	I-Premise
175	=	_	_	I-Premise
176	0.513	_	_	I-Premise
177	)	_	_	I-Premise
178	.	_	_	I-Premise

179	Mean	_	_	B-Premise
180	intraocular	_	_	I-Premise
181	pressure	_	_	I-Premise
182	at	_	_	I-Premise
183	postoperative	_	_	I-Premise
184	month	_	_	I-Premise
185	6	_	_	I-Premise
186	was	_	_	I-Premise
187	14.88	_	_	I-Premise
188	+/-	_	_	I-Premise
189	6.2	_	_	I-Premise
190	and	_	_	I-Premise
191	14.62	_	_	I-Premise
192	+/-	_	_	I-Premise
193	5.46	_	_	I-Premise
194	mmHg	_	_	I-Premise
195	in	_	_	I-Premise
196	the	_	_	I-Premise
197	study	_	_	I-Premise
198	group	_	_	I-Premise
199	and	_	_	I-Premise
200	control	_	_	I-Premise
201	group	_	_	I-Premise
202	,	_	_	I-Premise
203	respectively	_	_	I-Premise
204	(	_	_	I-Premise
205	P	_	_	I-Premise
206	=	_	_	I-Premise
207	0.837	_	_	I-Premise
208	)	_	_	I-Premise
209	.	_	_	I-Premise

210	There	_	_	B-Premise
211	was	_	_	I-Premise
212	no	_	_	I-Premise
213	statistically	_	_	I-Premise
214	significant	_	_	I-Premise
215	difference	_	_	I-Premise
216	in	_	_	I-Premise
217	the	_	_	I-Premise
218	mean	_	_	I-Premise
219	values	_	_	I-Premise
220	of	_	_	I-Premise
221	Schirmer	_	_	I-Premise
222	's	_	_	I-Premise
223	tear	_	_	I-Premise
224	test	_	_	I-Premise
225	1	_	_	I-Premise
226	and	_	_	I-Premise
227	the	_	_	I-Premise
228	level	_	_	I-Premise
229	of	_	_	I-Premise
230	conjunctival	_	_	I-Premise
231	hyperaemia	_	_	I-Premise
232	between	_	_	I-Premise
233	the	_	_	I-Premise
234	two	_	_	I-Premise
235	groups	_	_	I-Premise
236	at	_	_	I-Premise
237	baseline	_	_	I-Premise
238	,	_	_	I-Premise
239	months	_	_	I-Premise
240	1	_	_	I-Premise
241	and	_	_	I-Premise
242	6	_	_	I-Premise
243	post	_	_	I-Premise
244	surgery	_	_	I-Premise
245	.	_	_	I-Premise

246	The	_	_	B-Premise
247	treatment	_	_	I-Premise
248	group	_	_	I-Premise
249	had	_	_	I-Premise
250	a	_	_	I-Premise
251	statistically	_	_	I-Premise
252	significant	_	_	I-Premise
253	decrease	_	_	I-Premise
254	in	_	_	I-Premise
255	ocular	_	_	I-Premise
256	surface	_	_	I-Premise
257	disease	_	_	I-Premise
258	index	_	_	I-Premise
259	score	_	_	I-Premise
260	at	_	_	I-Premise
261	6	_	_	I-Premise
262	months	_	_	I-Premise
263	(	_	_	I-Premise
264	P	_	_	I-Premise
265	=	_	_	I-Premise
266	0.003	_	_	I-Premise
267	)	_	_	I-Premise
268	,	_	_	I-Premise
269	indicating	_	_	I-Premise
270	less	_	_	I-Premise
271	severity	_	_	I-Premise
272	of	_	_	I-Premise
273	dry	_	_	I-Premise
274	eye	_	_	I-Premise
275	symptoms	_	_	I-Premise
276	and	_	_	I-Premise
277	significant	_	_	I-Premise
278	reduction	_	_	I-Premise
279	in	_	_	I-Premise
280	ocular	_	_	I-Premise
281	pain	_	_	I-Premise
282	.	_	_	I-Premise

283	Topical	_	_	B-Claim
284	cyclosporine	_	_	I-Claim
285	0.05	_	_	I-Claim
286	%	_	_	I-Claim
287	had	_	_	I-Claim
288	no	_	_	I-Claim
289	effect	_	_	I-Claim
290	on	_	_	I-Claim
291	postoperative	_	_	I-Claim
292	bleb	_	_	I-Claim
293	function	_	_	I-Claim
294	and	_	_	I-Claim
295	intraocular	_	_	I-Claim
296	pressure	_	_	I-Claim
297	following	_	_	I-Claim
298	trabeculectomy	_	_	I-Claim
299	,	_	_	I-Claim
300	but	_	_	I-Claim
301	improved	_	_	I-Claim
302	subjective	_	_	I-Claim
303	ocular	_	_	I-Claim
304	surface	_	_	I-Claim
305	symptoms	_	_	I-Claim
306	in	_	_	I-Claim
307	these	_	_	I-Claim
308	patients	_	_	I-Claim
309	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	0.0015	_	_	O
8	%	_	_	O
9	tafluprost	_	_	O
10	ophthalmic	_	_	O
11	solution	_	_	O
12	(	_	_	O
13	Tafluprost	_	_	O
14	)	_	_	O
15	with	_	_	O
16	Placebo	_	_	O
17	ophthalmic	_	_	O
18	solution	_	_	O
19	(	_	_	O
20	Placebo	_	_	O
21	)	_	_	O
22	in	_	_	O
23	normal	_	_	O
24	tension	_	_	O
25	glaucoma	_	_	O
26	(	_	_	O
27	NTG	_	_	O
28	)	_	_	O
29	.	_	_	O

30	Total	_	_	O
31	of	_	_	O
32	94	_	_	O
33	patients	_	_	O
34	enrolled	_	_	O
35	in	_	_	O
36	a	_	_	O
37	randomized	_	_	O
38	,	_	_	O
39	double-blind	_	_	O
40	,	_	_	O
41	parallel-group	_	_	O
42	and	_	_	O
43	multicenter	_	_	O
44	study	_	_	O
45	.	_	_	O

46	Patients	_	_	O
47	with	_	_	O
48	NTG	_	_	O
49	were	_	_	O
50	randomly	_	_	O
51	assigned	_	_	O
52	to	_	_	O
53	either	_	_	O
54	Tafluprost	_	_	O
55	or	_	_	O
56	Placebo	_	_	O
57	.	_	_	O

58	Both	_	_	O
59	ophthalmic	_	_	O
60	solutions	_	_	O
61	were	_	_	O
62	instilled	_	_	O
63	once	_	_	O
64	a	_	_	O
65	day	_	_	O
66	in	_	_	O
67	the	_	_	O
68	morning	_	_	O
69	for	_	_	O
70	4	_	_	O
71	weeks	_	_	O
72	.	_	_	O

73	Mean	_	_	B-Premise
74	intraocular	_	_	I-Premise
75	pressure	_	_	I-Premise
76	(	_	_	I-Premise
77	IOP	_	_	I-Premise
78	)	_	_	I-Premise
79	changes	_	_	I-Premise
80	from	_	_	I-Premise
81	baseline	_	_	I-Premise
82	were	_	_	I-Premise
83	-4.0	_	_	I-Premise
84	+/-	_	_	I-Premise
85	1.7	_	_	I-Premise
86	mmHg	_	_	I-Premise
87	in	_	_	I-Premise
88	Tafluprost	_	_	I-Premise
89	administered	_	_	I-Premise
90	patients	_	_	I-Premise
91	and	_	_	I-Premise
92	-1.4	_	_	I-Premise
93	+/-	_	_	I-Premise
94	1.8	_	_	I-Premise
95	mmHg	_	_	I-Premise
96	in	_	_	I-Premise
97	Placebo	_	_	I-Premise
98	administered	_	_	I-Premise
99	patients	_	_	I-Premise
100	at	_	_	I-Premise
101	4	_	_	I-Premise
102	weeks	_	_	I-Premise
103	,	_	_	I-Premise
104	with	_	_	I-Premise
105	a	_	_	I-Premise
106	statistically	_	_	I-Premise
107	significant	_	_	I-Premise
108	difference	_	_	I-Premise
109	(	_	_	I-Premise
110	p	_	_	I-Premise
111	<	_	_	I-Premise
112	0.001	_	_	I-Premise
113	)	_	_	I-Premise
114	.	_	_	I-Premise

115	IOP	_	_	B-Premise
116	change	_	_	I-Premise
117	at	_	_	I-Premise
118	4	_	_	I-Premise
119	weeks	_	_	I-Premise
120	,	_	_	I-Premise
121	%	_	_	I-Premise
122	IOP	_	_	I-Premise
123	reduction	_	_	I-Premise
124	at	_	_	I-Premise
125	2	_	_	I-Premise
126	and	_	_	I-Premise
127	4	_	_	I-Premise
128	weeks	_	_	I-Premise
129	were	_	_	I-Premise
130	also	_	_	I-Premise
131	significantly	_	_	I-Premise
132	greater	_	_	I-Premise
133	in	_	_	I-Premise
134	Tafluprost	_	_	I-Premise
135	than	_	_	I-Premise
136	in	_	_	I-Premise
137	Placebo	_	_	I-Premise
138	.	_	_	I-Premise

139	A	_	_	B-Premise
140	total	_	_	I-Premise
141	of	_	_	I-Premise
142	51.0	_	_	I-Premise
143	%	_	_	I-Premise
144	in	_	_	I-Premise
145	Tafluprost	_	_	I-Premise
146	treated	_	_	I-Premise
147	group	_	_	I-Premise
148	and	_	_	I-Premise
149	8.9	_	_	I-Premise
150	%	_	_	I-Premise
151	in	_	_	I-Premise
152	Placebo	_	_	I-Premise
153	treated	_	_	I-Premise
154	group	_	_	I-Premise
155	reported	_	_	I-Premise
156	adverse	_	_	I-Premise
157	drug	_	_	I-Premise
158	reactions	_	_	I-Premise
159	.	_	_	I-Premise

160	These	_	_	B-Claim
161	results	_	_	I-Claim
162	indicate	_	_	I-Claim
163	that	_	_	I-Claim
164	Tafluprost	_	_	I-Claim
165	is	_	_	I-Claim
166	clinically	_	_	I-Claim
167	useful	_	_	I-Claim
168	in	_	_	I-Claim
169	the	_	_	I-Claim
170	treatment	_	_	I-Claim
171	of	_	_	I-Claim
172	NTG	_	_	I-Claim
173	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	(	_	_	O
6	IOP	_	_	O
7	)	_	_	O
8	-lowering	_	_	O
9	effect	_	_	O
10	and	_	_	O
11	safety	_	_	O
12	of	_	_	O
13	topical	_	_	O
14	brimonidine	_	_	O
15	to	_	_	O
16	that	_	_	O
17	of	_	_	O
18	timolol	_	_	O
19	,	_	_	O
20	and	_	_	O
21	to	_	_	O
22	study	_	_	O
23	the	_	_	O
24	additive	_	_	O
25	effect	_	_	O
26	of	_	_	O
27	topical	_	_	O
28	brimonidine	_	_	O
29	to	_	_	O
30	topical	_	_	O
31	prostaglandin	_	_	O
32	(	_	_	O
33	PG	_	_	O
34	)	_	_	O
35	analogues	_	_	O
36	in	_	_	O
37	475	_	_	O
38	patients	_	_	O
39	with	_	_	O
40	either	_	_	O
41	ocular	_	_	O
42	hypertension	_	_	O
43	or	_	_	O
44	primary	_	_	O
45	open	_	_	O
46	angle	_	_	O
47	glaucoma	_	_	O
48	.	_	_	O

49	The	_	_	O
50	primary	_	_	O
51	endpoint	_	_	O
52	was	_	_	O
53	the	_	_	O
54	mean	_	_	O
55	IOP	_	_	O
56	change	_	_	O
57	from	_	_	O
58	the	_	_	O
59	baseline	_	_	O
60	at	_	_	O
61	0	_	_	O
62	and	_	_	O
63	2	_	_	O
64	hours	_	_	O
65	at	_	_	O
66	week	_	_	O
67	4	_	_	O
68	.	_	_	O

69	The	_	_	B-Premise
70	mean	_	_	I-Premise
71	changes	_	_	I-Premise
72	were	_	_	I-Premise
73	-4.7	_	_	I-Premise
74	+/-	_	_	I-Premise
75	2.1	_	_	I-Premise
76	(	_	_	I-Premise
77	S.	_	_	I-Premise
78	D.	_	_	I-Premise
79	)	_	_	I-Premise
80	in	_	_	I-Premise
81	the	_	_	I-Premise
82	timolol	_	_	I-Premise
83	and	_	_	I-Premise
84	-4.0	_	_	I-Premise
85	+/-	_	_	I-Premise
86	2.0	_	_	I-Premise
87	mmHg	_	_	I-Premise
88	in	_	_	I-Premise
89	the	_	_	I-Premise
90	brimonidine	_	_	I-Premise
91	group	_	_	I-Premise
92	(	_	_	I-Premise
93	p	_	_	I-Premise
94	=	_	_	I-Premise
95	0.0138	_	_	I-Premise
96	)	_	_	I-Premise
97	.	_	_	I-Premise

98	The	_	_	B-Premise
99	95	_	_	I-Premise
100	%	_	_	I-Premise
101	confidence	_	_	I-Premise
102	interval	_	_	I-Premise
103	of	_	_	I-Premise
104	the	_	_	I-Premise
105	inter-group	_	_	I-Premise
106	difference	_	_	I-Premise
107	was	_	_	I-Premise
108	greater	_	_	I-Premise
109	than	_	_	I-Premise
110	the	_	_	I-Premise
111	pre-determined	_	_	I-Premise
112	criterion	_	_	I-Premise
113	of	_	_	I-Premise
114	non-inferiority	_	_	I-Premise
115	of	_	_	I-Premise
116	brimonidine	_	_	I-Premise
117	to	_	_	I-Premise
118	timolol	_	_	I-Premise
119	.	_	_	I-Premise

120	When	_	_	B-Premise
121	added	_	_	I-Premise
122	to	_	_	I-Premise
123	PG	_	_	I-Premise
124	analogues	_	_	I-Premise
125	,	_	_	I-Premise
126	the	_	_	I-Premise
127	IOP-lowering	_	_	I-Premise
128	effect	_	_	I-Premise
129	of	_	_	I-Premise
130	brimonidine	_	_	I-Premise
131	(	_	_	I-Premise
132	-2.9	_	_	I-Premise
133	+/-	_	_	I-Premise
134	1.8	_	_	I-Premise
135	mmHg	_	_	I-Premise
136	)	_	_	I-Premise
137	was	_	_	I-Premise
138	greater	_	_	I-Premise
139	than	_	_	I-Premise
140	that	_	_	I-Premise
141	of	_	_	I-Premise
142	the	_	_	I-Premise
143	placebo	_	_	I-Premise
144	(	_	_	I-Premise
145	-2.1	_	_	I-Premise
146	+/-	_	_	I-Premise
147	1.8	_	_	I-Premise
148	mmHg	_	_	I-Premise
149	)	_	_	I-Premise
150	(	_	_	I-Premise
151	p	_	_	I-Premise
152	=	_	_	I-Premise
153	0.0010	_	_	I-Premise
154	)	_	_	I-Premise
155	.	_	_	I-Premise

156	No	_	_	O
157	appreciable	_	_	O
158	adverse	_	_	O
159	side	_	_	O
160	effects	_	_	O
161	were	_	_	O
162	encountered	_	_	O
163	.	_	_	O

164	Topical	_	_	B-Claim
165	brimonidine	_	_	I-Claim
166	showed	_	_	I-Claim
167	an	_	_	I-Claim
168	additive	_	_	I-Claim
169	IOP-lowering	_	_	I-Claim
170	effect	_	_	I-Claim
171	to	_	_	I-Claim
172	topical	_	_	I-Claim
173	PG	_	_	I-Claim
174	analogues	_	_	I-Claim
175	,	_	_	I-Claim
176	although	_	_	B-Claim
177	its	_	_	I-Claim
178	IOP-lowering	_	_	I-Claim
179	effect	_	_	I-Claim
180	was	_	_	I-Claim
181	inferior	_	_	I-Claim
182	to	_	_	I-Claim
183	topical	_	_	I-Claim
184	timolol	_	_	I-Claim
185	as	_	_	I-Claim
186	monotherapy	_	_	I-Claim
187	.	_	_	I-Claim


0	To	_	_	O
1	evaluate	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure-lowering	_	_	O
5	efficacy	_	_	O
6	and	_	_	O
7	safety	_	_	O
8	of	_	_	O
9	travoprost	_	_	O
10	0.0015	_	_	O
11	%	_	_	O
12	and	_	_	O
13	0.004	_	_	O
14	%	_	_	O
15	,	_	_	O
16	dosed	_	_	O
17	daily	_	_	O
18	in	_	_	O
19	the	_	_	O
20	evening	_	_	O
21	compared	_	_	O
22	with	_	_	O
23	vehicle	_	_	O
24	,	_	_	O
25	in	_	_	O
26	patients	_	_	O
27	with	_	_	O
28	open-angle	_	_	O
29	glaucoma	_	_	O
30	or	_	_	O
31	ocular	_	_	O
32	hypertension	_	_	O
33	,	_	_	O
34	whose	_	_	O
35	intraocular	_	_	O
36	pressure	_	_	O
37	was	_	_	O
38	not	_	_	O
39	adequately	_	_	O
40	controlled	_	_	O
41	on	_	_	O
42	timolol	_	_	O
43	0.5	_	_	O
44	%	_	_	O
45	twice	_	_	O
46	daily	_	_	O
47	(	_	_	O
48	twice	_	_	O
49	daily	_	_	O
50	)	_	_	O
51	.	_	_	O

52	Subjects	_	_	O
53	who	_	_	O
54	qualified	_	_	O
55	at	_	_	O
56	screening	_	_	O
57	began	_	_	O
58	a	_	_	O
59	run-in	_	_	O
60	period	_	_	O
61	dosing	_	_	O
62	timolol	_	_	O
63	twice	_	_	O
64	daily	_	_	O
65	for	_	_	O
66	3	_	_	O
67	weeks	_	_	O
68	.	_	_	O

69	If	_	_	O
70	the	_	_	O
71	subjects	_	_	O
72	had	_	_	O
73	an	_	_	O
74	intraocular	_	_	O
75	pressure	_	_	O
76	of	_	_	O
77	24	_	_	O
78	to	_	_	O
79	36	_	_	O
80	mm	_	_	O
81	Hg	_	_	O
82	at	_	_	O
83	8	_	_	O
84	AM	_	_	O
85	and	_	_	O
86	21	_	_	O
87	to	_	_	O
88	36	_	_	O
89	mm	_	_	O
90	Hg	_	_	O
91	at	_	_	O
92	10	_	_	O
93	AM	_	_	O
94	and	_	_	O
95	4	_	_	O
96	pm	_	_	O
97	in	_	_	O
98	at	_	_	O
99	least	_	_	O
100	one	_	_	O
101	eye	_	_	O
102	on	_	_	O
103	timolol	_	_	O
104	,	_	_	O
105	they	_	_	O
106	were	_	_	O
107	randomized	_	_	O
108	to	_	_	O
109	one	_	_	O
110	of	_	_	O
111	two	_	_	O
112	concentrations	_	_	O
113	of	_	_	O
114	travoprost	_	_	O
115	(	_	_	O
116	0.0015	_	_	O
117	%	_	_	O
118	or	_	_	O
119	0.004	_	_	O
120	%	_	_	O
121	)	_	_	O
122	or	_	_	O
123	vehicle	_	_	O
124	solution	_	_	O
125	every	_	_	O
126	day	_	_	O
127	and	_	_	O
128	were	_	_	O
129	followed	_	_	O
130	for	_	_	O
131	6	_	_	O
132	months	_	_	O
133	.	_	_	O

134	Four	_	_	O
135	hundred	_	_	O
136	twenty-six	_	_	O
137	subjects	_	_	O
138	were	_	_	O
139	randomized	_	_	O
140	.	_	_	O

141	The	_	_	O
142	mean	_	_	O
143	intraocular	_	_	O
144	pressure	_	_	O
145	at	_	_	O
146	8	_	_	O
147	AM	_	_	O
148	,	_	_	O
149	10	_	_	O
150	AM	_	_	O
151	,	_	_	O
152	and	_	_	O
153	4	_	_	O
154	PM	_	_	O
155	in	_	_	O
156	the	_	_	O
157	patient	_	_	O
158	's	_	_	O
159	eye	_	_	O
160	with	_	_	O
161	the	_	_	O
162	higher	_	_	O
163	intraocular	_	_	O
164	pressure	_	_	O
165	was	_	_	O
166	used	_	_	O
167	for	_	_	O
168	the	_	_	O
169	analysis	_	_	O
170	.	_	_	O

171	Mean	_	_	B-Premise
172	baseline	_	_	I-Premise
173	values	_	_	I-Premise
174	(	_	_	I-Premise
175	25	_	_	I-Premise
176	mm	_	_	I-Premise
177	Hg	_	_	I-Premise
178	)	_	_	I-Premise
179	for	_	_	I-Premise
180	subjects	_	_	I-Premise
181	at	_	_	I-Premise
182	eligibility	_	_	I-Premise
183	(	_	_	I-Premise
184	while	_	_	I-Premise
185	maintained	_	_	I-Premise
186	on	_	_	I-Premise
187	timolol	_	_	I-Premise
188	)	_	_	I-Premise
189	were	_	_	I-Premise
190	not	_	_	I-Premise
191	significantly	_	_	I-Premise
192	different	_	_	I-Premise
193	(	_	_	I-Premise
194	P	_	_	I-Premise
195	<	_	_	I-Premise
196	.0001	_	_	I-Premise
197	)	_	_	I-Premise
198	among	_	_	I-Premise
199	the	_	_	I-Premise
200	treatment	_	_	I-Premise
201	groups	_	_	I-Premise
202	.	_	_	I-Premise

203	The	_	_	B-Premise
204	intraocular	_	_	I-Premise
205	pressure	_	_	I-Premise
206	was	_	_	I-Premise
207	lowered	_	_	I-Premise
208	an	_	_	I-Premise
209	additional	_	_	I-Premise
210	-5.7	_	_	I-Premise
211	to	_	_	I-Premise
212	-7.2	_	_	I-Premise
213	mm	_	_	I-Premise
214	Hg	_	_	I-Premise
215	and	_	_	I-Premise
216	-5.1	_	_	I-Premise
217	to	_	_	I-Premise
218	-6.7	_	_	I-Premise
219	mm	_	_	I-Premise
220	Hg	_	_	I-Premise
221	in	_	_	I-Premise
222	the	_	_	I-Premise
223	travoprost	_	_	I-Premise
224	0.004	_	_	I-Premise
225	%	_	_	I-Premise
226	and	_	_	I-Premise
227	0.0015	_	_	I-Premise
228	%	_	_	I-Premise
229	concentrations	_	_	I-Premise
230	,	_	_	I-Premise
231	respectively	_	_	I-Premise
232	.	_	_	I-Premise

233	These	_	_	B-Premise
234	changes	_	_	I-Premise
235	were	_	_	I-Premise
236	significantly	_	_	I-Premise
237	(	_	_	I-Premise
238	P	_	_	I-Premise
239	<	_	_	I-Premise
240	or	_	_	I-Premise
241	=.0001	_	_	I-Premise
242	)	_	_	I-Premise
243	different	_	_	I-Premise
244	from	_	_	I-Premise
245	the	_	_	I-Premise
246	vehicle	_	_	I-Premise
247	group	_	_	I-Premise
248	(	_	_	I-Premise
249	-1.3	_	_	I-Premise
250	to	_	_	I-Premise
251	-2.8	_	_	I-Premise
252	mm	_	_	I-Premise
253	Hg	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	The	_	_	B-Premise
257	intraocular	_	_	I-Premise
258	pressure	_	_	I-Premise
259	range	_	_	I-Premise
260	on	_	_	I-Premise
261	treatment	_	_	I-Premise
262	at	_	_	I-Premise
263	all	_	_	I-Premise
264	visit	_	_	I-Premise
265	times	_	_	I-Premise
266	over	_	_	I-Premise
267	the	_	_	I-Premise
268	6-month	_	_	I-Premise
269	treatment	_	_	I-Premise
270	period	_	_	I-Premise
271	ranged	_	_	I-Premise
272	from	_	_	I-Premise
273	17.9	_	_	I-Premise
274	to	_	_	I-Premise
275	19.2	_	_	I-Premise
276	mm	_	_	I-Premise
277	Hg	_	_	I-Premise
278	for	_	_	I-Premise
279	travoprost	_	_	I-Premise
280	0.004	_	_	I-Premise
281	%	_	_	I-Premise
282	and	_	_	I-Premise
283	18.3	_	_	I-Premise
284	to	_	_	I-Premise
285	20.1	_	_	I-Premise
286	mm	_	_	I-Premise
287	Hg	_	_	I-Premise
288	for	_	_	I-Premise
289	travoprost	_	_	I-Premise
290	0.0015	_	_	I-Premise
291	%	_	_	I-Premise
292	compared	_	_	I-Premise
293	with	_	_	I-Premise
294	22.4	_	_	I-Premise
295	to	_	_	I-Premise
296	24.1	_	_	I-Premise
297	mm	_	_	I-Premise
298	Hg	_	_	I-Premise
299	for	_	_	I-Premise
300	vehicle	_	_	I-Premise
301	.	_	_	I-Premise

302	Average	_	_	B-Premise
303	hyperemia	_	_	I-Premise
304	scores	_	_	I-Premise
305	ranged	_	_	I-Premise
306	from	_	_	I-Premise
307	trace	_	_	I-Premise
308	to	_	_	I-Premise
309	mild	_	_	I-Premise
310	(	_	_	I-Premise
311	mean	_	_	I-Premise
312	0.5	_	_	I-Premise
313	on	_	_	I-Premise
314	a	_	_	I-Premise
315	scale	_	_	I-Premise
316	of	_	_	I-Premise
317	0	_	_	I-Premise
318	=	_	_	I-Premise
319	none/trace	_	_	I-Premise
320	;	_	_	I-Premise
321	1=	_	_	I-Premise
322	mild	_	_	I-Premise
323	;	_	_	I-Premise
324	2	_	_	I-Premise
325	=	_	_	I-Premise
326	moderate	_	_	I-Premise
327	;	_	_	I-Premise
328	3	_	_	I-Premise
329	=	_	_	I-Premise
330	severe	_	_	I-Premise
331	)	_	_	I-Premise
332	for	_	_	I-Premise
333	all	_	_	I-Premise
334	treatment	_	_	I-Premise
335	groups	_	_	I-Premise
336	.	_	_	I-Premise

337	No	_	_	B-Premise
338	iris	_	_	I-Premise
339	pigmentation	_	_	I-Premise
340	changes	_	_	I-Premise
341	were	_	_	I-Premise
342	observed	_	_	I-Premise
343	in	_	_	I-Premise
344	any	_	_	I-Premise
345	patient	_	_	I-Premise
346	during	_	_	I-Premise
347	this	_	_	I-Premise
348	study	_	_	I-Premise
349	.	_	_	I-Premise

350	There	_	_	B-Premise
351	were	_	_	I-Premise
352	no	_	_	I-Premise
353	clinically	_	_	I-Premise
354	or	_	_	I-Premise
355	statistically	_	_	I-Premise
356	significant	_	_	I-Premise
357	changes	_	_	I-Premise
358	from	_	_	I-Premise
359	baseline	_	_	I-Premise
360	in	_	_	I-Premise
361	visual	_	_	I-Premise
362	acuity	_	_	I-Premise
363	,	_	_	I-Premise
364	ocular	_	_	I-Premise
365	cells	_	_	I-Premise
366	and	_	_	I-Premise
367	flare	_	_	I-Premise
368	,	_	_	I-Premise
369	fundus	_	_	I-Premise
370	parameter	_	_	I-Premise
371	,	_	_	I-Premise
372	cup-to-disk	_	_	I-Premise
373	ratio	_	_	I-Premise
374	and	_	_	I-Premise
375	visual	_	_	I-Premise
376	field	_	_	I-Premise
377	between	_	_	I-Premise
378	the	_	_	I-Premise
379	treatment	_	_	I-Premise
380	groups	_	_	I-Premise
381	.	_	_	I-Premise

382	There	_	_	B-Premise
383	were	_	_	I-Premise
384	no	_	_	I-Premise
385	serious	_	_	I-Premise
386	adverse	_	_	I-Premise
387	events	_	_	I-Premise
388	reported	_	_	I-Premise
389	for	_	_	I-Premise
390	any	_	_	I-Premise
391	treatment	_	_	I-Premise
392	group	_	_	I-Premise
393	.	_	_	I-Premise

394	Travoprost	_	_	B-Claim
395	produced	_	_	I-Claim
396	clinically	_	_	I-Claim
397	relevant	_	_	I-Claim
398	and	_	_	I-Claim
399	statistically	_	_	I-Claim
400	significant	_	_	I-Claim
401	additional	_	_	I-Claim
402	intraocular	_	_	I-Claim
403	pressure	_	_	I-Claim
404	reductions	_	_	I-Claim
405	from	_	_	I-Claim
406	baseline	_	_	I-Claim
407	when	_	_	I-Claim
408	used	_	_	I-Claim
409	adjunctively	_	_	I-Claim
410	with	_	_	I-Claim
411	timolol	_	_	I-Claim
412	in	_	_	I-Claim
413	subjects	_	_	I-Claim
414	with	_	_	I-Claim
415	open-angle	_	_	I-Claim
416	glaucoma	_	_	I-Claim
417	or	_	_	I-Claim
418	ocular	_	_	I-Claim
419	hypertension	_	_	I-Claim
420	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	short-	_	_	O
4	and	_	_	O
5	intermediate-term	_	_	O
6	results	_	_	O
7	of	_	_	O
8	two	_	_	O
9	commonly	_	_	O
10	used	_	_	O
11	glaucoma	_	_	O
12	surgical	_	_	O
13	procedures	_	_	O
14	,	_	_	O
15	trabeculectomy	_	_	O
16	and	_	_	O
17	Ahmed	_	_	O
18	glaucoma	_	_	O
19	valve	_	_	O
20	implant	_	_	O
21	.	_	_	O

22	A	_	_	O
23	randomized	_	_	O
24	clinical	_	_	O
25	trial	_	_	O
26	was	_	_	O
27	performed	_	_	O
28	at	_	_	O
29	two	_	_	O
30	international	_	_	O
31	centers	_	_	O
32	.	_	_	O

33	One	_	_	O
34	eye	_	_	O
35	each	_	_	O
36	of	_	_	O
37	consecutive	_	_	O
38	patients	_	_	O
39	requiring	_	_	O
40	glaucoma	_	_	O
41	surgery	_	_	O
42	for	_	_	O
43	intraocular	_	_	O
44	pressure	_	_	O
45	control	_	_	O
46	was	_	_	O
47	randomized	_	_	O
48	to	_	_	O
49	receive	_	_	O
50	either	_	_	O
51	trabeculectomy	_	_	O
52	or	_	_	O
53	the	_	_	O
54	Ahmed	_	_	O
55	implant	_	_	O
56	.	_	_	O

57	Of	_	_	O
58	the	_	_	O
59	117	_	_	O
60	patients	_	_	O
61	,	_	_	O
62	62	_	_	O
63	were	_	_	O
64	randomized	_	_	O
65	to	_	_	O
66	trabeculectomy	_	_	O
67	and	_	_	O
68	55	_	_	O
69	to	_	_	O
70	the	_	_	O
71	Ahmed	_	_	O
72	implant	_	_	O
73	.	_	_	O

74	With	_	_	B-Premise
75	a	_	_	I-Premise
76	mean	_	_	I-Premise
77	follow-up	_	_	I-Premise
78	of	_	_	I-Premise
79	9.7	_	_	I-Premise
80	months	_	_	I-Premise
81	,	_	_	I-Premise
82	the	_	_	I-Premise
83	trabeculectomy	_	_	I-Premise
84	group	_	_	I-Premise
85	had	_	_	I-Premise
86	statistically	_	_	I-Premise
87	lower	_	_	I-Premise
88	intraocular	_	_	I-Premise
89	pressures	_	_	I-Premise
90	at	_	_	I-Premise
91	weeks	_	_	I-Premise
92	6	_	_	I-Premise
93	to	_	_	I-Premise
94	15	_	_	I-Premise
95	(	_	_	I-Premise
96	12.6	_	_	I-Premise
97	mm	_	_	I-Premise
98	Hg	_	_	I-Premise
99	vs	_	_	I-Premise
100	16.4	_	_	I-Premise
101	mm	_	_	I-Premise
102	Hg	_	_	I-Premise
103	)	_	_	I-Premise
104	and	_	_	I-Premise
105	months	_	_	I-Premise
106	11	_	_	I-Premise
107	to	_	_	I-Premise
108	13	_	_	I-Premise
109	(	_	_	I-Premise
110	11.4	_	_	I-Premise
111	mm	_	_	I-Premise
112	Hg	_	_	I-Premise
113	vs	_	_	I-Premise
114	17.2	_	_	I-Premise
115	mm	_	_	I-Premise
116	Hg	_	_	I-Premise
117	)	_	_	I-Premise
118	than	_	_	I-Premise
119	the	_	_	I-Premise
120	Ahmed	_	_	I-Premise
121	implant	_	_	I-Premise
122	group	_	_	I-Premise
123	.	_	_	I-Premise

124	Compared	_	_	B-Premise
125	with	_	_	I-Premise
126	preoperative	_	_	I-Premise
127	status	_	_	I-Premise
128	,	_	_	I-Premise
129	no	_	_	I-Premise
130	statistically	_	_	I-Premise
131	significant	_	_	I-Premise
132	differences	_	_	I-Premise
133	between	_	_	I-Premise
134	groups	_	_	I-Premise
135	were	_	_	I-Premise
136	noted	_	_	I-Premise
137	for	_	_	I-Premise
138	visual	_	_	I-Premise
139	acuity	_	_	I-Premise
140	,	_	_	I-Premise
141	visual	_	_	I-Premise
142	field	_	_	I-Premise
143	,	_	_	I-Premise
144	lens	_	_	I-Premise
145	status	_	_	I-Premise
146	,	_	_	I-Premise
147	and	_	_	I-Premise
148	final	_	_	I-Premise
149	anterior	_	_	I-Premise
150	chamber	_	_	I-Premise
151	depth	_	_	I-Premise
152	.	_	_	I-Premise

153	The	_	_	B-Premise
154	cumulative	_	_	I-Premise
155	probabilities	_	_	I-Premise
156	of	_	_	I-Premise
157	success	_	_	I-Premise
158	(	_	_	I-Premise
159	intraocular	_	_	I-Premise
160	pressure	_	_	I-Premise
161	<	_	_	I-Premise
162	21	_	_	I-Premise
163	mm	_	_	I-Premise
164	Hg	_	_	I-Premise
165	and	_	_	I-Premise
166	at	_	_	I-Premise
167	least	_	_	I-Premise
168	15	_	_	I-Premise
169	%	_	_	I-Premise
170	reduction	_	_	I-Premise
171	in	_	_	I-Premise
172	intraocular	_	_	I-Premise
173	pressure	_	_	I-Premise
174	from	_	_	I-Premise
175	preoperative	_	_	I-Premise
176	level	_	_	I-Premise
177	)	_	_	I-Premise
178	were	_	_	I-Premise
179	83.6	_	_	I-Premise
180	%	_	_	I-Premise
181	for	_	_	I-Premise
182	trabeculectomy	_	_	I-Premise
183	and	_	_	I-Premise
184	88.1	_	_	I-Premise
185	%	_	_	I-Premise
186	for	_	_	I-Premise
187	Ahmed	_	_	I-Premise
188	implant	_	_	I-Premise
189	(	_	_	I-Premise
190	P	_	_	I-Premise
191	=.43	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	However	_	_	O
195	,	_	_	O
196	the	_	_	B-Premise
197	Ahmed	_	_	I-Premise
198	implant	_	_	I-Premise
199	group	_	_	I-Premise
200	had	_	_	I-Premise
201	a	_	_	I-Premise
202	greater	_	_	I-Premise
203	adjunctive	_	_	I-Premise
204	medication	_	_	I-Premise
205	requirement	_	_	I-Premise
206	.	_	_	I-Premise

207	On	_	_	B-Premise
208	the	_	_	I-Premise
209	last	_	_	I-Premise
210	visit	_	_	I-Premise
211	,	_	_	I-Premise
212	10	_	_	I-Premise
213	of	_	_	I-Premise
214	the	_	_	I-Premise
215	trabeculectomy	_	_	I-Premise
216	eyes	_	_	I-Premise
217	and	_	_	I-Premise
218	19	_	_	I-Premise
219	of	_	_	I-Premise
220	the	_	_	I-Premise
221	Ahmed	_	_	I-Premise
222	implant	_	_	I-Premise
223	eyes	_	_	I-Premise
224	required	_	_	I-Premise
225	at	_	_	I-Premise
226	least	_	_	I-Premise
227	one	_	_	I-Premise
228	topical	_	_	I-Premise
229	medication	_	_	I-Premise
230	(	_	_	I-Premise
231	P	_	_	I-Premise
232	=.01	_	_	I-Premise
233	)	_	_	I-Premise
234	.	_	_	I-Premise

235	There	_	_	B-Premise
236	was	_	_	I-Premise
237	no	_	_	I-Premise
238	statistically	_	_	I-Premise
239	significant	_	_	I-Premise
240	difference	_	_	I-Premise
241	in	_	_	I-Premise
242	the	_	_	I-Premise
243	rate	_	_	I-Premise
244	of	_	_	I-Premise
245	complications	_	_	I-Premise
246	between	_	_	I-Premise
247	the	_	_	I-Premise
248	two	_	_	I-Premise
249	groups	_	_	I-Premise
250	.	_	_	I-Premise

251	Lower	_	_	B-Premise
252	mean	_	_	I-Premise
253	intraocular	_	_	I-Premise
254	pressures	_	_	I-Premise
255	were	_	_	I-Premise
256	noted	_	_	I-Premise
257	for	_	_	I-Premise
258	the	_	_	I-Premise
259	trabeculectomy	_	_	I-Premise
260	group	_	_	I-Premise
261	.	_	_	I-Premise

262	All	_	_	B-Premise
263	other	_	_	I-Premise
264	results	_	_	I-Premise
265	,	_	_	I-Premise
266	including	_	_	I-Premise
267	success	_	_	I-Premise
268	(	_	_	I-Premise
269	as	_	_	I-Premise
270	defined	_	_	I-Premise
271	in	_	_	I-Premise
272	this	_	_	I-Premise
273	study	_	_	I-Premise
274	)	_	_	I-Premise
275	and	_	_	I-Premise
276	frequency	_	_	I-Premise
277	of	_	_	I-Premise
278	complications	_	_	I-Premise
279	,	_	_	I-Premise
280	were	_	_	I-Premise
281	comparable	_	_	I-Premise
282	between	_	_	I-Premise
283	the	_	_	I-Premise
284	two	_	_	I-Premise
285	groups	_	_	I-Premise
286	.	_	_	I-Premise


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	(	_	_	O
6	IOP	_	_	O
7	)	_	_	O
8	reducing	_	_	O
9	effect	_	_	O
10	and	_	_	O
11	safety	_	_	O
12	of	_	_	O
13	latanoprost	_	_	O
14	0.005	_	_	O
15	%	_	_	O
16	once	_	_	O
17	daily	_	_	O
18	with	_	_	O
19	unoprostone	_	_	O
20	0.12	_	_	O
21	%	_	_	O
22	twice	_	_	O
23	daily	_	_	O
24	in	_	_	O
25	patients	_	_	O
26	with	_	_	O
27	primary	_	_	O
28	open-angle	_	_	O
29	glaucoma	_	_	O
30	(	_	_	O
31	POAG	_	_	O
32	)	_	_	O
33	or	_	_	O
34	ocular	_	_	O
35	hypertension	_	_	O
36	(	_	_	O
37	OH	_	_	O
38	)	_	_	O
39	.	_	_	O

40	An	_	_	O
41	8-week	_	_	O
42	,	_	_	O
43	double-masked	_	_	O
44	,	_	_	O
45	randomized	_	_	O
46	,	_	_	O
47	parallel-group	_	_	O
48	,	_	_	O
49	single-center	_	_	O
50	clinical	_	_	O
51	trial	_	_	O
52	.	_	_	O

53	A	_	_	O
54	total	_	_	O
55	of	_	_	O
56	108	_	_	O
57	patients	_	_	O
58	with	_	_	O
59	POAG	_	_	O
60	or	_	_	O
61	OH	_	_	O
62	were	_	_	O
63	enrolled	_	_	O
64	.	_	_	O

65	After	_	_	O
66	completing	_	_	O
67	a	_	_	O
68	wash-out	_	_	O
69	of	_	_	O
70	ocular	_	_	O
71	hypotensive	_	_	O
72	medications	_	_	O
73	,	_	_	O
74	patients	_	_	O
75	were	_	_	O
76	randomized	_	_	O
77	to	_	_	O
78	receive	_	_	O
79	either	_	_	O
80	latanoprost	_	_	O
81	once	_	_	O
82	daily	_	_	O
83	in	_	_	O
84	the	_	_	O
85	evening	_	_	O
86	plus	_	_	O
87	placebo	_	_	O
88	once	_	_	O
89	daily	_	_	O
90	in	_	_	O
91	the	_	_	O
92	morning	_	_	O
93	,	_	_	O
94	or	_	_	O
95	unoprostone	_	_	O
96	twice	_	_	O
97	daily	_	_	O
98	(	_	_	O
99	morning	_	_	O
100	and	_	_	O
101	evening	_	_	O
102	)	_	_	O
103	.	_	_	O

104	IOP	_	_	O
105	was	_	_	O
106	measured	_	_	O
107	at	_	_	O
108	10:00	_	_	O
109	AM	_	_	O
110	and	_	_	O
111	at	_	_	O
112	5:00	_	_	O
113	PM	_	_	O
114	at	_	_	O
115	baseline	_	_	O
116	and	_	_	O
117	at	_	_	O
118	week	_	_	O
119	8	_	_	O
120	,	_	_	O
121	and	_	_	O
122	before	_	_	O
123	12:00	_	_	O
124	noon	_	_	O
125	at	_	_	O
126	week	_	_	O
127	2	_	_	O
128	.	_	_	O

129	Ocular	_	_	O
130	and	_	_	O
131	systemic	_	_	O
132	safety	_	_	O
133	assessments	_	_	O
134	were	_	_	O
135	performed	_	_	O
136	.	_	_	O

137	From	_	_	B-Premise
138	an	_	_	I-Premise
139	overall	_	_	I-Premise
140	baseline	_	_	I-Premise
141	of	_	_	I-Premise
142	24.1	_	_	I-Premise
143	mmHg	_	_	I-Premise
144	,	_	_	I-Premise
145	latanoprost	_	_	I-Premise
146	reduced	_	_	I-Premise
147	IOP	_	_	I-Premise
148	by	_	_	I-Premise
149	6.7	_	_	I-Premise
150	mmHg	_	_	I-Premise
151	(	_	_	I-Premise
152	28	_	_	I-Premise
153	%	_	_	I-Premise
154	)	_	_	I-Premise
155	and	_	_	I-Premise
156	unoprostone	_	_	I-Premise
157	reduced	_	_	I-Premise
158	IOP	_	_	I-Premise
159	by	_	_	I-Premise
160	3.3	_	_	I-Premise
161	mmHg	_	_	I-Premise
162	(	_	_	I-Premise
163	14	_	_	I-Premise
164	%	_	_	I-Premise
165	)	_	_	I-Premise
166	.	_	_	I-Premise

167	The	_	_	B-Premise
168	difference	_	_	I-Premise
169	between	_	_	I-Premise
170	the	_	_	I-Premise
171	groups	_	_	I-Premise
172	of	_	_	I-Premise
173	3.4	_	_	I-Premise
174	mmHg	_	_	I-Premise
175	was	_	_	I-Premise
176	significant	_	_	I-Premise
177	(	_	_	I-Premise
178	P	_	_	I-Premise
179	:	_	_	I-Premise
180	<	_	_	I-Premise
181	0.001	_	_	I-Premise
182	,	_	_	I-Premise
183	analysis	_	_	I-Premise
184	of	_	_	I-Premise
185	covariance	_	_	I-Premise
186	;	_	_	I-Premise
187	95	_	_	I-Premise
188	%	_	_	I-Premise
189	confidence	_	_	I-Premise
190	interval	_	_	I-Premise
191	[	_	_	I-Premise
192	CI	_	_	I-Premise
193	]	_	_	I-Premise
194	:	_	_	I-Premise
195	-4.7	_	_	I-Premise
196	to	_	_	I-Premise
197	-2.1	_	_	I-Premise
198	)	_	_	I-Premise
199	in	_	_	I-Premise
200	favor	_	_	I-Premise
201	of	_	_	I-Premise
202	latanoprost	_	_	I-Premise
203	.	_	_	I-Premise

204	A	_	_	B-Premise
205	>	_	_	I-Premise
206	/=30	_	_	I-Premise
207	%	_	_	I-Premise
208	reduction	_	_	I-Premise
209	in	_	_	I-Premise
210	mean	_	_	I-Premise
211	IOP	_	_	I-Premise
212	from	_	_	I-Premise
213	baseline	_	_	I-Premise
214	was	_	_	I-Premise
215	achieved	_	_	I-Premise
216	by	_	_	I-Premise
217	44	_	_	I-Premise
218	%	_	_	I-Premise
219	of	_	_	I-Premise
220	latanoprost-treated	_	_	I-Premise
221	patients	_	_	I-Premise
222	compared	_	_	I-Premise
223	with	_	_	I-Premise
224	8	_	_	I-Premise
225	%	_	_	I-Premise
226	of	_	_	I-Premise
227	unoprostone-treated	_	_	I-Premise
228	patients	_	_	I-Premise
229	.	_	_	I-Premise

230	The	_	_	O
231	incidence	_	_	O
232	of	_	_	O
233	adverse	_	_	O
234	events	_	_	O
235	was	_	_	O
236	low	_	_	O
237	and	_	_	O
238	comparable	_	_	O
239	between	_	_	O
240	the	_	_	O
241	groups	_	_	O
242	.	_	_	O

243	Latanoprost	_	_	B-Claim
244	administered	_	_	I-Claim
245	once	_	_	I-Claim
246	daily	_	_	I-Claim
247	was	_	_	I-Claim
248	significantly	_	_	I-Claim
249	more	_	_	I-Claim
250	effective	_	_	I-Claim
251	in	_	_	I-Claim
252	reducing	_	_	I-Claim
253	IOP	_	_	I-Claim
254	compared	_	_	I-Claim
255	with	_	_	I-Claim
256	unoprostone	_	_	I-Claim
257	administered	_	_	I-Claim
258	twice	_	_	I-Claim
259	daily	_	_	I-Claim
260	in	_	_	I-Claim
261	patients	_	_	I-Claim
262	with	_	_	I-Claim
263	POAG	_	_	I-Claim
264	and	_	_	I-Claim
265	OH	_	_	I-Claim
266	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	latanoprost	_	_	O
8	versus	_	_	O
9	timolol	_	_	O
10	in	_	_	O
11	pediatric	_	_	O
12	patients	_	_	O
13	with	_	_	O
14	glaucoma	_	_	O
15	.	_	_	O

16	Prospective	_	_	O
17	,	_	_	O
18	randomized	_	_	O
19	,	_	_	O
20	double-masked	_	_	O
21	,	_	_	O
22	12-week	_	_	O
23	,	_	_	O
24	multicenter	_	_	O
25	study	_	_	O
26	.	_	_	O

27	Individuals	_	_	O
28	aged	_	_	O
29	<	_	_	O
30	18	_	_	O
31	years	_	_	O
32	with	_	_	O
33	glaucoma	_	_	O
34	.	_	_	O

35	Stratified	_	_	O
36	by	_	_	O
37	age	_	_	O
38	,	_	_	O
39	diagnosis	_	_	O
40	,	_	_	O
41	and	_	_	O
42	intraocular	_	_	O
43	pressure	_	_	O
44	(	_	_	O
45	IOP	_	_	O
46	)	_	_	O
47	level	_	_	O
48	,	_	_	O
49	subjects	_	_	O
50	were	_	_	O
51	randomized	_	_	O
52	(	_	_	O
53	1:1	_	_	O
54	)	_	_	O
55	to	_	_	O
56	latanoprost	_	_	O
57	vehicle	_	_	O
58	at	_	_	O
59	8	_	_	O
60	am	_	_	O
61	and	_	_	O
62	latanoprost	_	_	O
63	0.005	_	_	O
64	%	_	_	O
65	at	_	_	O
66	8	_	_	O
67	pm	_	_	O
68	or	_	_	O
69	timolol	_	_	O
70	0.5	_	_	O
71	%	_	_	O
72	(	_	_	O
73	0.25	_	_	O
74	%	_	_	O
75	for	_	_	O
76	those	_	_	O
77	aged	_	_	O
78	<	_	_	O
79	3	_	_	O
80	years	_	_	O
81	)	_	_	O
82	twice	_	_	O
83	daily	_	_	O
84	(	_	_	O
85	8	_	_	O
86	am	_	_	O
87	,	_	_	O
88	8	_	_	O
89	pm	_	_	O
90	)	_	_	O
91	.	_	_	O

92	At	_	_	O
93	baseline	_	_	O
94	and	_	_	O
95	weeks	_	_	O
96	1	_	_	O
97	,	_	_	O
98	4	_	_	O
99	,	_	_	O
100	and	_	_	O
101	12	_	_	O
102	,	_	_	O
103	IOP	_	_	O
104	and	_	_	O
105	ocular	_	_	O
106	safety	_	_	O
107	were	_	_	O
108	assessed	_	_	O
109	and	_	_	O
110	adverse	_	_	O
111	events	_	_	O
112	were	_	_	O
113	recorded	_	_	O
114	.	_	_	O

115	Therapy	_	_	O
116	was	_	_	O
117	switched	_	_	O
118	to	_	_	O
119	open-label	_	_	O
120	latanoprost	_	_	O
121	pm	_	_	O
122	and	_	_	O
123	timolol	_	_	O
124	am	_	_	O
125	and	_	_	O
126	pm	_	_	O
127	for	_	_	O
128	uncontrolled	_	_	O
129	IOP	_	_	O
130	.	_	_	O

131	Mean	_	_	O
132	IOP	_	_	O
133	reduction	_	_	O
134	from	_	_	O
135	baseline	_	_	O
136	to	_	_	O
137	week	_	_	O
138	12	_	_	O
139	.	_	_	O

140	Latanoprost	_	_	O
141	was	_	_	O
142	considered	_	_	O
143	noninferior	_	_	O
144	to	_	_	O
145	timolol	_	_	O
146	if	_	_	O
147	the	_	_	O
148	lower	_	_	O
149	limit	_	_	O
150	of	_	_	O
151	the	_	_	O
152	95	_	_	O
153	%	_	_	O
154	confidence	_	_	O
155	interval	_	_	O
156	(	_	_	O
157	CI	_	_	O
158	)	_	_	O
159	of	_	_	O
160	the	_	_	O
161	difference	_	_	O
162	was	_	_	O
163	>	_	_	O
164	-3	_	_	O
165	mmHg	_	_	O
166	.	_	_	O

167	A	_	_	O
168	proportion	_	_	O
169	of	_	_	O
170	responders	_	_	O
171	(	_	_	O
172	subjects	_	_	O
173	with	_	_	O
174	15	_	_	O
175	%	_	_	O
176	IOP	_	_	O
177	reduction	_	_	O
178	at	_	_	O
179	weeks	_	_	O
180	4	_	_	O
181	and	_	_	O
182	12	_	_	O
183	)	_	_	O
184	were	_	_	O
185	evaluated	_	_	O
186	.	_	_	O

187	Analyses	_	_	O
188	were	_	_	O
189	performed	_	_	O
190	in	_	_	O
191	diagnosis	_	_	O
192	subgroups	_	_	O
193	:	_	_	O
194	primary	_	_	O
195	congenital	_	_	O
196	glaucoma	_	_	O
197	(	_	_	O
198	PCG	_	_	O
199	)	_	_	O
200	and	_	_	O
201	non-PCG	_	_	O
202	.	_	_	O

203	In	_	_	O
204	total	_	_	O
205	,	_	_	O
206	137	_	_	O
207	subjects	_	_	O
208	were	_	_	O
209	treated	_	_	O
210	(	_	_	O
211	safety	_	_	O
212	population	_	_	O
213	;	_	_	O
214	12-18	_	_	O
215	years	_	_	O
216	,	_	_	O
217	n=48	_	_	O
218	;	_	_	O
219	3-	_	_	O
220	<	_	_	O
221	12	_	_	O
222	years	_	_	O
223	,	_	_	O
224	n=55	_	_	O
225	;	_	_	O
226	0-	_	_	O
227	<	_	_	O
228	3	_	_	O
229	years	_	_	O
230	,	_	_	O
231	n=34	_	_	O
232	)	_	_	O
233	.	_	_	O

234	Mean	_	_	O
235	age	_	_	O
236	was	_	_	O
237	8.8±5.5	_	_	O
238	years	_	_	O
239	,	_	_	O
240	and	_	_	O
241	mean	_	_	O
242	baseline	_	_	O
243	IOP	_	_	O
244	was	_	_	O
245	27.7±6.17	_	_	O
246	mmHg	_	_	O
247	;	_	_	O
248	125	_	_	O
249	subjects	_	_	O
250	completed	_	_	O
251	the	_	_	O
252	study	_	_	O
253	,	_	_	O
254	and	_	_	O
255	107	_	_	O
256	subjects	_	_	O
257	were	_	_	O
258	in	_	_	O
259	the	_	_	O
260	per	_	_	O
261	protocol	_	_	O
262	population	_	_	O
263	.	_	_	O

264	Mean	_	_	B-Premise
265	IOP	_	_	I-Premise
266	reductions	_	_	I-Premise
267	for	_	_	I-Premise
268	latanoprost	_	_	I-Premise
269	and	_	_	I-Premise
270	timolol	_	_	I-Premise
271	at	_	_	I-Premise
272	week	_	_	I-Premise
273	12	_	_	I-Premise
274	were	_	_	I-Premise
275	7.2	_	_	I-Premise
276	and	_	_	I-Premise
277	5.7	_	_	I-Premise
278	mmHg	_	_	I-Premise
279	,	_	_	I-Premise
280	respectively	_	_	I-Premise
281	,	_	_	I-Premise
282	with	_	_	I-Premise
283	a	_	_	I-Premise
284	difference	_	_	I-Premise
285	of	_	_	I-Premise
286	1.5	_	_	I-Premise
287	mmHg	_	_	I-Premise
288	(	_	_	I-Premise
289	95	_	_	I-Premise
290	%	_	_	I-Premise
291	CI	_	_	I-Premise
292	,	_	_	I-Premise
293	-0.8	_	_	I-Premise
294	to	_	_	I-Premise
295	3.7	_	_	I-Premise
296	;	_	_	I-Premise
297	P=0.21	_	_	I-Premise
298	)	_	_	I-Premise
299	.	_	_	I-Premise

300	Responder	_	_	B-Premise
301	rates	_	_	I-Premise
302	were	_	_	I-Premise
303	60	_	_	I-Premise
304	%	_	_	I-Premise
305	for	_	_	I-Premise
306	latanoprost	_	_	I-Premise
307	and	_	_	I-Premise
308	52	_	_	I-Premise
309	%	_	_	I-Premise
310	for	_	_	I-Premise
311	timolol	_	_	I-Premise
312	(	_	_	I-Premise
313	P=0.33	_	_	I-Premise
314	)	_	_	I-Premise
315	.	_	_	I-Premise

316	Between-treatment	_	_	B-Premise
317	differences	_	_	I-Premise
318	in	_	_	I-Premise
319	mean	_	_	I-Premise
320	IOP	_	_	I-Premise
321	reduction	_	_	I-Premise
322	for	_	_	I-Premise
323	PCG	_	_	I-Premise
324	and	_	_	I-Premise
325	non-PCG	_	_	I-Premise
326	subgroups	_	_	I-Premise
327	were	_	_	I-Premise
328	0.6	_	_	I-Premise
329	mmHg	_	_	I-Premise
330	(	_	_	I-Premise
331	95	_	_	I-Premise
332	%	_	_	I-Premise
333	CI	_	_	I-Premise
334	,	_	_	I-Premise
335	-2.3	_	_	I-Premise
336	to	_	_	I-Premise
337	3.4	_	_	I-Premise
338	)	_	_	I-Premise
339	and	_	_	I-Premise
340	2.6	_	_	I-Premise
341	mmHg	_	_	I-Premise
342	(	_	_	I-Premise
343	95	_	_	I-Premise
344	%	_	_	I-Premise
345	CI	_	_	I-Premise
346	,	_	_	I-Premise
347	-0.8	_	_	I-Premise
348	to	_	_	I-Premise
349	6.1	_	_	I-Premise
350	)	_	_	I-Premise
351	,	_	_	I-Premise
352	respectively	_	_	I-Premise
353	.	_	_	I-Premise

354	Responder	_	_	B-Premise
355	rates	_	_	I-Premise
356	for	_	_	I-Premise
357	latanoprost	_	_	I-Premise
358	versus	_	_	I-Premise
359	timolol	_	_	I-Premise
360	were	_	_	I-Premise
361	50	_	_	I-Premise
362	%	_	_	I-Premise
363	versus	_	_	I-Premise
364	46	_	_	I-Premise
365	%	_	_	I-Premise
366	for	_	_	I-Premise
367	the	_	_	I-Premise
368	PCG	_	_	I-Premise
369	group	_	_	I-Premise
370	and	_	_	I-Premise
371	72	_	_	I-Premise
372	%	_	_	I-Premise
373	versus	_	_	I-Premise
374	57	_	_	I-Premise
375	%	_	_	I-Premise
376	for	_	_	I-Premise
377	the	_	_	I-Premise
378	non-PCG	_	_	I-Premise
379	group	_	_	I-Premise
380	.	_	_	I-Premise

381	Both	_	_	B-Claim
382	therapies	_	_	I-Claim
383	were	_	_	I-Claim
384	well	_	_	I-Claim
385	tolerated	_	_	I-Claim
386	.	_	_	I-Claim

387	Latanoprost	_	_	B-Claim
388	0.005	_	_	I-Claim
389	%	_	_	I-Claim
390	is	_	_	I-Claim
391	not	_	_	I-Claim
392	inferior	_	_	I-Claim
393	(	_	_	I-Claim
394	i.e.	_	_	I-Claim
395	,	_	_	I-Claim
396	is	_	_	I-Claim
397	either	_	_	I-Claim
398	more	_	_	I-Claim
399	or	_	_	I-Claim
400	similarly	_	_	I-Claim
401	effective	_	_	I-Claim
402	)	_	_	I-Claim
403	to	_	_	I-Claim
404	timolol	_	_	I-Claim
405	and	_	_	I-Claim
406	produces	_	_	I-Claim
407	clinically	_	_	I-Claim
408	relevant	_	_	I-Claim
409	IOP	_	_	I-Claim
410	reductions	_	_	I-Claim
411	across	_	_	I-Claim
412	pediatric	_	_	I-Claim
413	patients	_	_	I-Claim
414	with	_	_	I-Claim
415	and	_	_	I-Claim
416	without	_	_	I-Claim
417	PCG	_	_	I-Claim
418	.	_	_	I-Claim

419	Both	_	_	B-Claim
420	latanoprost	_	_	I-Claim
421	and	_	_	I-Claim
422	timolol	_	_	I-Claim
423	had	_	_	I-Claim
424	favorable	_	_	I-Claim
425	safety	_	_	I-Claim
426	profiles	_	_	I-Claim
427	over	_	_	I-Claim
428	the	_	_	I-Claim
429	duration	_	_	I-Claim
430	of	_	_	I-Claim
431	this	_	_	I-Claim
432	3-month	_	_	I-Claim
433	trial	_	_	I-Claim
434	.	_	_	I-Claim


0	The	_	_	O
1	purpose	_	_	O
2	of	_	_	O
3	this	_	_	O
4	study	_	_	O
5	is	_	_	O
6	to	_	_	O
7	compare	_	_	O
8	the	_	_	O
9	safety	_	_	O
10	and	_	_	O
11	intraocular	_	_	O
12	pressure	_	_	O
13	(	_	_	O
14	IOP	_	_	O
15	)	_	_	O
16	-lowering	_	_	O
17	efficacy	_	_	O
18	of	_	_	O
19	travoprost/timolol	_	_	O
20	in	_	_	O
21	a	_	_	O
22	benzalkonium	_	_	O
23	chloride	_	_	O
24	(	_	_	O
25	BAK	_	_	O
26	)	_	_	O
27	-free	_	_	O
28	fixed	_	_	O
29	combination	_	_	O
30	preserved	_	_	O
31	with	_	_	O
32	polyquaternium-1	_	_	O
33	(	_	_	O
34	TRA/TIM	_	_	O
35	BAK-free	_	_	O
36	)	_	_	O
37	,	_	_	O
38	with	_	_	O
39	travoprost/timolol-fixed	_	_	O
40	combination	_	_	O
41	preserved	_	_	O
42	with	_	_	O
43	BAK	_	_	O
44	(	_	_	O
45	TRA/TIM	_	_	O
46	)	_	_	O
47	,	_	_	O
48	in	_	_	O
49	patients	_	_	O
50	with	_	_	O
51	open-angle	_	_	O
52	glaucoma	_	_	O
53	or	_	_	O
54	ocular	_	_	O
55	hypertension	_	_	O
56	.	_	_	O

57	In	_	_	O
58	this	_	_	O
59	prospective	_	_	O
60	randomized	_	_	O
61	controlled	_	_	O
62	trial	_	_	O
63	,	_	_	O
64	subjects	_	_	O
65	with	_	_	O
66	IOP	_	_	O
67	of	_	_	O
68	at	_	_	O
69	least	_	_	O
70	22	_	_	O
71	mm	_	_	O
72	Hg	_	_	O
73	in	_	_	O
74	one	_	_	O
75	or	_	_	O
76	both	_	_	O
77	eyes	_	_	O
78	at	_	_	O
79	0900	_	_	O
80	h	_	_	O
81	,	_	_	O
82	and	_	_	O
83	IOP	_	_	O
84	of	_	_	O
85	at	_	_	O
86	least	_	_	O
87	21	_	_	O
88	mm	_	_	O
89	Hg	_	_	O
90	in	_	_	O
91	one	_	_	O
92	or	_	_	O
93	both	_	_	O
94	eyes	_	_	O
95	at	_	_	O
96	1100	_	_	O
97	h	_	_	O
98	and	_	_	O
99	1600	_	_	O
100	h	_	_	O
101	at	_	_	O
102	two	_	_	O
103	eligibility	_	_	O
104	visits	_	_	O
105	were	_	_	O
106	randomly	_	_	O
107	assigned	_	_	O
108	to	_	_	O
109	receive	_	_	O
110	either	_	_	O
111	TRA/TIM	_	_	O
112	BAK-free	_	_	O
113	(	_	_	O
114	n=195	_	_	O
115	)	_	_	O
116	or	_	_	O
117	TRA/TIM	_	_	O
118	(	_	_	O
119	n=193	_	_	O
120	)	_	_	O
121	,	_	_	O
122	dosed	_	_	O
123	once	_	_	O
124	daily	_	_	O
125	in	_	_	O
126	the	_	_	O
127	morning	_	_	O
128	(	_	_	O
129	0900	_	_	O
130	h	_	_	O
131	)	_	_	O
132	for	_	_	O
133	6	_	_	O
134	weeks	_	_	O
135	.	_	_	O

136	IOP	_	_	O
137	was	_	_	O
138	assessed	_	_	O
139	at	_	_	O
140	0900	_	_	O
141	h	_	_	O
142	,	_	_	O
143	1100	_	_	O
144	h	_	_	O
145	,	_	_	O
146	and	_	_	O
147	1600	_	_	O
148	h	_	_	O
149	at	_	_	O
150	each	_	_	O
151	scheduled	_	_	O
152	visit	_	_	O
153	(	_	_	O
154	baseline	_	_	O
155	,	_	_	O
156	2	_	_	O
157	and	_	_	O
158	6	_	_	O
159	weeks	_	_	O
160	after	_	_	O
161	randomization	_	_	O
162	)	_	_	O
163	.	_	_	O

164	Mean	_	_	B-Premise
165	IOP	_	_	I-Premise
166	reduction	_	_	I-Premise
167	across	_	_	I-Premise
168	all	_	_	I-Premise
169	visits	_	_	I-Premise
170	and	_	_	I-Premise
171	time	_	_	I-Premise
172	points	_	_	I-Premise
173	was	_	_	I-Premise
174	8.0	_	_	I-Premise
175	mm	_	_	I-Premise
176	Hg	_	_	I-Premise
177	in	_	_	I-Premise
178	the	_	_	I-Premise
179	TRA/TIM	_	_	I-Premise
180	BAK-free	_	_	I-Premise
181	group	_	_	I-Premise
182	and	_	_	I-Premise
183	8.4	_	_	I-Premise
184	mm	_	_	I-Premise
185	Hg	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	TRA/TIM	_	_	I-Premise
189	group	_	_	I-Premise
190	(	_	_	I-Premise
191	P=0.0943	_	_	I-Premise
192	)	_	_	I-Premise
193	.	_	_	I-Premise

194	The	_	_	B-Premise
195	difference	_	_	I-Premise
196	in	_	_	I-Premise
197	mean	_	_	I-Premise
198	IOP	_	_	I-Premise
199	between	_	_	I-Premise
200	groups	_	_	I-Premise
201	ranged	_	_	I-Premise
202	from	_	_	I-Premise
203	0.2	_	_	I-Premise
204	to	_	_	I-Premise
205	0.7	_	_	I-Premise
206	mm	_	_	I-Premise
207	Hg	_	_	I-Premise
208	across	_	_	I-Premise
209	visits	_	_	I-Premise
210	and	_	_	I-Premise
211	time	_	_	I-Premise
212	points	_	_	I-Premise
213	,	_	_	I-Premise
214	with	_	_	I-Premise
215	a	_	_	I-Premise
216	mean	_	_	I-Premise
217	pooled	_	_	I-Premise
218	difference	_	_	I-Premise
219	of	_	_	I-Premise
220	0.4	_	_	I-Premise
221	mm	_	_	I-Premise
222	Hg	_	_	I-Premise
223	(	_	_	I-Premise
224	95	_	_	I-Premise
225	%	_	_	I-Premise
226	CI	_	_	I-Premise
227	:	_	_	I-Premise
228	-0.1	_	_	I-Premise
229	to	_	_	I-Premise
230	0.8	_	_	I-Premise
231	)	_	_	I-Premise
232	,	_	_	I-Premise
233	demonstrating	_	_	O
234	equivalence	_	_	O
235	of	_	_	O
236	the	_	_	O
237	two	_	_	O
238	formulations	_	_	O
239	.	_	_	O

240	The	_	_	B-Premise
241	most	_	_	I-Premise
242	common	_	_	I-Premise
243	drug-related	_	_	I-Premise
244	adverse	_	_	I-Premise
245	event	_	_	I-Premise
246	was	_	_	I-Premise
247	hyperemia	_	_	I-Premise
248	of	_	_	I-Premise
249	the	_	_	I-Premise
250	eye	_	_	I-Premise
251	(	_	_	I-Premise
252	ocular	_	_	I-Premise
253	hyperemia	_	_	I-Premise
254	and	_	_	I-Premise
255	conjunctival	_	_	I-Premise
256	hyperemia	_	_	I-Premise
257	combined	_	_	I-Premise
258	)	_	_	I-Premise
259	,	_	_	I-Premise
260	occurring	_	_	I-Premise
261	in	_	_	I-Premise
262	11.8	_	_	I-Premise
263	%	_	_	I-Premise
264	of	_	_	I-Premise
265	the	_	_	I-Premise
266	TRA/TIM	_	_	I-Premise
267	BAK-free	_	_	I-Premise
268	group	_	_	I-Premise
269	and	_	_	I-Premise
270	13.0	_	_	I-Premise
271	%	_	_	I-Premise
272	of	_	_	I-Premise
273	the	_	_	I-Premise
274	TRA/TIM	_	_	I-Premise
275	group	_	_	I-Premise
276	.	_	_	I-Premise

277	Travoprost/timolol	_	_	B-Claim
278	BAK-free	_	_	I-Claim
279	demonstrated	_	_	I-Claim
280	equivalence	_	_	I-Claim
281	to	_	_	I-Claim
282	travoprost/timolol	_	_	I-Claim
283	preserved	_	_	I-Claim
284	with	_	_	I-Claim
285	BAK	_	_	I-Claim
286	in	_	_	I-Claim
287	efficacy	_	_	I-Claim
288	.	_	_	I-Claim

289	No	_	_	B-Claim
290	clinically	_	_	I-Claim
291	relevant	_	_	I-Claim
292	differences	_	_	I-Claim
293	in	_	_	I-Claim
294	the	_	_	I-Claim
295	safety	_	_	I-Claim
296	profiles	_	_	I-Claim
297	of	_	_	I-Claim
298	travoprost/timolol	_	_	I-Claim
299	BAK-free	_	_	I-Claim
300	and	_	_	I-Claim
301	travoprost/timolol	_	_	I-Claim
302	preserved	_	_	I-Claim
303	with	_	_	I-Claim
304	BAK	_	_	I-Claim
305	were	_	_	I-Claim
306	identified	_	_	I-Claim
307	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	treatment	_	_	O
6	with	_	_	O
7	latanoprost	_	_	O
8	or	_	_	O
9	brimonidine	_	_	O
10	on	_	_	O
11	intraocular	_	_	O
12	pressure	_	_	O
13	in	_	_	O
14	patients	_	_	O
15	with	_	_	O
16	glaucoma	_	_	O
17	or	_	_	O
18	ocular	_	_	O
19	hypertension	_	_	O
20	and	_	_	O
21	intraocular	_	_	O
22	pressure	_	_	O
23	inadequately	_	_	O
24	controlled	_	_	O
25	by	_	_	O
26	monotherapy	_	_	O
27	or	_	_	O
28	dual	_	_	O
29	therapy	_	_	O
30	.	_	_	O

31	Three	_	_	O
32	hundred	_	_	O
33	seventy-nine	_	_	O
34	patients	_	_	O
35	with	_	_	O
36	primary	_	_	O
37	open-angle	_	_	O
38	glaucoma	_	_	O
39	or	_	_	O
40	ocular	_	_	O
41	hypertension	_	_	O
42	were	_	_	O
43	recruited	_	_	O
44	for	_	_	O
45	this	_	_	O
46	6-month	_	_	O
47	prospective	_	_	O
48	,	_	_	O
49	randomized	_	_	O
50	,	_	_	O
51	observer-masked	_	_	O
52	multicenter	_	_	O
53	study	_	_	O
54	involving	_	_	O
55	30	_	_	O
56	eye	_	_	O
57	clinics	_	_	O
58	.	_	_	O

59	All	_	_	O
60	patients	_	_	O
61	were	_	_	O
62	receiving	_	_	O
63	monotherapy	_	_	O
64	or	_	_	O
65	dual	_	_	O
66	therapy	_	_	O
67	that	_	_	O
68	did	_	_	O
69	not	_	_	O
70	adequately	_	_	O
71	control	_	_	O
72	intraocular	_	_	O
73	pressure	_	_	O
74	.	_	_	O

75	After	_	_	O
76	appropriate	_	_	O
77	washout	_	_	O
78	periods	_	_	O
79	,	_	_	O
80	patients	_	_	O
81	were	_	_	O
82	randomized	_	_	O
83	to	_	_	O
84	treatment	_	_	O
85	with	_	_	O
86	latanoprost	_	_	O
87	once	_	_	O
88	daily	_	_	O
89	or	_	_	O
90	brimonidine	_	_	O
91	twice	_	_	O
92	daily	_	_	O
93	.	_	_	O

94	The	_	_	O
95	main	_	_	O
96	outcome	_	_	O
97	measure	_	_	O
98	was	_	_	O
99	change	_	_	O
100	in	_	_	O
101	mean	_	_	O
102	diurnal	_	_	O
103	intraocular	_	_	O
104	pressure	_	_	O
105	after	_	_	O
106	6	_	_	O
107	months	_	_	O
108	of	_	_	O
109	treatment	_	_	O
110	compared	_	_	O
111	with	_	_	O
112	baseline	_	_	O
113	.	_	_	O

114	Of	_	_	O
115	the	_	_	O
116	379	_	_	O
117	randomized	_	_	O
118	patients	_	_	O
119	,	_	_	O
120	375	_	_	O
121	were	_	_	O
122	included	_	_	O
123	in	_	_	O
124	the	_	_	O
125	intent-to-treat	_	_	O
126	analysis	_	_	O
127	.	_	_	O

128	From	_	_	B-Premise
129	an	_	_	I-Premise
130	overall	_	_	I-Premise
131	baseline	_	_	I-Premise
132	mean	_	_	I-Premise
133	intraocular	_	_	I-Premise
134	pressure	_	_	I-Premise
135	of	_	_	I-Premise
136	25.0	_	_	I-Premise
137	mm	_	_	I-Premise
138	Hg	_	_	I-Premise
139	,	_	_	I-Premise
140	latanoprost	_	_	I-Premise
141	monotherapy	_	_	I-Premise
142	reduced	_	_	I-Premise
143	mean	_	_	I-Premise
144	diurnal	_	_	I-Premise
145	intraocular	_	_	I-Premise
146	pressure	_	_	I-Premise
147	by	_	_	I-Premise
148	7.1	_	_	I-Premise
149	+/-	_	_	I-Premise
150	3.3	_	_	I-Premise
151	mm	_	_	I-Premise
152	Hg	_	_	I-Premise
153	(	_	_	I-Premise
154	mean	_	_	I-Premise
155	+/-	_	_	I-Premise
156	SD	_	_	I-Premise
157	,	_	_	I-Premise
158	P	_	_	I-Premise
159	<	_	_	I-Premise
160	0.001	_	_	I-Premise
161	)	_	_	I-Premise
162	,	_	_	I-Premise
163	whereas	_	_	I-Premise
164	brimonidine	_	_	I-Premise
165	monotherapy	_	_	I-Premise
166	yielded	_	_	I-Premise
167	an	_	_	I-Premise
168	intraocular-pressure	_	_	I-Premise
169	reduction	_	_	I-Premise
170	of	_	_	I-Premise
171	5.2	_	_	I-Premise
172	+/-	_	_	I-Premise
173	3.5	_	_	I-Premise
174	mm	_	_	I-Premise
175	Hg	_	_	I-Premise
176	(	_	_	I-Premise
177	P	_	_	I-Premise
178	<	_	_	I-Premise
179	0.001	_	_	I-Premise
180	)	_	_	I-Premise
181	.	_	_	I-Premise

182	This	_	_	B-Premise
183	1.9	_	_	I-Premise
184	mm	_	_	I-Premise
185	Hg	_	_	I-Premise
186	difference	_	_	I-Premise
187	in	_	_	I-Premise
188	intraocular-pressure	_	_	I-Premise
189	reduction	_	_	I-Premise
190	was	_	_	I-Premise
191	significantly	_	_	I-Premise
192	in	_	_	I-Premise
193	favor	_	_	I-Premise
194	of	_	_	I-Premise
195	latanoprost	_	_	I-Premise
196	(	_	_	I-Premise
197	P	_	_	I-Premise
198	<	_	_	I-Premise
199	0.001	_	_	I-Premise
200	)	_	_	I-Premise
201	.	_	_	I-Premise

202	Ocular	_	_	B-Premise
203	allergy	_	_	I-Premise
204	(	_	_	I-Premise
205	P	_	_	I-Premise
206	<	_	_	I-Premise
207	0.001	_	_	I-Premise
208	)	_	_	I-Premise
209	and	_	_	I-Premise
210	systemic	_	_	I-Premise
211	side	_	_	I-Premise
212	effects	_	_	I-Premise
213	(	_	_	I-Premise
214	P	_	_	I-Premise
215	=	_	_	I-Premise
216	0.005	_	_	I-Premise
217	)	_	_	I-Premise
218	were	_	_	I-Premise
219	reported	_	_	I-Premise
220	significantly	_	_	I-Premise
221	less	_	_	I-Premise
222	frequently	_	_	I-Premise
223	by	_	_	I-Premise
224	latanoprost-treated	_	_	I-Premise
225	patients	_	_	I-Premise
226	compared	_	_	I-Premise
227	with	_	_	I-Premise
228	brimonidine-treated	_	_	I-Premise
229	patients	_	_	I-Premise
230	.	_	_	I-Premise

231	Both	_	_	B-Claim
232	latanoprost	_	_	I-Claim
233	and	_	_	I-Claim
234	brimonidine	_	_	I-Claim
235	reduced	_	_	I-Claim
236	intraocular	_	_	I-Claim
237	pressure	_	_	I-Claim
238	in	_	_	I-Claim
239	patients	_	_	I-Claim
240	with	_	_	I-Claim
241	glaucoma	_	_	I-Claim
242	or	_	_	I-Claim
243	ocular	_	_	I-Claim
244	hypertension	_	_	I-Claim
245	after	_	_	I-Claim
246	6	_	_	I-Claim
247	months	_	_	I-Claim
248	of	_	_	I-Claim
249	treatment	_	_	I-Claim
250	.	_	_	I-Claim

251	However	_	_	B-Claim
252	,	_	_	I-Claim
253	latanoprost	_	_	I-Claim
254	once	_	_	I-Claim
255	daily	_	_	I-Claim
256	was	_	_	I-Claim
257	significantly	_	_	I-Claim
258	more	_	_	I-Claim
259	effective	_	_	I-Claim
260	than	_	_	I-Claim
261	brimonidine	_	_	I-Claim
262	twice	_	_	I-Claim
263	daily	_	_	I-Claim
264	in	_	_	I-Claim
265	reducing	_	_	I-Claim
266	mean	_	_	I-Claim
267	diurnal	_	_	I-Claim
268	intraocular	_	_	I-Claim
269	pressure	_	_	I-Claim
270	.	_	_	I-Claim

271	Latanoprost	_	_	B-Claim
272	was	_	_	I-Claim
273	better	_	_	I-Claim
274	tolerated	_	_	I-Claim
275	with	_	_	I-Claim
276	less	_	_	I-Claim
277	frequently	_	_	I-Claim
278	occurring	_	_	I-Claim
279	ocular	_	_	I-Claim
280	allergy	_	_	I-Claim
281	and	_	_	I-Claim
282	systemic	_	_	I-Claim
283	side	_	_	I-Claim
284	effects	_	_	I-Claim
285	.	_	_	I-Claim


0	To	_	_	O
1	assess	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure-lowering	_	_	O
5	efficacy	_	_	O
6	and	_	_	O
7	the	_	_	O
8	postoperative	_	_	O
9	complication	_	_	O
10	profile	_	_	O
11	of	_	_	O
12	viscocanalostomy	_	_	O
13	versus	_	_	O
14	trabeculectomy	_	_	O
15	.	_	_	O

16	Sixty	_	_	O
17	eyes	_	_	O
18	of	_	_	O
19	60	_	_	O
20	patients	_	_	O
21	with	_	_	O
22	medically	_	_	O
23	uncontrolled	_	_	O
24	open-angle	_	_	O
25	glaucoma	_	_	O
26	were	_	_	O
27	randomized	_	_	O
28	either	_	_	O
29	to	_	_	O
30	the	_	_	O
31	viscocanalostomy	_	_	O
32	or	_	_	O
33	to	_	_	O
34	the	_	_	O
35	trabeculectomy	_	_	O
36	group	_	_	O
37	of	_	_	O
38	the	_	_	O
39	trial	_	_	O
40	.	_	_	O

41	Viscocanalostomy	_	_	O
42	was	_	_	O
43	performed	_	_	O
44	according	_	_	O
45	to	_	_	O
46	Stegmann	_	_	O
47	's	_	_	O
48	technique	_	_	O
49	using	_	_	O
50	high-molecular-weight	_	_	O
51	sodium	_	_	O
52	hyaluronate	_	_	O
53	to	_	_	O
54	fill	_	_	O
55	the	_	_	O
56	ostia	_	_	O
57	of	_	_	O
58	the	_	_	O
59	Schlemm	_	_	O
60	canal	_	_	O
61	.	_	_	O

62	For	_	_	O
63	trabeculectomy	_	_	O
64	,	_	_	O
65	a	_	_	O
66	modified	_	_	O
67	Cairns-trabeculectomy	_	_	O
68	was	_	_	O
69	performed	_	_	O
70	.	_	_	O

71	Examinations	_	_	O
72	were	_	_	O
73	performed	_	_	O
74	before	_	_	O
75	surgery	_	_	O
76	and	_	_	O
77	postoperatively	_	_	O
78	daily	_	_	O
79	for	_	_	O
80	1	_	_	O
81	week	_	_	O
82	.	_	_	O

83	Follow-up	_	_	O
84	visits	_	_	O
85	were	_	_	O
86	scheduled	_	_	O
87	1	_	_	O
88	,	_	_	O
89	6	_	_	O
90	,	_	_	O
91	and	_	_	O
92	12	_	_	O
93	months	_	_	O
94	after	_	_	O
95	surgery	_	_	O
96	.	_	_	O

97	The	_	_	O
98	mean	_	_	O
99	(	_	_	O
100	SD	_	_	O
101	)	_	_	O
102	preoperative	_	_	O
103	intraocular	_	_	O
104	pressure	_	_	O
105	was	_	_	O
106	27.1	_	_	O
107	(	_	_	O
108	7.1	_	_	O
109	)	_	_	O
110	mm	_	_	O
111	Hg	_	_	O
112	for	_	_	O
113	all	_	_	O
114	patients	_	_	O
115	enrolled	_	_	O
116	.	_	_	O

117	One	_	_	B-Premise
118	day	_	_	I-Premise
119	after	_	_	I-Premise
120	surgery	_	_	I-Premise
121	,	_	_	I-Premise
122	mean	_	_	I-Premise
123	(	_	_	I-Premise
124	SD	_	_	I-Premise
125	)	_	_	I-Premise
126	intraocular	_	_	I-Premise
127	pressure	_	_	I-Premise
128	was	_	_	I-Premise
129	15.9	_	_	I-Premise
130	(	_	_	I-Premise
131	5.2	_	_	I-Premise
132	)	_	_	I-Premise
133	for	_	_	I-Premise
134	the	_	_	I-Premise
135	trabeculectomy	_	_	I-Premise
136	group	_	_	I-Premise
137	(	_	_	I-Premise
138	P	_	_	I-Premise
139	<	_	_	I-Premise
140	0.001	_	_	I-Premise
141	)	_	_	I-Premise
142	and	_	_	I-Premise
143	15.7	_	_	I-Premise
144	(	_	_	I-Premise
145	3.6	_	_	I-Premise
146	)	_	_	I-Premise
147	for	_	_	I-Premise
148	the	_	_	I-Premise
149	viscocanalostomy	_	_	I-Premise
150	group	_	_	I-Premise
151	(	_	_	I-Premise
152	P	_	_	I-Premise
153	<	_	_	I-Premise
154	0.001	_	_	I-Premise
155	)	_	_	I-Premise
156	,	_	_	I-Premise
157	respectively	_	_	I-Premise
158	.	_	_	I-Premise

159	The	_	_	B-Premise
160	success	_	_	I-Premise
161	rate	_	_	I-Premise
162	,	_	_	I-Premise
163	defined	_	_	I-Premise
164	as	_	_	I-Premise
165	an	_	_	I-Premise
166	intraocular	_	_	I-Premise
167	pressure	_	_	I-Premise
168	lower	_	_	I-Premise
169	than	_	_	I-Premise
170	22	_	_	I-Premise
171	mm	_	_	I-Premise
172	Hg	_	_	I-Premise
173	without	_	_	I-Premise
174	medication	_	_	I-Premise
175	,	_	_	I-Premise
176	was	_	_	I-Premise
177	56.7	_	_	I-Premise
178	%	_	_	I-Premise
179	in	_	_	I-Premise
180	the	_	_	I-Premise
181	trabeculectomy	_	_	I-Premise
182	group	_	_	I-Premise
183	and	_	_	I-Premise
184	30	_	_	I-Premise
185	%	_	_	I-Premise
186	in	_	_	I-Premise
187	the	_	_	I-Premise
188	viscocanalostomy	_	_	I-Premise
189	group	_	_	I-Premise
190	at	_	_	I-Premise
191	12	_	_	I-Premise
192	months	_	_	I-Premise
193	postoperatively	_	_	I-Premise
194	(	_	_	I-Premise
195	P	_	_	I-Premise
196	=	_	_	I-Premise
197	0.041	_	_	I-Premise
198	)	_	_	I-Premise
199	.	_	_	I-Premise

200	The	_	_	B-Premise
201	number	_	_	I-Premise
202	of	_	_	I-Premise
203	postoperative	_	_	I-Premise
204	complications	_	_	I-Premise
205	was	_	_	I-Premise
206	lower	_	_	I-Premise
207	in	_	_	I-Premise
208	the	_	_	I-Premise
209	viscocanalostomy	_	_	I-Premise
210	group	_	_	I-Premise
211	than	_	_	I-Premise
212	in	_	_	I-Premise
213	the	_	_	I-Premise
214	trabeculectomy	_	_	I-Premise
215	group	_	_	I-Premise
216	.	_	_	I-Premise

217	In	_	_	B-Claim
218	eyes	_	_	I-Claim
219	with	_	_	I-Claim
220	open-angle	_	_	I-Claim
221	glaucoma	_	_	I-Claim
222	,	_	_	I-Claim
223	viscocanalostomy	_	_	I-Claim
224	is	_	_	I-Claim
225	less	_	_	I-Claim
226	effective	_	_	I-Claim
227	in	_	_	I-Claim
228	reducing	_	_	I-Claim
229	intraocular	_	_	I-Claim
230	pressure	_	_	I-Claim
231	than	_	_	I-Claim
232	standard	_	_	I-Claim
233	filtering	_	_	I-Claim
234	surgery	_	_	I-Claim
235	.	_	_	I-Claim

236	However	_	_	O
237	,	_	_	O
238	postoperative	_	_	B-Claim
239	complications	_	_	I-Claim
240	are	_	_	I-Claim
241	more	_	_	I-Claim
242	frequent	_	_	I-Claim
243	after	_	_	I-Claim
244	filtering	_	_	I-Claim
245	surgery	_	_	I-Claim
246	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	intraocular	_	_	O
4	pressure	_	_	O
5	(	_	_	O
6	IOP	_	_	O
7	)	_	_	O
8	-lowering	_	_	O
9	effect	_	_	O
10	and	_	_	O
11	safety	_	_	O
12	of	_	_	O
13	latanoprost	_	_	O
14	0.005	_	_	O
15	%	_	_	O
16	once	_	_	O
17	daily	_	_	O
18	with	_	_	O
19	that	_	_	O
20	of	_	_	O
21	unoprostone	_	_	O
22	0.15	_	_	O
23	%	_	_	O
24	twice	_	_	O
25	daily	_	_	O
26	for	_	_	O
27	patients	_	_	O
28	with	_	_	O
29	primary	_	_	O
30	open-angle	_	_	O
31	glaucoma	_	_	O
32	or	_	_	O
33	ocular	_	_	O
34	hypertension	_	_	O
35	.	_	_	O

36	Randomized	_	_	O
37	clinical	_	_	O
38	trial	_	_	O
39	.	_	_	O

40	In	_	_	O
41	a	_	_	O
42	prospective	_	_	O
43	,	_	_	O
44	8-week	_	_	O
45	,	_	_	O
46	investigator-masked	_	_	O
47	,	_	_	O
48	parallel-group	_	_	O
49	study	_	_	O
50	conducted	_	_	O
51	at	_	_	O
52	numerous	_	_	O
53	centers	_	_	O
54	in	_	_	O
55	the	_	_	O
56	United	_	_	O
57	States	_	_	O
58	,	_	_	O
59	165	_	_	O
60	previously	_	_	O
61	treated	_	_	O
62	patients	_	_	O
63	with	_	_	O
64	IOP	_	_	O
65	>	_	_	O
66	or=	_	_	O
67	25	_	_	O
68	mm	_	_	O
69	Hg	_	_	O
70	in	_	_	O
71	one	_	_	O
72	or	_	_	O
73	both	_	_	O
74	eyes	_	_	O
75	after	_	_	O
76	washout	_	_	O
77	were	_	_	O
78	randomly	_	_	O
79	assigned	_	_	O
80	to	_	_	O
81	receive	_	_	O
82	either	_	_	O
83	latanoprost	_	_	O
84	0.005	_	_	O
85	%	_	_	O
86	once	_	_	O
87	daily	_	_	O
88	in	_	_	O
89	the	_	_	O
90	evening	_	_	O
91	or	_	_	O
92	unoprostone	_	_	O
93	0.15	_	_	O
94	%	_	_	O
95	twice	_	_	O
96	daily	_	_	O
97	.	_	_	O

98	Observations	_	_	O
99	procedures	_	_	O
100	were	_	_	O
101	Goldmann	_	_	O
102	applanation	_	_	O
103	tonometry	_	_	O
104	,	_	_	O
105	best-corrected	_	_	O
106	visual	_	_	O
107	acuity	_	_	O
108	,	_	_	O
109	slit	_	_	O
110	lamp	_	_	O
111	biomicroscopy	_	_	O
112	,	_	_	O
113	and	_	_	O
114	ophthalmoscopy	_	_	O
115	.	_	_	O

116	The	_	_	O
117	main	_	_	O
118	outcome	_	_	O
119	measure	_	_	O
120	was	_	_	O
121	change	_	_	O
122	in	_	_	O
123	the	_	_	O
124	mean	_	_	O
125	of	_	_	O
126	the	_	_	O
127	IOPs	_	_	O
128	measured	_	_	O
129	at	_	_	O
130	8:00	_	_	O
131	AM	_	_	O
132	,	_	_	O
133	12	_	_	O
134	noon	_	_	O
135	,	_	_	O
136	and	_	_	O
137	4:00	_	_	O
138	PM	_	_	O
139	between	_	_	O
140	baseline	_	_	O
141	(	_	_	O
142	before	_	_	O
143	treatment	_	_	O
144	)	_	_	O
145	and	_	_	O
146	after	_	_	O
147	8	_	_	O
148	weeks	_	_	O
149	of	_	_	O
150	treatment	_	_	O
151	.	_	_	O

152	The	_	_	B-Premise
153	change	_	_	I-Premise
154	in	_	_	I-Premise
155	the	_	_	I-Premise
156	mean	_	_	I-Premise
157	+/-	_	_	I-Premise
158	SD	_	_	I-Premise
159	of	_	_	I-Premise
160	the	_	_	I-Premise
161	IOPs	_	_	I-Premise
162	measured	_	_	I-Premise
163	at	_	_	I-Premise
164	8:00	_	_	I-Premise
165	AM	_	_	I-Premise
166	,	_	_	I-Premise
167	12	_	_	I-Premise
168	noon	_	_	I-Premise
169	,	_	_	I-Premise
170	and	_	_	I-Premise
171	4:00	_	_	I-Premise
172	PM	_	_	I-Premise
173	was	_	_	I-Premise
174	-7.2	_	_	I-Premise
175	+/-	_	_	I-Premise
176	3.2	_	_	I-Premise
177	mm	_	_	I-Premise
178	Hg	_	_	I-Premise
179	(	_	_	I-Premise
180	28	_	_	I-Premise
181	%	_	_	I-Premise
182	)	_	_	I-Premise
183	for	_	_	I-Premise
184	latanoprost	_	_	I-Premise
185	(	_	_	I-Premise
186	25.3	_	_	I-Premise
187	+/-	_	_	I-Premise
188	2.8	_	_	I-Premise
189	mm	_	_	I-Premise
190	Hg	_	_	I-Premise
191	at	_	_	I-Premise
192	baseline	_	_	I-Premise
193	to	_	_	I-Premise
194	18.2	_	_	I-Premise
195	+/-	_	_	I-Premise
196	2.8	_	_	I-Premise
197	mm	_	_	I-Premise
198	Hg	_	_	I-Premise
199	at	_	_	I-Premise
200	8	_	_	I-Premise
201	weeks	_	_	I-Premise
202	)	_	_	I-Premise
203	and	_	_	I-Premise
204	-3.9	_	_	I-Premise
205	+/-	_	_	I-Premise
206	2.6	_	_	I-Premise
207	mm	_	_	I-Premise
208	Hg	_	_	I-Premise
209	(	_	_	I-Premise
210	15	_	_	I-Premise
211	%	_	_	I-Premise
212	)	_	_	I-Premise
213	for	_	_	I-Premise
214	unoprostone	_	_	I-Premise
215	(	_	_	I-Premise
216	25.5	_	_	I-Premise
217	+/-	_	_	I-Premise
218	3.3	_	_	I-Premise
219	mm	_	_	I-Premise
220	Hg	_	_	I-Premise
221	at	_	_	I-Premise
222	baseline	_	_	I-Premise
223	to	_	_	I-Premise
224	21.6	_	_	I-Premise
225	+/-	_	_	I-Premise
226	4.0	_	_	I-Premise
227	mm	_	_	I-Premise
228	Hg	_	_	I-Premise
229	;	_	_	I-Premise
230	P	_	_	I-Premise
231	<	_	_	I-Premise
232	or=.001	_	_	I-Premise
233	.	_	_	I-Premise

234	No	_	_	B-Premise
235	serious	_	_	I-Premise
236	adverse	_	_	I-Premise
237	event	_	_	I-Premise
238	related	_	_	I-Premise
239	to	_	_	I-Premise
240	either	_	_	I-Premise
241	medication	_	_	I-Premise
242	was	_	_	I-Premise
243	reported	_	_	I-Premise
244	.	_	_	I-Premise

245	Over	_	_	B-Claim
246	an	_	_	I-Claim
247	8-week	_	_	I-Claim
248	period	_	_	I-Claim
249	,	_	_	I-Claim
250	latanoprost	_	_	I-Claim
251	0.005	_	_	I-Claim
252	%	_	_	I-Claim
253	once	_	_	I-Claim
254	daily	_	_	I-Claim
255	lowered	_	_	I-Claim
256	IOP	_	_	I-Claim
257	more	_	_	I-Claim
258	than	_	_	I-Claim
259	unoprostone	_	_	I-Claim
260	0.15	_	_	I-Claim
261	%	_	_	I-Claim
262	twice	_	_	I-Claim
263	daily	_	_	I-Claim
264	in	_	_	I-Claim
265	patients	_	_	I-Claim
266	with	_	_	I-Claim
267	elevated	_	_	I-Claim
268	IOP	_	_	I-Claim
269	.	_	_	I-Claim

270	Both	_	_	B-Claim
271	agents	_	_	I-Claim
272	were	_	_	I-Claim
273	safe	_	_	I-Claim
274	and	_	_	I-Claim
275	well	_	_	I-Claim
276	tolerated	_	_	I-Claim
277	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	viscocanalostomy	_	_	O
3	,	_	_	O
4	a	_	_	O
5	nonpenetrating	_	_	O
6	procedure	_	_	O
7	for	_	_	O
8	glaucoma	_	_	O
9	treatment	_	_	O
10	,	_	_	O
11	with	_	_	O
12	trabeculectomy	_	_	O
13	.	_	_	O

14	Randomized	_	_	O
15	controlled	_	_	O
16	trial	_	_	O
17	.	_	_	O

18	Twenty	_	_	O
19	white	_	_	O
20	subjects	_	_	O
21	(	_	_	O
22	20	_	_	O
23	eyes	_	_	O
24	)	_	_	O
25	with	_	_	O
26	open-angle	_	_	O
27	glaucoma	_	_	O
28	with	_	_	O
29	no	_	_	O
30	history	_	_	O
31	of	_	_	O
32	surgery	_	_	O
33	were	_	_	O
34	enrolled	_	_	O
35	.	_	_	O

36	Ten	_	_	O
37	subjects	_	_	O
38	were	_	_	O
39	randomly	_	_	O
40	assigned	_	_	O
41	to	_	_	O
42	viscocanalostomy	_	_	O
43	according	_	_	O
44	to	_	_	O
45	Stegmann	_	_	O
46	's	_	_	O
47	technique	_	_	O
48	and	_	_	O
49	10	_	_	O
50	subjects	_	_	O
51	to	_	_	O
52	a	_	_	O
53	modified	_	_	O
54	Cairns	_	_	O
55	trabeculectomy	_	_	O
56	.	_	_	O

57	A	_	_	O
58	complete	_	_	O
59	ophthalmologic	_	_	O
60	examination	_	_	O
61	was	_	_	O
62	performed	_	_	O
63	the	_	_	O
64	day	_	_	O
65	before	_	_	O
66	surgery	_	_	O
67	and	_	_	O
68	postoperatively	_	_	O
69	.	_	_	O

70	Further	_	_	O
71	visits	_	_	O
72	were	_	_	O
73	scheduled	_	_	O
74	monthly	_	_	O
75	for	_	_	O
76	6	_	_	O
77	to	_	_	O
78	8	_	_	O
79	months	_	_	O
80	after	_	_	O
81	surgery	_	_	O
82	.	_	_	O

83	Success	_	_	O
84	was	_	_	O
85	defined	_	_	O
86	as	_	_	O
87	intraocular	_	_	O
88	pressure	_	_	O
89	(	_	_	O
90	IOP	_	_	O
91	)	_	_	O
92	between	_	_	O
93	7	_	_	O
94	and	_	_	O
95	20	_	_	O
96	mmHg	_	_	O
97	,	_	_	O
98	with	_	_	O
99	no	_	_	O
100	medication	_	_	O
101	.	_	_	O

102	After	_	_	B-Premise
103	a	_	_	I-Premise
104	mean	_	_	I-Premise
105	follow-up	_	_	I-Premise
106	of	_	_	I-Premise
107	6	_	_	I-Premise
108	months	_	_	I-Premise
109	(	_	_	I-Premise
110	range	_	_	I-Premise
111	,	_	_	I-Premise
112	6-8	_	_	I-Premise
113	months	_	_	I-Premise
114	)	_	_	I-Premise
115	,	_	_	I-Premise
116	success	_	_	I-Premise
117	was	_	_	I-Premise
118	obtained	_	_	I-Premise
119	in	_	_	I-Premise
120	5	_	_	I-Premise
121	of	_	_	I-Premise
122	10	_	_	I-Premise
123	cases	_	_	I-Premise
124	in	_	_	I-Premise
125	the	_	_	I-Premise
126	trabeculectomy	_	_	I-Premise
127	group	_	_	I-Premise
128	and	_	_	I-Premise
129	in	_	_	I-Premise
130	0	_	_	I-Premise
131	of	_	_	I-Premise
132	10	_	_	I-Premise
133	case	_	_	I-Premise
134	in	_	_	I-Premise
135	the	_	_	I-Premise
136	viscocanalostomy	_	_	I-Premise
137	group	_	_	I-Premise
138	.	_	_	I-Premise

139	With	_	_	B-Premise
140	Kaplan-Meier	_	_	I-Premise
141	's	_	_	I-Premise
142	method	_	_	I-Premise
143	,	_	_	I-Premise
144	subjects	_	_	I-Premise
145	with	_	_	I-Premise
146	viscocanalostomy	_	_	I-Premise
147	showed	_	_	I-Premise
148	shorter	_	_	I-Premise
149	postoperative	_	_	I-Premise
150	IOP-reduction	_	_	I-Premise
151	periods	_	_	I-Premise
152	than	_	_	I-Premise
153	subjects	_	_	I-Premise
154	undergoing	_	_	I-Premise
155	trabeculectomy	_	_	I-Premise
156	.	_	_	I-Premise

157	According	_	_	B-Claim
158	to	_	_	I-Claim
159	the	_	_	I-Claim
160	results	_	_	I-Claim
161	of	_	_	I-Claim
162	this	_	_	I-Claim
163	short-term	_	_	I-Claim
164	study	_	_	I-Claim
165	,	_	_	I-Claim
166	trabeculectomy	_	_	I-Claim
167	was	_	_	I-Claim
168	more	_	_	I-Claim
169	effective	_	_	I-Claim
170	than	_	_	I-Claim
171	viscocanalostomy	_	_	I-Claim
172	in	_	_	I-Claim
173	lowering	_	_	I-Claim
174	IOP	_	_	I-Claim
175	in	_	_	I-Claim
176	glaucomatous	_	_	I-Claim
177	eyes	_	_	I-Claim
178	of	_	_	I-Claim
179	white	_	_	I-Claim
180	patients	_	_	I-Claim
181	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	outcomes	_	_	O
3	of	_	_	O
4	selective	_	_	O
5	laser	_	_	O
6	trabeculoplasty	_	_	O
7	(	_	_	O
8	SLT	_	_	O
9	)	_	_	O
10	with	_	_	O
11	drug	_	_	O
12	therapy	_	_	O
13	for	_	_	O
14	glaucoma	_	_	O
15	patients	_	_	O
16	in	_	_	O
17	a	_	_	O
18	prospective	_	_	O
19	randomized	_	_	O
20	clinical	_	_	O
21	trial	_	_	O
22	.	_	_	O

23	Sixty-nine	_	_	O
24	patients	_	_	O
25	(	_	_	O
26	127	_	_	O
27	eyes	_	_	O
28	)	_	_	O
29	with	_	_	O
30	open-angle	_	_	O
31	glaucoma	_	_	O
32	or	_	_	O
33	ocular	_	_	O
34	hypertension	_	_	O
35	were	_	_	O
36	randomized	_	_	O
37	to	_	_	O
38	SLT	_	_	O
39	or	_	_	O
40	medical	_	_	O
41	therapy	_	_	O
42	.	_	_	O

43	Target	_	_	O
44	intraocular	_	_	O
45	pressure	_	_	O
46	(	_	_	O
47	IOP	_	_	O
48	)	_	_	O
49	was	_	_	O
50	determined	_	_	O
51	using	_	_	O
52	the	_	_	O
53	Collaborative	_	_	O
54	Initial	_	_	O
55	Glaucoma	_	_	O
56	Treatment	_	_	O
57	Study	_	_	O
58	formula	_	_	O
59	.	_	_	O

60	Patients	_	_	O
61	were	_	_	O
62	treated	_	_	O
63	with	_	_	O
64	SLT	_	_	O
65	(	_	_	O
66	100	_	_	O
67	applications	_	_	O
68	360	_	_	O
69	degrees	_	_	O
70	)	_	_	O
71	or	_	_	O
72	medical	_	_	O
73	therapy	_	_	O
74	(	_	_	O
75	prostaglandin	_	_	O
76	analog	_	_	O
77	)	_	_	O
78	.	_	_	O

79	Six	_	_	O
80	visits	_	_	O
81	over	_	_	O
82	1	_	_	O
83	year	_	_	O
84	followed	_	_	O
85	initial	_	_	O
86	treatment	_	_	O
87	.	_	_	O

88	If	_	_	O
89	target	_	_	O
90	IOP	_	_	O
91	range	_	_	O
92	was	_	_	O
93	not	_	_	O
94	attained	_	_	O
95	with	_	_	O
96	SLT	_	_	O
97	,	_	_	O
98	additional	_	_	O
99	SLT	_	_	O
100	was	_	_	O
101	the	_	_	O
102	next	_	_	O
103	step	_	_	O
104	,	_	_	O
105	or	_	_	O
106	in	_	_	O
107	the	_	_	O
108	medical	_	_	O
109	arm	_	_	O
110	additional	_	_	O
111	medications	_	_	O
112	were	_	_	O
113	added	_	_	O
114	.	_	_	O

115	Primary	_	_	O
116	outcome	_	_	O
117	:	_	_	O
118	IOP	_	_	O
119	;	_	_	O
120	secondary	_	_	O
121	:	_	_	O
122	number	_	_	O
123	of	_	_	O
124	steps	_	_	O
125	.	_	_	O

126	Sixty-nine	_	_	O
127	patients	_	_	O
128	were	_	_	O
129	treated	_	_	O
130	.	_	_	O

131	Data	_	_	O
132	collection	_	_	O
133	terminated	_	_	O
134	with	_	_	O
135	54	_	_	O
136	patients	_	_	O
137	reaching	_	_	O
138	9	_	_	O
139	to	_	_	O
140	12-months	_	_	O
141	follow-up	_	_	O
142	.	_	_	O

143	Twenty-nine	_	_	O
144	patients	_	_	O
145	were	_	_	O
146	in	_	_	O
147	the	_	_	O
148	SLT	_	_	O
149	group	_	_	O
150	,	_	_	O
151	25	_	_	O
152	patients	_	_	O
153	in	_	_	O
154	the	_	_	O
155	medical	_	_	O
156	group	_	_	O
157	.	_	_	O

158	Baseline	_	_	B-Premise
159	mean	_	_	I-Premise
160	IOP	_	_	I-Premise
161	for	_	_	I-Premise
162	all	_	_	I-Premise
163	eyes	_	_	I-Premise
164	was	_	_	I-Premise
165	24.5	_	_	I-Premise
166	mm	_	_	I-Premise
167	Hg	_	_	I-Premise
168	in	_	_	I-Premise
169	the	_	_	I-Premise
170	SLT	_	_	I-Premise
171	group	_	_	I-Premise
172	,	_	_	I-Premise
173	24.7	_	_	I-Premise
174	mm	_	_	I-Premise
175	Hg	_	_	I-Premise
176	in	_	_	I-Premise
177	the	_	_	I-Premise
178	medical	_	_	I-Premise
179	group	_	_	I-Premise
180	.	_	_	I-Premise

181	Mean	_	_	I-Premise
182	IOP	_	_	I-Premise
183	(	_	_	I-Premise
184	both	_	_	I-Premise
185	eyes	_	_	I-Premise
186	)	_	_	I-Premise
187	at	_	_	I-Premise
188	last	_	_	I-Premise
189	follow-up	_	_	I-Premise
190	was	_	_	I-Premise
191	18.2	_	_	I-Premise
192	mm	_	_	I-Premise
193	Hg	_	_	I-Premise
194	(	_	_	I-Premise
195	6.3	_	_	I-Premise
196	mm	_	_	I-Premise
197	Hg	_	_	I-Premise
198	reduction	_	_	I-Premise
199	)	_	_	I-Premise
200	in	_	_	I-Premise
201	the	_	_	I-Premise
202	SLT	_	_	I-Premise
203	arm	_	_	I-Premise
204	,	_	_	I-Premise
205	17.7	_	_	I-Premise
206	mm	_	_	I-Premise
207	Hg	_	_	I-Premise
208	(	_	_	I-Premise
209	7.0	_	_	I-Premise
210	mm	_	_	I-Premise
211	Hg	_	_	I-Premise
212	reduction	_	_	I-Premise
213	)	_	_	I-Premise
214	in	_	_	I-Premise
215	the	_	_	I-Premise
216	medical	_	_	I-Premise
217	arm	_	_	I-Premise
218	.	_	_	I-Premise

219	By	_	_	B-Premise
220	last	_	_	I-Premise
221	follow-up	_	_	I-Premise
222	,	_	_	I-Premise
223	11	_	_	I-Premise
224	%	_	_	I-Premise
225	of	_	_	I-Premise
226	eyes	_	_	I-Premise
227	received	_	_	I-Premise
228	additional	_	_	I-Premise
229	SLT	_	_	I-Premise
230	,	_	_	I-Premise
231	27	_	_	I-Premise
232	%	_	_	I-Premise
233	required	_	_	I-Premise
234	additional	_	_	I-Premise
235	medication	_	_	I-Premise
236	.	_	_	I-Premise

237	There	_	_	B-Premise
238	was	_	_	I-Premise
239	not	_	_	I-Premise
240	a	_	_	I-Premise
241	statistically	_	_	I-Premise
242	significant	_	_	I-Premise
243	difference	_	_	I-Premise
244	between	_	_	I-Premise
245	the	_	_	I-Premise
246	SLT	_	_	I-Premise
247	and	_	_	I-Premise
248	medication	_	_	I-Premise
249	groups	_	_	I-Premise
250	.	_	_	I-Premise

251	IOP	_	_	B-Premise
252	reduction	_	_	I-Premise
253	was	_	_	I-Premise
254	similar	_	_	I-Premise
255	in	_	_	I-Premise
256	both	_	_	I-Premise
257	arms	_	_	I-Premise
258	after	_	_	I-Premise
259	9	_	_	I-Premise
260	to	_	_	I-Premise
261	12-months	_	_	I-Premise
262	follow-up	_	_	I-Premise
263	.	_	_	I-Premise

264	More	_	_	O
265	treatment	_	_	O
266	steps	_	_	O
267	were	_	_	O
268	necessary	_	_	O
269	to	_	_	O
270	maintain	_	_	O
271	target	_	_	O
272	IOP	_	_	O
273	in	_	_	O
274	the	_	_	O
275	medication	_	_	O
276	group	_	_	O
277	,	_	_	O
278	although	_	_	O
279	there	_	_	O
280	was	_	_	O
281	not	_	_	O
282	a	_	_	O
283	statistically	_	_	O
284	significant	_	_	O
285	difference	_	_	O
286	between	_	_	O
287	groups	_	_	O
288	.	_	_	O

289	These	_	_	B-Claim
290	results	_	_	I-Claim
291	support	_	_	I-Claim
292	the	_	_	I-Claim
293	option	_	_	I-Claim
294	of	_	_	I-Claim
295	SLT	_	_	I-Claim
296	as	_	_	I-Claim
297	a	_	_	I-Claim
298	safe	_	_	I-Claim
299	and	_	_	I-Claim
300	effective	_	_	I-Claim
301	initial	_	_	I-Claim
302	therapy	_	_	I-Claim
303	in	_	_	I-Claim
304	open-angle	_	_	I-Claim
305	glaucoma	_	_	I-Claim
306	or	_	_	I-Claim
307	ocular	_	_	I-Claim
308	hypertension	_	_	I-Claim
309	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	efficacy	_	_	O
4	and	_	_	O
5	safety	_	_	O
6	of	_	_	O
7	viscocanalostomy	_	_	O
8	and	_	_	O
9	trabeculectomy	_	_	O
10	in	_	_	O
11	patients	_	_	O
12	with	_	_	O
13	primary	_	_	O
14	open-angle	_	_	O
15	glaucoma	_	_	O
16	(	_	_	O
17	POAG	_	_	O
18	)	_	_	O
19	.	_	_	O

20	Department	_	_	O
21	of	_	_	O
22	Ophthalmology	_	_	O
23	,	_	_	O
24	Ankara	_	_	O
25	Education	_	_	O
26	and	_	_	O
27	Research	_	_	O
28	Hospital	_	_	O
29	,	_	_	O
30	Ankara	_	_	O
31	,	_	_	O
32	Turkey	_	_	O
33	.	_	_	O

34	In	_	_	O
35	this	_	_	O
36	prospective	_	_	O
37	randomized	_	_	O
38	trial	_	_	O
39	,	_	_	O
40	50	_	_	O
41	eyes	_	_	O
42	of	_	_	O
43	50	_	_	O
44	patients	_	_	O
45	with	_	_	O
46	medically	_	_	O
47	uncontrolled	_	_	O
48	POAG	_	_	O
49	were	_	_	O
50	randomized	_	_	O
51	to	_	_	O
52	have	_	_	O
53	a	_	_	O
54	trabeculectomy	_	_	O
55	(	_	_	O
56	25	_	_	O
57	eyes	_	_	O
58	)	_	_	O
59	or	_	_	O
60	a	_	_	O
61	viscocanalostomy	_	_	O
62	(	_	_	O
63	25	_	_	O
64	eyes	_	_	O
65	)	_	_	O
66	.	_	_	O

67	Visual	_	_	O
68	acuity	_	_	O
69	,	_	_	O
70	intraocular	_	_	O
71	pressure	_	_	O
72	(	_	_	O
73	IOP	_	_	O
74	)	_	_	O
75	,	_	_	O
76	and	_	_	O
77	slitlamp	_	_	O
78	examinations	_	_	O
79	were	_	_	O
80	performed	_	_	O
81	before	_	_	O
82	surgery	_	_	O
83	and	_	_	O
84	1	_	_	O
85	day	_	_	O
86	,	_	_	O
87	1	_	_	O
88	week	_	_	O
89	,	_	_	O
90	1	_	_	O
91	,	_	_	O
92	3	_	_	O
93	,	_	_	O
94	and	_	_	O
95	6	_	_	O
96	months	_	_	O
97	,	_	_	O
98	and	_	_	O
99	1	_	_	O
100	,	_	_	O
101	2	_	_	O
102	,	_	_	O
103	and	_	_	O
104	3	_	_	O
105	years	_	_	O
106	postoperatively	_	_	O
107	.	_	_	O

108	At	_	_	B-Premise
109	3	_	_	I-Premise
110	years	_	_	I-Premise
111	,	_	_	I-Premise
112	the	_	_	I-Premise
113	mean	_	_	I-Premise
114	IOP	_	_	I-Premise
115	was	_	_	I-Premise
116	16.0	_	_	I-Premise
117	mmHg	_	_	I-Premise
118	+/-	_	_	I-Premise
119	7.07	_	_	I-Premise
120	(	_	_	I-Premise
121	SD	_	_	I-Premise
122	)	_	_	I-Premise
123	in	_	_	I-Premise
124	the	_	_	I-Premise
125	trabeculectomy	_	_	I-Premise
126	group	_	_	I-Premise
127	and	_	_	I-Premise
128	17.8	_	_	I-Premise
129	+/-	_	_	I-Premise
130	4.6	_	_	I-Premise
131	mmHg	_	_	I-Premise
132	in	_	_	I-Premise
133	the	_	_	I-Premise
134	viscocanalostomy	_	_	I-Premise
135	group	_	_	I-Premise
136	(	_	_	I-Premise
137	P=.694	_	_	I-Premise
138	)	_	_	I-Premise
139	.	_	_	I-Premise

140	Complete	_	_	B-Premise
141	success	_	_	I-Premise
142	(	_	_	I-Premise
143	IOP	_	_	I-Premise
144	6	_	_	I-Premise
145	to	_	_	I-Premise
146	21	_	_	I-Premise
147	mm	_	_	I-Premise
148	Hg	_	_	I-Premise
149	without	_	_	I-Premise
150	medication	_	_	I-Premise
151	)	_	_	I-Premise
152	was	_	_	I-Premise
153	achieved	_	_	I-Premise
154	in	_	_	I-Premise
155	66.2	_	_	I-Premise
156	%	_	_	I-Premise
157	of	_	_	I-Premise
158	eyes	_	_	I-Premise
159	at	_	_	I-Premise
160	6	_	_	I-Premise
161	months	_	_	I-Premise
162	and	_	_	I-Premise
163	55.1	_	_	I-Premise
164	%	_	_	I-Premise
165	at	_	_	I-Premise
166	3	_	_	I-Premise
167	years	_	_	I-Premise
168	in	_	_	I-Premise
169	the	_	_	I-Premise
170	trabeculectomy	_	_	I-Premise
171	group	_	_	I-Premise
172	and	_	_	I-Premise
173	in	_	_	I-Premise
174	52.9	_	_	I-Premise
175	%	_	_	I-Premise
176	and	_	_	I-Premise
177	35.3	_	_	I-Premise
178	%	_	_	I-Premise
179	,	_	_	I-Premise
180	respectively	_	_	I-Premise
181	,	_	_	I-Premise
182	in	_	_	I-Premise
183	the	_	_	I-Premise
184	viscocanalostomy	_	_	I-Premise
185	group	_	_	I-Premise
186	(	_	_	I-Premise
187	P	_	_	I-Premise
188	>	_	_	I-Premise
189	.05	_	_	I-Premise
190	)	_	_	I-Premise
191	.	_	_	I-Premise

192	Qualified	_	_	B-Premise
193	success	_	_	I-Premise
194	(	_	_	I-Premise
195	IOP	_	_	I-Premise
196	6	_	_	I-Premise
197	to	_	_	I-Premise
198	21	_	_	I-Premise
199	mmHg	_	_	I-Premise
200	with	_	_	I-Premise
201	medication	_	_	I-Premise
202	)	_	_	I-Premise
203	was	_	_	I-Premise
204	achieved	_	_	I-Premise
205	in	_	_	I-Premise
206	95.8	_	_	I-Premise
207	%	_	_	I-Premise
208	of	_	_	I-Premise
209	eyes	_	_	I-Premise
210	at	_	_	I-Premise
211	6	_	_	I-Premise
212	months	_	_	I-Premise
213	and	_	_	I-Premise
214	79.2	_	_	I-Premise
215	%	_	_	I-Premise
216	at	_	_	I-Premise
217	3	_	_	I-Premise
218	years	_	_	I-Premise
219	in	_	_	I-Premise
220	the	_	_	I-Premise
221	trabeculectomy	_	_	I-Premise
222	group	_	_	I-Premise
223	and	_	_	I-Premise
224	in	_	_	I-Premise
225	90.7	_	_	I-Premise
226	%	_	_	I-Premise
227	and	_	_	I-Premise
228	73.9	_	_	I-Premise
229	%	_	_	I-Premise
230	,	_	_	I-Premise
231	respectively	_	_	I-Premise
232	,	_	_	I-Premise
233	in	_	_	I-Premise
234	the	_	_	I-Premise
235	viscocanalostomy	_	_	I-Premise
236	group	_	_	I-Premise
237	(	_	_	I-Premise
238	P	_	_	I-Premise
239	>	_	_	I-Premise
240	.05	_	_	I-Premise
241	)	_	_	I-Premise
242	.	_	_	I-Premise

243	Postoperative	_	_	B-Premise
244	hypotony	_	_	I-Premise
245	and	_	_	I-Premise
246	cataract	_	_	I-Premise
247	formation	_	_	I-Premise
248	occurred	_	_	I-Premise
249	more	_	_	I-Premise
250	frequently	_	_	I-Premise
251	in	_	_	I-Premise
252	the	_	_	I-Premise
253	trabeculectomy	_	_	I-Premise
254	group	_	_	I-Premise
255	than	_	_	I-Premise
256	in	_	_	I-Premise
257	the	_	_	I-Premise
258	viscocanalostomy	_	_	I-Premise
259	group	_	_	I-Premise
260	(	_	_	I-Premise
261	P=.002	_	_	I-Premise
262	)	_	_	I-Premise
263	.	_	_	I-Premise

264	Primary	_	_	B-Claim
265	trabeculectomy	_	_	I-Claim
266	lowered	_	_	I-Claim
267	IOP	_	_	I-Claim
268	more	_	_	I-Claim
269	than	_	_	I-Claim
270	viscocanalostomy	_	_	I-Claim
271	in	_	_	I-Claim
272	POAG	_	_	I-Claim
273	patients	_	_	I-Claim
274	.	_	_	I-Claim

275	However	_	_	O
276	,	_	_	O
277	the	_	_	B-Claim
278	complication	_	_	I-Claim
279	rate	_	_	I-Claim
280	was	_	_	I-Claim
281	lower	_	_	I-Claim
282	in	_	_	I-Claim
283	the	_	_	I-Claim
284	viscocanalostomy	_	_	I-Claim
285	group	_	_	I-Claim
286	.	_	_	I-Claim


0	To	_	_	O
1	investigate	_	_	O
2	risk	_	_	O
3	factors	_	_	O
4	associated	_	_	O
5	with	_	_	O
6	visual	_	_	O
7	field	_	_	O
8	progression	_	_	O
9	in	_	_	O
10	the	_	_	O
11	Low-pressure	_	_	O
12	Glaucoma	_	_	O
13	Treatment	_	_	O
14	Study	_	_	O
15	,	_	_	O
16	a	_	_	O
17	prospective	_	_	O
18	trial	_	_	O
19	designed	_	_	O
20	to	_	_	O
21	compare	_	_	O
22	the	_	_	O
23	effects	_	_	O
24	of	_	_	O
25	the	_	_	O
26	alpha2-adrenergic	_	_	O
27	agonist	_	_	O
28	brimonidine	_	_	O
29	tartrate	_	_	O
30	0.2	_	_	O
31	%	_	_	O
32	to	_	_	O
33	the	_	_	O
34	beta-adrenergic	_	_	O
35	antagonist	_	_	O
36	timolol	_	_	O
37	maleate	_	_	O
38	0.5	_	_	O
39	%	_	_	O
40	on	_	_	O
41	visual	_	_	O
42	function	_	_	O
43	in	_	_	O
44	low-pressure	_	_	O
45	glaucoma	_	_	O
46	.	_	_	O

47	Prospective	_	_	O
48	cohort	_	_	O
49	study	_	_	O
50	.	_	_	O

51	Low-pressure	_	_	O
52	Glaucoma	_	_	O
53	Treatment	_	_	O
54	Study	_	_	O
55	patients	_	_	O
56	with	_	_	O
57	≥5	_	_	O
58	visual	_	_	O
59	field	_	_	O
60	tests	_	_	O
61	during	_	_	O
62	follow-up	_	_	O
63	were	_	_	O
64	included	_	_	O
65	.	_	_	O

66	Progression	_	_	O
67	was	_	_	O
68	determined	_	_	O
69	using	_	_	O
70	pointwise	_	_	O
71	linear	_	_	O
72	regression	_	_	O
73	analysis	_	_	O
74	,	_	_	O
75	defined	_	_	O
76	as	_	_	O
77	the	_	_	O
78	same	_	_	O
79	3	_	_	O
80	or	_	_	O
81	more	_	_	O
82	visual	_	_	O
83	field	_	_	O
84	locations	_	_	O
85	with	_	_	O
86	a	_	_	O
87	slope	_	_	O
88	more	_	_	O
89	negative	_	_	O
90	than	_	_	O
91	-1.0	_	_	O
92	dB/year	_	_	O
93	at	_	_	O
94	P	_	_	O
95	<	_	_	O
96	5	_	_	O
97	%	_	_	O
98	,	_	_	O
99	on	_	_	O
100	3	_	_	O
101	consecutive	_	_	O
102	tests	_	_	O
103	.	_	_	O

104	Ocular	_	_	O
105	and	_	_	O
106	systemic	_	_	O
107	risk	_	_	O
108	factors	_	_	O
109	were	_	_	O
110	analyzed	_	_	O
111	using	_	_	O
112	Cox	_	_	O
113	proportional	_	_	O
114	hazards	_	_	O
115	model	_	_	O
116	and	_	_	O
117	further	_	_	O
118	tested	_	_	O
119	for	_	_	O
120	independence	_	_	O
121	in	_	_	O
122	a	_	_	O
123	multivariate	_	_	O
124	model	_	_	O
125	.	_	_	O

126	A	_	_	O
127	total	_	_	O
128	of	_	_	O
129	253	_	_	O
130	eyes	_	_	O
131	of	_	_	O
132	127	_	_	O
133	subjects	_	_	O
134	(	_	_	O
135	mean	_	_	O
136	age	_	_	O
137	,	_	_	O
138	64.7	_	_	O
139	10.9	_	_	O
140	years	_	_	O
141	;	_	_	O
142	mean	_	_	O
143	follow-up	_	_	O
144	,	_	_	O
145	40.6	_	_	O
146	12	_	_	O
147	months	_	_	O
148	)	_	_	O
149	were	_	_	O
150	analyzed	_	_	O
151	.	_	_	O

152	Eyes	_	_	B-Premise
153	randomized	_	_	I-Premise
154	to	_	_	I-Premise
155	timolol	_	_	I-Premise
156	progressed	_	_	I-Premise
157	faster	_	_	I-Premise
158	than	_	_	I-Premise
159	those	_	_	I-Premise
160	randomized	_	_	I-Premise
161	to	_	_	I-Premise
162	brimonidine	_	_	I-Premise
163	(	_	_	I-Premise
164	mean	_	_	I-Premise
165	rates	_	_	I-Premise
166	of	_	_	I-Premise
167	progression	_	_	I-Premise
168	,	_	_	I-Premise
169	-0.38	_	_	I-Premise
170	0.9	_	_	I-Premise
171	vs	_	_	I-Premise
172	0.02	_	_	I-Premise
173	0.7	_	_	I-Premise
174	dB/y	_	_	I-Premise
175	,	_	_	I-Premise
176	P	_	_	I-Premise
177	<	_	_	I-Premise
178	.01	_	_	I-Premise
179	)	_	_	I-Premise
180	.	_	_	I-Premise

181	In	_	_	O
182	the	_	_	O
183	final	_	_	O
184	multivariate	_	_	O
185	model	_	_	O
186	adjusting	_	_	O
187	for	_	_	O
188	all	_	_	O
189	tested	_	_	O
190	covariates	_	_	O
191	,	_	_	O
192	older	_	_	B-Premise
193	age	_	_	I-Premise
194	(	_	_	I-Premise
195	hazard	_	_	I-Premise
196	ratio	_	_	I-Premise
197	[	_	_	I-Premise
198	HR	_	_	I-Premise
199	]	_	_	I-Premise
200	=	_	_	I-Premise
201	1.41/decade	_	_	I-Premise
202	older	_	_	I-Premise
203	,	_	_	I-Premise
204	95	_	_	I-Premise
205	%	_	_	I-Premise
206	confidence	_	_	I-Premise
207	interval	_	_	I-Premise
208	[	_	_	I-Premise
209	CI	_	_	I-Premise
210	]	_	_	I-Premise
211	=	_	_	I-Premise
212	1.05	_	_	I-Premise
213	to	_	_	I-Premise
214	1.90	_	_	I-Premise
215	,	_	_	I-Premise
216	P	_	_	I-Premise
217	=	_	_	I-Premise
218	.022	_	_	I-Premise
219	)	_	_	I-Premise
220	,	_	_	I-Premise
221	use	_	_	I-Premise
222	of	_	_	I-Premise
223	systemic	_	_	I-Premise
224	antihypertensives	_	_	I-Premise
225	(	_	_	I-Premise
226	HR	_	_	I-Premise
227	=	_	_	I-Premise
228	2.53	_	_	I-Premise
229	,	_	_	I-Premise
230	95	_	_	I-Premise
231	%	_	_	I-Premise
232	CI	_	_	I-Premise
233	=	_	_	I-Premise
234	1.32	_	_	I-Premise
235	to	_	_	I-Premise
236	4.87	_	_	I-Premise
237	,	_	_	I-Premise
238	P	_	_	I-Premise
239	=	_	_	I-Premise
240	.005	_	_	I-Premise
241	)	_	_	I-Premise
242	,	_	_	I-Premise
243	and	_	_	I-Premise
244	mean	_	_	I-Premise
245	ocular	_	_	I-Premise
246	perfusion	_	_	I-Premise
247	pressure	_	_	I-Premise
248	(	_	_	I-Premise
249	HR	_	_	I-Premise
250	=	_	_	I-Premise
251	1.21/mm	_	_	I-Premise
252	Hg	_	_	I-Premise
253	lower	_	_	I-Premise
254	,	_	_	I-Premise
255	95	_	_	I-Premise
256	%	_	_	I-Premise
257	CI	_	_	I-Premise
258	=	_	_	I-Premise
259	1.12	_	_	I-Premise
260	to	_	_	I-Premise
261	1.31	_	_	I-Premise
262	,	_	_	I-Premise
263	P	_	_	I-Premise
264	<	_	_	I-Premise
265	.001	_	_	I-Premise
266	)	_	_	I-Premise
267	were	_	_	I-Premise
268	associated	_	_	I-Premise
269	with	_	_	I-Premise
270	progression	_	_	I-Premise
271	whereas	_	_	O
272	randomization	_	_	B-Premise
273	to	_	_	I-Premise
274	brimonidine	_	_	I-Premise
275	revealed	_	_	I-Premise
276	a	_	_	I-Premise
277	protective	_	_	I-Premise
278	effect	_	_	I-Premise
279	(	_	_	I-Premise
280	HR	_	_	I-Premise
281	=	_	_	I-Premise
282	0.26	_	_	I-Premise
283	,	_	_	I-Premise
284	95	_	_	I-Premise
285	%	_	_	I-Premise
286	CI	_	_	I-Premise
287	=	_	_	I-Premise
288	0.12	_	_	I-Premise
289	to	_	_	I-Premise
290	0.55	_	_	I-Premise
291	,	_	_	I-Premise
292	P	_	_	I-Premise
293	<	_	_	I-Premise
294	.001	_	_	I-Premise
295	)	_	_	I-Premise
296	.	_	_	I-Premise

297	While	_	_	O
298	randomization	_	_	B-Premise
299	to	_	_	I-Premise
300	brimonidine	_	_	I-Premise
301	0.2	_	_	I-Premise
302	%	_	_	I-Premise
303	was	_	_	I-Premise
304	protective	_	_	I-Premise
305	compared	_	_	I-Premise
306	to	_	_	I-Premise
307	timolol	_	_	I-Premise
308	0.5	_	_	I-Premise
309	%	_	_	I-Premise
310	,	_	_	I-Premise
311	lower	_	_	B-Premise
312	mean	_	_	I-Premise
313	ocular	_	_	I-Premise
314	perfusion	_	_	I-Premise
315	pressure	_	_	I-Premise
316	increased	_	_	I-Premise
317	the	_	_	I-Premise
318	risk	_	_	I-Premise
319	for	_	_	I-Premise
320	reaching	_	_	I-Premise
321	a	_	_	I-Premise
322	progression	_	_	I-Premise
323	outcome	_	_	I-Premise
324	in	_	_	I-Premise
325	the	_	_	I-Premise
326	Low-pressure	_	_	I-Premise
327	Glaucoma	_	_	I-Premise
328	Treatment	_	_	I-Premise
329	Study	_	_	I-Premise
330	.	_	_	I-Premise

331	This	_	_	B-Claim
332	suggests	_	_	I-Claim
333	that	_	_	I-Claim
334	the	_	_	I-Claim
335	beneficial	_	_	I-Claim
336	effect	_	_	I-Claim
337	of	_	_	I-Claim
338	randomization	_	_	I-Claim
339	to	_	_	I-Claim
340	the	_	_	I-Claim
341	brimonidine	_	_	I-Claim
342	arm	_	_	I-Claim
343	was	_	_	I-Claim
344	independent	_	_	I-Claim
345	of	_	_	I-Claim
346	possible	_	_	I-Claim
347	differences	_	_	I-Claim
348	in	_	_	I-Claim
349	ocular	_	_	I-Claim
350	perfusion	_	_	I-Claim
351	pressures	_	_	I-Claim
352	between	_	_	I-Claim
353	the	_	_	I-Claim
354	2	_	_	I-Claim
355	treatment	_	_	I-Claim
356	arms	_	_	I-Claim
357	.	_	_	I-Claim

358	The	_	_	B-Claim
359	current	_	_	I-Claim
360	results	_	_	I-Claim
361	and	_	_	I-Claim
362	large	_	_	I-Claim
363	number	_	_	I-Claim
364	of	_	_	I-Claim
365	drop-outs	_	_	I-Claim
366	in	_	_	I-Claim
367	the	_	_	I-Claim
368	brimonidine	_	_	I-Claim
369	0.2	_	_	I-Claim
370	%	_	_	I-Claim
371	arm	_	_	I-Claim
372	suggest	_	_	I-Claim
373	that	_	_	I-Claim
374	more	_	_	I-Claim
375	research	_	_	I-Claim
376	is	_	_	I-Claim
377	necessary	_	_	I-Claim
378	before	_	_	I-Claim
379	altering	_	_	I-Claim
380	clinical	_	_	I-Claim
381	practice	_	_	I-Claim
382	paradigms	_	_	I-Claim
383	.	_	_	I-Claim


0	To	_	_	O
1	compare	_	_	O
2	the	_	_	O
3	effect	_	_	O
4	of	_	_	O
5	time	_	_	O
6	on	_	_	O
7	therapy	_	_	O
8	,	_	_	O
9	efficacy	_	_	O
10	,	_	_	O
11	tolerability	_	_	O
12	and	_	_	O
13	resource	_	_	O
14	utilization	_	_	O
15	of	_	_	O
16	latanoprost	_	_	O
17	or	_	_	O
18	non-prostaglandin	_	_	O
19	analogues	_	_	O
20	(	_	_	O
21	non-PGs	_	_	O
22	)	_	_	O
23	in	_	_	O
24	patients	_	_	O
25	who	_	_	O
26	required	_	_	O
27	a	_	_	O
28	change	_	_	O
29	in	_	_	O
30	intraocular	_	_	O
31	pressure	_	_	O
32	(	_	_	O
33	IOP	_	_	O
34	)	_	_	O
35	-lowering	_	_	O
36	monotherapy	_	_	O
37	.	_	_	O

38	This	_	_	O
39	open-label	_	_	O
40	,	_	_	O
41	multicentre	_	_	O
42	study	_	_	O
43	(	_	_	O
44	Sweden	_	_	O
45	,	_	_	O
46	19	_	_	O
47	sites	_	_	O
48	;	_	_	O
49	Finland	_	_	O
50	,	_	_	O
51	seven	_	_	O
52	sites	_	_	O
53	)	_	_	O
54	included	_	_	O
55	adults	_	_	O
56	with	_	_	O
57	glaucoma	_	_	O
58	or	_	_	O
59	ocular	_	_	O
60	hypertension	_	_	O
61	with	_	_	O
62	mean	_	_	O
63	diurnal	_	_	O
64	IOP	_	_	O
65	>	_	_	O
66	or	_	_	O
67	=	_	_	O
68	21	_	_	O
69	mmHg	_	_	O
70	on	_	_	O
71	ocular	_	_	O
72	hypotensive	_	_	O
73	monotherapy	_	_	O
74	.	_	_	O

75	Patients	_	_	O
76	were	_	_	O
77	randomized	_	_	O
78	to	_	_	O
79	latanoprost	_	_	O
80	monotherapy	_	_	O
81	or	_	_	O
82	non-PG	_	_	O
83	therapy	_	_	O
84	(	_	_	O
85	commercially	_	_	O
86	available	_	_	O
87	therapy	_	_	O
88	other	_	_	O
89	than	_	_	O
90	a	_	_	O
91	PG	_	_	O
92	)	_	_	O
93	and	_	_	O
94	followed	_	_	O
95	for	_	_	O
96	36	_	_	O
97	months	_	_	O
98	.	_	_	O

99	End-points	_	_	O
100	included	_	_	O
101	:	_	_	O
102	time	_	_	O
103	to	_	_	O
104	treatment	_	_	O
105	failure	_	_	O
106	(	_	_	O
107	baseline	_	_	O
108	to	_	_	O
109	visit	_	_	O
110	with	_	_	O
111	a	_	_	O
112	change	_	_	O
113	in/addition	_	_	O
114	to	_	_	O
115	treatment	_	_	O
116	)	_	_	O
117	;	_	_	O
118	diurnal	_	_	O
119	IOP	_	_	O
120	(	_	_	O
121	mean	_	_	O
122	of	_	_	O
123	08.00	_	_	O
124	,	_	_	O
125	12.00	_	_	O
126	and	_	_	O
127	16:00	_	_	O
128	hr	_	_	O
129	measurements	_	_	O
130	)	_	_	O
131	at	_	_	O
132	months	_	_	O
133	6	_	_	O
134	,	_	_	O
135	12	_	_	O
136	,	_	_	O
137	24	_	_	O
138	and	_	_	O
139	36	_	_	O
140	;	_	_	O
141	tolerability	_	_	O
142	;	_	_	O
143	and	_	_	O
144	resource	_	_	O
145	utilization	_	_	O
146	,	_	_	O
147	where	_	_	O
148	analyses	_	_	O
149	used	_	_	O
150	Swedish	_	_	O
151	and	_	_	O
152	Finnish	_	_	O
153	2006	_	_	O
154	unit	_	_	O
155	costs	_	_	O
156	.	_	_	O

157	Three	_	_	O
158	hundred	_	_	O
159	and	_	_	O
160	twenty-six	_	_	O
161	patients	_	_	O
162	received	_	_	O
163	>	_	_	O
164	or	_	_	O
165	=	_	_	O
166	1	_	_	O
167	dose	_	_	O
168	of	_	_	O
169	latanoprost	_	_	O
170	(	_	_	O
171	n	_	_	O
172	=	_	_	O
173	162	_	_	O
174	)	_	_	O
175	or	_	_	O
176	non-PGs	_	_	O
177	(	_	_	O
178	n	_	_	O
179	=	_	_	O
180	164	_	_	O
181	)	_	_	O
182	.	_	_	O

183	Median	_	_	O
184	time	_	_	O
185	to	_	_	O
186	treatment	_	_	O
187	failure	_	_	O
188	was	_	_	O
189	longer	_	_	O
190	for	_	_	O
191	latanoprost	_	_	O
192	(	_	_	O
193	36	_	_	O
194	months	_	_	O
195	)	_	_	O
196	than	_	_	O
197	for	_	_	O
198	non-PGs	_	_	O
199	(	_	_	O
200	12	_	_	O
201	months	_	_	O
202	;	_	_	O
203	p	_	_	O
204	<	_	_	O
205	0.001	_	_	O
206	)	_	_	O
207	;	_	_	O
208	51	_	_	O
209	%	_	_	O
210	and	_	_	O
211	24	_	_	O
212	%	_	_	O
213	of	_	_	O
214	patients	_	_	O
215	remained	_	_	O
216	on	_	_	O
217	randomized	_	_	O
218	therapy	_	_	O
219	after	_	_	O
220	36	_	_	O
221	months	_	_	O
222	,	_	_	O
223	respectively	_	_	O
224	(	_	_	O
225	p	_	_	O
226	<	_	_	O
227	0.001	_	_	O
228	)	_	_	O
229	.	_	_	O

230	Decreases	_	_	B-Premise
231	in	_	_	I-Premise
232	mean	_	_	I-Premise
233	diurnal	_	_	I-Premise
234	IOP	_	_	I-Premise
235	from	_	_	I-Premise
236	baseline	_	_	I-Premise
237	were	_	_	I-Premise
238	significantly	_	_	I-Premise
239	greater	_	_	I-Premise
240	for	_	_	I-Premise
241	latanoprost	_	_	I-Premise
242	than	_	_	I-Premise
243	for	_	_	I-Premise
244	non-PGs	_	_	I-Premise
245	at	_	_	I-Premise
246	months	_	_	I-Premise
247	6	_	_	I-Premise
248	and	_	_	I-Premise
249	12	_	_	I-Premise
250	(	_	_	I-Premise
251	p	_	_	I-Premise
252	<	_	_	I-Premise
253	0.01	_	_	I-Premise
254	)	_	_	I-Premise
255	.	_	_	I-Premise

256	No	_	_	B-Premise
257	serious	_	_	I-Premise
258	adverse	_	_	I-Premise
259	events	_	_	I-Premise
260	were	_	_	I-Premise
261	judged	_	_	I-Premise
262	to	_	_	I-Premise
263	be	_	_	I-Premise
264	treatment-related	_	_	I-Premise
265	.	_	_	O

266	Mean	_	_	B-Premise
267	total	_	_	I-Premise
268	36-month	_	_	I-Premise
269	direct	_	_	I-Premise
270	costs	_	_	I-Premise
271	were	_	_	I-Premise
272	similar	_	_	I-Premise
273	in	_	_	I-Premise
274	patients	_	_	I-Premise
275	initiated	_	_	I-Premise
276	with	_	_	I-Premise
277	latanoprost	_	_	I-Premise
278	and	_	_	I-Premise
279	non-PGs	_	_	I-Premise
280	.	_	_	I-Premise

281	Patients	_	_	B-Premise
282	who	_	_	I-Premise
283	failed	_	_	I-Premise
284	previous	_	_	I-Premise
285	monotherapy	_	_	I-Premise
286	remained	_	_	I-Premise
287	on	_	_	I-Premise
288	therapy	_	_	I-Premise
289	longer	_	_	I-Premise
290	when	_	_	I-Premise
291	switched	_	_	I-Premise
292	to	_	_	I-Premise
293	latanoprost	_	_	I-Premise
294	.	_	_	I-Premise

295	The	_	_	B-Claim
296	IOP-reducing	_	_	I-Claim
297	effect	_	_	I-Claim
298	of	_	_	I-Claim
299	latanoprost	_	_	I-Claim
300	and	_	_	I-Claim
301	tolerability	_	_	I-Claim
302	were	_	_	I-Claim
303	sustained	_	_	I-Claim
304	over	_	_	I-Claim
305	the	_	_	I-Claim
306	long	_	_	I-Claim
307	term	_	_	I-Claim
308	.	_	_	I-Claim

309	Resource	_	_	B-Claim
310	utilization	_	_	I-Claim
311	and	_	_	I-Claim
312	costs	_	_	I-Claim
313	were	_	_	I-Claim
314	generally	_	_	I-Claim
315	similar	_	_	I-Claim
316	in	_	_	I-Claim
317	those	_	_	I-Claim
318	initiating	_	_	I-Claim
319	latanoprost	_	_	I-Claim
320	or	_	_	I-Claim
321	non-PG	_	_	I-Claim
322	therapy	_	_	I-Claim
323	.	_	_	I-Claim
